<SEC-DOCUMENT>0001437749-22-006332.txt : 20220315
<SEC-HEADER>0001437749-22-006332.hdr.sgml : 20220315
<ACCEPTANCE-DATETIME>20220315171939
ACCESSION NUMBER:		0001437749-22-006332
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220315
DATE AS OF CHANGE:		20220315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REVIVA PHARMACEUTICALS HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001742927
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38634
		FILM NUMBER:		22742300

	BUSINESS ADDRESS:	
		STREET 1:		19925 STEVENS CREEK BLVD.
		STREET 2:		SUITE 100
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014
		BUSINESS PHONE:		4085018881

	MAIL ADDRESS:	
		STREET 1:		19925 STEVENS CREEK BLVD.
		STREET 2:		SUITE 100
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tenzing Acquisition Corp.
		DATE OF NAME CHANGE:	20180606
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rvph20211231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:rvph="http://revivapharma.com/20211231" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>rvph20211231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/15/2022 9:01:38 AM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001742927</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">REVIVA PHARMACEUTICALS HOLDINGS, INC.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
<ix:nonFraction id="c81966282" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c81966283" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c81966287" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c81966288" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c81966289" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">115,000,000</ix:nonFraction>
<ix:nonFraction id="c81966290" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">115,000,000</ix:nonFraction>
<ix:nonFraction id="c81966291" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">14,433,286</ix:nonFraction>
<ix:nonFraction id="c81966293" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,433,286</ix:nonFraction>
<ix:nonFraction id="c81966292" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">9,231,737</ix:nonFraction>
<ix:nonFraction id="c81966294" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">9,231,737</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c81966522" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c81966523" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81966622" contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" unitRef="USD" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2016-06-01_2016-06-01_DebtInstrumentAxis-The2016NotesMember" name="us-gaap:DebtInstrumentTerm" id="c81966657" format="ixt-sec:durmonth">12</ix:nonNumeric>
<ix:nonFraction id="c81966680" contextRef="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2018-11-01_2018-11-01_DebtInstrumentAxis-The2018NotesMember" name="us-gaap:DebtInstrumentTerm" id="c81966709" format="ixt-sec:durmonth">6</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2018-11-01_2018-11-01_DebtInstrumentAxis-The2018NotesMember" name="rvph:DebtInstrumentRenewalTerm" id="c81966712" format="ixt-sec:durmonth">6</ix:nonNumeric>
<ix:nonFraction id="c81966836" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction>
<ix:nonFraction id="c81966837" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction>
<ix:nonFraction id="c81966784" contextRef="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81966788" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81966793" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81966876" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">11.50</ix:nonFraction>
<ix:nonFraction id="c81966880" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="USDPerShare" name="rvph:ClassOfWarrantOrRightRedemptionPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c81966911" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81966925" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81966947" contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c81966986" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c81967008" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c81967087" format="ixt-sec:durmonth">12</ix:nonNumeric>
<ix:nonFraction id="c81967095" contextRef="i_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember" unitRef="Share" name="us-gaap:SharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="rvph-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-03-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-13</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:InvestorWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-01_2021-06-01_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaCommonStockIntoCompanysCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOfRevivaCommonStockIntoCompanysCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2016-06-01_2016-06-01_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-10_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2016NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2016NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOf2016NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rvph:OneInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-02_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rvph:OneInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-02</xbrli:startDate><xbrli:endDate>2020-01-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-15_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rvph:OneInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-11-01_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2018ContingentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2018ContingentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-11-01_2018-11-01_DebtInstrumentAxis-The2018NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_DebtInstrumentAxis-The2018NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2018NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-01_DebtInstrumentAxis-The2020NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2020NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-01_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020ContingentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020ContingentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2020NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2020NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-08-01_DebtInstrumentAxis-August2020ToOctober2020NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:August2020ToOctober2020NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-10-31_DebtInstrumentAxis-August2020ToOctober2020NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:August2020ToOctober2020NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-08-01_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:RevivaContingentInterimPeriodNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-10_2020-12-10_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-10-31_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:RevivaContingentInterimPeriodNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-10_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-10</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EarnoutSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rvph:EarnoutSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2021-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-01_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-PrivateWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-InvestorWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:InvestorWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2016WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-The2016WarrantsMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2016WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2006Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">rvph:CorporateOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">rvph:CorporateOfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvph:HCWainwrightCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:TheMarketOfferingAgreementAtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvph:HCWainwrightCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:TheMarketOfferingAgreementAtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-IPOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001742927</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b><br /> <b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>WASHINGTON, D.C. 20549</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM</b>&#xa0;<b><ix:nonNumeric name="dei:DocumentType" contextRef="d_2021-01-01_2021-12-31">10-K</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>(Mark One)</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2612;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION</b>&#xa0;<b>13 OR 15(d)</b>&#xa0;<b>OF THE SECURITIES EXCHANGE ACT OF</b>&#xa0;<b>1934</b></p> </td></tr>
</tbody></table>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>For the Fiscal Year Ended </b><ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2021-01-01_2021-12-31"><b>December</b>&#xa0;<b>31, 2021</b></ix:nonNumeric><b></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b>or</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION</b>&#xa0;<b>13 OR 15(d)</b>&#xa0;<b>OF THE SECURITIES EXCHANGE ACT OF</b>&#xa0;<b>1934</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2021-01-01_2021-12-31">001-38634</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>REVIVA PHARMACEUTICALS HOLDINGS,</b>&#xa0;<b>INC.</b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Exact name of registrant as specified in its charter)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-12-31">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2021-01-01_2021-12-31">85-4306526</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p> </td></tr>
<tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation or organization)</p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification Number)</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2021-01-01_2021-12-31">19925 Stevens Creek Blvd., Suite 100</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2021-01-01_2021-12-31">Cupertino</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2021-01-01_2021-12-31">CA</ix:nonNumeric> 95014</p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:bottom;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2021-01-01_2021-12-31">95014</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip code)</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2021-01-01_2021-12-31">408</ix:nonNumeric>)</b>&#xa0;<b><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2021-01-01_2021-12-31">501-8881</ix:nonNumeric></b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Registrant&#x2019;s telephone number, including area code)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 78pt;">Securities registered pursuant to Section&#xa0;12(b)&#xa0;of the Act:</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom:solid 1px #000000;vertical-align:top;width:18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b>&#xa0;<b>of</b>&#xa0;<b>Each</b>&#xa0;<b>Class:</b></p> </td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol</b></p> </td><td style="border-bottom:solid 1px #000000;vertical-align:top;width:21.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name</b>&#xa0;<b>of</b>&#xa0;<b>Each</b>&#xa0;<b>Exchange</b>&#xa0;<b>on</b>&#xa0;<b>which</b>&#xa0;<b>Registered</b></p> </td></tr>
<tr><td style="vertical-align:top;width:18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">Common Stock, par value $0.0001 per share</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:6.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">RVPH</ix:nonNumeric></p> </td><td style="vertical-align:top;width:21.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
<tr><td style="vertical-align:top;width:18%;">&#xa0;</td><td style="vertical-align:bottom;width:6.2%;">&#xa0;</td><td style="vertical-align:top;width:21.4%;">&#xa0;</td></tr>
<tr><td style="vertical-align:top;width:18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">Warrants to purchase one share of Common Stock</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:6.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">RVPHW</ix:nonNumeric></p> </td><td style="vertical-align:top;width:21.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 33pt;">Securities registered pursuant to Section&#xa0;12(g)&#xa0;of the Act: <b>None</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#xa0;405 of the Securities Act. Yes &#x2610; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric> &#x2612;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#xa0;13 or Section&#xa0;15(d)&#xa0;of the Act. Yes &#x2610; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric> &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">Indicate by check mark whether the registrant (1)&#xa0;has filed all reports required to be filed by Section&#xa0;13 or 15(d)&#xa0;of the Securities Exchange Act of 1934 during the preceding 12&#xa0;months (or for such shorter period that the registrant was required to file such reports), and (2)&#xa0;has been subject to such filing requirements for the past 90&#xa0;days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#xa0;405 of Regulation&#xa0;S-T during the preceding 12&#xa0;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric> &#x2612; No &#x2610;&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule&#xa0;12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Large accelerated filer &#x2610;</p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#x2610;</p> </td></tr>
<tr><td style="vertical-align:top;width:22.4%;">&#xa0;</td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;">&#xa0;</td></tr>
<tr><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2021-01-01_2021-12-31">Non-accelerated filer</ix:nonNumeric> &#x2612;</p> </td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2612;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:22.4%;">&#xa0;</td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:top;width:22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2612;</ix:nonNumeric>&#xa0;</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#xa0;13(a)&#xa0;of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 18pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#xa0; <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#xa0;12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric> No &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of a share of the registrant&#x2019;s common stock on June 30, 2021 as reported by the Nasdaq Global Market on such date, was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="6" unitRef="USD" decimals="1" format="ixt:numdotdecimal" contextRef="i_2021-06-30">41.4</ix:nonFraction>&#xa0;million. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:18pt;">As of March 10, 2022 the number of outstanding shares of the registrant&#x2019;s common stock, par value $0.0001 per share, was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-03-10">15,133,286</ix:nonFraction>.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:45pt;">None.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:45pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:45pt;">&#xa0;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
   </div>
  </div>
 </div>
</div></div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>REVIVA PHARMCEUTICALS HOLDINGS, INC.</b></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ANNUAL REPORT ON FORM</b>&#xa0;<b>10-K</b></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021</b></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="toc" title="toc" href="#"></a>TABLE OF CONTENTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align:top;width:3.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:40.2%;">&#xa0;</td>
      <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Part</b>&#xa0;<b>I</b></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;1.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a1" style="-sec-extract:exhibit;">Business</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;1A.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a1a" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;1B.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a1b" style="-sec-extract:exhibit;">Unresolved Staff Comments</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">53</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;2.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a2" style="-sec-extract:exhibit;">Properties</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">53</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;3.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a3" style="-sec-extract:exhibit;">Legal Matters</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">53</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;4.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a4" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">53</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:40.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Part</b>&#xa0;<b>II</b></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">54</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;5.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a5" style="-sec-extract:exhibit;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">54</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;6.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a6" style="-sec-extract:exhibit;">[Reserved]</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">54</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;7.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a7" style="-sec-extract:exhibit;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">55</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;7A.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a7a" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;8.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a8" style="-sec-extract:exhibit;">Financial Statements and Supplementary Data</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;9.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9" style="-sec-extract:exhibit;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">62</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;9A.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9a" style="-sec-extract:exhibit;">Controls and Procedures</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">63</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;9B.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9b" style="-sec-extract:exhibit;">Other Information</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">64</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 9C.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a9c" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></p> </td>
      <td style="vertical-align: bottom; width: 2.7%; text-align: right;">64</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:40.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Part</b>&#xa0;<b>III</b></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">65</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;10.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a10" style="-sec-extract:exhibit;">Directors, Executive Officers and Corporate Governance</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">65</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;11.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a11" style="-sec-extract:exhibit;">Executive Compensation</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">69</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;12.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a12" style="-sec-extract:exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">73</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;13.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a13" style="-sec-extract:exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">75</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;14.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a14" style="-sec-extract:exhibit;">Principal Accountant Fees and Services</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">79</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:40.2%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Part</b>&#xa0;<b>IV</b></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">81</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;15.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a15" style="-sec-extract:exhibit;">Exhibits and Financial Statement Schedules</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">81</p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item&#xa0;16.</p> </td>
      <td style="vertical-align:bottom;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a16" style="-sec-extract:exhibit;">Form&#xa0;10-K Summary</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">84</p> </td>
     </tr>

     <tr>
      <td colspan="2" style="vertical-align:top;width:3.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#signatures" style="-sec-extract:exhibit;">Signatures</a></p> </td>
      <td style="vertical-align:bottom;width:2.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">85</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGNUM" style="text-align: center; width: 100%">
      &#xa0;
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
  </div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.&#xa0;Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#x2019;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;plan,&#x201d; &#x201c;possible,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report on Form 10-K may include, for example, statements about:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to maintain the listing of the Common Stock and Warrants on Nasdaq;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to grow and manage growth economically;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to retain key executives and medical and science personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the impact of the COVID-19 pandemic, and related responses of businesses and governments to the pandemic, on our operations and personnel, on commercial activity in the markets in which we operate and on our results of operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the possibility that our products in development succeed in or fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the possibility that we could be forced to delay, reduce or eliminate our planned clinical trials or development programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to obtain approval from regulatory agents in different jurisdictions for our current or future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in applicable laws or regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes to our relationships within the pharmaceutical ecosystem;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our current and future capital requirements to support our development and commercialization efforts and our ability to satisfy our capital needs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the accuracy of our estimates regarding expenses and capital requirements, including estimated costs of our clinical studies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our limited operating history;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our history of operating losses in each year since inception and expectation that we will continue to incur operating losses for the foreseeable future;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in the markets that we target;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to maintain or protect the validity of our patents and other intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our exposure to any liability, protracted and costly litigation or reputational damage relating to data security;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to develop and maintain effective internal controls; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the possibility that we may be adversely affected by other economic, business, and/or competitive factors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in such forward-looking statements. Please see &#x201c;Part I&#x2014;Item 1A&#x2014;Risk Factors&#x201d; for additional risks which could adversely impact our business and financial performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaims any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     1
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PART I</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a1" title="1" href="#"></a>ITEM 1.</b> <b>BUSINESS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All references in this report to &#x201c;Reviva,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d; mean Reviva Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burden to society, patients, and their families. Our current pipeline focuses on the central nervous system, respiratory, and metabolic diseases. We use a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Our pipeline currently has two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. We have been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our lead drug candidate, RP5063, is ready for continued clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention&#x2013;deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer&#x2019;s disease (BPSD), and Parkinson&#x2019;s disease psychosis. Furthermore, RP5063 is also ready for clinical development for two respiratory indications&#x2009;&#x2014;&#x2009;pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to RP5063 for the treatment of PAH in November&#xa0;2016 and IPF in April&#xa0;2018.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On January 10, 2022, the FDA notified us that we may proceed with our Phase 3 trial for RP5063. On February 1, 2022, we announced that the first patients have been dosed in our Phase 3 RECOVER trial to assess RP5063 for the treatment of subjects with an acute exacerbation of schizophrenia. RECOVER is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of RP5063 in approximately 400 patients with acute schizophrenia compared to placebo.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our primary focus is to complete the clinical development of RP5063 for the treatment of acute and maintenance schizophrenia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to the receipt of additional financing, we may also continue the clinical development of RP5063 for the treatment of BD, MDD, ADHD, BPSD, PDP, PAH and IPF. Moreover, subject to the receipt of additional financing, we may also advance the development of our second drug candidate, RP1208, for the treatment of depression and obesity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The development status of the Reviva product pipeline is presented below:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="a1.jpg" src="a1.jpg" /></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Impact of COVID-19</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As a result of the COVID-19 pandemic, we may experience disruptions that could adversely impact our business. The COVID-19 pandemic may negatively affect clinical site initiation, patient recruitment and enrollment, patient dosing, distribution of drug to clinical sites and clinical trial monitoring for our clinical trials. The COVID-19 pandemic may also negatively affect the operations of the third-party contract research organizations that we intend to rely upon to assist us in conducting our clinical trials and the contract manufacturers who manufacture our drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations. For additional information on the various risks posed by the COVID-19 pandemic, refer to Part I&#x2014;Item 1A&#x2014;Risk Factors of this Annual Report on Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Business Combination and Domestication</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On December&#xa0;14, 2020, our predecessor company, formerly known as Tenzing Acquisition Corp., a British Virgin Islands exempted company (&#x201c;Tenzing&#x201d;), and Reviva Pharmaceuticals,&#xa0;Inc., a Delaware corporation (together with its consolidated subsidiaries, &#x201c;Old Reviva&#x201d;), consummated the transactions (the &#x201c;Business Combination&#x201d;) contemplated by the Agreement and Plan of Merger, dated as of July&#xa0;20, 2020 (as amended, the &#x201c;Merger Agreement&#x201d;), by and among Tenzing, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#x201c;Merger Sub&#x201d;), Old Reviva, and the other parties thereto. Pursuant to the Merger Agreement, Merger Sub merged with and into Old Reviva, with Old Reviva surviving as our wholly owned subsidiary. We refer to this transaction as the Business Combination. In connection with and one day prior to the completion of the Business Combination, Tenzing re-domiciled out of the British Virgin Islands and continued as a company incorporated in the State of Delaware, and changed its name to Reviva Pharmaceuticals Holdings,&#xa0;Inc. Prior to the completion of the Business Combination, the Company was a shell company. Following the Business Combination, the business of Old Reviva is the business of the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Old Reviva was incorporated in the state of Delaware on May&#xa0;1, 2006 and its subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., was incorporated on December&#xa0;23, 2014. Tenzing was formed pursuant to the laws of the British Virgin Islands on March&#xa0;20, 2018.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About RP5063</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our RP5063 drug candidate is a novel, multimodal serotonin (5HT), dopamine (DA), and nicotinic receptor&#xa0;modulator. Our compound displays a high affinity for 5HT2A/2B//7&#xa0;and DA2/3/4&#xa0;receptors and a moderate affinity for nicotinic (nACh- &#x3b1;4&#x3b2;2) receptors (Rajagopal et al., 2017). The binding affinity of RP5063 to dopamine and serotonin sub-receptors in radioligand binding assays is the following (Ki, nM): dopamine D2S&#xa0;(0.28), D2L&#xa0;(0.45), D3&#xa0;(3.7), and D4.4&#xa0;(6.0); Serotonin 5HT1A&#xa0;(1.5), 5-HT2A&#xa0;(2.5), 5-HT2B&#xa0;(0.19), 5-HT2C&#xa0;(39), 5-HT6&#xa0;(51), and 5-HT7&#xa0;(2.7). RP5063 displayed moderate binding affinity to nicotine- nAChR, &#x3b1;4&#x3b2;2&#xa0;(Ki = 36.3 nM).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Radioactive and non-radioactive studies in rat and dog show that the gastrointestinal tract completely absorbs orally administered RP5063-related material, with acceptable bioavailability in rat (22%) and dog (85%) animal models. Exposure to RP5063 increased in a dose-dependent manner. Once absorbed, RP5063 rapidly and extensively distributes into various tissues. Noteworthy is the brain with a brain:plasma ratio of ~3.5, despite high plasma protein binding (&gt;99%) characteristics. Rat and dog hepatocytes rapidly metabolize RP5063; however, human hepatocytes metabolize this compound more slowly. This finding suggests that RP5063 will show a low clearance in humans. We believe the risk of RP5063 inducing or inhibiting cytochrome P450 (CYP) at anticipated pharmacologically relevant concentrations in humans is low. Hepatic metabolism via the cytochrome P450s is the primary route of elimination with CYP3A4/5, undertaking most of the metabolism (69%), a small contribution from CYP2D6 (17%) and minor contributions by other cytochromes including extra-hepatic CYP2J2. Two metabolites in human plasma and urine display no pharmacological activity. We believe there is a low risk of inhibition and induction of human cytochromes by RP5063 at expected plasma concentrations clinically.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A full battery of regulatory compliant toxicology and safety pharmacology studies is complete. We believe the results from these tests support the chronic administration of RP5063 in clinical trials. We believe the completed safety pharmacology and toxicology studies report several significant safety findings. These include (1)&#xa0;RP5063 is neither genotoxic nor clastogenic, (2)&#xa0;it does not affect the function of cardiovascular (QT&#xa0;interval or blood pressure) or respiratory systems, and (3)&#xa0;it is not phototoxic in the 3T3&#xa0;<i>in vitro</i>&#xa0;assay.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DEVELOPMENT OF RP5063 FOR NEUROPSYCHIATRIC DISEASES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Development for Schizophrenia</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Schizophrenia is a complex, chronic, and debilitating psychiatric syndrome. As presented in 2020, the Schizophrenia and Related Disorders Alliance of America (&#x201c;SARDAA&#x201d;) estimates schizophrenia can be found in approximately 1.1% of the world&#x2019;s population, regardless of racial, ethnic, or economic background, with approximately 3.5&#xa0;million people diagnosed in the U.S. It is a complex disease involving a mix of positive and negative symptoms, along with mood disorder and cognitive impairment. While the pathology of schizophrenia is not yet fully understood, scientists implicate the dysregulation or disruption of both dopaminergic and serotonergic functions in the development of this condition. The dysregulation of serotonergic function in the brain also contributes to schizoaffective disorders, such as bipolar, major depression, and mania. Thus, the optimal treatment for schizophrenia may not rely solely on dopamine blockade. Hypothetically, it may also include the stabilization of both the dopaminergic and serotonergic systems in the brain.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Current pharmacologic treatment involves antipsychotic therapy. There are two types of antipsychotics, typical and atypical agents. Tolerability issues (e.g., neuroleptic side effects with typical agents; metabolic and cardiovascular problems with atypical medications) limit compliance and the effectiveness of both classes of medications. Hence, compliance is poor. We estimate, pursuant to a review of multiple peer reviewed articles published between 1998 and 2015, discontinuation rates of 30&#x2009;&#x2013;&#x2009;50% in the short-term management of acute patients and 42&#x2009;&#x2013;&#x2009;74% in the long-term treatment. Also, both classes of antipsychotics fail to provide a broad spectrum of efficacy across the major symptoms or comorbidities of schizophrenia. Thus, we believe the optimal treatment of schizophrenia requires new compounds with broader efficacy, and better safety, tolerability and compliance profiles.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We believe the majority of the FDA approved antipsychotics in the last two decades block dopamine (D)&#xa0;and serotonin (5HT) receptors, particularly D2&#xa0;and 5HT2A&#xa0;receptors. RP5063 possesses a potent binding and functional activity for both D2&#xa0;and 5HT2A&#xa0;receptors. We believe these targets are critical for treating schizophrenia. In addition, RP5063 has potent activities for D4, 5HT1A, 5HT2B&#xa0;and 5HT7&#xa0;receptors implicated as targets for conditions associated with schizophrenia such as negative symptoms, mood symptoms (e.g., depression, anxiety) and cognitive impairment. RP5063 also exerts a moderate activity for nicotinic (nAChR, &#x3b1;4&#x3b2;2) receptor, implicated as a target for comorbid conditions in schizophrenia depression and cognitive impairment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Preclinical studies define the activity, pharmacokinetic, and safety profiles of RP5063 in animals. Rodent models of pharmacologic-induced behaviors associated with schizophrenia have demonstrated that RP5063 attenuates both psychosis and cognitive symptoms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have completed a clinical Phase&#xa0;1a study in healthy subjects, a Phase&#xa0;1b study in stable schizophrenia patients, and a Phase&#xa0;2 study in acute schizophrenia and schizoaffective patients. We are currently focusing our efforts on our Phase 3 RECOVER trial to assess RP5063 for the treatment of subjects with an acute exacerbation of schizophrenia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Phase</b>&#xa0;<b>1 Clinical Study in Stable Schizophrenia</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Phase&#xa0;1a and 1b studies have defined the initial clinical experience with RP5063. The first-in-human study Phase 1a involved a single-dose ascending study of 24 individuals. Initially, it examined patient cohorts receiving individual doses of 10 and 15 mg fasting; this was followed by a food-effect investigation (food versus fasting, crossover), with a 15 mg dose (Figure 1a). The multiple-dose Phase&#xa0;1b study examined doses of 10, 20, 50, and 100 mg given with food over ten days in 32 randomized patients (Figure 1b). Collectively, these studies characterized the initial safety and pharmacokinetic profiles in normal healthy volunteers (Caucasian or Japanese men, 20&#x2009;&#x2013;&#x2009;45&#xa0;years) and stable patients with schizophrenia (18&#x2009;&#x2013;&#x2009;65&#xa0;years, chronic, all types with Total Positive and Negative Syndrome Scale (PANSS) score&#xa0;<span style="text-decoration: underline; ">&lt;</span>&#xa0;90 points). RP5063 displayed a dose-dependent Cmax&#xa0;at 4 to 6 h, linear dose proportionality for both Cmax&#xa0;and AUC, and a half-life between 40 and 71 h. In the single-dose study, food slightly increased the extent of drug absorption. In the multiple-dose study, drug concentrations approached steady-state after 120 h (5&#xa0;days) of daily dosing. Pooled data in the single-dose study indicate that the pharmacokinetic profile appeared to be comparable between Caucasians and Japanese. Study data have suggested a straightforward pharmacokinetic profile for RP5063 that we believe supports once-daily dosing as an orally administered agent for Phase&#xa0;2 and Phase&#xa0;3 evaluation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 1. RP5063 Phase 1 Clinical Studies, Pharmacokinetics in Healthy Subjects and Stable Schizophrenia Patients</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1A. Single-dose pharmacokinetics profile </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>of RP5063 (15 mg) in healthy subjects</b></p> </td>
     <td style="vertical-align:top;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1B. Multiple-dose pharmacokinetics profile </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>of RP5063 (10, 20, 50 or 100 mg/day) in </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>stable schizophrenia patients for 10 days</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:24.7%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg002.jpg" src="rvph20211231_10kimg002.jpg" style="width:302;height:198;" /></p> </td>
     <td style="vertical-align:bottom;width:24.7%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg003.jpg" src="rvph20211231_10kimg003.jpg" style="width:295;height:181;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As the multiple-dose study included patients with stable schizophrenia, the data from this study provided an early assessment of the pharmacodynamics behavior and activity of RP5063 in this population. Notable were the results of secondary analyses to explore Positive and Negative Syndrome Scale (&#x201c;PANSS&#x201d;) observations relevant to the effect of RP5063 on positive symptoms, and Trails A and B tests to assess the effect on cognition, respectively. Pooled analysis of patients with PANSS scores &#x2265;50 at baseline showed a statistically significant reduction in positive symptoms subscale scores (Figure 2a). Furthermore, study analysis identified favorable trends in reducing PANSS total scores from baseline and in the General Psychopathology Score from baseline vs. placebo. Similarly, a pooled analysis of Trails A and B scores from baseline to day 16 showed favorable trends in the improvement of cognition in the RP5063 treatment groups vs. placebo.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 2. RP5063 Efficacy in the Phase 1B Clinical Study in Stable Schizophrenia Patients</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:23.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2A. A decrease in positive symptoms in stable</b><br /> &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>schizophrenia patients (PANSS positive data)</b></p> </td>
     <td style="vertical-align:top;width:23.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2B. An improvement in cognition in stable</b><br /> &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>schizophrenia patients (Trails A and B data)</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:23.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg004.jpg" src="rvph20211231_10kimg004.jpg" style="width:312;height:190;" /></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-11pt;"><b>&#x25cf;PANSS Baseline scores for sub-analysis: </b><b><span style="text-decoration: underline; ">&gt;</span></b><b>50</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-11pt;"><b>&#x25cf;Pooled data of RP5063 (10-100mg/day), N=19</b></p> </td>
     <td style="vertical-align:top;width:23.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg005.jpg" src="rvph20211231_10kimg005.jpg" style="width:291;height:195;" /></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-11pt;"><b>&#x25cf;PANSS Baseline scores: 39-69</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-11pt;"><b>&#x25cf;Pooled data of RP5063 (10-100mg/day), N=32</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Phase 1b study in stable schizophrenia patients found that RP5063 appears to be generally well-tolerated at doses ranging from 10&#x2009;&#x2013;&#x2009;100 mg administered once daily over ten days. Most adverse events were mild and occurred at the higher doses 50mg and 100 mg. Notable was the lack of clinically significant changes in glucose or prolactin levels, lipid profiles, and weight or ECG findings. A pharmacodynamic analysis of the multiple-dose Phase 1b study data provided early insight regarding the clinical activity of RP5063 relevant to psychosis, along with mood and cognitive comorbidities, in patients with stable schizophrenia. Although we believe the Phase 1b study safety and efficacy findings are encouraging, it is important to recognize its power limitations due to the relatively small sample size.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Phase</b>&#xa0;<b>2 Clinical Study in Acute Schizophrenia</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Phase&#xa0;2 clinical study involved patients with acute exacerbations of schizophrenia or schizoaffective disorder and was designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics of RP5063 versus placebo. The study was a double-blind, randomized, placebo-controlled 4-week trial. Aripiprazole was included in the study purely for assay sensitivity analysis and not as a comparator. A total of 234&#xa0;eligible subjects were randomized into one of five treatment groups (15, 30, 50mg RP5063, aripiprazole 15mg, or placebo; 3:3:3:1:2, respectively). Recruitment of male and female subjects occurred at 22 sites in the US,&#xa0;India, Philippines, Malaysia, and Moldova.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The sample size was calculated based on expected differences between the target dose of RP5063 and placebo of 8.3 points (standard deviation of 11.3 points, effect size = 0.735) in the primary efficacy analysis (mean change from baseline in PANSS Total Score). This plan projected a sample size of 180 completing subjects (i.e., 45 subjects in each RP5063 dose group; this cohort included 15 subjects in the aripiprazole group and 30 subjects in the placebo group) to achieve at least 85% power at an alpha level of 0.05% (two-sided). This level employed a t-test statistic for unequal group sizes, without controlling the alpha error in the pair-wise comparisons of the treatment groups with placebo. The statistical plan did not power the aripiprazole arm for statistical comparisons with other arms, as evaluation of this compound only assessed the study sensitivity; the study randomized 234 subjects to ensure that 180 would complete.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We conducted this study in compliance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Consolidated Guidelines. The FDA approved the protocol, investigational review boards/independent ethics committees, and all participating subjects provided informed consent.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The primary efficacy endpoint was the change from baseline to Day 28 or End of Treatment (EOT) on PANSS Total Score. The secondary efficacy endpoints were the change from baseline to Day 4, Day 8, Day 15, Day 22 and Day 28 on the following items: PANSS Total, PANSS Positive, and Negative subscales; 20% improvement in PANSS Total Score; Improvement by at least 1 point on the Clinical Global Impression (CGI-S); cognition by trail-making Tests A and B and the Digit Symbol Substitution Test (DSST). Safety variables included adverse events (AE), physical examinations, vital signs, body weight, laboratory measurements (hematology, serum chemistry including prolactin, urinalysis, and pregnancy tests), and electrocardiograms (ECGs). The measurement of extrapyramidal symptoms (EPS) utilized the Simpson Angus Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), and the Barnes Akathisia Rating Scale (BARS). The Columbia-Suicide Severity Rating Scale (C-SSRS) assessed and classified reported suicidal behavior and depression by the Calgary Depression Scale for Schizophrenia (CDSS). Investigators collected blood samples throughout the dosing period and for 220 h beyond using a sparse sampling routine. Analysis of these samples defined the population pharmacokinetics (PK) and correlated pharmacokinetic and pharmacodynamic (PK/PD) effects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063 demonstrated a sustained decrease in the total PANSS scores from Day 1 to 28 with statistically significant improvement within the group for all doses of RP5063 (p=&lt;0.001) and aripiprazole (p=0.013) (Figure 3).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 3. RP5063 Efficacy in the Phase 2 Clinical Study in Acute Schizophrenia patients, Total PANSS Scores, ITT Population (4 weeks, N = 234)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg006.jpg" src="rvph20211231_10kimg006.jpg" style="width:638;height:349;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For the primary efficacy endpoint, the change in PANSS Total Score from baseline to Day 28/EOT demonstrated a statistically significant treatment difference from placebo for the RP5063 15-mg and 50-mg arms (p = 0.0212 and p = 0.0167), with a statistically significant difference versus placebo seen as early as the Day 15 assessment (mixed-effect model with repeated measures (MMRM) analyses). The 30-mg arm did not reach statistical significance (p=0.2733), although it was numerically superior. Investigators attributed the lack of significance of the RP5063 30 mg dose to a larger than normal early discontinuations (within 2-7&#xa0;days) for reasons that were not related to the medication. Aripiprazole only showed efficacy in PANSS negative scores. PANSS subscales scores showed greater RP5063 improvement versus placebo in the PANSS Negative and Prosocial symptoms than the Positive symptoms (Figure 4). Both the RP5063 15-mg and 50-mg treatment groups displayed statistical significance from placebo as early as Day 15 for the PANSS Negative and Prosocial scales. The 50-mg treatment group showed statistical significance at Day 28 for PANSS Positive. All RP5063 groups were numerically superior to placebo.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 4. RP5063 Phase 2 Clinical Efficacy for Acute Schizophrenia and Major Comorbid Symptoms</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:24.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4A. Efficacy Data for Acute Schizophrenia</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg007.jpg" src="rvph20211231_10kimg007.jpg" style="width:310;height:239;" /></p> </td>
     <td style="vertical-align:middle;width:23.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4B. Efficacy Data for Negative Symptoms</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg008.jpg" src="rvph20211231_10kimg008.jpg" style="width:306;height:238;" /></p> </td>
    </tr>

    <tr>
     <td colspan="2" style="vertical-align:top;width:46.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:23.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4C. Efficacy Data for Positive Symptoms</b></p> </td>
     <td style="vertical-align:top;width:23.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fig 4D. Efficacy Data for Social Functioning</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:23.8%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg009.jpg" src="rvph20211231_10kimg009.jpg" style="width:309;height:239;" /></p> </td>
     <td style="vertical-align:top;width:23.5%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg010.jpg" src="rvph20211231_10kimg010.jpg" style="width:312;height:238;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">At Day 28/EOT, the frequency of a 30% improvement in total PANSS from baseline to EOT was 41%, 26%, and 39% for the respective RP5063 groups, versus 22% for the placebo cohort. RP5063 subjects improved &#x2265;2 points on the CGI-S by Day 28/EOT at twice the frequency of those on placebo. RP5063 15-mg, 30-mg, and 50-mg groups resulted in 46%, 37%, and 40% improvements, respectively, versus placebo showing a 19% change. Further, relative to &gt;1 point changes, the 15-mg, 30-mg, and 50-mg RP5063 groups produced 73%, 58%, and 72% improvements, respectively, in the CGI-S, as compared to placebo showing 57% change. The CGI-S changes from baseline to Day 28/EOT were statistically superior to placebo for RP5063 15 mg and 50 mg, while the change for 30 mg was numerically superior. Overall, RP5063 (15, 30, and 50mg) treated patients showed between 30-46% remission of acute schizophrenia symptoms, as compared with 22% in the placebo group (Figure 5a). As expected in a short study in patients with acute schizophrenia, there were no statistically significant differences in change from baseline for cognition scores. However, there were numerical improvements in RP5063 groups in the DSST, Trails A and Trails B scores for cognitive functions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 5. RP5063 Phase 2 Study, Remission of Acute Schizophrenia and Discontinuation due to Side Effects</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>5A. Remission of Schizophrenia Symptoms</b></p> </td>
     <td style="vertical-align:middle;width:24.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>5B. Discontinuation due to Side Effects</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:24.7%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg011.jpg" src="rvph20211231_10kimg011.jpg" style="width:262;height:167;" /></p> </td>
     <td style="vertical-align:top;width:24.7%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg012.jpg" src="rvph20211231_10kimg012.jpg" style="width:258;height:165;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Patients tolerated doses of RP5063 up to 50 mg with no side effect related discontinuation in the 15 mg and 30 mg dose groups. Only &lt;2% of patients discontinued the treatment in the 50 mg dose group compared to 10% of patients in the aripiprazole 15 mg group (Figure 5b). Treatment discontinuation for any reason with 15 mg, 30 mg, and 50 mg doses of RP5063; the 15 mg dose of aripiprazole; and placebo were 14%, 25%, 12%, 35%, and 26%, respectively. Investigators attribute the higher discontinuation in the 30 mg group of RP5063 to a larger than the normal number of early discontinued patients (~10%) due to non-treatment reasons. Such early discontinuation is not uncommon in a clinical study of acute schizophrenia. The discontinuation rates with aripiprazole (35% for any reason, and 10% due to side effects) are consistent with findings in published clinical studies. Common treatment-emergent adverse events (TEAEs) were EPS (3%, 5%, and 9%) and akathisia (2%, 5%, and 10%), and as expected there seemed to be a dose-dependent increase in TEAEs in the 15, 30, and 50 mg RP5063 treatment groups, respectively (Figure 6).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There were no clinically relevant changes from baseline in weight or body mass index (BMI); no subject had weight gain reported as a TEAE. This observation represented a clinically relevant finding because weight gain has been a common side effect of second-generation antipsychotics and identified as a key risk factor associated with increased morbidity and mortality in patients with schizophrenia with a major impact on compliance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There were no clinically meaningful trends in laboratory parameters (including glucose, cholesterol, triglycerides or thyroid hormone T4), ECG, or vital signs. The study observed small mean decreases from baseline in prolactin levels in all treatment groups at Day 28. In addition, there were no reports of sexual side effects and no increase in suicidal ideation compared to placebo (Figure 6).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 6. RP5063 Side Effect Profile in the Phase</b>&#xa0;<b>2 Clinical Study in Acute Schizophrenia (4 weeks, N=234)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6A. CNS or Neuroleptic Side effects</b></p> </td>
     <td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Extrapyramidal Side effects (%)</b></p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Akathisia (%)</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:auto;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg013.jpg" src="rvph20211231_10kimg013.jpg" style="width:292;height:179;" /></p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg014.jpg" src="rvph20211231_10kimg014.jpg" style="width:293;height:190;" /></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6B. Endocrine Side Effects</b></p> </td>
     <td style="vertical-align:middle;width:auto;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:24.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Change in Prolactin (mIU/L)</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg015.jpg" src="rvph20211231_10kimg015.jpg" style="width:293;height:179;" /></p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Change in Thyroid T-4 (pmol/L)</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg016.jpg" src="rvph20211231_10kimg016.jpg" style="width:292;height:177;" /></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6C. Metabolic Side Effects</b></p> </td>
     <td style="vertical-align:middle;width:auto;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Body weight Increase (%)</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg017.jpg" src="rvph20211231_10kimg017.jpg" style="width:293;height:179;" /></p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Diabetes / Blood Sugar (mmol/L)</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg018.jpg" src="rvph20211231_10kimg018.jpg" style="width:292;height:176;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cholesterol (mmol/L)</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg019.jpg" src="rvph20211231_10kimg019.jpg" style="width:292;height:178;" /></p> </td>
     <td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Lipids/Triglyceride (mmol/L)</b></p> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg020.jpg" src="rvph20211231_10kimg020.jpg" style="width:294;height:180;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The analysis of RP5063 pharmacokinetic-pharmacodynamics relationship (PK-PD) reflected a linear, dose-proportional increase in exposure with dose and with no evidence of time dependency. Noteworthy was that the finding of RP5063 dose dependent drug exposure, reflected by Cmax and AUC. These parameters increased in direct proportion to dose irrespective of the population studied (e.g., healthy volunteers, patients with stable schizophrenia, patients with acute exacerbations of schizophrenia or schizoaffective disorder). In Phase&#xa0;1 multi-dose study, drug levels approached steady-state after 120 h (5&#xa0;days) of daily dosing, with doses between 10 and 100 mg with maximum steady-state concentrations of 70.1 and 696 ng/mL and AUCs of 1361 and 12526 ng*h/mL at the 10 and 100 mg dose, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We believe these findings offer important clinical benefits. We believe the lack of excessive drug accumulation should translate to a potential clinical benefit of not needing titration of therapy. Such might be the case with other atypical antipsychotics (e.g., aripiprazole). We believe that lack of accumulation and the long half-life (~40-50 h) of RP5063 should translate easily to a once-daily dosing schedule. We believe this schedule is of clinical importance for the schizophrenic patient population since medication adherence, and missing doses with shorter half-life drugs can be a clinical issue leading to destabilization of clinical control. Such can lead to poor long-term functional outcomes in the treatment of schizophrenia. With RP5063, if a patient misses a single dose or two, we believe sufficient plasma concentrations remain for clinical control. Furthermore, the pharmacokinetic profile of RP5063 is independent of gender, age, ethnicity, glomerular filtration rate, smoking, concomitant medications, geographic location of the clinical site, and type of schizophrenia (acute or stable) patients treated. These observations mean that clinicians may not need dose adjustments based on the patient population (Figure 7b).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We performed the PK-PD modeling correlation with actual data using the observed and predicted PANSS demonstrating high predictability with relatively low variability. As shown in the graph below, both the regression line and line of identity are very close to each other. We believe this relationship indicates that the model is providing a very good fit (Figure 7a). The regression line is the line when one plots and regresses the observed data against the data predicted from the population model. The line of identity is when there is a perfect fit of the observed and predicted data (i.e., when each of the observed data is exactly equal to those of the corresponding predicted data, so the slope of the line is in exact unity). The dose-response curve showed that the total PANSS decrease was approaching its maximum response after a dose of approximately 15 mg. Thus, we believe RP5063 doses of 15 to 50 mg daily appear to be an effective clinical range of dosing (Figure 7b).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 7. RP5063 Phase 2 Clinical Study Pharmacokinetics and Pharmacodynamics Correlation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:23.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b>7A. Treatment PANSS vs. Predicted PANSS Scores</b></p> </td>
     <td style="vertical-align:top;width:23.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b>7B. Predicted Dose-Response Relationship</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:23.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg021.jpg" src="rvph20211231_10kimg021.jpg" style="width:296;height:206;" /></p> </td>
     <td style="vertical-align:top;width:23.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg022.jpg" src="rvph20211231_10kimg022.jpg" style="width:278;height:212;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Phase</b>&#xa0;<b>3 Studies in Schizophrenia</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Phase 1 and Phase 2 clinical experience in multiple populations (healthy volunteers, stable schizophrenia, and acute schizophrenia and schizoaffective disorder patients) reflect the promise of RP5063 as an addition to the treatment armamentarium of this disease. Both healthy volunteers and patients tolerated RP5063 well in both Phase&#xa0;1 and 2 studies. It did not produce any cardiometabolic, cardiovascular, prolactin, or neurologic effects, which would complicate current treatments. Investigators observed the early activity in Phase&#xa0;1 after 10-days of dosing in stable patients and we believe that results from the Phase&#xa0;2 trial may support the NDA for RP5063, as RP5063 demonstrated significance versus placebo in Total PANSS Score at Day 28 as compared to baseline. The pharmacokinetics proved to be highly predictable and consistent between Phase&#xa0;1 and 2 studies, participant type (healthy volunteer, patient), and racial characteristics (Caucasian, Black,&#xa0;Indian, and Japanese). Analyses showed substantive and relatively rapid oral absorption, linear, dose-proportional increases in Cmax and AUC, lack of undue accumulation, and a relatively long terminal half-life over 40 hours. We believe these findings translate to a straightforward once-daily dosing regimen with no need for titration or adjustments for the type of patient. These characteristics set the stage for further evaluation in Phase&#xa0;3.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As part of the Phase&#xa0;3 development plan in the end-of-Phase 2 (EOP2) meeting with the FDA in 2013, we presented the Phase&#xa0;2 schizophrenia study results, discussed the Phase&#xa0;3 development plans, and sought guidance from the FDA concerning a &#x201c;Superior Safety Label Claim&#x201d; to RP5063 for the treatment of schizophrenia. We received a favorable response from the FDA, as the agency agreed to consider granting RP5063 a &#x201c;Superior Safety Label Claim&#x201d; for the treatment of schizophrenia if there is a positive outcome on a relevant endpoint in a&#xa0;pivotal Phase&#xa0;3 study in schizophrenia. Further to support the &#x201c;Superior Safety Label Claim&#x201d; for RP5063, the FDA agreed to waive the requirement to conduct a drug interaction clinical study with CYP2D6 inhibitors in Phase&#xa0;3 development. We have accordingly planned Phase&#xa0;3 development of RP5063 for acute and maintenance schizophrenia. We have completed the required regulatory compliant non-clinical studies. These include safety pharmacology studies, toxicology studies, and chemistry, manufacturing, and controls (CMC) development for initiating pivotal Phase&#xa0;3 studies. Furthermore, the FDA has reviewed the results of these non-clinical studies and the Phase 3 protocols.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 8. Brilaroxazine (RP503) Phase 3 RECOVER Clinical Trial for Schizophrenia</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg023.gif" src="rvph20211231_10kimg023.gif" style="width:715;height:290;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">On January 10, 2022, the FDA notified us that we may proceed with our Phase 3 trial for RP5063. On February 1, 2022, we announced that the first patients have been dosed in our Phase 3 RECOVER trial to assess RP5063 for the treatment of subjects with an acute exacerbation of schizophrenia. RECOVER is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of RP5063 in approximately 400 patients with acute schizophrenia compared to placebo. RP5063 (brilaroxazine) will be administered at fixed doses of 15 mg or 50 mg once daily for 28 days. A 52-week open-label extension study will further evaluate the long-term safety and tolerability of RP5063 (brilaroxazine) in patients with stable schizophrenia. We anticipate enrolling approximately 50% patients in USA, 25% in Europe and 25% in Asia. We have initiated the Phase 3 study in January 2022. The Phase 3 trial outline is described in Figure 8 above.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Clinical Development for Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Attention-Deficit/Hyperactivity Disorder (ADHD)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Like schizophrenia, BD, MDD, and ADHD are major neuropsychiatric diseases. These neuropsychiatric diseases exhibit distinct symptoms yet share varying degrees of overlapping conditions that include psychosis, depression, and cognitive impairments. BD, a medical illness with substantial morbidity and mortality, involves episodic, recurrent mania or hypomania, and major depression. An article published in 2018 in the journal Therapeutic Advances in Psychopharmacology estimated that the global prevalence of bipolar spectrum disorders is approximately 2.4%, with approximately 0.6% for bipolar I and approximately 0.4% for bipolar II. The same journal article indicates prevalence of bipolar I in the U.S. has been found to be 1%, slightly higher than in other countries. Similarly, MDD is a common, chronic, recurrent, and debilitating psychiatric condition, leading to significant impairments in personal functional capacities. The National Institute of Mental Health (NIMH) estimated the prevalence of MDD among U.S. adults aged 18 or older at 17.3&#xa0;million in 2017. NIMH also indicated the prevalence was higher among females (8.7%) compared to males (5.3%). ADHD is a common developmental disorder in children and often continues into adulthood. The prevalence of ADHD in children is 5-12% worldwide, according to an article published in 2016 in the Journal of Advanced Pharmaceutical Technology&#xa0;&amp; Research. ADHD has a high rate of comorbid psychiatric disorders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The clinical community also uses the antipsychotic drugs (e.g., olanzapine, risperidone, quetiapine, and aripiprazole) for the treatment of BD, MDD, and/or ADHD. All these antipsychotics display pharmacological activities for dopamine (D)&#xa0;and serotonin (5HT) receptors. The majority are selective for D2&#xa0;and 5HT2A&#xa0;receptors, and may also be active for one or more of D4, 5HT1A, 5HT2B, and 5HT7&#xa0;receptors. RP5063 exhibits potent activity for D2&#xa0;and 5HT2A&#xa0;receptors, and each of D4, 5HT1A, 5HT2B, and 5HT7&#xa0;receptors are implicated as pharmacological targets for depression and cognitive impairment conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to the receipt of additional financing, we may proceed with Phase 2 studies for RP5063 in BD, MDD, and ADHD, potentially as early as the second half of 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Clinical Development for Psychosis and Behavioral Symptoms in Alzheimer</b>&#x2019;<b>s Disease (BPSD), and Parkinson</b>&#x2019;<b>s Disease Psychosis (PDP)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Patients with Alzheimer&#x2019;s disease (AD) manifest not only progressive memory impairment, cognitive deficits, and functional alterations but also a variety of neuropsychiatric symptoms (agitation, aggression, hallucinations, and delusions). An article published in 2002 in the journal Archives of General Psychiatry (now JAMA Psychiatry) states these symptoms ultimately affect up to 75% of individuals with dementia and, once present, sustain, or recur. Similarly, patients with Parkinson&#x2019;s disease also suffer from neuropsychiatric symptoms. There are very limited pharmacological treatment options for managing psychotic and behavioral symptoms in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Without an approved drug, clinicians often manage the psychosis and behavioral symptoms in Alzheimer&#x2019;s disease with antipsychotics (e.g., quetiapine and olanzapine). Primavanserin (Nuplazid), a serotonin 5HT2A&#xa0;inverse agonist, is the only FDA approved treatment for the treatment of hallucinations and delusions associated with Parkinson&#x2019;s disease psychosis. However, clinicians do use some antipsychotics (e.g., quetiapine, and olanzapine) as an off-label treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to the receipt of additional financing, we may also continue the clinical development of RP5063 for the treatment of BPSD and PDP.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DEVELOPMENT OF RP5063 FOR RESPIRATORY DISEASES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Development of RP5063 for Pulmonary Arterial Hypertension (PAH)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">PAH is a progressive, debilitating condition characterized by pulmonary vascular resistance leading to right ventricular failure and death. According to an article published in 2016 in the journal The Lancet Respiratory Medicine, the global prevalence of PAH is estimated at 6.6&#x2009;&#x2013;&#x2009;26.0 cases per million with 1.1&#x2009;&#x2013;&#x2009;7.6 incidences per million adults per year. The same article indicates PAH is frequently diagnosed in older patients, particularly those 65&#xa0;years and older. As presented in 2020, the National Organization for Rare Disorders (&#x201c;NORD&#x201d;) estimates PAH occurs 3&#x2009;&#x2013;&#x2009;5 times more frequently in females than in males, and it tends to affect females between the ages of 30 and 60. Pursuant to a study published in 2012, post-diagnosis of PAH, survival rates are approximately 1 year in 85%, 3&#xa0;years in 68%, and 5&#xa0;years in 57% of patients, respectively (Benza RL et al, CHEST 2012, 142(2):448-456).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">PAH occurs when the pulmonary arteries have narrowed, thickened, or become blocked due to the constricting and remodeling of the pulmonary vasculature. Endothelial dysfunction occurs early in the disease pathogenesis. Such pathology leads to the proliferation of the endothelium and smooth muscle tissue, the remodeling of pulmonary arteriole walls, the impaired production of vasodilators, and the overexpression of vasoconstrictors. Remodeling can involve a variety of smooth muscle (e.g., hyperplasia, medial hypertrophy, perivascular fibrosis) and other extrinsic pathologic changes (e.g., microthrombosis, inflammatory cell infiltration, angioproliferative plexiform lesions).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Current treatment involves influencing smooth muscle tone: 1&#x2009;&#x2014;&#x2009;decreasing the increased expression of phosphodiesterase 5 (PDE-5) inhibition (e.g., sildenafil) and increasing nitric oxide; 2&#x2009;&#x2014;&#x2009;antagonizing endothelin (e.g., bosentan); and 3&#x2009;&#x2014;&#x2009;providing exogenous prostacyclins (e.g., epoprostenol, iloprost, treprostinil) to address the reduced production of prostaglandin I2. Such treatments can reduce symptoms, improve the performance of activities of daily living, delay disease progression, and improve survival somewhat (e.g., epoprostenol). However, they fail to stem the ongoing cytoproliferative processes that significantly modify the pulmonary vascular structure and lead to progressive disease and/or the need for lung transplantation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Serotonin (5-hydroxytryptamine; 5HT) plays a role in both the proliferative and functional components of the pathogenesis of PAH, which involve a variety of contributing factors, including inflammatory cytokines and chemokines. Pulmonary arteries express several 5HT receptors, including the 5HT2A, 5HT2B, and 5HT7. The presence of 5HT in the pulmonary circulation activates vascular smooth muscle (VSM), 5HT2A&#xa0;and 5HT2B&#xa0;receptors, and SERT to cause constriction, the proliferation of pulmonary vascular smooth muscle cells, and fibroblast proliferation. Coupled with stimulating of the transforming growth factor &#x3b2;&#xa0;pathway, the 5HT pathway facilitates cell proliferation and vascular remodeling. These changes lead to the thickening of the medial layer. These accompany the narrowing and the remodeling of the pulmonary artery. Together these define the characteristics of PAH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063 is a novel candidate for the management of PAH. As a potent antagonist of the 5-HT receptor, it possesses a high binding affinity for several relevant targets associated with PAH. These include 5HT2A&#xa0;(2.5 nM), 5HT2B&#xa0;(0.19 nM), and 5HT7&#xa0;(2.7 nM), as well as a moderate affinity for SERT (107 nM) in preclinical models.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Preclinical Development for PAH</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA granted RP5063 Orphan Designation Status for clinical investigation in PAH in 2016. The agency based its decision on encouraging preclinical results with RP5063 in PAH, including disease-modifying antiproliferative effects. Two studies using the monocrotaline (MCT) and Sugen hypoxia (Su-Hx) models evaluated the effectiveness of RP5063 as monotherapy. Further, an additional study with the MCT model assessed this compound&#x2019;s effectiveness as an adjunct with several other standard treatments for PAH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The monotherapy MCT-induced model involved a 28-day treatment on single-agent RP5063. On Day&#xa0;0, adult male Wistar&#x2013;Kyoto rats, randomized into five groups of 10 animals, received a single intravenous 60-mg/kg MCT dose. Subsequently, on Days 0 to 27, the rats were gavaged twice daily (BID) with vehicle (MCT+Veh; 5% glucose solution), RP5063 (1, 3, or 10 mg/kg), or sildenafil (50 mg/kg). On Day 28, during terminal surgery, investigators obtained blood samples, hemodynamic readings, and harvested tissues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In this study, RP5063 produced significant functional and structural changes, as compared with those in the MCT+Veh group. Functionally, RP5063 displayed healthier pulmonary hemodynamic parameters, translating to reduced right ventricle (R.V.) hypertrophy and suggesting greater pulmonary vascular elasticity. This activity led to improved respiratory resistance and hemoglobin oxygen saturation, as compared with PAH animals without treatment. Structurally, RP5063 appeared to prevent the remodeling of the smooth muscle cells in the pulmonary vasculature. The 10 mg dose prevented vascular intimal thickening (endothelial and smooth muscle hyperplasia, and the multiplication of vascular smooth muscle cells) in the smaller vessels, mostly non-muscular in healthy animals. In exploring the cytokine response, the study found that all doses of RP5063 produced lower levels of tumor necrosis factor (TNF) &#x3b1;&#xa0;and interleukin (IL) &#x3b2;, and facilitated a significant reduction of IL-6 (p&lt;0.05). These observations suggest an antiproliferative capacity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the SuHx-induced PAH study, investigators gave RP5063 treatment for 21&#xa0;days. On Day 0, 4 groups of adult male Wistar&#x2013;Kyoto rats received a subcutaneous injection of Sugen 5416 (20 mg/kg). Investigators kept them at FiO2&#xa0;of 10% (Days 0&#x2009;&#x2013;&#x2009; 21) and 21% (Days 22&#x2009;&#x2013;&#x2009;35). During the treatment period starting at Day 14, rats were gavaged twice daily (BID) with vehicle (SuHx+Veh; 5% glucose solution), RP5063 (10 or 20 mg/kg; RP-10 and RP-20, respectively), or sildenafil 50 mg) on Days 14 to 35. On Day 35, during terminal surgery, investigators obtained blood samples, hemodynamic readings, and harvested tissues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Both doses of RP5063 and sildenafil produced a significant effect on functional and structural parameters, as compared with the induced group treated with vehicle (SuHx+Veh). Functionally, RP5063 improved pulmonary hemodynamics and respiratory function, resulting in higher oxygen saturation, as compared to non-treated, Sugen-induced animals. Structurally, RP5063 decreased small-vessel wall thickness and the&#xa0;percentage of muscular vessels. Most significantly, RP5063 limited arterial obliteration and prevented the formation of plexiform lesions. These observations suggest that the compound might exert antiproliferative effects and, potentially, a disease-modifying capacity. Concerning the cytokine effect, both RP5063 dose groups reflect lower levels of leukotriene-B4 at Days 21, 28, and 35.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Considering the initial observations with RP5063 as a single-agent treatment in both the MCT and SuHx models in rats, we undertook an additional MCT study with this compound to evaluate its role as adjunctive therapy to standard PAH treatments (Bhat et al., 2018). In the same MCT model as previously described, investigators examined RP5063 as monotherapy and as an adjunct to current standards of PAH care (bosentan, sildenafil, treprostinil).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As a single agent, RP5063 produced functional and structural effects seen in the MCT+Veh group and was consistent with those seen in the initial monotherapy MCT study. Furthermore, these effects were like (and in some cases, better than) the standard treatments. As an adjunct to all treatments, RP5063 significantly (p&lt;0.05) lowered mean and systolic pulmonary artery pressures and R.V. systolic pressure, and improved oxygen saturation, as compared with the untreated, induced animals. The combination of RP5063 and sildenafil displayed the most consistent and robust effects. The most notable was on pulmonary hemodynamics, respiratory parameters, and histopathologic changes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 9. Effect of RP5063 Treatment in MCT (9A) and Sugen-Hypoxia (9B) Induced PAH in Rats </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:22.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>9A. Treatment Effects on PAH</b></p> </td>
     <td style="vertical-align:middle;width:24%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>9B. Treatment Effects on Lung Vascular Structure</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.1%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg024.jpg" src="rvph20211231_10kimg024.jpg" style="width:302;height:226;" /></p> </td>
     <td style="vertical-align:top;width:24%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg025.jpg" src="rvph20211231_10kimg025.jpg" style="width:325;height:239;" /></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Clinical Development for PAH</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA granted Orphan Drug Designation to RP5063 for the treatment of PAH in 2016. We had a pre-IND meeting with the FDA, in which we presented RP5063 preclinical development data including efficacy results for PAH in rodent models, the data of regulatory compliant non-clinical studies (e.g., safety pharmacology studies, toxicology studies, and Chemistry, Manufacturing, and Controls (CMC) development), and the data of clinical Phase 1 studies. We discussed the Phase 2 clinical development plan with FDA and sought the agency&#x2019;s guidance for our clinical development plan for a &#x201c;Disease Modifying Label Claim&#x201d; based on the positive specific clinical outcome. Pursuant to the agency&#x2019;s guidance, we designed our clinical development plan to meet the &#x201c;Disease Modifying Label Claim&#x201d;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to the receipt of additional financing, we may also develop the clinical protocols and proceed with a Phase&#xa0;2 clinical trial for RP5063 in PAH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Development of RP5063 for Idiopathic Pulmonary Fibrosis (IPF)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IPF is a chronic, progressive, and debilitating lung disease. In 2019, Medscape reported the worldwide prevalence of IPF is estimated at 20 cases per 100,000 persons for males and 13 cases per 100,000 persons for females. Medscape also reported that in the U.S., the prevalence among individuals aged 50&#xa0;years or older ranges from 27.9 to 63 cases per 100,000. Medscape also reported, for patients suffering from IPF, the estimated mean survival is 2-5&#xa0;years from the time of diagnosis and that mortality rates are estimated at 64.3 deaths per million in men and 58.4 deaths per million in women.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IPF involves chronic inflammation and progressive fibrosis of the alveoli. This pathology leads to destroyed lung architecture, reduced lung capacity, impaired oxygenation, and a decline in lung function.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Treatment involves early referral for lung transplantation, palliative care, and clinical trials. Limitations exist with various interventions, including commonly used agents (e.g., corticosteroids and immunosuppressants), and current guidelines do not support them. Clinical studies of two Food and Drug Administration approved treatments&#x2009;&#x2014;&#x2009;Nintedanib (Ofev), and Pirfenidone (Esbriet)&#x2009;&#x2014;&#x2009;have not demonstrated significant relief to functional decline and disease progression (Maher &amp; Strek, Respiratory Research (2019)). Hence, we believe survival continues as an unmet need.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Various studies have implicated 5HT in the pathophysiology of IPF. It exerts a vasoactive effect on pulmonary arteries and stimulates lung myofibroblast actions. Pulmonary 5HT appears to mediate effects through 5-HT2A/2B/7&#xa0;receptors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063 may be a new candidate for the management of IPF. As a potent antagonist of the 5HT receptor, it possesses a high binding affinity for several relevant targets associated with IPF. These include 5HT2A&#xa0;(2.5 nM), 5HT2B&#xa0;(0.19 nM), and 5HT7&#xa0;(2.7 nM), as well as a moderate affinity for SERT (107 nM) in preclinical models.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Preclinical Development for IPF</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A bleomycin (BLM)-induced model involved a 21-day protocol using 34 Sprague Dawley rats divided into four groups- Group 1 (no induction, vehicle control), Group 2 (induction, vehicle control), Group 3 (induction, RP5063, 15 mg/kg, intervention at Day 1), and Group 4 (induction, RP5063, 15 mg/kg, intervention at Day 10). On Day 21, during terminal surgery, investigators obtained blood samples, hemodynamic readings, harvested tissues, and bronchoalveolar lavage fluid (BALF) samples. The histological analysis to evaluate effects on fibrosis involved several tests. Tissue stained with Masson&#x2019;s Trichrome and visualized using a scanner to determine the&#xa0;percentage of the fibrotic tissue, reflective of excessive collagen disposition in the lung. A colorimetric assay assessed the content of hydroxyproline, an amino acid for fibrillar collagens, from the right lung tissue sample. Finally, cytokine analysis of the BALF samples evaluated the effects on Macrophage inflammatory protein 1 (MIP1), Monocyte chemoattractant protein 1 (MCP1),&#xa0;Interleukin (IL)-6,&#xa0;Interferon gamma-induced protein 10 (IP10) and RANTES levels.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Compared with the bleomycin-induced vehicle group, the use of RP5063 at Day 0 and Day 10 sustained animal survival at 90.5% and 89.5%, respectively (P&lt;0.05). Furthermore, animals maintained their weight with both RP5063 interventions, as compared with the vehicle group (P&lt;0.01). Animals in both RP5063 groups restored cardiac output, with the Day 0 group displaying a significant effect as compared to those treated with vehicle (P&lt;0.01). The Day 0 RP5063 also normalized pulse pressure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063 treatment influenced multiple functional, histological, and cytokine parameters reflective of pulmonary fibrosis. Animals in the RP5063 Day 0 group displayed a significant reduction in respiratory resistance (P&lt;0.05). Those in Day 10 group showed improvement (P=0.10). Both RP5063 interventions produced a significant diminution in the concentration of hydroxyproline (P&lt;0.05, Day 0; P&lt;0.01, Day 10). Lung weights, which increased in the vehicle group suggesting the presence of edema, were significantly lower in the RP5063 Day 0 group (P&lt;0.05). From the BALF samples, total cell count (inflammation) was lower in both RP5063 groups (P&lt;0.05), as well as total protein content (edema) in the RP5063 Day 0 group (P&lt;0.05). Ashcroft Score from stained lung tissue reflected a significant reduction in the lung parenchymal fibrotic changes in the Day 0 group (P&lt;0.001). Concerning the&#xa0;percent of fibrosis areas measured with Masson&#x2019;s trichrome staining, the Day 0 RP5063 group significantly reduced these changes (P&lt;0.001), as compared with the vehicle group (Figure 9B). Furthermore, the Day 0 group showed significantly improved blood oxygen levels (P&lt;0.05). Both groups induced a diminution of blood lactate levels (P&lt;0.01, Day 0; P&lt;0.05, Day 5). Finally, both RP5063 groups reduced proinflammatory and fibrotic cytokines, with significant effects on MCP-1 (P&lt;0.05, Day 0),&#xa0;IP10 (P&lt;0.01, both RP5063 interventions), and RANTES (P&lt;0.01, both RP5063 interventions).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 10. Effect of RP5063 as a Monotherapy and Co-administered with Standard of Care Nintedanib and Pirfenidone in Bleomycin (BLM) Induced IPF in Rats </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:22.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>10A. Treatment Effects on Lung Hydroxyproline</b></p> </td>
     <td style="vertical-align:middle;width:24.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>10B. Treatment Effects on Lung Alveoli Fibrosis</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.5%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg026.jpg" src="rvph20211231_10kimg026.jpg" style="width:292;height:232;" /></p> </td>
     <td style="vertical-align:top;width:24.4%;"> <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg027.jpg" src="rvph20211231_10kimg027.jpg" style="width:314;height:193;" /></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RP5063</b>, PO: 15mg/kg, BID</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A follow-up preclinical study utilized the same BLM-induced model and methods. This study evaluated the effect of RP5063 (15 mg/kg twice daily) in combination with either nintedanib or pirfenidone (both dosed at 100 mg/kg once daily). Both nintedanib and pirfenidone are the current standard of care for patients with IPF. Single-agent treatment with nintedanib and pirfenidone (both dosed at 100 mg/kg once daily) served as controls. Treatment started on Day 7 following BLM-induction and continued until Day 20. Terminal surgery occurred on Day 21, in which harvesting of lung tissue and collecting of BALF occurred. Similar histological investigations evaluated the effects of treatment on mitigating the development of fibrosis via BLM-induction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 11. Effect of RP5063 Treatment in Bleomycin (BLM) Induced IPF in Rats </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg028.jpg" src="rvph20211231_10kimg028.jpg" style="width:609;height:207;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063, as an adjunct to nintedanib and pirfenidone, significantly augmented the functional and histological effects of nintedanib and pirfenidone, two standard treatments for IPF, as evidenced by reduction in hydroxyproline level (Fig 10A) and fibrosis (Fig 10B) in the lungs. The RP5063 treatment demonstrated a reduction in respiratory resistance (P&lt;0.05), an increase in blood oxygenation P&lt;0.05), and an improvement in survival rate (95%), as compared with vehicle control (62%) (Figure 11). Furthermore, RP5063, as an adjunct, mitigated lung fibrosis, and collagen disposition, the hallmarks of pulmonary fibrosis, as evidenced by the significantly (P&lt;0.001) reduced concentration of hydroxyproline in the lungs produced by the treatment combinations (Figure 9A), as compared with vehicle control.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP5063 Clinical Development for IPF</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA has granted Orphan Drug Designation to RP5063 for the treatment of IPF in 2018. We had a pre-IND meeting with the FDA, in which we presented RP5063 preclinical development data including efficacy results for IPF in rodent models, the data of regulatory compliant non-clinical studies (e.g., safety pharmacology studies, toxicology studies, and Chemistry, Manufacturing, and Controls (CMC) development), and the data of clinical Phase 1 studies. We have discussed the Phase 2 clinical development plan with FDA and sought the agency&#x2019;s guidance for our clinical development plan for a &#x201c;Disease Modifying Label Claim&#x201d; based on the positive specific clinical outcome. Pursuant to the agency&#x2019;s guidance, we designed our clinical development plan to meet the &#x201c;Disease Modifying Label Claim.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to the receipt of additional financing, we may also develop the clinical protocols and proceed with a Phase&#xa0;2 clinical trial for RP5063 in IPF.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DEVELOPMENT OF RP1208 FOR DEPRESSION AND OBESITY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About RP1208</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our RP1208 drug candidate, a new chemical entity (NCE), is a novel triple reuptake inhibitor (TRI) which we believe is ready to be in IND enabling studies for depression and ready to be in animal efficacy studies for obesity, following the receipt of adequate additional financing. We possess a granted composition of matter patent for RP1208 in the USA, Europe, and several other countries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Depression is a debilitating illness characterized by symptoms like anhedonia, depressed mood leading to suicidal thoughts, impaired cognitive functions, slowing of speech, and other actions. The NIMH estimated the prevalence of MDD among U.S. adults aged 18 or older at 17.3&#xa0;million in 2017. NIMH also indicated the prevalence was higher among females (8.7%) compared to males (5.3%). Although there are many antidepressants in the market, an article published in 2003 indicates clinicians believe that approximately 50&#x2009;&#x2013;&#x2009;60% of patients do not respond to the therapy (Fava M. Biological Psychiatry 2003, 53:649-659), which we believe reflects an unmet need to develop novel therapeutics to combat depression. The persistence of anhedonia originating from a depressed dopaminergic activity is one of the most treatment-resistant symptoms of depression. Currently, six major classes of antidepressant drugs, which target mainly monoamine transporters serotonin (SERT) and norepinephrine transporters (NET), are available. Therefore, though leaders have hypothesized that triple reuptake inhibitors (TRIs), with their potency to block dopamine reuptake by blocking dopamine transporter (DAT), in addition to serotonin transporter (SERT) and norepinephrine transporter (NET) should produce higher efficacy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Triple reuptake inhibitor active compounds stimulate satiety and act as an appetite suppressant. Pharmacological studies have demonstrated that stimulated monoaminergic activity induces profound effects on feeding behaviors and, thus, energy intake. Furthermore, they have shown that agents that enhance synaptic levels of norepinephrine (NE), serotonin (5HT), or dopamine (DA) by stimulating release or reducing reuptake can decrease feeding and weight gain.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have conducted several&#xa0;<i>in vitro</i>&#xa0;and&#xa0;<i>in vivo</i>&#xa0;studies on RP1208. In the radioligand binding assays, it has shown potent binding affinities for monoamine transporters DAT (Ki = 1.2 nM), SERT (0.8 nM), and NET (11 nM). Studies using in vitro functional assays assessed the functional activity of RP1208 for monoamine transporters. RP1208 showed potent functional inhibitory activities for monoamine transporters with IC50&#xa0;values &lt;1 nM for DAT, 6.6 nM for SERT, and 2 nM for NET. In the in vivo studies, RP1208 has shown acceptable bioavailability of 9% (t&#xbd;=2.3 h) in rat and 50% (t&#xbd;=13.1 h) in dog models. RP1208 rapidly and extensively distributes into tissues, including the brain with a brain:plasma ratio of ~1:1 (rat), despite high plasma protein binding (&gt;99%).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RP1208 Preclinical Studies for Depression and Obesity.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We evaluated the antidepressant activity of RP1208 in the tail-suspension test in the mouse model. The tail-suspension test is a mouse behavioral test useful in the screening of potential antidepressant drugs, and assessing other manipulations that investigators expect to affect depression-related behaviors. Mice are suspended by their tails with tape, in such a position that it cannot escape or hold on to nearby surfaces. During this test, typically six minutes in duration, the resulting escape-oriented behaviors are quantified. A tail-suspension test is a valuable tool in drug discovery for high-throughput screening of prospective antidepressant compounds.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The tail-suspension test in male BALB/c mice with 1, 3, 10, and 30mg/kg doses evaluated the antidepressant activity of RP1208. Venlafaxine, an approved antipsychotic drug, 60 mg/kg, was the positive control in the study. RP1208 has shown statistically robust significant reduction in immobility time at 3&#xa0;mg/kg (p = &lt;0.05), 10 mg/kg (p = &lt;0.01), and 30 mg/kg (p = &lt;0.001) doses. The antidepressant activity of RP1208, as measured by reduction in immobility time at different dose levels, was dose-dependent with no adverse effects (Figure 12).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to the receipt of additional financing, we may also advance the development of RP1208 for depression and obesity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 12. Effect of RP1208 in Immobility Time in Male BALB/c Mice in Tail Suspension Test</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg029.jpg" src="rvph20211231_10kimg029.jpg" style="width:335;height:264;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MARKET</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Neuropsychiatric Diseases Schizophrenia, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Attention-Deficit/Hyperactivity Disorder (ADHD)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Schizophrenia, BD, and MDD are major neuropsychiatric diseases often chronic in nature. These neuropsychiatric diseases exhibit distinct symptoms yet share varying degrees of overlapping conditions that include psychosis, depression, and cognitive impairments. Schizophrenia is a complex debilitating psychiatric disease involving a mix of positive and negative symptoms, along with mood disorder (e.g. depression and anxiety) and cognitive impairment. As presented in 2020, SARDAA estimates schizophrenia can be found in approximately 1.1% of the world&#x2019;s population, regardless of racial, ethnic or economic background, with approximately 3.5&#xa0;million people diagnosed in the U.S. Schizophrenia imposes substantial burden on patients, their families and overall society. Treatment and other economic costs due to schizophrenia are enormous, estimated by SARDAA to be between $32.5 and $65&#xa0;billion annually. Antipsychotic drugs are the first-line treatment for patients with schizophrenia. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of antipsychotic drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help to mitigate the symptoms and address unmet medical needs. According to a 2021 report from Verified Market Research, the total estimated drugs market size for schizophrenia is anticipated to reach approximately $10.1&#xa0;billion by 2028 (Figure 13).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 13. Global Antipsychotics Market Insights for Schizophrenia, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Attention-Deficit/Hyperactivity Disorder (ADHD)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg030.gif" src="rvph20211231_10kimg030.gif" style="width:632;height:322;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">BD, a medical illness with substantial morbidity and mortality, involves episodic, recurrent mania or hypomania, and major depression. An article published in 2018 in the journal Therapeutic Advances in Psychopharmacology estimates that the global prevalence of bipolar spectrum disorders is approximately 2.4%, with approximately 0.6% for bipolar I and approximately 0.4% for bipolar II. The same journal article indicates prevalence of bipolar I in the U.S. has been found to be 1%, slightly higher than in other countries. In recent&#xa0;years, the general public awareness of the symptoms and treatment of BD is on the rise. Typically, the treatment for BD is for a lifetime. Antipsychotic drugs are the standard of care for patients with BD. According to a 2021 article from Maximize Market Research, the total estimated drugs market size for BD treatment is estimated to reach approximately $6.2&#xa0;billion by the year 2027 (Figure 13).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">MDD is a common, chronic, recurrent, and debilitating psychiatric condition, leading to significant impairments in personal functional capacities. MDD is one of the most common mental disorders in the United States. NIMH has estimated the prevalence of MDD among U.S. adults aged 18 or older at 17.3&#xa0;million in 2017. NIMH also indicated the prevalence was higher among females (8.7%) compared to males (5.3%). Antipsychotic drugs are standard of care either as a monotherapy or as an adjuvant treatment for patients with MDD. According to a 2021 report from Research and Markets.Com, the total estimated drugs market size for the treatment of depression is estimated to reach approximately $24.5&#xa0;billion by the year 2030 (Figure 13).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;text-indent:36pt;">Attention Deficit Hyperactivity Disorder (ADHD) is a lifespan neurodevelopmental disorder, which typically manifest early in development, characterized by severe difficulties maintaining attention, coupled with impulsivity and hyperactivity (American Psychiatric Association, 2013). Other related secondary symptoms of ADHD may be social, emotional, and learning impairments, and comorbidity with psychiatric disorders such as disruptive behavioral disorders, depression and anxiety disorders is relatively high. The ADHD features are displayed in a persistent pattern that is pervasive across multiple settings and causes substantial functional impairment of personal, social, academic, or occupational functioning. An article published in Lancet 2020 reported worldwide estimated prevalence of ADHD is 5.29%. According to a 2022 report from Verified Market Research, the total estimated drugs market size for the treatment of ADHD is estimated to reach approximately $29.3 billion by the year 2028.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Respiratory Diseases Pulmonary Arterial Hypertension (PAH) and Idiopathic pulmonary Fibrosis (IPF)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">PAH and IPF are serious fatal lung diseases. Currently, there is no cure for PAH and IPF diseases. PAH is a progressive, debilitating condition characterized by pulmonary vascular resistance leading to right ventricular failure and death. According to an article published in 2016 in the journal The Lancet Respiratory Medicine, the global prevalence of PAH is estimated at 6.6&#x2009;&#x2013;&#x2009;26.0 cases per million with 1.1&#x2009;&#x2013;&#x2009;7.6 incidences per million adults per year. The same article indicates PAH is frequently diagnosed in older patients, particularly those 65&#xa0;years and older. As presented in 2020, NORD estimates PAH occurs 3&#x2009;&#x2013;&#x2009;5 times more frequently in females than in males, and it tends to affect females between the ages of 30 and 60. Pursuant to a study published in 2012, post-diagnosis of PAH, survival rates are approximately 1 year in 85%, 3&#xa0;years in 68%, and 5&#xa0;years in 57% of patients, respectively (Benza RL et al, CHEST 2012, 142(2):448-456). We believe the PAH treatment market may exhibit growth as drivers accountable for the potential market growth include a globally growing older population coupled with causative diseases including interstitial lung diseases (ILD), human immunodeficiency virus (HIV) infection, connective tissue disorders, chronic liver diseases, sedentary lifestyle and other idiopathic conditions. The presence of favorable government support in the U.S. such as Orphan Drug Act (ODA) 1983 and the Rare Disease Act (RDA) of 2002 to facilitate the development of orphan drugs with benefits including tax incentives (reduced taxes/tax credits equal to half of the development costs), clinical research subsidies, and improved patent protection and marketing rights. According to a 2022 report from Grand View Research, the global PAH treatment market is projected to reach USD 11.0&#xa0;billion by 2030 (Figure 14).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Figure 14. Global Market Insights for Pulmonary Arterial Hypertension (PAH) and Idiopathic Pulmonary Fibrosis (IPF)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="rvph20211231_10kimg031.gif" src="rvph20211231_10kimg031.gif" style="width:520;height:282;" /></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IPF is a chronic, progressive, and fatal lung disease. In 2019, Medscape reported the worldwide prevalence of IPF is estimated at 20 cases per 100,000 persons for males and 13 cases per 100,000 persons for females. Medscape also reported that in the U.S., the prevalence among individuals aged 50&#xa0;years or older ranges from 27.9 to 63 cases per 100,000. Medscape also reported, for patients suffering from IPF, the estimated mean survival is 2&#x2009;&#x2013;&#x2009;5&#xa0;years from the time of diagnosis and that mortality rates are estimated at 64.3 deaths per million in men and 58.4 deaths per million in women. IPF involves chronic inflammation and progressive fibrosis of the alveoli. This pathology leads to destroyed lung architecture, reduced lung capacity, impaired oxygenation, and a decline in lung function.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Treatment involves the FDA approved drugs Nintedanib (Ofev), and Pirfenidone (Esbriet), lung transplantation or palliative care. According to a 2022 report from Allied Market Research, the total estimated drugs market size for IPF is anticipated to reach approximately $6.2&#xa0;billion by 2030 (Figure 14).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The pharmaceutical industry is highly competitive and characterized by rapidly evolving technology and intense research and development efforts. We expect to compete with companies, including major international pharmaceutical companies, that have substantially greater financial, research and development, and marketing and sales capabilities, and have substantially greater experience in undertaking preclinical and clinical testing of products, obtaining regulatory approvals, and marketing and selling pharmaceutical products. We will face competition based on, among other things, product efficacy and safety, the timing and scope of regulatory approvals, product ease of use, and price.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">At the highest level, our potential competitors are any company developing treatments for schizophrenia, PAH,&#xa0;IPF, BD, MDD, ADHD, BPSD, and PDP.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There are numerous therapies currently used to treat schizophrenia patients, including olanzapine, risperidone, quetiapine, and aripiprazole. Such products are also often used for the treatment of comorbid neuropsychiatric disorders, including BD, MDD, ADHD, BPSD, and PDP. While these offer some clinical benefit, they are associated with adverse side effects, which include neuroleptic side effects (e.g. EPS, akathisia), metabolic side effects (e.g. weight gain, obesity, type 2 diabetes, dyslipidemia) and endocrine side effects (e.g. hypothyroidism, prolactin increase leading to sexual dysfunction). Thus, we believe there is an unmet medical need for safe and effective drugs for the treatment of schizophrenia, and related comorbid neuropsychiatric disorders, that could potentially address the totality of the disorders and help patients function and feel better, with minimal side effects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, there are numerous therapies currently used to treat PAH and IPF patients, including sildenafil, bosentan and treprostinil for PAH and nintedanib and pirfenidone for IPF. While these offer some clinical benefit, they are associated with treating the symptoms of such diseases, and not the underlying structural modification that causes the disease. Thus, we believe there is an unmet medical need for safe and effective drugs for the treatment of PAH and IPF that could potentially address the underlying cause for the disease while also treating known comorbid mental illness to potentially improve quality of life.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sales and Marketing</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We currently have no sales and marketing personnel. As a clinical stage pharmaceutical company, we currently have no customers. We intend to develop domestic and international marketing, commercial operation, distribution, market access and reimbursement capabilities, or collaborate with third parties that have such infrastructure, in connection with the potential for FDA approval for RP5063 and RP1208.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing and Supply</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have developed and validated a good manufacturing practice (&#x201c;GMP&#x201d;), process to manufacture the active pharmaceutical ingredient (&#x201c;API&#x201d;) for our RP5063 drug candidate through contract manufacturers. We have an API contract manufacturer to produce bulk batches under GMP for our anticipated clinical studies and anticipate entering into agreements to produce sufficient API required prior to submitting a New Drug Application (&#x201c;NDA&#x201d;) filing with the FDA. We do not own or operate manufacturing facilities for the production of RP5063. We expect to depend on third-party suppliers and manufacturing organizations for all of our clinical trial quantities of raw materials and drug substance. We believe there are readily available supplies of all raw materials necessary for the manufacture of RP5063 and RP1208.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employees</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have five full-time employees, and utilize consultants, clinical research organizations and third parties to perform our pre-clinical studies, clinical studies, manufacturing, regulatory, administrative, and financial functions. We believe our relations with our employees are good. We anticipate that the number of people we employ may grow significantly as we continue to develop our current products or if we develop new product candidates in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We strive to protect our intellectual property through a combination of patent, copyright, trademark and trade secrets laws, as well as through confidentiality provisions in our contracts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We strive to protect our intellectual property that we believe is important to our business, including our proprietary technology platform, our product candidates, and our processes. We seek patent protection in the U.S. and internationally for our products, their methods of use and processes of manufacture, and any other technology to which we have rights, where available and when appropriate. We also rely on trade secrets that may be important to the development of our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also plan to seek trademark protection in the U.S. and outside of the U.S. where available and when appropriate. We intend to use these registered marks in connection with our pharmaceutical research and development as well as our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are the sole owner of a patent portfolio that includes issued patents and pending patent applications covering compositions of matter and methods of use of our product candidates RP5063 and RP1208, as well as related compounds. As of December 31, 2020, our portfolio of intellectual property consists of 61&#xa0;granted patents and 13&#xa0;pending patent applications in the United States and in 23 foreign countries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">RP5063 is our first intended commercial product. The original RP5063 patents include composition of matter, and methods of use in treating acute mania, autism, BD, depression, psychosis, and schizophrenia. One RP5063 (brilaroxazine) original patent (U.S. Patent No.&#xa0;8,188,076) and its 7 divisional/continuation patents have been granted in US. The original RP5063 patents have also been granted in the following foreign countries: Australia, Brazil, Canada, Germany, Spain, France, Great Britain, Hong Kong,&#xa0;Israel,&#xa0;India,&#xa0;Italy, Japan, S. Korea, Liechtenstein, Mexico, Russia, and Slovakia; and pending in China, Columbia, Hong Kong, and Thailand. We believe that our patent portfolio provides good protection of RP5063. All of the US and foreign original RP5063 granted patents and pending patent applications will expire or are expected to expire in 2030, if a patent term extension is not obtained. If and when RP5063 receives regulatory approval, we intend to apply for patent term extensions on patents covering RP5063 in any jurisdiction where patent term extension is available. For example, the expiration date of the first US original RP5063 may be extendable up to 2035.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also own additional RP5063 granted patents and pending patent applications for additional indications such as attention hyperactivity disorder (U.S. Patent No.&#xa0;9,907,803, which will expire in 2036), pulmonary arterial hypertension (U.S. Patent No.&#xa0;10,441,590, Japanese Patent No. 6787926, Chinese Patent No. CN107206007B, Hong Kong Patent No. 1244448) and a pending application in Europe; all of which will expire or are expected to expire in 2036), and pulmonary fibrosis (pending applications in Brazil, China, Europe, Hong Kong, Japan, and US, which are expected to expire in 2038).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We further own three US patents (U.S. Patent Nos. 8,207,163; 8,247,420; 8,575,185; all of which will expire in 2030) directed to composition and use of compounds related to RP5063.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We intend to continue to file patent applications to cover additional patentable aspects of RP5063 including new indications and to endeavor to exclude competitors from entering the field.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP1208 may be our second intended commercial product. The RP1208 patents include composition of matter, and methods of use in treating depression and obesity. Three RP1208 patents have been granted in the US. RP1208 patents have also been granted in the following foreign countries: Australia, China, Columbia, Germany, Spain, France, Great Britain, Hong Kong, India, Italy, Mexico, Malaysia, Philippines, Russia, Singapore, and South Africa; and are pending in Canada and Thailand. We believe that our patent portfolio provides good protection of RP1208. The first RP1208 US patents will expire in 2033, and may be extendable up to 2038. The other two RP1208 continuation US patents will expire in 2032. All foreign RP1208 granted patents and pending patent applications will expire or are expected to expire in 2032. If and when RP1208 receives regulatory approval, we intend to apply for patent term extensions on patents covering RP1208 in any jurisdiction where patent term extension is available.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also own two families of US patents directed to related compounds of RP1208 covering composition and use. The first family consists of US Patent No.&#xa0;7,989,500 and its 5 granted continuation patents, which will expire in 2027 or 2028. The second family consists of US Patent No.&#xa0;8,604,244 and its 2 granted continuation patents, which will expire in 2031.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition to patents, we also rely upon proprietary know-how (including trade secrets) to protect our technology and maintain and develop our competitive position. In some situations, maintaining information such as a trade secret may be more appropriate to protect the type of technology than filing a patent application. We seek to protect our confidential and proprietary information in part by confidentiality agreements, and it is our policy generally to have our employees, consultants, scientific advisors, outside scientific collaborators, sponsored researchers, investors, prospective investors and contractors execute such agreements upon the commencement of a relationship with us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our success will depend on 1) the ability to obtain and maintain patent and other proprietary rights in commercially important technology, inventions and know-how related to our business, 2) the validity and enforceability of our patents, 3) the continued confidentiality of our trade secrets, and 4) our ability to operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot be certain that patents will be granted with respect to any of our pending patent applications, nor can we be certain that any of our existing patents will be successful in protecting our technology. For this and more comprehensive risks related to our intellectual property, please see &#x201c;Risk Factors&#x2009;&#x2014;&#x2009;Risks Related to our Intellectual Property.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Regulatory Matters</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, approval, labeling, manufacture, marketing and distribution of drug products. These agencies regulate, among other things, research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, advertising and promotion of our product candidates. The regulatory approval process is generally lengthy and expensive, with no guarantee of a positive result. Moreover, failure to comply with applicable requirements by the FDA or other requirements may result in civil or criminal penalties, recall or seizure of products, injunctive relief including partial or total suspension of production, or withdrawal of a product from the market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA regulates, among other things, the research, manufacture, promotion and distribution of drugs in the U.S. under the Federal Food, Drug and Cosmetic Act (&#x201c;FDCA&#x201d;) and other statutes and implementing regulations. The process required by the FDA before prescription drug product candidates may be marketed in the U.S. generally involves the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">completion of extensive nonclinical laboratory tests, animal studies and formulation studies, all performed in accordance with the FDA&#x2019;s Good Laboratory Practice regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">submission to the FDA of an Investigational New Drug application (&#x201c;IND&#x201d;), which must become effective before human clinical trials may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#x2019;s regulations, including Good Clinical Practices, to establish the safety and efficacy of the product candidate for each proposed indication;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">submission to the FDA of an NDA for drug products, or a Biologics License Application (&#x201c;BLA&#x201d;), for biologic products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">satisfactory completion of a preapproval inspection by the FDA of the manufacturing facilities at which the product is produced to assess compliance with current GMP (&#x201c;cGMP&#x201d;) regulations; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA&#x2019;s review and approval of the NDA or BLA prior to any commercial marketing, sale or shipment of the drug.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Nonclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals and other animal studies. The results of nonclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the FDA. Some nonclinical testing may continue even after an IND is submitted. The IND also includes one or more protocols for the initial clinical trial or trials and an investigator&#x2019;s brochure. An IND automatically becomes effective 30&#xa0;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions relating to the proposed clinical trials as outlined in the IND and places the clinical trial on a clinical hold. In such cases, the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Clinical trial holds also may be imposed at any time before or during studies due to safety concerns or non-compliance with regulatory requirements. An independent Institutional Review Board (&#x201c;IRB&#x201d;), at each of the clinical centers proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the consent form signed by the trial participants and must monitor the study until completed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical Trials</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified medical investigators according to approved protocols that detail the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor participant safety. Each protocol for a U.S. study is submitted to the FDA as part of the IND.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap, or be combined.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Phase&#xa0;1 clinical trials typically involve the initial introduction of the product candidate into healthy human volunteers. In Phase&#xa0;1 clinical trials, the product candidate is typically tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Phase&#xa0;2 clinical trials are generally conducted in a limited patient population to gather evidence about the efficacy of the product candidate for specific, targeted indications; to determine dosage tolerance and optimal dosage; and to identify possible adverse effects and safety risks. Phase&#xa0;2 clinical trials, in particular Phase&#xa0;2b trials, can be undertaken to evaluate clinical efficacy and to test for safety in an expanded patient population at geographically dispersed clinical trial sites.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Phase&#xa0;3 clinical trials are undertaken to evaluate clinical efficacy and to test for safety in an expanded patient population at geographically dispersed clinical trial sites. The size of Phase&#xa0;3 clinical trials depends upon clinical and statistical considerations for the product candidate and disease. Phase&#xa0;3 clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide an adequate basis for product labeling.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Post-approval clinical trials, sometimes referred to as Phase&#xa0;4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Clinical testing must satisfy the extensive regulations of the FDA. Reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted for serious and unexpected adverse events. Success in early-stage clinical trials does not assure success in later-stage clinical trials. We, or the FDA or an IRB, may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>New Drug Applications</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Assuming successful completion of the required clinical trials, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA (or BLA, in the case of a biologic product). An NDA or BLA also must contain extensive manufacturing information, as well as proposed labeling for the finished product. An NDA or BLA applicant must develop information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP. The manufacturing process must be capable of consistently producing quality product within specifications approved by the FDA. The manufacturer must develop methods for testing the quality, purity and potency of the final product. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life. Prior to approval, the FDA will conduct an inspection of the manufacturing facilities to assess compliance with cGMP.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA reviews all NDAs and BLAs submitted before it accepts them for filing. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA or BLA must be resubmitted with the additional information and is subject to review before the FDA accepts it for filing. After an application is filed, the FDA may refer the NDA or BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers them carefully when making decisions. The FDA may deny approval of an NDA or BLA if the applicable regulatory criteria are not satisfied. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to secure final approval of the NDA or BLA. If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require us to conduct Phase&#xa0;4 testing which involves clinical trials designed to further assess a drug&#x2019;s safety and effectiveness after NDA or BLA approval, and may require surveillance programs to monitor the safety of approved products which have been commercialized. Once issued, the FDA may withdraw product approval if ongoing regulatory requirements are not met or if safety or efficacy questions are raised after the product reaches the market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Section</i></b>&#xa0;<b><i>505(b)</i></b>&#xa0;<b><i>NDAs</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There are two types of NDAs: the Section&#xa0;505(b)(1)&#xa0;NDA, or full NDA, and the Section&#xa0;505(b)(2)&#xa0;NDA. A full NDA is submitted under Section&#xa0;505(b)(1)&#xa0;of the FDCA, and must contain full reports of investigations conducted by the applicant to demonstrate the safety and effectiveness of the drug. A Section&#xa0;505(b)(2)&#xa0;NDA may be submitted for a drug for which one or more of the investigations relied upon by the applicant was not conducted by or for the applicant and for which the applicant has no right of reference from the person by or for whom the investigations were conducted. A Section&#xa0;505(b)(2)&#xa0;NDA may be submitted based in whole or in part on published literature or on the FDA&#x2019;s finding of safety and efficacy of one or more previously approved drugs, which are known as reference drugs. Thus, the filing of a Section&#xa0;505(b)(2)&#xa0;NDA may result in approval of a drug based on fewer clinical or nonclinical studies than would be required under a full NDA. The number and size of studies that need to be conducted by the sponsor depends on the amount and quality of data pertaining to the reference drug that are publicly available, and on the similarity of and differences between the applicant&#x2019;s drug and the reference drug. In some cases, extensive, time-consuming, and costly clinical and nonclinical studies may still be required for approval of a Section&#xa0;505(b)(2)&#xa0;NDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Patent Protections</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An applicant submitting a Section&#xa0;505(b)(2)&#xa0;NDA must certify to the FDA with respect to the patent status of the reference drug upon which the applicant relies in support of approval of its drug. With respect to every patent listed in the FDA&#x2019;s Orange Book, which is the FDA&#x2019;s list of approved drug products, as claiming the reference drug or an approved method of use of the reference drug, the Section&#xa0;505(b)(2)&#xa0;applicant must certify that: (1)&#xa0;there is no patent information listed in the orange book for the reference drug; (2)&#xa0;the listed patent has expired; (3)&#xa0;the listed patent has not expired, but will expire on a particular date; (4)&#xa0;the listed patent is invalid or will not be infringed by the manufacture, use, or sale of the product in the Section&#xa0;505(b)(2)&#xa0;NDA; or (5)&#xa0;if the patent is a use patent, that the applicant does not seek approval for a use claimed by the patent. If the applicant files a certification to the effect of clause (1), (2)&#xa0;or (5), FDA approval of the Section&#xa0;505(b)(2)&#xa0;NDA may be made effective immediately upon successful FDA review of the application, in the absence of marketing exclusivity delays, which are discussed below. If the applicant files a certification to the effect of clause (3), the Section&#xa0;505(b)(2)&#xa0;NDA approval may not be made effective until the expiration of the relevant patent and the expiration of any marketing exclusivity delays.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If the Section&#xa0;505(b)(2)&#xa0;NDA applicant provides a certification to the effect of clause (4), referred to as a paragraph IV certification, the applicant also must send notice of the certification to the patent owner and the holder of the NDA for the reference drug. The filing of a patent infringement lawsuit within 45&#xa0;days of the receipt of the notification may prevent the FDA from approving the Section&#xa0;505(b)(2)&#xa0;NDA for 30&#xa0;months from the date of the receipt of the notification unless the court determines that a longer or shorter period is appropriate because either party to the action failed to reasonably cooperate in expediting the action. However, the FDA may approve the Section&#xa0;505(b)(2)&#xa0;NDA before the 30&#xa0;months have expired if a court decides that the patent is invalid or not infringed, or if a court enters a settlement order or consent decree stating the patent is invalid or not infringed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Notwithstanding the approval of many products by the FDA pursuant to Section&#xa0;505(b)(2), over the last few&#xa0;years certain brand-name pharmaceutical companies and others have objected to the FDA&#x2019;s interpretation of Section&#xa0;505(b)(2). If the FDA&#x2019;s interpretation of Section&#xa0;505(b)(2)&#xa0;is successfully challenged in court, the FDA may be required to change its interpretation of Section&#xa0;505(b)(2)&#xa0;which could delay or even prevent the FDA from approving any Section&#xa0;505(b)(2)&#xa0;NDA that we submit. The pharmaceutical industry is highly competitive, and it is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. Moreover, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Marketing Exclusivity</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Market exclusivity provisions under the FDCA can delay the submission or the approval of Section&#xa0;505(b)(2)&#xa0;NDAs, thereby delaying a Section&#xa0;505(b)(2)&#xa0;product from entering the market. The FDCA provides five-year marketing exclusivity to the first applicant to gain approval of an NDA for a new chemical entity (&#x201c;NCE&#x201d;), meaning that the FDA has not previously approved any other drug containing the same active moiety. This exclusivity prohibits the submission of a Section&#xa0;505(b)(2)&#xa0;NDA for any drug product containing the active ingredient during the five-year exclusivity period. However, submission of a Section&#xa0;505(b)(2)&#xa0;NDA that certifies that a listed patent is invalid, unenforceable, or will not be infringed, as discussed above, is permitted after four&#xa0;years, but if a patent infringement lawsuit is brought within 45&#xa0;days after such certification, FDA approval of the Section&#xa0;505(b)(2)&#xa0;NDA may automatically be stayed until 7&#xbd;&#xa0;years after the NCE approval date. The FDCA also provides three&#xa0;years of marketing exclusivity for the approval of new and supplemental NDAs for product changes, including, among other things, new indications, dosage forms, routes of administration or strengths of an existing drug, or for a new use, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by FDA to be essential to the approval of the application. Five-year and three-year exclusivity will not delay the submission or approval of another full NDA; however, as discussed above, an applicant submitting a full NDA under Section&#xa0;505(b)(1)&#xa0;would be required to conduct or obtain a right of reference to all of the nonclinical and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Other types of exclusivity in the United States include orphan drug exclusivity and pediatric exclusivity. The FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Seven-year orphan drug exclusivity is available to a product that has orphan drug designation and that receives the first FDA approval for the indication for which the drug has such designation. Orphan drug exclusivity prevents approval of another application for the same drug for the same orphan indication, for a period of seven&#xa0;years, regardless of whether the application is a full NDA or a Section&#xa0;505(b)(2)&#xa0;NDA, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Pediatric exclusivity, if granted, provides an additional six&#xa0;months to an existing exclusivity or statutory delay in approval resulting from a patent certification. This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section&#xa0;505(b)(2)&#xa0;NDAs are similar to full NDAs filed under Section&#xa0;505(b)(1)&#xa0;in that they are entitled to any of these forms of exclusivity if they meet the qualifying criteria. They also are entitled to the patent protections described above, based on patents that are listed in the FDA&#x2019;s Orange Book in the same manner as patents claiming drugs and uses approved for NDAs submitted as full NDAs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Breakthrough Therapy Designation</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On July&#xa0;9, 2012, the Food and Drug Administration Safety and Innovation Act (&#x201c;FDASIA&#x201d;), was signed. FDASIA Section&#xa0;902 provides for a new drug designation, Breakthrough Therapy. A Breakthrough Therapy is a drug:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Fast Track Designation</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A Fast Track is a designation by the FDA of an investigational drug which:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">non-clinical or clinical data demonstrate the potential to address an unmet medical need</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The benefits of a Fast Track designation include rolling submission of portions of the NDA for the drug candidate and eligibility for priority review of the NDA. Additionally, more frequent meetings and written communication with the FDA regarding the development plan and trial design for the drug candidate are encouraged throughout the entire drug development and review process, with the goal of having earlier drug approval and access for patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Other Regulatory Requirements</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Maintaining substantial compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Drug manufacturers are required to register their establishments with the FDA and certain state agencies, and after approval, the FDA and these state agencies conduct periodic unannounced inspections to ensure continued compliance with ongoing regulatory requirements, including cGMPs. In addition, after approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. The FDA may require post-approval testing and surveillance programs to monitor safety and the effectiveness of approved products that have been commercialized. Any drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">record-keeping requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">reporting of adverse experiences with the drug;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">providing the FDA with updated safety and efficacy information;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">reporting on advertisements and promotional labeling;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">drug sampling and distribution requirements; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">complying with electronic record and signature requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. There are numerous regulations and policies that govern various means for disseminating information to health-care professionals as well as consumers, including to industry sponsored scientific and educational activities, information provided to the media and information provided over the Internet. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA has very broad enforcement authority and the failure to comply with applicable regulatory requirements can result in administrative or judicial sanctions being imposed on us or on the manufacturers and distributors of our approved products, including warning letters, refusals of government contracts, clinical holds, civil penalties, injunctions, restitution and disgorgement of profits, recall or seizure of products, total or partial suspension of production or distribution, withdrawal of approvals, refusal to approve pending applications, and criminal prosecution resulting in fines and incarceration. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. In addition, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Coverage and Reimbursement</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Sales of our product candidates, if approved, will depend, in part, on the extent to which such products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical products and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug candidates that we develop will be made on a payor-by-payor basis. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of our product candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Other Healthcare Laws</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because of our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors, we will also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we will conduct our business, including our clinical research, proposed sales, marketing and educational programs. Failure to comply with these laws, where applicable, can result in the imposition of significant civil penalties, criminal penalties, or both. The U.S. laws that may affect our ability to operate, among others, include: the federal Health Insurance Portability and Accountability Act of 1996 (&#x201c;HIPAA&#x201d;), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; certain state laws governing the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; the federal healthcare programs&#x2019; Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs; federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that our products are sold in a foreign country, we may be subject to similar foreign laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>The Impact of New Legislation and Amendments to Existing Laws</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDCA is subject to routine legislative amendments with a broad range of downstream effects. In addition to new legislation, such as the FDA Reauthorization Act of 2017 or the FDASIA in 2012, Congress introduces amendments to reauthorize drug user fees and address emerging concerns every five&#xa0;years. We cannot predict the impact of these new legislative acts and their implementing regulations on our business. The programs established or to be established under the legislation may have adverse effects upon us, including increased regulation of our industry. Compliance with such regulation may increase our costs and limit our ability to pursue business opportunities. In addition, the FDA&#x2019;s regulations, policies and guidance are often revised or reinterpreted by the agency or the courts in ways that may significantly affect our business and products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect that additional federal and state, as well as foreign, healthcare reform measures will be adopted in the future, any of which could result in reduced demand for our products or additional pricing pressure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b>Where You Can Find More Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the internet at the SEC&#x2019;s website at&#xa0;<i>http://www.sec.gov.</i>&#xa0;Our SEC filings are also available on our website at&#xa0;<i>http://www.</i> <i>https://revivapharma.com/</i>&#xa0;as soon as reasonably practicable after they are filed with or furnished to the SEC.&#xa0;Our website and the information contained on or connected to that site are not incorporated into this Annual Report on Form 10-K. <b>We will</b>&#xa0;<b>provide,</b>&#xa0;<b>without</b>&#xa0;<b>charge,</b>&#xa0;<b>to</b>&#xa0;<b>each</b>&#xa0;<b>person</b>&#xa0;<b>upon written request of such person, a copy of this Annual Report on Form 10-K, including the financial statements and financial statement schedules included herein. You should direct requests for those documents to:</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reviva Pharmaceuticals Holdings, Inc.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>19925 Stevens Creek Blvd., Suite 100</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cupertino, CA 95014</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Attn: Investor Relations</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Email:</b>&#xa0;<b><span style="text-decoration: underline; ">info.rp@revivapharma.com</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     25
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a1a" title="1a" href="#"></a>Item</b>&#xa0;<b>1A.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>RISK FACTORS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>An investment in our common stock is speculative and illiquid and involves a high degree of risk including the risk of a loss of your entire investment. You should carefully consider the risks and uncertainties described below and the other information contained in this report and our other reports filed with the Securities and Exchange Commission. The risks set forth below are not the only ones facing us. Additional risks and uncertainties may exist that could also adversely affect our business, operations and financial condition. If any of the following risks actually materialize, our business, financial condition and/or operations could suffer. In such event, the value of our common stock could decline, and you could lose all or a substantial portion of the money that you pay for our common stock.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Summary Risk Factors</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business is subject to numerous risks and uncertainties. The following summarizes key risks and uncertainties that could materially adversely affect us. You should read this summary together with the more detailed risk factors contained below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we have never generated any product revenues;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we are heavily dependent on the success of RP5063, our only advanced product candidate, which is still under clinical development, and if RP5063 does not receive regulatory approval or is not successfully commercialized, our business will be harmed;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the COVID-19 outbreak and global pandemic could adversely impact our business, including our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of RP5063 or RP1208;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if the interpretations, estimates or judgments we use to prepare our financial statements prove to be incorrect, we may be required to restate our financial results, which could have a number of material adverse effects on us;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">clinical trials are very expensive, time-consuming, difficult to design and implement and involve an uncertain outcome;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of RP5063, RP1208 and any future product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">if we fail to maintain compliance with the requirements of The Nasdaq Capital Market for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">certain of our warrants are accounted for as liabilities and the changes in value of such warrants could have a material effect on our financial results;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we are an emerging growth company within the meaning of the Securities Act and have taken advantage of certain exemptions from disclosure requirements available to emerging growth companies; this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, any gains from an investment in our common stock will likely depend on appreciation in the price of our common stock; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our officers, directors, and principal stockholders exercise significant control over our Company, and will control our company for the foreseeable future, including the outcome of matters requiring stockholder approval.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Business, Financial Position and Capital Requirements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have never generated any product revenues.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a clinical-stage biopharmaceutical company. Although we were formed in May&#xa0;2006, to date, we have not generated any product revenues from our product candidates currently in development. We have not yet demonstrated an ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our ability to generate revenue and become profitable depends upon our ability to successfully complete the development of our product candidates, RP5063 for the treatment of schizophrenia, respiratory/pulmonary diseases such as Pulmonary Arterial Hypertension, or PAH, and Idiopathic Pulmonary Fibrosis, or IPF, and for other neuropsychiatric diseases, such as bipolar disorder, or BD, major depressive disorder, or MDD, Alzheimer&#x2019;s psychosis/agitation, or AD, Parkinson&#x2019;s psychosis, or PD, and attention deficit hyperactivity disorder, or ADHD/ADD, and RP1208 for the treatment of depression and obesity, and obtain the necessary regulatory approvals for their commercialization. We have never been profitable, have no products approved for commercial sale and to date have not generated any revenue from product sales.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even if we receive regulatory approval for the commercialization of RP5063, we do not know when this product candidate will generate revenue, if at all. RP1208 is in pre-clinical development. Our ability to generate product revenue depends on a number of factors, including our ability to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">successfully complete clinical trials and obtain regulatory approval for the marketing of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">set an acceptable price for our product candidates and obtain coverage and adequate reimbursement from third-party payors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">establish sales, marketing and distribution systems for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">add operational, financial and management information systems and personnel, including personnel to support our clinical, manufacturing and planned future commercialization efforts and operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">initiate and continue relationships with third-party manufacturers and have commercial quantities of our product candidates manufactured at acceptable cost levels;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">attract and retain an experienced management and advisory team;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">achieve broad market acceptance of our products in the medical community and with third party payors and consumers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">launch commercial sales of our products, whether alone or in collaboration with others; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">maintain, expand and protect our intellectual property portfolio.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability. Our expenses could increase beyond expectations if we are required by the FDA, and comparable non-U.S. regulatory authorities, to perform studies or clinical trials in addition to those that we currently anticipate. Even if our product candidates are approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of these products. If we cannot successfully execute any one of the foregoing, our business, prospects and results of operations may be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. We have never generated any revenues and cannot estimate with precision the extent of our future losses. We do not currently have any products that are available for commercial sale and we may never generate revenue from selling products or achieve profitability. We expect to continue to incur substantial and increasing losses through the projected commercialization of RP5063 and RP1208. For the year ended December 31, 2021, we reported a loss of $8.5&#xa0;million, and a negative cash flow from operations of $10.7&#xa0;million. We had an accumulated deficit of $66.8&#xa0;million and had cash and cash equivalents of $29.7&#xa0;million as of December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063 has not been approved for marketing in the United States and may never receive such approval. Although RP1208 may be in IND enabling studies for depression and may be in animal efficacy studies for obesity within a short time frame following the receipt of adequate additional financing, it is not currently in an IND-enabling study or animal efficacy study, respectively, and may never meet the requirements for filing an IND. As a result, we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain it. Our ability to produce revenue and achieve profitability is dependent on our ability to complete the development of our product candidates, obtain necessary regulatory approvals, and have our product candidates manufactured and successfully marketed. We cannot assure you that we will be profitable even if we successfully commercializes our product candidates. If we do not successfully obtain regulatory approval to market our product candidates, our revenues will be dependent, in part, upon, among other things, the size of the markets in the territories for which we gain regulatory approval, the number of competitors in such markets, the accepted price for our product candidates and whether we own the commercial rights for that territory. If the indication approved by regulatory authorities is narrower than we expects, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of our product candidates, even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Failure to become and remain profitable may adversely affect the timing of our clinical results and our ability to raise capital and continue operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect our research and development expenses to be significant in connection with the following ongoing and planned research:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Phase 3 studies for RP5063 for the treatment of schizophrenia;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Phase 2 studies for the treatment of PAH,&#xa0;IPF, BD, MDD, AD, PD, ADHD/ADD;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">pre-clinical studies and clinical studies for RP1208 for the treatment of depression and obesity.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, we will require additional capital to proceed with the planned research described above. See &#x201c;Risks Related to Our Business and Industry&#x2009;&#x2014;&#x2009;Risks Related to Our Business, Financial Position and Capital Requirements&#x2009;&#x2014;&#x2009;We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of RP5063.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, if we obtain regulatory approval for RP5063, we expect to incur increased sales and marketing expenses. As a result, we expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have had and will continue to have an adverse effect on our financial position and working capital.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are heavily dependent on the success of RP5063, our only advanced product candidate, which is still under clinical development, and if RP5063 does not receive regulatory approval or is not successfully commercialized, our business will be harmed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We currently have no products that are approved for commercial sale and may never be able to develop marketable drug products. We expect that a substantial portion of our efforts and expenditures in the foreseeable future will be devoted to RP5063. Our only other product candidate is RP1208, which is in the pre-clinical phase. We do not expect to allocate a significant portion of our efforts or resources to the clinical trials or development of this product candidate in the foreseeable future. Accordingly, our business currently depends heavily on the successful development, regulatory approval and commercialization of RP5063. We cannot be certain that RP5063 will receive regulatory approval or be successfully commercialized even if we receive regulatory approval. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are and will remain subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing regulations. We are not permitted to market RP5063 in the United States until we receive approval of a new drug application, or NDA, from the FDA, or in any foreign countries until we receives the requisite approval from such countries. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities and do not expect to be in a position to do so for the foreseeable future. Obtaining approval of an NDA is an extensive, lengthy, expensive and inherently uncertain process, and the FDA may delay, limit or deny approval of RP5063 for many reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We may not be able to demonstrate that RP5063 is safe and effective as a treatment for our targeted indications to the FDA&#x2019;s satisfaction;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may require additional Phase 3 trials of RP5063 in schizophrenia, which would increase our costs and prolong its development;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the contract research organizations, or CROs, that we retain to conduct clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of RP5063 outweigh its safety risks;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may disagree with our interpretation of data from our preclinical studies and clinical trials or may require that we conduct additional studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may not accept data generated at our clinical trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if our NDA is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may identify deficiencies in the manufacturing processes or facilities of our third party manufacturers; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may change its approval policies or adopt new regulations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The COVID-19 outbreak and global pandemic could adversely impact our business, including our clinical trials.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December&#xa0;2019, a novel strain of coronavirus, or COVID-19, surfaced in Wuhan, China. Since then, COVID-19 has spread globally. As a result of the COVID-19 outbreak, or similar pandemics, and government response to pandemics, we have and may in the future experience disruptions that could severely impact our business and clinical trials, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">delays or difficulties in enrolling patients in our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">delays or disruptions in preclinical experiments and investigational new drug application-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations and vendors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages&#xa0;and disruptions in delivery systems.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of RP5063 or RP1208.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect to spend substantial amounts to complete the development of, seek regulatory approvals for, and commercialize RP5063 and RP 1208. We will require additional capital to complete the development and potential commercialization of RP5063 for the treatment of schizophrenia and to continue the development of RP5063 for PAH,&#xa0;IPF, BD, MDD, AD, PD, ADHD/ADD and other potential indications, and to continue the development of RP1208 for the treatment of depression and obesity. No assurance can be given that such additional capital will be available on terms acceptable to us, if at all. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our planned development programs or any future commercialization efforts. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. Because the length of time and activities associated with successful development of RP5063 and RP1208 is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the initiation, progress, timing, costs and results of our planned clinical trials for RP5063 and pre-clinical research for RP1208;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us with respect to RP5063, RP1208 or any future product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the effect of competing technological and market developments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the cost and timing of completion of commercial-scale manufacturing activities;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the cost of establishing sales, marketing and distribution capabilities for RP5063, RP1208 or any future product candidates, in regions where we choose to commercialize our products on our own; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the initiation, progress, timing and results of our commercialization of RP5063, RP1208 or any future product candidates, if approved for commercial sale.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot be certain that such funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of RP5063 or RP1208 or potentially discontinue operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Raising additional funds by issuing securities may cause dilution to existing shareholders, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect that significant additional capital will be needed in the future to continue our planned operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we raises additional capital by issuing equity securities, our existing shareholders&#x2019; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect then-existing stockholders&#x2019; interests. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. Any debt financing we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our shares or make investments. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December&#xa0;31, 2021, we had five&#xa0;employees, and we are highly dependent on our management personnel, especially Laxminarayan Bhat, our Chief Executive Officer, Narayan Prabhu our Chief Financial Officer and Marc Cartillon, our Chief Medical Officer. We expect to hire a significant number of additional employees for our managerial, clinical, scientific, operational, sales and marketing teams. We may have operational difficulties in connection with identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management has no prior experience in managing these growth activities and may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to such activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize RP5063 and RP1208 and compete effectively will depend, in part, on our ability to effectively manage any future growth.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and our business will be limited.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We</i></b>&#xa0;<b><i>will</i></b>&#xa0;<b><i>be impacted by new state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">In September 2018, California enacted SB 826, requiring public companies headquartered in California to maintain minimum female representation on their boards of directors as follows: by December&#xa0;31, 2019, public company boards must have a minimum of one female director; by December&#xa0;31, 2021, public company boards with five members will be required to have at least two female directors, and public company boards with six or more members will be required to have at least three female directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">Additionally, on September&#xa0;30, 2020, California enacted AB 979, requiring public companies with principal executive offices in California to each have at least one director from an underrepresented community based on ethnicity and sexual orientation by December&#xa0;31, 2021. By December&#xa0;31, 2022, each of these companies will be required to have at least two directors from such underrepresented communities if such company has more than four but fewer than nine directors, or at least three directors from underrepresented communities if the company has nine or more directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">The current composition of our board of directors does not include a female director. In order to meet the requirements of applicable California law, we expect to onboard the requisite number of female and diverse directors. Failure to achieve designated minimum levels in a timely manner will expose us to financial penalties and reputational harm. We cannot assure that we can recruit, attract and/or retain qualified members of the board and meet gender and diversity quotas as required by California law (provided that such laws are not repealed before the compliance deadlines), which may cause certain investors to divert their holdings in our securities and expose us to financial penalties and/or reputational harm.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are exposed to the risk that our employees and contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; federal and state healthcare fraud and abuse and health regulatory laws and other similar foreign fraudulent misconduct laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we seek to enter into strategic alliances for the development of RP5063 or RP1208 but fail to enter into and maintain successful strategic alliances, our development costs may increase and our ability to develop RP5063 or RP1208 may be significantly delayed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may seek to enter into strategic alliances or collaborative arrangements with pharmaceutical companies or other industry participants in order to advance our development of RP5063 or, in the future, RP1208 or other product candidates, and to reduce our costs of development. If we seek such alliances or collaborative arrangements, we may not be able to negotiate such alliances or collaborative arrangements on acceptable terms, if at all. We face significant competition from other biopharmaceutical companies for appropriate partners in such alliances or arrangements. Furthermore, if we are successful in entering strategic alliances or collaborative arrangements, we may not be able to maintain such alliances or arrangements for a sufficient amount of time to commercialize RP5063, RP1208 or other product candidates, or such alliances or arrangements may not result in successful development of our products. If we seek suitable alliances or arrangements but then fail to create or to maintain these, we may have to limit the size or scope of, or delay, our development of RP5063, RP1208 or other future product candidates. If we elect to fund our development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms. See &#x201c;<i>Risks Related to Our Business and Industry</i>&#x2009;&#x2014;&#x2009;<i>Risks Related to Our Business, Financial Position and Capital Requirements</i>&#x2009;&#x2014;&#x2009;<i>We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of RP5063.</i>&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>To the extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Biotechnology companies at our stage of development may become dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of drug candidates, particularly after the Phase 2 stage of clinical testing. If we elect to enter into collaborative arrangements or strategic alliances, these arrangements may place the development of RP5063, RP1208 or other future product candidates outside our control, may require that we relinquish important rights or may otherwise be entered on terms unfavorable to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Dependence on collaborative arrangements or strategic alliances will subject us to a number of risks, including the risk that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We may not be able to control the amount and timing of resources that our collaborators may devote to RP5063 and RP1208;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">our collaborators may experience financial difficulties;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">we may be required to relinquish important rights, such as marketing and distribution rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">business combinations or significant changes in a collaborator&#x2019;s business strategy may also adversely affect a collaborator&#x2019;s willingness or ability to complete our obligations under any arrangement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business and operations would suffer in the event our computer systems and networks fail.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our business depends on the proper functioning and availability of our computer systems and networks. Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of RP5063, RP1208 or any future product candidate could be delayed. Any successful cyber security attack or other unauthorized attempt to access our systems also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to substantial penalties under HIPAA and other federal and state privacy laws, in addition to private litigation with those affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The use of RP5063 and RP1208 in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">impairment of our business reputation and significant negative media attention;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">withdrawal of participants from our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">significant costs to defend the related litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">distraction of management&#x2019;s attention from our primary business;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">substantial monetary awards to patients or other claimants;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">inability to commercialize RP5063, RP1208 or any future product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">decreased demand for RP5063, RP1208 or any future product candidate, if approved for commercial sale; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">loss of revenue.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any product liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses it may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for RP5063 or RP1208, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><b><i>If we fail to maintain an effective system of internal control over financial reporting our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock and warrants could be adversely affected. In addition, because of our status as an emerging growth company, our independent registered public accountants are not required to provide an attestation report as to our internal control over financial reporting for the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected in a timely manner. We are also required to disclose changes made in our internal control and procedures on a quarterly basis. Section 404 of the Sarbanes-Oxley Act ("Section 404"), requires that we evaluate and determine the effectiveness of internal controls over financial reporting and provide a management report on internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have a limited operating history and limited personnel in our finance and accounting functions, which may result in a lack of segregation of duties and we are at the very early stages of establishing, and we may be unable to effectively establish such systems, especially in light of the fact that we now have to operate as a publicly reporting company. This would leave us without the ability to reliably assimilate and compile financial information and significantly impair our ability to prevent error and detect fraud, all of which would have a negative impact on our internal controls over financial reporting. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If we identify material weaknesses in our internal control over financial reporting in the future or if we are unable to successfully remediate the identified material weaknesses, or if we are otherwise unable to maintain an effective system of internal control over financial reporting, the reliability of our financial reporting, investor confidence in our Company and the value of our common stock and warrants could be materially and adversely affected. Effective internal control over financial reporting is necessary for us to provide reliable and timely financial reports and, together with adequate disclosure controls and procedures, are designed to reasonably detect and prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. For as long as we are a &#x201c;smaller reporting company&#x201d; under the U.S. securities laws, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of internal control over financial reporting could detect problems that management&#x2019;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Moreover, we do not expect that disclosure controls or internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#x2019;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely impact our Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If the interpretations, estimates or judgments we use to prepare our financial statements prove to be incorrect, we may be required to restate our financial results, which could have a number of material adverse effects on us.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">We are subject to complex securities laws and regulations and accounting principles and interpretations. The preparation of our financial statements requires us to interpret accounting principles and guidance and to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. We base our interpretations, estimates and judgments on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for the preparation of our financial statements. Generally accepted accounting principles presentation is subject to interpretation by the SEC, the Financial Accounting Standards Board and various other bodies formed to interpret and create appropriate accounting principles and guidance. If one of these bodies disagrees with our accounting recognition, measurement or disclosure or any of our accounting interpretations, estimates or assumptions, it may have a significant effect on our reported results and may retroactively affect previously reported results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">Specifically, prior to and in connection with the closing of our Business Combination, our predecessor company, Tenzing, issued public warrants to purchase 6,325,000 shares (the &#x201c;Public Warrants&#x201d;) and private placement warrants to purchase 556,313 shares (the &#x201c;Private Warrants,&#x201d; together with the Public Warrants, the &#x201c;Warrants&#x201d;). For a full description of the Warrants, refer to (i) the registration statement on Form S-4 (File No. 333-245057), filed in connection with the Business Combination, declared effective by the SEC on November 10, 2020 and (ii) our &#x201c;Description of Securities&#x201d; included as Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 22, 2021. Each Warrant entitles the holder to purchase one share of our common stock at a price of $11.50 per share, subject to adjustment. We originally classified the Warrants as equity in our previously issued audited consolidated balance sheet as of December 31, 2020, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for the year then ended, and the related notes (collectively, referred to as the "Financial Statements") included in our Annual Report on Form 10-K filed on March 22, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">On April 12, 2021, the Staff of the Securities and Exchange Commission (&#x201c;SEC Staff&#x201d;) released the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the &#x201c;Statement&#x201d;). In the Statement, SEC Staff made the observation that certain contractual provisions included in many Special Purpose Acquisition Company warrant agreements may result in such warrants needing to be classified as a liability rather than as equity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">We have reviewed the Statement and the terms of our Warrants with our third-party technical accounting advisor and our independent auditors and management has concluded that the Private Warrants should be reclassified as liabilities measured at fair value, which will result in non-cash gains or losses from changes in fair value reported each period in earnings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 38pt;">However, no assurance can be given that additional guidance or new regulations or accounting principles and interpretations will not be released that would require us to reclassify the Public Warrants as liabilities measured at fair value, with changes in fair value reported each period in earnings and/or require a restatement of our Financial Statements with respect to treatment of the Public Warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Any restatement of our financial results could, among other potential adverse effects:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">result in us incurring substantial costs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">affect our ability to timely file our periodic reports until the restatement is completed;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">divert the attention of our management and employees from managing our business;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">result in material changes to our historical and future financial results;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">result in investors losing confidence in our operating results;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">subject us to securities class action litigation; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:26pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cause our stock price to decline.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Clinical Development, Regulatory Approval and Commercialization</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical trials are very expensive, time-consuming, difficult to design and implement and involve an uncertain outcome.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our only advanced product candidate, RP5063, is still in development and will require extensive clinical testing before we are prepared to submit an NDA for regulatory approval. We cannot predict with any certainty if or when we might submit an NDA for regulatory approval for RP5063 or whether any such NDA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We estimate that the Phase 3 clinical trials of RP5063 for schizophrenia indication will take at least three&#xa0;years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, and the results of early clinical trials of RP5063 therefore may not be predictive of the results of our planned clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The commencement and completion of clinical trials may be delayed by one or more factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to obtain regulatory approval to commence a trial, including in other countries in the global portion of our planned clinical studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unforeseen safety issues;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">determination of dosing issues;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">lack of effectiveness during clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">slower than expected rates of patient recruitment or failure to recruit suitable patients to participate in a trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to manufacture sufficient quantities of a drug candidate for use in clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to monitor patients adequately during or after treatment; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability or unwillingness of medical investigators to follow our clinical protocols.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, our management has limited prior experience in managing and completing late-stage clinical trials, and may not be able to successfully design and implement these trials or respond to adverse factors that may arise in the course of conducting these trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, we, the FDA or an institutional review board, or IRB, at a clinical trial site may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#x2019;s current Good Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our investigational new drug, or IND, submissions or the conduct of these trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of RP5063 could be harmed, and our ability to generate revenues from RP5063 may be delayed. In addition, any delays in our clinical trials could increase our costs, slow down the approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Moreover, while we are not currently intending to engage any principal investigators as advisors or consultants, it is conceivable that principal investigators for our clinical trials may serve as scientific advisors or consultants from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The results of our clinical trials may not support our RP5063, RP1208 and any future product candidate claims.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even if our clinical trials are completed as planned, we cannot be certain that our results will support the safety and effectiveness of RP5063 for the treatment of schizophrenia or any other potential indication, including but not limited to PAH,&#xa0;IPF, BD, MDD, AD, PD, ADHD/ADD, or any of other product candidates, including RP1208. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. A failure of a clinical trial to meet its predetermined endpoints would likely cause us to abandon a product candidate and may delay development of any other product candidates. Any delay in, or termination of, our clinical trials will delay the submission of our NDAs with the FDA and, ultimately, our ability to commercialize RP5063, RP1208 or any future product candidate, and generate product revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside of our control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the study. Furthermore, any negative results we may report in clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop RP5063, RP1208 or any future product candidate, or could render further development impossible. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The continued spread of COVID-19 globally could adversely impact our clinical trial operations, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Disruptions or restrictions on the ability of patients enrolled in our clinical studies to travel, or the ability of staff at study sites to travel, as well as temporary closures of our facilities or the facilities of our clinical trials partners and their contract manufacturers, would negatively impact our clinical trial activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Drug development is highly competitive and subject to rapid and significant technological advancements. As a significant unmet medical need exists for the treatment of schizophrenia, there are several large and small pharmaceutical companies focused on delivering therapeutics for the treatment of schizophrenia. Further, it is likely that additional drugs will become available in the future for the treatment of schizophrenia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are aware of other companies that are working to develop drugs that would compete against RP5063 for schizophrenia treatment. Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drugs that are more effective or less costly than any product candidate that we may develop.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We will face competition from other drugs currently approved or that will be approved in the future for the treatment of schizophrenia. Therefore, our ability to compete successfully will depend largely on our ability to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">develop and commercialize medicines that are superior to other products in the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">demonstrate through our clinical trials that RP5063 is differentiated from existing and future therapies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">attract qualified scientific, product development and commercial personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtain patent or other proprietary protection for our medicines;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtain required regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtain coverage and adequate reimbursement from, and negotiate competitive pricing with, third- party payors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new medicines.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The availability of our competitors&#x2019; products could limit the demand, and the price we are able to charge, for any product candidate it develops. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make RP5063 less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval for or commercializing medicines before we do, which would have an adverse impact on our business and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are not able to obtain required regulatory approvals, we will not be able to commercialize RP5063, RP1208 or any other product candidates, and our ability to generate revenue will be materially impaired.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">RP5063 and the activities associated with its development and commercialization, including its design, research, testing, manufacture, safety, efficacy, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain marketing approval for RP5063 will prevent us from commercializing it.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have not received approval from regulatory authorities to market any product candidate in any jurisdiction, and it is possible that none of RP5063, RP1208 nor any other product candidates we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us to commence product sales.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Prior to submitting an NDA to the FDA, a marketing authorization application, or MAA, to the EMA, or an equivalent application to other foreign regulatory authorities for approval of RP5063, we will need to complete our Phase 3 RECOVER trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect to rely on third-party CROs and consultants to assist us in filing and supporting the applications necessary to gain marketing approvals. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish RP5063&#x2019;s safety and efficacy for that indication. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have been granted orphan drug designation in the United States for RP5063 for the treatment of IPF and PAH. Upon receipt of regulatory approval, orphan drug status will provide us with seven&#xa0;years of market exclusivity in the United States under the Orphan Drug Act. However, there is no guarantee that the FDA will grant orphan drug designation for any of our drug candidates for any future indication, which would make us ineligible for the additional exclusivity and other benefits of orphan drug designation. Moreover, there can be no assurance that another company also holding orphan drug designation for the same indication or which may receive orphan drug designation in the future will not receive approval prior to when we do, in which case our competitor would have the benefit of the seven&#xa0;years of market exclusivity, and we would be unable to commercialize our product candidate for the same indication until the expiration of such seven-year period. Even if we are the first to obtain approval for the orphan drug indication, there are circumstances under which a competing product may be approved for the same indication during our seven-year period of exclusivity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug available in the Unites States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation makes a company eligible for grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption from the FDA application user fee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market the same drug for the same indication for seven&#xa0;years, except in limited circumstances, such as (i)&#xa0;the drug&#x2019;s orphan designation is revoked; (ii)&#xa0;its marketing approval is withdrawn; (iii)&#xa0;the orphan exclusivity holder consents to the approval of another applicant&#x2019;s product; (iv)&#xa0;the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v)&#xa0;a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan drug designation for RP5063 for any additional indications or for RP1208, if we elect to seek such designation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>RP5063, RP1208 and any future product candidate may cause adverse effects or have other properties that could delay or prevent its regulatory approval or limit the scope of any approved label or market acceptance.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Adverse events caused by RP5063, RP1208 and any future product candidate could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events are reported in our clinical trials for RP5063, RP1208 or any future product candidates, our ability to obtain regulatory approval for such product candidates may be negatively impacted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Furthermore, if any of our product candidates are approved and then cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory authorities may withdraw their approval of the product or require a REMS to impose restrictions on its distribution or other risk management measures;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be required to change the way the product is administered or to conduct additional clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we could be sued and held liable for harm caused to patients;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we could elect to discontinue the sale of our products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our reputation may suffer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing RP5063, RP1208 and any future product candidate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The results of pre-clinical testing are not necessarily predictive of future results, and RP1208 may not have favorable results in our planned clinical trials.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any positive results from our pre-clinical testing of RP1208 may not necessarily be predictive of the results from our planned clinical trials. Many companies in the pharmaceutical industry have suffered significant setbacks in clinical trials after achieving positive results in pre-clinical development, and we cannot be certain that we will not face similar setbacks. The pre-clinical data we have obtained for RP1208 may not predict results from studies in larger numbers of subjects drawn from more diverse populations or in a commercial setting, and also may not predict the ability of RP1208 to achieve its intended goals, or to do so safely.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. If we fail to produce positive results in our clinical trials, the development timeline and regulatory approval and commercialization prospects for our products and, correspondingly, our business and financial prospects, would be materially adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if we obtain FDA approval for RP5063, RP1208 or any future product candidate in the United States, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if we obtain regulatory approval for RP5063, RP1208 or any future product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and current GCP requirements for any clinical trials that we conduct post-approval. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including any requirement to implement a REMS. If RP5063, RP1208 or any future product candidate receives marketing approval, the accompanying label may limit the approved use of our drug candidate, which could limit sales of the product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on manufacturing such products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on the labeling or marketing of a product;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on product distribution or use;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">requirements to conduct post-marketing studies or clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">warning letters;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">withdrawal of the products from the market;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal to approve pending applications or supplements to approved applications that we submit;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">recall of products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fines, restitution or disgorgement of profits or revenues;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">suspension or withdrawal of marketing approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal to permit the import or export of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product seizure; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">injunctions or the imposition of civil or criminal penalties.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA&#x2019;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of RP5063, RP1208 or any future product candidate. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if RP5063, RP1208 or any future product candidate receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If RP5063, RP1208 or any future product candidate receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues and become profitable. The degree of market acceptance of RP5063, RP1208 or any future product candidate, if approved for commercial sale, will depend on a number of factors, including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the efficacy and potential advantages compared to alternative treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">effectiveness of sales and marketing efforts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to offer our products for sale at competitive prices;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the convenience and ease of administration compared to alternative treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the strength of marketing and distribution support;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the availability of third-party coverage and adequate reimbursement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the prevalence and severity of any side effects; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any restrictions on the use of our product together with other medications.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because we expects sale of RP5063, RP1208 or any future product candidate, if approved, to generate substantially all of our product revenues for the foreseeable future, the failure of this product to find market acceptance would harm our business and require us to seek additional financing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third-parties, we may not be successful in commercializing RP5063, RP1208 or any future product candidate, if approved.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any product that may be approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. To achieve commercial success for any product for which we have obtained marketing approval, we will need a sales and marketing organization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect to build a focused sales, distribution and marketing infrastructure to market RP5063, RP1208 or any future product candidate in the United States, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of RP5063, RP1208 or any future product candidate. For example, if the commercial launch of RP5063, RP1208 or any future product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Factors that may inhibit our efforts to commercialize our products on our own include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the inability of sales personnel to obtain access to physicians or attain adequate numbers of physicians to prescribe any drugs; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of RP5063 in markets outside of the United States. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#x2019;s strategic interest in the product and such collaborator&#x2019;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of RP5063, RP1208 or any future product candidate, if approved, for markets outside of the United States; however, we cannot assure you that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of RP5063, RP1208 or any future product candidate we may be forced to delay the potential commercialization of RP5063, RP1208 or any future product candidate or reduce the scope of our sales or marketing activities for RP5063, RP1208 or any future product candidate. If we elect to increase our expenditures to fund commercialization activities itself, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring RP5063, RP1208 or any future product candidate to market or generate product revenue. We could enter into arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to RP5063, RP1208 or any future product candidate or otherwise agree to terms unfavorable to it, any of which may have an adverse effect on our business, operating results and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing RP5063, RP1208 or any future product candidate and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If RP5063, RP1208 or any future product candidate is approved for commercialization, we intend to enter into agreements with third parties to market it in certain jurisdictions outside the United States. We expect that it will be subject to additional risks related to international operations or entering into international business relationships, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">different regulatory requirements for drug approvals and rules&#xa0;governing drug commercialization in foreign countries;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reduced protection for intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">foreign reimbursement, pricing and insurance regimes;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">foreign taxes;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; ands</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our subsidiary may not be in compliance with the laws of foreign countries, and it may face penalties and fines imposed by the Indian government.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have not retained local counsel to assess whether our subsidiary, Reviva Pharmaceuticals India Private Limited, is in compliance with applicable local law. There can be no assurance that we will be able to initially meet such requirements or maintain compliance with the laws and regulations of each foreign country in which our subsidiary operates. As a result, we, Reviva Pharmaceuticals India Private Limited and our other subsidiary may be subject to adverse legal consequences, including but not limited to penalties and fines, which could adversely affect our business, financial condition or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are subject to U.S. foreign investment regulations, which may impose additional burdens on or may limit certain investors</i></b>&#x2019;<b><i> ability to purchase our common stock in amounts deemed by the U.S. government to confer control, potentially making our common stock less attractive to investors, and may also impact our ability to generate revenues outside of the U.S.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In 2018, Congress passed the Foreign Investment Risk Review Modernization Act of 2018 (&#x201c;FIRRMA&#x201d;), which expanded the jurisdiction of the Committee on Foreign Investment in the United States (&#x201c;CFIUS&#x201d;) to review direct or indirect foreign investments in U.S. companies. Among other things, FIRRMA empowers CFIUS to require certain foreign investors to make mandatory filings, permits CFIUS, to charge filing fees related to such filings, and empowers CFIUS to self-initiate national security reviews of foreign direct and indirect investments in U.S. companies. In the case that CFIUS determines an investment to be a threat to national security, CFIUS has the power to unwind or place restrictions on the investment. Any such restrictions on the ability to purchase shares of our common stock may have the effect of delaying or deterring any particular investment and could also affect the price that some investors are willing to pay for our common stock. In addition, such restrictions could also limit the opportunity for our stockholders to receive a premium for their shares of our common stock in relation to any potential change in control.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our current and future relationships with foreign actors such as, health care and administrative professionals at foreign state owned hospitals or foreign government healthcare regulators will be subject to applicable anti-corruption laws regulatory laws, which could expose us to penalties.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable anti-corruption and anti-bribery laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we market, sell and distribute our products. Such laws include the Foreign Corrupt Practices Act of 1977, as amended (the &#x201c;FCPA&#x201d;) prohibits any offer, payment, promise to pay or authorization to pay any money, gift or thing of value to any Foreign Official, political party, or candidate for office for the purpose of influencing any act or failure to act by the recipient, in his or her official capacity, in order to obtain or retain business, or inducing the recipient to use influence to affect a decision of a foreign government or agency in order to obtain or retain business for anyone. The FCPA also imposes recordkeeping requirements and internal controls provisions, which, among other things, require the issuer to keep accurate books, records, and accounts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our products for which we obtain marketing approval. Such laws include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#x201c;transfers of value&#x201d;&#xa0;made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other &#x201c;transfers of value&#x201d;&#xa0;to such physician owners (covered manufacturers are required to submit reports to the government by the 90th&#xa0;day of each calendar year); and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to it, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize RP5063, RP1208 or any future product candidate and affect the prices we may obtain.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system and efforts to control health care costs, including drug prices, that could have a significant negative impact on our business, including preventing, limiting or delaying regulatory approval of our drug candidates and reducing the sales and profits derived from our products once they are approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For example, in the United States, the Patient Protection and Affordable Care Act of 2010 (&#x201c;ACA&#x201d;) substantially changed the way health care is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. Many provisions of ACA impact the biopharmaceutical industry, including that in order for a biopharmaceutical product to receive federal reimbursement under the Medicare Part&#xa0;B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the drug pricing program under the Public Health Services Act, or PHS. Since its enactment, there have been judicial and Congressional challenges and amendments to certain aspects of ACA. There is continued uncertainty about the implementation of ACA, including the potential for further amendments to the ACA and legal challenges to or efforts to repeal the ACA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot be sure whether additional legislative changes will be enacted, or whether government regulations, guidance or interpretations will be changed, or what the impact of such changes would be on the marketing approvals, sales, pricing, or reimbursement of our drug candidates or products, if any, may be.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Coverage and adequate reimbursement may not be available for RP5063, RP1208 or any future product candidate, which could make it difficult for us to sell our products profitably.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Market acceptance and sales of any product candidates that we develop, will depend in part on the extent to which reimbursement for these products and related treatments will be available from third-party payors, including government health administration authorities and private health insurers. Third-party payors decide which drugs they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a plan-by-plan basis. One payer&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#x2019;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Each plan determines whether or not it will provide coverage for a drug, what amount it will pay the manufacturer for the drug, and on what tier of its formulary the drug will be placed. The position of a drug on a formulary generally determines the co-payment that a patient will need to make to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product candidates that we develop.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, there have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell any future drugs profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future drugs, following approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Dependence on Third Parties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of RP5063, RP1208 and any future product candidate.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not have experience in drug formulation or manufacturing and does not own or operate, and does not expect to own or operate, facilities for product manufacturing, storage and distribution, or testing. We also will rely on third-party manufacturers to supply us with sufficient quantities of RP5063 to be used, if approved, for the commercialization of RP5063. If we are unable to initiate or continue our relationship with one or more of these third-party contractors, we could experience delays in our development efforts as we locate and qualify new manufacturers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to meet our product specifications and quality requirements consistently;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delay or inability to procure or expand sufficient manufacturing capacity;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">manufacturing and product quality issues related to scale-up of manufacturing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">costs and validation of new equipment and facilities required for scale-up;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to comply with cGMP and similar foreign standards;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell RP5063, RP1208 or any future product candidate in a timely fashion, in sufficient quantities or under acceptable terms;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">carrier disruptions or increased costs that are beyond our control; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to deliver our products under specified storage conditions and in a timely manner.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our products. Some of these events could be the basis for FDA action, including injunction, recall, seizure, or total or partial suspension of production.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. We expect to control only certain aspects of our CROs&#x2019; activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We and our CROs will be required to comply with the Good Laboratory Practices and GCPs, which are regulations and guidelines enforced by the FDA and are also required by the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our CROs will be independent contractors and not our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If our relationship with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to RP5063, RP1208 and any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that cover RP5063, RP1208 or any future product candidate in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover RP5063, RP1208 or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents that we own could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If the patent applications we hold with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for RP5063, RP1208 or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future drugs. Any such outcome could have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#xa0;years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#xa0;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Moreover, we may be subject to a third party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse may in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering RP5063, RP1208 or any future product candidate. Our competitors might be able to enter the market, which would have an adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of RP5063, RP1208 and any future product candidate.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our commercial success depends in part on avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter party review, and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. Based on our general knowledge in this field of technology and based on the patent prosecution of RP5063 conducted in the United States and in foreign countries, we do not believe that there are valid patents which contain granted claims that could be asserted with respect to RP5063, however, we may be incorrect.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because patent applications can take many&#xa0;years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our future drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Competitors may infringe or otherwise violate our patents or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us, such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Grounds for a patent invalidity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of securities that may be issued by us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Filing, prosecuting and defending patents covering RP5063, RP1208 and any future product candidate throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where Revive does not have any issued patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because we expect to rely on third parties to manufacture RP5063, RP1208 and any future product candidates, and we expect to collaborate with third parties on the development of RP5063, RP1208 and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our officers, directors, and principal stockholders exercise significant control over our Company, and will control our company for the foreseeable future, including the outcome of matters requiring stockholder approval.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our officers, directors and principal stockholders who beneficially own more than 5% of our common stock, in the aggregate, beneficially own shares representing approximately 41.79% of our outstanding capital stock as of March 1, 2022. As a result, such entities and individuals have the ability, acting together, to control the election of our directors and the outcome of corporate actions requiring stockholder approval, such as: (i) a merger or a sale of our company, (ii) a sale of all or substantially all of our assets, and (iii) amendments to our certificate of incorporation and bylaws. This concentration of voting power and control could have a significant effect in delaying, deferring or preventing an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our stockholders with interests different from those entities and individuals. These individuals also have significant control over our business, policies and affairs as officers and directors of our company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>An active trading market for our common stock or warrants may not be sustained.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An active trading market for our common stock or warrants may not develop or continue or, if developed, may not be sustained The lack of an active market for our common stock or warrants may impair investors&#x2019; ability to sell their common stock or warrants at the time they wish to sell them or at a price that they consider reasonable, may reduce the fair market value of their shares of common stock or warrants and may impair our ability to raise capital to continue to fund operations by selling securities and may impair our ability to acquire additional intellectual property assets by using our securities as consideration</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>A sale of a substantial number of shares of our common stock or warrants in the public market could cause the market price of our common stock or warrants to drop significantly, even if our business is doing well.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The price of our common stock or warrants could decline as a result of sales of a large number of shares of our common stock or warrants or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, in the future, we may issue additional shares of common stock, warrants or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock or warrants to decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock or warrants, the price of our common stock or warrants could decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The trading market for our common stock and warrants relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline if one or more equity analysts downgrade our common stock or warrants or if analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The price of our common stock or warrants may be volatile, which could subject us to securities class action litigation and our stockholders could incur substantial losses.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The market price for our common stock or warrants may be volatile and subject to wide fluctuations in response to factors including the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated fluctuations in our quarterly or annual operating results;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated changes in our growth rate relative to our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">issuance of new or updated research or reports by securities analysts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our securities; additions or departures of key management or other personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">announcement or expectation of additional debt or equity financing efforts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sales of our securities by us, our insiders or our other stockholders; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">general economic, market or political conditions in the United States or elsewhere.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In particular, the market prices of pharmaceutical companies like ours have been highly volatile due to factors, including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any delay or failure to conduct a clinical trial for a company&#x2019;s product or to receive approval from the FDA and other regulatory agents;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developments or disputes concerning a company&#x2019;s intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">technological innovations of such companies or their competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in market valuations of similar companies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">announcements by such companies or their competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies, or patents;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">failure to complete significant transactions or collaborate with vendors in manufacturing a product; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">proposals for legislation that would place restrictions on the price of pharmaceutical products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">These and other market and industry factors may cause the market price and demand for our Common Stock and warrants to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their shares of Common Stock or warrants and may otherwise negatively affect the liquidity of our Common Stock or warrants. In addition, the stock market in general, and Nasdaq and emerging growth companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>If we fail to maintain compliance with the requirements of The Nasdaq Capital Market for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our common stock is listed for trading on The Nasdaq Capital Market. There can be no assurance that we will be able to continue to maintain compliance with the Nasdaq continued listing requirements, and if we are unable to maintain compliance with the continued listing requirements, including the $1.00 Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2), our securities may be delisted from Nasdaq, which could reduce the liquidity of our common stock materially and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and business development opportunities. Such a delisting likely would impair your ability to sell or purchase our common stock when you wish to do so. Further, if we were to be delisted from Nasdaq, our common stock may no longer be recognized as a &#x201c;covered security&#x201d; and we would be subject to regulation in each state in which we offer our securities. Thus, delisting from Nasdaq could adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly impact the ability of investors to trade our securities and would negatively impact the value and liquidity of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain of our warrants are accounted for as liabilities and the changes in value of such warrants could have a material effect on our financial results.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On April 12, 2021, the Staff of the Securities and Exchange Commission (&#x201c;SEC Staff&#x201d;) released the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (the &#x201c;Statement&#x201d;). In the Statement, SEC Staff made the observation that certain contractual provisions included in many Special Purpose Acquisition Company warrant agreements may result in such warrants needing to be classified as a liability rather than as equity. As a result of the SEC Statement, we reevaluated the accounting treatment of our Warrants, and determined to classify the Private Warrants as derivative liabilities measured at fair value, with changes in fair value each period reported in earnings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result, included on our restated consolidated balance sheet as of December 31, 2021 contained elsewhere in this Annual Report on Form 10-K, are derivative liabilities related to embedded features contained within our Private Warrants. Accounting Standards Codification 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;), provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value being recognized in earnings in the statement of operations. As a result of the recurring fair value measurement, our consolidated financial statements and results of operations may fluctuate quarterly, based on factors, which are outside of our control. Due to the recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our Private Warrants each reporting period and that the amount of such gains or losses could be material.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are an emerging growth company within the meaning of the Securities Act and have taken advantage of certain exemptions from disclosure requirements available to emerging growth companies; this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are an &#x201c;emerging growth company&#x201d; within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and have taken advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#xa0;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on certain executive compensation matters. As a result, our shareholders may not have access to certain information they may deem important. We may be an emerging growth company for up to five&#xa0;years from the IPO of Tenzing, although circumstances could cause the loss of that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700&#xa0;million as of the last business day in any August&#xa0;before that time, in which case we would no longer be an emerging growth company as of the end of that fiscal year. We cannot predict whether investors will find our securities less attractive because we rely on these exemptions. If some investors find the securities less attractive as a result of reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of the securities may be more volatile.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, Section&#xa0;102(b)(1)&#xa0;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period. Accordingly, when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will adopt the new or revised standard at the time private companies adopt the new or revised standard, unless early adoption is permitted by the standard, and we elect early adoption. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will incur significantly increased costs and devote substantial management time as a result of operating as a public company particularly after we are no longer an </i></b>&#x201c;<b><i>emerging growth company.</i></b>&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As a newly public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. For example, we are required to comply with certain of the requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as amended, as well as rules&#xa0;and regulations subsequently implemented by the SEC, including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. We expect that compliance with these requirements will increase our legal and financial compliance costs and will make some activities more time consuming and costly. In addition, we expect that our management and other personnel will need to divert attention from operational and other business matters to devote substantial time to these public company requirements. In particular, we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section&#xa0;404 of the Sarbanes-Oxley Act. In addition, after we no longer qualify as an emerging growth company, we expect to incur additional management time and cost to comply with the more stringent reporting requirements applicable to companies that are deemed accelerated filers or large accelerated filers, including complying with the auditor attestation requirements of Section&#xa0;404 of the Sarbanes-Oxley Act. We have not yet completed the process of compiling the system and processing documentation needed to comply with such requirements. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. In that regard, we currently do not have an internal audit function, and we will need to hire or contract for additional accounting and financial staff with appropriate public company experience and technical accounting knowledge.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, any gains from an investment in our common stock will likely depend on appreciation in the price of our common stock.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have never declared or paid cash dividends on our common stock and do not anticipate paying any cash dividends to holders of our common stock in the foreseeable future. Consequently, investors must rely on sales of their common stock and warrants after price appreciation, which may never occur, as the only way to realize any future gains on their investments. There is no guarantee that shares of our common stock or warrants will appreciate in value or even maintain the price at which the stockholders have purchased their shares or warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Upon our dissolution, the stockholders may not recoup all or any portion of their investment.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of our liquidation, dissolution or winding-up, whether voluntary or involuntary, the proceeds and/or assets of remaining after giving effect to such transaction, and the payment of all debts and liabilities and distributions required to be made to holders of any outstanding preferred stock will then be distributed to the stockholders of Common Stock on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of our Common Stock, or any amounts, upon such a liquidation, dissolution or winding-up.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our amended and restated certificate of incorporation allows for our board of directors to create new series of preferred stock without further approval by the stockholders, which could adversely affect the rights of the holders of our Common Stock.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to issue up to 10 million shares of preferred stock without further stockholder approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation and the right to receive dividend payments before dividends are distributed to the holders of our Common Stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater voting power than the Common Stock or that is convertible into our Common Stock, which could decrease the relative voting power of our Common Stock or result in dilution to existing stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Delaware law and our certificate of incorporation, as amended, and our bylaws contain certain provisions, including anti-takeover provisions that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our certificate of incorporation, as amended, and our bylaws, and the Delaware General Corporation Law, as amended (the &#x201c;DGCL&#x201d;), contain provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by our board of directors and therefore depress the trading price of our Common Stock. These provisions could also make it difficult for stockholders to take certain actions, including electing directors who are not nominated by the current members of our board of directors or taking other corporate actions, including effecting changes in management. Among other things, our certificate of incorporation, as amended, and our bylaws include provisions regarding:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability of our board of directors to issue shares of preferred stock, including &#x201c;blank check&#x201d;&#xa0;preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the limitation of the liability of, and the indemnification of, our directors and officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a prohibition on stockholder action by written consent (except as required for holders of future series of preferred stock), which forces stockholder action to be taken at an annual or special meeting of stockholders and could delay the ability of stockholders to force consideration of a stockholder proposal or to take action, including the removal of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the requirement that a special meeting of stockholders may be called only by our board of directors, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">controlling the procedures for the conduct and scheduling of our board of directors and stockholder meetings;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the requirement for the affirmative vote of holders of at least a majority of the voting power of all of the voting power of the then outstanding shares of the voting stock, voting as a single class, to amend, alter, change or repeal any provision of our bylaws and certain provisions in our certificate of incorporation, as amended, respectively, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our board of directors and also may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability of our board of directors to amend our bylaws by an affirmative vote of a majority of our board of directors, which may allow our board of directors to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend our bylaws to facilitate an unsolicited takeover attempt; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019;&#xa0;meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our board of directors and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of us.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our board of directors or management. In addition, as a Delaware corporation, we will generally be subject to provisions of Delaware law, including Section 203 of the DGCL.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any provision of our certificate of incorporation, as amended,, our bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our certificate of incorporation, as amended, designates a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders</i></b>&#x2019;<b><i> ability to choose the judicial forum for disputes with us or our directors, officers, or employees.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our certificate of incorporation, as amended, provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware, or if such court does not have subject matter jurisdiction, any other court located in the State of Delaware with subject matter jurisdiction, will be the sole and exclusive forum for (i)&#xa0;any derivative action or proceeding brought on the Company&#x2019;s behalf, (ii)&#xa0;any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of the Company to the Company or the Company&#x2019;s stockholders, (iii)&#xa0;any action asserting a claim against the Company or our officers or directors arising pursuant to any provision of the Delaware General Corporate Law or our certificate of incorporation, as amended, or our bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&#xa0;any action asserting a claim against the Company or any director or officer of the Company governed by the internal affairs doctrine of the law of the State of Delaware; provided, that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state court sitting in the State of Delaware. Additionally, our certificate of incorporation, as amended, provides that, unless the Company consents to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended; provided, however, that such provision will not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any person or entity purchasing or otherwise acquiring any interest in any of our securities will be deemed to have notice of and consented to these provisions. These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find these exclusive-forum provisions to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a1b" title="1b" href="#"></a>ITEM 1B.</b>&#xa0;&#xa0;<b> UNRESOLVED STAFF COMMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 30pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a2" title="2" href="#"></a>ITEM 2.</b>&#xa0;<b> </b>&#xa0;<b> PROPERTIES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our principal offices are located at 19925 Stevens Creek Blvd., Suite&#xa0;100, Cupertino, California 95014. The lease for this facility was renewed for twelve months beginning February 2022. The facility is used for office space only, and we believe the facility is adequate for our foreseeable needs. We operate primarily as a virtual company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a3" title="3" href="#"></a>ITEM 3.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>LEGAL PROCEEDINGS </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may from time to time, become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Except as described above, we are currently not aware of any such legal proceedings or claims that may be, individually or in the aggregate, material to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a4" title="4" href="#"></a>ITEM 4.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>MINE SAFETY DISCLOSURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 30pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     53
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PART</b>&#xa0;<b>II</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="a5" title="5" href="#"></a>ITEM 5.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>MARKET FOR REGISTRANT</b>&#x2019;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our common stock and warrants trade on Nasdaq under the symbols &#x201c;RVPH&#x201d; and &#x201c;RVPHW,&#x201d; respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December&#xa0;31, 2021, there were approximately 316 holders of record of our common stock and 2 holders of record of our Warrants. These numbers do not include beneficial owners whose shares or warrants were held in street name. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Unregistered Sales of Equity Securities</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On November&#xa0;30, 2021, we issued an aggregate of 11,000 shares of common stock to a&#xa0;consultant&#xa0;in consideration for services under a consulting agreement, valued at $39,930.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Securities Act Exemptions</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We deemed the offers, sales and issuances of the securities described above to be exempt from registration under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), in reliance on Section 4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, relative to transactions by an issuer not involving a public offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All certificates representing the securities issued in the transactions described above included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer of the securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="a6" title="6" href="#"></a>ITEM 6.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>[RESERVED]</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     54
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="a7" title="7" href="#"></a>ITEM 7.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>MANAGEMENT</b>&#x2019;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>As a result of the completion of the Business Combination, the financial statements of Old Reviva are now our financial statements. Prior to the Business Combination, we had no operating assets but, upon consummation of the Business Combination, the business and operating assets of Old Reviva acquired by us became our sole business and operating assets. Accordingly, the financial statements of Old Reviva and their respective subsidiaries as they existed prior to the Business Combination and reflecting our sole business and operating assets going forward, are now our financial statements.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>All statements other than statements of historical fact included in this section regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward- looking statements. When used in this section, words such as </i>&#x201c;<i>anticipate,</i>&#x201d;<i> </i>&#x201c;<i>believe,</i>&#x201d;<i> </i>&#x201c;<i>estimate,</i>&#x201d;<i> </i>&#x201c;<i>expect,</i>&#x201d;<i> </i>&#x201c;<i>intend</i>&#x201d;<i> and similar expressions, as they relate to our management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those contemplated by the forward- looking statements as a result of certain factors detailed herein. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Some of the information contained in this discussion and analysis or set forth elsewhere, including information with respect to our plans and strategy for our business include forward-looking statements that involve risks, uncertainties and assumptions. You should read the sections titled </i>&#x201c;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#x201d;<i> and </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We are a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burden to society, patients, and their families. Our current pipeline focuses on the central nervous system, respiratory, and metabolic diseases. We use a chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Our pipeline currently has two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. We have been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our lead drug candidate, RP5063, is ready for continued clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention&#x2013;deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer&#x2019;s disease (BPSD), and Parkinson&#x2019;s disease psychosis. Furthermore, RP5063 is also ready for clinical development for two respiratory indications&#x2009;&#x2014;&#x2009;pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to RP5063 for the treatment of PAH in November&#xa0;2016 and IPF in April&#xa0;2018.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">On January 10, 2022, the FDA notified us that we may proceed with our Phase 3 trial for RP5063. On February 1, 2022, we announced that the first patients have been dosed in our Phase 3 RECOVER trial to assess RP5063 for the treatment of subjects with an acute exacerbation of schizophrenia. RECOVER is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of RP5063 in approximately 400 patients with acute schizophrenia compared to placebo.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our primary focus is to complete the clinical development of RP5063 for the treatment of acute and maintenance schizophrenia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to the receipt of additional financing, we may also continue the clinical development of RP5063 for the treatment of BD, MDD, ADHD, BPSD, PDP, PAH and IPF. Moreover, subject to the receipt of additional financing, we may also advance the development of our second drug candidate, RP1208, for the treatment of depression and obesity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Impact of COVID-19</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In response to the spread of COVID-19, we have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees and community, including temporarily requiring employees to work remotely and suspending all non-essential travel for our employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As a result of the COVID-19 pandemic, we may experience disruptions that could adversely impact our business. The COVID-19 pandemic may negatively affect clinical site initiation, patient recruitment and enrollment, patient dosing, distribution of drug to clinical sites and clinical trial monitoring for our clinical trials. The COVID-19 pandemic may also negatively affect the operations of the third-party contract research organizations that we intend to rely upon to assist us in conducting our clinical trials and the contract manufacturers who manufacture our drug candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations. For additional information on the various risks posed by the COVID-19 pandemic, refer to Part I&#x2014;Item 1A&#x2014;Risk Factors of this Annual Report on Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Business Combination and Domestication</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On December&#xa0;14, 2020, our predecessor company, formerly known as Tenzing Acquisition Corp., a British Virgin Islands exempted company (&#x201c;Tenzing&#x201d;), and Reviva Pharmaceuticals,&#xa0;Inc., a Delaware corporation (together with its consolidated subsidiaries, &#x201c;Old Reviva&#x201d;), consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of July&#xa0;20, 2020 (as amended, the &#x201c;Merger Agreement&#x201d;), by and among Tenzing, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#x201c;Merger Sub&#x201d;), Old Reviva, and the other parties thereto. Pursuant to the Merger Agreement, Merger Sub merged with and into Old Reviva, with Old Reviva surviving as our wholly owned subsidiary. We refer to this transaction as the Business Combination. In connection with and one day prior to the completion of the Business Combination, Tenzing re-domiciled out of the British Virgin Islands and continued as a company incorporated in the State of Delaware, and changed its name to Reviva Pharmaceuticals Holdings,&#xa0;Inc. Prior to the completion of the Business Combination, the Company was a shell company. Following the Business Combination, the business of Old Reviva is the business of the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Old Reviva was incorporated in the state of Delaware on May&#xa0;1, 2006 and its subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., was incorporated on December&#xa0;23, 2014. Tenzing was formed pursuant to the laws of the British Virgin Islands on March&#xa0;20, 2018.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Business Combination was accounted for as a reverse merger in accordance with U.S. GAAP. Under this method of accounting, Tenzing was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on the holders of Old Reviva expecting to have a majority of the voting power of the post-combination company, Old Reviva senior management comprising substantially all of the senior management of the post-combination company, the relative size of Old Reviva compared to Tenzing, and Old Reviva operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Business Combination is treated as the equivalent of Old Reviva issuing stock for the net assets of Tenzing, accompanied by a recapitalization. The net assets of Tenzing were stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of Old Reviva.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a clinical-stage biopharmaceutical company and have not generated any revenues from the sale of products. We have never been profitable, and our accumulated deficit as of December 31, 2021 was $66.8&#xa0;million. Our net loss for the year ended December 31, 2021 was $8.5&#xa0;million. We expect to incur significant expenses and increased operating losses for the next several years. We expect our expenses to increase in connection with our ongoing activities to research, develop and commercialize our product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We expect our expenses will increase substantially in connection with our ongoing activities, as we:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">invest significantly to further research and develop, through clinical trials for RP5063 (brilaroxazine) and pre-clinical research for RP1208, and seek regulatory approval for our product candidates RP5063 (brilaroxazine) and RP1208;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.1%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">identify and develop additional product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">hire additional clinical, scientific and management personnel;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">seek regulatory and marketing approvals for any product candidates that we may develop;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">ultimately establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we may obtain marketing approval;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">maintain, expand and protect our intellectual property portfolio;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">acquire or in-license other drugs and technologies; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;&#xa0;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">add operational, financial and management information systems and personnel, including personnel to support our product candidate development, any future commercialization efforts and our transition to a public company.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have funded our operations to date primarily from the issuance and sale of our equity and convertible equity securities. As of December 31, 2021, we had cash and cash equivalents of approximately $29.7&#xa0;million. To fund our current operating plans, we will need to raise additional capital. Our existing cash and cash equivalents&#xa0;will not be sufficient for us to complete development of our product candidates and, if applicable, to prepare for commercializing any product candidate that may receive approval. Accordingly, we will continue to require substantial additional capital beyond our existing cash and cash equivalents to continue our clinical development and potential commercialization activities; however, we believe that our existing cash and cash equivalents, will be sufficient to fund our current operating plans through at least December 2022. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We focus our resources on research and development activities, including the conduct of preclinical and clinical studies and product development and expenses such costs as they are incurred. We have not historically tracked or recorded research and development expenses on a project-by-project basis, primarily because we use our employee and infrastructure resources across multiple research and development projects, and it is not practical for us to allocate such costs on a project-by-project basis. Our research and development expenses primarily consist of employee-related expenses, including deferred salaries, salaries, benefits and taxes for personnel in research and development functions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The largest recurring component of our total operating expenses has historically been research and development activities. we expect our research and development expenses will increase for the next several years as we advance our development programs, pursues regulatory approval of our product candidates in the U.S. and other jurisdictions and prepare for potential commercialization, which would require a significant investment in costs related to contract manufacturing, inventory buildup and sales and marketing activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our primary product candidates and their current status is as follows:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Drug Candidate</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px; vertical-align: top; width: 15.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Indication</span></b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Status</span></b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Schizophrenia</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Initiated pivotal phase 3 and long-term safety studies.&#xa0;Topline data for the pivotal phase 3 study is anticipated in mid-2023</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bipolar Disorder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Depression-MDD</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Alzheimer&#x2019;s (AD-Psychosis/Behavior)</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Parkinson&#x2019;s</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ADHD/ADD</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PAH</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP5063</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">IPF</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Phase 1 complete**</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP1208</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Depression</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Completed pre-clinical development studies, including in vitro receptor binding studies, animal efficacy studies, and PK studies. Compound ready for IND enabling studies.</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">RP1208</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.6%; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Obesity</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.1%; border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Completed pre-clinical development studies, including in vitro receptor binding studies and PK studies. Compound ready for animal efficacy studies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">**&#xa0;We completed the Phase 1 clinical study for RP5063 (brilaroxazine) prior starting the Phase 2 study in schizophrenia and schizoaffective disorder. We collected safety data for RP5063 (brilaroxazine) in over 200 patients, including healthy subjects and patients with stable schizophrenia, acute schizophrenia and schizoaffective disorder. Generally, no separate Phase 1 study is required for conducting a Phase 2 study for an additional indication, provided the treatment doses in the Phase 2 study for an additional indication are within the range of doses tested in the previously completed Phase 1 study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The successful development of our platform and product candidates is highly uncertain, and we may never succeed in achieving marketing approval for our product candidates RP5063 (brilaroxazine), RP1208, or any future product candidates. We estimate that initial costs to conduct our Phase 3 clinical study for RP5063 could total approximately $25.5&#xa0;million, with approximately $1.0 million having been paid over the course of calendar 2021, with approximately $12.0&#xa0;million payable during calendar 2022, approximately $8.0&#xa0;million payable during calendar 2023, and approximately $4.5&#xa0;million payable during calendar 2024. At this time, other than our estimates for conducting our Phase 3 clinical study for RP5063, we cannot reasonably estimate the nature, timing, or costs of the efforts necessary to finish developing any of our product candidates or the period in which material net cash, if any, from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing therapeutics, including the uncertainty of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the scope, rate of progress, expense, and results of clinical trials;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the scope, rate of progress, and expense of process development and manufacturing;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">preclinical and other research activities; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:175.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.4%;">&#xa0;</td>
     <td style="vertical-align:top;width:4.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:175.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the timing of regulatory approvals.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">General and administrative expenses primarily consist of payroll and related costs for employees in executive, business development, finance, and administrative functions. Other significant general and administrative expenses include professional fees for accounting and legal services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect general and administrative expenses to increase as we expand infrastructure and continue the development of our clinical programs. Other increases could potentially include increased costs for director and officer liability insurance, costs related to the hiring of additional full-time personnel, and increased fees for directors, outside consultants, lawyers, and accountants. We expect to incur significant costs to comply with corporate governance, internal controls, and similar requirements applicable to public companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Interest Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the year ended December 31, 2020, interest expense consisted primarily of interest associated with our promissory notes and beneficial conversion feature recognized on conversion of promissory notes. The Company incurred no interest expense during the year ended December&#xa0;31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest Income and Other Income</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest income and other, net consists largely of interest earned on our cash&#xa0;&amp; cash equivalents and gain recorded on issuance of common stock in lieu of salaries.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Policies and Use of Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the period. Significant items subject to such estimates and assumptions include stock-based compensation, beneficial conversion features, warrant values, and deferred taxes and related valuation allowances. Our actual results could differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our significant accounting policies are more fully described in Note 2 to the consolidated financial statements included in Item 8 of this Annual Report on Form 10-K, we believe that the following accounting policies are the most critical to assist stockholders and investors reading the consolidated financial statements in fully understanding and evaluating our financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Research and development costs</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Income taxes</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We utilize FASB ASC 740, &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is &#x201c;more likely-than-not&#x201d; that a deferred tax asset will not be realized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We account for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In evaluating the ability recover its deferred income tax assets, we considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. We generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of our realization of the net operating loss carry forward prior to its expiration.&#xa0; In the event we determine that we would be able to realize our&#xa0;deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes.&#xa0; Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value Measurements of Warrants</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">ASC 820 &#x201c;Fair Value Measurements&#x201d; defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1)&#xa0;market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2)&#xa0;an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#xa0;1) and the lowest priority to unobservable inputs (Level&#xa0;3).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The three levels of the fair value hierarchy under ASC 820 are described below:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:6.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 1&#x2009;&#x2014;&#x2009;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:6.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 2&#x2009;&#x2014;&#x2009;Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:6.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 3&#x2009;&#x2014;&#x2009;Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In determining the fair value of warrants, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Beneficial Conversion Features</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In accordance with FASB ASC 470-20, &#x201c;Debt with Conversion and Other Options&#x201d; we record a beneficial conversion feature (&#x201c;BCF&#x201d;) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Comparison of the years ended December 31, 2021 and 2020:</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table summarizes our results of operation for the years ended December 31, 2021 and 2020:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;$</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,851,602</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">295,150</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,556,452</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,544</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">5,252,911</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,139,501</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,113,410</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">146</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,104,513</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,434,651</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Gain on remeasurement of warrant liabilities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,591,055</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,591,055</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">100</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Interest and other income (expense), net</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,414</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">105,183</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(107,597</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(102</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Interest expense</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,453,120</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,453,120</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(100</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total other income (expense), net</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,588,641</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,347,937</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss</b></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(8,521,876</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(3,783,388</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research</i>&#xa0;<i>and Development Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We incurred approximately $4.9&#xa0;million&#xa0;and $0.3&#xa0;million in research and development expenses for the years ended December 31, 2021 and 2020, respectively. The primary reason for the&#xa0;increase of $4.6&#xa0;million, or 1544%, was due to the acceleration of research and development activities ahead of clinical trials, higher drug development costs, salary expenditures and increased consulting costs. Our research and development expenses are expected to increase for the foreseeable future as we continue to advance our platform and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">For the years ended December 31, 2021 and 2020, we incurred approximately $5.3&#xa0;million&#xa0;and $2.1 million in general and administrative expenses. The increase of $3.1&#xa0;million, or 146%, was primarily attributable to $1.8&#xa0;million related to an increase in consulting expenses in connection with&#xa0;legal and accounting activities, an increase of insurance costs by $1.2&#xa0;million as a result of an increase in premiums as the Company is now a public company, and a $0.9&#xa0;million increase in salary and related expenses for new personnel, offset by a decrease of approximately $1.1&#xa0;million in warrant expense due to the recognition of expense upon warrant issuance during the year ended December&#xa0;31, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Interest expense for the years ended December 31, 2021 and 2020 was approximately $0 and $1.5&#xa0;million, respectively. The decrease of $1.5&#xa0;million, or 100%, in interest expense was due to the investor notes issued in 2020 and a beneficial conversion feature recognized on conversion of notes payable immediately prior to the Business Combination.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest</i>&#xa0;<i>and Other Income (Expense), Net</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Interest and other income (expense), net for the year ended December&#xa0;31, 2021 consisted of approximately $6,000 in foreign currency translation-related expense offset by approximately $4,000 of interest earned on our cash and cash equivalents. Interest and other income (expense), net for the year ended December&#xa0;31, 2020 consisted of interest earned on our cash&#xa0;and cash equivalents and other income of $25,000 recognized in the year ended December 31, 2020, related to a non-refundable transaction payment made by Tenzing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December 31, 2021, we had cash and cash equivalents of approximately $29.7&#xa0;million. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue our research and preclinical and clinical development of our product candidates; expand the scope of our current studies for our product candidates; initiate additional preclinical, clinical or other studies for our product candidates; change or add additional manufacturers or suppliers; seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical studies; seek to identify, evaluate and validate additional product candidates; acquire or in-license other product candidates and technologies; maintain, protect and expand our intellectual property portfolio; attract and retain skilled personnel; and experience any delays or encounter issues with any of the above.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On June 1, 2021, we completed a public offering (the &#x201c;Offering&#x201d;) of Units (each, a &#x201c;Unit&#x201d;), with each Unit consisting of (a) one share of common stock (or pre-funded warrant to purchase one share of common stock in lieu thereof, with an exercise price of $0.0001 per share, each a &#x201c;Pre-Funded Warrant&#x201d;) and (b) one warrant to purchase 0.75 of a share of our common stock, with an exercise price of $4.125 per share (each, an &#x201c;Investor Warrant&#x201d;). Pursuant to the Offering, we sold 4,133,400 Units consisting of (a) one share of common stock and (b) one Investor Warrant (inclusive the underwriter&#x2019;s overallotment option of 1,200,000 of such Units), and 5,066,600 Units consisting of (a) one Pre-Funded Warrant and (b) one Investor Warrant. The Units had no stand-alone rights and were not certificated or issued as stand-alone securities. Accordingly, as result of the sale of such Units in the Offering, we issued in aggregate 4,133,400 shares of common stock, Pre-Funded Warrants exercisable for 5,066,600 shares of common stock, and Investor Warrants exercisable for 6,900,000 shares of common stock. The offering price was $3.75 for each Unit consisting of (a) one share of common stock and (b) one Investor Warrant, and $3.7499 for each Unit consisting of (a) one Pre-Funded Warrant and (b) one Investor Warrant. Net proceeds from the Offering were approximately $31.5&#xa0;million, after underwriter discounts, commissions, legal and accounting fees, and certain other costs of approximately $3.0&#xa0;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In January 2022, we entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp; Co., LLC, as sales agent (&#x201c;Wainwright&#x201d;), pursuant to which we may offer and sell, from time to time through Wainwright, shares of our common stock for aggregate gross proceeds of up to $12.9 million (the &#x201c;Shares&#x201d;). To date, we have not made any sales pursuant to the ATM Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Until such time as we can generate substantial product revenue, if ever, we will need to raise additional capital to fund our operations, including our clinical trials, and expect to finance our cash needs through a combination of equity or debt financings and collaboration agreements. We do not currently have any committed external sources of capital.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we raise additional funds through collaboration agreements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below sets forth selected cash flow data for the periods presented:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;$</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by (used in)</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(10,668,462</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(4,066,624</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,601,838</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">162</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">31,595,944</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">12,826,893</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,769,051</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">146</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">20,927,482</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">8,760,269</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net Cash Used in Operating Activities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in operating activities for the year ended December&#xa0;31, 2021 was $10.7&#xa0;million, consisting primarily of a net loss of $8.5&#xa0;million and change in our operating assets and liabilities totaling $0.7&#xa0;million, offset by non-cash charges of $1.4&#xa0;million. Non-cash charges largely related to change in fair value of warrant liability of $1.6&#xa0;million, issuance of common stock in exchange for services of $40,000 and stock-based compensation expense of $0.1&#xa0;million. The increase in net operating assets was primarily due to increases in prepaid expenses and other current assets and accrued expenses and other current liabilities, offset by a decrease in accounts payable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in operating activities for the year ended December&#xa0;31, 2020 was $4.1&#xa0;million, consisting primarily of a net loss of $3.8&#xa0;million and changes in our operating assets and liabilities totaling $2.3&#xa0;million, offset by non-cash charges of $2.0&#xa0;million. Non-cash charges largely related to change in fair value of warrant liability of $1.1 million and noncash interest expense related to beneficial conversion feature of $1.0&#xa0;million. The increase in net operating assets was primarily due to&#xa0;decreases in the deferred costs and accrued expenses and other current liabilities, offset by increases in accounts payable and accrued interest.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net Cash Provided by Financing Activities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash provided by financing activities in the year ended December 31, 2021 of $31.6&#xa0;million primarily related to proceeds of $31.5&#xa0;million related to proceeds from the Offering and $0.1&#xa0;million from the issuance of stock upon the exercise of warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash provided by financing activities in the year ended December 31, 2020 of $12.8&#xa0;million primarily related to proceeds of $9.4 million from the Business Combination, $3.1 million from the issuance of convertible promissory notes, and the issuance of common stock in lieu of deferred compensation of $0.3&#xa0;million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We did not have during the periods presented, and do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>JOBS Act Accounting Election</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As an emerging growth company under the JOBS Act, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We have elected not to opt out of such extended transition period. Accordingly, when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will adopt the new or revised standard at the time private companies adopt the new or revised standard, unless early adoption is permitted by the standard, and we elect early adoption. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a7a" title="7a" href="#"></a>ITEM 7A.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 42pt; text-indent: 0pt;">Not Applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a8" title="8" href="#"></a>ITEM 8.</b>&#xa0;&#xa0;<b> </b>&#xa0;<b> FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The information required by this item appears in a separate section of this Annual Report on Form&#xa0;10-K beginning on page F-1 and is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a9" title="9" href="#"></a>ITEM 9.</b>&#xa0;&#xa0;<b> </b>&#xa0;<b> CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Prior to the Business Combination, Tenzing&#x2019;s consolidated financial statements were audited by Marcum LLP. For accounting purposes, the Business Combination is treated as a reverse acquisition and, as such, the historical financial statements of the accounting acquirer, Reviva, which have been audited by Armanino LLP (&#x201c;Armanino&#x201d;) became the historical consolidated financial statements of the Company. In a reverse acquisition, a change of accountants is presumed to have occurred unless the same accountant audited the pre-transaction financial statements of both the legal acquirer and the accounting acquirer, and such change is generally presumed to occur on the date the reverse acquisition is completed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On December 17, 2020, our audit committee elected to continue to engage Marcum LLP (&#x201c;Marcum&#x201d;), an independent registered accounting firm, as our independent registered public accounting firm to review our condensed consolidated financial statements for the three and nine month period ended November 30, 2020, and, following Marcum&#x2019;s review of our condensed consolidated financial statements for the three and nine month period ended November 30, 2020, we decided to terminate Marcum&#x2019;s engagement and appoint Armanino, as the independent registered public accounting firm engaged to audit our consolidated financial statements for the year ended December 31, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Marcum has since completed its review of our condensed consolidated financial statements for the three and nine month period ended November 30, 2020, and we terminated our relationship with Marcum effective January 15, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The reports of Marcum on our financial statements for the fiscal year ended February 29, 2020 and for the period from March 20, 2018 (inception) through February 28, 2019, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles except that, the reports on the financial statements as of and for the year ended February 29, 2020 and for the period from March 20, 2018 (inception) through February 28, 2019, each contained a separate explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">During the fiscal year ended February 29, 2020 and for the period from March 20, 2018 (inception) through February 28, 2019, and the subsequent interim period through November 30, 2020, there have been no &#x201c;disagreements&#x201d; (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference thereto in their reports on the financial statements for such fiscal years.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">During the fiscal year ended February 29, 2020 and for the period from March 20, 2018 (inception) through February 28, 2019, and any subsequent interim period through November 30, 2020, there have been no &#x201c;reportable events&#x201d; (as defined in Item 304(a)(1)(v) of Regulation S-K).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have provided Marcum with a copy of this disclosure made in response to Item 304(a) of Regulation S-K and requested that Marcum furnish us with a copy of its letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether Marcum agrees with the statements made by us in response to Item 304(a) of Regulation S-K. A copy of Marcum&#x2019;s letter to the SEC dated January 20, 2021, is filed as Exhibit 16.1 hereto.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a9a" title="9a" href="#"></a>ITEM 9A.</b>&#xa0;&#xa0;<b> CONTROLS AND PROCEDURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules&#xa0;and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules&#xa0;and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As required by Rule&#xa0;13a-15(b)&#xa0;under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#xa0;13a-15(e)&#xa0;and 15d-15(e)&#xa0;under the Exchange Act) as of December&#xa0;31, 2021. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of December&#xa0;31, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Management</b>&#x2019;<b>s Annual Report on Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule&#xa0;13a-15(f)&#xa0;of the Exchange Act. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <i>Internal Control</i>&#x2014;<i>Integrated Framework</i> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the results of this evaluation, management has concluded that the Company&#x2019;s internal control over financial reporting was effective at the reasonable assurance level as of December&#xa0;31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">This Annual Report on Form&#xa0;10-K does not include an attestation report of our registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d; In addition, we are currently a non-accelerated filer and are therefore not required to provide an attestation report on our internal control over financial reporting until such time as we are an accelerated filer or large accelerated filer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Remediation of Material Weakness in Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As of December 31, 2021, we have remediated the previously reported material weakness in our internal control over financial reporting related to the operation of internal controls related to the accounting for certain non-routine transactions and related disclosures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In connection with the audit of our annual 2020 consolidated financial statements, we identified a material weakness in our internal control over the accounting for certain complex non-routine transactions and related disclosures which resulted in (i) errors in accrued consulting expenses, (ii) improperly recorded interest expense related to the beneficial conversion feature triggered upon the conversion of certain notes into common stock and incorrect calculations of the related beneficial conversion feature and (iii) errors in recording gain for common stock issued in lieu of salary. A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected and corrected on a timely basis. The 2020 material weakness did not result in any identified misstatements to the 2020 financial statements, and there were no changes to previously released financial results. In light of the material weakness, we performed additional analyses and other post-closing procedures to ensure our 2021 consolidated financial statements are prepared in accordance with U.S. GAAP. Accordingly, our CEO and CFO have certified that, based on their knowledge, the consolidated financial statements, and other financial information included in this Form 10-K, fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented in this Annual Report on Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We began remediation efforts in 2021 for our accounting of non-routine complex transactions controls by (a) implementing changes to our internal control over financial reporting to remediate the control deficiencies that gave rise to the material weakness, including further improvements in processes and analyses that support the accounting for complex non-routine transactions and related disclosures in a timely manner, (b) engaging a new third-party technical accounting specialist with technical accounting expertise to review complex non-routine transactions on a prospective basis, and (c) hiring experienced additional accounting and financial reporting personnel. The initiatives we implemented to remediate the material weakness were subject to continued management review as well as audit committee oversight. The material weakness was not considered remediated until our remediation efforts had been fully implemented and we had concluded that these controls are operating effectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We believe these measures remediated the material weakness in internal control over financial reporting described above. The related modified and new controls are adequately designed and have operated for a sufficient period of time; therefore, management has concluded, through testing, that such controls are operating effectively at the reasonable assurance level at December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Changes in Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Other than the changes to remediate the 2020&#xa0;material weakness noted above, there were no changes in our internal controls over financial reporting identified in management&#x2019;s evaluation pursuant to Rules&#xa0;13a-15(d)&#xa0;and 15d-15(d)&#xa0;of the Exchange Act that occurred during the year ended December 31, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Inherent Limitations on Effectiveness of Controls</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our&#xa0;management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a9b" title="9b" href="#"></a>ITEM 9B.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>OTHER INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a9c" title="9c" href="#"></a>ITEM 9C.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     64
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PART</b>&#xa0;<b>III</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a10" title="10" href="#"></a>ITEM 10.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The following sets forth certain information with respect to our officers and directors.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 19.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p> </td>
     <td style="vertical-align:bottom;width:auto;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b></p> </td>
     <td style="vertical-align:bottom;width:auto;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 19.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laxminarayan Bhat</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">56</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President Chief Executive Officer, Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Marc Cantillon, MD</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">63</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Medical Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Narayan Prabhu</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">50</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Parag Saxena</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">66</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Richard Margolin</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">71</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Purav Patel</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">39</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Les Funtleyder</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">52</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Management</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Laxminarayan Bhat</i></b> - see description below under the heading &#x201c;Directors.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Marc Cantillon</i></b> has served as Chief Medical Officer of Reviva Pharmaceuticals,&#xa0;Inc. since 2013, and previously served as Consulting Medical Director of Reviva from 2008 to 2013. Dr.&#xa0;Bhat became the Company&#x2019;s Chief Medical Officer in December&#xa0;2020. From 1995 to 1997, Dr.&#xa0;Cantillon served as Sr.&#xa0;Director at AstraZeneca plc, (NYSE: AZN), a public company engaged in the biopharmaceuticals business. From 1997 to 1999, he served as US Lead at Sanofi- Aventis S.A. (Nasdaq: SNY), also a publicly-traded biopharmaceuticals company. From 2000 to 2002, he served as Global CNS Lead Medical Affairs at Wyeth/Pfizer (NYSE: PFE), another publicly-traded biopharmaceuticals company, and, from 2006 to 2010, served as AVP at Schering-Plough/Merck Sharp&#xa0;&amp; Dohme Corp., now Merck&#xa0;&amp; Co.,&#xa0;Inc. (NYSE: MRK), another public company engaged in the biopharmaceuticals business. Dr.&#xa0;Cantillon has over 25&#xa0;years of experience in translational Proof-of-Mechanism (POM), Proof-of-Concept (POC) and Phases 1 through IV trials and development in multiple therapeutics areas. Dr.&#xa0;Cantillon earned his MD from the Karolinska Institute of Medicine. He is board certified by the American Board of Neurology and Psychiatry.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Narayan Prabhu</i></b> joined the Company as Chief Financial Officer in December&#xa0;2020. Since May&#xa0;2019, Mr.&#xa0;Prabhu served as an independent consultant providing Interim Chief Financial Officer and Controller services. Mr.&#xa0;Prabhu previously served as the Chief Financial Officer of Sony Biotechnology Inc., a biotechnology company focused on reagents, flow cytometry and spectral imaging from November&#xa0;2014 to April&#xa0;2019. From September&#xa0;2009 to October&#xa0;2014, Mr.&#xa0;Prabhu served as the M&amp;A Controller at Cisco Systems,&#xa0;Inc. (Nasdaq: CSCO). Mr.&#xa0;Prabhu is a CPA and received his B.S. in Accounting&#xa0;&amp; Finance from Indiana University at Bloomington&#x2009;-&#x2009;Kelley School of Business and MBA from the University of California at Berkeley&#x2009;-&#x2009;Haas School of Business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Directors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Laxminarayan Bhat</i></b> is the founder of our company and has served as our President, Chief Executive Officer and Director since inception of Reviva in 2006. From 2000 to 2004, Dr. Bhat served as research scientist at XenoPort, Inc., now a part of Arbor Pharmaceuticals, LLC (NYSE: ABR), a public company engaged in the pharmaceuticals business. Dr. Bhat also served as a research scientist, from 2004 to 2006, at ARYx Therapeutics Inc, (previously trading under OTCM: ARYX), a former public company that focused on the development of pharmaceutical products. From 1997 to 2000, Dr. Bhat served as a post-doctoral researcher in the Drug Discovery Program at the Higuchi Biosciences Center, a biomedical research center at the University of Kansas. Dr. Bhat has over 20 years&#x2019; experience in drug discovery and development. Dr. Bhat has received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universit&#xe4;t, G&#xf6;ttingen, Germany and the Universit&#xe9; du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship, an internationally recognized award for young scientists to pursue advanced research in Germany. Dr. Bhat received his Ph.D. in synthetic organic chemistry from the Central University (NEHU), India.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe Dr.&#xa0;Bhat&#x2019;s history as the founder of Reviva and his experience in drug discovery and development qualifies him to serve on our board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Les </i></b>&#xa0;<b><i>Funtleyder</i></b> has served as a member of our Board of Directors since December 2020. Mr. Funtleyder has served as a member of the board of directors of Applied Therapeutics Inc. (NASDAQ: APLT), a clinical-stage biopharmaceutical company, since June 2016 and served as its interim Chief Financial Officer from December 2018 to April 2019. Mr. Funtleyder has also served as a healthcare portfolio manager at E Squared Capital Management, LLC since January 2014, a senior external advisor with McKinsey and Co. since June 2017, and a consulting partner at Bluecloud Health, a private equity healthcare fund, since December 2013. Mr. Funtleyder previously served as the director of strategic investments and communications of OPKO Health Inc. (NASDAQ: OPK), a publicly traded healthcare company, from April 2014 to June 2016. Mr. Funtleyder currently serves on the board of directors of several private healthcare companies and foundations. Mr. Funtleyder is also an adjunct professor of Healthcare Investing at Columbia University&#x2019;s School of Public Health. Mr. Funtleyder received his B.A. from Tulane University and MPH from Columbia University Mailman School of Public Health.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe Mr.&#xa0;Funtleyder&#x2019;s extensive experience managing and investing in the healthcare industry and his experience serving as the CFO of another publicly-traded pharmaceutical company qualifies him to serve on our board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Richard </i></b>&#xa0;<b><i>Margolin</i></b> has served as a member of our Board of Directors since December 2020. Since February 2020, Dr. Margolin has served as Senior Vice President, Translational Sciences and Clinical Development at TauC3 Biologics Ltd., a privately held British biopharmaceutical company. Dr. Margolin also currently serves as the Chief Medical Officer of Eikonizo Therapeutics, Inc., a biotechnology company since January 2020, and he is the Founder and Principal Consultant of CNS Research Solutions LLC, a consulting firm supporting the development of novel therapeutics for CNS disorders since May 2018. From December 2016 to April 2018, Dr. Margolin served as Executive Director, Internal Medicine Research Unit at Pfizer, Inc. (NYSE: PFE), a publicly-traded pharmaceutical company. From November 2013 to December 2016, Dr. Margolin served as the Vice President, Clinical Development at CereSpir, Inc., a biotechnology company. Previously, he held positions in two major pharmaceutical companies, and earlier in his career he held leadership positions in psychiatry departments of two major U.S. medical schools. Dr. Margolin earned his AB from Harvard College and his MD from the University of California, Irvine and received research training at the National Institutes of Health.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe Dr.&#xa0;Margolin&#x2019;s 30&#xa0;years of experience in pharmaceutical research and development qualifies him to serve on our board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Purav Patel</i></b> has served as a member of our Board of Directors since May 2017. Mr. Patel has also been Founder and Managing Partner of Buena Vista Fund I, a company engaged in the business of startup investments since 2014. Mr. Patel has over 14 years of experience in business operations and scaling startups. Mr. Patel serves on the Board of Pratham, a charitable organization with the mission to vastly improve the quality of education for underprivileged children and youth across India. Mr. Patel holds a Bachelor&#x2019;s Degree in Biology and Business from the University of Texas. Mr. Patel is skilled at financial analysis, business operations and fundraising.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe Mr.&#xa0;Patel&#x2019;s 12&#xa0;years of knowledge of Reviva&#x2019;s history, team, investors and product candidates qualifies him to serve on our board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Parag Saxena</i></b> served as Chairman of the board of directors of Tenzing since 2018, and continues to serve as Charmian of our board of directors. Mr. Saxena has extensive investment experience in the U.S. and in the Indian subcontinent. Mr. Saxena co-founded Vedanta Management LP (or Vedanta) and NSR Advisors in 2006, private equity investment management firms, which currently collectively manage over $1 billion in assets. He is the Managing Partner and Chief Executive Officer of both firms. Previously, he was Chief Executive Officer of INVESCO Private Capital (and its predecessor firms), a venture capital firm in the U.S. During his 23-year tenure, over 300 investments were made, including Amgen, Costco, PictureTel, Polycom, Staples and Starbucks. Mr. Saxena led more than 90 investments for INVESCO Private Capital (and its predecessor firms), a third of which went on to become public companies. These investments include Alkermes, Celgene, Genomic Health, Indigo, Masimo, Transgenomic, Xenon Pharmaceuticals, Amber Networks, ARM Holdings, MetroPCS, and Volterra. Mr. Saxena has served on committees advising the Prime Minister of India on foreign direct investments, and the Planning Commission of India on venture capital. He was also a Director of the Indian Institute of Technology, Bombay&#x2019;s Heritage Fund as well as a Trustee of the Bharatiya Vidya Bhavan. He is on the Advisory Board of the Center for Advanced Studies on India at the University of Pennsylvania and is on the Indian Advisory Council of Brown University. Mr. Saxena was the President of TiE Tri-State (NY, CT, NJ) from 2003 to 2010. He was also on Mayor Bloomberg&#x2019;s Applied Sciences NYC Advisory Committee. Mr. Saxena received an M.B.A. from the Wharton School of the University of Pennsylvania. He earned a B.Tech. from the Indian Institute of Technology, Bombay and an M.S. in Chemical Engineering from the West Virginia College of Graduate Studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe Mr.&#xa0;Saxena&#x2019;s deep financial, entrepreneurial and business expertise and extensive experience as a member of the boards and board committees of other public companies qualifies him to serve on our board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Committees of the Board of Directors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has an audit committee, compensation committee and nominating and corporate governance committee. All of the committees comply with all applicable requirements of the Sarbanes-Oxley Act, Nasdaq and SEC rules&#xa0;and regulations as further described below. The responsibilities of each of the committees of our board of directors is described below. Members will serve on these committees until their resignation or until as otherwise determined by the our board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Audit Committee</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The members of our audit committee are Mr.&#xa0;Funtleyder, Mr.&#xa0;Patel and Mr.&#xa0;Margolin, and Mr.&#xa0;Funtleyder serves as the chairperson of the audit committee. Each of the members of our audit committee satisfies the requirements for independence and financial literacy under the applicable rules&#xa0;and regulations of the SEC and rules&#xa0;of Nasdaq. We have determined that Mr.&#xa0;Funtleyder qualifies as an &#x201c;audit committee financial expert&#x201d; as defined in the SEC rules&#xa0;and satisfies the financial sophistication requirements of Nasdaq. Our audit committee is responsible for, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">appointing (and recommending that our board of directors submit for stockholder ratification, if applicable) compensate, retain and oversee the work performed by the independent auditor retained for the purpose of preparing or issuing an audit report or performing other audit or audit-related services;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reviewing the performance and independence of the independent auditor;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">pre-approving all audit, review, and non-audit services (including any internal control-related services) to be provided to us or its subsidiaries by the independent auditor;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">discussing the scope and results of the audit with the independent registered public accounting firm and reviewing, with management and the independent registered public accounting firm, our interim and year-end financial statements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reviewing our policies on and oversees risk assessment and risk management, including enterprise risk management; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reviewing the adequacy and effectiveness of internal control policies and procedures and our disclosure controls and procedures.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has adopted a written charter for the audit committee which is available on our website.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Compensation Committee</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The members of our compensation committee are Mr.&#xa0;Patel, Mr.&#xa0;Margolin and Mr.&#xa0;Saxena, and Mr.&#xa0;Patel serves as the chairperson of the compensation committee. Each of the members of our compensation committee meets the requirements for independence under the under the applicable rules&#xa0;and regulations of the SEC and rules&#xa0;of Nasdaq. Our compensation committee is responsible for, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing and reviewing compensation policies and practices applicable to executive officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">determining bases for and fixing compensation levels executive officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reviewing, approving and determining compensation and benefits, including equity awards, to directors for service on our board of directors or any committee thereof; supervising, administering and evaluating incentive, equity-based and our other compensatory plans in which executive officers and key employees participate; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reviewing, approving and making recommendations to our board of directors regarding incentive compensation and equity compensation plans.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has adopted a written charter for the compensation committee which is available on our website.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Nominating and Corporate Governance Committee</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The members of our nominating and corporate governance committee are Mr. Saxena (chair), Mr.&#xa0;Funtleyder and Mr.&#xa0;Patel, and Mr.&#xa0;Saxena serves as the chairperson of the nominating and corporate governance committee. Each of the members of the nominating and corporate governance committee meets the requirements for independence under the applicable rules&#xa0;and regulations of the SEC and rules&#xa0;of Nasdaq. Our nominating and corporate governance committee is responsible for, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">making recommendations to our board of directors regarding, the size of our board of directors, the composition of our board of directors, the process for filling vacancies on our board of directors and the tenure of our board of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">making recommendations to our board of directors regarding the criteria for our board of directors and committee membership;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">developing, reviewing and overseeing our corporate governance practices and procedures; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">making recommendations to our board of directors regarding corporate governance guidelines and matters.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has adopted a written charter for the nominating and corporate governance committee which is available on our website.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors undertook a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that Mr.&#xa0;Saxena, Mr.&#xa0;Funtleyder, Dr.&#xa0;Margolin, and Mr.&#xa0;Patel do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#x201c;independent&#x201d; as that term is defined under the Rules&#xa0;of the Nasdaq Market and the SEC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Code of Business Conduct and Ethics</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have adopted a written code of business conduct and ethics that applies to our employees, officers and directors. A current copy of the code is posted on the Corporate Governance section of our website, which is located at http://revivapharma.com/. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of such provisions applicable to any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, and our directors, on our website identified above or in filings with the SEC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Limitations on Liability and Indemnification of Officers and Directors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors&#x2019; fiduciary duties, subject to certain exceptions. Our certificate of incorporation, as amended, includes a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except for liability (i)&#xa0;for any breach of the director&#x2019;s duty of loyalty to the Company or its stockholders, (ii)&#xa0;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#xa0;under Section&#xa0;174 of the DGCL or (iv)&#xa0;for any transaction from which the director derived an improper personal benefit. The effect of these provisions is to eliminate the rights of the Company and its stockholders, through stockholders&#x2019; derivative suits on the Company&#x2019;s behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any director if the director has acted in bad faith, knowingly or intentionally violated the law, authorized illegal dividends or redemptions or derived an improper benefit from his or her actions as a director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our certificate of incorporation, as amended and our bylaws provide that we must indemnify and advance expenses to directors and officers to the fullest extent authorized by the DGCL. We are also expressly authorized to carry directors&#x2019; and officers&#x2019; liability insurance providing indemnification for directors, officers and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The limitation of liability, indemnification and advancement provisions in our certificate of incorporation, as amended, and our bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit the Company and its stockholders. In addition, your investment may be adversely affected to the extent we pays the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, liability insurance and the indemnity agreements are necessary to attract and retain talented and experienced directors and officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There is currently no pending material litigation or proceeding involving any of our respective directors, officers or employees for which indemnification is sought.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="a11" title="11" href="#"></a>ITEM 11.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>EXECUTIVE COMPENSATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As we are an emerging growth company, we have opted to comply with the executive compensation disclosure rules&#xa0;applicable to emerging growth companies. The scaled down disclosure rules&#xa0;are those applicable to &#x201c;smaller reporting companies,&#x201d; as such term is defined in the rules&#xa0;promulgated under the Securities Act, which require compensation disclosure for our principal executive officer and our two most highly compensated executive officers, other than the principal executive officer, whose total compensation for 2021 exceeded $100,000 and who were serving as executive officers as of December&#xa0;31, 2021. We refer to these individuals as &#x201c;named executive officers.&#x201d; Our named executive officers, consisting of our principal executive officer and the next two most highly compensated executive officers, for the year ended December&#xa0;31, 2021, were:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laxminarayan Bhat, our Chief Executive Officer and President;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:auto;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Narayan Prabhu, our Chief Financial Officer; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:auto;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Marc Cantillon, our Chief Medical Officer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2021 Summary Compensation Table</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table presents information regarding the total compensation awarded to, earned by, or paid to our named executive officers during the fiscal&#xa0;years ended December&#xa0;31, 2021 and 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name and Principal Position</b></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Salary</b><br /> <b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Bonus</b><br /> <b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Option</b><br /> <b>Awards</b><br /> <b>($) (1)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b><br /> <b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laxminarayan Bhat, PhD (2)</p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">400,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">200,054</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">600,054</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Chief Executive Officer and President</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">247,952</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5)&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">247,952</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Marc Cantillon, MD (3)</p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">385,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116,981</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">501,981</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Chief Medical Officer</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,042</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,042</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 10%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Narayan Prabhu (4)</p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">275,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6)&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162,134</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">437,134</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Chief Financial Officer</i></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,573</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,731</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,304</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)&#xa0;Amounts reflect the grant date fair value of option awards granted in 2021 and 2020 in accordance with Accounting Standards Codification Topic 718. For information regarding assumptions underlying the valuation of equity awards, see Note 11 to our Consolidated Financial Statements included in this report. These amounts do not correspond to the actual value that may be received by the named executive officers if the stock options are exercised.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)&#xa0;Laxminarayan Bhat has served as Chief Executive Officer and President since the formation of Old Reviva in May&#xa0;2006.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)&#xa0;Marc Cantillon has served as our Chief Medical Officer since 2013.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)&#xa0;Narayan Prabhu began serving as our Chief Financial Officer on December&#xa0;14, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)&#xa0;Includes salary amount earned but deferred during the fiscal year ended December&#xa0;31, 2020. The total salary amount paid, or to be paid, in cash to Dr.&#xa0;Bhat during the fiscal year ended December&#xa0;31, 2020 was approximately $187,952. Pursuant to a Stock Issuance Agreement and Release entered into as of September 24, 2020 with Dr. Bhat, 132,506 shares common stock of Reviva were issued to Dr.&#xa0;Bhat in full satisfaction of the entire deferred salary balance owed to Dr.&#xa0;Bhat.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(6) As of March 15, 2022, the amount of bonus for fiscal 2021 has not yet been determined. The actual amount of bonus is expected to be determined during the second quarter of&#xa0;2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Laxminarayan Bhat.</i></b>&#xa0;&#xa0;&#xa0;On December&#xa0;14, 2020 we entered into a customary employment agreement with Dr.&#xa0;Bhat (the &#x201c;Bhat Employment Agreement&#x201d;). The Bhat Employment Agreement provides for Dr.&#xa0;Bhat to serve as Chief Executive Officer reporting to our board of directors and provides for an annual base salary of $400,000 (the &#x201c;Base Salary&#x201d;). In addition, Dr.&#xa0;Bhat is eligible to receive an annual bonus of up to fifty&#xa0;percent (50%) of his then-Base Salary (the &#x201c;Target Bonus&#x201d;), subject to the satisfaction of certain subjective or objective criteria established and approved by our compensation committee. Pursuant to the terms of the Bhat Employment Agreement, Dr.&#xa0;Bhat is eligible to receive equity awards under the Company&#x2019;s equity incentive plan. The Bhat Employment Agreement contains customary confidentiality and assignment of inventions provisions. In addition, we will indemnify and hold Dr.&#xa0;Bhat harmless, to the maximum extent permitted under applicable law, from and against any liabilities, costs, claims and expenses incurred in defense of any Proceeding (as defined in the Bhat Employment Agreement) that Dr.&#xa0;Bhat is made a party to.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we terminate Dr.&#xa0;Bhat&#x2019;s employment without Cause or Dr.&#xa0;Bhat terminates his employment for Good Reason (each as defined in the Bhat Employment Agreement), Dr.&#xa0;Bhat will be entitled to receive (i)&#xa0;the Accrued Amounts (as defined in the Bhat Employment Agreement), and subject to Dr.&#xa0;Bhat&#x2019;s execution and nonrevocation of a release of claims, (ii)&#xa0;eighteen (18) months of his Base Salary plus one and one-half times his annual Target Bonus (reduced to six (6)&#xa0;months of Base Salary and one-half of his annual Target Bonus if Dr.&#xa0;Bhat&#x2019;s employment is terminated after the third anniversary of the effective date of the Bhat Employment Agreement) payable in equal installments in accordance with the Company&#x2019;s normal payroll practices, (iii)&#xa0;twelve (12) months of service credit under all outstanding unvested equity incentive awards granted during Dr.&#xa0;Bhat&#x2019;s employment (reduced to six (6)&#xa0;months of service credit if Dr.&#xa0;Bhat&#x2019;s employment is terminated after the third anniversary of the effective date of the Bhat Employment Agreement) and (iv)&#xa0;reimbursement of COBRA coverage for up to eighteen (18) months. If Dr.&#xa0;Bhat&#x2019;s employment is terminated on account of his death or Disability (as defined in the Bhat Employment Agreement), Dr.&#xa0;Bhat will be entitled to receive the Accrued Amounts and a lump sum payment equal to eighteen (18) months Base Salary and Target Bonus. In addition, if we terminate Dr.&#xa0;Bhat&#x2019;s employment without Cause or Dr.&#xa0;Bhat terminates his employment for Good Reason within twelve (12) months following a Change in Control (as defined in the Bhat Employment Agreement), Dr.&#xa0;Bhat will be entitled to receive (i)&#xa0;the Accrued Amounts and, subject to Dr.&#xa0;Bhat&#x2019;s execution and nonrevocation of a release of claims, (ii)&#xa0;a lump sum payment equal to 1.5 times his Base Salary and Target Bonus for the year in which the termination occurs, (iii)&#xa0;accelerated vesting of all of his outstanding equity incentive awards and cash incentive payments and (iv)&#xa0;reimbursement of COBRA coverage for up to eighteen (18) months.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Simultaneously with the execution of the Merger Agreement, Dr.&#xa0;Bhat entered into non-competition and non-solicitation agreement (the &#x201c;Non-Competition Agreement&#x201d;) , which became effective on December&#xa0;14, 2020, pursuant to which Dr.&#xa0;Bhat agreed not to compete with Tenzing, Reviva and their respective affiliates during the three (3)&#xa0;year period following the Closing in North America, Europe or India or in any other markets in which Tenzing and Reviva are engaged. Dr.&#xa0;Bhat also agreed that during such three (3)&#xa0;year restricted period to not solicit employees or customers of such entities. The Non-Competition Agreement also contains customary confidential and mutual non-disparagement provisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Narayan Prabhu.</i></b>&#xa0;&#xa0;&#xa0; On December&#xa0;14, 2020, an offer letter Reviva entered into with Narayan Prabhu, dated October&#xa0;19, 2020, became effective (the &#x201c;Prabhu Offer Letter&#x201d;). The Prabhu Offer Letter provides for Mr.&#xa0;Prabhu to serve as Chief Financial Officer reporting to our Chief Executive Officer or our board of directors and provides for an annual base salary of $275,000. Pursuant to the Prabhu Offer Letter, Mr.&#xa0;Prabhu&#x2019;s employment with the Company will be at-will.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, Mr.&#xa0;Prabhu is eligible for a discretionary bonus. Pursuant to the Prabhu Offer Letter, subject to approval by the board of directors, Mr.&#xa0;Prabhu was granted a stock option to purchase up to fifty thousand (50,000) shares of our common stock pursuant to our 2020 Equity Incentive Plan on April 14, 2021. Pursuant to the terms of the Prabhu Offer Letter, Mr.&#xa0;Prabhu is also eligible to receive, from time to time, equity awards under our 2020 Equity Incentive Plan, or any other equity incentive plan that we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our board of directors, or a committee thereof, in their discretion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Prabhu Offer Letter contains customary confidentiality and assignment of inventions provisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Marc Cantillon</i></b><b>. </b>Old Reviva entered into an Offer Letter on December&#xa0;12, 2012 with Marc Cantillon as its Chief Medical Officer (the &#x201c;2012 Offer Letter&#x201d;). In October&#xa0;2015, Dr.&#xa0;Cantillon entered into a letter agreement with Old Reviva pursuant to which Dr.&#xa0;Cantillon agreed to a reduction in his base annual salary to $100,000.00 for an indefinite period of time (the &#x201c;2015 Reduction Letter&#x201d;). In March&#xa0;2016, Dr.&#xa0;Cantillon entered into a letter agreement with Old Reviva pursuant to which Dr.&#xa0;Cantillon agreed to a reduction in his base annual salary to $30,000.00 for an indefinite period of time (the &#x201c;2016 Reduction Letter,&#x201d; together with the 2012 Offer Letter and the 2015 Reduction Letter, the &#x201c;Prior Cantillon Offer Letter&#x201d;). The Cantillon Offer Letter was assumed by us at the Effective Time and constituted an at-will employment agreement. On April 14, 2021, we entered into an employment letter with Dr. Cantillon (the &#x201c;2021 Cantillon Employment Letter&#x201d;). The 2021 Employment Letter supersedes the Prior Cantillon Offer Letter. The 2021 Employment Letter provides for Dr.&#xa0;Cantillon to continue to serve as the Company&#x2019;s Chief Medical Officer reporting to the Company&#x2019;s Chief Executive Officer or its board of directors and provides for an annual base salary of $385,000, retroactive to December 15, 2020 (the day following the Business Combination). Under the 2021 Employment Letter, Dr.&#xa0;Cantillon is eligible for annual bonuses in the discretion of the Company&#x2019;s board of directors, but will receive a&#xa0;bonus for 2021 equal to 30% of his 2021 base salary. To receive any bonus, Dr.&#xa0;Cantillon must be employed by the Company at the time of payment. Dr.&#xa0;Cantillon may also receive, in the discretion of the Company&#x2019;s board of directors, equity awards under the Company&#x2019;s 2020 Equity Incentive Plan or any other equity incentive plan that the Company may adopt in the future. Pursuant to the 2021 Employment Letter, Dr.&#xa0;Cantillon&#x2019;s employment with the Company will continue to be at-will. The 2021 Employment Letter also contains customary confidentiality and assignment of inventions provisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Dr.&#xa0;Cantillon is also eligible to receive, from time to time, equity awards under our 2020 Equity Incentive Plan, or any other equity incentive plan we may adopt in the future, and the terms and conditions of such awards, if any, will be determined by our board of directors, or a committee thereof, in their discretion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Outstanding Equity Awards at Fiscal Year-End</b>&#x2009;&#x2014;&#x2009;<b>2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table summarizes, for each of the named executive officers, the number of shares of our common stock underlying outstanding stock options held as of December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); width: 40%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); width: 47%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Option Awards</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 40%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number of Securities Underlying Unexercised Options</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt; text-align: center;">Name</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Exerciseable</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unexerciseable</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 5%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Option Exercise Price ($)</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Option Expiration Date</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
     <td style="border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Laxminarayan Bhat, PhD (CEO)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 108pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 126pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">(1)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 153pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 135pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Marc Cantillon, MD (COO)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,226</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 126pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">(2)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.89</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">09/20/2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 40%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,453</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 126pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">(3)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.89</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">12/04/2022</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 40%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,613</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 126pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">(4)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31.33</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">12/04/2024</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Narayan Prabhu (CFO)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">(5)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4.30</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">04/13/2031</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2021 our principal executive officer did not hold any outstanding equity awards.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Represents options to purchase shares of our common stock granted on September&#xa0;21, 2012 with an exercise price of $11.89 per share. The shares underlying the option vest straight-line on a monthly basis over 24 months from June 2012 to May 2014. The option grant was made pursuant to our 2006 Equity Incentive Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Represents options to purchase shares of our common stock granted on December&#xa0;5, 2012 with an exercise price of $11.89 per share. The shares underlying the option vest straight-line on a monthly basis over 24 months from December 2012 to November 2014. The option grant was made pursuant to our 2006 Equity Incentive Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Represents options to purchase shares of our common stock granted on December&#xa0;5, 2014 with an exercise price of $31.33 per share. The shares underlying the option vest straight-line on a monthly basis over 24 months from February 2014 to January 2016. The option grant was made pursuant to our 2006 Equity Incentive Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Represents options to purchase shares of our common stock granted on April&#xa0;14, 2021 with an exercise price of $4.30 per share. The shares underlying the option vest starting December 2020 with 25% after a one-year cliff in December 2021, then straight-line on a monthly basis over the following 36 months from January 2022 to December 2024. The award was made pursuant to the 2020 Equity Incentive Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Compensation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;">The following table sets forth information concerning the compensation paid to certain of our non-employee directors during 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="2" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 0pt; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Name</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Fees</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Earned</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>or Paid</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>in Cash</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Option</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Awards</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($) (1)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 2%;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>($)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Les Funtleyder</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,252</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,134</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">(2)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,386</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Richard Margolin</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,134</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">(3)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,134</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Purav Patel</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">53,751</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">77,818</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">(4)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">131,569</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Parag Saxena</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70,252</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,134</td>
     <td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">(5)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">98,386</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amounts reflect the aggregate grant date fair value of each stock option granted in 2021 in accordance with the Accounting Standards Codification Topic 718. For information regarding assumptions underlying the valuation of equity awards, see Note 11 to our Consolidated Financial Statements included in this report. These amounts do not correspond to the actual value that may be received by the directors if the stock options are exercised.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2021 held by Mr. Funtleyder was 9,300.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2021 held by Dr. Margolin was 9,300.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2021 held by Mr. Patel was 24,527.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:44pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate number of shares of common stock underlying stock options outstanding as of December 31, 2021 held by Mr. Saxena was 9,300.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Non-Employee Director Compensation</i></b>&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our board of directors approved a non-employee director compensation policy on June 15, 2021. This policy provides for the following compensation:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Non-Employee Director Compensation Policy provides for the following cash compensation:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director is entitled to receive an annual cash retainer fee of $32,500, except that the Chairman of the Board is entitled to receive an annual cash retainer fee of $57,500;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director sitting on the Audit Committee is entitled to receive an annual cash retainer fee of $7,500, except that the Chairman of the Audit Committee is entitled to receive an annual cash retainer fee of $15,000;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director sitting on the Compensation Committee is entitled to receive an annual cash retainer fee of $5,000, except that the Chairman of the Compensation Committee is entitled to receive an annual cash retainer fee of $10,000;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director sitting on the Governance Committee is entitled to receive an annual cash retainer fee of $3,750, except that the Chairman of the Governance Committee is entitled to receive an annual cash retainer fee of $7,750; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">No per meeting fees shall be paid.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">All annual cash retainer fees under the Non-Employee Director Compensation Policy will be paid quarterly in arrears.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Non-Employee Director Compensation Policy also provides generally for the following equity compensation under the Company&#x2019;s existing 2020 Equity Incentive Plan, or any other equity incentive plan the Company may adopt in the future:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director is entitled to receive, upon initial election, a one-time initial equity grant of nonqualified stock options (the &#x201c;Initial Equity Grant&#x201d;) in respect of a whole number of shares of our Common Stock (as defined in the 2020 Equity Incentive Plan) with an approximate value of $20,000. All of the shares subject to the Initial Equity Grant shall vest 33% per year over three years from the date of initial election, provided that the recipient remains a director of through each vesting date.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director is entitled to receive an annual equity grant of nonqualified stock options (the &#x201c;Annual Equity Grant&#x201d;) in respect of a whole number of shares of the our Common Stock (as defined in the 2020 Equity Incentive Plan) with an approximate value of $20,000. All of the shares subject to the Annual Equity Grant shall cliff vest after 1-year, provided that the recipient remains a director through the vesting date.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Indemnification Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On December&#xa0;14, 2020, our board of directors adopted and entered into (a)&#xa0;a form of&#xa0;indemnification agreement&#xa0;(the &#x201c;Indemnification Agreement&#x201d;) between the Company and each of its&#xa0;directors&#xa0;and executive officers, except for Parag Saxena, and (b)&#xa0;a form of indemnification agreement (the &#x201c;Saxena Indemnification Agreement&#x201d;) with Parag Saxena.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The&#xa0;Indemnification Agreement&#xa0;requires us to indemnify each director and officer to the fullest extent permitted by applicable law, for certain expenses, including attorneys&#x2019; fees, judgments, penalties, fines and settlement amounts actually and reasonably incurred in any threatened, pending or completed action, suit, claim, investigation, inquiry, administrative hearing, arbitration or other proceeding to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of us. Subject to certain limitations, the Indemnification Agreement provides for the advancement of expenses incurred by the indemnitee, and the repayment to us of the amounts advanced to the extent that it is ultimately determined that the indemnitee is not entitled to be indemnified by us. The Indemnification Agreement also creates certain rights in favor of us, including the right to assume the defense of claims and to consent to settlements. The Indemnification Agreement does not exclude any other rights to indemnification or advancement of expenses to which the indemnitee may be entitled under applicable law, the certificate of incorporation or our bylaws, any agreement, a vote of stockholders or disinterested directors, or otherwise.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Saxena Indemnification Agreement is on substantially the same form as the Indemnification Agreement, except that it includes a provision specifying that the we will act as the indemnitor of first resort and that we will not assert that Mr.&#xa0;Saxena, as indemnitee under the Saxena Indemnification Agreement, must seek expense advancement or reimbursement, or indemnification, from any stockholder of the Company and/or certain of any such stockholder&#x2019;s affiliates who Mr.&#xa0;Saxena may have rights to indemnification, advancement of expenses and/or insurance from, before we must perform our expense advancement and reimbursement, and indemnification obligations, under the Saxena Indemnification Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     72
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a12" title="12" href="#"></a>ITEM 12.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>2020 Equity Incentive Plan</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On December&#xa0;14, 2020, the Reviva Pharmaceuticals Holdings,&#xa0;Inc. 2020 Equity Incentive Plan (the &#x201c;2020 Equity Incentive Plan&#x201d;) became effective. The general purpose of the 2020 Equity Incentive Plan is to provide a means whereby employees, officers, directors, consultants, advisors or other individual service providers may develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to us, thereby advancing our interests and the interests of our stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2006 Equity Incentive Plan</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Old Reviva&#x2019;s board of directors adopted, and Old Reviva&#x2019;s stockholders approved, the Reviva Pharmaceuticals,&#xa0;Inc. 2006 Equity Incentive Plan, effective as of August&#xa0;2006. The Reviva Pharmaceuticals,&#xa0;Inc. 2006 Equity Incentive Plan provided for the grant of incentive stock options, or ISOs, within the meaning of Section&#xa0;422 of the Code, to Reviva&#x2019;s employees, and for the grant of nonstatutory stock options, or NSOs, and restricted stock awards to Old Reviva&#x2019;s employees, officers, directors and consultants; provided such consultants render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. As of 2016, no new grants of awards are permitted under the Reviva Pharmaceuticals,&#xa0;Inc. 2006 Equity Incentive Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Reviva Pharmaceuticals,&#xa0;Inc. 2006 Equity Incentive Plan was amended to change its name to the Reviva Pharmaceuticals Holdings,&#xa0;Inc. 2006 Equity Incentive Plan (the &#x201c;2006 Equity Incentive Plan&#x201d;), and each outstanding option to acquire Old Reviva common stock (whether vested or unvested) under the 2006 Equity Incentive Plan was assumed by us and automatically converted into an option to acquire shares of our Common Stock, with its price and number of shares equitably adjusted based on the conversion of the shares of common stock of Old Reviva into shares of our Common Stock pursuant to the Merger Agreement.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table provides information with respect to our compensation plans under which equity compensation was authorized as of December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>securities</b><br /> <b>to be issued</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>upon</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>outstanding</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>options,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>warrants</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>and rights</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>outstanding</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>options,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>warrants</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>and rights</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>securities</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>available for</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>future</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>issuance</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>under equity</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>compensation</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>plans</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(excluding</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>securities</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>reflected in</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>column a)</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Plan category</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(a)</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(b)</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(c)(3)</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equity compensation plans approved by security holders(1)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192,898</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.46</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,257,334</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equity compensation plans not approved by security holders</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192,898</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.46</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,257,334</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p> </td>
     <td style="vertical-align:bottom;width:44.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The amounts shown in this row include securities under the 2006 Equity Incentive Plan and the 2020 Equity Incentive Plan.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p> </td>
     <td style="vertical-align:bottom;width:44.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 65,471&#xa0;and 127,427&#xa0;shares of common stock issuable upon exercise of outstanding options pursuant to the 2006 Equity Incentive Plan and 2020 Equity Incentive Plan, respectively, as of December 31, 2021.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(3)</p> </td>
     <td style="vertical-align:bottom;width:44.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In accordance with the &#x201c;evergreen&#x201d;&#xa0;provision in our 2020 Equity Incentive Plan, an additional 1,443,329&#xa0;shares were automatically made available for issuance on the first day of 2022, which represents 10% of the number of shares outstanding on December 31, 2021; these shares are excluded from this calculation.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(4)</p> </td>
     <td style="vertical-align:bottom;width:44.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes 0&#xa0;and 1,257,334&#xa0;shares of common stock available for issuance under the 2006 Equity Incentive Plan and 2020 Equity Incentive Plan, respectively, as of December 31, 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Security Ownership of Certain Beneficial Owners and Management</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth information regarding the beneficial ownership of the Company, on March 1, 2022, by:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">each person known by the Company to be, or expected to be, the beneficial owner of more than 5% of shares of the Company&#x2019;s Common Stock; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:6.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">each of the Company&#x2019;s executive officers and directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Beneficial ownership is determined according to the rules&#xa0;of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60&#xa0;days.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The beneficial ownership of the common stock of the Company is based on 15,133,286&#xa0;shares of common stock issued and outstanding as of March 1, 2022,.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name of Beneficial Owner</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Beneficially</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Owned</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percentage of Shares</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Beneficially</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Owned</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Officers and Directors (1)</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laxminarayan Bhat (2)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,490,334</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.45</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Marc Cantillon (3)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69,012</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Les Funtleyder (4)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,333</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Richard Margolin (5)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,333</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purav Patel (6)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,746</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Narayan Prabhu (7)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,666</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Parag Saxena (8) (9)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,302,209</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.21</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>All Directors and Officers as a Group (seven persons)</b></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>4,958,633</b></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>32.58</b></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>%</b></b></p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Greater than Five Percent Holders:</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tang Capital Partners, L.P. (10)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,546,422</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.99</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 53pt;">* Less than one&#xa0;percent.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The business address of each of the officers and directors is c/o Reviva Pharmaceuticals Holdings,&#xa0;Inc., 19925 Stevens Creek Blvd., Suite&#xa0;100, Cupertino, CA 95014.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes (a)&#xa0;5,388 shares of Common Stock held by Dr.&#xa0;Bhat&#x2019;s spouse and (b)&#xa0;6,090 shares of Common Stock issuable upon the exercise of Assumed Options held by Dr.&#xa0;Bhat&#x2019;s spouse, that are exercisable or will be exercisable within 60 days of March 1, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes 53,292 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of March 1, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes 1,333 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of March 1, 2022. Does not include 7,967 shares of our common stock issuable upon the exercise of stock options that are not exercisable within sixty days of March 1, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes 1,333 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of March 1, 2022. Does not include 7,967 shares of our common stock issuable upon the exercise of stock options that are not exercisable within sixty days of March 1, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(6)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes 5,139 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of March 1, 2022. Does not include 19,388 shares of our common stock issuable upon the exercise of stock options that are not exercisable within sixty days of March 1, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(7)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes 16,666 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of March 1, 2022. Does not include 33,334 shares of our common stock issuable upon the exercise of stock options that are not exercisable within sixty days of March 1, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(8)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on the information provided in the Schedule 13D/A filed with the SEC on June 3, 2021 by Mr. Saxena with respect to himself, Vedanta Associates, L.P., Beta Operators Fund, L.P., Vedanta Associates-R, L.P. and Vedanta Partners, LLC. Includes (a) 99,539 shares held by Vedanta Associates, L.P. (b) 399,000 shares held by Beta Operators Fund, L.P. (c) 931,000 shares held by Vedanta Associates-R, L.P . Vedanta Partners, LLC is the general partner of Vedanta Associates, L.P and Vedanta Associates-R, L.P. Vedanta Associates, L.P. is the general partner of Beta Operators Fund, L.P. Vedanta Partners, LLC has voting and dispositive power over the securities held by Vedanta Associates, L.P. and Vedanta Associates-R, L.P. Vedanta Associates, LP. has voting and dispositive power over securities held by Beta Operators Fund L.P. Parag Saxena is the majority owner of Vedanta Partners, LLC and controls Vedanta Partners, LLC, Vedanta Associates-R, L.P. and Beta Operators Fund, L.P. and may be deemed to be the beneficial owner of such securities. Mr. Saxena, however, disclaims beneficial ownership over any securities owned by Vedanta Associates, L.P. Vedanta Associates-R, L.P. and Beta Operators Fund, L.P in which he does not have any pecuniary interest and (d) 1,333 shares of common stock issuable upon the exercise of stock options that are exercisable or will be exercisable within 60 days of March 1, 2022. Does not include (a) 299,250 shares of common stock issuable upon the exercise of 399,000 warrants held by Beta Operators Fund, L.P. which are subject to a 4.99% beneficial ownership limitation blocker, (b) 698,250 shares of common stock issuable upon the exercise of 931,000 warrants held by Vedanta Associates-R, L.P. which are subject to a 4.99% beneficial ownership limitation blocker and (c) 7,967 shares of common stock issuable upon the exercise of stock options held by Mr. Saxena that are not exercisable within 60 days of March 1, 2022..</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(9)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The business address of Vedanta Associates, L.P., Beta Operators Fund, L.P., Vedanta Associates-R, L.P. and Vedanta Partners, LLC is c/o Vedanta Partners, LLC, 250 West 55th Street, New York, New York 10019.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:1.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:1.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(10)</p> </td>
     <td style="vertical-align:top;width:42.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on the information provided in the Schedule 13G filed with the SEC on June 3, 2021 by Tang Capital Partners, L.P. with respect to itself, Tang Capital Management, LLC and Kevin Tang. Includes 346,422 shares of Common Stock issuable upon the exercise of warrants that are exercisable or will be exercisable within 60 days. The exercise of the warrants are subject to a 9.99% beneficial ownership limitation blocker which the holder has elected. The amounts and percentages in the&#xa0;table give effect to the beneficial ownership limitation. Tang Capital Management, LLC is the general partner of Tang Capital Partners, L.P. and has voting and dispositive power over the securities held by Tang Capital Partners, L.P. Kevin Tang is the manager of Tang Capital Management, LLC. The address for Tang Capital Partners, L.P., Tang Capital Management, LLC and Kevin Tang is 4747 Executive Drive, Suite 210, San Diego, CA 92121. Does not include 6,386,823 shares of common stock issuable upon the exercise of warrants held by Tang Capital Partners, L.P. which are subject to a 9.99% beneficial ownership limitation blocker.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a13" title="13" href="#"></a>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following includes a summary of transactions since January 1, 2020, to which we or Tenzing have been a participant in which the amount involved exceeded or will exceed the lesser of (i)&#xa0;$120,000 or (ii)&#xa0;1% of our average total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described in the section entitled &#x201c;<i>Executive Compensation</i>.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Tenzing Related Person Transactions </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Related Party Loans</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In order to finance transaction costs in connection with a business combination, Tenzing LLC (the &#x201c;Sponsor&#x201d;) or an affiliate of Sponsor, or Tenzing&#x2019;s officers and directors were permitted, but were not obligated to, making working capital loans. Such working capital loans were evidenced by promissory notes. The notes were to be repaid upon consummation of a business combination, without interest, or, at the lender&#x2019;s discretion, up to $2,000,000 of notes were permitted to be converted upon consummation of a business combination into additional units at a price of $10.00 per unit. The units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On February&#xa0;10, 2020, Tenzing entered into a convertible promissory note with Sponsor, pursuant to which Tenzing borrowed an aggregate amount of $750,000 (the &#x201c;February&#xa0;Working Capital Loan&#x201d;). Of such amount, $567,182 was used to fund an extension loan into the Trust Account and the balance was used to finance transaction costs in connection with a business combination. The February&#xa0;Working Capital Loan was non-interest bearing and became due to be paid upon the consummation of the Business Combination. The February&#xa0;Working Capital Loan was converted into&#xa0;units at a purchase price of $10.00 per unit. The units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On May&#xa0;21, 2020, Tenzing entered into a convertible promissory note with Sponsor, pursuant to which Tenzing borrowed an aggregate amount of $375,000 (the &#x201c;May&#xa0;Working Capital Loan&#x201d;). Of such amount, $210,836 was used to fund the extension loan into the Trust Account and the balance was used to finance transaction costs in connection with a business combination. The May&#xa0;Working Capital Loan was non-interest bearing and became due to be paid upon the consummation of the Business Combination. The May&#xa0;Working Capital Loan was converted into&#xa0;units at a purchase price of $10.00 per unit. The&#xa0;units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On July&#xa0;24, 2020, Tenzing entered into a convertible promissory note with Sponsor, pursuant to which Tenzing borrowed an aggregate amount of $175,000 (the &#x201c;July&#xa0;Working Capital Loan&#x201d;). Of such amount, $105,418.17 was used to fund the extension loan into the Trust Account. The July&#xa0;Working Capital Loan was non-interest bearing and became due to be paid upon the consummation of the Business Combination. The July&#xa0;Working Capital Loan was converted into&#xa0;units at a purchase price of $10.00 per unit. The&#xa0;units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On August&#xa0;18, 2020, Tenzing entered into a convertible promissory note with Sponsor, pursuant to which Tenzing borrowed an aggregate amount of $125,000 (the &#x201c;August&#xa0;Working Capital Loan&#x201d;). Of such amount, $105,418.17 was used to fund the extension loan into the Trust Account and the balance was used to finance transaction costs in connection with a business combination. The August&#xa0;Working Capital Loan was non-interest bearing and became due to be paid upon the consummation of the Business Combination. The August&#xa0;Working Capital Loan was converted into&#xa0;units at a purchase price of $10.00 per unit. The&#xa0;units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On September&#xa0;24, 2020, Tenzing entered into a convertible promissory note with Sponsor, pursuant to which Tenzing borrowed an aggregate amount of $350,000 (the &#x201c;September&#xa0;Working Capital Loan&#x201d;). Of such amount, $105,084.14 was used to fund the extension loan into the Trust Account and the balance was used to finance transaction costs in connection with a business combination and to fund additional contributions in connection with the extension. The September&#xa0;Working Capital Loan was non-interest bearing and became due to be paid upon the consummation of the Business Combination. The September&#xa0;Working Capital Loan was converted into&#xa0;units at a purchase price of $10.00 per unit, provided that conversion greater than $75,000 of the unpaid balance of the note was subject to the approval of Tenzing shareholders, which approval was obtained at the Shareholders Meeting. The&#xa0;units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On November&#xa0;12, 2020, Tenzing entered into a convertible promissory note with Sponsor, pursuant to which Tenzing borrowed an aggregate amount of $200,000 (the &#x201c;November&#xa0;Working Capital Loan&#x201d;, together with the February&#xa0;Working Capital Loan, the May&#xa0;Working Capital Loan, the July&#xa0;Working Capital Loan, the August&#xa0;Working Capital Loan and the September&#xa0;Working Capital Loan, the &#x201c;Working Capital Loans&#x201d;). Of such amount, $105,084.14 was used to fund the extension loan into the Trust Account and the balance was used to finance transaction costs in connection with a business combination and to fund additional contributions in connection with the extension. The November&#xa0;Working Capital Loan was non-interest bearing and became due to be paid upon the consummation of the Business Combination. The November&#xa0;Working Capital Loan was converted into&#xa0;units at a purchase price of $10.00 per unit, provided that conversion of the unpaid balance of the note was subject to the approval of Tenzing shareholders, which approval was obtained at the Shareholders Meeting. The&#xa0;units were identical to the private units that were issued simultaneously with the closing of Tenzing&#x2019;s IPO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On December&#xa0;14, 2020, in connection with the consummation of the Business Combination, Sponsor elected to have the Working Capital Loans converted, pursuant to the terms of the Working Capital Loans, into Private Placement Units, resulting in the issuance of an aggregate of 197,500 shares of the Company&#x2019;s common stock (the &#x201c;Working Capital Shares&#x201d;) and warrants to purchase 197,500 shares of the Company&#x2019;s common stock (the &#x201c;Working Capital Warrants,&#x201d; together with the Working Capital Shares, the &#x201c;Conversion Securities&#x201d;). Upon issuance of the Conversion Securities all of the existing obligations of the Company under the Working Capital Loans were satisfied in full and irrevocably discharged, terminated and released, and Sponsor retained no rights with respect to such Working Capital Loans, other than the registration rights provided pursuant to such Working Capital Loans.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On December 28, 2020, Sponsor conducted a liquidating distribution of all of the shares of Company common stock that it held on such date, including the founder shares of common stock issued to Sponsor (the &#x201c;Founder Shares&#x201d;), shares of common stock that were issued to Sponsor as part of the private placement of units &#xa0;that took place simultaneously with the closing of Tenzing&#x2019;s IPO (the &#x201c; Sponsor&#x2019;s Private Placement Shares,&#x201d; and Working Capital Shares, to its members (as permitted transferees pursuant to a liquidating distribution) and assigned its registration rights in connection with the distribution. As a result, each of the members of Sponsor have the same registration rights and transfer restrictions with respect to the shares of Company common stock, including the Founder Shares, Sponsor&#x2019;s Private Placement Shares, and Working Capital Shares, received by such member pursuant to the liquidating distribution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Related Party Non-Redemption Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the Non-Redemption Agreement, on December&#xa0;14, 2020 Sabby Volatility Warrant Master Fund,&#xa0;Ltd. (&#x201c;Sabby&#x201d;) received (a)&#xa0;fifty-five thousand fifty (55,050) shares of common stock that were issued by the Company, (b)&#xa0;three hundred forty-three thousand (343,000) Private Placement Warrants that were acquired by Sponsor as part of the private placement units issued to Sponsor in connection with Tenzing&#x2019;s IPO, which Sponsor transferred to Sabby on December&#xa0;15, 2020 pursuant to the terms of the Non-Redemption Agreement and (c)&#xa0;the Working Capital Warrants, which Sponsor transferred to Shareholder on December&#xa0;15, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Old Reviva Related Person Transactions</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Promissory Notes</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On July&#xa0;11, 2016, Old Reviva issued a note to Purav Patel, one of Old Reviva&#x2019;s directors, in the name of PENSCO Trust Company, Custodian, FBO Purav Patel IRA, pursuant to which Old Reviva borrowed an aggregate principal amount of $50,000.00. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note initially accrued interest at a rate of 8% per annum with a maturity date of July&#xa0;11, 2017. The convertible promissory note had been in default since the maturity date, and was accruing interest at a default rate of 12% per annum. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $24,499) by (B)&#xa0;a conversion price equal to $1.329698. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released, and Mr.&#xa0;Patel retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On July&#xa0;11, 2016, Old Reviva issued a note to Purav Patel, one of Old Reviva&#x2019;s directors, pursuant to which Old Reviva borrowed an aggregate principal amount of $50,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note initially accrued interest at a rate of 8% per annum with a maturity date of July&#xa0;11, 2017. The convertible promissory note had been in default since the maturity date, and was accruing interest at a default rate of 12% per annum. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $24,499) by (B)&#xa0;a conversion price equal to $1.329698. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and Mr.&#xa0;Patel retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On November&#xa0;13, 2018, Old Reviva issued a note to Purav Patel, one of Old Reviva&#x2019;s directors, pursuant to which Old Reviva borrowed an aggregate principal amount of $50,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note accrued interest at a rate of 8% per annum with a maturity date of May&#xa0;13, 2019. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $8,296) by (B)&#xa0;a conversion price equal to $0.831018. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and Mr.&#xa0;Patel retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On December&#xa0;13, 2018, Old Reviva issued a note to Buena Vista Fund&#xa0;II, LLC of which Purav Patel, one of Old Reviva&#x2019;s directors, is Managing Member, in the principal amount of $25,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note accrued interest at a rate of 8% per annum with a maturity date of June&#xa0;13, 2019. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $3,984) by (B)&#xa0;a conversion price equal to $1.330045. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and Buena Vista Fund II, LLC retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On October&#xa0;14, 2016, Old Reviva issued a note to The Firdos Sheikh Family Trust of which Firdos Sheikh, a holder of greater than 5% of Old Reviva&#x2019;s preferred stock, is Trustee, in the principal amount of $100,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note initially accrued interest at a rate of 8% per annum with a maturity date of October&#xa0;14, 2017. The note had been in default since the maturity date, and was accruing interest at a default rate of 12% per annum. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $45,874) by (B)&#xa0;a conversion price equal to $1.329698. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and The Firdos Sheikh Family Trust retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On April&#xa0;2, 2020, Old Reviva issued a note to The Firdos Sheikh Family Trust of which Firdos Sheikh, a holder of greater than 5% of Old Reviva&#x2019;s preferred stock, is Trustee, in the principal amount of $100,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note accrued interest at a rate of 8% per annum with a maturity date of October&#xa0;2, 2020. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $5,523) by (B)&#xa0;a conversion price equal to $1.329770. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and The Firdos Sheikh Family Trust retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On September&#xa0;9, 2016, Old Reviva issued a note to the Thaker Family Limited Partnership, of which Pankaj Thaker, a holder of greater than 5% of Old Reviva&#x2019;s preferred stock, is the General Partner, in the principal amount of $25,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note initially accrued interest at a rate of 8% per annum with a maturity date of September&#xa0;9, 2017. The note had been in default since the maturity date, and was accruing interest at a default rate of 12% per annum. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $11,756) by (B)&#xa0;a conversion price equal to $1.329698. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and Thaker Family Limited Partnership retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On September&#xa0;9, 2016, Old Reviva issued a note to the 2012 Satyen P. Thaker Revocable Trust, of which Satyen Thaker, a holder of greater than 5% of Old Reviva&#x2019;s preferred stock, is the Trustee, in the principal amount of $25,000. The entire balance of the note was used to help finance Old Reviva&#x2019;s operations. The note initially accrued interest at a rate of 8% per annum with a maturity date of September&#xa0;9, 2017. The 2016 Note had been in default since the maturity date, and was accruing interest at a default rate of 12% per annum. Pursuant to an amendment to the note, on December&#xa0;14, 2020, immediately prior to the consummation of the Business Combination, the note converted into a number of shares of Old Reviva common stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (A)&#xa0;the sum of all then outstanding principal and accrued but unpaid interest on a date that was no more than five (5)&#xa0;days prior to the consummation of the Business Combination (which interest balance was approximately $11,756) by (B)&#xa0;a conversion price equal to $1.329698. Upon issuance of such shares of Old Reviva common stock all of the existing obligations of Old Reviva under the note were satisfied in full and irrevocably discharged, terminated and released and 2012 Satyen P. Thaker Revocable Trust retained no rights with respect to such note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Related Party Payable</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Old Reviva had related party payables due to Laxminarayan Bhat, Old Reviva&#x2019;s Chief Executive Officer, for expenses that were incurred on Old Reviva&#x2019;s behalf by Dr.&#xa0;Bhat totaling $75,707 as of December 4, 2020, which amount was reimbursed to Dr.&#xa0;Bhat on December&#xa0;7, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Indian Subsidiary</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Mr.&#xa0;Krishnamurthy Bhat, an Indian resident and the brother of Dr.&#xa0;Bhat, the Company&#x2019;s Chief Executive Officer, holds a 1% ownership stake and is a director of the Company&#x2019;s subsidiary, Reviva Pharmaceuticals India Private Limited. The Indian government regulates ownership of Indian companies by non-residents. Foreign investment in Indian securities is generally regulated by the Consolidated Policy on Foreign Direct Investment issued by the Government and the Foreign Exchange Management Act, 1999, which prevents 100% ownership by a foreign parent company of its Indian subsidiary.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Employment</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Reviva employs Seema R. Bhat, the spouse of Laxminarayan Bhat, the Company&#x2019;s Chief Executive Officer, as its Vice President for Program&#xa0;&amp; Portfolio Management, pursuant to an Offer Letter dated March&#xa0;1, 2011 (the &#x201c;Bhat 2011 Offer Letter&#x201d;). In October&#xa0;2015, Ms.&#xa0;Bhat entered into a letter agreement with Old Reviva pursuant to which Ms.&#xa0;Bhat agreed to a reduction in her base annual salary to $30,000.00 for an indefinite period of time. Effective since October&#xa0;2018, Ms.&#xa0;Bhat had agreed to defer her entire salary, without interest. Effective as of October&#xa0;2, 2020, 35,385 shares of Old Reviva common stock were issued to Ms.&#xa0;Bhat in full satisfaction of the entire deferred salary balance owed to Ms.&#xa0;Bhat, pursuant to a Stock Issuance Agreement and Release.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On June 16, 2021, the Company entered into an Employment Letter with Ms. Bhat (the &#x201c;Bhat 2021 Employment Letter&#x201d;), which supersedes the Bhat 2011 Offer Letter. The Bhat 2021 Employment Letter provides for Ms. Bhat to continue to serve as our Vice President for Program&#xa0;&amp; Portfolio Management reporting to our Chief Executive Officer or our Board and provides for an annual base salary of $277,000, retroactive to December 15, 2020 (the day following the Business Combination). Under the Bhat 2021 Employment Letter, Ms. Bhat is eligible for annual bonuses in the discretion of our Board.&#xa0; The Bhat 2021 Employment Letter provides that to receive any bonus, Ms.&#xa0;Bhat must be employed by the Company at the time of payment. The Bhat 2021 Employment Letter provides that Ms. Bhat may also receive, in the discretion of our Board, equity awards under the Company&#x2019;s 2020 Equity Incentive Plan or any other equity incentive plan that the Company may adopt in the future. The Bhat 2021 Employment Letter contains customary confidentiality and assignment of inventions provisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Effective since October&#xa0;2018, Dr.&#xa0;Cantillon had agreed to defer his entire salary, without interest. Effective as of October&#xa0;2, 2020, 35,385 shares of Old Reviva common stock were issued to Dr.&#xa0;Cantillon in full satisfaction of the entire deferred salary balance owed to Dr.&#xa0;Cantillon, pursuant to a Stock Issuance Agreement and Release.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Effective since April&#xa0;2019, Dr.&#xa0;Bhat had agreed to the deferral of his past salary as necessary, without interest. Effective as of October&#xa0;2, 2020, 132,506 shares of Old Reviva common stock were issued to Dr.&#xa0;Bhat in full satisfaction of the entire deferred salary balance owed to Dr.&#xa0;Bhat, pursuant to a Stock Issuance Agreement and Release.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Participation in 2021 Offering</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vedanta Associates, LP (&#x201c;VA&#x201d;), an affiliate of Parag Saxena, the Chairman of our Board, or one or more accounts affiliated with VA (such funds or accounts, together with VA, the &#x201c;Vedanta Accounts&#x201d;) purchased an aggregate of $4,987,500 in units in the Company&#x2019;s public offering completed in June 2021 at the public offering price. The underwriters received the same discount on the units purchased by the Vedanta Accounts as they did from any other units sold to the public in this public offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Indemnification Agreements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has entered into indemnification agreements with each of its directors and named executive officers. These agreements require the Company to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to the Company, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. The Company also intends to enter into indemnification agreements with its future directors and executive officers. For a more fulsome description of the indemnification agreements refer to the disclosure in &#x201c;<i>Executive Compensation</i>&#x201d;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Policies and Procedures for Related Party Transactions:</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has adopted a policy that its executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of its common stock, any members of the immediate family of any of the foregoing persons and any firms, corporations or other entities in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has a 5% or greater beneficial ownership interest (collectively &#x201c;related parties&#x201d;), are not permitted to enter into a transaction with the Company without the prior consent of the our board of directors acting through the Audit Committee or, in certain circumstances, the chairman of the Audit Committee. Any request for the Company to enter into a transaction with a related party, in which the amount involved exceeds $100,000 and such related party would have a direct or indirect interest must first be presented to the Audit Committee, or in certain circumstances the chairman of the Audit Committee, for review, consideration and approval. In approving or rejecting any such proposal, the Audit Committee, or the chairman of the Audit Committee, is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the benefits to us, the availability of other sources of comparable products or services and the extent of the related party&#x2019;s interest in the transaction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors undertook a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that Mr.&#xa0;Saxena, Mr.&#xa0;Funtleyder, Dr.&#xa0;Margolin, and Mr.&#xa0;Patel do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#x201c;independent&#x201d; as that term is defined under the Rules&#xa0;of the Nasdaq Market and the SEC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a14" title="14" href="#"></a>ITEM 14.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fees Paid to the Independent Registered Public Accounting Firm</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table summarizes the fees for professional services rendered by Armanino LLP, the Company&#x2019;s (and Old Reviva&#x2019;s, prior to the Business Combination) independent registered public accounting firm, for each of the respective last two fiscal years:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Year ending December 31,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Audit fees(1)(2)(3)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">336,417</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">253,077</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Audit related fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">All other fees</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">336,417</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">253,077</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:0.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="vertical-align:top;width:44.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Audit fees consist of fees incurred for professional services rendered for the audit of our annual financial statements and review of the quarterly financial statements, assistance with registration statements filed with the SEC, and services that are normally provided by our independent registered public accounting firm in connection with regulatory filings or engagements.&#xa0;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:0.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="vertical-align:top;width:44.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the fiscal year ended December 31, 2021, Audit fees of $384,300 were paid to Armanino LLP.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:0.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="vertical-align:top;width:44.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the fiscal year ended December 31, 2020, Audit fees of $88,957 were paid to Armanino LLP.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Auditor Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In our fiscal year ended December 31, 2021, there were no other professional services provided by Armanino LLP that would have required our audit committee to consider their compatibility with maintaining the independence of Armanino LLP.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our audit committee has established a policy governing our use of the services of our independent registered public accounting firm.&#xa0; Under this policy, our audit committee is required to pre-approve all audit and non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair the public accountants&#x2019; independence.&#xa0; All fees paid to Armanino LLP for our fiscal years ended December 31, 2021 and 2020 were pre-approved by our audit committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     80
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PART</b>&#xa0;<b>IV</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="a15" title="15" href="#"></a>ITEM 15.</b>&#xa0;&#xa0;&#xa0;&#xa0;<b>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(a)(1)</b></p> </td>
     <td style="vertical-align:top;width:43.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Statements</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 17pt;text-indent:36pt;">The financial statements and related notes, together with the report of Armanino LLP appear at pages F-2&#xa0;through F-20 following the Exhibit List as required by &#x201c;Part II&#x2014;Item 8&#x2014;Financial Statements and Supplementary Data&#x201d; of this Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(a)(2)</b></p> </td>
     <td style="vertical-align:top;width:43.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Statement Schedules</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(a)(3)</b></p> </td>
     <td style="vertical-align:top;width:43.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibits</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form&#xa0;10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b><br /> <b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex2-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2.1+</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex2-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement and Plan of Merger, dated as of July</span>&#xa0;<span style="text-decoration: underline; ">20, 2020, by and among the Company, Merger Sub, Sponsor in the capacity as the Purchaser Representative, Reviva, and Dr.</span>&#xa0;<span style="text-decoration: underline; ">Bhat in the capacity as the Seller Representative (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">2.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on July</span>&#xa0;<span style="text-decoration: underline; ">24, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Corporate Domestication (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">3.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920135081/tm2038397d1_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920135081/tm2038397d1_ex3-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Interim Certificate of Incorporation (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">3.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex3-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex3-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Certificate of Incorporation (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">3.3 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920135081/tm2038397d1_ex3-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.4</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920135081/tm2038397d1_ex3-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Bylaws of Reviva Pharmaceuticals Holdings,</span>&#xa0;<span style="text-decoration: underline; ">Inc. (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">3.2 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000143774921006681/ex_230521.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000143774921006681/ex_230521.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Securities (filed as exhibit 4.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Annual Report on Form 10-K filed with the SEC on March 22, 2021, and incorporated herein by reference).</span>&#xa0;</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Assumed Warrant (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">4.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418042170/tv500126_ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.3</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen Warrant Certificate (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">4.3 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">S-1 (File No.</span>&#xa0;<span style="text-decoration: underline; ">333-226263) as filed on August</span>&#xa0;<span style="text-decoration: underline; ">16, 2018, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.4</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Warrant Agreement, dated August</span>&#xa0;<span style="text-decoration: underline; ">20, 2018, between the Company and Continental Stock Transfer</span>&#xa0;<span style="text-decoration: underline; ">&amp; Trust Company (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">4.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on August</span>&#xa0;<span style="text-decoration: underline; ">24, 2018, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920120670/tm2027235d6_ex4-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.5</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920120670/tm2027235d6_ex4-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen common stock certificate of the Company (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">4.4 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">S-4 (File No.</span>&#xa0;<span style="text-decoration: underline; ">(333-245057) as filed on November</span>&#xa0;<span style="text-decoration: underline; ">3, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268126.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.6</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268126.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 10-Q as filed on August 16, 2021, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268127.htm" style="-sec-extract:exhibit;">4.7</a></td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268127.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Common Stock Purchase Warrant (filed as Exhibit 4.2 to the Company</span></a>&#x2019;<a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268127.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">s Form 10-Q as filed on August 16, 2021, and incorporated herein by reference).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268127.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.8</span></a></td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268127.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Common Stock Purchase Warrant (filed as Exhibit 4.2 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 10-Q as filed on August 16, 2021, and incorporated herein by reference).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268128.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.9</span></a></td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921019983/ex_268128.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Warrant Agency Agreement, dated June 1, 2021, between the Company and Continental Stock Transfer &amp; Trust Company (filed as Exhibit 4.3 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 10-Q as filed on August 16, 2021, and incorporated herein by reference).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.1#</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, dated as of December</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, by and between the Company and Dr.</span>&#xa0;<span style="text-decoration: underline; ">Bhat. (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Lock-Up Agreement (General) (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.2 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on July</span>&#xa0;<span style="text-decoration: underline; ">24, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.3</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lock-Up Agreement, dated as of July</span>&#xa0;<span style="text-decoration: underline; ">20, 2020, by and among Dr.</span>&#xa0;<span style="text-decoration: underline; ">Bhat, Tenzing and the Purchaser Representative (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.3 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on July</span>&#xa0;<span style="text-decoration: underline; ">24, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.4</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920086490/tm2025546d1_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Non-Competition Agreement, dated as of July</span>&#xa0;<span style="text-decoration: underline; ">20, 2020, by Dr.</span>&#xa0;<span style="text-decoration: underline; ">Bhat in favor of Tenzing, Reviva and their respective affiliates (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.4 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on July</span>&#xa0;<span style="text-decoration: underline; ">24, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920122454/tm2027235d10_ex10-16.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.5++ #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920122454/tm2027235d10_ex10-16.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Offer of Employment, dated as of</span>&#xa0;<span style="text-decoration: underline; ">October</span>&#xa0;<span style="text-decoration: underline; ">19, 2020, by and between Narayan Prabhu and Reviva</span>&#xa0;<span style="text-decoration: underline; ">Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc. (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.16 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">S-4 (File No.</span>&#xa0;<span style="text-decoration: underline; ">(333-245057) as filed on November</span>&#xa0;<span style="text-decoration: underline; ">6, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-6.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.6 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-6.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Offer of Employment, dated as of</span>&#xa0;<span style="text-decoration: underline; ">December</span>&#xa0;<span style="text-decoration: underline; ">12, 2012, by and between Marc Cantillon, MD and Reviva</span>&#xa0;<span style="text-decoration: underline; ">Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc. (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.6 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-7.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.7 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-7.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter Agreement, dated as of October</span>&#xa0;<span style="text-decoration: underline; ">28, 2015, by and between Marc Cantillon, MD and Reviva</span>&#xa0;<span style="text-decoration: underline; ">Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc. (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.7 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.8 #</span></a></td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter Agreement, dated as of March</span>&#xa0;<span style="text-decoration: underline; ">15, 2016, by and between Marc Cantillon, MD and Reviva</span>&#xa0;<span style="text-decoration: underline; ">Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc. (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.8 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921009052/ex_241277.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.9 ++#</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001742927/000143774921009052/ex_241277.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter Agreement, dated as of April 14, 2021, by and between Marc Cantillon, MD and Reviva Pharmaceuticals Holdings, Inc. (filed as Exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form 8-K as filed on April 15, 2021 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-9.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.10 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-9.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Indemnification Agreement (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.9 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.11 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-10.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Saxena&#xa0;Indemnification Agreement (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.10 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-11.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.12</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-11.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Non-Redemption Agreement, dated as of December</span>&#xa0;<span style="text-decoration: underline; ">8, 2020, by and among the Company, Tenzing LLC and the shareholder party thereto (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.11 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-12.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.13</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-12.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Registration Rights Agreement, dated as of December</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, by and between the Company and the shareholder party thereto (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.12 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-13.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.14 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-13.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Reviva Pharmaceuticals Holdings,</span>&#xa0;<span style="text-decoration: underline; ">Inc. 2020 Equity Incentive Plan (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.13 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-14.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.15 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-14.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Incentive Stock Option Grant Agreement (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.14 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-15.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.16 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-15.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Nonqualified Stock Option Grant Agreement (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.15 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-16.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.17 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-16.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Reviva Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc. 2006 Equity Incentive Plan (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.16 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-17.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.18 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-17.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to Reviva Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc. 2006 Equity Incentive Plan (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.17 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-18.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.19 #</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-18.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Assumed Option (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.18 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-19.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.20</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-19.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Note Purchase Agreement, dated as of August</span>&#xa0;<span style="text-decoration: underline; ">27, 2020, by and between the Company and the investors party thereto (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.19 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-20.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.21</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-20.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Note Purchase Agreement, dated as of August</span>&#xa0;<span style="text-decoration: underline; ">29, 2020, by and between the Company and the investors party thereto (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.20 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.22</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter Agreement, dated as of December</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, by and between the Company, Maxim Group LLC and Maxim Partners LLC (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.21 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.23</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter Agreement, dated August</span>&#xa0;<span style="text-decoration: underline; ">20, 2018, by and among the Company, its officers, its directors and the Sponsor (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.3 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on August</span>&#xa0;<span style="text-decoration: underline; ">24, 2018, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.24</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement, dated as of August</span>&#xa0;<span style="text-decoration: underline; ">20, 2018, by and among Tenzing, the Sponsor, Maxim and the holders party thereto (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.2 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on August</span>&#xa0;<span style="text-decoration: underline; ">24, 2018, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-24.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.25</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex10-24.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Escrow Agreement, dated as of December</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, by and among the Company, Tenzing LLC, Laxminarayan Bhat and Continental Stock Transfer</span>&#xa0;<span style="text-decoration: underline; ">&amp; Trust Company (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.24 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920117007/tm2033999d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.26</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920117007/tm2033999d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Backstop Agreement, by and among Tenzing Acquisition Corp., Reviva Pharmaceuticals,</span>&#xa0;<span style="text-decoration: underline; ">Inc., and the Investor named therein (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on October</span>&#xa0;<span style="text-decoration: underline; ">21, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.27</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter Agreement, dated August</span>&#xa0;<span style="text-decoration: underline; ">20, 2018, by and among Tenzing, its officers, its directors and the Sponsor (incorporated by reference to Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.3 of Tenzing</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K (File No.</span>&#xa0;<span style="text-decoration: underline; ">001-38634), filed with the SEC on August</span>&#xa0;<span style="text-decoration: underline; ">24, 2018).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.28</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418046269/tv501602_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Investment Management Trust Agreement, dated August</span>&#xa0;<span style="text-decoration: underline; ">20, 2018, by and between Tenzing and Continental Stock Transfer</span>&#xa0;<span style="text-decoration: underline; ">&amp; Trust Company, as trustee (incorporated by reference to Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.1 of Tenzing</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K (File No.</span>&#xa0;<span style="text-decoration: underline; ">001-38634), filed with the SEC on August</span>&#xa0;<span style="text-decoration: underline; ">24, 2018).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418039143/tv498887_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.29</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418039143/tv498887_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement between Tenzing and Tenzing LLC (incorporated by reference to Exhibit 10.4 of Tenzing's Form S-1 (File No. 333-226263), filed with the SEC on July 20, 2018).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418045184/tv500263_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.30</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418045184/tv500263_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Amended and Restated Unit Purchase Agreement between Tenzing and the Sponsor (incorporated by reference to Exhibit 10.4 of Tenzing</span>&#x2019;<span style="text-decoration: underline; ">s Form S-1 (File No. 333-226263), filed with the SEC on August 16, 2018).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418045184/tv500263_ex10-7.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.31</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000114420418045184/tv500263_ex10-7.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form</span>&#xa0;<span style="text-decoration: underline; ">of Unit Purchase Agreement between Tenzing and Maxim Group LLC (incorporated by reference to Exhibit</span>&#xa0;<span style="text-decoration: underline; ">10.7 of Tenzing</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">S-1 (File No.</span>&#xa0;<span style="text-decoration: underline; ">333-226263), filed with the SEC on August</span>&#xa0;<span style="text-decoration: underline; ">16, 2018).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920021688/tm208113d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.32</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920021688/tm208113d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Promissory Note, dated February</span>&#xa0;<span style="text-decoration: underline; ">10, 2020, issued by Tenzing Acquisition Corp. to Tenzing LLC (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on February</span>&#xa0;<span style="text-decoration: underline; ">14, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920064743/tm2020397d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.33</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920064743/tm2020397d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Promissory Note, dated May</span>&#xa0;<span style="text-decoration: underline; ">21, 2020, issued by Tenzing Acquisition Corp. to Tenzing LLC (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on May</span>&#xa0;<span style="text-decoration: underline; ">21, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920087859/tm2026025d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.34</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920087859/tm2026025d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Promissory Note, dated July</span>&#xa0;<span style="text-decoration: underline; ">24, 2020, issued by Tenzing Acquisition Corp. to Tenzing LLC (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on July</span>&#xa0;<span style="text-decoration: underline; ">29, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920096546/tm2028913d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.35</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920096546/tm2028913d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Promissory Note, dated August</span>&#xa0;<span style="text-decoration: underline; ">18, 2020, issued by Tenzing Acquisition Corp. to Tenzing LLC (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on August</span>&#xa0;<span style="text-decoration: underline; ">18, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920108939/tm2031806d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.36</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920108939/tm2031806d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Promissory Note, dated September</span>&#xa0;<span style="text-decoration: underline; ">24, 2020, issued by Tenzing Acquisition Corp. to Tenzing LLC (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on September</span>&#xa0;<span style="text-decoration: underline; ">25, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920125104/tm2035967d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.37</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920125104/tm2035967d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Promissory Note, dated November</span>&#xa0;<span style="text-decoration: underline; ">12, 2020, issued by Tenzing Acquisition Corp. to Tenzing LLC (filed as exhibit 10.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form</span>&#xa0;<span style="text-decoration: underline; ">8-K filed on</span>&#xa0;<span style="text-decoration: underline; ">November</span>&#xa0;<span style="text-decoration: underline; ">13, 2020, and incorporated herein by reference).</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465921005919/tm213611d1_ex16-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">16.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465921005919/tm213611d1_ex16-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Letter from Marcum LLP, dated January 20, 2021 (filed as exhibit 16.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K/A filed on January 20, 2021, and incorporated herein by reference).</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex21-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">21.1</span></a></td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"><a href="http://www.sec.gov/Archives/edgar/data/1742927/000110465920137506/tm2038449d1_ex21-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">List of Subsidiaries of the Company (filed as Exhibit</span>&#xa0;<span style="text-decoration: underline; ">21.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Current Report on Form</span>&#xa0;<span style="text-decoration: underline; ">8-K as filed on December</span>&#xa0;<span style="text-decoration: underline; ">18, 2020 and incorporated herein by reference).</span></a></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_346563.htm" style="-sec-extract:exhibit;">23.1*</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_346563.htm" style="-sec-extract:exhibit;">Consent of Armanino LLP</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">24.1*</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (included on the signature page).</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1*</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_345157.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2*</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_345158.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1**</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_345159.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;">104*</td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">**</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#x201c;filed&#x201d;&#xa0;for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">+</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The exhibits and schedules to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby agrees to furnish a copy of any omitted schedules to the Commission upon request.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">++</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain information in this exhibit has been omitted pursuant to Item 601(a)(6) of Regulation S-K.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">#</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicates management contract or compensatory plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="a16" title="16" href="#"></a>ITEM 16.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>FORM</b>&#xa0;<b>10-K SUMMARY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     84
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="signatures" title="signatures" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">Pursuant to the requirements of Section&#xa0;13 and 15(d)&#xa0;of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form&#xa0;10-K to be signed on its behalf by the undersigned thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Reviva Pharmaceuticals Holdings, Inc.</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Registrant)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 57pt;">Date: March 15, 2022</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Laxminarayan Bhat</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Laxminarayan Bhat</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Chief Executive Officer</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Principal Executive Officer)</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 57pt;">Date: March 15, 2022</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Narayan Prabhu</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Narayan Prabhu</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Chief Financial Officer</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Principal Financial and Accounting Officer)</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="poa" title="poa" href="#"></a>POWER OF ATTORNEY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laxminarayan Bhat and Narayan Prabhu, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#xa0;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form&#xa0;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 15,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Laxminarayan Bhat</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief&#xa0;Executive&#xa0;Officer&#xa0;and&#xa0;Director</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Laxminarayan Bhat</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal&#xa0;Executive&#xa0;Officer)</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 15,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Narayan Prabhu</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief&#xa0;Financial&#xa0;Officer</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Narayan Prabhu</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal&#xa0;Financial&#xa0;and&#xa0;Accounting&#xa0;Officer)</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 15,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Parag Saxena</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chairman of the Board</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Parag Saxena</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 15,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Richard Margolin</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Richard Margolin</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 15,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Purav Patel</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 13.3%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Purav Patel</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 15,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:13.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Les Funtleyder</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 13.3%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Les Funtleyder</p> </td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:23.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:6.8%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     85
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>REVIVA</b>&#xa0;<b>PHARMACEUTICALS HOLDINGS, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>INDEX TO C</b><b>ONSOLIDATED</b><b> FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#report" style="-sec-extract:exhibit;">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID:<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorFirmId">32</ix:nonNumeric>)</p> </td>
     <td style="vertical-align:bottom;width:4.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-2</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Statements:</p> </td>
     <td style="vertical-align:bottom;width:4.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 20pt;text-indent:-10pt;"><a href="#balance" style="-sec-extract:exhibit;">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></p> </td>
     <td style="vertical-align:bottom;width:4.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-3</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 20pt;text-indent:-10pt;"><a href="#operations" style="-sec-extract:exhibit;">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</a></p> </td>
     <td style="vertical-align:bottom;width:4.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-4</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 20pt;text-indent:-10pt;"><a href="#equity" style="-sec-extract:exhibit;">Consolidated Statements of Stockholders&#x2019;&#xa0;Equity (Deficit)&#xa0;for the years ended December 31, 2021 and 2020</a></p> </td>
     <td style="vertical-align:bottom;width:4.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-5</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 20pt;text-indent:-10pt;"><a href="#cashflows" style="-sec-extract:exhibit;">Consolidated Statements of Cash Flows&#xa0;for the years ended December 31, 2021 and 2020</a></p> </td>
     <td style="vertical-align:bottom;width:4.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-6</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:41.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes to&#xa0;Consolidated Financial Statements</a></p> </td>
     <td style="vertical-align:bottom;width:4.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">F-7</p> </td>
    </tr>

   </tbody>
  </table>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="report" title="report" href="#"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Board of Directors and Stockholders of</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reviva Pharmaceuticals Holdings, Inc.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cupertino, California</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Opinion on the Financial Statements</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have audited the accompanying consolidated balance sheets of Reviva Pharmaceuticals Holdings, Inc. (the "Company") as of December 31, 2021 and 2020, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes <i>(</i>collectively referred to as the "financial statements").&#xa0; In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the consolidated results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Basis for Opinion</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These consolidated financial statements are the responsibility of the Company's management.&#xa0; Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits.&#xa0; We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB.&#xa0; Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.&#xa0; The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&#xa0; As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.&#xa0; Accordingly, we express no such opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&#xa0; Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.&#xa0; Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.&#xa0; We believe that our audits provide a reasonable basis for our opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:22.8%;">&#xa0;</td>
     <td style="vertical-align:middle;width:22.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorName">ArmaninoLLP</ix:nonNumeric></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#x2019;s auditor since 2016.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorLocation">San Ramon, California</ix:nonNumeric></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">March 15, 2022</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="balance" title="balance" href="#"></a>REVIVA PHARMACEUTICALS HOLDINGS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSOLIDATED BALANCE SHEETS</b><br /> <b>December</b>&#xa0;<b>31, 2021 and 2020</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: 9pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966263" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">29,687,944</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966264" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">8,760,462</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966265" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,716,057</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966266" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,816</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total Assets</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966267" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">31,404,001</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966268" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">8,762,278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and Stockholders' Equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966271" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">509,583</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966272" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,008,046</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: 9pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966273" contextRef="i_2021-12-31" unitRef="USD" name="rvph:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,835,228</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966274" contextRef="i_2020-12-31" unitRef="USD" name="rvph:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">324,697</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: 9pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966275" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,344,811</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966276" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,332,743</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: 9pt;">Warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966277" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">372,730</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966278" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,963,785</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total Liabilities</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966279" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,717,541</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966280" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">3,296,528</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt;">Commitments and contingencies (Note 12)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c81966282">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c81966283">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Stockholders' equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: 0pt;">Common stock, par value of <span style="-sec-ix-hidden:c81966287"><span style="-sec-ix-hidden:c81966288">$0.0001</span></span>; <span style="-sec-ix-hidden:c81966289"><span style="-sec-ix-hidden:c81966290">115,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c81966291"><span style="-sec-ix-hidden:c81966293">14,433,286</span></span> and <span style="-sec-ix-hidden:c81966292"><span style="-sec-ix-hidden:c81966294">9,231,737</span></span> shares issued and outstanding as of December 31, 2021, and December 31, 2020, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966285" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,443</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966286" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">923</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966295" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">95,516,986</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966296" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="INF">63,774,920</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966297" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">66,831,969</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966298" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,310,093</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966299" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">28,686,460</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966300" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">5,465,750</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total Liabilities and Stockholders' Equity</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966301" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">31,404,001</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966302" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">8,762,278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="operations" title="operations" href="#"></a>REVIVA PHARMACEUTICALS HOLDINGS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b><br /> <b>For the Years Ended December</b>&#xa0;<b>31, 2021 and 2020</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966304" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">4,851,602</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966305" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">295,150</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966306" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">5,252,911</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966307" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,139,501</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966308" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">10,104,513</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966309" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">2,434,651</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966310" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10,104,513</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966311" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,434,651</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income (expense)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">Gain on remeasurement of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966313" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,591,055</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966314" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">Interest and other income (expense), net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966315" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="rvph:InterestAndOtherIncomeExpenseNet" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,414</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966316" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:InterestAndOtherIncomeExpenseNet" scale="0" format="ixt:numdotdecimal" decimals="INF">105,183</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">Interest expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966317" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81966318" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,453,120</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total other income (expense), net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966319" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,588,641</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81966320" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,347,937</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">Loss before provision for income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966321" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,515,872</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966322" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,782,588</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966323" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF">6,004</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966324" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF">800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81966325" contextRef="d_2021-01-01_2021-12-13" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,521,876</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81966326" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,783,388</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss per share:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;"><b>Basic and diluted</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81966328" contextRef="d_2021-01-01_2021-12-13" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.58</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81966329" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.24</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted average shares outstanding</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt; margin-left: 9pt;"><b>Basic and diluted</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966331" contextRef="d_2021-01-01_2021-12-13" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">14,790,843</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966332" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">3,061,670</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="equity" title="equity" href="#"></a>REVIVA PHARMACEUTICALS HOLDINGS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS</b>&#x2019;<b> EQUITY (DEFICIT)</b><br /> <b>For the Years Ended December</b>&#xa0;<b>31, 2021 and 2020</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Series 1,2,3,4</b><br /> <b>Convertible</b><br /> <b>Preferred Stock</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common Stock</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Additional</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Paid-in</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b><br /> <b>Stockholders</b>&#x2019;</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Equity </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Capital</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Deficit</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Deficit)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 30%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2019</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c81966333" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,597,585</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c81966334" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">29,069,974</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c81966335" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,768,346</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c81966336" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">618</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c81966337" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">18,644,683</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c81966338" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">54,526,705</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c81966339" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">6,811,430</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock in lieu of deferred compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966341" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966342" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">38,992</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966343" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">25</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966344" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">340,907</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966345" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966346" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">340,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Beneficial conversion feature on conversion of notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966348" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966350" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966351" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="INF">961,680</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966352" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966353" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="INF">961,680</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock upon conversion of notes and accrued interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966355" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966356" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,099,947</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966357" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">110</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966358" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">8,499,233</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966359" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966360" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">8,499,343</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Reclassification of warrant liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966362" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966364" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966365" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">1,185,577</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966366" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966367" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">1,185,577</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from reverse acquisition, net of costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966369" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966371" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966372" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" scale="0" format="ixt:numdotdecimal" decimals="INF">9,375,961</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966373" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966374" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" scale="0" format="ixt:numdotdecimal" decimals="INF">9,375,961</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of reverse recapitalization, net of costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966375" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="rvph:EffectOfReverseReverseRecapitalizationNetOfCostsShares" format="ixt:numdotdecimal" decimals="0" sign="-">1,597,585</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966376" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="rvph:EffectOfReverseRecapitalizationNetOfCostsValue" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">29,069,974</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966377" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="rvph:EffectOfReverseReverseRecapitalizationNetOfCostsShares" scale="0" format="ixt:numdotdecimal" decimals="INF">5,324,452</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966378" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="rvph:EffectOfReverseRecapitalizationNetOfCostsValue" scale="0" format="ixt:numdotdecimal" decimals="INF">170</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966379" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="rvph:EffectOfReverseRecapitalizationNetOfCostsValue" scale="0" format="ixt:numdotdecimal" decimals="INF">24,766,879</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966380" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="rvph:EffectOfReverseRecapitalizationNetOfCostsValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966381" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:EffectOfReverseRecapitalizationNetOfCostsValue" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,302,928</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966383" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966385" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966386" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966387" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,783,388</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966388" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,783,388</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2020</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966389" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966390" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c81966391" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">9,231,737</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c81966392" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">923</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c81966393" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">63,774,920</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>(<ix:nonFraction id="c81966394" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,310,093</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c81966395" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">5,465,750</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Additional</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Total</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Common Stock</b></b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Paid-In</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Accumulated</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Stockholders</b></b></b>&#x2019;</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Year Ended December 31, 2021</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Shares</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Amount</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Capital</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Deficit</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Equity (Deficit)</b> </b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966396" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">9,231,737</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966397" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">923</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966398" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">63,774,920</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966399" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,310,093</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966400" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">5,465,750</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Issuance of Units in public offering, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966401" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">4,133,400</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966402" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">413</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966403" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">31,497,050</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966404" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966405" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">31,497,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt; margin-left: 9pt;">Common stock issued in connection with warrant exercises</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966406" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="rvph:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">1,057,149</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966407" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="rvph:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">106</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966408" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="rvph:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">98,375</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966409" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="rvph:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966410" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">98,481</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock issued to consultant in exchange for services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966411" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">11,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966412" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966413" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">39,928</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966414" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966415" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">39,929</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966417" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966418" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">106,713</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966419" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966420" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">106,713</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966422" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966424" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,521,876</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966425" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,521,876</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966426" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,433,286</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966427" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">1,443</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966428" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">95,516,986</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81966429" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">66,831,969</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966430" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">28,686,460</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="cashflows" title="cashflows" href="#"></a>REVIVA PHARMACEUTICALS HOLDINGS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b><br /> <b>For the Years Ended December</b>&#xa0;<b>31, 2021 and 2020</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year Ended December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash flows from operating activities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966432" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">8,521,876</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966433" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,783,388</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Adjustments to reconcile net loss to net cash used in operating activities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966435" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966436" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">591</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Change in fair value of warrant liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966437" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,591,055</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966438" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">1,084,052</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Noncash interest expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966439" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966440" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">961,680</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Issuance of stock in exchange for services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966441" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" format="ixt:numdotdecimal" decimals="INF">39,929</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966442" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966443" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">106,713</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966444" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 27pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966446" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966447" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,330,738</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 27pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966448" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">1,714,241</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966449" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 27pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81966450" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">498,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966451" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">775,101</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 27pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966452" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966453" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 27pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966454" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">1,510,531</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966455" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">773,922</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net cash used in operating activities</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966456" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10,668,462</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966457" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">4,066,624</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash flows from financing activities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Issuance of common stock in lieu of deferred compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966459" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:ProceedsFromIssuanceOfCommonStockForDeferredCompensation" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966460" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:ProceedsFromIssuanceOfCommonStockForDeferredCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">340,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from business combination, net of costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966461" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:ProceedsFromReverseRecapitalization" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966462" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:ProceedsFromReverseRecapitalization" scale="0" format="ixt:numdotdecimal" decimals="INF">9,375,961</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from issuance of Units in public offering, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966463" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">31,497,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966464" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from issuance of stock upon warrant exercises</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966465" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">98,481</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966466" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from issuance of convertible promissory notes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966467" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966468" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">3,110,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net cash provided by financing activities</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966469" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">31,595,944</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966470" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">12,826,893</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net increase (decrease) in cash</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966471" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">20,927,482</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966472" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">8,760,269</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash, beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966473" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">8,760,462</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966474" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">193</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash, end of period</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966475" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">29,687,944</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81966476" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">8,760,462</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Supplemental disclosures of cash flow information:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Cash paid for taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966478" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="0" format="ixt:numdotdecimal" decimals="INF">2,400</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966479" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="0" format="ixt:numdotdecimal" decimals="INF">800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Cash paid for interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966480" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966481" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="0" format="ixt:numdotdecimal" decimals="INF">327,076</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Supplemental schedule of noncash financing and investing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Conversion of convertible promissory notes into common stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966483" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966484" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" format="ixt:numdotdecimal" decimals="INF">6,875,088</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Payment of certain deferred costs from proceeds from business combination</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966485" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:PaymentOfCertainDeferredCosts" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966486" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:PaymentOfCertainDeferredCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><a id="notes" title="notes" href="#"></a>REVIVA PHARMACEUTICALS HOLDINGS, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b><br /> <b>December</b>&#xa0;<b>31, 2021 and 2020</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2060581" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#xa0;&#xa0;&#xa0;<b>ORGANIZATION AND NATURE OF OPERATIONS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">14,</em> <em style="font: inherit;">2020,</em> Reviva Pharmaceuticals Holdings,&#xa0;Inc. (the &#x201c;Company&#x201d;), a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp. (&#x201c;Tenzing&#x201d;), a British Virgin Islands exempted company, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#x201c;Merger Sub&#x201d;), and Reviva Pharmaceuticals,&#xa0;Inc., a Delaware corporation (together with its consolidated subsidiary), consummated a business combination (the &#x201c;Business Combination&#x201d;) through the merger of Merger Sub with and into Reviva Pharmaceuticals,&#xa0;Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of <em style="font: inherit;"> July&#xa0;</em><em style="font: inherit;">20,</em> <em style="font: inherit;">2020</em> (the &#x201c;Merger Agreement&#x201d;), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals,&#xa0;Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), Merger Sub merged with and into Reviva Pharmaceuticals,&#xa0;Inc., with Reviva Pharmaceuticals,&#xa0;Inc.&#xa0;as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals,&#xa0;Inc.&#xa0;becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings,&#xa0;Inc. (together with its consolidated subsidiary).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Reviva Pharmaceuticals,&#xa0;Inc. was originally incorporated in the state of Delaware and commenced operations on <em style="font: inherit;"> May 1, 2006 </em>and its Indian subsidiary, Reviva Pharmaceuticals India Pvt. Ltd. was incorporated in <em style="font: inherit;">2014.</em> The Company is an emerging research based pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective therapeutic drugs by using an integrated chemical genomics technology platform and proprietary chemistries. The Company is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), metabolic and inflammatory diseases.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGFTR" style="text-align: center; width: 100%"><div class="hf-row"><div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
       &#xa0;
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2060582" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#xa0;&#xa0;&#xa0;<b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c81968005" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Basis of Presentation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The summary of significant accounting policies presented below is designed to assist in understanding the Company&#x2019;s financial statements. Such financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c81968006" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Principals of consolidation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:UseOfEstimates" id="c81968007" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The preparation of&#xa0;consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are <em style="font: inherit;">not</em> limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c81968008" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company&#x2019;s cash are held in demand deposit form by <em style="font: inherit;">one</em> financial institution. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are <em style="font: inherit;">not</em> limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company&#x2019;s operating results <em style="font: inherit;"> may </em>be materially affected by the foregoing factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c81968009" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Cash</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of <em style="font: inherit;">three</em>&#xa0;months or less to be cash equivalents. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company&#x2019;s cash was maintained in demand deposit forms at <em style="font: inherit;">two</em> financial institutions. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, have exceed federally insured limits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c81968010" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Property and equipment</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than <em style="font: inherit;">one</em> year for: (<em style="font: inherit;">1</em>)&#xa0;assets purchased; (<em style="font: inherit;">2</em>)&#xa0;existing assets that are replaced, improved or the useful lives have been extended. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs are expensed as incurred. Assets classified as property and equipment are stated at cost less accumulated depreciation and are depreciated using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:c81966522">three</span> and <span style="-sec-ix-hidden:c81966523">five</span>&#xa0;years, or the lease term of the respective assets, whichever is less. When assets are retired or otherwise disposed, their original cost and related accumulated depreciation are removed from the consolidated balance sheet, and any resulting gain or loss is reflected in related operating expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c81968011" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Leases</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In <em style="font: inherit;"> February&#xa0;</em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">2,</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, as amended. The ASU introduces a new lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&#x2019;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of consolidated financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this standard effective <em style="font: inherit;"> January 1, 2019, </em>and determined that there is <em style="font: inherit;">no</em> material impact that the new accounting guidance will have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c81968012" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Research and development costs</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are <em style="font: inherit;">not</em> limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="c81968013" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">General and administrative costs</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are <em style="font: inherit;">not</em> limited to, payroll and personnel expenses, travel and entertainment, consulting costs, conference and meeting costs, legal expenses and allocated overhead, including rent depreciation, and utilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c81968015" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Income taxes</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company utilizes FASB ASC <em style="font: inherit;">740,</em> &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is &#x201c;more likely-than-<em style="font: inherit;">not&#x201d;</em> that a deferred tax asset will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#xa0; The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis.&#xa0; The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of <em style="font: inherit;">100%</em> has been established due to the uncertainty of the Company&#x2019;s realization of the net operating loss carry forward prior to its expiration.&#xa0; In the event the Company determines that it would be able to realize its&#xa0;deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes.&#xa0; Conversely, in the event that all or part of the net deferred tax assets are determined <em style="font: inherit;">not</em> to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c81968016" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Stock-based compensation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC <em style="font: inherit;">718</em> which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">9</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; <span style="text-decoration: underline; ">Expected term</span>&#x2009;&#x2014;&#x2009;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; <span style="text-decoration: underline; ">Expected volatility</span>&#x2009;&#x2014;&#x2009;Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; <span style="text-decoration: underline; ">Expected dividend</span>&#x2009;&#x2014;&#x2009;The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has <em style="font: inherit;">no</em> plans to pay dividends.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; <span style="text-decoration: underline; ">Risk-free interest rate</span>&#x2009;&#x2014;&#x2009;The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury <em style="font: inherit;">zero</em>-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; <span style="text-decoration: underline; ">Forfeiture rate</span>&#x2009;&#x2014;&#x2009;The Company made the <em style="font: inherit;">one</em>-time election to recognize forfeitures when they occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2019,</em> the Company adopted ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">07,</em> Compensation-Stock Compensation (Topic <em style="font: inherit;">718</em>): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting of share-based payment awards issued to employees and nonemployees. The adoption did <em style="font: inherit;">not</em> materially impact our consolidated financial statements. The Company recognizes fair value of stock options granted to non-employees as a stock-based compensation expense over the period in which the related services are received. Non-employee option grants that do <em style="font: inherit;">not</em> vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes-Merton option-pricing model, is determined, and compensation expense recognized during the period is adjusted accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c81968021" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value Measurements of Warrants</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">ASC <em style="font: inherit;">820</em> &#x201c;Fair Value Measurements&#x201d; defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC <em style="font: inherit;">820</em> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC <em style="font: inherit;">820</em> establishes a fair value hierarchy that distinguishes between (<em style="font: inherit;">1</em>)&#xa0;market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (<em style="font: inherit;">2</em>)&#xa0;an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <em style="font: inherit;">three</em> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#xa0;<em style="font: inherit;">1</em>) and the lowest priority to unobservable inputs (Level&#xa0;<em style="font: inherit;">3</em>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">three</em> levels of the fair value hierarchy under ASC <em style="font: inherit;">820</em> are described below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; Level&#xa0;<em style="font: inherit;">1&#x2009;&#x2014;&#x2009;Quoted</em> prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#xa0;<em style="font: inherit;">1</em> inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; Level&#xa0;<em style="font: inherit;">2&#x2009;&#x2014;&#x2009;Directly</em> or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are <em style="font: inherit;">not</em> active. Level&#xa0;<em style="font: inherit;">2</em> also includes assets and liabilities that are valued using models or other pricing methodologies that do <em style="font: inherit;">not</em> require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022; Level&#xa0;<em style="font: inherit;">3&#x2009;&#x2014;&#x2009;Unobservable</em> inputs that are supported by little or <em style="font: inherit;">no</em> market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#x200b;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="rvph:BeneficialConversionFeaturePolicyTextBlock" id="c81968019" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Beneficial Conversion Features</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In accordance with FASB ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">20,</em> &#x201c;Debt with Conversion and Other Options&#x201d; the Company records a beneficial conversion feature (&#x201c;BCF&#x201d;) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-IPOMember" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2060583" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#xa0;&#xa0; <b>PUBLIC OFFERING</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> June 1, 2021, </em>the Company completed a public offering (the &#x201c;Offering&#x201d;) of Units (each, a &#x201c;Unit&#x201d;), with each Unit consisting of (a) <em style="font: inherit;">one</em> share of common stock (or pre-funded warrant to purchase <em style="font: inherit;">one</em> share of common stock in lieu thereof, with an exercise price of $<ix:nonFraction id="c81966577" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction> per share, each a &#x201c;Pre-Funded Warrant&#x201d;) and (b) <em style="font: inherit;">one</em> warrant to purchase <ix:nonFraction id="c81966579" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">0.75</ix:nonFraction>&#xa0;of a share of our common stock, with an exercise price of $<ix:nonFraction id="c81966580" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.125</ix:nonFraction> per share (each, an &#x201c;Investor Warrant&#x201d;). Pursuant to the Offering, the Company sold <ix:nonFraction id="c81966581" contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="Share" name="rvph:NumberOfUnitsOneIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">4,133,400</ix:nonFraction> Units consisting of (a) <em style="font: inherit;">one</em> share of common stock and (b) <em style="font: inherit;">one</em> Investor Warrant (inclusive the underwriter&#x2019;s overallotment option of <ix:nonFraction id="c81966584" contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="rvph:NumberOfUnitsOneIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction> of such Units), and <ix:nonFraction id="c81966585" contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="Share" name="rvph:NumberOfUnitsTwoIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">5,066,600</ix:nonFraction> Units consisting of (a) <em style="font: inherit;">one</em> Pre-Funded Warrant and (b) <em style="font: inherit;">one</em> Investor Warrant. The Units had <em style="font: inherit;">no</em> stand-alone rights and were <em style="font: inherit;">not</em> certificated or issued as stand-alone securities. Accordingly, as result of the sale of such Units in the Offering, the Company issued in aggregate <ix:nonFraction id="c81966590" contextRef="d_2021-06-01_2021-06-01_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">4,133,400</ix:nonFraction> shares of common stock, Pre-Funded Warrants exercisable for <ix:nonFraction id="c81966591" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">5,066,600</ix:nonFraction> shares of common stock, and Investor Warrants exercisable for <ix:nonFraction id="c81966592" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">6,900,000</ix:nonFraction> shares of common stock. The offering price was $<ix:nonFraction id="c81966593" contextRef="i_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="USDPerShare" name="rvph:SharesIssuedPricePerShareOne" scale="0" format="ixt:numdotdecimal" decimals="INF">3.75</ix:nonFraction> for each Unit consisting of (a) <em style="font: inherit;">one</em> share of common stock and (b) <em style="font: inherit;">one</em> Investor Warrant, and $<ix:nonFraction id="c81966596" contextRef="i_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="USDPerShare" name="rvph:SharesIssuedPricePerShareTwo" scale="0" format="ixt:numdotdecimal" decimals="INF">3.7499</ix:nonFraction> for each Unit consisting of (a) <em style="font: inherit;">one</em> Pre-Funded Warrant and (b) <em style="font: inherit;">one</em> Investor Warrant. Net proceeds from the Offering were approximately $<ix:nonFraction id="c81966599" contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="USD" name="rvph:ProceedsFromIssuanceOrSaleOfEquityNet" scale="6" format="ixt:numdotdecimal" decimals="-5">31.5</ix:nonFraction> million, after underwriter discounts, commissions, legal and accounting fees, and certain other costs of approximately $<ix:nonFraction id="c81966600" contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:numdotdecimal" decimals="-6">3.0</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="c2060584" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#xa0;&#xa0;&#xa0;<b>BUSINESS COMBINATION</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">14,</em> <em style="font: inherit;">2020,</em> Reviva Pharmaceuticals Holdings,&#xa0;Inc., a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp., a British Virgin Islands exempted company (&#x201c;Tenzing&#x201d;), Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#x201c;Merger Sub&#x201d;), and Reviva Pharmaceuticals,&#xa0;Inc., a Delaware corporation (together with its consolidated subsidiaries)&#xa0;Reviva Pharmaceuticals,&#xa0;Inc., consummated a business combination (the &#x201c;Business Combination&#x201d;) through the merger of Merger Sub with and into Reviva Pharmaceuticals,&#xa0;Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of <em style="font: inherit;"> July&#xa0;</em><em style="font: inherit;">20,</em> <em style="font: inherit;">2020</em> (the &#x201c;Merger Agreement&#x201d;), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals,&#xa0;Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), Merger Sub merged with and into Reviva Pharmaceuticals,&#xa0;Inc., with Reviva Pharmaceuticals,&#xa0;Inc.&#xa0;as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals,&#xa0;Inc.&#xa0;becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings,&#xa0;Inc. (together with its consolidated subsidiaries).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Upon the closing of the Business Combination, all shares of Reviva Pharmaceuticals, Inc. common stock and preferred stock issuance and outstanding immediately prior to the Business Combination converted into common stock of Reviva Pharmaceuticals Holdings, Inc., with a par value of $<ix:nonFraction id="c81966606" contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction> per share at an exchange rate of <ix:nonFraction id="c81966607" contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" unitRef="Pure" name="rvph:ConversionOfStockConversionRate" scale="0" format="ixt:numdotdecimal" decimals="INF">0.152268</ix:nonFraction> for common stock and <ix:nonFraction id="c81966608" contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" unitRef="Pure" name="rvph:ConversionOfStockConversionRate" scale="0" format="ixt:numdotdecimal" decimals="INF">0.414647</ix:nonFraction> for preferred stock.&#xa0; Each issued and outstanding warrant to acquire shares of Reviva Pharmaceuticals, Inc. common stock were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into a warrant for Reviva Pharmaceuticals Holdings, Inc. common stock, with its price and number of shares adjusted based on the common stock exchange rate of <em style="font: inherit;">0.152268.</em>&#xa0; Each outstanding option to acquire Reviva Pharmaceuticals, Inc. common stock (all of which were vested at the date of the Business Combination), were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into an option to acquire shares of Reviva Pharmaceuticals Holdings, Inc. common stock at the common stock exchange rate of <em style="font: inherit;">0.152268.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In addition to the merger consideration set forth above, the Reviva Pharmaceuticals,&#xa0;Inc.&#xa0;Security holders also have a contingent right to receive up to an additional <ix:nonFraction id="c81966611" contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" unitRef="Share" name="rvph:AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000</ix:nonFraction> shares of Reviva Pharmaceuticals Holdings,&#xa0;Inc.&#xa0;(the &#x201c;Earnout Shares&#x201d;)&#xa0;based on the stock price performance of the common stock and the achievement by the Company&#xa0;of certain clinical trial milestones during the <em style="font: inherit;">three</em> (<ix:nonNumeric contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" name="rvph:StockPricePerformanceMilestonePeriod" id="c81966613" format="ixt-sec:duryear">3</ix:nonNumeric>)&#xa0;year period following the Closing (the &#x201c;Earnout Period&#x201d;). In order to receive the Earnout Shares, during the Earnout Period, both:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.3%;">&#xa0;</td><td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the closing price of the Company&#x2019;s&#xa0;common stock has to be equal to or greater than $<ix:nonFraction id="c81966615" contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" unitRef="USDPerShare" name="rvph:ThresholdClosingPriceForSpecifiedNumberOfTradingDays" scale="0" format="ixt:numdotdecimal" decimals="INF">15.00</ix:nonFraction> per share for any <ix:nonNumeric contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" name="rvph:ThresholdTradingDaysForSaleOfShares" id="c81966616" format="ixt-sec:durday">20</ix:nonNumeric> trading days within any <ix:nonNumeric contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" name="rvph:ThresholdConsecutiveTradingDaysForSaleOfShares" id="c81966617" format="ixt-sec:durday">30</ix:nonNumeric> trading day period; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.3%;">&#xa0;</td><td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company&#xa0;must receive positive data from (i)&#xa0;its <em style="font: inherit;">first</em> Phase <em style="font: inherit;">3</em> trial in Acute Schizophrenia and (ii)&#xa0;either a Phase <em style="font: inherit;">2</em> clinical trial in pulmonary arterial hypertension or idiopathic pulmonary fibrosis.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Business Combination was accounted for as a reverse merger in accordance with U.S. GAAP. Under this method of accounting, Tenzing is treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on the holders of Reviva&#xa0;Pharmaceuticals,&#xa0;Inc. having a majority of the voting power of the post-combination company, Reviva Pharmaceuticals,&#xa0;Inc. senior management comprising substantially all of the senior management of the post-combination company, the relative size of Reviva compared to Tenzing, and Reviva Pharmaceuticals,&#xa0;Inc. operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Reviva&#xa0;Pharmaceuticals,&#xa0;Inc. issuing stock for the net assets of Tenzing, accompanied by a recapitalization. The net assets of Tenzing are stated at historical cost, with <ix:nonFraction id="c81966621" contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember" unitRef="USD" name="us-gaap:Goodwill" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> goodwill or other intangible assets recorded.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The accompanying financial statements and related notes reflect the historical results of Reviva Pharmaceuticals,&#xa0;Inc.&#xa0;prior to the merger and do <em style="font: inherit;">not</em> include the historical results of Tenzing prior&#xa0;to the consummation of the Business Combination.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2060585" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#xa0;&#xa0;&#xa0;<b>PROPERTY AND EQUIPMENT, NET</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">Property and equipment, net consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2060586" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966630" contextRef="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">32,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966631" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">32,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966632" contextRef="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">9,208</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966633" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">9,208</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966634" contextRef="i_2021-12-13" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">41,708</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966635" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">41,708</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Property and equipment, net</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966636" contextRef="i_2021-12-13" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966637" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">Depreciation expense for the&#xa0;years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81966628" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction> and $<ix:nonFraction id="c81966629" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:numdotdecimal" decimals="INF">591</ix:nonFraction> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="c2060587" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#xa0;&#xa0;&#xa0;<b>EMPLOYEE BENEFIT PLAN</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In <em style="font: inherit;">2014,</em>&#xa0;Reviva&#xa0;Pharmaceuticals,&#xa0;Inc. implemented a tax deferred savings plan, commonly referred to as a <em style="font: inherit;">401</em>(k) plan. Employee&#x2019;s contributions are withheld from standard payroll checks and are automatically withdrawn from the Company checking account and deposited into individual employee retirement accounts a few days following each payroll period. Employees can defer or contribute the statutory legal limits. There has been <ix:nonFraction id="c81966641" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> Company matching of employee contributions to the plan through <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:DebtDisclosureTextBlock" id="c2060588" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#xa0;&#xa0;&#xa0;<b>CONVERTIBLE PROMISSORY NOTES</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2016</em> Notes</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">From <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">2016</em> through <em style="font: inherit;"> April&#xa0;</em><em style="font: inherit;">2017,</em> the Company issued an aggregate of $<ix:nonFraction id="c81966648" contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">4,795,088</ix:nonFraction> in convertible promissory notes to various investors (the <em style="font: inherit;">&#x201c;2016</em> Notes&#x201d;). Upon next equity financing close of at least $<ix:nonFraction id="c81966650" contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="rvph:QualifiedFinancingMinimumThreshold" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction>, (&#x201c;Qualified Financing&#x201d;), the <em style="font: inherit;">2016</em> Notes were to be converted if the entire balance had <em style="font: inherit;">not</em> been paid, at which time the then outstanding balance and accrued interest was to automatically be cancelled and converted into that number of conversion shares at a price equal to the lower of either (i)&#xa0;a <ix:nonFraction id="c81966653" contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember" unitRef="Pure" name="rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% discount to the price paid by investors in the qualified financing (&#x201c;Qualified Financing Event Share Price&#x201d;), or (ii)&#xa0;an $<ix:nonFraction id="c81966654" contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="rvph:PreofferingValuationPriorToQualifiedFinancingEvent" scale="0" format="ixt:numdotdecimal" decimals="INF">85,000,000</ix:nonFraction> pre-offering valuation divided by the number of shares of the Company&#x2019;s common stock outstanding on a fully diluted basis immediately prior to the closing of such a qualified financing event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Interest was initially accrued at <ix:nonFraction id="c81966655" contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">8</ix:nonFraction>% per annum and was scheduled to be paid in cash at maturity date. The <em style="font: inherit;">2016</em> Notes were scheduled to mature <span style="-sec-ix-hidden:c81966657">twelve</span>&#xa0;months from the dates of issue. The <em style="font: inherit;">2016</em> Notes were neither converted nor paid back, and therefore were in default since <em style="font: inherit;">2017</em> and were accruing interest at a default rate of <ix:nonFraction id="c81966660" contextRef="i_2020-12-31_DebtInstrumentAxis-The2016NotesMember" unitRef="Pure" name="rvph:DebtInstrumentDebtDefaultInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="2">12</ix:nonFraction>% per annum. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2019,</em> the Company owed $<ix:nonFraction id="c81966663" contextRef="i_2019-12-31_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">3,490,087</ix:nonFraction> and $<ix:nonFraction id="c81966664" contextRef="i_2019-12-31_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,192,496</ix:nonFraction> as principle and accrued interest, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The original&#xa0;stated conversion term for the <em style="font: inherit;">2016</em> Notes created a contingent BCF that was <em style="font: inherit;">not</em> measurable due to a contingency in the conversion mechanics that would allow a conversion to take place at the lower of either a <em style="font: inherit;">20%</em> discount to the Qualified Financing Event Share Price or a <em style="font: inherit;">$85</em>&#xa0;million valuation. Consequently, the BCF would have been recognized as additional interest expense had the conversion taken place under the original terms of the <em style="font: inherit;">2016</em> Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 10, 2020, </em>Reviva executed an amendment to the <em style="font: inherit;">2016</em> Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the <em style="font: inherit;">2016</em> Notes (with the exception of $<ix:nonFraction id="c81966673" contextRef="i_2020-12-10_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction> principal on <em style="font: inherit;">one</em> note which was repaid in cash subsequent to the Business Combination) automatically converted into <ix:nonFraction id="c81966675" contextRef="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">3,788,461</ix:nonFraction> shares of Reviva common stock at a conversion price equal to $<ix:nonFraction id="c81966676" contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.329698</ix:nonFraction>. On consummation of the Business Combination, these shares converted into <ix:nonFraction id="c81966677" contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">576,836</ix:nonFraction> shares of the Company&#x2019;s common stock. The holders have <em style="font: inherit;">no</em> further rights under the <em style="font: inherit;">2016</em> notes. The Company evaluated whether there was a BCF to be recognized at the time of conversion and determined that there was <span style="-sec-ix-hidden:c81966680">none.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">2,</em> <em style="font: inherit;">2020,</em> there was a judgement issued by the District Court of Harris County, Texas, pursuant to an agreement reached between the Company and an investor in the <em style="font: inherit;">2016</em> Notes. Under the terms of the judgements, the Company was obligated to repay an investor of the <em style="font: inherit;">2016</em> Notes, the principal investment of $<ix:nonFraction id="c81966685" contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction>, accrued interest of $<ix:nonFraction id="c81966686" contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember" unitRef="USD" name="us-gaap:InterestPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">242,236</ix:nonFraction>, and legal fees of $<ix:nonFraction id="c81966687" contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember" unitRef="USD" name="us-gaap:DebtInstrumentFeeAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction>. The $<ix:nonFraction id="c81966688" contextRef="d_2020-01-02_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember" unitRef="USD" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">1,447,236</ix:nonFraction> obligatory payment accrued interest at <ix:nonFraction id="c81966689" contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">5.5</ix:nonFraction>% per annum and was fully paid, (including accrued interest of $<ix:nonFraction id="c81966690" contextRef="i_2020-12-15_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember" unitRef="USD" name="us-gaap:InterestPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">79,840</ix:nonFraction> subsequent to the judgement).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2018</em> Notes</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">From <em style="font: inherit;"> November&#xa0;</em><em style="font: inherit;">2018</em> through <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">2019,</em> the Company issued an aggregate of $<ix:nonFraction id="c81966694" contextRef="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">275,000</ix:nonFraction> in convertible promissory notes to various investors (the <em style="font: inherit;">&#x201c;2018</em> notes&#x201d;). Upon a Qualified Financing, the <em style="font: inherit;">2018</em> Notes could have been converted if the entire balance had <em style="font: inherit;">not</em> been paid. The principal and accrued interest of the <em style="font: inherit;">2018</em> notes would have automatically been converted into that number of shares at a price equal to a <ix:nonFraction id="c81966699" contextRef="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember" unitRef="Pure" name="rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% discount to the Qualified Financing event price (price paid by investors in the Qualified Financing).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Additionally, the holders of the <em style="font: inherit;">2018</em> notes were also eligible for an equivalent number of contingent warrants (i.e. as the number of converted shares), to purchase common stock (<em style="font: inherit;">&#x201c;2018</em> Contingent Warrants&#x201d;) with a strike price equal to the Qualified Financing event price with a maturity of <ix:nonNumeric contextRef="i_2018-11-01_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81966702" format="ixt-sec:duryear">5</ix:nonNumeric>&#xa0;years from the date of such a conversion event. These warrants are <ix:nonFraction id="c81966703" contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> longer exercisable and were cancelled during the year ended&#xa0;<em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2019.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Interest on the <em style="font: inherit;">2018</em> Notes accrued at <ix:nonFraction id="c81966707" contextRef="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">8</ix:nonFraction>% per annum and was scheduled to be paid in cash at maturity unless converted. The <em style="font: inherit;">2018</em> Notes were scheduled to mature <span style="-sec-ix-hidden:c81966709">six</span>&#xa0;months from the date of issue with an option to extend the maturity by an additional <em style="font: inherit;">six</em>&#xa0;months with certain additional conversion privileges. Pursuant to the option, the maturity dates of all <em style="font: inherit;">2018</em> notes were extended an additional <span style="-sec-ix-hidden:c81966712">six</span>&#xa0;months. The <em style="font: inherit;">2018</em> Notes were neither converted nor paid back and continued to accrue interest at a default rate of <ix:nonFraction id="c81966714" contextRef="i_2020-12-31_DebtInstrumentAxis-The2018NotesMember" unitRef="Pure" name="rvph:DebtInstrumentDebtDefaultInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="2">8</ix:nonFraction>% per annum.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 10, 2020, </em>Reviva executed an amendment to the <em style="font: inherit;">2018</em> Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the <em style="font: inherit;">2018</em> Notes automatically converted into <ix:nonFraction id="c81966717" contextRef="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">370,811</ix:nonFraction> shares of Reviva common stock at a conversion price equal to $<ix:nonFraction id="c81966718" contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.831018</ix:nonFraction> for each holder of the <em style="font: inherit;">2018</em> Notes who purchased at least <em style="font: inherit;">$50,000</em> in aggregate principal amount of <em style="font: inherit;">2018</em> Notes or (ii)&#xa0;$<ix:nonFraction id="c81966722" contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.330045</ix:nonFraction> for each holder of the <em style="font: inherit;">2018</em> Notes who purchased less than <em style="font: inherit;">$50,000</em> in aggregate principal amount of <em style="font: inherit;">2018</em> Notes. On consummation of the Business Combination, these shares converted into <ix:nonFraction id="c81966726" contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">56,461</ix:nonFraction> shares of the Company&#x2019;s common stock. The holders have <em style="font: inherit;">no</em> further rights under the <em style="font: inherit;">2018</em> notes. The conversion terms included in the amendment created a BCF of $<ix:nonFraction id="c81966729" contextRef="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2018NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="INF">159,025</ix:nonFraction> at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Notes</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">From <em style="font: inherit;"> March&#xa0;</em>through <em style="font: inherit;"> May&#xa0;</em><em style="font: inherit;">2020,</em> the Company issued an aggregate of $<ix:nonFraction id="c81966732" contextRef="i_2020-03-01_DebtInstrumentAxis-The2020NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">610,000</ix:nonFraction> in convertible promissory notes to various investors (<em style="font: inherit;">&#x201c;2020</em> Notes&#x201d;). Upon a Qualified Financing, the <em style="font: inherit;">2020</em> Notes could be converted if the entire balance had <em style="font: inherit;">not</em> been paid. The principal and accrued interest of the <em style="font: inherit;">2020</em> notes was to automatically be converted into that number of shares at a price equal to a <ix:nonFraction id="c81966737" contextRef="i_2020-03-01_DebtInstrumentAxis-The2020NotesMember" unitRef="Pure" name="rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% discount to the Qualified Financing event price (price paid by investors in the Qualified Financing).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">Additionally, the holders of the <em style="font: inherit;">2020</em> Notes were also eligible for an equivalent number of warrants (i.e. as the number of converted shares), to purchase common stock (<em style="font: inherit;">&#x201c;2020</em> contingent warrants&#x201d;) with a strike price equal to the Qualified Financing event price with a maturity of <ix:nonNumeric contextRef="i_2020-03-01_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81966740" format="ixt-sec:duryear">5</ix:nonNumeric> years from the date of such a conversion event. The holders of the <em style="font: inherit;">2020</em> Notes, for entering into the Notes agreement, were also eligible to receive common stock when the <em style="font: inherit;">2020</em> Notes were converted into preferred shares in a Qualified Financing event (<em style="font: inherit;">&#x201c;2020</em> Contingent Stock&#x201d;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 10, 2020, </em>Reviva executed an amendment to the <em style="font: inherit;">2020</em> Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the <em style="font: inherit;">2020</em> Notes automatically converted into <ix:nonFraction id="c81966747" contextRef="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">744,916</ix:nonFraction> shares of Reviva common stock at a conversion price equal to $<ix:nonFraction id="c81966748" contextRef="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.831009</ix:nonFraction> for each holder of the <em style="font: inherit;">2020</em> Notes who purchased at least <em style="font: inherit;">$50,000</em> in aggregate principal amount of the <em style="font: inherit;">2020</em> Notes or (ii)&#xa0;$<ix:nonFraction id="c81966752" contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.329770</ix:nonFraction> for each holder of the <em style="font: inherit;">2020</em> Notes who purchased less than <em style="font: inherit;">$50,000</em> in aggregate principal amount of <em style="font: inherit;">2020</em> Notes. On consummation of the Business Combination, these shares converted into <ix:nonFraction id="c81966756" contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">113,422</ix:nonFraction> shares of the Company&#x2019;s common stock. The holders have <em style="font: inherit;">no</em> further rights under the <em style="font: inherit;">2020</em> notes and the warrants issued in connection with the notes are <ix:nonFraction id="c81966759" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> longer exercisable. The conversion terms included in the amendment created a BCF of $<ix:nonFraction id="c81966760" contextRef="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2020NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="INF">317,730</ix:nonFraction> at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Between <em style="font: inherit;"> August 2020 </em>and <em style="font: inherit;"> October 2020, </em>the Company issued and received an aggregate principal amount of $<ix:nonFraction id="c81966761" contextRef="i_2020-08-01_DebtInstrumentAxis-August2020ToOctober2020NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">500,000</ix:nonFraction> in unsecured convertible promissory notes to certain investors to finance its ordinary course of administrative costs and expenses and other expenses incurred in connection with the consummation of the Business Combination. These notes were interest free. These notes provided that they automatically converted, immediately prior to consummation of the business combination, into <ix:nonFraction id="c81966762" contextRef="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">601,632</ix:nonFraction> shares of Reviva common stock at a conversion rate equal to $<ix:nonFraction id="c81966763" contextRef="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.831063</ix:nonFraction>. The conversion terms created a BCF of $<ix:nonFraction id="c81966764" contextRef="d_2020-08-01_2020-10-31_DebtInstrumentAxis-August2020ToOctober2020NotesMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="INF">274,083</ix:nonFraction> at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In addition, the Company entered into a contingent capital commitment with certain investors for $<ix:nonFraction id="c81966765" contextRef="i_2020-08-01_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000,000</ix:nonFraction> (&#x201c;Reviva Contingent Interim Period Notes&#x201d;) that became effective upon consummation of the Business Combination. The Reviva Contingent Interim Period Notes were interest free. The Reviva Contingent Interim Period Notes provided that the notes automatically converted, immediately prior to consummation of the Business Combination, into <ix:nonFraction id="c81966766" contextRef="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,718,280</ix:nonFraction> shares of Reviva common stock at a conversion price equal to $<ix:nonFraction id="c81966767" contextRef="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.163953</ix:nonFraction>. On consummation of the Business Combination, these shares converted into <ix:nonFraction id="c81966768" contextRef="d_2020-12-10_2020-12-10_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">261,626</ix:nonFraction> shares of the Company&#x2019;s common stock. The holders have <em style="font: inherit;">no</em> further rights under these notes. The conversion terms created a BCF of $<ix:nonFraction id="c81966770" contextRef="d_2020-08-01_2020-10-31_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember" unitRef="USD" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="0" format="ixt:numdotdecimal" decimals="INF">210,842</ix:nonFraction> at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2060589" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#xa0;&#xa0;&#xa0;<b>INCOME TAXES</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As a result of the Company's history of net operating losses and full valuation allowance against its deferred tax assets, there was <em style="font: inherit;">no</em> current or deferred income tax provision other that current state minimum taxes for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Reconciliations to the statutory federal income tax rate and the Company's effective tax rate consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2060590" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Statutory federal income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966804" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,788,135</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966805" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">794,343</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal tax benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966806" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">58,152</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966807" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">114,864</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966808" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">8,924</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966809" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966810" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" format="ixt:numdotdecimal" decimals="INF">1,414</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966811" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81966812" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">334,122</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966813" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">227,651</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beneficial conversion feature related to notes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966814" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="rvph:EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966815" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="rvph:EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">201,953</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966816" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" format="ixt:numdotdecimal" decimals="INF">5,301</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81966817" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" format="ixt:numdotdecimal" decimals="INF">19,204</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966818" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">2,173,051</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966819" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">461,244</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966820" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF">8,281</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81966821" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF">800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The components of deferred tax assets included on the balance sheet are:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2060591" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NOL carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966822" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">11,262,916</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966823" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">9,177,607</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accruals and reserves</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966824" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">81,911</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966825" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">10,898</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966826" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">197,508</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966827" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">237,976</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed assets/capitalized start-up costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966828" contextRef="i_2021-12-31" unitRef="USD" name="rvph:DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">2,557</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966829" contextRef="i_2020-12-31" unitRef="USD" name="rvph:DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">3,332</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966830" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">11,544,892</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966831" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:numdotdecimal" decimals="INF">9,429,813</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966832" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">11,544,892</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81966833" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">9,429,813</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966834" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81966835" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81966836">&#x2014;</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81966837">&#x2014;</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets.&#xa0; The total increase in valuation allowance is $<ix:nonFraction id="c81966775" contextRef="d_2021-01-10_2021-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,115,079</ix:nonFraction> for the year ending <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company currently has net operating loss carryforwards of approximately $<ix:nonFraction id="c81966776" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">49.2</ix:nonFraction>&#xa0;million and $<ix:nonFraction id="c81966777" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">13.2</ix:nonFraction>&#xa0;million for U.S. Federal and state purposes respectively. Approximately $<ix:nonFraction id="c81966778" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember" unitRef="USD" name="rvph:OperatingLossCarryforwardsSubjectToExpiration" scale="6" format="ixt:numdotdecimal" decimals="-5">35.3</ix:nonFraction> million of the U.S. federal losses begin to expire in <em style="font: inherit;">2029.</em> The balance, all post-<em style="font: inherit;">2018</em> federal net operating losses <em style="font: inherit;"> may </em>be carried forward indefinitely. The deferred tax asset relates to the NOL carryforwards. Management has determined based on all the available information that a <em style="font: inherit;">100%</em> valuation reserve is required.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company had <ix:nonFraction id="c81966783" contextRef="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> research and development credit carryforwards to offset federal and California state income taxes, respectively, available to reduce its future taxable income, if any.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Tax Reform Act of <em style="font: inherit;">1986</em> limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company.&#xa0; In the event that the Company has a change in ownership, utilization of carryforwards could be limited.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company has elected to recognize interest and penalties related to uncertain tax positions as components of income tax expense.&#xa0; As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company has <ix:nonFraction id="c81966787" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> accrual for payment of interest related to unrecognized tax benefits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company&#x2019;s income tax returns for all years remain open to examination by federal and state taxing authorities.&#xa0; The Company does <em style="font: inherit;">not</em> expect that its unrecognized tax benefit will change significantly in the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company has <ix:nonFraction id="c81966792" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> unrecognized tax benefits that, if recognized, would change its effective rate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> March&#xa0;</em><em style="font: inherit;">27,</em> <em style="font: inherit;">2020,</em> the Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act was enacted and signed into law. Certain provisions of the CARES Act impacted the <em style="font: inherit;">2019</em> and <em style="font: inherit;">2020</em> income tax provision computations of the Company and were reflected in the appropriate periods. The CARES Act contains modifications on the limitation of business interest for tax&#xa0;years beginning in <em style="font: inherit;">2019</em> and <em style="font: inherit;">2020.</em> The modifications to Section&#xa0;<em style="font: inherit;">163</em>(j) increase the allowable business interest deduction from <em style="font: inherit;">30%</em> of adjusted taxable income to <em style="font: inherit;">50%</em> of adjusted taxable income. As the company is in losses, there is <em style="font: inherit;">no</em> modification for the current year.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:EarningsPerShareTextBlock" id="c2060592" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#xa0;<b> </b>&#xa0;<b>LOSS</b>&#xa0;<b>PER SHARE</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Loss per share calculations for all periods prior to the Business Combination have been retrospectively adjusted for the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Subsequent to the Business Combination, earnings per share is calculated based on the weighted average shares of common stock then outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. The weighted average shares of common stock outstanding is based on the <ix:nonFraction id="c81966839" contextRef="i_2020-12-14" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">9,231,737</ix:nonFraction> shares of common stock outstanding immediately after the reverse recapitalization in connection with the Business Combination and assumes these shares have been outstanding as of the beginning of the earliest period presented.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company has excluded the potential effect of warrants to purchase shares of common stock totaling <ix:nonFraction id="c81966841" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">13,883,732</ix:nonFraction> and <ix:nonFraction id="c81966842" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">7,007,581</ix:nonFraction> shares and the dilutive effect of outstanding stock options totaling <ix:nonFraction id="c81966843" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">192,898</ix:nonFraction> and <ix:nonFraction id="c81966844" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">65,471</ix:nonFraction>, as described in Note&#xa0;<em style="font: inherit;">11,</em> in the calculation of diluted loss per share, as the effect would be anti-dilutive due to losses incurred. Additionally, <ix:nonFraction id="c81966846" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EarnoutSharesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000</ix:nonFraction> earn-out shares have been excluded as they are <em style="font: inherit;">not</em> considered issued for accounting purposes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2060593" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#xa0;&#xa0;&#xa0;<b>STOCKHOLDERS</b>&#x2019;<b> EQUITY (DEFICIT)</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our authorized capital stock consists of:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;">&#xa0;</td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonFraction id="c81966855" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">115,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction id="c81966856" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction> per share; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;">&#xa0;</td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonFraction id="c81966857" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction id="c81966858" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction> per share.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were <ix:nonFraction id="c81966861" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,433,286</ix:nonFraction> shares of our common stock outstanding, and <ix:nonFraction id="c81966862" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of preferred stock outstanding. In <em style="font: inherit;"> November 2021, </em>the Company issued <ix:nonFraction id="c81966863" contextRef="d_2021-11-01_2021-11-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">11,000</ix:nonFraction> shares of common stock to a consultant in exchange for services provided. In <em style="font: inherit;"> September&#xa0;</em><em style="font: inherit;">2020,</em> the Company&#xa0;issued <ix:nonFraction id="c81966865" contextRef="d_2020-09-01_2020-09-30" unitRef="Share" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">38,992</ix:nonFraction> shares of common stock to current and past employees in lieu of certain dues and obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Common Stock</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Voting.&#xa0;&#xa0;&#xa0;The holders of our common stock are entitled to <em style="font: inherit;">one</em> vote for each share held of record on all matters on which the holders are entitled to vote (or consent pursuant to written consent). Directors are elected by a plurality of the votes present in person or represented by proxy and entitled to vote.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Dividends.&#xa0;&#xa0;&#xa0;The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Liquidation Rights.&#xa0;&#xa0;&#xa0;In the event of the Company&#x2019;s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Conversion Right.&#xa0;&#xa0;&#xa0;The holders of common stock have <em style="font: inherit;">no</em> conversion rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Preemptive and Similar Rights.&#xa0;&#xa0;&#xa0;The holders of common stock have <em style="font: inherit;">no</em> preemptive or similar rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Redemption/Put Rights.&#xa0;&#xa0;&#xa0;There are <em style="font: inherit;">no</em> redemption or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of common stock will be fully-paid and nonassessable.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Preferred Stock</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has the authority to issue shares of preferred stock from time to time on terms it <em style="font: inherit;"> may </em>determine, to divide shares of preferred stock into <em style="font: inherit;">one</em> or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were public warrants outstanding to purchase an aggregate of <ix:nonFraction id="c81966873" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">6,325,000</ix:nonFraction> shares of common stock and private warrants outstanding to purchase an aggregate of <ix:nonFraction id="c81966874" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PrivateWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">556,313</ix:nonFraction> shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each public warrant entitles the holder thereof to purchase <ix:nonFraction id="c81966875" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> share of common stock at a price <span style="-sec-ix-hidden:c81966876">of&#x2009;$11.50</span> per share, subject to adjustment. <em style="font: inherit;">No</em> public warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to such shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We <em style="font: inherit;"> may </em>call the public warrants for redemption, in whole and <em style="font: inherit;">not</em> in part, at a price <span style="-sec-ix-hidden:c81966880">of&#x2009;$0.01</span> per warrant:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if, and only if, the reported last sale price of the common stock equals or exceeds $<ix:nonFraction id="c81966881" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="USDPerShare" name="rvph:ThresholdClosingPriceForSpecifiedNumberOfTradingDays" scale="0" format="ixt:numdotdecimal" decimals="INF">21.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" name="rvph:ThresholdTradingDaysForSaleOfShares" id="c81966882" format="ixt-sec:durday">20</ix:nonNumeric> trading days within a <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" name="rvph:ThresholdConsecutiveTradingDaysForSaleOfShares" id="c81966883" format="ixt-sec:durday">30</ix:nonNumeric> trading day period ending on the <em style="font: inherit;">third</em> trading business day prior to the notice of redemption to holders of the public warrants, and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire <em style="font: inherit;">30</em>-day trading period referred to above and continuing each day thereafter until the date of redemption.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">at any time while the public warrants are exercisable,</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">upon <em style="font: inherit;">not</em> less than <em style="font: inherit;">30</em>&#xa0;days&#x2019;&#xa0;prior written notice of redemption to each warrant holder,</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The private warrants are substantially similar to the public warrants except such private warrants;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">are exercisable for cash or on a cashless basis, at the holder&#x2019;s option</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#xa0;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The redemption price is to be calculated as the <em style="font: inherit;">10</em>-day average trading price ending <em style="font: inherit;">one</em> trading business day prior to the notice of redemption.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 26pt; text-indent: 18pt;">In <em style="font: inherit;">no</em> event will the Company be required to net cash settle either the public or the private warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company classified the private warrants pursuant to ASC <em style="font: inherit;">815</em> as derivative liabilities with subsequent changes in their fair values to be recognized in the consolidated financial statements at each reporting date. The Company calculated the fair value of the private warrants as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> as $<ix:nonFraction id="c81966894" contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">372,730</ix:nonFraction> using a Black-Scholes model. The key inputs used in the Black-Scholes calculation were, the risk-free interest rate, expected volatility, expected life, exercise price and stock price. The risk-free interest rate was estimated to be <ix:nonFraction id="c81966895" contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">1.11</ix:nonFraction>%, the expected volatility was estimated to be <ix:nonFraction id="c81966896" contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="2">73.0</ix:nonFraction>%, and the expected life was estimated to be <ix:nonFraction id="c81966897" contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">3.96</ix:nonFraction>&#xa0;years. The exercise price was $<ix:nonFraction id="c81966898" contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">11.50</ix:nonFraction>, and the stock price $<ix:nonFraction id="c81966899" contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">2.89</ix:nonFraction>. Due to fair value changes during the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company recorded a gain on remeasurement of warrant liabilities of $<ix:nonFraction id="c81966902" contextRef="d_2021-01-01_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,591,055</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The exercise price and number of shares of common stock issuable on exercise of the warrants <em style="font: inherit;"> may </em>be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or a recapitalization, reorganization, merger or consolidation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Further, there were assumed warrants outstanding to purchase an aggregate of <ix:nonFraction id="c81966903" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">126,268</ix:nonFraction> shares of common stock. These warrants were classified as equity as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em> The fair value of these warrants on the date of issuance was $<ix:nonFraction id="c81966908" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,279,182</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for <ix:nonFraction id="c81966909" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">5,066,600</ix:nonFraction> shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $<ix:nonFraction id="c81966910" contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-6">19.0</ix:nonFraction>&#xa0;million and the Pre-Funded Warrants are exercisable into <span style="-sec-ix-hidden:c81966911">one</span> share of common stock at an exercise price of $<ix:nonFraction id="c81966912" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction> per share at any time after issuance. Additionally, in connection with the Offering, the Company issued Investor Warrants exercisable for&#xa0;<ix:nonFraction id="c81966913" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">6,900,000</ix:nonFraction>&#xa0;shares of common stock&#xa0;with an&#xa0;exercise price of $<ix:nonFraction id="c81966914" contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.125</ix:nonFraction> per share of common stock any time after issuance. The Investor Warrants expire on <em style="font: inherit;"> June 1, 2026. </em>During the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> Investor Warrants for <ix:nonFraction id="c81966917" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="Share" name="rvph:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">23,849</ix:nonFraction>&#xa0;shares of common stock were exercised with proceeds of $<ix:nonFraction id="c81966918" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-InvestorWarrantMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">98,378</ix:nonFraction> and Pre-Funded Warrants for <ix:nonFraction id="c81966919" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">1,033,300</ix:nonFraction>&#xa0;shares of common stock were exercised with proceeds of $<ix:nonFraction id="c81966920" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">103</ix:nonFraction>. The Company has determined that&#xa0;as the&#xa0;Pre-Funded Warrants and&#xa0;Investor Warrants&#xa0;were issued at fair value in a public offering of Units with <em style="font: inherit;">no</em> debt funding included in the offering, the&#xa0;Pre-Funded Warrants and Investor Warrants should be classified as equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><ix:exclude></ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Common stock warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;"> July&#xa0;</em><em style="font: inherit;">2020,</em> the company issued warrants with a <span style="-sec-ix-hidden:c81966925">five</span>-year term to purchase <ix:nonFraction id="c81966926" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">120,456</ix:nonFraction> shares of common stock at $<ix:nonFraction id="c81966927" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">22.99</ix:nonFraction> per share to certain current and past consultants (<em style="font: inherit;">&#x201c;2020</em> warrants&#x201d;). The <em style="font: inherit;">2020</em> warrants were exercisable immediately. The Company estimated the fair value of the <em style="font: inherit;">2020</em> warrants to be $<ix:nonFraction id="c81966931" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,178,182</ix:nonFraction>, using the Black-Scholes-Merton option-pricing model with the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" id="c2060594" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Assumptions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966952" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">2.25</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966953" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966954" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">0.28</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yields</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966955" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81966956" contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="2">126</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The&#xa0;<em style="font: inherit;">2020</em> warrants are classified as equity and included in general and administrative expense during the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2016</em> Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company issued warrants in connection with the <em style="font: inherit;">2016</em> Notes (the <em style="font: inherit;">&#x201c;2016</em> Warrants&#x201d;) to purchase <ix:nonFraction id="c81966936" contextRef="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">5,812</ix:nonFraction> shares of its common stock which will expire on <em style="font: inherit;"> April&#xa0;</em><em style="font: inherit;">28,</em> <em style="font: inherit;">2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of the warrants was originally estimated to be approximately $<ix:nonFraction id="c81966939" contextRef="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">101,000</ix:nonFraction> and they were classified as a liability on the balance sheet as the strike price was <em style="font: inherit;">not</em> established at the time of grant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Business Combination, the strike price was set at $<ix:nonFraction id="c81966941" contextRef="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">42.29</ix:nonFraction> based on the terms of the warrants at a common stock conversion rate of <ix:nonFraction id="c81966942" contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:numdotdecimal" decimals="INF">0.152268</ix:nonFraction>.&#xa0;&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Immediately following the Business Combination, the fair value of the warrant was estimated to be $<ix:nonFraction id="c81966943" contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">7,395</ix:nonFraction> using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be <ix:nonFraction id="c81966944" contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">0.36</ix:nonFraction>%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be <ix:nonFraction id="c81966945" contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="2">126</ix:nonFraction>%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be <ix:nonFraction id="c81966946" contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">1.4</ix:nonFraction> years. The dividend yield was assumed to be <span style="-sec-ix-hidden:c81966947">zero</span> since the Company had <em style="font: inherit;">not</em> historically declared dividends and did <em style="font: inherit;">not</em> have any plans to declare dividends in the future</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $<ix:nonFraction id="c81966950" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-The2016WarrantsMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">94,175</ix:nonFraction> being recorded as a reduction of general and administrative expense during the year ending <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC <em style="font: inherit;">480,</em> &#x201c;Distinguishing Liabilities from Equity&#x201d;, the warrants should be reclassified to equity.&#xa0;</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2060595" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#xa0;&#xa0;&#xa0;<b>STOCK OPTION PLAN AND STOCK-BASED COMPENSATION</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2006</em> Equity Incentive Plan</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Reviva&#x2019;s board of directors adopted, and Reviva&#x2019;s stockholders approved, the Reviva Pharmaceuticals,&#xa0;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan, effective as of <em style="font: inherit;"> August&#xa0;</em><em style="font: inherit;">2006.</em> The Reviva Pharmaceuticals,&#xa0;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan provided for the grant of incentive stock options, or ISOs, within the meaning of Section&#xa0;<em style="font: inherit;">422</em> of the Code, to Reviva&#x2019;s employees, and for the grant of nonstatutory stock options, or NSOs, and restricted stock awards to Reviva&#x2019;s employees, officers, directors and consultants; provided such consultants render bona fide services <em style="font: inherit;">not</em> in connection with the offer and sale of securities in a capital-raising transaction. As of <em style="font: inherit;">2016,</em> <em style="font: inherit;">no</em> new grants of awards are permitted under the Reviva Pharmaceuticals,&#xa0;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon the Business Combination, the Reviva Pharmaceuticals,&#xa0;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan was amended to change its name to the Reviva Pharmaceuticals Holdings,&#xa0;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan (the <em style="font: inherit;">&#x201c;2006</em> Equity Incentive Plan&#x201d;), and each outstanding option to acquire Reviva common stock (whether vested or unvested) under the <em style="font: inherit;">2006</em> Equity Incentive Plan was assumed by the Company and automatically converted into an option to acquire shares of common stock, with its price and number of shares equitably adjusted based on the conversion of the shares of common stock of Reviva into shares of common stock of the Company pursuant to the Merger Agreement. Pursuant to such assumption and automatic conversion, as of the consummation of the Business Combination there are outstanding options under the <em style="font: inherit;">2006</em> Equity Incentive Plan exercisable for an aggregate of <ix:nonFraction id="c81966972" contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2006Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">65,471</ix:nonFraction> shares of Company common stock, and <em style="font: inherit;">no</em> new grants of awards are permitted under the <em style="font: inherit;">2006</em> Equity Incentive Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Equity Incentive Plan</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">14,</em> <em style="font: inherit;">2020,</em> the Reviva Pharmaceuticals Holdings,&#xa0;Inc. <em style="font: inherit;">2020</em> Equity Incentive Plan (the <em style="font: inherit;">&#x201c;2020</em> Equity Incentive Plan&#x201d;) became effective. The general purpose of the <em style="font: inherit;">2020</em> Equity Incentive Plan is to provide a means whereby employees, officers, directors, consultants, advisors or other individual service providers <em style="font: inherit;"> may </em>develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to us, thereby advancing our interests and the interests of our stockholders.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2021, </em>an aggregate of <ix:nonFraction id="c81966982" contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,384,761</ix:nonFraction> shares of common stock <em style="font: inherit;"> may </em>be issued under the <em style="font: inherit;">2020</em> Equity Incentive Plan, subject to equitable adjustment in the event of stock splits and other capital changes (the &#x201c;Share Reserve&#x201d;). The Share Reserve will automatically increase on <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1st</em> of each year, for a period of <em style="font: inherit;">not</em> more than <span style="-sec-ix-hidden:c81966986">ten</span>&#xa0;years, commencing on <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1st</em> of the year following the year in which the effective date of the <em style="font: inherit;">2020</em> Equity Incentive Plan occurs, and ending on (and including) <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2030,</em> in an amount equal to the lesser of (i)&#xa0;<em style="font: inherit;">ten</em>&#xa0;percent (<ix:nonFraction id="c81966992" contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member" unitRef="Pure" name="rvph:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" scale="-2" format="ixt:numdotdecimal" decimals="1">10</ix:nonFraction>%) of the total number of shares of Common Stock outstanding on <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31st</em> of the preceding calendar year or (ii)&#xa0;such number of shares of common stock determined by the Company&#x2019;s board of directors (the &#x201c;Annual Increase&#x201d;). Notwithstanding the foregoing and, subject to adjustment as provided in the <em style="font: inherit;">2020</em> Equity Incentive Plan, the maximum number of shares which <em style="font: inherit;"> may </em>be issued in respect of Incentive Stock Options shall be equal to <ix:nonFraction id="c81966995" contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">1,384,761</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Stock-Based Compensation Expense</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the Company recorded stock-based compensation of $<ix:nonFraction id="c81966999" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">106,713</ix:nonFraction> and $<ix:nonFraction id="c81967000" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>, respectively. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company had unrecognized stock-based compensation expense of $<ix:nonFraction id="c81967004" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">281,397</ix:nonFraction> and $<ix:nonFraction id="c81967005" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Determining Fair Value</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Valuation and Recognition &#x2013; The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Expected Term &#x2013; Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Expected Volatility - Expected volatility is based on the Company&#x2019;s historical stock volatility data over the expected term of the awards.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury <em style="font: inherit;">zero</em>-coupon issues with an equivalent expected term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Dividend Yield &#x2013; The Company has <em style="font: inherit;">not</em> paid a dividend and does <span style="-sec-ix-hidden:c81967008">not</span> anticipate paying a dividend in the foreseeable future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The assumptions used in estimating the fair value of options granted in <em style="font: inherit;">2021</em> are summarized as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Expected Term in years - <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81967010" format="ixt-sec:duryear">5.20</ix:nonNumeric> - <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81967011" format="ixt-sec:duryear">6.08</ix:nonNumeric></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Volatility &#x2013; <ix:nonFraction id="c81967012" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">87.1</ix:nonFraction>% - <ix:nonFraction id="c81967013" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">93.9</ix:nonFraction>%</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Risk-free interest rate &#x2013; <ix:nonFraction id="c81967014" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">0.95</ix:nonFraction>% - <ix:nonFraction id="c81967015" contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">1.31</ix:nonFraction>%</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Dividend Yield &#x2013; <ix:nonFraction id="c81967016" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.00</ix:nonFraction>%</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company granted <ix:nonFraction id="c81967017" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> stock options during the year ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em>&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Activity under the stock plans for the years ending <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2021</em> is as follows.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2060596" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Shares</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Available for</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Grant</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Options</b><br /> <b>Outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Weighted</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Average</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Exercise</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Price per</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Share</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2019</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967024" contextRef="i_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">343,871</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967025" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">112,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967026" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">15.37</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options authorized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967027" contextRef="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">461,587</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967030" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="rvph:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" scale="0" format="ixt:numdotdecimal" decimals="INF">47,461</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81967031" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">47,461</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967032" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Effect of plan amendment on business combination</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81967033" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="rvph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" scale="0" format="ixt:numdotdecimal" decimals="INF">391,332</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2020</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81967036" contextRef="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">461,587</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81967037" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">65,471</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967038" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">16.86</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options authorized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967039" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">923,174</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81967042" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">127,427</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81967043" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">127,427</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967044" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.14</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2021</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81967045" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">1,257,334</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81967046" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">192,898</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967047" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">8.46</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested and expected to vest, December 31, 2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81967049" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">192,898</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81967050" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">8.46</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Options outstanding under the stock plans are as follows as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="c2060621" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b><br /> <b>Outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br /> <b>Average</b><br /> <b>Remaining</b><br /> <b>Contractual</b><br /> <b>Life (Years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b><br /> <b>Exercisable</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br /> <b>Average</b><br /> <b>Exercise</b><br /> <b>Prices per Share</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c81969461" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">48,724</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81969462" format="ixt-sec:duryear">0.85</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969463" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">48,724</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969464" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">11.89</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c81969465" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">16,747</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81969466" format="ixt-sec:duryear">2.93</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969467" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">16,747</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969468" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">31.33</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c81969469" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">81,227</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81969470" format="ixt-sec:duryear">9.31</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969471" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">17,832</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969472" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81969473" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">46,200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81969474" format="ixt-sec:duryear">9.89</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81969475" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">12,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969476" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.72</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81969477" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">192,898</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81969478" format="ixt-sec:duryear">6.76</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81969479" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">95,803</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81969480" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">8.46</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:exclude>&#xa0;</ix:exclude></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2060598" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#xa0;&#xa0;&#xa0;<b>COMMITMENTS AND CONTINGENCIES</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline; ">Clinical trials</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Since <em style="font: inherit;">2010,</em> the Company has entered into multiple clinical trial agreements with medical institutions in the United States, Europe and Asia for the purpose of enrolling patients into various clinical trials. The agreements are substantially similar by trial and include a detailed listing of the clinical trial services for which the Company will pay, how much will be paid for each service, a set-up charge (if any), Investigational Review Board fees, contractual term, and other provisions. The clinical trial services provided by each site generally include the screening of prospective patients and, for those patients to be enrolled in the study, administration of the Company&#x2019;s investigation drug according to the trial protocol, any required hospitalization, ancillary medical supplies, and <em style="font: inherit;">2</em>-week patient follow-up. Further, each agreement requires the Company to indemnify each respective clinical site against any and all liability, loss, or damage it <em style="font: inherit;"> may </em>suffer as a result of <em style="font: inherit;">third</em>-party claims; the Company maintains general product liability insurance of <em style="font: inherit;">not</em> less than $<ix:nonFraction id="c81967080" contextRef="i_2021-12-31_RangeAxis-MinimumMember" unitRef="USD" name="rvph:GeneralProductLiabilityInsurance" scale="6" format="ixt:numdotdecimal" decimals="-6">5</ix:nonFraction>&#xa0;million in conjunction with this indemnification. The agreements <em style="font: inherit;"> may </em>be terminated upon <em style="font: inherit;">30</em>&#xa0;days&#x2019; written notice, subject to conditions of paying all liabilities incurred through the date of termination. Additionally, with each screened patient, the Company incurs expense with other entities engaged to provide independent review of patient medical records.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline; ">Indemnification</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">From time to time, in its normal course of business, the Company <em style="font: inherit;"> may </em>indemnify other parties, with whom it enters into contractual relationships, including lessors and parties to other transactions with the Company. The Company <em style="font: inherit;"> may </em>agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or <em style="font: inherit;">third</em>-party infringement claims. It <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be possible to determine the maximum potential amount of liability under such indemnification obligations due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Historically, there have been <em style="font: inherit;">no</em> such indemnification claims. The Company has also indemnified its directors and executive officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual <em style="font: inherit;"> may </em>be involved by reason of such individual being or having been a director or executive officer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline; ">Operating Leases</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company adopted ASC <em style="font: inherit;">842</em> to its existing lease on <em style="font: inherit;"> January 1, 2020. </em>The Company has elected to apply the short-term lease exception to leases of <em style="font: inherit;">one</em> year or less. Presently, the Company has a single <span style="-sec-ix-hidden:c81967087">twelve</span>-month lease on its Corporate Office located at <em style="font: inherit;">19925</em> Stevens Creek Blvd., Suite <em style="font: inherit;">100,</em> Cupertino, CA <em style="font: inherit;">95014.</em> The monthly lease payment is approximately $<ix:nonFraction id="c81967091" contextRef="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember" unitRef="USD" name="rvph:LesseeOperatingLeaseMonthlyLeasePayment" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200</ix:nonFraction> and the lease was renewed on <em style="font: inherit;"> February 1, 2021, </em>for another <ix:nonNumeric contextRef="i_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c81967092" format="ixt-sec:durmonth">12</ix:nonNumeric>-month term.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2060599" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em></b>&#xa0;&#xa0;&#xa0;<b>SUBSEQUENT EVENTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2022, </em>the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp; Co., LLC, as sales agent (&#x201c;Wainwright&#x201d;), pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell, from time to time through Wainwright, shares of its common stock for aggregate gross proceeds of up to $<ix:nonFraction id="c81967094" contextRef="d_2022-01-01_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember" unitRef="USD" name="rvph:SaleOfStockAgreementMaximumAggregateGrossProceeds" scale="6" format="ixt:numdotdecimal" decimals="-5">12.9</ix:nonFraction> million (the &#x201c;Shares&#x201d;). As of the date of this filing, the Company has <span style="-sec-ix-hidden:c81967095">not</span> made any sales pursuant to the ATM Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR" style="text-align: center;">
     F-20
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex_346563.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_346563.htm</title>

	<!-- Generated by ThunderDome Portal - 3/15/2022 8:22:39 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-254551) and the Registration Statement on Form S-3 (No. 333- 262348), of Reviva Pharmaceuticals Holdings, Inc. of our report dated March 15, 2022 relating to the consolidated financial statements which appears in this Form 10-K for the year ended December 31, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">/s/Armanino<font style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">LLP</sup></font></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">San Ramon, California</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 15, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex_345157.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_345157.htm</title>

	<!-- Generated by ThunderDome Portal - 3/15/2022 4:44:52 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 15pt;"><b>Exhibit</b>&nbsp;<b>31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</b><br>
<b>Pursuant to</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities Exchange Act Rules</b>&nbsp;<b>13a-14(a)</b>&nbsp;<b>and 15d-14(a),</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Adopted Pursuant to</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Section</b>&nbsp;<b>302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">I, Laxminarayan Bhat, hereby certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">1.&nbsp;&nbsp;&nbsp;&nbsp; I have reviewed this Annual Report on Form&nbsp;10-K of Reviva Pharmaceuticals Holdings, Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Dated: March&nbsp;15, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Laxminarayan Bhat</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laxminarayan Bhat</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Chief Executive Officer</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer)</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex_345158.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_345158.htm</title>

	<!-- Generated by ThunderDome Portal - 3/15/2022 4:45:11 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 15pt;"><b>Exhibit</b>&nbsp;<b>31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</b><br>
<b>Pursuant to</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Securities Exchange Act Rules</b>&nbsp;<b>13a-14(a)</b>&nbsp;<b>and 15d-14(a),</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Adopted Pursuant to</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Section</b>&nbsp;<b>302 of the Sarbanes-Oxley Act of 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">I, Narayan Prabhu, hereby certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report on Form&nbsp;10-K of Reviva Pharmaceuticals Holdings, Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:24pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Dated: March&nbsp;15, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Narayan Prabhu</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Narayan Prabhu</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Chief Financial Officer</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Financial and Accounting Officer)</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex_345159.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_345159.htm</title>

	<!-- Generated by ThunderDome Portal - 3/15/2022 4:45:35 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 15pt;"><b>Exhibit</b>&nbsp;<b>32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>AND CHIEF FINANCIAL OFFICER</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PURSUANT TO</b><br>
<b>18 U.S.C. SECTION</b>&nbsp;<b>1350,</b><br>
<b>AS ADOPTED PURSUANT TO</b><br>
<b>SECTION</b>&nbsp;<b>906 OF THE SARBANES-OXLEY ACT OF</b>&nbsp;<b>2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">In connection with the Annual Report of Reviva Pharmaceuticals Holdings, Inc. (the &#8220;Company&#8221;) on Form&nbsp;10-K for the period ended December&nbsp;31, 2021, as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Laxminarayan Bhat, as Chief Executive Officer of the Company, and Narayan Prabhu, Chief Financial Officer of the Company, each hereby certifies, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section&nbsp;1350), to his knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>IN WITNESS WHEREOF</b>, the undersigned have set their hands hereto as of the 15 day of March, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Laxminarayan Bhat</p>
			</td>
			<td style="vertical-align:top;width:1.1%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:21.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Narayan Prabhu</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laxminarayan Bhat</p>
			</td>
			<td style="vertical-align:top;width:1.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Narayan Prabhu</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Chief Executive Officer</i></p>
			</td>
			<td style="vertical-align:top;width:1.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Chief Financial Officer</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer)</i></p>
			</td>
			<td style="vertical-align:top;width:1.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Financial and Accounting Officer)</i></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">This certification accompanies the Form&nbsp;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&nbsp;10-K), irrespective of any general incorporation language contained in such filing.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>rvph-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59PM UTC 2022-03-15--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:rvph="http://revivapharma.com/20211231" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://revivapharma.com/20211231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvph-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://revivapharma.com/20211231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-deficit" roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-nature-of-operations" roleURI="http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" roleURI="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Summary of Significant Accounting Policies and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-public-offering" roleURI="http://revivapharma.com/20211231/role/statement-note-3-public-offering">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Public Offering</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-business-combination" roleURI="http://revivapharma.com/20211231/role/statement-note-4-business-combination">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Business Combination</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-net" roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-employee-benefit-plan" roleURI="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-convertible-promissory-notes" roleURI="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Convertible Promissory Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes" roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-loss-per-share" roleURI="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockholders-equity-deficit" roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-option-plan-and-stockbased-compensation" roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies" roleURI="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-events" roleURI="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-net-tables" roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 5 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-tables" roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 8 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockholders-equity-deficit-tables" roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 10 - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-option-plan-and-stockbased-compensation-tables" roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-public-offering-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 3 - Public Offering (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-business-combination-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 4 - Business Combination (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-net-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-net-property-and-equipment-net-details" roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-employee-benefit-plan-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 6 - Employee Benefit Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-convertible-promissory-notes-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 7 - Convertible Promissory Notes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-provision-for-income-taxes-details" roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 8 - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-deferred-tax-assets-details" roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-loss-per-share-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 9 - Loss Per Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockholders-equity-deficit-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 10 - Stockholders' Equity (Deficit) (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-events-details-textual" roleURI="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 13 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" name="AccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" name="AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" name="AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_August2020ToOctober2020NotesMember" name="August2020ToOctober2020NotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_BeneficialConversionFeaturePolicyTextBlock" name="BeneficialConversionFeaturePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ClassOfWarrantOrRightRedemptionPricePerShare" name="ClassOfWarrantOrRightRedemptionPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="rvph_ClosingMember" name="ClosingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2016NotesIntoCommonStockMember" name="ConversionOf2016NotesIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2018NotesIntoCommonStockMember" name="ConversionOf2018NotesIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" name="ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" name="ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2020NotesIntoCommonStockMember" name="ConversionOf2020NotesIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" name="ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" name="ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" name="ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" name="ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" name="ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" name="ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ConversionOfStockConversionRate" name="ConversionOfStockConversionRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_CorporateOfficeLeaseMember" name="CorporateOfficeLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_DebtInstrumentDebtDefaultInterestRate" name="DebtInstrumentDebtDefaultInterestRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="rvph_DebtInstrumentRenewalTerm" name="DebtInstrumentRenewalTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" name="DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="rvph_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_EarnoutSharesMember" name="EarnoutSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" name="EffectOfReverseRecapitalizationNetOfCostsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" name="EffectOfReverseReverseRecapitalizationNetOfCostsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" name="EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" name="EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_EquityIncentivePlan2006Member" name="EquityIncentivePlan2006Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_GeneralProductLiabilityInsurance" name="GeneralProductLiabilityInsurance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="rvph_HCWainwrightCoMember" name="HCWainwrightCoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_InterestAndOtherIncomeExpenseNet" name="InterestAndOtherIncomeExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_InvestorWarrantMember" name="InvestorWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_LesseeOperatingLeaseMonthlyLeasePayment" name="LesseeOperatingLeaseMonthlyLeasePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_NumberOfUnitsOneIssued" name="NumberOfUnitsOneIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_NumberOfUnitsTwoIssued" name="NumberOfUnitsTwoIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_OneInvestorMember" name="OneInvestorMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="rvph_PaymentOfCertainDeferredCosts" name="PaymentOfCertainDeferredCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_PreofferingValuationPriorToQualifiedFinancingEvent" name="PreofferingValuationPriorToQualifiedFinancingEvent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="rvph_PrivateWarrantsMember" name="PrivateWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" name="ProceedsFromIssuanceOfCommonStockForDeferredCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ProceedsFromIssuanceOrSaleOfEquityNet" name="ProceedsFromIssuanceOrSaleOfEquityNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ProceedsFromReverseRecapitalization" name="ProceedsFromReverseRecapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_PublicOfferingMember" name="PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" name="QualifiedFinancingDiscountRateToPricePaidByInvestors" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="rvph_QualifiedFinancingMinimumThreshold" name="QualifiedFinancingMinimumThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="rvph_Range1Member" name="Range1Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_Range2Member" name="Range2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_Range3Member" name="Range3Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_Range4Member" name="Range4Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_RevivaContingentInterimPeriodNoteMember" name="RevivaContingentInterimPeriodNoteMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_RevivaPharmaceuticalsIncMember" name="RevivaPharmaceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" name="SaleOfStockAgreementMaximumAggregateGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" name="SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_SharesIssuedPricePerShareOne" name="SharesIssuedPricePerShareOne" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="rvph_SharesIssuedPricePerShareTwo" name="SharesIssuedPricePerShareTwo" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="rvph_StockPricePerformanceMilestonePeriod" name="StockPricePerformanceMilestonePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2016NotesMember" name="The2016NotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2016WarrantsMember" name="The2016WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2018ContingentWarrantsMember" name="The2018ContingentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2018NotesMember" name="The2018NotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2020ContingentWarrantsMember" name="The2020ContingentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2020NotesMember" name="The2020NotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_The2020WarrantsMember" name="The2020WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_TheMarketOfferingAgreementAtmAgreementMember" name="TheMarketOfferingAgreementAtmAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" name="ThresholdClosingPriceForSpecifiedNumberOfTradingDays" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" name="ThresholdConsecutiveTradingDaysForSaleOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="rvph_ThresholdTradingDaysForSaleOfShares" name="ThresholdTradingDaysForSaleOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-10-stockholders-equity-deficit-tables" name="statement-statement-note-10-stockholders-equity-deficit-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" name="statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" name="statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" name="statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" name="statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" name="statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-5-property-and-equipment-net-tables" name="statement-statement-note-5-property-and-equipment-net-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" name="statement-statement-note-8-income-taxes-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" name="statement-statement-note-8-income-taxes-provision-for-income-taxes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-note-8-income-taxes-tables" name="statement-statement-note-8-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="rvph_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>rvph-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59PM UTC 2022-03-15--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InterestAndOtherIncomeExpenseNet" xlink:label="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromReverseRecapitalization" xlink:label="rvph_ProceedsFromReverseRecapitalization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rvph_ProceedsFromReverseRecapitalization" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:label="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="rvph-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>rvph-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59PM UTC 2022-03-15--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations" xlink:href="rvph-20211231.xsd#statement-note-1-organization-and-nature-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-document-and-entity-information" xlink:href="rvph-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
	<link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
	<link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
	<link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="rvph-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" xlink:href="rvph-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-3-public-offering" xlink:href="rvph-20211231.xsd#statement-note-3-public-offering" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-3-public-offering" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-4-business-combination" xlink:href="rvph-20211231.xsd#statement-note-4-business-combination" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-4-business-combination" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaPharmaceuticalsIncMember" xlink:label="rvph_RevivaPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rvph_RevivaPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan" xlink:href="rvph-20211231.xsd#statement-note-6-employee-benefit-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes" xlink:href="rvph-20211231.xsd#statement-note-7-convertible-promissory-notes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_August2020ToOctober2020NotesMember" xlink:label="rvph_August2020ToOctober2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClosingMember" xlink:label="rvph_ClosingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OneInvestorMember" xlink:label="rvph_OneInvestorMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaContingentInterimPeriodNoteMember" xlink:label="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018ContingentWarrantsMember" xlink:label="rvph_The2018ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018NotesMember" xlink:label="rvph_The2018NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020ContingentWarrantsMember" xlink:label="rvph_The2020ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020NotesMember" xlink:label="rvph_The2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rvph_ClosingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="rvph_OneInvestorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2018NotesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2018ContingentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2020NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2020ContingentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_August2020ToOctober2020NotesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share" xlink:href="rvph-20211231.xsd#statement-note-9-loss-per-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EarnoutSharesMember" xlink:label="rvph_EarnoutSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rvph_EarnoutSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PrivateWarrantsMember" xlink:label="rvph_PrivateWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicWarrantsMember" xlink:label="rvph_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016WarrantsMember" xlink:label="rvph_The2016WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PublicWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2016WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2006Member" xlink:label="rvph_EquityIncentivePlan2006Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2020Member" xlink:label="rvph_EquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rvph_EquityIncentivePlan2006Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rvph_EquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:href="rvph-20211231.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_CorporateOfficeLeaseMember" xlink:label="rvph_CorporateOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="rvph_CorporateOfficeLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events" xlink:href="rvph-20211231.xsd#statement-note-13-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_HCWainwrightCoMember" xlink:label="rvph_HCWainwrightCoMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rvph_HCWainwrightCoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="rvph-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:label="rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" xlink:href="rvph-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual" xlink:href="rvph-20211231.xsd#statement-note-3-public-offering-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NumberOfUnitsOneIssued" xlink:label="rvph_NumberOfUnitsOneIssued" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NumberOfUnitsTwoIssued" xlink:label="rvph_NumberOfUnitsTwoIssued" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharesIssuedPricePerShareOne" xlink:label="rvph_SharesIssuedPricePerShareOne" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharesIssuedPricePerShareTwo" xlink:label="rvph_SharesIssuedPricePerShareTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_NumberOfUnitsOneIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_NumberOfUnitsTwoIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharesIssuedPricePerShareOne" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharesIssuedPricePerShareTwo" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual" xlink:href="rvph-20211231.xsd#statement-note-4-business-combination-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:label="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfStockConversionRate" xlink:label="rvph_ConversionOfStockConversionRate" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaPharmaceuticalsIncMember" xlink:label="rvph_RevivaPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockPricePerformanceMilestonePeriod" xlink:label="rvph_StockPricePerformanceMilestonePeriod" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdTradingDaysForSaleOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rvph_RevivaPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ConversionOfStockConversionRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_StockPricePerformanceMilestonePeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdTradingDaysForSaleOfShares" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual" xlink:href="rvph-20211231.xsd#statement-note-6-employee-benefit-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual" xlink:href="rvph-20211231.xsd#statement-note-7-convertible-promissory-notes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_August2020ToOctober2020NotesMember" xlink:label="rvph_August2020ToOctober2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClosingMember" xlink:label="rvph_ClosingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DebtInstrumentDebtDefaultInterestRate" xlink:label="rvph_DebtInstrumentDebtDefaultInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DebtInstrumentRenewalTerm" xlink:label="rvph_DebtInstrumentRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OneInvestorMember" xlink:label="rvph_OneInvestorMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:label="rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:label="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_QualifiedFinancingMinimumThreshold" xlink:label="rvph_QualifiedFinancingMinimumThreshold" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaContingentInterimPeriodNoteMember" xlink:label="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018ContingentWarrantsMember" xlink:label="rvph_The2018ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018NotesMember" xlink:label="rvph_The2018NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020ContingentWarrantsMember" xlink:label="rvph_The2020ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020NotesMember" xlink:label="rvph_The2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rvph_ClosingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="rvph_OneInvestorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2018NotesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2018ContingentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2020NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2020ContingentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_August2020ToOctober2020NotesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_QualifiedFinancingMinimumThreshold" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_DebtInstrumentDebtDefaultInterestRate" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_DebtInstrumentRenewalTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual" xlink:href="rvph-20211231.xsd#statement-note-9-loss-per-share-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EarnoutSharesMember" xlink:label="rvph_EarnoutSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rvph_EarnoutSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PrivateWarrantsMember" xlink:label="rvph_PrivateWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicWarrantsMember" xlink:label="rvph_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016WarrantsMember" xlink:label="rvph_The2016WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdTradingDaysForSaleOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PublicWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2016WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdTradingDaysForSaleOfShares" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2006Member" xlink:label="rvph_EquityIncentivePlan2006Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2020Member" xlink:label="rvph_EquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rvph_EquityIncentivePlan2006Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rvph_EquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="rvph-20211231.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_CorporateOfficeLeaseMember" xlink:label="rvph_CorporateOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_GeneralProductLiabilityInsurance" xlink:label="rvph_GeneralProductLiabilityInsurance" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:label="rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="rvph_CorporateOfficeLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_GeneralProductLiabilityInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual" xlink:href="rvph-20211231.xsd#statement-note-13-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_HCWainwrightCoMember" xlink:label="rvph_HCWainwrightCoMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:label="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rvph_HCWainwrightCoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range1Member" xlink:label="rvph_Range1Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range2Member" xlink:label="rvph_Range2Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range3Member" xlink:label="rvph_Range3Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range4Member" xlink:label="rvph_Range4Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="rvph_Range1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="rvph_Range2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="rvph_Range3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="rvph_Range4Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rvph_The2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:label="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InterestAndOtherIncomeExpenseNet" xlink:label="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PaymentOfCertainDeferredCosts" xlink:label="rvph_PaymentOfCertainDeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromReverseRecapitalization" xlink:label="rvph_ProceedsFromReverseRecapitalization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rvph_ProceedsFromReverseRecapitalization" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rvph_PaymentOfCertainDeferredCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:label="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:label="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:label="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="rvph-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>rvph-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59PM UTC 2022-03-15--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DocumentAndEntityInformation" xlink:label="rvph_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="rvph_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_DocumentAndEntityInformation" xlink:to="rvph_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="rvph_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="rvph_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-significant-accounting-policies-policies" xlink:label="rvph_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-significant-accounting-policies-policies" xlink:to="rvph_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:label="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:type="locator"/>
    <link:label xlink:label="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination</link:label>
    <link:label xlink:label="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Effect of plan amendment on business combination (in shares)</link:label>
    <link:label xlink:label="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in shares associated with the effect of plan amendment on business combination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:to="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-5-property-and-equipment-net-tables" xlink:label="rvph_statement-statement-note-5-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-5-property-and-equipment-net-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-5-property-and-equipment-net-tables" xlink:to="rvph_statement-statement-note-5-property-and-equipment-net-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statutory federal income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-8-income-taxes-tables" xlink:label="rvph_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-8-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-8-income-taxes-tables" xlink:to="rvph_statement-statement-note-8-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-10-stockholders-equity-deficit-tables" xlink:label="rvph_statement-statement-note-10-stockholders-equity-deficit-tables" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-10-stockholders-equity-deficit-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stockholders' Equity (Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-10-stockholders-equity-deficit-tables" xlink:to="rvph_statement-statement-note-10-stockholders-equity-deficit-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:label="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock Option Plan and Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:to="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:label="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:to="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:label="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Provision for Income Taxes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:to="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" xlink:label="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" xlink:to="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:label="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:to="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:label="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:to="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:label="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:type="locator"/>
    <link:label xlink:label="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:to="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:type="locator"/>
    <link:label xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares available for grant, options cancelled (in shares)</link:label>
    <link:label xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares cancelled under share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:to="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatements" xlink:label="rvph_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="rvph_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_NotesToFinancialStatements" xlink:to="rvph_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="rvph_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="rvph_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, weighted average exercise price per share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options cancelled, weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted, weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, number of shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, number of shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant, options granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, number of shares available for grant (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, number of shares available for grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental schedule of noncash financing and investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares available for grant, options authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentNet</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Goodwill</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on remeasurement of warrant liabilities</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockSharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFeeAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature on conversion of notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon conversion of notes and accrued interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon conversion of notes and accrued interest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:type="locator"/>
    <link:label xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability</link:label>
    <link:label xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase to additional paid-in capital (APIC) for reclassification of warrant liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:to="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Reviva Preferred Stock into Company's Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the conversion of Reviva preferred stock into the company's common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:to="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2020WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Warrants [Member]</link:label>
    <link:label xlink:label="rvph_The2020WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2020 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2020WarrantsMember" xlink:to="rvph_The2020WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PaymentOfCertainDeferredCosts" xlink:label="rvph_PaymentOfCertainDeferredCosts" xlink:type="locator"/>
    <link:label xlink:label="rvph_PaymentOfCertainDeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of certain deferred costs from proceeds from business combination</link:label>
    <link:label xlink:label="rvph_PaymentOfCertainDeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payment of certain deferred costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_PaymentOfCertainDeferredCosts" xlink:to="rvph_PaymentOfCertainDeferredCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfStockConversionRate" xlink:label="rvph_ConversionOfStockConversionRate" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOfStockConversionRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ConversionOfStockConversionRate</link:label>
    <link:label xlink:label="rvph_ConversionOfStockConversionRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Conversion Rate</link:label>
    <link:label xlink:label="rvph_ConversionOfStockConversionRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion rate of stock conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOfStockConversionRate" xlink:to="rvph_ConversionOfStockConversionRate-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="rvph_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="rvph_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="rvph_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="rvph_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options outstanding, options granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant, assumptions</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding, options cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016WarrantsMember" xlink:label="rvph_The2016WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2016WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2016 Warrants [Member]</link:label>
    <link:label xlink:label="rvph_The2016WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2016 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2016WarrantsMember" xlink:to="rvph_The2016WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Units in public offering, net (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to consultant in exchange for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued to consultant in exchange for services (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Units in public offering, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="rvph_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in connection with warrant exercises</link:label>
    <link:label xlink:label="rvph_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="rvph_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLiabilityMeasurementInput</link:label>
    <link:label xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_PreFundedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label xlink:label="rvph_PreFundedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Pre-Funded Warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_PreFundedWarrantMember" xlink:to="rvph_PreFundedWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_InvestorWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor Warrant [Member]</link:label>
    <link:label xlink:label="rvph_InvestorWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the investor warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_InvestorWarrantMember" xlink:to="rvph_InvestorWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="rvph_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in connection with warrant exercises (in shares)</link:label>
    <link:label xlink:label="rvph_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued for warrants exercised during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="rvph_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaPharmaceuticalsIncMember" xlink:label="rvph_RevivaPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_RevivaPharmaceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reviva Pharmaceuticals, Inc. [Member]</link:label>
    <link:label xlink:label="rvph_RevivaPharmaceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Reviva Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_RevivaPharmaceuticalsIncMember" xlink:to="rvph_RevivaPharmaceuticalsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharesIssuedPricePerShareOne" xlink:label="rvph_SharesIssuedPricePerShareOne" xlink:type="locator"/>
    <link:label xlink:label="rvph_SharesIssuedPricePerShareOne-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_SharesIssuedPricePerShareOne</link:label>
    <link:label xlink:label="rvph_SharesIssuedPricePerShareOne-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share, One (in dollars per share)</link:label>
    <link:label xlink:label="rvph_SharesIssuedPricePerShareOne-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per unit amount of first portion units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_SharesIssuedPricePerShareOne" xlink:to="rvph_SharesIssuedPricePerShareOne-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharesIssuedPricePerShareTwo" xlink:label="rvph_SharesIssuedPricePerShareTwo" xlink:type="locator"/>
    <link:label xlink:label="rvph_SharesIssuedPricePerShareTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_SharesIssuedPricePerShareTwo</link:label>
    <link:label xlink:label="rvph_SharesIssuedPricePerShareTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share, Two (in dollars per share)</link:label>
    <link:label xlink:label="rvph_SharesIssuedPricePerShareTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per unit amount of second portion units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_SharesIssuedPricePerShareTwo" xlink:to="rvph_SharesIssuedPricePerShareTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NumberOfUnitsOneIssued" xlink:label="rvph_NumberOfUnitsOneIssued" xlink:type="locator"/>
    <link:label xlink:label="rvph_NumberOfUnitsOneIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_NumberOfUnitsOneIssued</link:label>
    <link:label xlink:label="rvph_NumberOfUnitsOneIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units, One, Issued (in shares)</link:label>
    <link:label xlink:label="rvph_NumberOfUnitsOneIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First portion of units issued during period. Each unit is consisting of (a) one share of common stock and (b) one Investor Warrant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_NumberOfUnitsOneIssued" xlink:to="rvph_NumberOfUnitsOneIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label xlink:label="rvph_PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_PublicOfferingMember" xlink:to="rvph_PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NumberOfUnitsTwoIssued" xlink:label="rvph_NumberOfUnitsTwoIssued" xlink:type="locator"/>
    <link:label xlink:label="rvph_NumberOfUnitsTwoIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_NumberOfUnitsTwoIssued</link:label>
    <link:label xlink:label="rvph_NumberOfUnitsTwoIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units, Two, Issued (in shares)</link:label>
    <link:label xlink:label="rvph_NumberOfUnitsTwoIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second portion of units issued during period. Each unit is consisting of one Pre-Funded Warrant and (b) one Investor Warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_NumberOfUnitsTwoIssued" xlink:to="rvph_NumberOfUnitsTwoIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:label xlink:label="rvph_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ProceedsFromIssuanceOrSaleOfEquityNet</link:label>
    <link:label xlink:label="rvph_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net</link:label>
    <link:label xlink:label="rvph_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:to="rvph_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InterestAndOtherIncomeExpenseNet" xlink:label="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="rvph_InterestAndOtherIncomeExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income (expense), net</link:label>
    <link:label xlink:label="rvph_InterestAndOtherIncomeExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of interest and other income (expense), net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_InterestAndOtherIncomeExpenseNet" xlink:to="rvph_InterestAndOtherIncomeExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range3Member" xlink:label="rvph_Range3Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_Range3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 3 [Member]</link:label>
    <link:label xlink:label="rvph_Range3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to third range of exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_Range3Member" xlink:to="rvph_Range3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range4Member" xlink:label="rvph_Range4Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_Range4Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 4 [Member]</link:label>
    <link:label xlink:label="rvph_Range4Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to fourth range of exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_Range4Member" xlink:to="rvph_Range4Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock in lieu of deferred compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of stock in exchange for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock in lieu of deferred compensation (in shares)</link:label>
    <link:label xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of convertible promissory notes into common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssued</link:label>
    <link:label xlink:label="us-gaap_SharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Issued, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value of $0.0001; 115,000,000 shares authorized; 14,433,286 and 9,231,737 shares issued and outstanding as of December 31, 2021, and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockParOrStatedValuePerShare</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:type="locator"/>
    <link:label xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in lieu of deferred compensation</link:label>
    <link:label xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation</link:label>
    <link:label xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of proceeds from issuance of common stock for deferred compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:to="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IPOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses incurred but not yet paid nor invoiced, and current liabilities classified as other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfWarrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock upon warrant exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of Units in public offering, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:type="locator"/>
    <link:label xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from reverse acquisition, net of costs</link:label>
    <link:label xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from the proceeds from reverse recapitalization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:to="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:label="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:type="locator"/>
    <link:label xlink:label="rvph_EffectOfReverseRecapitalizationNetOfCostsValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of reverse recapitalization, net of costs</link:label>
    <link:label xlink:label="rvph_EffectOfReverseRecapitalizationNetOfCostsValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of effect of reverse recapitalization, net of costs, during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:to="rvph_EffectOfReverseRecapitalizationNetOfCostsValue-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:label="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:type="locator"/>
    <link:label xlink:label="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of reverse recapitalization, net of costs (in shares)</link:label>
    <link:label xlink:label="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effect on the number of shares from reverse recapitalization, net of costs, during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:to="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:label="rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="rvph_BeneficialConversionFeaturePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</link:label>
    <link:label xlink:label="rvph_BeneficialConversionFeaturePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for beneficial conversion feature.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:to="rvph_BeneficialConversionFeaturePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromReverseRecapitalization" xlink:label="rvph_ProceedsFromReverseRecapitalization" xlink:type="locator"/>
    <link:label xlink:label="rvph_ProceedsFromReverseRecapitalization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ProceedsFromReverseRecapitalization</link:label>
    <link:label xlink:label="rvph_ProceedsFromReverseRecapitalization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from business combination, net of costs</link:label>
    <link:label xlink:label="rvph_ProceedsFromReverseRecapitalization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from reverse recapitalization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ProceedsFromReverseRecapitalization" xlink:to="rvph_ProceedsFromReverseRecapitalization-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</link:label>
    <link:label xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other current liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:type="locator"/>
    <link:label xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ThresholdConsecutiveTradingDaysForSaleOfShares</link:label>
    <link:label xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold Consecutive Trading Days for Sale of Shares (Day)</link:label>
    <link:label xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold period of specified consecutive trading days within which closing stock price must exceed a price per share amount for specified number of trading days, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:to="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:type="locator"/>
    <link:label xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays</link:label>
    <link:label xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold Closing Price for Specified Number of Trading Days (in dollars per share)</link:label>
    <link:label xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The threshold closing price, as adjusted for stock splits, stock dividends, reorganizations or recapitalizations, for any 20 trading days within any 30-trading day period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:to="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdTradingDaysForSaleOfShares" xlink:type="locator"/>
    <link:label xlink:label="rvph_ThresholdTradingDaysForSaleOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ThresholdTradingDaysForSaleOfShares</link:label>
    <link:label xlink:label="rvph_ThresholdTradingDaysForSaleOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold Trading Days for Sale of Shares (Day)</link:label>
    <link:label xlink:label="rvph_ThresholdTradingDaysForSaleOfShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold number of specified trading days that the closing price of ordinary shares must meet or exceed a price per share, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ThresholdTradingDaysForSaleOfShares" xlink:to="rvph_ThresholdTradingDaysForSaleOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertibleNotesPayable</link:label>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClosingMember" xlink:label="rvph_ClosingMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ClosingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing [Member]</link:label>
    <link:label xlink:label="rvph_ClosingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the business combination referred to as "Closing".</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ClosingMember" xlink:to="rvph_ClosingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:label="rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:type="locator"/>
    <link:label xlink:label="rvph_LesseeOperatingLeaseMonthlyLeasePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_LesseeOperatingLeaseMonthlyLeasePayment</link:label>
    <link:label xlink:label="rvph_LesseeOperatingLeaseMonthlyLeasePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Lease Payment</link:label>
    <link:label xlink:label="rvph_LesseeOperatingLeaseMonthlyLeasePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monthly lease payment for lessee's operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:to="rvph_LesseeOperatingLeaseMonthlyLeasePayment-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_CorporateOfficeLeaseMember" xlink:label="rvph_CorporateOfficeLeaseMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_CorporateOfficeLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Office Lease [Member]</link:label>
    <link:label xlink:label="rvph_CorporateOfficeLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the corporate office lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_CorporateOfficeLeaseMember" xlink:to="rvph_CorporateOfficeLeaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:label="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:type="locator"/>
    <link:label xlink:label="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance</link:label>
    <link:label xlink:label="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Shares to be Issued to Security Holders, Contingent on Stock Price Performance (in shares)</link:label>
    <link:label xlink:label="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents additional shares to be issued to security holders contingent on stock price performance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:to="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockPricePerformanceMilestonePeriod" xlink:label="rvph_StockPricePerformanceMilestonePeriod" xlink:type="locator"/>
    <link:label xlink:label="rvph_StockPricePerformanceMilestonePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_StockPricePerformanceMilestonePeriod</link:label>
    <link:label xlink:label="rvph_StockPricePerformanceMilestonePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price Performance, Milestone Period (Year)</link:label>
    <link:label xlink:label="rvph_StockPricePerformanceMilestonePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the milestone period for stock price performance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_StockPricePerformanceMilestonePeriod" xlink:to="rvph_StockPricePerformanceMilestonePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_GeneralProductLiabilityInsurance" xlink:label="rvph_GeneralProductLiabilityInsurance" xlink:type="locator"/>
    <link:label xlink:label="rvph_GeneralProductLiabilityInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_GeneralProductLiabilityInsurance</link:label>
    <link:label xlink:label="rvph_GeneralProductLiabilityInsurance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Product Liability Insurance</link:label>
    <link:label xlink:label="rvph_GeneralProductLiabilityInsurance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of general product liability insurance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_GeneralProductLiabilityInsurance" xlink:to="rvph_GeneralProductLiabilityInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_QualifiedFinancingMinimumThreshold" xlink:label="rvph_QualifiedFinancingMinimumThreshold" xlink:type="locator"/>
    <link:label xlink:label="rvph_QualifiedFinancingMinimumThreshold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_QualifiedFinancingMinimumThreshold</link:label>
    <link:label xlink:label="rvph_QualifiedFinancingMinimumThreshold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified Financing, Minimum Threshold</link:label>
    <link:label xlink:label="rvph_QualifiedFinancingMinimumThreshold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold amount of money that must be raised by the Company through a future equity financing in order for the principal and interest due on the note to convert into the same equity issued in that financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_QualifiedFinancingMinimumThreshold" xlink:to="rvph_QualifiedFinancingMinimumThreshold-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2016NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2016 Notes [Member]</link:label>
    <link:label xlink:label="rvph_The2016NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2016 Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2016NotesMember" xlink:to="rvph_The2016NotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InternalRevenueServiceIRSMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DebtInstrumentDebtDefaultInterestRate" xlink:label="rvph_DebtInstrumentDebtDefaultInterestRate" xlink:type="locator"/>
    <link:label xlink:label="rvph_DebtInstrumentDebtDefaultInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_DebtInstrumentDebtDefaultInterestRate</link:label>
    <link:label xlink:label="rvph_DebtInstrumentDebtDefaultInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Interest Rate</link:label>
    <link:label xlink:label="rvph_DebtInstrumentDebtDefaultInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest rate of outstanding debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_DebtInstrumentDebtDefaultInterestRate" xlink:to="rvph_DebtInstrumentDebtDefaultInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:label="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:type="locator"/>
    <link:label xlink:label="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors</link:label>
    <link:label xlink:label="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified Financing, Discount Rate to Price Paid by Investors</link:label>
    <link:label xlink:label="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of discount to the price paid by investors in the qualified financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:to="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:label="rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:type="locator"/>
    <link:label xlink:label="rvph_PreofferingValuationPriorToQualifiedFinancingEvent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_PreofferingValuationPriorToQualifiedFinancingEvent</link:label>
    <link:label xlink:label="rvph_PreofferingValuationPriorToQualifiedFinancingEvent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-offering Valuation Prior to Qualified Financing Event</link:label>
    <link:label xlink:label="rvph_PreofferingValuationPriorToQualifiedFinancingEvent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of pre-offering valuation prior to the qualified financing event.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:to="rvph_PreofferingValuationPriorToQualifiedFinancingEvent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfConvertibleDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2016 Notes into Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2016 Notes into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OneInvestorMember" xlink:label="rvph_OneInvestorMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_OneInvestorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Investor [Member]</link:label>
    <link:label xlink:label="rvph_OneInvestorMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to one investor.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_OneInvestorMember" xlink:to="rvph_OneInvestorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DebtInstrumentRenewalTerm" xlink:label="rvph_DebtInstrumentRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="rvph_DebtInstrumentRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_DebtInstrumentRenewalTerm</link:label>
    <link:label xlink:label="rvph_DebtInstrumentRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Renewal Term (Month)</link:label>
    <link:label xlink:label="rvph_DebtInstrumentRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Renewal of the maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_DebtInstrumentRenewalTerm" xlink:to="rvph_DebtInstrumentRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2018 Notes into common stock with aggregate principal amount of at least $50,0000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018NotesMember" xlink:label="rvph_The2018NotesMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2018NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Notes [Member]</link:label>
    <link:label xlink:label="rvph_The2018NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2018 Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2018NotesMember" xlink:to="rvph_The2018NotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018ContingentWarrantsMember" xlink:label="rvph_The2018ContingentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2018ContingentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Contingent Warrants [Member]</link:label>
    <link:label xlink:label="rvph_The2018ContingentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2018 Contingent Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2018ContingentWarrantsMember" xlink:to="rvph_The2018ContingentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020NotesMember" xlink:label="rvph_The2020NotesMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2020NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Notes [Member]</link:label>
    <link:label xlink:label="rvph_The2020NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2020 Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2020NotesMember" xlink:to="rvph_The2020NotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Reviva Common Stock into Company's Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of Reviva common stock into Company's common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:to="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2018 Notes into common stock with aggregate principal amount less than $50,0000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2020 Notes into Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2020 Notes in common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2020 Notes into common stock with aggregate principal amount less than $50,0000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020ContingentWarrantsMember" xlink:label="rvph_The2020ContingentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_The2020ContingentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Contingent Warrants [Member]</link:label>
    <link:label xlink:label="rvph_The2020ContingentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2020 Contingent Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_The2020ContingentWarrantsMember" xlink:to="rvph_The2020ContingentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2018 Notes into Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2018 Notes in common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of 2020 Notes into common stock with aggregate principal amount of at least $50,0000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_August2020ToOctober2020NotesMember" xlink:label="rvph_August2020ToOctober2020NotesMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_August2020ToOctober2020NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2020 to October 2020 Notes [Member]</link:label>
    <link:label xlink:label="rvph_August2020ToOctober2020NotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the August 2020 to October 2020 Notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_August2020ToOctober2020NotesMember" xlink:to="rvph_August2020ToOctober2020NotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of August 2020 to October 2020 Notes into Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of August 2020 to October 2020 Notes into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:to="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaContingentInterimPeriodNoteMember" xlink:label="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_RevivaContingentInterimPeriodNoteMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reviva Contingent Interim Period Note [Member]</link:label>
    <link:label xlink:label="rvph_RevivaContingentInterimPeriodNoteMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the Reviva Contingent Interim Period Note.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_RevivaContingentInterimPeriodNoteMember" xlink:to="rvph_RevivaContingentInterimPeriodNoteMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Reviva Contingent Interim Period Note into Common Stock [Member]</link:label>
    <link:label xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of Reviva Contingent Interim Period Note into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:label xlink:label="rvph_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_OperatingLossCarryforwardsSubjectToExpiration</link:label>
    <link:label xlink:label="rvph_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label xlink:label="rvph_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="rvph_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:label="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="locator"/>
    <link:label xlink:label="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed assets/capitalized start-up costs</link:label>
    <link:label xlink:label="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment and start up costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:to="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EarnoutSharesMember" xlink:label="rvph_EarnoutSharesMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_EarnoutSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earn-out Shares [Member]</link:label>
    <link:label xlink:label="rvph_EarnoutSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to earn-out shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EarnoutSharesMember" xlink:to="rvph_EarnoutSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicWarrantsMember" xlink:label="rvph_PublicWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_PublicWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Warrants [Member]</link:label>
    <link:label xlink:label="rvph_PublicWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to public warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_PublicWarrantsMember" xlink:to="rvph_PublicWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PrivateWarrantsMember" xlink:label="rvph_PrivateWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_PrivateWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Warrants [Member]</link:label>
    <link:label xlink:label="rvph_PrivateWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to private warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_PrivateWarrantsMember" xlink:to="rvph_PrivateWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding Basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2020Member" xlink:label="rvph_EquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_EquityIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2020 [Member]</link:label>
    <link:label xlink:label="rvph_EquityIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2020 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EquityIncentivePlan2020Member" xlink:to="rvph_EquityIncentivePlan2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="rvph_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_ClassOfWarrantOrRightRedemptionPricePerShare</link:label>
    <link:label xlink:label="rvph_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Redemption Price Per Share (in dollars per share)</link:label>
    <link:label xlink:label="rvph_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption price per share or per unit of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:to="rvph_ClassOfWarrantOrRightRedemptionPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range1Member" xlink:label="rvph_Range1Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_Range1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 1 [Member]</link:label>
    <link:label xlink:label="rvph_Range1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to first range of exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_Range1Member" xlink:to="rvph_Range1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range2Member" xlink:label="rvph_Range2Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_Range2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 2 [Member]</link:label>
    <link:label xlink:label="rvph_Range2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to second range of exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_Range2Member" xlink:to="rvph_Range2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2006Member" xlink:label="rvph_EquityIncentivePlan2006Member" xlink:type="locator"/>
    <link:label xlink:label="rvph_EquityIncentivePlan2006Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006 [Member]</link:label>
    <link:label xlink:label="rvph_EquityIncentivePlan2006Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the 2006 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EquityIncentivePlan2006Member" xlink:to="rvph_EquityIncentivePlan2006Member-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:type="locator"/>
    <link:label xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease</link:label>
    <link:label xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percent of Increase</link:label>
    <link:label xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum percentage of increase, based on total number of common stock outstanding, in shares to be issued under share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:to="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_HCWainwrightCoMember" xlink:label="rvph_HCWainwrightCoMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_HCWainwrightCoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">H.C. Wainwright &amp; Co [Member]</link:label>
    <link:label xlink:label="rvph_HCWainwrightCoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents an agreement with H.C. Wainwright &amp; Co.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_HCWainwrightCoMember" xlink:to="rvph_HCWainwrightCoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Market Offering Agreement "ATM Agreement" [Member]</link:label>
    <link:label xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:to="rvph_TheMarketOfferingAgreementAtmAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:label="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds</link:label>
    <link:label xlink:label="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock Agreement, Maximum Aggregate Gross Proceeds</link:label>
    <link:label xlink:label="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the maximum aggregate gross proceeds to be received from the agreement with H.C. Wainwright &amp; Co.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:to="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="locator"/>
    <link:label xlink:label="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant expense</link:label>
    <link:label xlink:label="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to warrant expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="locator"/>
    <link:label xlink:label="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature related to notes</link:label>
    <link:label xlink:label="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to beneficial conversion feature.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>rvph-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59PM UTC 2022-03-15--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations" xlink:href="rvph-20211231.xsd#statement-note-1-organization-and-nature-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-document-and-entity-information" xlink:href="rvph-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
	<link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
	<link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
	<link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="rvph-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" xlink:href="rvph-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-3-public-offering" xlink:href="rvph-20211231.xsd#statement-note-3-public-offering" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-3-public-offering" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-4-business-combination" xlink:href="rvph-20211231.xsd#statement-note-4-business-combination" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-4-business-combination" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaPharmaceuticalsIncMember" xlink:label="rvph_RevivaPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="rvph_RevivaPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan" xlink:href="rvph-20211231.xsd#statement-note-6-employee-benefit-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes" xlink:href="rvph-20211231.xsd#statement-note-7-convertible-promissory-notes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_August2020ToOctober2020NotesMember" xlink:label="rvph_August2020ToOctober2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClosingMember" xlink:label="rvph_ClosingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OneInvestorMember" xlink:label="rvph_OneInvestorMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaContingentInterimPeriodNoteMember" xlink:label="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018ContingentWarrantsMember" xlink:label="rvph_The2018ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018NotesMember" xlink:label="rvph_The2018NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020ContingentWarrantsMember" xlink:label="rvph_The2020ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020NotesMember" xlink:label="rvph_The2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="rvph_ClosingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="rvph_OneInvestorMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2018NotesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2018ContingentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2020NotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2020ContingentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_August2020ToOctober2020NotesMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share" xlink:href="rvph-20211231.xsd#statement-note-9-loss-per-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EarnoutSharesMember" xlink:label="rvph_EarnoutSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="rvph_EarnoutSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PrivateWarrantsMember" xlink:label="rvph_PrivateWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicWarrantsMember" xlink:label="rvph_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016WarrantsMember" xlink:label="rvph_The2016WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PublicWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2016WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2006Member" xlink:label="rvph_EquityIncentivePlan2006Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2020Member" xlink:label="rvph_EquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="rvph_EquityIncentivePlan2006Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="rvph_EquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:href="rvph-20211231.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_CorporateOfficeLeaseMember" xlink:label="rvph_CorporateOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="rvph_CorporateOfficeLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events" xlink:href="rvph-20211231.xsd#statement-note-13-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_HCWainwrightCoMember" xlink:label="rvph_HCWainwrightCoMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NotesToFinancialStatementsAbstract" xlink:label="rvph_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="rvph_HCWainwrightCoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="rvph-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:label="rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-significant-accounting-policies-policies" xlink:label="rvph_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rvph_BeneficialConversionFeaturePolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-5-property-and-equipment-net-tables" xlink:label="rvph_statement-statement-note-5-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-5-property-and-equipment-net-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-8-income-taxes-tables" xlink:label="rvph_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-8-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-10-stockholders-equity-deficit-tables" xlink:label="rvph_statement-statement-note-10-stockholders-equity-deficit-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-10-stockholders-equity-deficit-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:label="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" xlink:href="rvph-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual" xlink:href="rvph-20211231.xsd#statement-note-3-public-offering-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NumberOfUnitsOneIssued" xlink:label="rvph_NumberOfUnitsOneIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NumberOfUnitsTwoIssued" xlink:label="rvph_NumberOfUnitsTwoIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="rvph_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharesIssuedPricePerShareOne" xlink:label="rvph_SharesIssuedPricePerShareOne-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharesIssuedPricePerShareTwo" xlink:label="rvph_SharesIssuedPricePerShareTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_NumberOfUnitsOneIssued-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_NumberOfUnitsTwoIssued-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharesIssuedPricePerShareOne-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharesIssuedPricePerShareTwo-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual" xlink:href="rvph-20211231.xsd#statement-note-4-business-combination-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance" xlink:label="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:label="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfStockConversionRate" xlink:label="rvph_ConversionOfStockConversionRate-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaPharmaceuticalsIncMember" xlink:label="rvph_RevivaPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockPricePerformanceMilestonePeriod" xlink:label="rvph_StockPricePerformanceMilestonePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdTradingDaysForSaleOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="rvph_RevivaPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ConversionOfStockConversionRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_StockPricePerformanceMilestonePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdTradingDaysForSaleOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual" xlink:href="rvph-20211231.xsd#statement-note-6-employee-benefit-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual" xlink:href="rvph-20211231.xsd#statement-note-7-convertible-promissory-notes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_August2020ToOctober2020NotesMember" xlink:label="rvph_August2020ToOctober2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClosingMember" xlink:label="rvph_ClosingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:label="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:label="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:label="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DebtInstrumentDebtDefaultInterestRate" xlink:label="rvph_DebtInstrumentDebtDefaultInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DebtInstrumentRenewalTerm" xlink:label="rvph_DebtInstrumentRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OneInvestorMember" xlink:label="rvph_OneInvestorMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreofferingValuationPriorToQualifiedFinancingEvent" xlink:label="rvph_PreofferingValuationPriorToQualifiedFinancingEvent-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors" xlink:label="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_QualifiedFinancingMinimumThreshold" xlink:label="rvph_QualifiedFinancingMinimumThreshold-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_RevivaContingentInterimPeriodNoteMember" xlink:label="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018ContingentWarrantsMember" xlink:label="rvph_The2018ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2018NotesMember" xlink:label="rvph_The2018NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020ContingentWarrantsMember" xlink:label="rvph_The2020ContingentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020NotesMember" xlink:label="rvph_The2020NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2016NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="rvph_ClosingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="rvph_OneInvestorMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2018NotesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2018ContingentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2018NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2020NotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2020ContingentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOf2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_August2020ToOctober2020NotesMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_RevivaContingentInterimPeriodNoteMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_QualifiedFinancingMinimumThreshold-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_PreofferingValuationPriorToQualifiedFinancingEvent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_DebtInstrumentDebtDefaultInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_DebtInstrumentRenewalTerm-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="rvph_OperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_OperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual" xlink:href="rvph-20211231.xsd#statement-note-9-loss-per-share-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EarnoutSharesMember" xlink:label="rvph_EarnoutSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="rvph_EarnoutSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="rvph_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="rvph_ClassOfWarrantOrRightRedemptionPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InvestorWarrantMember" xlink:label="rvph_InvestorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PreFundedWarrantMember" xlink:label="rvph_PreFundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PrivateWarrantsMember" xlink:label="rvph_PrivateWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicOfferingMember" xlink:label="rvph_PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PublicWarrantsMember" xlink:label="rvph_PublicWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016NotesMember" xlink:label="rvph_The2016NotesMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2016WarrantsMember" xlink:label="rvph_The2016WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays" xlink:label="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdConsecutiveTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ThresholdTradingDaysForSaleOfShares" xlink:label="rvph_ThresholdTradingDaysForSaleOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PublicWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="rvph_PrivateWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_PreFundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="rvph_PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_InvestorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2016WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="rvph_The2016NotesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ClassOfWarrantOrRightRedemptionPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdTradingDaysForSaleOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ThresholdConsecutiveTradingDaysForSaleOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2006Member" xlink:label="rvph_EquityIncentivePlan2006Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EquityIncentivePlan2020Member" xlink:label="rvph_EquityIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease" xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="rvph_EquityIncentivePlan2006Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="rvph_EquityIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="rvph-20211231.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_CorporateOfficeLeaseMember" xlink:label="rvph_CorporateOfficeLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_GeneralProductLiabilityInsurance" xlink:label="rvph_GeneralProductLiabilityInsurance-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_LesseeOperatingLeaseMonthlyLeasePayment" xlink:label="rvph_LesseeOperatingLeaseMonthlyLeasePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="rvph_CorporateOfficeLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_GeneralProductLiabilityInsurance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_LesseeOperatingLeaseMonthlyLeasePayment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual" xlink:href="rvph-20211231.xsd#statement-note-13-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_HCWainwrightCoMember" xlink:label="rvph_HCWainwrightCoMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_NoteToFinancialStatementDetailsTextual" xlink:label="rvph_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds" xlink:label="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:label="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="rvph_HCWainwrightCoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="rvph_TheMarketOfferingAgreementAtmAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range1Member" xlink:label="rvph_Range1Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range2Member" xlink:label="rvph_Range2Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range3Member" xlink:label="rvph_Range3Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_Range4Member" xlink:label="rvph_Range4Member" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:label="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="rvph_Range1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="rvph_Range2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="rvph_Range3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="rvph_Range4Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:href="rvph-20211231.xsd#statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_The2020WarrantsMember" xlink:label="rvph_The2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:label="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="rvph_The2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:href="rvph-20211231.xsd#statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination" xlink:label="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination-n8" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:label="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_InterestAndOtherIncomeExpenseNet" xlink:label="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="rvph_InterestAndOtherIncomeExpenseNet" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_PaymentOfCertainDeferredCosts" xlink:label="rvph_PaymentOfCertainDeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation" xlink:label="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_ProceedsFromReverseRecapitalization" xlink:label="rvph_ProceedsFromReverseRecapitalization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rvph_ProceedsFromReverseRecapitalization-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rvph_PaymentOfCertainDeferredCosts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:href="rvph-20211231.xsd#statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:label="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:label="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:label="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectOfReverseRecapitalizationNetOfCostsValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:href="rvph-20211231.xsd#statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:label="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:label="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:label="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details" xlink:href="rvph-20211231.xsd#statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:label="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" xlink:label="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="rvph-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="rvph-20211231.xsd#rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="rvph_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a1.jpg
<TEXT>
begin 644 a1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $R/44;AZC\ZC+ $^I.,
M]1GJ0>. 1SQUY],5&"&[D>RC/ZMSVH5[_#*W5V]/G\[?@2Y)-*ZN_L\R4GMM
M=I;7W[%C</4?G1N'J/SJ# _O-^2T8']YOR6G;^[+[GY>7]?)AS_W7_X'3\O[
MWF_Z3)]P]1^=&X>H_.H,#^\WY+1@?WF_):+?W9?<_+R_KY,.?^[_ .3T_P"[
MY^;_ %V9/N'J/SHW#U'YU!@?WF_):,#^\WY+1;^[+[GY>7]?)AS_ -U_^!T_
M+^]YO^DR?</4?G1N'J/SJ# _O-^2T8']YOR6BW]V7W/R\OZ^3#G_ +O;[=/R
M\_-_TF3[AZC\Z-P]1^=08']YOR6C _O-^2T6_NR^Y^7E_7R8<_\ =[?;I^7G
MYO\ I,GW#U'YT;AZC\Z@P/[S?DM&!_>;\EHM_=E]S\O+^ODPY_[O;[=/R\_-
M_P!)D^X>H_.C</4?G4&!_>;\EHP/[S?DM%O[LON?EY?U\F'/_=[?;I^7GYO^
MDR?</4?G1N'J/SJ# _O-^2T8']YOR6BW]V7W/R\OZ^3#G_NO_P #I^7][S?]
M)D^X>H_.C</4?G4&!_>;\EHP/[S?DM%O[LON?EY?U\F'/_=[?;I_W?/S>_Z,
MGW#U'YT;AZC\Z@P/[S?DM&!_>;\EHM_=E]S\O+^ODPY_[K_\#I^7][S?])D^
MX>H_.C</4?G4&!_>;\EHP/[S?DM%O[LON?EY?U\F'/\ W?\ R>G_ '?/S?Z[
M,GW#U'YT;AZC\Z@P/[S?DM&!_>;\EHM_=E]S\O+^ODPY_P"Z_P#P.GY?WO-_
MTF3[AZC\Z-P]1^=08']YOR6C _O-^2T6_NR^Y^7E_7R8<_\ =[?;A_=\_-_T
MF3[AZC\Z-P]1^=08']YOR6C _O-^2T6_NR^Y^7E_7R8<_P#=?_@=/R_O>;_I
M,GW#U'YT;AZC\Z@P/[S?DM&!_>;\EHM_=E]S\O+^ODPY_P"[V^W3\O/S?])D
M^X>H_.C</4?G4&!_>;\EHP/[S?DM%O[LON?EY?U\F'/_ '>WVZ?EY^;_ *3)
M]P]1^=&X>H_.H,#^\WY+1@?WF_):+?W9?<_+R_KY,.?^Z_\ P.GY?WO-_P!)
MD^X>H_.C</4?G4&!_>;\EHP/[S?DM%O[LON?EY?U\F'/_=[?;I_W?/S>_P"C
M)]P]1^=&X>H_.H,#^\WY+1@?WF_):+?W9?<_+R_KY,.?^Z__  .GY?WO-_TF
M3[AZC\Z-P]1^=08']YOR6C _O-^2T6_NR^Y^7E_7R8<_]W_R>']WS\W]VNS)
M]P]1^=&X>H_.H,#^\WY+1@?WF_):+?W9?<_+R_KY,.?^Z_\ P.GY?WO-_P!)
MD^X>H_.C</4?G4&!_>;\EHP/[S?DM%O[LON?EY?U\F'/_=_\GI_W?/S?Z[,G
MW#U'YT;AZC\Z@P/[S?DM&!_>;\EHM_=E]S\O+^ODPY_[K_\  Z?E_>\W_29/
MD'H12U"I"D\L>">@X ]^WX]?PJ4'(SC'M_\ JX^E+Y/YC3NKVM\T_P 5H+11
M10,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\F/^"VWC7Q
MC\./^";'[1GC3X?^*?$/@GQ?H,/@*XT3Q/X6U>^T/7M*FN?B'X:L;B2PU33I
M[>[MFGLKNZM)?+E DM[B6)@5<BO\^%_V\OVV_E(_:V_:)&0W3XN^-DZ2R*/N
MZN <  9//O7]^_\ P7J_Y18_M1?]>?P\_P#5G>$:_P U=\83.>C]-W_/:7TK
M^C_!S+LOQV1X^6,P.#Q4XYFXQEB<+1KR45AZ<N2+JPDU&_O632OKOJ?R5X\Y
MIF>"XGRRG@\PQV%IO)J,W3PV*KT(.;S#,HN3C2J03DXPC%MZN,8QO9*WU=_P
MWG^VY_T=M^T5_P"'@\<?_+>C_AO/]MS_ *.V_:*_\/!XX_\ EO7R;Q_M?^/T
M<?[7_C]?L'^KV1_]";*?_#;A/+_IUY?UI;\-_P!8,^_Z'6;]/^9AC?[O_3_^
MK^>GUE_PWG^VY_T=M^T5_P"'@\<?_+>C_AO/]MS_ *.V_:*_\/!XX_\ EO7R
M;Q_M?^/T<?[7_C]'^KV1_P#0FRG_ ,-N$\O^G7E_6EC_ %@S[_H=9OT_YF&-
M_N_]/_ZOYZ?67_#>?[;G_1VW[17_ (>#QQ_\MZ/^&\_VW/\ H[;]HK_P\'CC
M_P"6]?)O'^U_X_1Q_M?^/T?ZO9'_ -";*?\ PVX3R_Z=>7]:6/\ 6#/O^AUF
M_3_F88W^[_T__J_GI]9?\-Y_MN?]';?M%?\ AX/''_RWH_X;S_;<_P"CMOVB
MO_#P>./_ );U\F\?[7_C]''^U_X_1_J]D?\ T)LI_P##;A/+_IUY?UI8_P!8
M,^_Z'6;]/^9AC?[O_3_^K^>GUE_PWG^VY_T=M^T5_P"'@\<?_+>C_AO/]MS_
M *.V_:*_\/!XX_\ EO7R;Q_M?^/T<?[7_C]'^KV1_P#0FRG_ ,-N$\O^G7E_
M6EC_ %@S[_H=9OT_YF&-_N_]/_ZOYZ?67_#>?[;G_1VW[17_ (>#QQ_\MZ/^
M&\_VW/\ H[;]HK_P\'CC_P"6]?)O'^U_X_1Q_M?^/T?ZO9'_ -";*?\ PVX3
MR_Z=>7]:6/\ 6#/O^AUF_3_F88W^[_T__J_GI]9?\-Y_MN?]';?M%?\ AX/'
M'_RWH_X;S_;<_P"CMOVBO_#P>./_ );U\F\?[7_C]''^U_X_1_J]D?\ T)LI
M_P##;A/+_IUY?UI8_P!8,^_Z'6;]/^9AC?[O_3_^K^>GUE_PWG^VY_T=M^T5
M_P"'@\<?_+>C_AO/]MS_ *.V_:*_\/!XX_\ EO7R;Q_M?^/U/:V[WEU:V<.?
M.N[F"UBW%U7S;B5(8]QYPN]QN.#@9.#2?#^113;R?*4HJ[?]FX31*S?_ "Z\
MOZTLXY_G\G&,<YSB4I.*2688UMMN*27[_5MZ>=_/3ZK_ .&\_P!MS_H[;]HK
M_P /!XX_^6]'_#>?[;G_ $=M^T5_X>#QQ_\ +>OH#XV?\$L_C5\%K?XTPK\5
M/V>_BQXO_9PTG2_$OQ[^%GPF\>>*-3^*'PM\&ZK8:=J4?C;6/#7B_P !^#+7
M7/#&G6NLZ.?$&H>#=7\2MX?.I6\FIQ16YEFB^2(?V6OVDKC2/A_KT'[/GQR?
M1/BWJ%II?PHU?_A5GC7^S?B9J%]!-=VFG^!;P:2;;Q1J%[9VUU=6-EHTU[=W
M5O;3SI;^4H)\C"K@K&4HUJ.&R%0E55%.M@,)AY>T]C2KVY*U*G.WL:E.IS<O
M+R24D[6M[6)I\=X.LJ&(K<10JVIN4%C,;-P=2N\,H5.2O)0J1KTYTZM.34Z<
MD_:1C?3M_P#AO/\ ;<_Z.V_:*_\ #P>./_EO1_PWG^VY_P!';?M%?^'@\<?_
M "WKRC2?@-\:/$,6DW'ASX1_%'7K?7_B!<_";09M(\"^)M236_BG96OVZ_\
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M\T<?[7_C]=_^KV1_]";*?_#;A/+_ *=>7]:6\_\ U@S[_H=9OT_YF&-_N_\
M3_\ J_GI]9?\-Y_MN?\ 1VW[17_AX/''_P MZ/\ AO/]MS_H[;]HK_P\'CC_
M .6]?)O'^U_X_1Q_M?\ C]'^KV1_]";*?_#;A/+_ *=>7]:6/]8,^_Z'6;]/
M^9AC?[O_ $__ *OYZ?67_#>?[;G_ $=M^T5_X>#QQ_\ +>C_ (;S_;<_Z.V_
M:*_\/!XX_P#EO7R;Q_M?^/T<?[7_ (_1_J]D?_0FRG_PVX3R_P"G7E_6EC_6
M#/O^AUF_3_F88W^[_P!/_P"K^>GUE_PWG^VY_P!';?M%?^'@\<?_ "WH_P"&
M\_VW/^CMOVBO_#P>./\ Y;U\F\?[7_C]''^U_P"/T?ZO9'_T)LI_\-N$\O\
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M''^U_P"/T?ZO9'_T)LI_\-N$\O\ IUY?UI8_U@S[_H=9OT_YF&-_N_\ 3_\
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MQV-Q>,=',<)&D\7B*V(=*,L-*4HT_;3GR*4O>DHV4GJU<6BBBOQD_H$****
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M>WB9YIG6*-R/Q6^+G_!$"R;_ ()\V/PR\%^&?%'QD_:N^*MM_P $_O"GQ_\
M$7[0/QUU?XBW!^%G[/WQ4^%WC7XA?!_POXH\7:I)HNA_"WPM8:5XWN/#?@[P
MS%96FLSW,=O"]V!IJVX!^_J_M1_LS/<_#JR3]HKX%->?&"/S?A):+\7/ #7/
MQ2B^W'2_-^', \0&7QO'_:8.G;_#*ZFOVX&SS]H!CJ36OVG?V;/#?Q"'PC\1
M?M"? _0/BN6@0?#'6_BQX"TKXA[[JP_M2U3_ (0J_P!?M_$N^YTS_B8P+_9F
MZ6Q_TM UO^\K^;K]N+_@DU\?OB/\8OVU?!OP0_9B_9T\8?#C]M7PQ^R5X2^"
M/[1>N^+/!_P\UO\ X)Y:3\!KBRM/%UAX/^&Y\(2^*)=,M[VUF^(O@*U^#%[I
MBWGBS4KB'Q-]GVM,_P"7?[.^M>$?%_\ P5[^)6A>,] T/XD^)]=_;5_X*#^$
M_@5X?\%/\!;WXR^#_B;X\^&WB7X?6OQ4_:.\/>()I_VLM*^!T>C:%CPKK7B.
MQ\-_#?PGXH\0^'-6\':CJ'A\Z'IMP ?VVWO[8G[(^F^'KGQ=J/[4W[.5AX3L
M]9TCP[=^*+WXW_#*U\.VOB#Q!HT7B+0="N=:G\3QZ;!K.M^'[B#7=(TR6Y6^
MU+1IX=4LH)[&19STOB+]I#]GGPAK6G>&_%OQX^#7A7Q%J]UX>L=)T#Q+\3_!
M.@ZWJEYXO2[E\)6NFZ5JNN6E_?7'BJ&POIO#45K;ROKT-G<S:4MW'!*R_P J
M_P 6/^"0_P"V'X>_X)Y?L"?LO_ /X ? +2/%'@_]GWXM>!?VL;/PRG[+VG?$
MM?C'\1O!.AZ3IOBH_%OXY_"3XS:!K7PYEUNUU&;XKW7P_P!(L_C!J5O8^%E\
M%>+-,BL(_LD/CC_@B5^T?\0OV>OV@_#GCCX&?"'QG\7=?_X)1?\ !/?]EGX+
M:UXG\5^!M;U+0?CO\!KC4I/C#8:%XIU1KFY\*64"0Z*8?%D5U;VOB=(/LR7%
MS"MPDH!_6MX$^+/PM^*=KJM_\,/B1X#^)%CH.O7_ (6UZ^\ ^+M \96>A^)M
M+P-3\.ZS=>'-0U*#2]<TXLHOM)OI(+^T+*)[>,D5Z!7Y&_L&_L5>*OV5_P!L
M3]O[QOI7PW\$?##]GGXWZ7^QK_PI;0/A]+X:TG19-<^%'P/N/ _Q8NY_ _AF
M&TM_#-W)XC_LZ&2_N+&*3Q-%:QZ@9;C:)I/URH **** "BBB@ HHHH Y_P 4
M:S;>'=!U?Q!?RR0Z;H.E:EK>IRPHTDL>GZ59RWUX\<*,KS.EM#+(D2$-*Z+$
M"N_</RK_ &6_^"T'['7[4VO:#HVG0_&KX%P^-OA#K7Q\^&'B;]IOX:R_!WP%
M\5OA!X7U6WT;Q7XZ\!>.=4UO4O#&HZ3X4N[_ $T:ZVIZKHTL%OJUC>16MU!Y
MK6_Z>_$K2+[Q!\/O'.@:9&DNIZ[X-\4:+IL4LD<$,NH:KHE[86<<UQ*/+@C>
MXN(U>60A(T+2."J''\P'PR_X(4>)/ O_  2/\:> M8T/QAX]_P""BGBC]@SQ
MA^S!H.E_$WX_ZAX[^'/PB/C#4;C4O$OPY^";:EJK?#WX9>#?%NH1:7/KMQH4
M"B1+"VMUO[>#[='= '[N>&/VUOA=XX_:.U7X$^#I[7Q5X<T+X&:S\;]9^/?A
MGX@?#'Q!\'],/A[XC7?PY\2_#;4+O2/&E[XFT_QKX<U"SN-6U^YN= B\,Z-8
M6TEA?ZW::M_Q+Z]?T[]J#]FG7? :?$K0_P!HGX':U\.&U[_A%5^(6D?%SP%?
M^")/%$5LU[)X:'B^S\03Z#_;_P!CBENWTC^T#J"VD4URUOY$4CK_ #N?M??\
M$;_C1\1-<^(/AC]FSP+\(?A)\-M1_P""37PL_9>T+1M.U71O!OA'Q)\8_ O[
M5/AGXW^+_A+XHTOPO:/K5IX*^*?A/0-0\.>*O';:;JMK?OX@NI-9DO\ _2%K
M@?$/_!)3]HCXY^-/&/Q4\0?LD? G]G?X9_%S]M[_ ()L^/\ Q%^Q'X8\?_#O
MQ5X,T+X0?LCZ9X\TKXN_%+Q5=>%M#\._#+6_$WCZW\7:;I5MX&\-6=Y>:QX1
M\-64&ORW-_>2V< !^RDG_!6G]D#PKXE\=6'Q<^(VA?"#P9H'QP^%OP'^&OQ9
M\5^,_ NK_#KX[>(OB[X'TOQWX<\1_#W5O!?B3Q')IG@.RTC5[%_$'C3QS!X9
M\.:+:S0:SJ&IVFAW4&HR>H^!?^"AG[/6KZC\9/\ A:'C7P=^SUH'PM^-VL_!
M'P_XK^-GQ9^#_A;PQ\8]0T;PKX<\6/XM^&.I?\)U.M]X?O-+\264EO8ZO'IG
MB-(XVO9]'@L;BUN)_P 4OC[_ ,$J?V@[_P >?M9?$?P'^S;\&OB5X>E_X*<_
ML0_M;_ _X.ZMXF^&GA?2?B7\"?@)\%_"?PY^)OP^M+G7-+U'PQ\-FU5]/N-)
MM]&UW38=)U;0M)BMI;&6PFMX7\V_: _X)N?MK^*O!_[37P]T_P#8S^%?Q;^$
MW[47_!3FY_:0^(G@F'XQ_!KPOXXT_P#9DTSX4_"&T'P_^'7C/Q;IMYI?@#7/
MB%XS\&W7@'Q-JVCVUIXAT[X<:3J%EIL&F_\ "1V%_IX!_4C/\?\ X$VWC/PG
M\-[GXT_">V^(GC[2(O$'@3P#/\1/",/C;QMH%Q;W%W;Z[X/\*2:NNO>)M'N;
M6TNKJVU31+"^L;BWMIYX9WBBD9?G3XJ_M]_ GX;?M&_L_?LM66OZ9\0?BI\=
M_B?XD^%5WHW@7Q?X+UG4_@_KGA_X7^(/BK%=_%OPZGB!/$WANQUS0/#UU!HJ
M-I,EY=W5Q;3+;BQ9KE/Y\?'7_!(;]K/Q9^WQXN^,.J>$=8@^$_Q5_:*_97_:
M2\,Z[X"^-O[+/@VU_9RT[X)^&OAW:W'PD\47?C#]F/XD?M&WP^'%QX(U'P]X
M1L/V?/B7X8^&GC'1-7TNSU2TT :IXIU2#M?V9_\ @F!^UM\+?VP?V5O%'B_]
MFSX%)H?[-G[<G[:7QW\>_MK:/\4/"5Y\7_VAOAM^TYIOQ4U'P6=6\%#PW;>-
M+>?PC/XD\-^&O$^D^(O$UQ):7&D:'+X3TG4-+AU74;0 _7?]J3_@J3\-_P!D
M_P".7A#X!>-?V;?VW/''B_XE:L="^%6M?![X!'QUX)^*7B2W\'WOCW5_#/@'
MQ!_PF.E?V]KOASPQ8:IJ/B/38["UDTV/1-6#R316AEKZY\!_M8?L\>.?#OB;
MQ'8?&KX66R>!+719OB?I&H_$GP"FN_!V]UHK;V_ASXO6-CXFOH_A[XGM=4,N
MA:AI7B&:QDAUZWN-(B:YN+<L_P @_MQ_LT_&/XW_ +3G_!-7XK_"[2/#][X=
M_9E^/?QG^(GQ1U/7M5LK"WT/1?&?[,OQ(^&GAJ^_L9KJVU/Q0A\8>(-%@U32
M=%>2\.G-/-NBMLO%_-EH?_!&?_@IGXP\+?M>K\1OA!\*]*\1_&#_ ()^:C^S
M#HVC^%/''[,7@[X=^(?B7;_M.?#7XG6T7@'PS\#_ (6_"=_"GP:G\#Z3XE/@
MR;XQ:K\1/BII5S97UCKWBNW%YIMG. ?V%Z[^V1^R'X7TW0-9\2_M4_LW^'='
M\5RZ_!X7U77?CC\,=(TWQ)-X3U630_%,6@7VH>*+>UUB7PUK<,VC^((].EN7
MT;5(I-/U$6UVC0CMI?C[\"H/'D?PKG^-'PG@^)\OAY_%T7PWG^(GA"'Q])X4
MBLY=1E\4)X.DUA?$3^'8]/@GOWUM=..F+8PRWANA;1M*/X:_^"K.F? [X*_\
M%'-2^$^L_#+X>Z3^SG\-O@-_P3NT[Q3\ _ASIG[/.A_&OQ_#X+^./CCXG6_A
M7]DSP;\9DM_%?B'5+_Q)<:=;?$RU_9@T'6KGQAHESJ'A_P"(.I6.KW'VNS_1
MCPK_ ,$AOVJ(/^"DOB+XR>,M#\1>)_@WKO\ P4(C_;?\)_%OP_\ %3]FCP;H
M6C>"IK.VFL/A7X\\&>(?V9/%?[6NLZQHGA>35?@[/\/]!^-&E?!K7?!SZ7!&
M/#-J;QK( _H8^"_[=7[*7[3/PD^(7QJ_9Y^-/A/XO^!/A7/XV@\=77@B\>YU
MK0;GX?7GB.QUNWOO#MZNGZW:)?S^%-:E\+7U[96VD^,]*@AU[PO?ZMH%]9:G
M/G_"C]OS]DOXF?!7X/?'*3XX?#[X;^%/CE\//!/Q3\!Z5\9O''@CX;>-+CP?
M\1WGA\&WFI^'-=\1Q36D^NWMI>:;8I!+<6]YJMG>Z=837$]K+&GP+_P3C_8W
M^,?[,?[)'[7O[,/C'X$?#;X>ZWKOQ*_:IO\ X9?$KP)XF\$W5G\=O"/QK\>?
M%KQA\.+S6M-T32=)UCP0G@31O&>A>"[72/&MW>SV4,4\>D-;Z/9HH_,S2O\
M@BW^T3X@^$/ASPM\5/@)\'O&?BOP9_P;Z0?L)>!I?%6M?#WQ4_A/]LNT\9^)
M=7M+;P_>:DFHQ:':VNE:G93VGQ/TZ>WM+&66>&UU"*5]@ /Z%/VT/V_?@-^Q
M=X,37?'/B/3/$WC2;7?A=IEA\&_"7C#P1'\7-7T7XJ?%/PK\(].\::5X+U_Q
M#I.K:CX1T#Q!XNL;[7=7L[>:&&PLKU;=I[I%MGO?#G]MOX2^)/#WQR\;_%"^
ML?V;_!OP-_:.\?\ [.6I>*/CI\0/AAX5\-^*]:\!7FGV4?C+0M>MO&M]I%CX
M>\8RWPC\.:-XFO-$\8K]DG_M3PW8/- LO\W7QE_X)*_MQ>)]<^*NG0_LS? G
MXUZ[\8]>_P""8OQ,T+]IKQM\7?"%I\3OV=_^&1O"'P@\(?&#X,Z%8:YH&IZ]
MJMS?ZKX.\;:MX9UGPYXDTOPQK&C>+O$,^K:W=^(9K&TN?8]?_P""9O[8'A;X
MO6_QUE_9P^$7[4GA;P3_ ,%2_P#@HI^T[)^R5XV^)W@/1=(^*7PK_:Q\!>&O
M"/PC^+$>K^+](USX=VWCSP!>:7J\LWA7QKIQU+3M*UN[DTF2VO#!;D _I@NO
MC_\  BQ\:Z%\-;[XU?"6R^(WBG0E\4>&? %W\1_!UMXV\1>&7M+B_7Q%H7A6
M;64UW5]":QM+N]75]/L+C3S:6MS<"X\F"1U^(=&_X*I?LJ?$V]^$0_9Q\96W
M[2>F?$[]IN[_ &7?$&H?##Q)X3MYOA/XLLCXRCO?%7CG0_&>N^&O$LW@K[5X
M(UNWT+4?"ND:[)XSL%@\1^"TUWPXZ:K7XG_&;_@FA_P4!^)W[>'P(^*T/P"^
M!G@7X#?"W]IG]B/XTZ9IOPF\1_LV:%X5\&_#'X1^ ?"/@SXH^!->N=6^"&F?
MM-_$3XC>$7@UGPYX6U/3OBGX9^#^M?"70] TBT\ W>I1Z?ID75?#C_@EI^U3
MX1U3X&> -/\ @%\*/ .B? K_ (+!_%3]K:Y^.?@7QS\-[74/B!^SO\1F_:3U
M+PEXAM?"=II>F>)M*UOX20?$SPCX<TCPEK5W<ZA:B:<>&K>+1=,92 ?TIZ9^
MT;^S]J.K_$3PU9?';X-WWB/X06-]JGQ8T&S^*'@:[UKX8:5I2.=2U+XB:5;:
M]-?>"+#3UAE>^O/$\&EV]F(W-S+'L8T_3OVD?V=]8T;QUXCTGX]?!C5/#OPO
M@CNOB9K^G?%#P1?:)\.K::U%]#/X[U:UUR6P\(0RV+"]BD\07&G)+:9N8RT(
M+C^33P'_ ,$=?VS[?X:>"?A9<?L[_ #X2>(/V8OV+/\ @H/^S]J/[07@OXI^
M%]5\6_\ !0WXB_M1^ /$7@_X>ZEXEM(/#NEZ]X4\-WFNW</Q+\::A\:M7OM7
MTGQ7*B:1;R6\-Y>#V3Q+_P $;_B5I/A'Q7X6T/\ 97\&WGP]\4?\$NOV#O@5
MXO\ A_\ !_XO_#/X"^(?%G[5_P"S]\<K/X@>,/$]OX@N?"GB;P/J_BSP9;VT
M'B;P_P"*?B5X4\0^"/B!=6,GA'7ICI6LWV #]5/VS/\ @L1^SO\ LC^.?V:?
M")TK5_C+IO[3,^DZAX-\<_"?Q1X2UWP6WA35KS5= T_Q!#XCL=7O=!M+.Y\9
M1^%])'B'QYJ7P_\ AA<:#KNN:W9_$F\O/!?B#P^GZV6%Q]JBCN!DI+!%*C!U
M='60%U96CDFA8%&5U>&62-E?Y))4"/7YR?L ?LM>-_"W['G[.'A3]M#X?_!3
M5_V@?AK/XP\372^#?!'PYMM$\(ZWXE\1?$5])G@B\">&?#OP^_X3I/!'Q!U7
M3?'^K> O#6A>#-8\5^(O&EYH&E1Z9JJRW'Z310B( *SD;0N'8OT).<L2Q;DY
M))+<;B<# !+1110!^./_  7J_P"46/[47_7G\//_ %9WA&O\U=\X3&.C]O\
MIM+[BO\ 2G_X+U$#_@EC^U$20 +/X><G@?\ )3O"-?YJCR1$)\R'A^=R?\]I
M?4U_37@FU_8.8WU_X57II_T"T]=3^//I!)OBK*]'_P B2CTO_P S'-/D+SZC
M\O\ Z]'/J/R_^O4>^+U3_OI/_BJ-\7JG_?2?_%5^UWCV7_DO^9^"V?9_^ KR
M_K_AW:3GU'Y?_7HY]1^7_P!>H]\7JG_?2?\ Q5&^+U3_ +Z3_P"*HO'LO_)?
M\PL^S_\  5Y?U_P[M)SZC\O_ *]'/J/R_P#KU'OB]4_[Z3_XJC?%ZI_WTG_Q
M5%X]E_Y+_F%GV?\ X"O+^O\ AW:3GU'Y?_7HY]1^7_UZCWQ>J?\ ?2?_ !5&
M^+U3_OI/_BJ+Q[+_ ,E_S"S[/_P%>7]?\.[2<^H_+_Z]'/J/R_\ KU'YD7JG
M_?4?_P 51OB]4_[Z3_XJB\>R_P#)?\PL^S_\!7E_7_#NTG/J/R_^O1SZC\O_
M *]1[XO5/^^D_P#BJ-\7JG_?2?\ Q5%X]E_Y+_F%GV?_ ("O+^O^'=I.?4?E
M_P#7HY]1^7_UZCWQ>J?]])_\51OB]4_[Z3_XJB\>R_\ )?\ ,+/L_P#P%>7]
M?\.[2<^H_+_Z]7=,N%M-2TV[ESY5IJ%C=2A4W,8[>ZBFD"KN&YBB' R,GC(Z
MUG;XO5/^^D_^*HWQ>J?]])_\54R4)1E%K247%V<+V:L[:[C@Y0E":6L)1DKQ
M6\7%J^JZ^G7N[?T"_'_]O;]C-/C#^W!^U)\$_$OQ<^)?QC_;%^$5U\#M ^'7
MC?X2:;\/?AW\)O#7BOPKX)\-^.?$OB3Q2WC3Q/JWQ!U![#P9%:Z%I>G:!H4
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M +-'[/WQ=\,^";/Q[^T#\3O^%<_'W]O_ .*7C;XI>,/"D=AXP\%^,_C7\/\
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M/M_"=]J_@_3-!^!VE^*8[_6;.WO-31XM2D?^<K?%ZI_WTG_Q5&^+U3_OI/\
MXJNV? /#\J]/$)8JG*E6]O&-.O25-R]LZ_+*+A*\>=K5-3Y8Q7/\3ERKQ%XC
MY*L)/#2]M35.3=&5TEAXX:\;559^SYM'=<S;:LK+^B;Q3_P5C^#FI_%KXO\
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M,2:UL#T'7/3OZ_7WI:* $P/0=<]._K]?>E_#V_S^5%% "8&2<#)ZG')QZFC
MSG SG.<<YQC/UQQ].*6B@!, = /R].GY8'Y48'/ YX/'4<\'\S^9]:6B@!,#
MT'4GIW/4_4]Z,#I@<'(X[CD'ZYI:* $      '  & /H*6BB@ HHHH _._\
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MP[#_ * /BK_P51?_ "91_P +#L/^@#XJ_P#!5%_\F5RNQ?3^?^-&Q?3^?^-
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M  51?_)E'_"P[#_H ^*O_!5%_P#)E<H A&X%67@ JVX$DA0 03DEB  ,DG@
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M=<W%WXDM?[>^SZ_=W1^:ZNM6BNY9G16?<2U?N1_P]&_X)O?]'Q_LN?\ AZ?
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M1MO#A.3H-O?-XD>[MM%925ET>"<:?-($NFB6955?VV_X>C?\$WO^CX_V7/\
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M8NGW%H]E#;PI:R0;%Q^\7_#T;_@F]_T?'^RY_P"'I\#?_+FC_AZ-_P $WO\
MH^/]ES_P]/@;_P"7-']D9M_T*\Q_\(<3_P#*@_L#/O\ H29O_P"&W&?_ "GS
M7WGX;:9_P3__ ."CVC75K>Z19^*M+N]/O=9U+3KG3/C!_9]Q8:EXDEMYO$>H
MV4]IKL4EG>Z_-:6LVLW,!%QJ;P1F]FF:-6J2Z_8$_P""D-]9Z[IU[:^+;W3O
M%36\GBK3[SXPBZLO$TEG:6MC:/X@MI]<>+6I+:TL;2VAEU1;N6&W@B@@>)(D
MQ^XO_#T;_@F]_P!'Q_LN?^'I\#?_ "YH_P"'HW_!-[_H^/\ 9<_\/3X&_P#E
MS1_9&;?]"O,?_"'$_P#RH/[ S[_H29O_ .&W&?\ RGS7WGX6:S_P3Q_X*(>(
M]#TGPSXAT;7M>\.:$5&A^'M<^*D&LZ'H21PBWC&D:3J>N7.GV/EVX6V@6TM;
M6.W@#+&A\Q\XVK?\$S?V[]>NH[[7?!$NN7L5G96$=[K/Q!TK5;U++3[=+2QL
MDNK_ %2XFCLK"TB@L[&TC=+>VM;>*.*) ,5^]G_#T;_@F]_T?'^RY_X>GP-_
M\N:/^'HW_!-[_H^/]ES_ ,/3X&_^7-']D9M_T*\Q_P#"'$__ "H/[ S[_H29
MO_X;<9_\I\U]Y^ '_#K/]M7_ *)CI_\ X5_AW_Y-JQ:_\$N?VTX+BVE?X86'
MEQW5M(Y7Q?X=+!(Y09&"_;.=J98#.6(VJ,D5^^__  ]&_P"";W_1\?[+G_AZ
M? W_ ,N:/^'HW_!-[_H^/]ES_P /3X&_7_B<\_Y-']D9M_T*\Q_\(<3_ /*@
M_L#/O^A)F_\ X;<9_P#*?-?>?@KKO_!,#]L_4=<UK4+;X8V1MK_5M2O;<R>+
M?#T<A@NKV>>$O&U[N1S'(I9#RC94\BLK_AUG^VK_ -$QT_\ \*_P[_\ )M?O
M_P#\/1O^";W_ $?'^RY_X>GP/_\ +FC_ (>C?\$WO^CX_P!ES_P]/@;_ .7-
M']D9M_T*\Q_\(<3_ /*@_L#/O^A)F_\ X;<9_P#*?-?>?@I8_P#!-#]O'2[7
M5+'3O!,EC9ZW:1V.M6EC\0-*LK76+.&Z6]BLM6M[?5%CU"R2\CCNDM;D/"DZ
M+(J;E4C1TO\ X)S_ /!0;1+?2[71/#NL:+;Z)JMSKNCQ:/\ %&TTM-)UN^M8
MK.^U?2DLM7ACT_5;VVMX+2YU6UCCU&:SC^RRW#VY,)_=K_AZ-_P3>_Z/C_9<
M_P##T^!O_ES1_P /1O\ @F]_T?'^RY_X>GP-_P#+FC^R,V_Z%>8_^$.)_P#E
M0?V!GW_0DS?_ ,-N,_\ E/FOO/PYC_8$_P""DL>CZ5X>2/QE'H.B26D^CZ+'
M\9&31](N-/O%U'3Y=)T<:\-.TYM/OTAO+$V<,#6EY:PW<+"=G*V;?]A#_@I=
M:>([SQC:MXVMO&&I62Z;J?BRW^-=Q;^)=0TV/_5:?>Z]'XA_MB\LXP% M;J^
MEM\(!'%#BV-I^WO_  ]&_P"";W_1\?[+G_AZ? W_ ,N:/^'HW_!-[_H^/]ES
M_P /3X&_^7-']D9M_P!"O,?_  AQ/_RH/[ S[_H29O\ ^&W&?_*?-?>?@]:_
M\$W/V^[%=76Q\*:A9#Q"\,GB$V?Q*L+;_A(9+6^_M*TEUQ(M6"ZJUM?LVH0K
MJ1O?+U!(;P.UQ%'+'G:G_P $QOVZ=:U&]U;6? *ZOJFHW<U]J&JZKX\T;4=4
MU"[N,&>YU#4+O4);J^NI6P9+FYDDG<(A=V.XU^^7_#T;_@F]_P!'Q_LN?^'I
M\#?_ "YH_P"'HW_!-[_H^/\ 9<_\/3X&_P#ES1_9&;?]"O,?_"'$_P#RH/[
MS[_H29O_ .&W&?\ RGS7WGX ?\.L_P!M7_HF.G_^%?X=_P#DVMWP]_P3%_;,
MTR\O)KOX8V8CN-#U_3D,?BSP](1<:EI%W9VVY1>Y$9FE0.W\.02,9(_>+_AZ
M-_P3>_Z/C_9<_P##T^!O_ES1_P /1O\ @F\?^;X_V7/_  ]/@;_Y<_\ ZNO6
MC^R,V_Z%>8_^$.)_^5!_8&??]"3-_P#PVXS_ .4^:^\_ #_AUI^VL>OPPT\9
MYQ_PF'AT_>.[!_TSJ-VT^XXXK0TG_@F7^W9H&IV.M:!X%;1-9TRY2[T_5M(\
M?:3I>IV4\>=LEGJ.GZG;7MG*3A6EMYD<QEXSN21E/[W_ /#T;_@F]_T?'^RY
M_P"'I\#?_+FC_AZ-_P $WO\ H^/]ES_P]/@;_P"7-']D9M_T*\Q_\(<3_P#*
M@_L#/O\ H29O_P"&W&?_ "GS7WGX*V7_  3/_;PTV'5[?3O!4MA!K]H^GZ]%
M9>/]*M(]=L&GCN#::Y%;:K"FK6DD\,%U-9WPE@>\MK>Z8-*@8=;;_L'_ /!2
MVS_M3[%)XZLCKKVSZZUM\;9XO[:-E80Z59#6$BU^+^U!::; EA;-=NTMO9[;
M2&1+9/*?]O/^'H__  3=R1_PW'^RYD<G_B]/@;IC/_09].:^F?A'\>?@A\?-
M D\5?!'XL?#WXL^&X;@VD^M_#[Q;HOBS3;>Z +?9[F[T:]NXK><JK,L4[1NZ
MJQ52%)&=7+<QH0=6O@,;1IQMS5*N%KTX1N[*\YTU%7;LKO5Z&&(RC-L)3=;%
M99F&&HQMS5<1@L31IKF=E>=2E&*NVDKO5O0_F;N?^"?G_!1R]7PU'>V'BFZC
M\%&-O!:7/QA^TKX1:%(HX6\,K/KCC0#!'!"D"Z5]E2)(PJ*N 1%>?\$]/^"B
M>H>)(?&NH:3XCU#QI;^5Y'BZ_P#BS%=^*+?R('M8!;^(YM;;6(A;P2LD.+HX
M0>2,1R25_6& C#*\C .>>AY%+L7T_G_C7$>>?R9+_P $Z?\ @H6+-]/?0=9D
ML)-$;PV]DWQ1M19MX>:_75?^$?-H-8\HZ!_:<:7_ /8K9TT7IDO([:.=F9N:
M_P"'6G[:O'_%L-/SU/\ Q5_ASEB22<_;!GD]3SC&2:_KRV+Z?S_QHV+Z?S_Q
MH _E%^&/_!-+]L3PK\2OA[XHUCX:6D6D^'?&OAG6M4D@\4Z#<31Z?IVK6MU=
MR1017;/,\<$;N(D^>3&U<FOZNP<@'!&>QZ_CZ'VZCOS2;%Z[>1T/<9XR#U!Q
MW&#3O\^M !1110 5PGQ'_P"15NO^O_0?_4ATFN[KA?B/_P BK=?]?^@_^I%I
M/3O^5 ')'J?J?YTE*>I^I_G24 %%%% !1110 4444 %*OWE^I_\ 06I*5?OK
M]3_Z"U &!X6_Y%W2_P#=O/\ TX7=;U8/A;_D7=+_ -V\_P#3A=UJ7-]96<EK
M%=WEK:RWTTD%A%<W,,$M]<0VTUW+!91RNCW<\5I!/<R0VZR2)!#),RA$9@TF
MW9)MO1);M]$-*4G:*<F]DE=LM5C^(?\ D7]>_P"P+JO_ *07%7;&_LM3M+>_
MTV[MM0L+N&.YM+ZRGBNK.[MYEW0SVUU SPW$,J8>*6)WCDC*NC,K FEXA_Y%
M_7O^P+JO_I!<4*\9>\FG%JZZIK=>HGU5W=:2T:<9=5KU1S?CC4;O2/A?XQU6
MPU>X\/7^F^ O$5]8:_::%=^*+K0KZR\.3WEEK-OX9T^*XU+Q#+I<UNM]%HMC
M;W,VI-;K9K;RRS0J?Y]_@=^WS\</A1\&M(L$\32_&BXU7XYV7@+6_P!J;XY>
M(?BY\1_@)JQ'PS/BR2U^'6H>%?A'X*^).B:OX]U_38_#>D_#_7]#U'1/AKXU
MUQ].L?$?BBVG:%OZ.K+*V5KG@?9H5;G@YMX#C_:!4^XYQ5TSR%@QE8L,X8N<
MC.[.#G(SN;/KN;.=QSZN7YCA\+1Q%#%9=A\;3K5/:1YW*$HOHVX_$U?9WB]+
MIVU][+<VPF#P^+PV,RK#YC#$3HU(>U?)*G*E3<%)R49.4KMM)IPM\49;'\\6
MM_M4_M4_"GP[^UKH]QHJ:OX!\9>*O^"C&M_#/Q'INO\ Q,M?C5X+\4?!:TT_
MQ1INFVFMW=NVBZ'X/NX=3&B>"(_#EE!KFEW5DNI&6)#=6,7;^(O^"I'QCT+Q
M+\>/#NF6G[/,VB?"WXK?#?X8:=XYU[P]\?H[7X>:=X@M-8D\6_$?XY:3I-IJ
M&K:KX6\/ZO::%X#TOQ-X'.C6?B#QYKMY-#-;Z%IXO=0_>3S#C&\XZ\,1S\PS
MUY.&;D\\GUIWG/\ +^];Y"2GS_=)&#MYXR...U=W]L99-\U;),.YM6DX59I:
M<L863NKQA%*[5GKS*5]/5?$>3U*CJU>&\+SR;O[.O.*M=*'+S1DE*,$HZQ<=
MW*,KV/P(U'_@JS^T#!>_!+3!\(_A/IOBOXC> /A-XQNOAUJEG\:5\;?$P_$#
MXY>/OA3?6GP4@BT)5T&"[\(>%-.^+/A6[^*UK:?8O#NHSV.I0ZK#*=4L\']G
MO]L_]L/X8_ +P7X(UOP/\/?&WB&[^&O[/OB;X2^+_$UY\6-2U"XL?B_^TS/\
M!M7_ .%VZA.KZI>:[H=O=CQOYWA;R;6PT.$6%^=2M89;T_O);>!/!UKX_P!6
M^*=OHEG#\0M<\):/X#UCQ0)+LW^H^#] U;5];T;0[B,SM9-;:=JWB+6]0B:.
M"WO))+N1);QD6!(^P\YR#F5SEM[9<_,Y18RS?,<L8U5"22=JA<D 5I+.\KC3
M=*CD&%C&=2$Y\]6H[Q@FE!6V5VVVW>5]TK115XDR:5!4:/#.%C&4Z,ZJK8BI
M54O8\UHQM"#C%\[;;<I-I:V22_!70/\ @J#^U;+K/[2?A;6_@C\&[?QI\%6T
M?2-)\-#4?'6FW]IXA;X^>!/@P]UXQTN]U2]U[4_!GBNR\:S?$'P[K^A:/HW]
MC:+#IL%Z_BJVO9-5M\;5/^"BG[2/@;7/V@]6\?\ ACP;H'C/X,>%M/\ AK*E
MI8?%G7OV>]3\76?[2WBOP%)XRLO"\U[HVM>'[?4_#$=DTOB77?&-C%!/#I;W
MFHQZ7<:=9S?T!>:V /,8  * '(  5D &#P-CLG'\+,O0D4HE8'(E8'UWMGJ3
MUSG.23UZDGO4_P!M96O:6X?PG[SV6KJU>:FH5*4Y*#NTM(2C'2R4M5I</]8\
MDY\0_P#5?!*%94^6U:K[2E*,Z,IR@VW%<RIRA%V;49:\S1\X_LB_&?7_ -HG
M]FGX-_&OQ7X:@\'>)OB'X236-?\ #=HFI166F:K;ZA?Z7>+80ZQ_Q-;>PNY]
M/:]L;2_:6YM+2ZAMI+BZ\KSY?HRD+ ]6R>.2<G@!1R?10!] !VHW#U'YU\[6
M=&5:O/#T/J]&I6J5(45.=104Y.5KR>EMM--+GR->=.>(Q-2A16'H5<15JT:"
MG.:I0J/FY+RZI]M/G<6BDW#U'YT;AZC\ZS,A:*3</4?G1N'J/SH 6BDW#U'Y
MT;AZC\Z %HI-P]1^=&X>H_.@!:*3</4?G1N'J/SH 6BDW#U'YT;AZC\Z %HI
M-P]1^=&X>H_.@#\E/^"Z?_*+;]IK_KC\-/\ U:7@NO\ .CK_ %.OVK?V;? G
M[7_P5UW]FWXEZGXGTCP/\4=7\.:=X@U#P9?Z=IGB:V@T;48O%MDVDW^KZ1KN
MG0RR:CH%G%<&XTB]5K*2YB5(972>+\GC_P &NO[ 63N^*/[5O)) 3QY\,P "
M>^[X/K^G Z=J_9?#CCO(>&<IQ>"S*6-56MC7B(NEA)223A&"C=SC=W5U)>ZU
M:S;/Z&\(?$WAK@CA['9;G;S"&(Q6;UL?36&P<JR]G5PF6X51?OQ;E&6"E4NK
MKDJ0V=S^":BO[V?^(77]@#_HJ'[6'_A>_#']/^+0\_A1_P 0NO[ '_14/VL/
M_"]^&'Z?\6AY/TK]#_XB_P '_P#/S,O_  B]/^GWI^'D?JO_ !,!P!_-G?3_
M )E<_P"[_P!/>G_MOW?P345_>S_Q"Z_L ?\ 14/VL/\ PO?AA^O_ !:'C\:/
M^(77]@#_ **A^UA_X7OPQ_\ G0]/?I1_Q%_@_P#Y^9E_X1>G_3[T_#R#_B8#
M@#^?.^G_ #*Y_P!W_I]TO^!_!-17][/_ !"Z_L ?]%0_:P_\+WX8_I_Q:'G\
M*/\ B%U_8 _Z*A^UA_X7OPP_^=#U]NM'_$7^#_\ GYF7_A%Z?]/O3\/(/^)@
M. /YL[Z?\RN?]W_I[T_]M^[^":BO[V?^(77]@#_HJ'[6'_A>_#']?^+0\?C1
M_P 0NO[ '_14/VL/_"]^&/\ \Z'I[]*/^(O\'_\ /S,O_"+T_P"GWI^'D"^D
M#P!_/G?3_F5S_N_]/NE_P/X)J*_O9_XA=?V /^BH?M8?^%[\,/T_XM#S^%'_
M !"Z_L ?]%0_:P_\+WX8?K_Q:'@_6C_B+_!__/S,O_"+T_Z?>GX>0?\ $P'
M'\^=K;_F5S_N_P#3W^N7[OX)J*_O9_XA=?V /^BH?M8?^%[\,?U_XM#Q^-'_
M !"Z_L _]%0_:P_\+WX8_I_Q:'G\*/\ B+_!_P#S\S+_ ,(O3_I]Z?AY OI
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M  B]/^GWI^'D"^D!P!_/G?3_ )E<_P"[_P!/O/\ #[OX)J*_O9_XA=?V /\
MHJ'[6'_A>_##]/\ BT/)^E'_ !"Z_L ?]%0_:P_\+WX8?K_Q:'@_6C_B+_!_
M_/S,O_"+T_Z?>GX>0?\ $P' '\^=K;_F5S_N_P#3W^N7[OX)J*_O9_XA=?V
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M7O\ OUH7_P IJ/[%U+_H;->_[]:%_P#*:NBHH YW^Q=2_P"ALU[_ +]:%_\
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M^2P4?\1/G_!1C(_XHK]E3IU_X5G\0N/;_DL%'_$)>-M/]APO3_F.CY?W?/\
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M?] .%UM_S'1_N_W?/\O*Y_Q 7Q [93T_YF[_ +B_Y^=K_=Y']YG_  CNI?\
M0X^*/_ ?PY_\SU.7P[J!X/C/Q,#GC,7AI2?8 ^'^?<U_!B/^#GS_ (*,<?\
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M8I4\/".0*<E',.@12;6&5;9(C8/# \UU &!CG\22?S-+10 4444 %<)\1_\
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MO9WTRRMV1;".0:99^S?\);X>_P"@@?\ P"U'_P"1*/\ A+?#W_00/_@%J/\
M\B5SX[/,SS*G"EC<3[:$*<::3IPB^6.B2<5&UHZ+1[+LD<V8<2YUFE&%#&XZ
M=2$*<::Y(4Z;Y8+EBKJ#VCIWLDKZ(Z.BN<_X2WP]_P!! _\ @%J/_P B4?\
M"6^'O^@@?_ +4?\ Y$KR3PEIIOYLZ.BN<_X2WP]_T$#_ . 6H_\ R)1_PEOA
M[_H('_P"U'_Y$H Z.BN<_P"$M\/?]! _^ 6H_P#R)1_PEOA[_H('_P  M1_^
M1* .CHKG/^$M\/?]! _^ 6H__(E'_"6^'O\ H('_ , M1_\ D2@#HZ*YS_A+
M?#W_ $$#_P" 6H__ ")1_P );X>_Z"!_\ M1_P#D2@#HZ*YS_A+?#W_00/\
MX!:C_P#(E'_"6^'O^@@?_ +4?_D2@#HZ*YS_ (2WP]_T$#_X!:C_ /(E'_"6
M^'O^@@?_  "U'_Y$H _/S_@KK\(OB5\>?^"?GQQ^$?P?\':K\0/B3XS?P':>
M%O!^BO81:IK=QIGC[PUKM_#:2:G>Z?8JUMI&EZA?R_:+N!3!:2!2TA2-_P")
M<?\ !&+_ (*EX_Y,K^*>#@C_ (F?P[S@]B#XZ)SZY /MFO\ 1AD\6>'_ .UO
M"C?VAE8O$]I,Y%EJ/$?]FZHF<?8\G]XR1X /S-G[H)'L_P#PG/A?C&I-C''_
M !+]4_\ D$U]UPMQ_FO">#K8+ 8/+:U.MB98F4J]+$*?-**CRJ=#$TII6U?O
M:MZJVA^G<#>*N>\!9=B<LRW Y5CL/B<=/'2GF-+%2Q,)SPN"PSIT\3A,5A*L
M*:6#C-*,E?GE":E%(_S-_P#AS#_P5*_Z,K^*G_@S^'7_ ,W-'_#F'_@J5_T9
M7\5/_!G\.?\ YN:_TR/^$Y\,?]!%O_ #5/\ Y!H_X3GPQ_T$6_\  #5/_D&O
MJ?\ B-7$G_0NRC_S)_\ SR]?Z6OW'_$Q_%G_ $(^'?\ P+/_ "_ZG?E^78_S
M-_\ AS#_ ,%2O^C*_BI_X,_AU_\ -S1_PYA_X*E?]&5_%3_P:?#K\_\ D>:_
MTR/^$Y\,?]!%O_ #5/\ Y!H_X3GPQ_T$6_\  #5/_D&C_B-7$G_0MR?_ ,RG
ME_U,O)_?Y!_Q,?Q9_P!"/AW_ ,"S_P O^IWY?EV/\S?_ (<P_P#!4K_HROXJ
M?^#/X=?_ #<T?\.8?^"I7_1E?Q4_\&?PY_\ FYK_ $R/^$Y\,?\ 01;_ , -
M4_\ D&C_ (3GPQ_T$6_\ -4_^0:/^(U<2?\ 0NR?_P RG_SR]?Z6I_Q,?Q9_
MT(^'?_ L_P#+_J=^7Y=C_,W_ .',/_!4K_HROXJ?^#/X=?\ S<T?\.8?^"I7
M_1E?Q4_\&?PZ_P#FYK_3(_X3GPQ_T$6_\ -4_P#D&C_A.?#'_01;_P  -4_^
M0:/^(U<2?]"[)_\ S*>7_4R]?O\ (/\ B8_BS_H1\._^!9_Y?]3OR_+L?YF_
M_#F'_@J5_P!&5_%3_P &?PZ_^;FC_AS#_P %2O\ HROXJ?\ @S^'/_S<U_ID
M?\)SX8_Z"+?^ &J?_(-'_"<^&/\ H(M_X :I_P#(-'_$:N)/^A=D_P#YE/\
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M/^(U<2?]"[)__,IY?]3+U^_R#_B8_BS_ *$?#O\ X%G_ )?]3OR_+L?YF_\
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M?]&5_%3_ ,&?PZ_^;FO],C_A.?#'_01;_P  -4_^0:/^$Y\,?]!%O_ #5/\
MY!H_XC5Q)_T+LH_\R?\ \\O7^EJ?\3'\6?\ 0CX=_P# L_\ +_J=^7Y=C_,W
M_P"',/\ P5*_Z,K^*G_@S^'/_P W-'_#F'_@J5_T97\5/_!G\.O_ )N:_P!,
MC_A.?#'_ $$6_P# #5/_ )!H_P"$Y\,?]!%O_ #5/_D&C_B-7$G_ $+<G_\
M,IY?]3+R?W^0?\3'\6?]"/AW_P "S_R_ZG?E^78_S-_^',/_  5*_P"C*_BI
M_P"#/X=?_-S1_P .8?\ @J5_T97\5/\ P9_#G_YN:_TR/^$Y\,?]!%O_   U
M3_Y!H_X3GPQ_T$6_\ -4_P#D&C_B-7$G_0NRC_S)_P#SR]?Z6I_Q,?Q9_P!"
M/AW_ ,"S_P O^IWY?EV/\S?_ (<P_P#!4K_HROXJ?^#3X=<?^7S_ #S1_P .
M8?\ @J5_T97\5/\ P9_#K_YN:_TR/^$Y\,?]!%O_   U3_Y!H_X3GPQ_T$6_
M\ -4_P#D&C_B-7$G_0NR?_S*>7_4R]?O\@_XF/XL_P"A'P[_ .!9_P"7_4[\
MOR[:_P"9O_PYA_X*E?\ 1E?Q4_\ !G\.O_FYI/\ AS#_ ,%2F94'[%OQ34L0
MNY]4^'@0!CMW97QHX!4D$EG153<=K$#'^F3_ ,)SX8_Z"+?^ &J?_(-'_"<^
M&/\ H(M_X :I_P#(-3+QIXDE%Q_L_)TVM)<F/G9Z:J-7'U*;:UMS0=M&M5<F
M?TC>+91:62<-Q?24J>;UU%JUI*EB<VK47)6O%RIRY7RRC:44S^?/_@@=_P $
MN?BW^PKHOQ0^+O[0UO8^'?BS\8],T#PU8?#[3-0MM8_X0OP9H-Y?:PR^(M5L
MA_9\OB37=:NC=2Z?IL^HP:-I]E:6]QJEU?75U#9_T=5R/_"<^&/^@BW_ ( :
MI_\ (-'_  G/AC_H(M_X :I_\@U^9YWG&,S_ #/%YKCO9?6,7.,I*C3]G3BH
MPC",5&[O91^)N[OK=J[_ !?B3B',>*<ZQV>YI*G+&8ZI&=14H*G3@H4X4X0A
M%7]V,8:7;=M&W:YUU%<C_P )SX8_Z"+?^ &J?_(-'_"<^&/^@BW_ ( :I_\
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M\-N?MH_]'>?M0?\ A_\ XM__ #84EX'Y_I_PJX3I_P P6+_N_P!SR_JRN?\
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M[G_#?]NH/^);^(_^BDRKI_S#8O\ N_\ 3KR_+S/]8O+^C_Y_&C+^C_Y_&O\
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M@ *, 8 I:* "BBB@ KA?B/\ \BK=?]?^@_\ J1:3T[_E7=5PGQ'_ .15NO\
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M[A];Q/M'5^L5N>3;G)59Q<[WW<6FK<TK6:^)E+3O ?@31YOM.C^!_!FD7/\
M;-]XC%SI7A70-.N/^$BU.WN+34_$'GV>GPR_V[J5I=W5KJ&L;O[1O;6YN+>Y
MN989Y$:A<_"SX7WNGZ/I-Y\-/AW=Z5X>O)=2T#2[GP1X7GTW0M1N)OM%QJ&B
MZ?+I;6FE7]Q<'[1<7=A#;W$T_P"_ED:7YZW/LOB?_H/:7_X3X_\ D^C[+XG_
M .@]I?\ X3X_^3Z<<3B5_P OZC?=R>UDFM.C_P" )8G$1E&2Q.*O%S>N*KNZ
MJ04&G^\V25XVLTWN4M1\!^!=7\1:=XOU;P1X.U7Q=I B&D>*]2\+Z%?^)]*$
M.\PC3?$%U83:O8>299#%]EO(?+:20I@L^43P#X#CUBV\11^!O!D?B&RGU"ZL
MM?3PKH*:Y976KR_:-7NK/5UL!J%K=:K/^^U2XM[F.;4)B9+R29SN-[[+XG_Z
M#VE_^$^/_D^C[+XG_P"@]I?_ (3X_P#D^B.)KPY5&K52C=<KJU'%W[Q<FKIW
M:TTOL3[?$>SA3^LXI<D7&,EB:RE9N+UM/E?PVO:YGZ3\/O &@6XM-!\!^"=$
MM%UM/$RVNC^$_#^F6R^)8Q(L?B)+>QT^")=?C5W5-:5!J2*Y5;D*<52N/A9\
M+[L:W]J^&?PZN?\ A)S<MXE^T>!_"T__  D;7EY9ZC>-XA\S2F_MIKO4-/L-
M0NFU/[4US?6-G>3%[FU@ECW?LOB?_H/:7_X3X_\ D^C[+XG_ .@]I?\ X3X_
M^3Z2Q&(5[5JNKO\ &_+_ "_JY7UK$^UJ5HXBO%U9<TH^VJ2BGRQC[O/*4DFH
MK3F:[60NC^%O#'AU$3P[X:\.^'TBL+#28TT+1-*T=8]*THW#:7I<:Z=:VP33
M=,-W=G3K% +2Q^U7/V6*+SY=^[6#]E\3_P#0>TO_ ,)\?_)]'V7Q/_T'M+_\
M)\?_ "?63;D^:3<I[.<FW)K33MY[?@C&4I3?-4E*I4V=2;;DU9:=K:7VN;U%
M8/V7Q/\ ]![2_P#PGQ_\GT?9?$__ $'M+_\ "?'_ ,GTA&]16#]E\3_]![2_
M_"?'_P GT?9?$_\ T'M+_P#"?'_R?0!O45@_9?$__0>TO_PGQ_\ )]'V7Q/_
M -![2_\ PGQ_\GT ;U%8/V7Q/_T'M+_\)\?_ "?1]E\3_P#0>TO_ ,)\?_)]
M 'QI_P %)?V;?'/[7_['/Q/_ &;OAKJ?AC1O'/Q1O/!^F^']3\:W>IV/ABUN
M-$\6:/XKNCJMWI&D:[J44<FG:!>06YM-*O6>\FMHY%BA>2XB_EQ'_!KA^WQ@
M?\7?_9-R>2#XR^*F5/\ =_Y(YV]N_P"%?VH26OB8ZIX6#:[IA+>)[-;<C0BX
MAE&G:H9'>-=3B;#IN4?. K,&Y (/KYLO%V?^1DT<_3PM-_77C7UV0<;\0<-X
M6I@LLK8:&'JUY8B<*V#P]9.<HJ/VX6LDKJ^M];W/O>$O$GBK@G XC+<AQ.%I
MX+$XN6-JT,7@</C4Z\\/A<.VIXB,ZBCRX2G)1Y[*3ET:2_A0_P"(7#]OC_HK
M_P"R9_X67Q4_^<[1_P 0N'[?'_17_P!DS_PLOBI_\YVO[KOL7B__ *&/2/\
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M%GC#_G[EG_AJP?\ \K#_ (CUX@_]!&3_ /ADP/\ \@?PH_\ $+A^WQ_T5_\
M9,_\++XJ?_.=H_XA</V^/^BO_LF?^%E\5/\ YSM?W7?8O%__ $,>D?\ A+3?
M_+VC[%XO_P"ACTC_ ,):;_Y>T?\ $6>,/^?N6?\ AJP?_P K&O'KQ!_Z",G^
M>28'_P"0/X4?^(7#]OC_ **_^R9_X67Q4_\ G.T?\0N'[?'_ $5_]DS_ ,++
MXJ?_ #G:_NN^Q>+_ /H8](_\):;_ .7M'V+Q?_T,>D?^$M-_\O:/^(L\8?\
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MK;V5I#^Q>]?[R_F/\:Y#[%XO_P"ACTC_ ,):;_Y>T?8O%_\ T,>D?^$M-_\
M+VOA,RS/'9QCL3F.98B6*Q>*FIU*DHPC91A&$81C",4HQ4=-&]7KL?E.;YOF
M&>YCB<US7$3Q>.Q<^>O7G:\G:R22LHQC%*,8I)1BDEL=?O7^\OYC_&C>O]Y?
MS'^-<A]B\7_]#'I'_A+3?_+VC[%XO_Z&/2/_  EIO_E[7">:=?O7^\OYC_&C
M>O\ >7\Q_C7(?8O%_P#T,>D?^$M-_P#+VC[%XO\ ^ACTC_PEIO\ Y>T =?O7
M^\OYC_&C>O\ >7\Q_C7(?8O%_P#T,>D?^$M-_P#+VC[%XO\ ^ACTC_PEIO\
MY>T =?O7^\OYC_&C>O\ >7\Q_C7(?8O%_P#T,>D?^$M-_P#+VC[%XO\ ^ACT
MC_PEIO\ Y>T =?O7^\OYC_&C>O\ >7\Q_C7(?8O%_P#T,>D?^$M-_P#+VC[%
MXO\ ^ACTC_PEIO\ Y>T =?O7^\OYC_&C>O\ >7\Q_C7(?8O%_P#T,>D?^$M-
M_P#+VC[%XO\ ^ACTC_PEIO\ Y>T =?O7^\OYC_&C>O\ >7\Q_C7(?8O%_P#T
M,>D?^$M-_P#+VC[%XO\ ^ACTC_PEIO\ Y>T =?O7^\OYC_&C>O\ >7\Q_C7(
M?8O%_P#T,>D?^$M-_P#+VC[%XO\ ^ACTC_PEIO\ Y>T =?O7IN!/L<_RI0<C
M(S^((/Y$ _I7)0V?BP3PM+X@TF6$.#+&OAR6!W7^ZDIUQPA/][RI<?W:ZT9
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M\1_85MAI]E?O>RQZ>(C;0?8H96CF^!_[87PC^,_P@^''Q7N?$_A7X?ZIX_\
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M.%ABZWU.I5K4'>$:U96J5%&2M4DDVN::CS.VEWH%*OWE^I_]!:DI5^\OU/\
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M\:/A[]N2'X<^(_#_ .T*-#USPM;/J/A6>#QQXCCU/X;V>F:?$3X=T271A?\
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M_0+EG3_FH*OE_P!1/]7];_T/_P#$5O\ &S_HS7X4_P#AV?%W_P QM'_$5O\
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M !%;_&S_ *,U^%/_ (=GQ=_\QM'_ !%;_&S_ *,U^%/_ (=GQ=_\QM?SP?\
M#$'[:O\ T9]^U'_XCW\7?_F3H_X8@_;5_P"C/OVH_P#Q'OXN_P#S)_YZ]*/]
M2O#;_H$P'_A[EY?]/_3[O(/^(=^"J_YA<L_\2"KY+_H)_J_K?^A__B*W^-G_
M $9K\*?_  [/B[_YC:/^(K?XV?\ 1FOPI_\ #L^+O_F-K^>#_AB#]M7_ *,^
M_:C_ /$>_B[_ /,G1_PQ!^VK_P!&??M1_P#B/?Q=_P#F3_S^!H_U*\-O^@3
M?^'N7E_T_P#3[O(/^(=>"O\ T"Y9_P")!5\O^HGR_'UO_0__ ,16_P ;/^C-
M?A3_ .'9\7?_ #&T?\16_P ;/^C-?A3_ .'9\7?_ #&U_/!_PQ!^VK_T9]^U
M'_XCW\7?_F3H_P"&(/VU?^C/OVH__$>_B[_\R?\ G\#1_J5X;?\ 0)@/_#W+
MR_Z?^GW>0O\ B'?@K_T"Y9_XD%7^[_U$_P!7];_T/_\ $5O\;/\ HS7X4_\
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M &YHG_09TG_P967_ ,>IEGIVGO:VKM86+,;6)F)M+?+;8(-SM^[^8C(W.<D
MC<>:M'3-. 8G3K$!,[R;*V 7!(.XF+"X((.<8((-3=;:1E=7DK*;TNN9];VO
MY[[$MQYW+W(S=KM**;V:OW;LK=;;$']N:)_T&=)_\&5E_P#'Z#KFB]M9TG\=
M2L__ (]4_P#9NF\_\2^PXW9_T.VXV9W_ /++^$JP8]BI!Q@T?V;IO_0.L/\
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M%KF3[VE'1I6:35M8JRMV(/[<T3_H,Z3_ .#*SQ_Z._SSZT?VYHG_ $&=)_\
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MW_QJDH16RMZ=?4F-HJ5HQO+>37O?)]"#^W-$_P"@SI/_ (,K+_X_1_;FB?\
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MZ'CX6_\ A2^$_P#Y-H^KUO\ GS5_\%S\O+R0?5*__0/B/_!=7RMT]/Z9U_\
MPDGAW_H8=$_\&VG?_'Z/^$D\._\ 0PZ)_P"#;3O_ (_7(?\ "P_@I_T/'PM_
M\*7PG_\ )M'_  L/X*?]#Q\+?_"E\)__ ";1]7K?\^:O_@N?EY>2#ZI7_P"@
M?$?^"ZOE;IZ?TSK_ /A)/#O_ $,.B?\ @VT[_P"/T?\ "2>'?^AAT3_P;:=_
M\?KD/^%A_!3_ *'CX6_^%+X3_P#DVC_A8?P4_P"AX^%O_A2^$_\ Y-H^KUO^
M?-7_ ,%S\O+R0?5*_P#T#XC_ ,%U?*W3T_IG7_\ "2>'?^AAT3_P;:=_\?H_
MX23P[_T,.B?^#;3O_C]<A_PL/X*?]#Q\+?\ PI?"?_R;1_PL/X*?]#Q\+?\
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M J?\)/X;_P"AAT/_ ,&UA_\ )%'_  D_AO\ Z&'0_P#P;6'_ ,D5;_LC2?\
MH%Z=_P" -M_\:H_LC2?^@7IW_@#;?_&J *G_  D_AO\ Z&'0_P#P;6'_ ,D4
M?\)/X;_Z&'0__!M8?_)%6_[(TG_H%Z=_X VW_P :H_LC2?\ H%Z=_P" -M_\
M:H J?\)/X;_Z&'0__!M8?_)%'_"3^&_^AAT/_P &UA_\D5;_ +(TG_H%Z=_X
M VW_ ,:H_LC2?^@7IW_@#;?_ !J@"I_PD_AO_H8=#_\ !M8?_)%'_"3^&_\
MH8=#_P#!M8?_ "15O^R-)_Z!>G?^ -M_\:H_LC2?^@7IW_@#;?\ QJ@"I_PD
M_AO_ *&'0_\ P;6'_P D4?\ "3^&_P#H8=#_ /!M8?\ R15O^R-)_P"@7IW_
M ( VW_QJC^R-)_Z!>G?^ -M_\:H J?\ "3^&_P#H8=#_ /!M8?\ R11_PD_A
MO_H8=#_\&UA_\D5;_LC2?^@7IW_@#;?_ !JC^R-)_P"@7IW_ ( VW_QJ@"I_
MPD_AO_H8=#_\&UA_\D4?\)/X;_Z&'0__  ;6'_R15O\ LC2?^@7IW_@#;?\
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MGQ=KGC_P>-)2")%L%\,^-_$WB+Q7HBVPC73]<UO4K^ ++=2$LU+]EC]FO6-
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M;]>_XC+X6_\ 0VI=/^:=QW]W_J"]/P[G\9/V2U_Y][?_ ,!HJ/LEK_S[V_\
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M_1]'BGK_ -&_Z'Q[_P#)5Z/^(3GPQS_QG1XI]O\ C'_0^?\ S*_%"\3^!/\
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M1_Q"<^&./^,Z/%/O_P 8_P"A\?\ F5^:/^(G\"?]#*?3_F25?+_IW_7WV/\
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MI- ')GJ?J?YTE*>I^I_G24 %%%% !1110 4444 %*OWE^I_]!:DI5^\OU/\
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M_P#E31YOBO\ Y\O#?_@SU7_Y4UOX'H/RHP/0?E0!@>;XK_Y\O#?_ (,]5_\
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M_92_\$OQ=_\ GJ5[_P#Q"CC;3_8,-T_YF>&_N_\ 3SK_ .W>I])_Q #Q%_Z
M\!_X<Z'_ ,U?U?TM_<SY_C;_ *!7A?\ \'.L_P#S/T>?XV_Z!7A?_P '.L__
M #/U_#-_Q%-?MT_]$*_92_\ !+\7?_GJ?RI?^(IK]NG_ *(5^RE_X)/B[_\
M/4H_XA1QMI_L&&Z?\S/#?W?^GG7_ -N]0_X@!XB_] > _P##G0_^:OZOZ6_N
M8\_QM_T"O"__ (.=9_\ F?H\_P ;?] KPO\ ^#G6?_F?K^&?_B*:_;I_Z(5^
MRE_X)/B[_P#/4_G2?\13/[='_1"OV4O_  2_%W_YZE'_ !"CC;3_ &##=/\
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MD^+O_P ]3^='_$*.-M/]@PW3_F9X;^[_ -/.O_MWJ'_$ /$7_H#P'_ASH?\
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M@^%GPE_X*>>$_%/[*OAR63QIX9\+>#/ _P"RQHVOVOA7Q_\  71?@%X:\/\
MA;1+>']I+P9\6?AUIVES>-O%GC_6M0BNH/AOK/PMW^#-(M[S19;:_P!*M8+S
M/D'P5N_^"G?Q8^!'COXB>']5_:*\2:7XZ^&?@NU\.S:Q\7O@1H/BS7_&EO\
M%YHM?\:? !4LM$N/ /AS2OAOIEW8>*O"_P 5=4\.:MXSUJXBFT[5XW6VU)/Z
M/MC>G3Z4;6]/?J/\:]!<22O4J2RK*G6J5J%;VD</*/)[&I[248Q4[+VFFM[1
MDN?E<FV>G+B^I-SG/)<E=:=?#UG5AA)0Y50J^U<(053EBJC[>["7O\LI-W_G
M2UO]DS]O_P ;^%]2UCXG1?&+QK\1/B3_ ,$Y?BI\"O%6G3_%OX.GP/8?%^V\
M0>-T\&Z-XWT"*^LUU2]\8^&9_#.M6_B#P=J=YI%OXYFO[_Q%JNF:=Y5G7?ZW
M^SY_P4L\(^-OB.O@+Q5XR\>:9X4^$_Q0\.? _P"*/Q$\2_ Z\^)H_P"$ZT?]
ME74]0\,^'?$4FFV!T+4?^$@\-_'31_ J:KI%KX.TB]TOP\?$<]U9)I.JP_O=
MM;T_4?XT;&]/Y?XT2XIQ<FN?!Y;4C%S<(SPJ:AS\J?+:4;:14=K66B1K_KQC
MKT[Y=E%2$)5'[.K@H5%:HE%J.JY;1BH[-<JM9:M_B-\=_P!AGXQ_M?>'/V(_
M"'Q07QWH&C>"-,_:(7XN^*_C!;_L\?''XJ^$++QEHFF:7X#L?$Z7FAZI\-_$
M/C[4M-TX:4/&W@30KS4/"5Y&FI6.K6NH27&H77&?M+_ ?]OS_A"_B_\ LK_!
M;PEX\\7_  3O?L^A?#'QO?\ Q:^&(L+OX&6_['>I_":?X-ZW8>(M=TOQG)J^
MI_&B*S\7ZU=OI<>E7%S=6VJPZW-#(NGP?O9L;T]^W^>PHVMZ?J/\:SH<28RB
MZ%Z&#G##>T=&DZ"5.$ZE7VO.E=R;7P\KDU:VVM^?#\88^@L/2>#RVK@\+*M6
MP^!GA8_5J.*KU'4GBHI/VCJ-2G#EG4E"TY:7;O\ AMXC_9T_X*0ZIKWB.?0/
MCO\ 'CX>^&6U7XQ:%X:\*>"_'GP9M/#N@>"O#'P&\#7_ ,!I-!75-&U;5=,O
M]?\ CI8:]X?UB<ZA<W$?A2&YM+ZW\-Z)=)K!YKQ]X#_X*_:SXGUR]\*:O\2M
M*U\^#/,TR\TGXG_ ;3O@-'IO_#-ATN^\(-X!DM(/'J?M!G]H0F_T[QM#J"?#
M:PM!!/!XA_L2T"/^]VUO3]1_C1L;T_E_C5?ZS8EV<L!E51I))SP46[)MV]V4
M79W]Y._-UTT*CQAB%-3EE&1RY8J*3P"6TI2WYV[.]FMG&*7=O^?+XN?"G_@K
MIX6N+WP_\(?'/QY^(NG:=XOT#Q1X+^(&I?&#X"V>H2M>_#OX97_BSPM\1/#=
M]'X0BUWX:VWQ&M?B+IFAV&EQS:CIEJSV%EHFK:?J=MKD'L/QWN/VW/@!\.OB
MC^T3;?$OX@>)?'*_M9ZQX5^&GP&\2>*/"6J?#+Q%\&OB)J]_\,_A-IOA_2]!
MT26\TK5;77O&_A[QTR:OK%_JR0>#CIEY8:;;>=;/^UFP_P!W^5&UAT&/Q'^-
M+_6.JW0OEV5J-*?-+V>%Y)U$U9Q<G.:46MUROJU9NXUQ:YO#*MDN4>SHU'.H
MJ&'=&I7BTKP<W*K&$965[4VM6TDW=?COXX_85^+7C?\ :J^!'Q(\4^*+?QG:
M?!/]C^T\'ZU\3_&7@+X.?$?5?B3\;]/\:7&O7^E);^/M'U?7?A[=:V]Y)K-O
MXX^'MEH%UIRH=$L_$)AMC:)\H^$?V9/^"CGP^\1> M8^'7A_X@^"O%%_\&_V
M3O#7C74O#/Q(^ >F_!U;[X5?!36/#WQ7T'XB> X#)XC\0ZP=;N'T/X:WWPY;
M3?#&F^)&O-6,UEI@6^G_ *-MK>GZC_&C8?3^5%/B7&PA.FZ.$G3E2A2494(>
MZH5756JW3=DXO2R\])P_&68X>+B\-@*JEAZ6'DIX:#@XT<1+$1?+J[MM0G[S
MYHQMHK)?A5\0/A+_ ,%2=+\/? W3O OQ,^/?B[Q)+\)/"FJ^)/$T/Q>^ 6D6
M'A+]I#4O$FEWWQ ;]H"QUSPQ9W7Q"^!NG:%YVE>#/#/PJBU.[M[>RUGS!>C4
M+#49N3T3X0?\%/;GPNFL^)8OBM+\0M"@_;"M/"?C;5?%7[..N?%O3H/B#X2^
M%=G\*;CPII?_  E$/@GP/#-KVE^+H-(\/:=\0EL#:V2ZAXKO]!\RPTS3_P"@
M'8WI_+_&C8?3^5./$V(C!P6791J_>?U+5KEY;*]1J/\ -;6/->3CS/F''C"O
M&E4I1R?(E[2HYN:P+YE>$H.*YJLHKXKZ1MS*[BY:G@G[+]E\5=-_9\^$5A\<
M;;5;3XMV?@G2[?Q[#KOBC3?&NN#7X_-%P^M>*-%M;31=8U:2,PR7]SI:3627
M#O;6U[J$,$=_<^\T[8WI_+_&C8WI_+_&OGJM3VM2=3DITW.3DX4H\M.+>K48
MW=E?7?>[/E\37^LXBOB/94J/MZM2K[*A%PI4_:2<G&$;NR5^^KN]+V&T4[8W
MI_+_ !HV-Z?R_P :@P&T4[8WI_+_ !HV-Z?R_P : &T4[8WI_+_&C8WI_+_&
M@#\K_P#@M5X4\4^./^":G[1/A3P3X9\1>,?%.KCX=Q:3X:\)Z'JGB3Q#JLEM
M\2_"-[<QZ;HFBVM[J=_);V5M<WDZ6MM*T-I;W%S(%AAD=?X"_P#AD+]K8\C]
MEC]I3D C_BPGQ7[C/'_%)_SK_4YD#+K/A$892/%-H>A&Y6TG5LD$=5P=K?7'
M2O;PP(SAA]58?TK]$X2\0\;PEEM?+,/E^'QE#$8KZU/V]24;2LDHI1IMZ6O?
MFUVMH?K' 7BOF' 658K*L%E6$QU/%8^6.E/%5IQY92PN!PW(H1I2NE]24U+F
M3_>.-GRIO_)7_P"&0OVM_P#HU?\ :4_\,)\5_P#YDZ/^&0OVM_\ HU?]I3_P
MPOQ7_P#F4K_6IS]?R/\ A1GZ_D?\*^F_XC1F'_0@R[_P=4\O^G?E^/K?[?\
MXF.SS_HF\H_\&U>EO^G7]U'^2M_PR%^UO_T:O^TI_P"&$^*__P R='_#(7[6
M_P#T:Q^TI_X83XK_ )?\BG7^M3GZ_D?\*,_7\C_A1_Q&C,/^A!EW_@ZKY?\
M3OR?W_>?\3'9Y_T3>4?^#:O2W_3K^ZC_ "5O^&0OVM_^C5_VE/\ PPGQ7_\
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MY?CZW/\ B8[//^B;RC_P;5Z6_P"G7]U'^2M_PR%^UO\ ]&K_ +2G_AA?BO\
M_,I1_P ,A?M;_P#1J_[2G_AA/BO_ /,G7^M3GZ_D?\*,_7\C_A3_ .(T9A_T
M(,N_\'5?+_IWY/[P_P")CL\_Z)O*/_!M7I;_ *=?W4?Y*W_#(7[6_P#T:O\
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M ,?H_L/2O^?0?]_[K_X_6K119=E]P<S[O[S*_L/2O^?0?]_[K_X_1_8>E?\
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M ,?H_L/2O^?0?]_[K_X_6K119=E]P<S[O[S*_L/2O^?0?]_[K_X_1_8>E?\
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MGE16>/B0%%5F'R:O[&W[-WACP%J7A&?2=4TKP-#^S5>?LMZK/J7CC6+6&R^
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M7ZB_VQJ7_0M:G_X&:+_\LZ/[8U+_ *%K4_\ P,T7_P"6='^N_%__ $4^??\
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M%_\ ?^,W_AQ+#_YDJ_47^V-2_P"A:U/_ ,#-%_\ EG1_;&I?]"UJ?_@9HO\
M\LZ/]=^+_P#HI\^_\.5;R_R?WA_Q+]X)?]&RX3_\-.$_^4GY=#_@B[^Q@#D/
M\9O;_BX>G\=.?^12[?\ ZN172^%O^"0'[%WAKQ#I6OW6A?$7Q<FE7*7*:%XN
M\<G4?#UTR'Y4U+3=.TG1YM0MB3^]MGNUBE4%)4="RG](/[8U+_H6M3_\#-%_
M^6=']L:E_P!"UJ?_ (&:+_\ +.LY\9<554U6X@S:O%Q<&JV-JU+)JSY7=.-^
MNYOA_ CP;P=>CB<+X:<'TJ^'JQKT*_\ 8V&=:E5A\,H3C&"25D^649)M7-JU
MM+6PMK6QL;:WLK*Q@BM+*SM(XX;6TM+>%;:WM;>&)4BC@@MXTABC10D<:!5
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M?]"UJ?\ X&:+_P#+.C^V-2_Z%K4__ S1?_EG0!T-%<]_;&I?]"UJ?_@9HO\
M\LZ/[8U+_H6M3_\  S1?_EG0!T-%<]_;&I?]"UJ?_@9HO_RSH_MC4O\ H6M3
M_P# S1?_ )9T =#17/?VQJ7_ $+6I_\ @9HO_P LZ/[8U+_H6M3_ / S1?\
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MQUV?3''(K]K\-^$^'L[R7%XC.<'"6(AF+A"53$QI-P5**TBYJZM9WMHOG?\
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ME;7,]J[+#*J?IM_G@8_3M].U?R-?\$K_ -GKXE?$+]I_X9_%'2M"UG3?AO\
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M*<_7\C_A1GZ_D?\ "O5O^$!\-_\ /"]_\&FH?_)%'_" ^&_^>%[_ .#34/\
MY(HYY?U_7]7] Y%Y_P!?U^/I;RG/U_(_X4G5DQGJW\+_ -P^BFO5_P#A ?#?
M_/"]_P#!IJ'_ ,D4X>!/#J_=AOACTU34.XQ_S\>A_#M1SR\OZ_K\0Y%Y_P!?
MU^/I;PGPN0- TP9SE+H CD9^W71Q[$#G!QQ6_7H,'PL\*VT2PV[:]%"K%EB3
MQ'K(12Q<DA?MF.2['_\ 54W_  K/PW_SUU__ ,*/6?\ Y,HYY>0<B\_Z_K\?
M2WG%9.OC.@ZX/71]4'YV,]>N_P#"L_#?_/77_P#PH]9_^3*CF^%WA>XAEMYG
MU]XIXI(94/B/60'CE0I(IQ>9PRL0<=C2YY?U_7]7] Y%Y_U_7X^EO-+0$6MI
MG/-I;,,A@"&MXL,"0%/<'!R#P:L5Z*GPP\,QHD:2:^L<:A$4>)-:PJ* %49O
M.@  %._X5GX;_P">NO\ _A1ZS_\ )E4JDE%06RV[^EQ<D>W]?U^;\K><?A1^
M%>C_ /"L_#?_ #UU_P#\*/6?_DRC_A6?AO\ YZZ__P"%'K/_ ,F4>UJ?S.W;
M[OGT0>SCV_K3_+^M+>2W6C:1?:CI>KWNCZ1?:MH8OO[#U2^TRSN]1T4ZI;&R
MU,:1?RP_;M+74[,BVU/[%<QK?6\<5O<Q31H -/\ 7ZUZ/_PK/PW_ ,]=?_\
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MY_U_7X^EO.**]'_X5GX;_P">NO\ _A1ZS_\ )E'_  K/PW_SUU__ ,*/6?\
MY,HYY?U_7]7] Y%Y_P!?U^/I;SBBO1_^%9^&_P#GKK__ (4>L_\ R91_PK/P
MW_SUU_\ \*/6?_DRCGE_7]?U?T#D7G_7]?CZ6\XHKT?_ (5GX;_YZZ__ .%'
MK/\ \F4?\*S\-_\ /77_ /PH]9_^3*.>7]?U_5_0.1>?]?U^/I;SBBO1_P#A
M6?AO_GKK_P#X4>L__)E'_"L_#?\ SUU__P */6?_ ),HYY?U_7]7] Y%Y_U_
M7X^EO%O$"I(="5@KJ?$EB-K@%6Q9ZAD;7&&VGKP1GD$DY.T+6VYS:V_WF_Y8
M0^O;"<"O2)_A5X5N?(\]]?D^S3)<09\2:UF*:/?M="+P8.)'4]BK8.14P^&7
MAH?\M=?ZD_\ (QZSW.?^?RJC6J4U)4ISI1E4=64:<ZD(N<HJ#;2EU27SU1%2
MA1K.+JTU5<8J"=5NLU!5<164$ZKFXQ4\35:C&R2Y4E:)YE]EM?\ GUMO_ >'
M_P"(H^RVO_/K;?\ @/#_ /$5Z=_PK/PW_P ]=?\ _"CUG_Y,H_X5GX;_ .>N
MO_\ A1ZS_P#)E7]:Q/\ S_K_ /@ZI_\ )_U?TMG]3PG_ $#4/_!4/\CS'[+:
M_P#/K;?^ \/_ ,11]EM?^?6V_P# >'_XBO3O^%9^&_\ GKK_ /X4>L__ "91
M_P *S\-_\]=?_P#"CUG_ .3*/K6)_P"?]?\ \'5/_D_ZOZ6/J>$_Z!J'_@J'
M^1YC]EM?^?6V_P# >'_XBC[+:_\ /M;?^ \/_P 17IW_  K/PW_SUU__ ,*/
M6?\ Y,H_X5GX;_YZZ_\ ^%'K/_R91]:Q/_/^L_6K4U]??_J[\K'U+!O1X3#2
M3T<94*<HR76,HRBXRBUHXM--:-6/-E1$4(B*J#)"*H503U(50%!(X)QW-.KT
M?_A6?AO_ )ZZ_P#^%'K/_P F4?\ "L_#?_/77_\ PH]9_P#DRLG-MN3UD[7F
MW*4FELFY2>BULE;=FD*%*FK4Z<():*-.$:<(I?9C"G&,$O2)YQ17H_\ PK/P
MW_SUU_\ \*/6?_DRC_A6?AO_ )ZZ_P#^%'K/_P F4<\OZ_K^K^A?(O/^OZ_'
MTMYQ17H__"L_#?\ SUU__P */6?_ ),H_P"%9^&_^>NO_P#A1ZS_ /)E'/+^
MOZ_J_H'(O/\ K^OQ]+><45Z/_P *S\-_\]=?_P#"CUG_ .3*/^%9^&_^>NO_
M /A1ZS_\F4<\OZ_K^K^@<B\_Z_K\?2WG%%>C_P#"L_#?_/77_P#PH]9_^3*/
M^%9^&_\ GKK_ /X4>L__ "91SR_K^OZOZ!R+S_K^OQ]+><45Z/\ \*S\-_\
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M_P">NO\ _A1ZS_\ )E'/+^OZ_J_H'(O/^OZ_'TMYQ17H_P#PK/PW_P ]=?\
M_"CUG_Y,H_X5GX;_ .>NO_\ A1ZS_P#)E'/+^OZ_J_H'(O/^OZ_'TMYQ17H_
M_"L_#?\ SUU__P */6?_ ),H_P"%9^&_^>NO_P#A1ZS_ /)E'/+^OZ_J_H'(
MO/\ K^OQ]+><45Z/_P *S\-_\]=?_P#"CUG_ .3*/^%9^&_^>NO_ /A1ZS_\
MF4<\OZ_K^K^@<B\_Z_K\?2WG%%>C_P#"L_#?_/77_P#PH]9_^3*/^%9^&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA#X^WGA?QEX(O/&O@VZ^+.C^.FT/4-075H)H=;GU">8 ^:==_P""RWQ.T?\
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M1TB.V5]'N;.66=G /S;B_P""CO[8&F:QXI^ 7BW]EWX&Z=^U]JOQ>^"?P_\
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MU.WO]7NQKEIXS_MG4XI%UHZ@^C6UXZ>'Y-*:* 1@'P%XQ_;2_:<\$?'[Q?\
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M ^4/C_\ &W_@H]X>T']D1/%?P9^"_@?]HKQ#^W%#\/=%\$?#3]I#Q?J'[/\
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MAE7\VOBQ_P $L?AYJ'P,OOV:O@EI^@:#\-/C;\7_ (<>*_VMO&/QP\8_&?\
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MWTG2]/2UT];8 _-[4O\ @I-^VM\,_"'C&;XQ_L4> M5^)GB?]E[7/VK?V;O
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M;1O"OAWQ?.EO-=?9M2LM-U2Q /DCQM^W;^V!I<_C/X7_ +57[.?PL^&>J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>rvph20211231_10kimg002.jpg
<TEXT>
begin 644 rvph20211231_10kimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& 2X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y3Q;K<NCZEH")J5M;1W
M5\L4T,NW=*A!R06/ !QT'4CD=^*_X3S7&E&=4MT6Y<K<?N4_XE7^D",;L^JY
M/S]QGI0![!17/^#]2NM6\-6]W=RK-*7E03(H43*LC(K@#@;E4-QQSQQ6R9]M
MPL11OF!(;C'':@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***0]#0 M%%% %6]>YCL9FM%A:X524
M$[%4S[D9(%<O;ZQK\>MV5C/=Z)=&YW,8K<2!E1-NXALD9&X8! S76S0QW$+P
MRHLD;J59&&00>"".XKS7P%:QGQ'<7<6E16J9GC1H-(C@BPK[0%E!WMP.A S0
M!Z//9VURR-/;12LGW2Z D?3/2@VEL1*#;Q$2_P"L^0?/_O>OXU8HH 8B+&@1
M%"HHP !@ 5#-_P ?=O\ \"_E5FJTW_'W;_\  OY4 6:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#T
M-+2'H: %HHHH J7\%Q<V4D5K=-:3L!LF5%<H0<_=;@^GXUP6B&UT77X9/L^A
MW3WL[6_V^PNQ&Y<G+!H68@G(R=K$^U>D5XSX<\.Z1K?C-KF+_1UMKEY%A748
MW<E)<X:()E06&<[LXP,T >S4444 %5IO^/NW_P"!?RJS5:;_ (^[?_@7\J ,
MK4/%NAZ5JUOI5[J$<-]<;?*A8-EMQP.@QR:W:\<^+MII\6KZ?J5H9)/$J&,V
ML"DL'"N,97'U[UT.D?$6#3M(TN'Q@TECK5V"3"ULRY^8J#@ XK3D32<=7U$U
M)?$K)['H=%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "D/0TM(>AH 6BBB@"M>VQN[.6W%Q-!O7;YL+;77W4D
M'FL&T\+WL%_'<3^(KV9$?=L6W@B+\YPS*@8CUY&:Z>O/O"EQJ-YXE8O=7\^F
M6HN$MY7M2BREI!NWN6.\J5PN%'>@#T&BBB@!O]*P/%>M+X>TLZFT$DPA!^1!
MR<X'7L.>M=!7)^/]6AT7PU/<3AV\R-X$"KGYV&!GVI2=D:48\U1*U[O8\KM-
M3N_BAKNHS6\,,&IV<"O8,&(,>'Y!/=N>IX'I6GXFT/6C-X?GU[2(M0FME5)K
M])G.Q0V?FQ@ C.=Q!!KLO 'ASP[:Q-KVBVSPO=IL+-(Q)7@D%22 =U=NZ))&
MR, 5(P01D&ERI.\&T=4\6[^SG!-)O3L>>^"OB+=^(M<U&POM/6U@M%)2X!8^
M9AMN3QCD<\5V%SXBT:SN8;>ZU.TAFFQY2/* S9..!]>*Y70/#OBCP[J-]*MY
M;WMC(V(+5Y&78N<C:<$+@<8Z5R_CB+2+SQKH-SK&GZE9WBNJ+Y;)Y>%?(.>=
MW)YZ<5?/!N\E9&$L-)RY:34O0]GR*6O-O%F@^-KGQ-IMSX=U.1=,B5#-&]UL
M#$-\P( ^8%>YSUK5UOXB:=X>U^RT2_M;H75V5"-& 5&Y]H.<_C3Y&_AU.>_<
M[6BD!R!4;31H0&D52>@9@,U(R6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I#T-+2'H: %HHHH 3.!DUYEX/@,7CBY8:6D,DJSO,
M5MI8_(.\;<.S%)-X.[*CC%>B7]HM_IUS9L[(L\31EEZ@,",C\ZYW1M!U6#5[
M6XU35+2X73[9K:VBM8#&2K;<L^6/.$7@8% '6454U"^BTW3Y[V?>8H4+MY:%
MFP!G@#DUBR^-M%BEL4:2?_3(HYE80L5B61MJ&0CA=S<#/>@#I*YSQG&DOA^X
M1T5E,;<,,CJ*Z.N=\6NITB1-PW%>5SS@LM*6QI2_B+U-33518I%C "+*RJHZ
M*!Q@>@XZ5>QFJ>FC%J2>K2.>_P#>/K5VF9O<3%5[BTM[E"L\$<JX(PZAA@]>
MM6:* 6FQYYK3>)?#>L62:';R76AL0UQ&PWF$ _,%.=P&WD#GG@>E=)/H?A[Q
M');:I<6%I>R*JF&=UW$#.1@_6MS@]JX'6KW6O#/B>U31M+EN=+NVWW*HA8(V
M?F*X^Z2.<=":B[@[ILZ5_M"4+)-+?:_KYE;Q1=^-[#Q?IUKX>@EET5MGVA_*
M5@F7^8;B<@!?RJ7QI\.+OQ=K.FZ@=6C@-HH!00DAOFW<<UVEEJEE?1(]O<QO
MN) &[!R.H(/((]*O;E!&2!GIS6JJ6U70Y73:=F4_M-S <7$&Y,_ZR'D=NHZC
MJ?7I4%QXCT:SFBANM4LX)I?N1RS*K-SC@$YZ\?6M6N*\5_#C3_%FNV&K7-Y<
M02V:@*D07:V&W<Y'K0N5O4'>VAVH.:6L_P J\@7]W(LZ@?=D^5N@_B'X]1WK
MG=<^(FE^'=:L](O[:]6ZNROE[8U91N?:"3N]>?I246W9 VEN=E1358,H(((/
M0BG4AA1110 4444 %%%% !1110 4444 %%&:* "BBFAE;(!!(.#CL: '4AZ&
MEHH **:&#*"""#T(/6G4 %>6>"M)@3QY>:G:_P!HO"ZSHTT\ 59'W@,=V\MC
MY>!M'<UZG7EO@=].A\8W-O:S6D\CFX?SET]DD+;P65I2YRR[ER-O0B@#T/5K
M26_TJYLX)Q;R3QM&)2F_:",$XR,\5RD?P]?%B)M8D>.*""WN56!5\]87+Q]S
MM()P<9S[5W5% "5SOBX+_9>[:,ET&<<_?6NB/2N.^(6L6.CZ-#+?7"PK),BK
MD$EL.K'@>@!-)JZLBZ6DTSI=-_X\8SZ@M^9)]!_*KM9'AS4K/5M"M+VPF$UN
M\8"N 1DC@]>>M:]-W3LR HHHH *3%+10!QFO> K;7/$=GK(O9[26W(++#@%R
M#D'/8]L^E5=?\"7VK7EC<6WB*\B:U?>%F.X$YR,;<>F.<\5W?>C J'"+OYG1
M'%5HVL]E9&)!KK6\JVVKP?8YCPLF<PR'_9;L?9L&MK((R.E,G@CN86BF17C8
M896&0?PKAM;T7Q39:I8GPO=!-/5]TUO++\J\]!D$[2.PZ&FVXJ^Y,(1J.UTG
MY['?5CZEX8T75[^"^U#38+FZ@QY4LBY9,'(Q^/-1)XB2W(35;2:P<\;W&Z(_
M1QP/QQ6Q%/%-&LD<J.C#*E6!!^AJD]=&9.#6Z*[:?&&+0LT#8P#&<#IC[O3_
M /57!>+=5\=Z?XLTZWT:V>XTM@AN9([0,!EOFR><';Z5Z515*5G=JY+5T5X+
MF*X'[M_F7[RGAA]0>15BJ\]G#<$,ZX<='4X8?B/J:X#QMJGC?2];TN#P_;R7
M=E( ;B1;96*_,!@GL=N>F*$N9V0-V1Z115)-1@+!7+1,>TJE?_K5;#!@"""#
MT(/6I&.HHHH **** $[52O[>YN852VO'M'SDND:L<>F&!%7J* 3L<)XK\,^)
M-3TCR+'Q#(9=X;#(L0('^THS6M9Z+K<-E!%+XDG,BHH8BWC.2!SR5R?QK2U7
M6]-T2!9]3O8;2)VVJTK8!/I5NUN8;RVCN;>198)5#HZG(8'D$5/)9\VIN\1-
MQ4-++R0MM'+%;(DTS32 8:0J%+'UP.!7D<"^+O#\EK'I\&H2_:M2GFNG:!6#
M+YP4!L*3]SY@25&.GI7L0YK,T_7M.U.:ZBM9PQM9S;N2,*9!U52?O8]JHP//
MXKCQ=<W]G+<2:KLM]59&=+<(DT;1MMRI4,$#!5).1SD'T@L=5\>RZ>S:A]KC
M5[E%G-O8EIH05?<$5E 9=P49&[ [\UZ8=6LQK$>E^:#=R1/*J 9PJE0V3V/S
M+Q5^@#GO ]M<V?@;1;>\BDBN8[1%D20896 Y!'K70T44 5KR\AL+.2ZN&988
MEW.RHS$#Z*"3^%>9>"VO9O']Q.VK2W5O)%-($=)$4,S+PJLB@8QG.><@=J]*
MU.WFN]+N[>VE\F>6%XXY.?D8J0#QZ&N8\&>'M>\.236UW<6#Z<YWI'"96=&V
MJ#@N3P2"Q]S0!V=%%% !7,>,?#FF^)M/CM-3C9HD+2*4;:RD+V-=/6;JS%8"
M1U\J3&,_W?:A-IW0$/AK1;3P_H-KIMD'6WB7*AVW')Y//U-;%1Q<1J/113Z'
M=O42V%HHHH&%%%% !1110 4444 ,95="K*"I&"",BN&UWP"]_K=CJ&EW[::L
M#[I(X5^5VSG( .,]CGK7=T8I-)JS-*=6=-WBS!$^O6'^OMH=1C'5[<^7)CW5
MN#^!JE<>/M%L]0MK"Z:XM[JX8*(Y867:2<#)/&">XS75FLG4?#NDZM<PW&H:
M?!<RPY"-(N=H]/?\:33MH5"=-R_>+[C5!HR*P_\ A'!;?-I=_=6/I&&\R+_O
MELX_ BL#7=5\:Z5>V$5KIT&H0/(?/E@C.=O'!4GY3C)SG%#=E=A"C[1VBU\]
M#NF57&& (]",U4.G0CF R6['O$V!TQT/'IV[57L=<L+]S%'/LN%^]!*I20?\
M!;!_$<5J9'K33OL9.+3LT4\7T+\&.=,]QM8<_D>/Y5QOBCXFV_A;7=/TNZTN
M=GNU5B_F* F6V_CBN_JG<Z787DR375E;3RI]QY8E9E[\$CBKBTGJKDM.VA:2
M1)%W(P8>H.:?5-M/MRV]$,3GJT9VD_7'6F^7>PMF.5)D])%VM^8_PJ1EZH)[
M:.X $BD@=,,1_*J_VWRSBXADBYQG&Y?S']?6B;6-,MVC6;4;2(R\H'F52WTR
M>>HHU Y[QEX!LO&&F0V4MS+:K%+YN^,;B3@C')]ZV-)T"UTO2;2Q4O(+:)8@
M[,06V@#) ..U:XHI\\FK7T%97N,CC6) B_=4  $] *\RO?A9-/JB74-Q;I&;
MN>=XD+1X#R*ZD$*?F 7';ZUZC12&<+X;\$W>B^)_[3EFM)%6.XC,B*WG3>9(
MKAG)X)4#;7<GH:6D/0T +1110!4U"2>+3;J6T17N$B9HE)X9@#@'\:Y/PW?^
M*W\0"VUJ>RF@:%R\<$85H2NS8S?,2-^6^4]-M=1K1MQH>H&[W_9_L[^;Y?WM
MFTYQ[XKS/P#;"+Q@+B]>X^T75M++:LWD$R(?+#;VB8G( 3 ; '..: /6Z***
M $KB_B3)X@308/\ A&86EOVFVLJJ&)C*G=P?PKM:K3?\?=O_ ,"_E3B[.XFK
MHS?";ZK+X7L)-<1DU-H_](5E"D-D]AQTQ6U2TE)N^HQ:*** "BBB@ HHHH *
M*** "BBB@ HHHH *0TM% %"^TRSU&()=VT<P7E2R\J?4'J#]*SO[)U&P);3=
M09T'2WO,R+] WWA^M;YHI612FTK&$/$!M#MU>REL?^FP_>0G_@2_=_X$!6FE
M_9R+$4NH2)?N$.#N^GK5@@$'(X]ZXW7/AWIVLZO::C'/+926[;BML H8YR#[
M'/<4GS)::FD%2D[3=CL\TN>*POLVOVG^HN[:^0?PW*>6_P#WTO'_ ([0=?EM
MSMU#2[RV ZR(HF3\TR1^(%/F74CV;Z.YND9KA_&'PWLO%VK6%_+>RVK6G18D
M4ASD')S_ +H%=59ZOI]__P >MY#*>ZJXR/PZU=W#UJHR:=TR''HT"C"@4ZBB
MD 4444 %(>AI:0]#0 M%%% %'5FF31[UK4H+A8',9?&W=M.,YXQGUXK@?A_:
MW,FJ-K%LFG?8[T3)/':1Q8@9678 R<DMER0>.E=SX@\@>'-3^T[_ "/LLGF>
M60&V[3G&>,XKSGX:7<<OB"X2UO;EE,>;B*:]@=6<*@0HL:@MA0 6X /')H ]
M9HHK,T[6[34[_4+. 2B:PD6.;S(RHRPR",]1CO0!IU6F_P"/NW_X%_*K-5IO
M^/NW_P"!?RH LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %)BEHH S;W1M.O\_:K*&1O[Q7#?F.:Y;6_">N/J.G2:%K,]M:PRAIH
M99F88R/NYSD8R,'BNZ[4=12<4S6G6G!W6OJ !QS2T44S(**** "D/0TM(>AH
M 6BBB@!CHDJ,CJK*PP5(R"/<55M])TZSE\VUL+6"3&-T4*J<>F0*NT4 %8&E
M:%=6'B#5M4EU+[0FH%#Y(@">7L&U<')S\O'OUK?HH *J368GGCE,DHV@@A7(
M!R/:K=4=4U*UT?3Y+V[=EA0J/E4LS,Q"J% Y))(  ]: )/L2?\]9_P#O\W^-
M'V)/^>L__?YO\:@TG5K36K!;RS9S&69&#H4964X(93R"",8-:- %7[$G_/6?
M_O\ -_C3&L074B><*"=P\UN1CZU=K'U3Q#8Z-=6D%[]H3[5((TE$#-&&8X56
M8#"DG@9H O?8D_YZS_\ ?YO\:/L2?\]9_P#O\W^-4].U^PU34]0L+25I)[!E
M2?Y2%!;/0]&P58''0@BM:@"K]B3_ )ZS_P#?YO\ &F/8@LA6:< -EAYK<C!X
MZ^N*NUDZOK^GZ')9K?2LK7DRP0JJEBS,0 <#H,D D\#(]: +GV)/^>L__?YO
M\:/L2?\ /6?_ +_-_C69I7BK2M:U*XL+&65YH S'="RJP5MK%6(PP##'%;M
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MK)YL10 N77&550023QR*Z:*5)X4EC8,CJ&5AT((R#0!%]B3_ )ZS_P#?YO\
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M@ HHHH *0]#2T'I0 4444 %%%% !1110 4E%% !1110 4444 %%%% !1110
M4444 (0,C(&>QQTIH6/LBC&/X1110 FR/</D7*]#M''TJ&.QMH;N>ZCA59IR
MIE;^\5& ?KCBBB@ ALK6WO+BYBA5)Y]GFN.K8&%'T JU110 4444 %%%% !1
:110 4444 %%%% "T444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>rvph20211231_10kimg003.jpg
<TEXT>
begin 644 rvph20211231_10kimg003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "U 2<# 2(  A$! Q$!_\0
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M8J["-2Q5%)8X&< #J?:O+/#MFEW\3QK47]I!96F9OM-C,F,J0%W,=J@#VSD
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M #$W[%WXWX&['3/?%.(R*6B@#*LM(^Q2W<D=S('N9S,_"\G 'IZ 5<^SS?\
M/W)_WRO^%8^G>++#4M=FTJ&.Y25#($E= (Y3&P60(<Y.UC@Y ]JZ"@+W*K6]
MQCY+M\Y'55Z9Y[4[[/-_S]R?]\K_ (5S5S\0-)MYM2C$=U*]A-' WEQC$KN2
M %8D#@J022!Q70Z5J,&KZ7;:A;AQ#<1AT#KAL'U% $GV>;_G[D_[Y7_"FBWN
M-[9NGV\;<*N??M5/7=>M] M(IYX;B=II!%%# H9W;!.!D@= 3R>U4],\76&M
M:A%:Z=%<3*\"3M.% 2(.N]%;)SN*D'@'&1F@#:^SS?\ /W)_WRO^%(UO/L;9
M=ONQQE5QG\JL$X4GG@9X&:Y6?Q[I5MX=FUN6&[2**X>W\@Q?O6=2=V%SV +'
M/0 T =']GF_Y^Y/^^5_PH^SS?\_<G_?*_P"%9T/B2QG\43^'XA*UW#!Y[N%^
M0#(&W=_>^8''O4NM:W!H:6TEQ%.ZW$Z6ZF)-P5G8*"Q[#)% %K[/<^9_Q]/L
MV_W5SG\J=]GF_P"?N3_OE?\ "N?3QK93ZA=6-M97T\T0D\L)&N+@QL%<(2P^
MZQ&<X]JU]#UBUU_1K;5+0.L,X)42+M92"5((]0010!9-O-@XNY,]OE7_  I%
MM[C:NZ[DW8YPJ]?RK&F\6V-KJM]87EO=VSVMLUUYDD8VRQJ<$I@DGD@ $ G/
M%4H/B)I-PNGLMM>A;P(68Q#%OOD,:^9SQE@1QF@#I_L\W_/W)_WRO^%-:WN-
MZXNY-O.[*K_A5#Q#XAA\-V(O;JTNYK93^]D@56$2Y W-DCCGMDUD3?$/2+>\
MU"!X;O\ T)6)<(NV0JRJRK\V0=SJ,M@'/7B@#J/L\W_/W)_WRO\ A1]GF_Y^
MY/\ OE?\*K:-J\.MZ7%?VZ21QN67;*H#*58J0<$CJ#R"16;+XMMXM6O-,_L^
M^-U;0M.JA5Q,BL 2IW<<D?>VYH V5M[C'SW;YR>BKTSQVIWV>;_G[D_[Y7_"
MN?T_QO8:H^FQV=M=RR7J&4KM4>2@8J6?+=-P(&W.<9'%;U_=?8;*6Y\B6?RU
MSY<6-S>PR0/S-  UO<_+MNWZ_-E5Z?E3OL\W_/W)_P!\K_A7+Q?$72)I--58
M+W-^0!^[7]T3+Y0W?-S\XQ\N[CGI6OHWB.RUV\U*VLQ*383")W9<*Y(SE3W'
M!&?4&@#1^SS?\_<G_?*_X4U;>XRVZ[?&?EPJ]/RJAJ_B2RT6_P!-LK@2O-J$
MZPQK&N[;DA=S>B[F49]36<?'%MY&JNNEZDTFF,OVB%8T+;2I8,/FQC"DXSGI
MQS0!T7V>;_G[D_[Y7_"FM!.,%;ER01P57!&>>U.L;N'4+"WO8"6AN(UEC)&"
M589''T-<S<?$#28&U!4ANIFL[E+;Y%4"5VW?<+,!@%&!)(&5H Z^BN6L/'>E
M:CJ5G:017FVZ5-DS1817:/S!&3G(;8,],>]=30 4444 %%%% !1110 4444
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D :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>rvph20211231_10kimg004.jpg
<TEXT>
begin 644 rvph20211231_10kimg004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "^ 3@# 2(  A$! Q$!_\0
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M:;XTO]1U%;62*ZMSYES$YR[F0L!M/(VKM7TP!7=,,C&2/<4 +14>64?,,CU
M_I3U(89!R* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_\ =7_OH_X5S?@'_D6A_P!=G_G745Z].7-%-]3Q*L%&;BNC&YD_NK_WT?\
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M]?#?^@UZIE_[H_.O*?C>6_LK1\@#_2'Z'_9H \TL?NBM^TZBL"Q^Z*W[3J*
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M'[HK?M.HK L?NBMZSZB@#H8/]7^%4;G[QJ]!_J_PJC<_>- $GAG_ )'#3/\
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M_NBGT4 ,\I/[HKE_B(BCP#K!"@'RA_Z$M=77+_$7_D0-8_ZY#_T): /"-/\
MNBMVTZBL+3_NBMZU[4 ;</\ JJHW74_6KL/^JJE=?>_&@#&OO]6U9>D]!]:U
M+W_5M63I)X_&O/S'X$>EEGQLZVS/ K<MONCZ5@VAX%;MJ?E'TKYJ>Y],O@'W
M'2LN[/R&M*<\5F71^4U,?B''X3T#X?*&\+J2 3YS_P ZZKRT_NBN6^'G_(KK
M_P!=G_G75U]AAOX4?1'QN)_C2]1OE)_=%'E)_=%/HK<P&>4G]T5Y3\;U5=*T
M?"@?Z0W_ *#7K->4?''_ )!6D?\ 7PW_ *#0!YE8_=%;UGU%8-C]T5O6?44
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MK'_7(?\ H2UTOE)Z9^O-<O\ $1%'@'6"% /E#_T): /"]/\ NBMRU[5AZ?\
M=%;EMVH VH?]552YZU:A/[JJESUH Q[[_5M6-I)_G6S??ZMJQ-*/\Z\_,?@1
MZ66?&SJK0\"MRU^X*P;0\"MNU/RBOF9[GT\/A)9CQ67='Y36E.?EK+NC\IJ8
M_$6_A/2/AU_R*J_]=G_G76UR'PZ4-X54D GSG_G76^6G]T?E7V.&_A1]$?%8
MG^-+U'T4SRX_[@_*CRX_[@_*MS ?7E'QQ_Y!6D?]?#?^@UZIY<?]P?E7E/QO
M55TK1\*!_I#?^@T >:6/W16]:=16#8_=%;UI0!N0_<_"JEQU-6H?N?A56?J:
M .?US_CQE^G]:HZ6?E6KVN_\>$OT_K6?I9^5:\S,.AZN7=3JK,]*W[8_+7.V
MC<"MVU/RUX%1ZGT45[I9E/%9UVW[LU=F:LZ[;Y#646^8JWNGL>G?\@ZV_P"N
M2_R%6JI:>BG3;;Y1_JE_D*MA57H *^UA\*/B)?$QU%%%42%%%% &'KF@'6KG
M3YCJ%Q;"QG%PB1*A#.,@%MP)Q@D8'K59?"LBZQ?:BNM7Z27K1&14"* (V)50
M0N<8)4^H-=+10!BVN@)!KLFL3W=Q=77E&"+S=H$49;<5&T#/(')R>*VJ** "
MBBD+!>IH 6N7^(O_ "(&L?\ 7(?^A+72[F/1>/<XKE_B(6_X0'6,J /*'\7^
MTM 'A>G_ '16Y;=JP]/^Z*W+;M0!L0_ZJJMQUJS#_JJK7% &/??ZMJP]+_K6
MY??ZMJPM+/\ .O/S'X$>EEWQLZBU/ K;M3\HK"M3P*VK4_**^9GN?40^$FG/
MRUEW1^4UHSGY369<GY340W+E\)Z7\./^137_ *[R?SKKJX_X<%O^$37 !_?O
MW]ZZ[+_W1^=?98;^%'T1\3B?XTO4?13,O_='YT9?^Z/SK<P'UY1\<?\ D%:1
M_P!?#?\ H->J9?\ NC\Z\I^-Y8Z5H^5 _P!(;O\ [- 'FEC]T5NVO:L*Q^Z*
MW;7M0!MP_<_"JT_4U8A/R?A5>;O0!S^O?\@^7Z5F:8?E6M+7O^0=-_NUDZ:?
ME6O,S#H>KEO4ZFT;@5O6I^6N=M&Z5NVC?+7SU3<^CI[%J5N*S;IOD-7IFXK,
MNF^0UG#XC26D3VS3O^0;:_\ 7)?Y"K=4M.+_ -FVN%'^I3O["K:ECU 'XYK[
M:'PH^%E\3'44451(4444 %8.MZY=:5J^BVL=FDMOJ%P;=YC+M,9VLPPN.?N^
MHK>K&U?P_#K%[87,MW>0M8R^=$L+*%W8(R00<\$C\: (M(UJZO\ 7M9TZYM$
MM_L#Q^6Z2;_,5PQ!/ P?EZ<]:W68*"3T%8]AX?BT_6K_ %1+R[DFOMOFI*ZE
M!MSMP H(P"0.:V: (/.#=&VKZD<TJO$/XLGU/6IJ* (_-3U_2J>J6-GK&F3Z
M?>9:WG7:X!*G&<]?PK0HH \^_P"%6Z$G^HO+V,=@65O_ &6GK\.;)/NZG-CW
MC%=]10!Q2>!K11C^T9#_ -LQ2GP'IK_?OK@_0 ?TKM** ..C\ >'0091//[/
M(0#_ -\@52E^%WALRL]LUS;;CG:DF5'TW G]:[ZDJ)PC-6DKEPJ2@[Q=C@E^
M'&GI]S49P/=0:L1^!K:/IJ#G_@ KM>?2BN9X'#/>)TK,,2MI''GP39-]Z]E/
MT4"A? >C'_6SW$@]"P&?R%=A1BG' X>.JBA2Q^)DK.;,[2["QT>S6TLT\N$$
MMC)/)ZG)J]YJ>OZ5)174DDK(Y6VW=D?FIZ_I1YJ>OZ5)13$1^:GK^E8WB#P]
MI'B:VCM]3B:1(GWH5=E*G&,Y%;M% 'GQ^%F@I_J;R]C'8%E;'_CM/7X;V$9^
M34Y_Q0&N^HH XI? MHHQ_:,A_P"V8_QH_P"$"T]C\]_<'Z*!_2NUHH XU?A[
MX=92MRDURK#!$DA _P#'<52;X6>&@V;=KJ#T59=P'_?0)KOJ*B=.$_B5RX5)
MP^%V."7X;::G^KU&Y'^\%/\ 058B\"VT734'/U05VN:.:YY8'#RWB=*Q^)6T
MCCCX)M&^]?2_@@%*O@/2,_OKBXD'<;@ ?R%=A12C@</%W412Q^)DK.;(8C##
M$L:'"(H '/ %/\U/7]*DHKLT.0C\U/7]*/-3U_2I** "BBB@ HHHH **** "
MBBB@ HHHH **** *VH,RZ==,A(986*D=0<&O*='\43:=I]C>6^L7%["^E>;J
M+2RFY6WN"R*A)+?(6W."NX !<X&,UZ_48BC"D!%"GJ !@T >9Z?X_P!;NO[&
MB-K;&35F,5NZ*2H>.9EE+88C'E@,.>N>36[K>IK9_$3P[;_VPT2W"S))9&<*
MK?+\K%>I);@9].*Z673+2>_M;V2%6GM0X@;)&S<,-@=,D=ZM&-&8.44L.A(Y
M% $E%5Y[NVMK>2XGN(H88QEY'<!5^I/ JQ0 44572YMWGEMTGC::+;YD8<%D
MW<KN'49[9ZT 6**** "BC(]::75< L 3TR>M #J*;N7=MW#/IGFD#JQ*A@6'
M4 T /HIH92,A@0.IS2;TX^8<].>M #ZY/Q_=/9>'(I!>26:-?6R2S1S&(JC2
MJ&^<$%1@G)S764UD5UPR@CT(S0!Y/>>.+SP_I]W]FO#>6ZWT@L);D>9]HA58
M]RB0L-V&9@&^8G'?!-=/H/B;5-4\67FBW$$4?]GAVN9%4@,KD&#:<]T))]UK
ML#&A4 HI Z CI56WTZUM;V[O(8=MQ=LIF?))?:-J]>@ ["@#SV[\26&G7?C!
M;[7[F>""2$PQ17@6178$>6A4C:-V >F,<GK79>$/M?\ PB.F_;[^/4+OR )K
MF.0.KMW^8<-CIGOBM@P0G),2$GK\HYIZJJKA0 !T &* '4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <MXZEN8-$C:VDEC?S@"T3$
M'&#Z5D^";F]GM]4^U3SR[81M\UF;'!Z9KOZ* /GS2_#&H6OPMOM9>&"UM[C2
MHXA;P,S-</YP;S9%( 5@.,#/'>MN;QEXEC\:ZG;Z>]Q*D<%XL=E,@8J\<>Y"
M%"C )''S,6'I7M%% 'B>J^*=9BT/2'TKQ+-/#<&0W6HW4?E"*8(A6+(B; R6
M.-O.,9XJ"ZU?6++Q+>7::E-'J]Q%IFRVM[8M%?.5PZY9<@ $G^$C.>U>YT4
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; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>rvph20211231_10kimg005.jpg
<TEXT>
begin 644 rvph20211231_10kimg005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ## 2,# 2(  A$! Q$!_\0
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ME*!@1ME*  GAP0,EEX!XKM:Q=+\,Z5I%X]W9P.DK*R#,K,L:LVYE4$D*"W)
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MO0!+146V7_GHO_?'_P!>C;+_ ,]%_P"^/_KT 2T5%ME_YZ+_ -\?_7HVR_\
M/1?^^/\ Z] $M%1;9?\ GHO_ 'Q_]>C;+_ST7_OC_P"O0!)7S//_ ,C+J?\
MU]R?^A&OI3;+_P ]%_[Y_P#KU\US9_X234L\G[7)_P"A&N+'? COR_\ B,Z?
M3/O+702?ZD?2N>TWJE="_P#J1]*^;ENSZ2.R*VF?\C#I_P#UW7^=>M5Y+IN3
MXAL,'!\]><>]>K;9?^>B_P#?'_UZ]S*?X3]3PLW_ (R]"6BHMLO_ #T7_OC_
M .O1ME_YZ+_WQ_\ 7KU3R26BD[4M !1110 5R/A]KF?QAK9CU&\N-.LPEL$F
M<,IN#\[D<#&U2BX]S775!$D$;ND0C1BQ=U4 $D]20.Y]: )6+!<JNX^F<4SS
M<?>1U_#/\JEHH 8)HST=?SH\Q/[R_G3BJMU /U%-\M/[B_\ ?- !YB?WE_.C
MS$_O+^='EI_<7_OFCRT_N+_WS0 >8G]Y?SH\Q/[R_G1Y:?W%_P"^:/+3^XO_
M 'S0 >8G]Y?SH\Q/[R_G1Y:?W%_[YH\M/[B_]\T 'F)_>7\Z/,3^\OYT>6G]
MQ?\ OFCRT_N+_P!\T 'F)_>7\Z/,3^\OYT>6G]Q?^^:/+3^XO_?- !YB?WE_
M.CS$_O+^='EI_<7_ +YH\M/[B_\ ?- !YB?WE_.CS$_O+^='EI_<7_OFCRT_
MN+_WS0 >8G]Y?SH\Q/[R_G1Y:?W%_P"^:/+3^XO_ 'S0 >8G]Y?SH\Q/[R_G
M1Y:?W%_[YK%T?7(=:NKV**S,:6LSPF1G0[V5BI^4$L!D=P* -KS$_O+^='F)
M_>7\ZQ+/7K:[UF^TN2TDMIK2-9B\A1E*$D!LJQV]#P<'%/'B30##;R_VC:>7
M<,5A<L 'P0#CVR1STY% &QYB?WA^=?-,W/B34L?\_<G_ *$:]^/B/0?M!@_M
M&T\T3>1LW DR<_*/4\'Z8KP&88\2:E_U]R?^A&N+'? COR_^(SIM-ZI70/\
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MY>=_TSD_[YKP[XNMN\;6IVLO^AKU'^TU &)8]%KI[?\ X]JYBQZ+730?\>]
M&9>?=:N6TS_CYD_WS_.NIN^C5RVF?\?,G^^?YUQ8[X$=^7_Q&=IIOWDK??\
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M]%KI(/\ 44 9UY]UJY?3?^/J3_?/\ZZB\^ZU<OIO_'U)_OG^=<6.^!'?E_\
M$9V6G]5K=?\ U7X5A:?U6MU_]5^%?-SW/IH;(BTT@>(-/).!YZ\_C7K'GQ?\
M]%_.O*-+_P"1@T__ *[K_.O6J]S*?X3]3P,X_C+T&>?%_P ]%_.CSXO^>B_G
M4E%>J>2 .:*** "BBB@ JM#):O-*L+PM)&=L@0@LI/.&QT_&K-<AX;M9+;Q;
MXDD&ESVEO=21/%(T8"2%5VL>.Y//O0!U],:14X)Y[ <FE9=RXR1[BD5%3H,>
M] #=TAY" #_:/-+^^_V/S-244 1_OO\ 8_,UROQ'\S_A =4R%QL3H3_?6NNK
ME?B/_P B!JG^ZG_H:T >)Z=]Q:Z6S_U8KFM.^XM=)9_<H AO.IKF+K_D*1_0
MUTUW]XUS-U_R%(_H:PQ7\)G3A/XR.GT_[JUT,?\ J_PKGM/^ZM=!'_J_PKY6
MI\1]7#X3.O?NM7H_@[S?^$5LL!,;6ZD_WC7G%YT:O2O!O_(J67T;_P!"->IE
M/QOT/+SCX%ZFW^^_V/S-'[[_ &/S-245[I\^1_OO]C\S1^^_V/S-244 1_OO
M]C\S1^^_V/S-244 1_OO]C\S7AOQ=W?\)O:[MN?L:]/]YJ]VKPKXO_\ (\6O
M_7FO_H34 8=CT6NBA_U-<[8]%KHH#^YH H7?W6KE]-_X^I/]\_SKJ+O[K5R^
MF_\ 'U)_OG^=<6.^!'?E_P#$.RT_JM;C?ZL?2L+3_P"&MUO]6*^;GN?30V0S
M3<_\)!88QGSUQGZUZM^^_P!C\S7E.E_\C!I__7=?YUZU7N93_"?J>!G'\9>@
MS]]_L?F:/WW^Q^9J2BO5/)"BBB@ HHHH *Q=,\2Z;JVH36-I+(98E9@60JLB
MJVUBI/W@&X/O6U7'^&_"=UHNJI/<7,,L%M#-;VH0,&*R3"0E\\9& ./<T =>
M2 ,DXJ/S"W^K7(_O'I_]>GNBR+M=01Z&F?9X?^>:_E0 >4#R_P Y]3V_"E\F
M/^XOY4GV>'_GFOY4?9X?^>:_E0 ODQ_W%_*L/Q=HDFL^%KW3[-8Q<3*H3<<#
M(8'K^%;?V>'_ )YK^5'V>'_GFOY4 >+V_P /?$5JH5[-6QW613_6M6V\):VB
MX:Q8?\#7_&O4_L\/_/-?RH^SP_\ /-?RH \LD\%:W.3MMU7_ 'G4?UK.NOA?
MKS2QW*M:E@2#'YG('KG&*]D\B'_GFOY4>1#_ ,\U_*HG%3BXLN$W"2E'H>56
MW@W6[? :TSCT=3_6M6/P[J@3!M2#_O#_ !KT#[/#_P \U_*C[/#_ ,\U_*N"
M65TF[W9Z*S6LE:R/.9O"&K3@@1(,_P!YQ7::!I9TS1;>TG"-)&#N(Y'))K1\
MB+O&OY4OD0_\\U_*NC#X2G0;<;G-B,;4Q"2G;3L+Y,?]Q?RH\F/^XOY4GV>'
M_GFOY4?9X?\ GFOY5U'(+Y,?]Q?RH\F/^XOY4GV>'_GFOY4?9X?^>:_E0 OD
MQ_W%_*CR8_[B_E2?9X?^>:_E1]GA_P">:_E0 ODQ_P!Q?RKS3X@> =5\0:]!
MJ.G?9RB0"-D9]K9!)SZ=Z]*^SP_\\U_*C[/#_P \U_*@#QF'P#XA@P&L@<?W
M9%/]:U8O"FMK%M-DP/\ O+_C7J/V>'_GFOY4?9X?^>:_E0!Y2W@;7+C(%O&F
M>[.!67'\+/$%E<.RFVF1FW963!_(@5[5]GA_YYK^5'V>'_GFOY5E5I1J1M(U
MI594I<T3RVU\'ZU 1OM#QZ,I_K6G_P ([JFW'V5O^^A_C7?_ &>'_GFOY4?9
MX?\ GFOY5PRRNDW>[.]9K62M9'!:=X5U%-5M;B2-%BBE#MN89P/85WPAC_N+
M^5)]GA_YYK^5'V>'_GFOY5V8?#QH1Y8G%B,1.O+FF+Y,?]Q?RH\F/^XOY4GV
M>'_GFOY4?9X?^>:_E6Y@2T5%]GA_YYK^5 @B!R(UR/:@"6BBB@ HHHH ****
M "BBB@ HHHH *PO$^JW>E6%JUDL1N+F]@M5,H)5?,<*6P.3C-;M9VKZ3:ZS:
M);7?F!$E296C<JRNIRI!'H10!S,/CZ*S3R=5M\7*7S6+F"1=K," &568,0=R
M\ ''-:.G>+;?6X+LZ9;RO<6]KYS(RCY7)8",X/WLH<CZ4K^!=!<VY-J^Z DA
MA*VYR7#DN<_,=X#<]ZGT3PU;:-_:Y1LMJ=Y)=2E1LV[@ %&#V Z^I- #/"NL
MSZQ93"\95OH&"W$ @>)H6*A@K!N3UX(X(KH:RM*TJPTD3_92S2W#[YI))"[R
M,  ,L>3@  4[^W=).I2::-3LS?Q@EK83*9%&,\KG/3F@#3HJGINI6FKZ=#J%
MC,)K6=-\4@!&X>N" :N4 %%4H]2M)=3GTV.8->01I+)'@_*K$A3G&.=I_*KM
M !113!(A. RD^F: 'T5FG7=)&J?V6=3LQJ'_ #ZF=?,Z9^[G/3FHH?$VA7$-
MS+#K-A)':C-PR7"$1#.,L0?E_&@#7HK(_P"$FT+^SUU#^V;#[$S^6MQ]H787
M_NALXS[58EUG2[>Z@M9M0M8[B<;H8WF4-(,9RHSDB@"_5:]F-M87$Z@%HHF<
M ]"0":BT_5M.U9'?3KZVNUC;8[02JX4^AP>#5J:))X9(9!E)%*L/4$8- '#:
M?XVOH;:"76(+9ENM/6_B:W<1A064,K&1@!C<N#GGGBM#3O'NEZG=6=M!#<B6
M[\MH5*CYD=&??U^Z-K GU%2Q^ ]"2T^SF&9P%1%D>=F>-4.5"MGY0#S@4ZR\
M':?I^NV&I6Z[5L+$V4$9&2%+9R6)YXX_$T 4-<\7W^B:CJ\4EI!)#;6L,UMM
M+%W:201C< .FX]!SBM_P_J8U?2A<&9)9%=HY2D31[74X*E6Y!'O56\\(Z9J.
MH7=Y="XDDN8A#(IF8+M!#+@=B&&X$=#6CIFEVND6?V6T0JFYG8LQ9F9CDL2>
M22>] %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F/GRV
M ZX-/HH \L\.:+J=MXHM9YK"YCB61BSO&0 -I[U-:^#[Z_\ '.LZG='[/9V^
MHBYMT%MB2=_(" B0G[G)! ')'6O3:* /"M+T_P 6V=[X3AAT[4[9;6&V20JD
MA0J2P</\P1<9&05).<Y&*LW-AXCE\+PQQP^(8;TWBG6'=))/,.U_FB574LF[
M;G80,;>N#7ME% 'A]YHWB%-0@F2#7[C46L+*.WO8T:)1*LCES. QP IY!)Z^
MIKH="M/$ \:PR7$.KK<K=7!OYYF;[') <^4(QG;G[G09&#FO3Z* &GH?I7G6
MEZ5?Q^(H)7LYEC6;<69" !GKFO1J3'>N>MAU5DI-VL=%#$RHQDDKW5CRC5/#
MVK2?$&?539RRZ8FJVKO$EN-[ 0[1*DG7:K8#*.,9J'P]X&GA\,7-_K<=SF2S
MEM%LK*T"3JC3%RS9.7;@$<#CM7K]%=!SGBW]G:VD-G=ZCH^I:EIL3WL%M;R6
MB&X"NBB-Y$7 '(8;L9 (S3-(T3Q1H&N6:M8W-PYBLT<"U26$PI%MD4RMRKJ0
M0J@C)/?->V44 >=_#W3[VVU[7[J6SO8[2X,/E3WMJMO*Y4$%0BX&Q>,''.3U
MKT2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>rvph20211231_10kimg006.jpg
<TEXT>
begin 644 rvph20211231_10kimg006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %= GX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH KM_R$(O^N3_ ,UJQ5=O^0A%_P!<G_FM6* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *[?\ (0B_ZY/_ #6K%5V_Y"$7_7)_YK5B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0D*,DX%+3)(TFC,<J*Z,.589!H 575QE
M&##U!S3JQO"T$,'AG3UABCC#0*Q"*%R<#GCO6S0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !15,ZKIXAFF-];".%]DK^:,(WH3V-6P00"#D'TH @;_D(1?]<G
M_FM6*KM_R$(O^N3_ ,UJQ0 4444 %%%% !1110 4444 %%%% !1110 4453@
MU.QN;N2T@NX9+B/[\2N"R_4?A0!<HHHH **** "BBB@ HHHH **** "BBB@
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M6L=S;2"2%QD,/Y$=C[5/69H%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 455MM1LKQV2UO;>=D^\L4JL5YQSCWJU0 4444 5W_Y"$7_ %R?^:UQ
MNI>+[K?>68MHMN7BW9.>XS78O_R$(O\ KD_\UKRS4O\ D*7?_7=__0C79@Z<
M:DFI(X\74E!)Q9O1>-KN.*./[)"=JA<[CVKJ[S49+'4K-)E065R?*\SH8Y3]
MT'V;D?7 YSQY:.M>MWEG#J%C):SJ&CD7!]O0CW!YS58VE"GR\J%@ZLYWYF6J
M*R=#O9IH)+.];-_:-Y<YQC?_ '7 ]&'ZYK6KA.T**** "BBB@ HHHH ****
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MT/7K77M!AUB!)8;>4,0)QM90I(.1VZ577QGX9>QEO5U[3S:Q,JR2BX7:I;D
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M_75OYFO8#TKQ^\_X_;C_ *ZM_,UZ.7[R//Q^T1D/_'Q'_O#^=;GB#_D/7?\
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MS.@251+Y;E?FSUZ9]:Z#PIXVM?%=WJ-O!9SVTED^UEFDC+'DCE58E3D'A@*
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MH9?\3.#'_"BL.M:VJ?\ (6O/^N[_ /H1K)'6M;5/^0M>?]=W_P#0C59A]DG
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MI_C/_D:[SZ)_Z"*93_&?_(UWGT3_ -!%>G6^)'!]DP:ZGQ/_ ,A>/_KTM_\
MT4M<M74^)_\ D+Q_]>EO_P"BEKS<;LCIP6[,:G>-O^0U;?\ 8/M?_12TVG>-
MO^0U;?\ 8/M?_12UAA/C.JM\)S=?3_@G_D2-%_Z](_Y5\P5]/^"?^1(T7_KT
MC_E6V,^%&=#<PO'7_(2MO^N1_G7*UU7CK_D)6W_7(_SKE:[,+_!B>=B?XK-E
M_P#D7-/_ .NLO\Q5*KK_ /(N:?\ ]=9?YBJ5>37_ (LCUJ'\->A6\2_\BQI_
M_7W)_P"@BN1KKO$O_(L:?_U]R?\ H(KD:]G ?P$<.)_B,OZE_P B'#_V$_\
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M_@/\Q5RN [B"TNH;ZTBNK>020RJ'1AW!J>L L=!U;YLC3+Y^"?NV\Q[>RO\
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MHRW^(_0VQ?PHRT_UB_[PH\9?\C?J7^^O_H"T)_K%_P!X4>,O^1OU+_?7_P!
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M\D_["W_M(5D5Y&(_B,]3#_PT:5U_R3J]_P"PE%_Z :XNNTNO^2=7O_82B_\
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M&8;Q# ;,RSTK)\:?\C5=?[D?_H"UK'I63XT_Y&JZ_P!R/_T!:66_Q7Z&V+^
MY^G^,_\ D:[SZ)_Z"*93_&?_ "-=Y]$_]!%>G6^)'!]DP:ZGQ/\ \A>/_KTM
M_P#T4M<M74^)_P#D+Q_]>EO_ .BEKS<;LCIP6[,:G>-O^0U;?]@^U_\ 12TV
MG>-O^0U;?]@^U_\ 12UAA/C.JM\)S=?3_@G_ )$C1?\ KTC_ )5\P5]/^"?^
M1(T7_KTC_E6V,^%&=#<PO'7_ "$K;_KD?YURM=5XZ_Y"5M_UR/\ .N5KLPO\
M&)YV)_BLV7_Y%S3_ /KK+_,52JZ__(N:?_UUE_F*I5Y-?^+(]:A_#7H5O$O_
M "+&G_\ 7W)_Z"*Y&NN\2_\ (L:?_P!?<G_H(KD:]G ?P$<.)_B,OZE_R(</
M_83_ /:1KE:ZK4O^1#A_["?_ +2-<K1]I^IA/H=-9?\ (@W7_83C_P#13UDU
MK67_ "(-U_V$X_\ T4]9->/B/XK/4P_\-&C<?\D^U'_L(0?^@O7&5V=Q_P D
M^U'_ +"$'_H+UQE=>$_AF5?XCUOX(?\ 'QJ_^['_ %KV+O7COP0_X^-7_P!V
M/^M>Q=ZY,3_$9O2^ 6BBBL#0**** "BBB@ HHHH **** "BBB@"N_P#R$(O^
MN3_S6O*]2_Y"EY_UW?\ ]"->J/\ \A"+_KD_\UKRO4O^0I>?]=W_ /0C7H9?
M\3.#'_"BL.M:VJ?\A:\_Z[O_ .A&LD=:UM4_Y"UY_P!=W_\ 0C59A]DG ?:*
M\?\ K8_]X?SKF_$__(TZI_U\O_.NDC_UL?\ O#^=<WXG_P"1IU3_ *^7_G1E
MO\1^AMB_A1EI_K%_WA1XR_Y&_4O]]?\ T!:$_P!8O^\*/&7_ "-^I?[Z_P#H
M"UZ-;XD<#^ PQUKJ/%7_ ",,W_7&#_T2E<N.M=1XJ_Y&&;_KC!_Z)2O,QNR.
MK!;LQ3TIWCH#_A)VX_Y=+;_T2E-/2G^.O^1G;_KTMO\ T2E8X3X_D=5?X3FB
M!CI7U)X0_P"1/TG_ *]D_E7RV>E?4OA#_D4-)_Z]D_E6N,^%&=#=F%X\_P"/
MBR_W&_F*Y"NO\>?\?%E_N-_,5R%=N$_@H\_%?Q6:8_Y UO\ ]=7_ *5!4X_Y
M UO_ -=7_I4%>3B/XK/4P_\ "B5O$_\ R+>F_P#7S+_(5R-==XG_ .1;TW_K
MYE_D*Y&O:P/\!'#B?XC+^J?\B%:_]A.3_P!%+7*UU6J?\B%:_P#83D_]%+7*
MU"W?JS&IN=/:?\D\D_["W_M(5D5KVG_)/)/^PM_[2%9%>1B/XC/4P_\ #1I7
M7_).KW_L)1?^@&N+KM+K_DG5[_V$HO\ T UQ==N%_AF5?XCV+X'?ZC6_]^'^
M35Z'XI_Y%V[^@_F*\\^!W^HUO_?A_DU>A^*?^1=N_H/YBN>7^\+U1?\ RY?H
M>95H:3_K[C_KVD_E6?6AI/\ K[C_ *]I/Y5ZE?\ A2]#RZ'\1>I'5BW_ -1?
M?]><_P#Z :KU8M_]1??]><__ * :\.G\2/:E\+. K5\/?\A&7_KSN?\ T4U9
M5:OA[_D(R_\ 7G<_^BFKZ.M_"?H>3'XCCZW?!W_(T6W^[+_Z U85;O@[_D:+
M;_=E_P#0&KDJ? R:?QHI>M;/A)MGBS36(^[.#6-ZUL>%?^1GT_\ ZZUXJW/:
M.MNOC1I4\$D)TF_&[C.Y/\:OZ3\7=-U35;/3H]+O4>YE6)79DP"3C)P:\*?[
M[?4UM>#O^1TT7_K]B_\ 0A7H2PU-1NCD563=CZB[5Y!>?\?MQ_UU;^9KV ]*
M\?O/^/VX_P"NK?S-&7[R,L?M$9#_ ,?$?^\/YUN>(/\ D/7?^\/_ $$5AP_\
M?$?^\/YUN>(/^0]=_P"\/_011F&\0P&S,L]*R?&G_(U77^Y'_P"@+6L>E9/C
M3_D:KK_<C_\ 0%I9;_%?H;8OX#GZ?XS_ .1KO/HG_H(IE/\ &?\ R-=Y]$_]
M!%>G6^)'!]DP:ZGQ/_R%X_\ KTM__12URU=3XG_Y"\?_ %Z6_P#Z*6O-QNR.
MG!;LQJ=XV_Y#5M_V#[7_ -%+3:=XV_Y#5M_V#[7_ -%+6&$^,ZJWPG-U]/\
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M@ HHHH **** "BBB@"N__(0B_P"N3_S6O*]2_P"0I>?]=W_]"->J/_R$(O\
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M4_Y$*U_["<G_ **6N5J%N_5F-3<Z>T_Y)Y)_V%O_ &D*R*U[3_DGDG_86_\
M:0K(KR,1_$9ZF'_AHTKK_DG5[_V$HO\ T UQ==I=?\DZO?\ L)1?^@&N+KMP
MO\,RK_$>Q? [_4:W_OP_R:O0_%/_ "+MW]!_,5YY\#O]1K?^_#_)J]#\4_\
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MV#[7_P!%+3:=XV_Y#5M_V#[7_P!%+6&$^,ZJWPG-U]/^"?\ D2-%_P"O2/\
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MO_0#7%UVEU_R3J]_["47_H!KBZ[<+_#,J_Q'L7P._P!1K?\ OP_R:O0_%/\
MR+MW]!_,5YY\#O\ 4:W_ +\/\FKT/Q3_ ,B[=_0?S%<\O]X7JB_^7+]#S*M#
M2?\ 7W'_ %[2?RK/K0TG_7W'_7M)_*O4K_PI>AY=#^(O4CJQ;_ZB^_Z\Y_\
MT U7JQ;?ZB^_Z\Y__0#7AT_B1[4OA9P%:OA[_D(R_P#7G<_^BFK*K5\/?\A&
M7_KSN?\ T4U?1UOX3]#R8_$<?6[X._Y&BV_W9?\ T!JPJW?!W_(T6W^[+_Z
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MQ_\ 7I;_ /HI:\W&[(Z<%NS&IWC;_D-6W_8/M?\ T4M-IWC;_D-6W_8/M?\
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M-6[OX>Z%>S"6<7+.$5 ?-[*,#MZ"M70?$>G>)+>6;3WE(B?:ZS0M&PR,J<,
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MQPJGC;UR1DBN>T#6##\1=1-SJ<^,SI=Q3R'RX5#HMO@'A=V3TZT=0Z'3>'O
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>rvph20211231_10kimg007.jpg
<TEXT>
begin 644 rvph20211231_10kimg007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O 38# 2(  A$! Q$!_\0
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M+B5("_F27&H.82GFV:2B,2(K'*EMVX#_ &30!ZS]GE_Y_9_^^4_^)H^SR_\
M/[/_ -\I_P#$UYIXJ^(>I:%XBUZQ7RA:IIRR:?.4!5;C87VL>^Y02/\ =J2\
M\7:Y:^,[:UN[R&PL97@6W2>S8PW:.!O/GCA'R2 IXXYZT >C_9Y?^?V?_OE/
M_B:/L\O_ #^S_P#?*?\ Q->?:%XJUN?QV^EZM>16I:695T^>T:,E%SL>&7D2
M$C!(/X=*NZ_=>)K;QOIMC::Y;6]A?++)L>R#-$L2J2-V[G.3SVH [3[/+_S^
MS_\ ?*?_ !-'V>7_ )_9_P#OE/\ XFN O_BBJZ#J%Y8Z5="9+5KJQ:X4*EU&
M&"%Q@Y !(.#@X(K1O/'R6VHQ:5-IMS;75Q;,\4DC(5$@B,FW:&W$#!&[&,C%
M '7?9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\36;H&IS7G@[3M5O,--+9)<2
M[%P"2@8X':N7TC5_%UWH@\2RWNGOIUU937"VHA*M;84F/#9^?I\V<>U '=?9
MY?\ G]G_ .^4_P#B:/L\O_/[/_WRG_Q-<5HGQ"DN_#[SW>E7@O[>SM[AX\(O
MG+(,!U.["KN#9W$8%-?XIZ?_ &=;WL.EW\Z26\MS(L6QO*2-]CDG=@X/(QG/
M:@#M_L\O_/[/_P!\I_\ $T?9Y?\ G]G_ .^4_P#B:Y:Y^(%E#K2V*6%Y+ ;J
M*S:\4*(UED&X*<G/"D$G'M4WAOQWIOB>^N+6SAE1HX_.A+LI\Z/<5W#!)7D=
M&P<$&@#H_L\O_/[/_P!\I_\ $T?9Y?\ G]G_ .^4_P#B:\Z\._$+4+B98M3T
MV[FGOKZX2VBB1%6&*%E5BS;N<9R2>X..U:8^)^FK:W5U+I]_# D#75JS(O\
MI<2L%+)SZD'!P<'- '9?9Y?^?V?_ +Y3_P")H^SR_P#/[/\ ]\I_\37):;\0
M[>_UJ#39-)U"TDDN6M&>8)M24+O"G#'.5YR.G2N9\6^.]:T?Q3JUM:ZA'''8
M_9S#;26#.DN\#<'F!P@YZF@#U/[/+_S^S_\ ?*?_ !-'V>7_ )_9_P#OE/\
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M-5U"YMK6:2XM+&5E,<$CYW$'&XCYFP"<#-;5]H=O?ZWI^IRN^^R25$CXVL)
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MK?"/QZ5LI'%G+\]J6.5EB)Y1O4KT_(U[QX3\6Z?XMTQ;FU8).H'G0,?FC/\
M4>AJG\1/!D/C3PQ+98"WT69;.4_PR =/H>A_/M7SSX0UJ_T#6_)>1K*^MG9"
MS#A&!PRN.Z$]?3.11*#LYQZ;K]4:.]1:?$OQ7^9]:TM<YX9\40:_$\4B?9M1
M@ ^T6K')7T93_$IZ@BNBI1::NC)-,6BBBF,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ?_ ,>UM_OG^5%'B_\
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MP0L$7##!W'/WN>N:YSQV=5%S8_9+_P JT"/YUM%J"6DKL2-K!V!RHY&..2*
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M(##O@@8K>C446T]4UL";333LT<WX$\21ZB-/T7R+6\O$N78SSSL1<ILE]5;
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MGWE\UKJ.G6P0,+N5T))^[M1FR/\ OG%:%8NK?\A[0/\ KXE_]$O6U0 4444
M%8S_ /(Y1?\ 8/?_ -&)6S6,_P#R.47_ &#W_P#1B4 ;-%%% '-^+_\ CVMO
M]\_RHH\7_P#'M;?[Y_E12&;EO_K[O_KL/_0$KAOB)=WEG?Z7(M[+#8E9!+%#
MJ26;.W&T[FY8#G@>M=S;_P"ON_\ KL/_ $!*\[^)TVE6U_IAO8W$TD;1K,9T
MB2-3(GS N""ZMM8 =@<\4Q'7^$;A;KPS:3+))(K!L-)=BY8\GK(.&I=>\+Z1
MX@DM9M2L8[B:S?S(&8#(/=3ZJ>X/%4O #0/X-LVMFF*%I"6F*DLV]LL"H"[2
M<D8&,$5TSR(A 9U4GIDXH P_"NGK9Z4LTFBV6E7LW^OAM54+P3CD=>#G\:W&
M17^\JGZC-0V]Y;7B,]M<13*K%&:-PP# X(..X/:H;ZQFNV5H]2O+0*""(/+P
MWUW*WZ4 5/"O_(O0]OWLW_HUZVJPO":&/PU;J79RKRY9L9;]ZW)Q@9K=H **
M** "LVTTN*V,GF;96:Z>Y0LOW&;T^@)&?>M*B@"E>69NKBQD#!?L\YE((^]\
MCKC_ ,>S^%7.@I:* ;.9UWP3HVO-Y\L+6M^O*7EJWERJ?7(Z_CFN5N_^$M\+
M7%O-J=H/$^EVKEHYHP5N8>.I7HQ [G/U%>G$U!=PO<6<T,4S0O(A594&60D8
MR/<4):W-8UFERR5UYGBFA:_INJ3:>\8@,=GI0MKR!EVSMM"YD4_[!Z8YP&/8
M5VT7AK3-2MM(LKJ$R(]AYIEW$2!_DPP;J".@]N*P-8^%MG<76GV9OS$]O9MM
MGAMU61M@4#<0?F//7K6/I]KK?AG[&VJV4VL6#61>&:TE?SHE(4Y9=W(&0*=;
ME:5TMBX8>E5;E%_)[G>"?Q%X/XNEEUS1U/$Z+_I,"_[2_P 8'J.:ZC2M8L-:
MM%NM/NHYXCU*GE3Z$=0?8UA^%/&6AZUIEG!;ZI#)=B%%DB=MKE@H!X;D\^F:
M=JO@Z.:].J:+<-I6J]3+$/DF]I$Z,/?K62O%76J.6=*I2=K?>;.NVTMWH-];
MP+NEE@=$7.,DC@59$BVMDKS,$2.,%R3P !S7+6?C"XTZZCT_Q3;"PN&.V.[4
MYMYC[-_"?8UM^()$_P"$;U!]R[#;.0<\'*\<U2DFFT)333\C6'-+5"VO5FOK
MBTVG-ND;%NS;@?\ "K]478*YO7["W$L-Z4+SRW5O&6<[@%#CY5!Z ]3CKWKI
M*QO$?_'I:?\ 7[!_Z&* ,^\\ >%;VW\B[T:UE7<2C%<-'DYPC#!49Z 'BLG_
M (5S>:7\WA;Q7JNF <BWN'%U!]-K\C\S76:U_J+7_KZB_P#0JT1TI7UL*^IP
M0U/XC:(,:AHNG:[ .LVG3&&7'^X_!/T(J6V^*WA\2K;ZQ'?:'<$X*:C;M&N?
M0,,J?SKNJKW5G;7L#074$<T3J599%# @_6F,Y*X\5:-?ZQIDL-_ 5M+F4RD2
M*1M\E\,,$Y4]L=^.M=997'VNTCN!%+$)!D+*N& [9';Z5Y9J'PJT5/$NG3VU
ME%II>=XX$M68KA8W<,^3R2RC@8P.^>GI&BV'V#3UC:+RIB=TJK,T@W=,@L2<
M'&<4 :E%%% $%S.EK;23RMM1%W,VTMC\!R:\W?QY''XJ2T8*VI_8WCC80R")
M@74B3&-P4!3D<G(QGG->FG)4X...#Z5QLGARU?Q(D;RS-=/9M,;S.)?,$BX8
M'M@<!>F.,4 =58W27EE'/'+YBL.6"%<D<'@\CFK5,0,L:AVW,  6QC)]<4^@
M#F_%_P#Q[6W^^?Y44>+_ /CVMO\ ?/\ *BD,W+?_ %]W_P!=A_Z E>%^/]<=
M?%>H6EMXHNKAHY1OTV94AAB.!PLC\?C@]:]TM_\ 7W?_ %V'_H"5S'B[Q?9>
M&)H(9=.:ZN;F-FA52J^8^Y55 3U)+=N@!-,1<\#SO<>#]/FDE$K,ARRW"S#J
M>-R@ X]A6#\1[?PS</IL6N6=])=NY6RFM;5IB'Z[2 "&SC.T@YP:ZCPUK*:]
MH,&H);_9P[,ACWAE#*Q4X8<,,C@CK6E/;Q7$826-'VL&7>H;:PZ$9[CUH XK
MX9Z7I^DZ=>6]K97D5PTIDFGN=->S\T,6*A0W4+DCCIGWKK;Z^GM758M.N;L,
M"28F0 >QW,*9H=E>Z?I$-KJ%^U]=)NWW#+M+98D<>P('X5>>:*(@/(BD]-S
M9H QO"3&3PW;LR,C%Y25;&1^];@XXK=K%\*D'P] 0<@R38([_O7K:H ****
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MS([+('P6GD;!8<$C/)'&:Y2]\)S^%]%M[B[M[&.TB&FFX@=\17$D882!R%(
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M98!Y)1?*C55)^\1N;+'@9)IF9@0^)_$4>EI]NU680W":?/<78MEW6J3*Q?:
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MG%92?\CI-_V#T_\ 1CTGV#7?^@[%_P" (_\ BJ=8:7=6^IRWUY?BZE>%80!
M(PJABW8G)R: -BBBB@ HHHH **2EH ***Q+CQ5HEMJ-I82:C#]HNS^Y"G<&.
M2HR1P,L"!D\D$4 ;=%8]YXDTFPU>UTJZO4CO;K'E1X/.3@9.,#)! SUQQ2:3
MXFTK7;FZ@TZY:9[5BLI\ME4$,5."0 W*D<9H V:*** "BBB@ HHHH **** *
M&DVCV.F6]M*5+QKM)7I5ZBEH!N["BBB@ HHHH YOQ?\ \>UM_OG^5%'B_P#X
M]K;_ 'S_ "HI#-RW_P!?=_\ 78?^@)5BJ]O_ *^[_P"NP_\ 0$JQ3$%,=UC0
ML[*JCJ2<"GUYE\4$L7O],-S.9)(X97-I+8O=0^7E=TK(C @KP,\_>/% 'I:L
MKJ&5@5/0@Y%4;^UO[AT-GJ7V0*"&'D*^X^O)XKAOA?!%;3:Q'B2UN6\EWL!:
MF"*)"&VNBEFY;G)S_",BNYOM0FLV18M+O+P,,DV_EX7V.YU_3- %+PDKKX:M
ME=][!Y06VXR?-;G':MVLCPY!/;:'!'<PO#+ND9HW*EEW.S ':2,X(Z$TR77R
M+ZXM;;2;^\,#!9'A$04$@''S.IZ$=J -JBL7^W;O_H6]7_\ ('_QVC^W;O\
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MPOM/TSRPOD7=T)PT^]BSQD'A"".PR>U=(-=NB 1X<U?!_P"O?_X[2_V[=_\
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MQ-%.Q+Y*@Y:$$9(&< XK7^)DVDMJFE:?=V^VYNL!K]H7D^S0JZL=FT'#LR@
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ML:CU/X::1JM[?ZC<O*=4N)TGBO </;;-NQ4&<8&WOZFNL^U3?\^%S_WU'_\
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844[7H+S4H(5BLI5*,2=[H.WLQHI%'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>rvph20211231_10kimg008.jpg
<TEXT>
begin 644 rvph20211231_10kimg008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N 3(# 2(  A$! Q$!_\0
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M_P :LU"9XEN%@,B^<Z%U3/S%00"<>@+#\Z &?8XO[\__ ($/_C1]CB_OS_\
M@0_^-6:* *WV.+^_/_X$/_C1]CB_OS_^!#_XU9JKJ#M%IEU(A*ND+LK#L0IP
M: %^QQ?WY_\ P(?_ !H^QQ?WY_\ P(?_ !KQ'0?%/B&P\/2:[-=:U+9#26>:
M75$58C=,0L9@;&2,DY[8JXGB_7+GX=QIIFKK?ZW8ZPEHUPC@BZ4DNN2.S+\O
MX&@#V+['%_?G_P# A_\ &C['%_?G_P# A_\ &O(SXGUCQ3I%]=Z-<W;POJD8
M-K!.D5QY7DJSQQ%N-RMDD=3@TV\U?7+W0=+FLM4UJ[M;=+@7@M0D5_$ZOA3)
M&?OJGW2%ZGK0!Z]]CB_OS_\ @0_^-'V.+^_/_P"!#_XUPOBS6=4/P[TB^\/Z
M@9+ZYGM5BGV;/.W$9#+SC=W'O6+:?%"46M_?Q 3FZU&*VMH+B0JENWD*SJQ5
M21A@PQ@\F@#U3['%_?G_ / A_P#&C['%_?G_ / A_P#&O/Y/B7>2QK<V.C*U
MK%#:O>&:<H\;3MM557;\V.23QVJKXA^(^I07&O:;8V]F)K:TN)+:9)RY5HBH
M;=\NW=AB0H)((P<4 >E?8XO[\_\ X$/_ (T?8XO[\_\ X$/_ (UP%OXTN],U
M&Z?582(5NK:"[;S]R6YDAW!E&!\I; .?7-11?%25M2T^WDTE469())U\QC(J
MS,0A50I!PN&;)'!XH ]$^QQ?WY__  (?_&C['%_?G_\  A_\:P/'FI7FF^&L
MV%Q]GN+FYAM1<  F$2.%+#/&0#QGOBN=U7^V?#-O;VMCK\VJS-JUM''#<R*)
M$5U.4D8#.UC\W3.* /0?L<7]^?\ \"'_ ,:/L<7]^?\ \"'_ ,:\ZU'XGW6F
M^'K+4GTZT\UFF6ZMVN3O'E2%&\L!22"03N; '<U>7XA72Z\T$^E(NF"]GLA<
M+/ER\<7F9V8Z8!'7K0!V_P!CB_OS_P#@0_\ C1]CB_OS_P#@0_\ C7G1^*%[
M:Z?+=ZAHT,*O817UJ$N"^Y991&@?Y?EP2"<9]JN:CXNU/4/A9K&L6$"6VH6R
MR1$K(VU2IP71BH)&#D9 H [G['%_?G_\"'_QH^QQ?WY__ A_\:\[M?&^KZ5I
M]W!<:8MPNG?9[/SGO"SSW,JH5!)7[N7Y8^W%33_$/5H@+)=%MCJT<]Q!<1?:
M3Y2F.(2[E;;D@J>F <T =]]CB_OS_P#@0_\ C1]CB_OS_P#@0_\ C7+^$O%U
MWXBEN(KK3TLV^QP7L&R;S-T<H)7=P,,,=!QS7!^"O$6MC5M"N+^]U?[-?+<B
M9[]D-O<,H8J(B!E2-N<M@8!H ]D^QQ?WY_\ P(?_ !H^QQ?WY_\ P(?_ !KS
M-?BO>'2]2G_LJV>6UE@7S8)7D@5)0WSNP3<0NW!*@@Y&#5N3XIA=0TRWBLH)
MTF@@EN6AF+[?-8J!'A<-MP2=VWCCK0!Z#]CB_OS_ /@0_P#C1]CB_OS_ /@0
M_P#C7E=CXVOM-L%O;I[B]>&UU&XVM+M1Q'<A5!&.H!P#V%:EW\2+ZPMYX;S2
M[:'4DO([>-#<,T6UX_,#,P7=D*,$ =?:@#T#['%_?G_\"'_QH^QQ?WY__ A_
M\:J>'M7&NZ!9:H(6@^TQAS$W5#G!'Y@UJ4 5OL<7]^?_ ,"'_P :/L<7]^?_
M ,"'_P :LT4 5K'+6%LS,Q8Q*22<]A12V'_(.M?^N*?R%% %71/^08O_ %T?
M_P!"-:59NB?\@Q?^NC_^A&M*@ HHHH *Q9O^1TLO^P?/_P"C(JVJQ9O^1TLO
M^P?/_P"C(J -JBBB@ J*6)9X9(9!E)%*L >H(P:EHH PCX4TDZ+I^D- 6L;%
MXVAB9R1E.5W?W@#S@TQ_!^BOJ37_ -D\N9Y89F$;%5+Q9V-M'&1N(]ZZ"B@#
MEKCP!X>N+>ZA%K)#]IO#?,\$S1NDQ&"RD'*Y&>GJ:AG^&_AR>PM;007,*VH9
M5EAN725@QRX=@<L&/)SUKKZ* ,J70=-DT^QL?LX2UL9(Y;>-&*A&C.4_ 8K+
MF\!:#+%>(EO+"UU>?;7D@F9'2;;M+*0<KD9''J:ZFB@#SCQ#\.)M2UFQ>Q-I
M%811P1N\DDOG*(GW#@';(>P+\C)ZUMGX>>'FN;J=K><FZ6='1KARJK-S(%7.
M%R>>.]=910!S'_""Z$^E7VF2P2S6]\L:W'FS,S/Y8 4[B<Y&!S4UQX.T>XU6
MVU'RIHIH%10L,[HCJGW Z@X;;VS70T4 8,?AJTD\-/H>HEKVWE+&0R,V3N8L
M,'.1@G@YXP*KV'@;1-.MTBAAG=ENTO#+-.[R/(HPI9F)+ #@ \5TU% '(WGP
MZ\.W\:QS07"IB56$=PZ[UD<NP;!Y&XY [5?'A'24=)$A;S$NGO%+L2/-=-A)
M'<;>W2M^B@#S/PW\,39RZ@-96T:WGM5M8XK224_*LA<-ESE"#MVJO"XZUV*>
M%].7P[-H3">6SG5A*9IV=WW'))8G.:VZ* ,"?PEI%S9ZE:RVS-%J+J\X+G.Y
M55593U4@(N".XS4%KX(T.SB@2."5C"TS^9),S.[2KL=F8G+$KQD],5TU% &/
MI?AS3=(E\RSB=&^RQ6F2Y;]W&"$'/<9/-8VG_#3PWIMPLT<%S+L1UCCGNGD2
M,."'VJ3A202,CUKL:* ..@^&WA^WMI(8?MZ%Q$/-%Y)YB>7N";6SD8#$8]*L
M1> - AEL)(+>>$V2JB"*=U$BJQ90X!^?#$GGN374T4 <N_@+0'MFMVMI#&T,
M\)'FM]R9P[C\6&?:I;_P9H]_]H:6.=)9Y8YC-#,R.CHNQ65@<J=I(XZYKHZ*
M *EA90Z=8P6=L&$,*!$#,6.!ZD\D^YJW110 4444 5[#_D'6O_7%/Y"BBP_Y
M!UK_ -<4_D** *6E!O[&(3[Q:3;CUW-7E7]L^,K32VL[FPU 2OI;:>DKWT(W
M7>X_O 2^<@$#^][5ZMHZ[](V9(W/(,CJ/F->;K\)[\Z=/;3W.EW$BVYL[0O;
MMMB5F+/.1GF8\<CC(ZT >I6"RIIUJL^?.6)0^XY.[ SD_6K506T/V>UAAWL_
MEH%WMU.!C)]ZGH *Q9O^1TLO^P?/_P"C(JVJQ9O^1TLO^P?/_P"C(J -JBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"%)HY))(T<,\1"NH/*D@$ _@0:F
MK&TG_D.Z_P#]?$7_ *)2MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** *]A_R#K7_KBG\A118?\@ZU_P"N*?R%% %71/\ D&+_ -='_P#0C7,:
MYX;\3WNM7]S::[MM9M/F@B@\H+M=ONKN!R/7?U%=/HG_ "#%_P"NC_\ H1KR
MKQ1J4NBZYJUH?$GB&=G*EH(9(4$<?EL[%689 50.1C)(&<T >I7%G?R>&9+*
MVNOLVH-:>4EQC=LDVX#>^#S7"Z;X3\5PZA9R>?);-%,C3W+ZS/<K*H/S+Y3C
M;\PR.V,^U>BV+*^GV[QLY1HE*F3[Y&!@M[^M6J (ITDD@=(I#$[*0'"@[3ZX
M-<];VMW;>,[;[5?O=$Z?/MW1JNW]Y%Z=:Z:L6;_D=++_ +!\_P#Z,BH 7Q#;
MZU/IG_$BO8;:]1@P,T>Y) /X3Z9]17$Q?%671KT:=XQT>;3[D<>?""\3#U Z
MD?3->F]ZSM8T/3M=L6L]3M$N(3T##E3Z@]0?I4R4MTS6$XVY9+Y]4.TO6M-U
MNT%UIE]!=PG^*)PV/KW!]C5_O7@GB7X5ZSX7NVU?PK=W3QKR?(D*SQCZ#AQ^
MOM3_  Q\7/$=LZV^J6T.L(O#>61#<C'^R?E<^PP34JHKVEHR)P<==UW/9-0O
M)X-9T>WC8".YDD648ZA8V8?3D"M:O*+7XIZ#KVHZ3,CO!>6]S,C6<O#L3$P7
M&>,$D#/8]?6NXT;7FU:VTV;RXE-U;F614?=Y;#'&1]:TMI<BYOT444#"F;UW
M[-R[\9QGG'KBGUD+_P CC)_V#U_]&-0!KT452U+5]/T>V:XU&]M[2$#)>:0*
M/UH NU7NIVM[:22./S9 I*Q[@NX^@)XKAW^)8U21H/"&A:AKD@./M 3R;93[
MR/C/X#GUJCJ7@_QEXPL'3Q%J]C9PD%H["PA# -CC=*X)'_ 1]#0!LZ-XELKG
M7M22S)GFN;F,M&"%:%1$@9GS]W!XQU)X%=K7B,/P=AMKJY_X1Z^6#4["XC0R
MWJ":*<-$C,&0@CJ21]<5UVG>/9](NXM'\;6"Z/=-A(;R,[K.X]-K_P !_P!E
MJ /0**8CK(@=&#*1D$'((I] !115'3+YKZ*=V0*8KB2$ 'J%8KG]* +U%%%
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M&GH^J$Z<)M<CY7VZ,[3P[H?B6\T.UO\ 2/B#=[G0;XKVWCN51NZYX(Q6EO\
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M,>WEFZYSR,8XKT*@ HHHH X#XB^(QI6A:DC>9);-;/!,GV=P49QA65\;6&2
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MXUO-;M;FTDTZ&&QO+2ZEM9A,2Y6)PGS+CY23SU->FT %-(# @@$'@@]Z=10
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M>O9J\9MM#UBRO[]9K6[BTO3K.\BMS/&J@"24,H5E8E^YS@8&!UKV:@ HHHH
M**** "BBB@"K>V:7T*Q2%@%D60$'NK!A_*K-+11T **** .8\0>"- U\_:KJ
MU^SWB#<E[;-Y4R8[[AU_'->4W5[J%O/:73ZYIGB"W+O';I<7D<-U"H5PI+9V
M@G.[)Y)"@GI7OE>=^+?$>M:?XFM8;3P\]U#;L9()%+?OG,4FY1A>H# X]CSU
MQTT,1*.CU0FC/\*?%32(-+,>N1W-C,+B42W!A+P%V<M@2+D$_,*]"TS7-*UF
M,R:9J5K>)C)\F4,1]0.1^-36@\_3HS/:I$94W208R 6Y8'(&>2<\5S^H_#?P
MKJ4GG'2TM;H<K<6;&!U/J"N!G\*ANC)[-?C_ )"2:5CK*CDB2:)HY45T8896
M&01[BN('A'Q5I'.A>,)Y8U^[;ZK$)U^F\8:D;Q1XQT8XUKPD;R)?O7.D3B3C
MU\ML-1[&_P +3_#\RKV,'7/#&H>%_$*WOA-#+"UM+)+ILC94)N4,J ]B2#CM
MCBI/"OB5;R2VU);9[AK:PE1XD=1]G"LF5"GD' .2>6^@IEOXUC\0^*7O].FG
M1;.QE#:?-"R2/'N7>2#P6[@ G[GN:OVVF3R7UO<6>D6D5S>Z3(C2K=E1*IV
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MO8Y/[/D5$^T#<%#)@#CI@$X]JEL?#*Z3XQTQH=1NY+>WTR6)897+9(=.2?\
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MX$WS1>:NZ-?[S#.0/<TBZI8/:1W:7UL]M*P6.=95*.2<  YP23QQ0!=HHHH
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M:7.I1R0N;2:VFQ%%%N4M&8!R7*@C=\V?:N_^V>(_^@-IW_@R;_XS1]L\1_\
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M$UI#J.H2M%JX@>S\O-NMKY(9F+;< AL8^;.3C'-=W]L\1_\ 0&T[_P &3?\
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M^-ISMSVXH [NBO,_^%J?VBEI_8^FM-)->P1LIF0YAD+8;@_*QVGY3R.]>F4
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M:GTKP=#HDD#6-Y=8^TM<71DDRUPQ38 V !@8!Z=L]:W]]_\ \^UM_P"!#?\
MQ%&^_P#^?:V_\"&_^(H ACTFVAUNXU9-WVF>%('RWR[5+$8'K\QK /P[T8W-
MW*\MZ5NDGC,1G^2-9B#(%&.,D9KI=]__ ,^UM_X$-_\ $4;[_P#Y]K;_ ,"&
M_P#B* ,J?PCIMQHNI:4QG%OJ+F2<K)A@QQ]TXX^Z*S#\.=(:V*/<ZB]RUPEP
MUX]P6G+*I51N(^Z%8@#'&:ZC??\ _/M;?^!#?_$4;[__ )]K;_P(;_XB@#E&
M^&>BXA$-SJ$/DQ01ILGZ>3G8W(/S ,1GWJ2+X=:-%)IQ\V^DAL-OE02S[HR5
M+%201U&X]",\9S73[[__ )]K;_P(;_XBC??_ //M;?\ @0W_ ,10!S,/P\TJ
M"R^RQW6HA$GBFA_TCF#RR2JIQ@ 9(YR?>NPJKOO_ /GVMO\ P(;_ .(HWW__
M #[6W_@0W_Q% %JBJN^__P"?:V_\"&_^(HWW_P#S[6W_ ($-_P#$4 6J*J[[
M_P#Y]K;_ ,"&_P#B*-]__P ^UM_X$-_\10!:HJKOO_\ GVMO_ AO_B*-]_\
M\^UM_P"!#?\ Q% %JBJN^_\ ^?:V_P# AO\ XBC??_\ /M;?^!#?_$4 .L/^
90=:_]<4_D**+5)([.!#LRL:CCV%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>rvph20211231_10kimg009.jpg
<TEXT>
begin 644 rvph20211231_10kimg009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O 34# 2(  A$! Q$!_\0
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M!QP3CI4WP^\5ZQK.L7-EJ]_ URD'F3:?)9/;3VLF[!5<Y$B8_BSG./6@#O\
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M9HH P[F>YAOWA^V2;!&K#*IU);/\/L**;J'_ "%I/^N*?S:B@9K6_P#K[O\
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MTTRLNW;@+*ZKQ_N@<]^M<CK6GZSI%WJ_B"Z\136@2[C-@QE>2W9'*H(9( ,
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M ,C%KO\ OP_^BQ0!M4444 8.H?\ (6D_ZXI_-J*-0_Y"TG_7%/YM10,UK?\
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M9?OMT>0!F_$?IBN(^)GP^L[BQO\ 6K 3_;+HK'-!M:9&+LJ;U4,"K+G<2.,
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M%KXDT>.ZQ\0]<TNXL_[=T*>*2.X6ZC4D?(-KH1QR5RP(ZGJ.>#6FGQ7\-?\
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M617WJ"KLI*M@;E)7(.!D$4V^\5:#I@E^V:K:QF&012 OEE<C<%P,G..<>G-
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MUKU,5;5DPC;<PM0_Y"TG_7%/YM11J'_(6D_ZXI_-J*LT-:W_ -?=_P#74?\
MH"UP7Q%;5I-7T>VTN[ E(>86OVK[,9"K)EMY4A@%++MR/OYYQ7>V_P#K[O\
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M%3;BV]>IT15*<'LF_N_X!["?I1VKR^W^+\>FWO\ 9WBW1KK2KH<&6-3)&??
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MO>_1/_0UH UY_P#CWD_W3_*N?T6^G@\/:8D>G7,Z_98SOC9 /N].6!KH)_\
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MN=@"DXR0!5C^PKO_ *&35_\ R7_^-4?V%=_]#)J__DO_ /&J -NL/PYUU?\
M["4W\EI?["N_^ADU?_R7_P#C56]*TR/2K>2))YIVEE::228J69CU/R@#MV%
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M9(]ZO>*;_P 46WA[3Y=(@D9G0?;YD@5[B%<#+)"6"LV<Y&3CL#6S_;EW_P!
M#4O_ "'_ /%U7F\2RP3V\4FAZDKW$ACB&(_F8*S$??\ [JL?PH \]M+\+\0;
M6X.I7,EVMU#$OVF0HS61LV=F=#@ ;P6)P,,*34-3+_$">\M]0_TIKP1PD2LR
M_838L^X*,Y3?\VX#K7H37OF7!N7\+WC3%#&92D);8>JYWYQ[4+>!)DF7PK=+
M*D?E(XCA#*G]T'=D+[=* .:^$ZQ6UEJ6G1R6MR;9H"U]:3.\=QOC#?Q$X8=\
M8ZC@5Z/7/6M\;&,Q6GAB]@C)+%8DA523U. _6K']N7?_ $ -2_\ (?\ \70!
MLT5SQ\2RK>I:'0]2$SHTBKB/E5(!.=_JPJQ_;EW_ - #4O\ R'_\70!LT5C?
MVY=_] #4O_(?_P 71_;EW_T -2_\A_\ Q= &S16-_;EW_P! #4O_ "'_ /%U
M7'B67[:UH-#U'SUC$I3$?W22,YW^HH Z&BL;^W+O_H :E_Y#_P#BZ/[<N_\
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MVB7_ )\Y_P#OI/\ XJC[1+_SYS_]])_\50!9HJM]HE_Y\Y_^^D_^*H^T2_\
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MVB7_ )\Y_P#OI/\ XJC[1+_SYS_]])_\50!9HJM]HE_Y\Y_^^D_^*H^T2_\
M/G/_ -])_P#%4 6:*K?:)?\ GSG_ .^D_P#BJ/M$O_/G/_WTG_Q5 %FBJWVB
M7_GSG_[Z3_XJC[1+_P ^<_\ WTG_ ,50!E:A_P A:3_KBG\VHIUS!=3WS3):
0/L,:J,LN<@M_M>XHH&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>rvph20211231_10kimg010.jpg
<TEXT>
begin 644 rvph20211231_10kimg010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N 3@# 2(  A$! Q$!_\0
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MYQ97_CPW=H -7DN3+&+B*\L+>.V"DC?AT<L !G!&3TXKU.B@"&8S"%S J-*
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M,D[B8B>2=W8/*@1V)+9)(4=_RKJ:* ,.^\,:?JVAVNE:BKS);!#'*'*2*ZC
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M1I6F:"%(C*_WG*J!D^YQFK= !6-<?\CCIW_7C<_^APULUC7'_(XZ=_UXW/\
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MCD9Z5G^!O$UCJ-C!9VEQ;/"@<&4S@,\A<D*B]2 .K=.@&>< '<4444 %%%%
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MT/3+>#?NF,=JH=E'.T-_#D]3UQP,=:Y31_A38S+;ZWHNH7>BW3HX+6AX#J[
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MLV"*U: "BBB@"O>_ZA?^NL?_ *&M%%[_ *A?^NL?_H:T4 5](_U%Q_U\R_\
MH1KR[QUJC:7XSO);&?4(IFMXDN3%':>7D*[)S,"<E5;I@=!R:]1TC_CWN/\
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M_P @";_KK#_Z-6MJ%:4)*VS$T>#BVN=&\0ZC+X@$_ARYFMF,-S9IFWD9LY#
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M "..G?\ 7C<_^APULUC7'_(XZ=_UXW/_ *'#0!LT444 %%%% !1110 4444
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MI6T997><R;8+>,,K;DP S,/7J* /2-&CNM<\%?9+JT&E1W%KY, MKDRLL+(
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MTN]NXH--M;C5DEBL;>=YTA"VLNYLG!)8X)4?W174_#CQ3J'B)M52_NDNEMS
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MBL,^'KV_^)%]]EL(/+M-2LIGU%G"R1)'"-R*,9.X''''7/:O0-OB;_GKI/\
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M=*O?$>IZ9%>*=*C$F[Y3'(<88C^][5=V^)O^>ND_]^Y/_BJ .5U?X<2NFO\
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>rvph20211231_10kimg011.jpg
<TEXT>
begin 644 rvph20211231_10kimg011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "G 08# 2(  A$! Q$!_\0
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M#4M\]O=SR"[8':^ $ +$#@<GYB-QYP%':@#I:*C\K_;?_OJCRO\ ;?\ [ZH
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MY?N5!IW_ "']/_Z[K_.IY?N"H-/!.OV&#@^>O/XURX+_ 'B'JBZW\&7HSU3
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MQF15\.Z?M4 _;!T_W&KTK$G]]?\ OG_Z]>;?&4,/#VG[B"/M@[8_@:O0Q/\
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M:X+)X82I[12;9EB,?.O#D:LB6BH_+;_GJ_Z?X4>6W_/5_P!/\*]DX"2BBB@
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MFJ+?$J"VO@;S3YET^:6:&TGA?S'E>-PC H ,98\<G\*Z75_#>FZZD:7T<S1
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K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>rvph20211231_10kimg012.jpg
<TEXT>
begin 644 rvph20211231_10kimg012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "E 0(# 2(  A$! Q$!_\0
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M6_O?I1M;^]^E)O\ ]EORHW_[+?E0 NUO[WZ4;6_O?I2;_P#9;\J-_P#LM^5
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MN%@=Y44$+@;E08Z G KV2B@#Q_5_'GBC2].5)VMX[B=H6CF-MM5%>!I&4AF
MPK+@MG(!Z9KU:PD:73[>1Y4F9XE9I$Z.2!R/8U%J&DZ?JT:)J%G#<K&VY!*H
M;:<8./PJVB+&BQH JJ %4#  '84 24444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>rvph20211231_10kimg013.jpg
<TEXT>
begin 644 rvph20211231_10kimg013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S 20# 2(  A$! Q$!_\0
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MJ72-8M-<T];VS9S&69"LB%61U)5E93R&!!!% %WRW_Y[/^2_X4>6_P#SV?\
M)?\ "GD@=31N'J/SH 9Y;_\ /9_R7_"CRW_Y[/\ DO\ A3]P]1^=&X>H_.@!
MGEO_ ,]G_)?\*/+?_GL_Y+_A3]P]1^=&X>H_.@!GEO\ \]G_ "7_  H\M_\
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M@NZU:^\*6=[K3A[NY4S#]V$(1CE 5' .W&?>@#H:*:Q88PN?QQ3=S_\ //\
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M^10!)14?DQ?\\T_[Y%'DQ?\ /-/^^10!)14?DQ?\\T_[Y%'DQ?\ /-/^^10
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M3^-$Q+/[@^E7#TJG9_<'TJX>E?GE3XCZQ;(R-6_X]W^E>M:+YO\ 86G8*_\
M'M'U!_NBO)=6_P"/=_I7KNB?\@'3O^O:/_T$5]5P[M+Y'B9OO$M_O?\ 8_(U
MQ'Q.W_V-8;MN/M8Z#_9:N[[UPOQ0_P"0+8?]?8_]!:O=QO\ N\O0\S"_Q8^I
MREA]P?2M#M6?8?<'TK0[5^<5?B/KH[(SM1_U+?2O1?!OF?\ "(:;M*X\KC(/
MJ:\ZU'_4M]*](\&?\B?IG_7+^IKZ;AWXI>AXV;_"O4VOWO\ L?D:Y7XB;_\
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M%_044 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>rvph20211231_10kimg014.jpg
<TEXT>
begin 644 rvph20211231_10kimg014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "^ 24# 2(  A$! Q$!_\0
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MBH\2_P#/1?\ OG_Z]&)?^>B_]\__ %Z )**CQ+_ST7_OG_Z]&)?^>B_]\_\
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M'_OH5)10!'OD_P">1_[Z%8WBIF_X135<H1_HLG<?W:W*Q?%G_(IZK_UZR?\
MH)K.K\$O1E0^)'E6D_ZI/I6TO2L72?\ 5)]*VEZ5^:XCXV?8T_@15O/]6?I7
M6?#EF'A^?"$_Z4_.1Z"N3O/]6?I77?#?_D79_P#KZ?\ D*]WA_\ C/T/-S;^
M$O4Z[?)_SR/_ 'T*-\G_ #R/_?0J2BOL3YXCC_UDO^\/Y"BB/[\O^_\ T%%
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M 'T:^Q/G@C^_+_O_ -!11'_K)?\ >'\A10 1_?E_W_Z"I*CC^_+_ +_]!4E
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MZI/I6TO2OS7$?&S["G\"*MY_JS]*Z[X;_P#(NS_]?3_R%<C>?ZL_2NN^&_\
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>rvph20211231_10kimg015.jpg
<TEXT>
begin 644 rvph20211231_10kimg015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S 24# 2(  A$! Q$!_\0
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M-<%>E.4G9'UV5XW#TJ24Y),X^;_5"NH^%'_)1K'_ *YR_P#H)K2D^$GB=D
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MS\O/'/>M"TN[:_M8[FSN(KB"0;DEB<,K#U!'!H F*JW4 _44GEQ_W5_*GT4
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MHY?M,BS%F*'HBX).&(R<<"NY\%Z3=Z1H<L=["MO+<7D]T+='#"$22,P3(X)
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M #<GPP3<-<M!]KN/L;7)8R&W\QO+SN^;[N,9YQBNKHH :P8]"!]128?^\O\
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M;8B(Q"SMQ&6+%!&NW)X)QCJ14C6EJQB+6T1,/^KS&#L_W?3\* )4;>BL002
M<'M7G'Q'\3:EIM_:V>CRW:S6D#:A<);0&7S%5@%C? .U6 DY./NBO2JB\F/S
M&D\M-SJ%9L#+ = ?4<F@#S36/%][J2ZD]J;9M)M[C3Q$R.ZRR^<8V!W*P  #
M=.^?ST?&?B.ZMO#\5ZL]SH<D>HPQ"*Y:)6N4,B!B"&;Y=K$\8/'.!7;+96RI
ML6VA"G;E1& #M^[QCM@8]*+BRM;Q5%U;0SA3D"5 V/ID4 >=ZAKMWIWQ"WKJ
MJWUG=MMMK.VO@Q@Q!N+20[>4)4G<&_B!JI%\0O$Z6,=]<6^DM"+.SOY%19 Q
MCFD\LH"3C</O;NG;'>O3UL[5)3(MM"LA0(6$8!*^F?3VH-E:E#&UO"5*!"NP
M8VCD#Z#L* .*\#>,-3\5:OJ*RBS6QMUP%B5@Z2;V7:26^;"J#N  ^;':K_Q$
MO;ZQ\,Q-ITT\=Q+?VT/^CN$=E:55959N%)!QD\"K?A_P1H?AF\FN]-MY%FE3
MR\R2E]J9W;5ST&>:WWB24 2(K@,& 8 X(Y!^HH \5.M^*]1AT>RL+_49-1DA
MU#;%%)$KQRQRJL:W!8!6"@X; YSQGK7=^)=8O[?PEK'FO<Z3<V=KE=08Q*D\
M@4G$>6)Y88Y4'GBNL6U@24S)!&LA))8* ><9Y]\#/TIT]O!=1&*XACEC."5D
M4,N?H: /+]9\0W<,WA[58M;2>S>UMEEL;6_5)YI6<*75-K>8.<$9'0TV3Q]X
MH-I)=1PZ1Y?V2]O$4I)N"6TNPJ?FP2W'/0>]>FKI]E&T1CM(%:$$1E8P-@/7
M;QQ^%.^QVVW;]GBQAEQL&,,<L/H3U]: .$T;QOJ>M^/7TB%+-+*$,9D(8R*H
M1&5@VX [F8C 7@+SUKN=1D:+3+N6-BKI"[*1V(4D&L6V\#Z'9^(WUV*WD^VL
M[R#,I**S##,J] 2.*Z,@,"I ((P0>] 'A%CXG\1_\(Q,;C4=3$TL>ER(C31M
M/()Y '>)@H4(P.T*22I'.*]&T6]URPT-+;7(;[S)/M#_ &]FA/V6$%C'YS9Q
MO"XR55AGKWKJ?L5J=F;:$[  OR#Y0#D >@!Y%6"H8$$ @C!!'6@#Q:P\4:F[
M2:;=Z_/;V;:O'!+?+=13>1$T#.%6X"A268<Y4;>G>K.C>/O%<VG0<6$WEM9P
MM+<HZO-]HD=$?Y2 !A5;ISGC%>LBPLQ;&V%I +<\F(1KM/X8Q3OLL')\B(DE
M23L'.WI^7;TH \LN_B3KJ/8:?%'IJZA+//;L61BDK1SB+Y06&P;<OR3TQ7K"
MYVC.,XYQ7-ZYX%T#Q!?175_:L98UV$1R%%<;MV& X/S<^M=( %4 #  P!0!X
MT?$>OP^)=6)U"[BM?,U*.)IG1H7,4>Y410NY'4_-DG!"GK70^"=0\2P:2;_4
M;35M0M+E+<VT<KPO.&9,R/D,H$><8!);GI7>M:6SC#6\3#<7Y0?>(P3]2">:
MF1%C4(BA548  P * /'=3\3:SHMYXB2+5?[0N&@N+BW>VO%GCLD651AXMHV.
MJMQ\S#Y34UOXRUVRU'4--TK4+;5;*$W$MO?7Q\PLL4*.RAH]H;YF(SVS[8KU
MA+2WC:5TMXE:4YD*H 7^OK^--6RMHXT1+:%452JJ(P H/4 8X![T >7WOQ+U
MC3[&4W<6G13.;21)51V2))XW?:5R"S IC((^]G'&*]%\/75[>^'M/N]16);R
M:!9)EB^ZK,,X')Z9QUJMKOA32/$-O#!>P,!$ZR(T+F-@5!4<CL Q&/>M#2],
MM-&TRWTVQB\JUMT"1IDG 'N: +4?W3_O'^9HH3Y0?<G^=% #Z*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>rvph20211231_10kimg016.jpg
<TEXT>
begin 644 rvph20211231_10kimg016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q 20# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W@;G>3]XR
MA6P  /0'N/>G^6__ #V?\E_PHC^_+_O_ -!6%;^,-(N]?.CQ23&XWO$DAA81
M22(,NBOC!9>X]CZ4 ;OEO_SV?\E_PH\M_P#GL_Y+_A6.OB>R?Q)+H4<%W)=0
M[?-D6 F*/<NX;GZ#(K<H C\M_P#GL_Y+_A1Y;_\ /9_R7_"I*,T 1^6__/9_
MR7_"CRW_ .>S_DO^%29HS0!'Y;_\]G_)?\*/+?\ Y[/^2_X5)FC- $?EO_SV
M?\E_PH\M_P#GL_Y+_A4F:,T 1^6__/9_R7_"CRW_ .>S_DO^%29HS0!'Y;_\
M]G_)?\*/+?\ Y[/^2_X5)FC- $?EO_SV?\E_PH\M_P#GL_Y+_A4F:,T 1^6_
M_/9_R7_"CRW_ .>S_DO^%29HS0!'Y;_\]G_)?\*/+?\ Y[/^2_X5)FC- $?E
MO_SV?\E_PH\M_P#GL_Y+_A4F:,T 1^6__/9_R7_"CRW_ .>S_DO^%249%%P(
M_+?_ )[/^2_X4>6__/9_R7_"GY'K1FBX#/+?_GL_Y+_A1Y;_ //9_P E_P *
MDS1F@"/RW_Y[/^2_X4>6_P#SV?\ )?\ "I,T9H C\M_^>S_DO^%'EO\ \]G_
M "7_  J3-&: (_+?_GL_Y+_A1Y;_ //9_P E_P *DS1F@"*,L2X+,=K8[>@/
M]:*6/[\O^_\ T%% !']^7_?_ *"N&M_!.IVFL-<0ZC:FWMKF[OK%'A;<)YPW
M$A#<HI9N!@D'K7<Q_?E_W_Z"I* .*NO!]YJ/B[3]9N'TV$VDB2O-;0,MQ*P3
M:49RV-A)SC&< #WKM:** &&)"<E%S]*3R8_[B_E4E% '/^*]9'AO09=22TCG
M9&5=C-M!W''7!KD(/B;),H)T: ?]MC_\36[\4/\ D1KG_KK'_P"A"O);'[H^
ME 'HW_"PWVY_LF'_ +^G_P")JM<?$V2!21HT#8'_ #V/_P 37)G[E9U__JV^
ME 'O6CW*ZIHUE?- L;7,"2E <A=R@XSWZU>\F/\ N+^597A/_D4-'_Z\XO\
MT$5LT 1^3'_<7\J/)C_N+^5244 1^3'_ '%_*CR8_P"XOY5)10!'Y,?]Q?RH
M\F/^XOY5)10!'Y,?]Q?RH\F/^XOY5)10!'Y,?]Q?RH\F/^XOY5)10!'Y,?\
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M==;T*#7],?3[V640.0Q,9"MD'(YP:PXOAGHD(PL][^,B_P#Q- 'FY^Y6=?\
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MU3_D<-6_Z^3_ $K2B^X*Z^;P-ID^HW%Z\USYT[EV^<;<GT&*G'@^P4<2S_\
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MY?\ ?_H*DH YX>%(E\51Z\FI7R210?9TM%,8@6/CY0-F[&0#][J/3BNAHHH
M**** "BBB@ HHHH **** /'/C[_QX:%_UWE_]!6O&HN@KV7X^_\ 'AH7_7>7
M_P!!6O&HN@KS<5\1]KP__NZ]62G[M):_\A2R_P"NZ?\ H0I3]VDM?^0I9?\
M7=/_ $(5ST_B1[.-_A2]#[#'W12T@^Z*6O:/S$**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH CC^_+_ +_]!11']^7_ '_Z"B@ C^_+_O\
M]!5:'5;"XU&?3X;R&2\MU#30JX+1@]"1VJ*_M;J\MY8;/4)+"7S ?/BC1SC
MR,,".?I7-+9:Y;>/-2U6#18C:R:>+>)_M2J9I$+N"0!D;BP7/;K0!T3>(M(7
M6QHS7\(U(X_T;/S\C</TYK5KA9M"UB;QO:ZK96K:<&DCDU"==09TN$$>#$8<
M8W X ;CA<]\5W5 !14?E#/WG_P"^C1Y(_O/_ -]&@"2BH_)']Y_^^C1Y(_O/
M_P!]&@"2BH_)']Y_^^C1Y(_O/_WT: )**C\D?WG_ .^C1Y(_O/\ ]]&@#R#X
M^_\ 'AH7_7>7_P!!6O&HN@KV/X]H%L-"Y8_OY>I)_A6O'(N@KS<5\1]KP_\
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M5[+\??\ CPT+_KO+_P"@K7C4705YN*^(^UX?_P!W7JR4_=I+7_D*67_7=/\
MT(4I^[26O_(4LO\ KNG_ *$*YZ?Q(]G&_P *7H?88^Z*6D7[HI:]H_,0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"./[\O^__ $%%$?WY
M?]_^@HH (_OR_P"__056U&>\M[)Y+"S6[N!C;"TPB#<\_,0<?E5F/[\O^_\
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M9H IZ[X7TSQ,D*:Q:1W*P,6C!=UVDC!^Z160/A?X37_F#Q?]_I?_ (JNAO\
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M6>9V(! 52",+AC^E95U\-Y]0U:ZO))["W@GG1WMK>!PEP!.LK-*&8@N0I7(
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M)@9IPEW(%&Q692NPACNWA<G*@KC&>2#Z?4?G1?\ /5/^^A1YT7_/5/\ OH4
M245'YT7_ #U3_OH4>=%_SU3_ +Z% !']^7_?_H**;$ZLTI5@1OZY]A10!-11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>rvph20211231_10kimg017.jpg
<TEXT>
begin 644 rvph20211231_10kimg017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S 24# 2(  A$! Q$!_\0
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MNDW_ *,:M\'\3]#RN)?]W7JCN=H]!^5&T>@_*EHKTCXH3:/0?E1M'H/RI:*
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M9F3Y %(&T$=P&YKMVW8.,9[9JI8Z;8Z9 8;"RM[2(L6*01*@+'J<* ,^]7*
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M\:DHH CQ+_>3_OD_XT8E_O)_WR?\:DHH CQ+_>3_ +Y/^- $N1EEQWP*DHH
MC7_CX?\ W%_F:*%_X^'_ -Q?YFB@ 7_CX?\ W5_FU,N+B&TMI;F>18X8D+R.
MQP%4#))^@IZ_\?#_ .ZO\VJIJ]I-?Z->V=O*D4T\#QH\B!U5B" 2#P1[4 5]
M%\1Z9XA29M-N6E\DJ)%>)XV&X94[6 .".0>AK6) &2>*XOP!X3O_  K%?I>2
M6P2<Q>7#!(\H4JNUF+N QW<?+T7''6NT(!&",CWH 9YT?]]?SKP7XJ%6^(I(
M((^R1]/^!5[[@5X'\5?^2BG_ *](_P#V:@#-L>U;_P#RP_"L"Q[5O_\ +O\
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M'_?7\Z?@48% #/.C_OK^='G1_P!]?SI^!1@4 ,\Z/^^OYT>='_?7\Z?@4<4
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ME?%3W/H.J-SP)_K]4_[9?^S5VE<5X&=4GU/<P&3'C/\ P*NQ$T9( 8$FOO\
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M<Q9DE;<[$GDL6&=QK"\7?#'^V]0BO],OQ9S[M\IE5G&X(J(RX(P55!P>#WH
M[^VF^T6L4VQD\Q VQL9&1G!QWKAO%WCZ[\.^*H-)M[2TG#V\,RQN[+-.SS&/
M9& I&1C/-=S;1R16L4<DIE=$"M(P +D#!; X&>M9&K>$M*UJYN+B\CD,EQ;Q
MV[LLA7"HYD4KCHP8YS0!S6F_$66Y\876DW4-BEI%<W4#RQW!\RW6  ^9*",*
MC9P#D<UN7'BA_P"W]"MK)+6YTS5#(JWD<^[YE5F^4 8(^7KGO6IIFAV.DK>"
MVC/^F7#W,Q<[BSN<G\/:J>I>%;+4M6L-2>XO89;$Y@C@G*1J><G:..02#ZCB
M@#FK;XBS6LFH#7K/[,T# 0VD4$HN)%:81*P#J%9267E2>M7H?B5I+-*MQ9:E
M:"-;C<T\ P'@&9$&&.6 Y]#ZU=D\":-<3S3W1O;J:1DVO/=.YC59%D"ID_*N
MY5)'?%0ZUX#T_4=-NX;:22WNIFNI$E+%@LDZ[7)'<8[=J -'PWXEA\3074L-
MG<VPMI_(83[<E]H8XVD@\,/SI_BS6I/#OA74M8BB262T@,JQN2 Q'8D50\#^
M&;SPII$EA=7PN5,I>)$0JL2X P"<DY()Y/>MO5])M=;TFZTV]5FMKE-D@5L$
MCV/:@#SQ_B???V7;W BTA/-U![,7DEPZVKJL)D+*Q4-U&S!'WJZ>W\81WOAI
M+V(VMOJK62WCZ?/*Q>)" 2615+D#/9>>/6K9\'Z0=4&H>3)YPO#>A2Y*><8_
M++;>G*]??FM+4--AU"WDB9I86D !FMW,<@P01AAR.E ' 0_$K4[[289;+3;)
M[L0W=S.K7#*AB@8 [?EW*S9X5@"O>M&#XH:=<B(0Z3JLIE9HT\N%2K2K&)"@
M)8<A3G)P.*O/\.?#\EI';[+Q6#2M).MTXEF\W'FB1LY8/@9!].,5=M_!NCVT
MT<L,+H8[F2Z50YVJ[Q>4V!Z;. .U &;%\1=)N=0TRUM+>]N/MXA*2*BA4,J%
ME# L#G:&)P"!CUKLZ\XM_AI+I_C&RU?3=4^SV5K'%$L+(6D$:+M*;B<$-W)&
M17H] 'GUSX^NX?B*WAI+2UFC%U# $61O/(>(2-*!MV[%[\@U#X0^)G]MRRMJ
MJZ=:6B6OVAKF*Y.R ^84$4I8 *YQN STKJ+CPEI5SJ,M^\<HN9+N*]+K(01)
M&FQ2/0;>".^35S2="T_1-(BTNSA M8@=JR?-G))Y)Z\F@#E+OQ[<6'B*[@O8
M((=,CC>2UE9)=UXJP^9F-]OEMWXW9P#4-I\2+B&ZCL]7TEOMERD$MI%IS>;O
M$RNRJ=VW##RV!/3FNDN/".EW>K?;[O[3<%0PC@FN':&(LI1BB9P"5)'XG&*J
MV'@+0].FMIHDNGFMYDEBDFN'=EV(R(F2?NJKL />@"C;?$_1[FU:X^QZC&OD
M)<0+)"%,ZM((QLY_OD+\V/7IS70^'M=B\1Z/'J4%O/;Q.[H$G"ALJQ4GY21C
M(/?M7-:[\-+&_P!!6PTV5K62.!+=&E+.#$LHE*G!!Y8=>M;_ (5T>ZT'P[;:
M;=WOVN2'<!(%VA5))"@=< <9/- &RO\ Q\/_ +B_S-%"_P#'P_\ N+_,T4 *
M8XW.612?<4GD1?\ /)/^^1110 >1%_SR3_OD4>1%_P \D_[Y%%% !Y$7_/)/
M^^11Y$7_ #R3_OD444 'D1?\\D_[Y%'D1?\ /)/^^1110 >1%_SR3_OD4>1%
M_P \D_[Y%%% !Y$7_/)/^^11Y$7_ #R3_OD444 'D1?\\D_[Y%'D1?\ /)/^
M^1110 >1%_SR3_OD4>1%_P \D_[Y%%% !Y$7_/)/^^11Y$7_ #R3_OD444 '
MD1?\\D_[Y%'D1?\ /)/^^1110 >1%_SR3_OD4>1%_P \D_[Y%%% !Y$7_/)/
M^^11Y$7_ #R3_OD444 'D1?\\D_[Y%'D1?\ /)/^^1110 >1%_SR3_OD4>1%
M_P \D_[Y%%% !Y$7_/)/^^11Y$7_ #R3_OD444 'D1?\\D_[Y%'D1?\ /)/^
M^1110 >1%_SR3_OD4>1%_P \D_[Y%%% !Y$7_/)/^^11Y$7_ #R3_OD444 .
..6-$SM11GK@4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>rvph20211231_10kimg018.jpg
<TEXT>
begin 644 rvph20211231_10kimg018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "P 20# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WB.,,I)+?
M>;HQ'<^]/\E?5_\ OXW^-$7W#_O-_P"A&I* *336:7D=H]RBW+J62$SD.RCJ
M0N<D#UJSY*^K_P#?QO\ &N-U6ROC\2]&U&VT*62WA@EBN+Y'B4'>%"Y!8.0N
MT]N_%=M0!'Y*^K_]_&_QH\E?5_\ OXW^-!B!).YQGT8TGDC^_)_WV: %\E?5
M_P#OXW^-'DKZO_W\;_&D\D?WY/\ OLT>2/[\G_?9H 7R5]7_ ._C?XT>2OJ_
M_?QO\:3R1_?D_P"^S1Y(_OR?]]F@!?)7U?\ [^-_C1Y*^K_]_&_QI/)']^3_
M +[-'DC^_)_WV: %\E?5_P#OXW^-'DKZO_W\;_&D\D?WY/\ OLT>2/[\G_?9
MH 7R5]7_ ._C?XT>2OJ__?QO\:3RA_?D_P"^S1Y0_OR?]]F@!?)7U?\ [^-_
MC1Y*^K_]_&_QI/)']^3_ +[-'DC^_)_WV: %\E?5_P#OXW^-'DKZO_W\;_&D
M\D?WY/\ OLT>2/[\G_?9H 7R5]7_ ._C?XT>2OJ__?QO\:3R1_?D_P"^S1Y(
M_OR?]]F@!?)7U?\ [^-_C1Y*^K_]_&_QI/)']^3_ +[-'DC^_)_WV: %\E?5
M_P#OXW^-'DKZO_W\;_&D\D?WY/\ OLT>2/[\G_?9H 7R5]7_ ._C?XT>2OJ_
M_?QO\:3R1_?D_P"^S1Y(_OR?]]F@!?)7U?\ [^-_C1Y*^K_]_&_QI/)']^3_
M +[-'DC^_)_WV: %\E?5_P#OXW^-'DKZO_W\;_&D\D?WY/\ OLT>2/[\G_?9
MH 7R5]7_ ._C?XT>2OJ__?QO\:3R1_?D_P"^S1Y(_OR?]]F@!?)7U?\ [^-_
MC1Y*^K_]_&_QI/)']^3_ +[-'DC^_)_WV: $B&&D'S<-W)/844+_ *R7_>_H
M** '1?</^\W_ *$:DJ.+[A_WF_\ 0C6>=?TD:T-&.HVHU$C<+;S!OZ9Z>N.<
M=<<T :E%95UXAT>RU*'3KK4K:&]FQY<#R .V3@<>YX'KVK5H *QO$'B73/#-
MM#<:I*\4<TGEH5C+9;!/;V!K9KR[XW?\B_I7_7[_ .R-0!TD7Q)\,S8V7<IS
M_P!,'_PJVGC;0Y%RMQ(1_P!<6_PKP;3_ +JUT]I_JJ /3W\>:!&"6N9!C_IB
MW^%;UM<QWEI%<PDF.5 Z$C&01D5X->_=?Z5[;X=_Y%S3?^O9/_010!I4QY$C
M1G=@JJ"S$] !U-251U;_ ) U[_U[R?\ H)H&M698\<^%F^[K^GGZ3K4@\9^&
MVZ:W8GZ3+7R):?=%:]H/F%<4\4XO8^FPV0TZT4W)K[CZD;QEX<4\ZS9#_ML*
MN:=K6FZQYG]G7T%UY>-_E.&VYZ9Q]#7RK<CFO6/@3]W7/]Z'^34Z.)=25FC/
M,LDIX2@ZJDVU8]DHHHKL/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'^F^O^PU 'F^G_=6NGM/]57,:?\ =6NGM/\ 54 4[W[K_2O;?#O_ "+FF_\
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MQD>S5Y3==:]8^!'W=<_WH?Y-587^(C+/_P#<W\OS1Z_Y$7_/-?\ OFCR(O\
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MR^H_.C<OJ/SIOE1_\\U_[Y%'E1_\\U_[Y% #MR^H_.C<OJ/SIOE1_P#/-?\
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M_H**(_OR_P"__044 1-<0VMLTT\T<4:LVYY&"J.3U)KE1X[#>(19III?33J
MTW[>LX)^T&,/C9C[N"!NW=>U=1):V][:/;W5O%/"S-NCE0,IY/4'BL#_ (03
M2QK+7\<]W$GG_:5LT=1 D^S9YJKMR&"XQS@$ XH ?KGB:ZT77-+LVTM9[34+
MA;5)TN0) [!B2(]N2J@<G(QFNGKE#X*C.NV6L'7-6-W:6ZVZEWB8,H.23E#@
MMCYBN,^U=70!&9H@2#(@(Z@L*/.B_P">J?\ ?0J2B@"/SHO^>J?]]"CSHO\
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M<]W#*/L@6.V1(MR,)?XGW\;>>/2O4?.7T?\ []M_A52.SL8TN(X[556Y=GG
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MNVCE-M;+/*5$3M\JMP3E1^&:U_#.@V?A?21I]I)=2Q^8TA:8$G+=<  !1[
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>rvph20211231_10kimg019.jpg
<TEXT>
begin 644 rvph20211231_10kimg019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "R 20# 2(  A$! Q$!_\0
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M(?*(0JN,C=T)Y' KFX/!%_:ZW]JAU2#[-;W5S?6436YW+/,I4AVW89%W,0
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MG^S:%UH_O.QTOQ"VKS31V]H T0!;<^.OX>U:@DO>]O$!_P!=3_A7)>!_^/\
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MA[_D: #:OH/RHVKZ#\J-P]_R-&X>_P"1H -J^@_*C:OH/RHW#W_(T;A[_D:
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MS-=MCW-?>9/_ +E#YGS.8_[S(;']^7_?_H**(_OR_P"__045ZAQ!']^7_?\
MZ"I*CC^_+_O_ -!534]-74X$B:ZN[<*X;=:S&)CCL2.H]J *%CXLT?4=9?2K
M:Y=KI2X4F)PDA0X<(Y&UBI.#@G%2'Q+IJZ^FBR-/'=R[A$9+=UCE*C<P5R-K
M$ Y.#7,:?X,UG3+Z*6*[L7BTYKV73PZON9YV+?O?]E<D?+UZ\5=F\*ZC<^/+
M+7GEL[>.U#9:%I&DG4IMV,K':HSSD<G ]Z .THHI-H/4"@#S;XU$#PE9\_\
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M<(\F0W+ C"DYX'H*?YR^C_\ ?MO\* )**C\Y?1_^_;?X4><OH_\ W[;_  H
MDHJ/SE]'_P"_;?X4><OH_P#W[;_"@#Q:[\2>+Y]-\17B7M_]@MWOHFF:..-(
M2DP6$0L@#,V P;.:V[GXJ36>L:M:_8H+BUM()WAD1W4LT;*I#%ATRW) P,'K
M7H7V/3S:26OV&+[/,S/)%]G^1V8Y)88P23R<]348TK2%N9KH:7;"XG!667[*
M-T@(P0S;<D$ 9S0!P^J?$/6=,U"RL(],L=0N6A%Q<-9SDQLI?:%1FQ@@9))X
MS@=ZH6/C_4=&N[]+Q8K^U^W:B$1;AFN8_)5I "I& F%VCTR/6O1!HFA^5;Q?
MV/9^7;$M GV-=L1)R2HV_*<^E21:;I<%V]U#IMNERX8-,EJ [ G+ D#)R>3Z
MT 8?A+Q1=ZW?7EG>Q67FPP0W*RV,QEC*R;L*20,.-O/J"#6WX@U>+0?#U_JL
MWW;6!I O]X@<#ZDX'XU+9V6GZ;$T=A916B,=S+!;[ 3ZD*!DU)<I;7</E7$
MEC)!*20EE)!R.".Q /X4 >8:'X^UM-(DLYV2_P!9&I6]NKW<+6RF.<95BH4'
M"L&7..=M=+X;UZXFEO[6>VO99#J=Q 9U)EAAVXZLQ!5<]%[5TLEG8370N9;*
M&2<;<2M;[G&TDKR1G@DD>A)J6*.UA21([=469V>0+ 0'8]2W')/<GK0!YTFM
M^(+[PQJ L]=@DOK36G@,YD@A+VZ\[5+*R GL2#TZU$OQ(U4:7!<V%C%=0Q:=
M!=S/?2[)7+S-$0/+7:>5R&  QVYKNE\.^'HX)($T+3UAD(9XA8H%8CH2-N"1
MDX^M6GL=.=2'L(6!18SFVSE%.57IT!Y Z"@#SO5/B9K.GQ?8QIMC)JJ7EQ:E
M0\CQR-&$*A<+D%O, RV ,')YKU"'S?(C\X*)2HWA>@;'./;-<MXB\#:#XFEC
MEO(9XF7?N\A-OF;PH8ME3R0JC<,,,<&NEA$5O!'#&KA(U"J-C'  P.U 'B%E
MX[\4GPWJMW)JEQYR::+F(SV\(8N;GR]T(5<,@7*G<,[B.*]$\,:KKL=L;?6K
M34I'GN91:W,MNBM'  -IG"D*K9W=!T K?.E:0\:1-I=L8T0HB&T!54)#%0,<
M D X]1FK[21NI5E<J1@@QL01^5 'FL.M^(+_ ,,ZH+378)+^TUN2W$Y>"$M;
MJ?NJ65E!(S@D$\'FH/\ A96J1:5;W-C8QW4,>FPWLSWTNV5]\[0E1Y:[3R 0
MP &.U=VOASP]';R6Z:#IZPRD&2-;% KD9P2-N#C)QGUJW)8:;("KZ? P,:PD
M&VSE%.57I]T'D#H#0!YWJGQ+UG3XC:?V98MJL=Y<6I59)&CD:-4*A,+N!;S
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(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>rvph20211231_10kimg020.jpg
<TEXT>
begin 644 rvph20211231_10kimg020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "T 28# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WH;RS %0
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M_P"^#_C1B7^^G_?!_P :,O\ W!^=&7_N#\Z #$O]]/\ O@_XT8E_OI_WP?\
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M/SHW+ZC\Z %HI-R^H_.C<OJ/SH 6BDW+ZC\Z-R^H_.@!:*3<OJ/SHW+ZC\Z
M&C_7-_NC^9HH'^N;_='\S10 )]Y_][^@I],3[S_[W]!65J?B31M&O+>TU+48
M;:>X(\M')Y!. 3Z#/&3@9H P[;P&;*^>XM=9N8UB-P]A'Y*,+22<Y=QD?/R3
M@-P,GK5B+PI>)XQ;7WUJ24F-8A#);(=D8'*JW\.YOF) R3[ 5MZGK.FZ.(#J
M%Y%;^?(L40<\NY.  .IY(J&#Q)I-UK,VDP7>^^A)62-8WPI !(+8VYP1WH U
MZ;M4_P (_*G44 >4?&X!=.T7  _TE^@_V:\_T_[JUZ#\;O\ D':+_P!?+_\
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ML7^Z/RHV+_='Y4ZB@!NQ?[H_*C8O]T?E3J* &#_7-_NC^9HH'^N;_='\S10
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M_?1I]% #/+'JW_?1H\L>K?\ ?1I]% #/+'JW_?1H\L>K?]]&GT4 ,\L>K?\
M?1H\L>K?]]&GT4 ,\L>K?]]&CRQZM_WT:?10 SRQZM_WT:/+'JW_ 'T:?10
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MP5+<=#45C]P5+<=#7QDMSWU\1U_@IE'A_D@?OGZGWKHMZY^\/SKG?!(!\/\
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M7TH ZS1_$&DZ_'*^E7T5TL+!7V$Y7(R,@\X(Y!Z&M&>>*VMY;B9PD42EW8]
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>rvph20211231_10kimg021.jpg
<TEXT>
begin 644 rvph20211231_10kimg021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. 2@# 2(  A$! Q$!_\0
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MUMKX'U2ZT:^G@#VMQ=+:"&&>?+K BQF2%N"H9F4Y."#WXH ]3JN+J!KQK02
MSJ@D*8.0I) /YJ?RKSG_ (0C65DL]C.R)I[VTQFNU9U!#X6-@@VME@,_=*@
MC@5$O@?Q$+:W\[['(D=O;Q2V:2F..=4FE<HV!@95UR0,$@\8H ]3K.76=/;4
M9-/%RIND=4:(9R&*E@/^^037 6W@'6DFL+B>\5Y[1+41D7#XCV7#O(H]?W;!
M 3U JWKG@W5[_7-3O;.:)([ER4_>%6_X]'B&<?[; _3F@#T6BO*KWX?:R+#[
M+:7/^B?:(YGMQ<',A\@(S;F##(DR_(]^"!7I6GP26NG6UO*[/)%$J,SMEF(
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MT)QDDUK:]_R!KCZK_P"A"@#3'2BD'04M !1110 4444 %%%% !1110 4444
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M;2Q*CX5W((D&.HP>GUJW0!1M]*L[:[EO(X%-W,JI+,1EG"] 35ZBB@ HHHH
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ME@% ))QUP #[^E>Q:=X";3K#3+R[M!#!=#?J$F#PJC*,6?)0'(RI'4'(P,4
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M0*W_ ! ]RNF2+' CQ'9N=I,%?F';!S^= &R.@I:!THH **** "B@G%)D#K0
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M\-O=G&9XE<A6)4 'CC(ZXS734 5OL%I_SZP?]^U_PH^P6G_/K!_W[7_"K-%
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/A5R>IP*MT4 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>rvph20211231_10kimg022.jpg
<TEXT>
begin 644 rvph20211231_10kimg022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 18# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $)_X_%_ZYG^8J:H3_P ?B_\ 7,_S%34 %%%% !1110 4
M444 %%%% !1110 4457NK:*\MI+:=2T,JE7 8J2#UY!!'X4 -U#4;/2K*2\O
M[F.VMHAEY96VJOXTZSO+;4+6*ZM)XY[>5=T<L; JP]017&:O\)?"NJZ9)9BW
MN;9GP5E2ZE<J0<@X9BI_$4[3/A3X4TW3H+/[)<3&)-ID>[E4L>I)"L .3V%
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M IZ$\SM:^A:HHHH$<%I5OXCM_$DSZCIUQ=6<TLA,DMTCI&WFL8WC0G*@1X!
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M;:7'D7%_;13 $E'E4$ #))!/ P,T7&DWL6I)XHBOF2*F]@J[B!DGH!ZFO/\
MQM=W&HZL=%M;F6[<Q973;$X<N<X:>3I'&.#CJ:J?8=2\;>(GU*PO9HM*C;%O
MJ$D>W:.A^SH>K'_GJW_ 17>Z+H.GZ!9?9M/@$:L=TCL2SRMW9V/+,?4U-KJS
M-5)4FG!W=ON9YO\ #OX37&C37%WXI,%Y*'7[/"DC/&N.=S @ G/3(.*]:P%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>rvph20211231_10kimg023.gif
<TEXT>
begin 644 rvph20211231_10kimg023.gif
M1TE&.#EARP(B ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M#]RI($$IE,>7!J%P  $ !T$I!C_P SB  *# IFD@L#C0L  KLDC)IIE+IV_
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M:8#W,N!+YD,CIU"N?2:\RNF0DYH,=6Y$)O_Z$,+\Y*$[E6]!*>H8L(0'N^&
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MH#S ZT'O8CR'6"]B2#R,X$$87($5_#K&$,9@NS;"BP%H&$#O>L!@2KQ,J <
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M;(/0J1I!(%2&%2! =<107XK9.UI!;6/6]'K5$NS&;QQ, LPE>P0 #>S'F,7
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M,;]7^?4%!I\.D@:,!^O1E>0''=KN?#*9;)V/I0*2(<7:#X0" AS #[#OS>;
MS3KO]((",6@OTJ+O :2!^V[J ?!T)H1"&M2L(K>O TPR#G#J,G0$SRH?*2OH
MF,RJL(FM2#PDDWB4Q U$IE74#9=>>K"><XS&6>O-+Q=<34"<$L*U)A"#V! 9
MF[F'0$BA" UQ"LN$%,(S2CWD.$X,U.UFL52%)JA 0I@+?!P9RPQ# ,@))L1
MQFU$'KN6,A!T1>2QM1S_1!@(R96)BE& %&#?DTRHC6L!J*4I X*H1X;4'DJL
M *6=3PL=@'CD7MTR3 !6X8N)IJ.,=(^XF)(H*<+&V^[(2^U48H>AX.]TQS!(
M5DM-@B:@37<U\6BXQYA.HM55(/RP12JKLMG:5QVUSEF@VE^ZFLP>0%PJPP.
M+X1$=:<6-2AK<O@VM?3NK";X@/,> %-',@XD-?@2@^^9K_LVP(*F=U/=XT.H
M:6*$MV*L,J]&R(85<T6EP4YH%WUN3C.1RTZD1TE,PM"IR,:Y!D=( AOM6LE^
M=MAH!838B6E0FG](DR3L!-J8^)")R'6!PL'0V#*<]&3T;;*!7CXAAZV8"G']
M_[ !\(K97!EHF)="W!#@/D1Y29-4W! YU4JK"(2$1$00$>BHT(63#P<' 0 ,
M'$ L+TLS;5<YT3)PE C:JNZ*WE+K80R+R)68DIO-T"Z4V*!W/LF,^0]KWD?P
M%#KLX,Z<0$:AL]5AGUV,0+$>BE+*X5?/&E+."5).2R\H"/+0@B\<?+)1VY0F
M(X!1?V_WY@#YVNP;*(/-@H(:O('-AJ_U5*_-VJS3^IZK#>;N.8;^MD^DBRUX
MNE@:: X7SO6:AP:FT4.QB &=<837%H<,]8ULL%EWG02B>L@24Y.*P%,,+(,2
M5G=%<2&3,9E&M=1_3-T \MF6H*1@B!2(>!P.#$,:6/]3?GR&:_5CQDD$:!#H
M?BZ1Y7&$02S#=EP$5][0O+-'E\4 0PC$Y)B&A@R%.-&G>+2&/O20:6S?1FC%
M&S [.:700CQ,)XKFQ/Z,).YF7OGA_R7@C1#EL2Z-2 ]B&N>ATOQF*@&0V_IK
MW>7,J#E/^W"@3>W7JJ6O)1LMT6</TUH/J2JM(&6/SEHRTEJR)2,]T5>/)8MJ
MI4.2RQ$F*I=WEX#TM39=F=!+M=,$,:2!1%RW<8 "2-U&X%)%?_@-4&B$)*B'
M/L@A4'A955C:IE17,^E#R59["P4A>1!#;3L[DHGF?>SZ9'!NP[#88<DV1&#<
MEG\-RWS* <  >4$\H&Z0/O'_.$,83JLDB)6KZ^6,Q+,8P J41@P$0*NDMHI<
MBZA8&H.@_@%\2$W0)^C48=\X/'!L!'708LV3'7'^ZBXJ%XU!\?\X>+#92"G&
M4HV::0.Y9-55A(?!/.V4?.-;A+@^!X0_N#,O_KF0JE.MW#S2&CRB(W]ITJN5
MOSHZP!M\:AMN=?<?QJ]C&-+Y3+3V?MG+1(U7-T!D@B9&T[!)RG#0B[9/68Q,
MQ)0-PZ%,3 QZ,<8,$P--DQAEF3)UW#=RGYA,^^A-+)E)61IE88AE,D!L$II,
M./9E$K,/S22='V/N[(D&3;U]T%#NTV>4'DFG3Z%&E>HT6KUH^A9:'?E1&3&C
M$$=F_SJX;UG2G"%'@H4V["M+9<JTGB6VE1C2LO3<*B,)4B]#OG,_0@,+MFM:
MD/H8]O6:D]C"M]'F,IR+=>F^JV6S6M;:E.S(>H@Q&XVF4%]HT):77AV=>6IK
MRR/IZ;WK>>3J?59+8^U\V[/NVU>-_N9=-C5#I?7L:K:L\#96K:/AOI4>/7J]
MZM>C0[-.?7IWZ?4T>1<_GGSYM_0TL<2!X($#!P\0N'<0?_[[^O7;PW>?P'[\
M^/G9FZ\]]P8<D#[WZ/-//@/A0P"':,R+<#S()*S0PNF(T<>[96)39ID++?S0
MP\=BJJNOJD;"+">;$!-##$E.8DB2-(;)*3AE)DE#DC>Z0O\CIH\R\3&LFJRK
M<1G$P(HF$Z.408.1DXBQ"2(<8]J'&$TD6_&@PMXB)@W$M"I+N[Y<*[.USS[C
MC;2X:D.,+#='*BZXI^9$ZJGBXG2*LX5(2M/,J<BD[2BC[%2J+*6V(JDLY,S2
M2Z&FEK*S*>T6@I11SM($#;&F< N.44#_-*ZX(T=S"LS>4%*-.2:/<^PXI-RL
MRLU#TR0MSL]D34I$O> :TU=EH.D5V+>T"]:ZT: YDL-2E56HGB/?^NRN:5.M
MQUEGD3,J6^.VU?9-HY89)I-EUGLO00?XDT]!^ 9,-P$<ZN,O0'07E$]>_>9]
M0(;V IQ77OO<PT'9>JRSBIYE#R[_S=G2JFT8S;<8 K>T;'NU[C;MN,U8+X*U
MR[;8;:,M:U&&FE68+&=E0_GDJE)F>65Z'E482(N/3'6IRIPRJ4^H<@L53JKP
MY.SG4!&%BD_/D+(T4:*9)JDJ5WM#$]&:@RNNYT1MI37%U*KN3-E!*TNSK(U[
M#@YCT4C[VBG<+H8-Q:2L,MLHY[;N#$P^]7J[J:=Y>W.AL5-$3;B:#XUJSC)E
M.^[NKO@:-+E2YT:NKYKW]A3"R8@SCN_MGL-ULZ9!!S7TT2'>)X?[^!L0/P+O
M2_ '3>#0!-XW8$?@7 4/S%T_ 1'DMT#_X/MA=,2'+[[TXI%/+%$Y7X/<L1-]
MH]2SHYOC_]-RMK_>>]2ZER.)5Z6N&O1O39.R=?"CC$N^->TVS:I8S2Y3U+E*
M^SXR.!3URJU4P1-'[%3-D/*TRL3/.!A#"L;Z%B=E8:4IM.*3_M#'L$3A"E.G
M85]PT@:V F+P.,N+VZ:6)I5"$2\I?QO))&X@EBU@24]4\<P-(K.^&.X&55;"
M@9M6A2AE4$]]H9IA#T-5KOO$RUZK:X^\X "' QS  6K0A ,T\08'Q0<'\*IB
M?7)PQ73MIX@ 6Y=\< )$/15.C&8*5!E#MS'Z71 U<X(<;1P%G$AUZX",J@QG
MUG8K!FX-;:P9F9^ZYS3/B"DI83LC&OG6-MZD*7)VJM5"+H.8JO^P+W""LE_?
MG"5 JC7G-SC#U*!X<[/5+$QKKRI?9KQUL:H=BI#$$8W?(J<HI^3M.9PY5'$V
M=J8_6<Q5D"K)),*RDR9-8B%B<8F5;)*0:-1$+R#Q428D09U)S$@O-8F,6-"P
M$ZHQ4%:'0V-K=OC-,D7C=/0R9^_H@R\P(@ 44<Q! S3Q@P.\ 0[QR8$R8@<[
M4*0!!U$,!2C*]2]S*FB+P'.0. \I3JC 1:%I5*!R]E>/3TC-,3V)47!4M"=.
M!2Y,RPD/2Q@2'MI@C'[5\^5'1J()2;!PF RI4=+.][Z&0HIJJID?PV05&CEB
M%$XUFR-23I3!0O)4-8PBE%;T@D!:LB;_56YCF /?Y#CC] 6G-M/631D)/MQ0
MSC:6(BE- PD<T9E1:I7LR4AZ0A&*3.(BT/0(#"M"#XMZ) 8FB8%/Q" 1#6D"
M!D%YR4<\$H88>$\Y*1IA0Q>*1\1"18A;Y,\66V>N^B2QGSD !1H0D 90V#,:
M58R& ]( .TT<( W+&.) S:6Z=(*1ASW\T&*EDE#83F59'&Q?26" F:80PR2\
M1<-([ 2G_3U0CXB*$CT L)-]P%"12.L,23M3$8:8)*\ET<19A70H.3X4L6]S
M)6\BRC WN0FI'<Q?W(X6N?\Q2K=BS:H$/]FV1^:F<#ELWWCC)JA6E6]ZH#2+
MF#[(R;CL;3>Y__I<]SYE/-20JC)IN$$V-U(/EMQ #-$(PY'$<%9HQ( 88:2N
M7FZPC('H!*W 3"%%LHFECD@P*>RKV6R?(EO8EO-<J#-GNF['1#C0[@>9M8,]
M00%:3606% !%@ ]" 2_VG&MWP*M/?/@31C3*&+''@[%KJ&H;%4D"!SL98!AB
M])%Z9!,B+CK)6"01)1?-)7YE$4-CPN"1Y<X%J,08!B@B@S.S9**N*\E)&DA,
MD7V(!#%J[ Q#%?HHL&ER<K[AG(?<-#E09NY119VD!C^#:/;"\J:D6E5R;D7
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MAJ^!*RX:"3VIM%243KYHPZ"%8ZG>J[R(+BY$:=-AI=/?<5"?:S_I9H.&RCE
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M@/&*-['IS2\ VD2,&.27&'P[)TYND-\8."2]DN!.G?)[@X7<( 8!NQ]/7@E
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M"([<,_8@2Z!V6]<%';*K\E?"*OGTRH]O>J<?[/[MM'AQ;J:P#;OA(_(@*[*
MR]!=.]P5"YXO$)[%9*J'$,4\$+E8T(V^+DI)_\<1F<HTQ0B-,J^AK2-)5M38
M/*"GWWN^)VS^$*@Y.IWH];2#VANY\E[DJ!C+ M<6TJH&H];;[9:,O2CJ\BB$
MZ?F3IBICR=E8T5TNO17I<B=KZ]):ZGO3/WTT3E_+\:RG@%P'\CIB_5E1BZ_H
MX/F'NEQ<SI_LXIR2#A&AG395-]VY2J7]T2ZONR RO(\2'1V("Q: !FC4CW[I
M;TJ@7:'.ZWKU!4<T]* 3+*RJFQ"YS(I:B4OI0%<#7<=. \=X!^!' F7YH/KO
M2OH"(5H0^U^)_;YUGW[]W_^:S%Z 6+9O7SU]T0CNBU8/X3YH^P1&HS=PX$)]
MR_3MD\@06L&)^PQJ!+9Y\.% CB,M#L38,1I&>@<O1HPXL1Y+@0)5SIPH<>$^
M910Q^JRIKQ[/C@L5'O0YM.'"BD4/2C3I<JC*EQZO4L2J=2O7KEZ_@@TK=BS9
MLF;/HDVK=BW;MF[?PHTK=RY9C$Q3PEPXM:!0IP9[9@IZE*9%E N5!29Y=.?'
M99GH92(V4*+/?9-\0APF^>!2@BQI$D,C^2/?>@XY.HPV3%/"P@\-%EUZ$'5"
MTQE)US[(%R5MB0H_4GS9LO]QU\ITCR-/KGPY\^;.GT./+EUM48Y9'0X<R=-S
MSAB94J;<CE'T/C&2,;+T#%M?#&63OB?,BH:U71QB&/:\.S &#/CQMP]$S'V9
M2'*51A.EEI]&3>&$%%49Z?995K^A)!!'&$%$TVW3<=CA6+"!E]55VP'HH8DG
MHGA6B5S9E5V*+W9%6W[6*>,3,3Y!H\PRR@!%C$/UW"#9CLIH6*--,6 2'Y$U
M$O3C0,JTE]^22EU$$(]BH/&1,J,1]-<P4>YSHV_T;#G0)#?09%H]1B9$9HUZ
M!3?C:S)A6!MI/PH%X5(/OG;;4-AM91R,@\XEWD&_M=9D1\ !=]&B#1$:J:3*
M\03_:$H*_1450C+FI]Y((TTZ74$",02E&   ()D8,0#@'JI1!@DEJEG*J@)B
M  20R1;*I'&#"@"D,=./."B#QF4QG&J JM_A $ ,,61Y*@ W*,.2;C?@6NRK
MRD CK1C0L"K&)&A R>H-$J7QZGTD74C2@KD]B%*7\Y)JH88W:8@4?EBM&*J_
MR'V*E78>M?BOP0>'53"_\2$L*4PZ61NF 9(L@T8,^]PP8*K=HDEM)I>M2H\8
MW[ZWCW= *K.J>S#,>=BY8@0& ,5BW& R,9*T1\P!EP&@B3YC2 8GE#6*@5@,
MDQ#3:K'U9'(Q&D4#$-@*F31]([*,:LC7G!+)EB93PF&Z_V%%CD+E9Y5;6=JP
MVE]I@H/;17L$:D*:5#G;&(*NG;?>'M4C!A=^$]/O0L1P64\C7$RR;V=[TS4J
MB(==/%"0,%NV;CWMF9?R#3&H$$V0'H7Q77O&]@3FHJ-?5O-',1 3!BB4[_-T
M><Z*89=+"47Y-+9IL'? T?MD4O.XEP\$LR19 G]?4G?^Q)"]&%GWX-BUG784
M:1&3RE6_C*_M4"8.:/)&#EE&\_ R$6GB@''$X*#^D]S#_^](RU31R"23[&HE
M18>).]'(DW!A& 0Y4/SD4ADX88<841I:&%B#"1P\J3V3^Q8#69,?UIE,&8QX
M0YC05!*:T",&RX"9 B.H#!P("/\^6&H(U:Y6&WTH8PNJ\4YY"N2821@ :35#
M@R24X4&8C0%YLM,(J4 (MG=12%\.(97TVL2=G0"E. 7D7OH&\@891 ,.-Y !
M'&+GMO;AP#=B\,$#;$0L%TTQC2FJ!Q>:8@7"^6T,]"#&W[C A17X8B"1*4\C
MRF-!-<;E86%3!@!P@+/[W. [ICID!C,V"5;5(PTQD,3(RD,M:JT02M#8XT1&
M1[%I2?(^[<D$ ,8% $9 Z3T9B\9C!K*,]FAB:J<2C7<R,35"$B,-18N!0W!P
M+#%( @#KDHF,N%:=_ R%0@+IR.T@HI&]M*9>@(0?>JR( +>!+W::^ $.HF&?
M:+0-%%G_688#+(2W::)3.LJP@AUCP(A]^ )I*R#<//O6"X:%B0N2X9+<TED6
MESSS-DD) QI6\*U]-&(TQ+C! 9!7-!]""VYB.$ 8#F++CR%&D?<95Y-&")G
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M[^C(_TL,1$,,R$P2VDX1)P$:T(S1 ''?E($,"VX#T:RPZH@28BTH9BEHE@P
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M+\D/Y$32[^I+/!BK*+J*2)XJ!@  !VY@,=%L,?4*U>H,SRBJ7VH"HC K!F!
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M5$*?6!A7("]7_\#D4#70UI;0'-F&(3!L46Z)8YA?8C@L8  6E[85WZEN]^$
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M$8QD8C!":F %4RB4"()E;IF(5]9 >+\B=J2''$R)X!@RFHO<L"!0_$0"10A
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)E$[YE"@9$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>rvph20211231_10kimg024.jpg
<TEXT>
begin 644 rvph20211231_10kimg024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B 2X# 2(  A$! Q$!_\0
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MY76&)V9EC0%=RL"P^96 QD8/% 'H-%%% !1110 4444 %%%% !1110 4444
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M7_QNMNB@#$_X1^Y_Z&+6!_P*'_XW2?\ "/W/_0QZS_WW#_\ &ZW** ,,:!=
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MKB*]$CY8#"['7//7E@/QK;H P_[2U\]- B'NU^O]%-+]O\0?] *V_P#!A_\
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M3JCFYMY!_LG^5 &-'XGT^5!-#!>O'( 5D2S<AQV(..13_P#A);3_ )]=0_\
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M?HG_ "![?Z'_ -"-:%91^%'G9A_O=3_$SJOA+_R-NO\ _7"'^M>OUY!\)?\
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M *]4_P#0J]SU3_D%W?\ UQ?_ -!->&?L^_\ (?UC_KU3_P!"KW/5/^07=_\
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M'_D;[?\ W'_]!KU?5O\ D#WO_7!__037E'@'_D;[?_<?_P!!KU?5O^0/>_\
M7!__ $$U4?A/4RSX/F?.6B?\@>W^A_\ 0C6A6?HG_('M_H?_ $(UH5E'X4>=
MF'^]U/\ $SJOA+_R-NO_ /7"'^M>OUY!\)?^1MU__KA#_6O7ZTI;'T4_AA_A
MC^2%HHHK0S,)/%>D23P11SRO)//);H$@=B70@-G X +#D\<UH:K_ ,@N?Z#^
M8K!?P3!*&6?4;N5&O3>L"D8.XLK85@NY1E1T(/O6UK,*2Z;(74,5P5SV.10!
ME^,?$%SX=T^WN+6*.1I9MA$F< ;2>WTKAKCXB:G<M SVML/)D$B[=PR0",'G
MIS72?%'_ ) EE_U\_P#LK5Y92&CT#3/B)J=]JMG:O;6JI/.D;%0V0&8 XY]Z
M]-[5X'H'_(QZ9_U]Q?\ H0KWSM3!GRU\8_\ DINH_P"Y%_Z *X.N\^,?_)3=
M1_W(O_0!7!U[M'^&O1'GU/B9[%^S[_R']8_Z]4_]"KW/5/\ D%W?_7%__037
MAG[/O_(?UC_KU3_T*O<]3_Y!=W_UQ?\ ]!->5C/XK.S#;(^.J***\ _1EL?3
M'PC_ .2<Z=_O2_\ H;5#\6?^16A_Z^E_DU3?"/\ Y)SIW^]+_P"AM4/Q9_Y%
M:'_KZ7^35[N7_P 6G\C\[SG_ )>^K_,\7JQ9?\A"V_ZZI_Z$*KU8LO\ D(6W
M_75/_0A7UL]F?%P^)'T\/NU\U>*/^1]\0_\ 7T?Y5]*C[M?-7BC_ )'WQ!_U
M]'^5?+X#_>H?UT/K\7_N57T7YHSN]:W@W_DHV@?]=7_] -9/>M;P;_R4;0/^
MNK_^@&O9S3_=GZK\SQLB_P!\7I+\F?1Y^Z?I7 '[Q^M=^?NGZ5P!^\?K7Y9Q
M3_R[^?Z'VF6_:^0G:NJ\._\ (./^^:Y7M75>'?\ D''_ 'S7G\-_[Y\F;9A_
M"^9R7Q2_U_AG_L)#_P!!-//6F?%+_7^&?^PD/_033SUK?B?_ 'B/H:X+_=X_
M/\S,\1?\BWJ?_7K)_P"@FNT\$?\ (CZ+_P!>D?\ Z#7%^(O^1<U/_KUD_P#0
M37:^"/\ D2-&_P"O1/Y5V\,?PY^ICF/\&/K^AQ?Q-_Y#MI_U[_\ LQKB:[;X
MF_\ (=M/^O?_ -F-<37TTMSX3%_QV=-X!_Y&^W_W'_\ 0:]7U;_D#WO_ %P?
M_P!!->4> ?\ D;[?_<?_ -!KU?5O^0/>_P#7!_\ T$U4?A/4RSX/F?.6B?\
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M_K_#/_82'_H)IYZUOQ/_ +Q'T-<%_N\?G^9F>(O^1<U/_KUD_P#037:^"/\
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M^TRW[7R$[5U7AW_D''_?-<KVKJO#O_(./^^:\_AO_?/DS;,/X7S.2^*7^O\
M#/\ V$A_Z":>>M,^*7^O\,_]A(?^@FGGK6_$_P#O$?0UP7^[Q^?YF9XB_P"1
M<U/_ *]9/_037:^"/^1(T;_KT3^5<5XB_P"1;U/_ *]9/_037:^"/^1(T;_K
MT3^5=O#'\.?J8YC_  8^OZ'%_$W_ )#MI_U[_P#LQKB:[;XF_P#(=M/^O?\
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MY'3OC!ZC('3(SUK1K'T;P_:Z(;IH)9YGN) [/.X9@ H4*#@< *!SDG')-;%
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MA=7$T\HG,DVPL1<R+@J<J0 WRD>HQU- &?;>)],N=DAMGCMRKI'.4!!92H9
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>rvph20211231_10kimg025.jpg
<TEXT>
begin 644 rvph20211231_10kimg025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O 44# 2(  A$! Q$!_\0
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M5"]M#]DMXS+Y$T+'&#C=ZC]*WH6+6Z"0 .PP1V)INRV'L<U!-]JB3 7$AVD
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ML*K^'X"@NI2VY7<*OX#G]:HZQ>1W=WL!;; 2!Z,W_P!:G:['NS0TGY!=.2"
M!^@-0&=[R16N8Q%&8BZ,K9R<XZ_3M4-I.(H+A$?=),,(H[G.#5RRCCOK%K.9
M2&CY'MG.,4/3436MR"W9]+595)G$I8%1QP.1CWK16"'5+?-S HDQC&>@/(JH
MNFQ;)%DDDD>%P5<G&3CIBI3>O:W\*,BM&R*DC@X"FAZ[">K)=*>2_P!/D2[^
M8ARA&,8 K0MX$MH$ACSM48&>IJKIS)NN A##S"P(Z'-:%2Q2*.IMBU4%RJLZ
MAR.ZYY'Y5!'I>F0 95&;^\SY-2:U!YU@S D&,[^.X[BLS36M+F.XPBF1-JN6
M_B3IUIK8%M<?,B1->)L"QR%(E<'J,\Y/UK4:VB,<;P*K/$V4.?;'7Z5(;2#[
M(;;8#&5QM/-9UOJ,%M \,2AI5DV;2W!/KFC=:!N/E@)NXY;M/-65/+&1PF>H
M_'BNU\'B.(W4"#"HJ8'H/F_PKARMYJ,HCD81B&7+%3C/<<5UG@6=Y;O54E&)
M(C&A'MAL'/O45/A L>,V@\^Q68J"2WE@GJW%<)KMQ- WR?*C+C<#S[G\*['Q
MP$;5M*1DW?*Y7_9.1S7$:JK64T:3>9/9[22>K1#&.O<?K40=DKFM.-]MR<K*
MUJ/+E#2#;O Y*C;P?S'ZU/9R/.K$P$!2=QWY(]L4RW2"= Z!-VX%"C8W+MP,
M_A4DD#VULZ12^7*W.0.GO6MPM;<MZ;;NMCLN0IRY9%Q]T9XJM!92AKQ0"NY_
MW;'N"<G_ #[U-!=K::>7N'9G5@'+=231>7OE3VZ+@-,#@D9VTM;DZW"YEFBM
M&,ULLVT9*CZ52E@<:>B:?\CJWFL ^"IQPOTYK4^T,R[ !YC$A<]#6;;)%:WK
MQSL5NKI^0,D$#T]J:!&IY*W-BJ7*JX9 '!Z'CFN?UI;K2K2,PN7M(W#JV>8^
M1P3W'O6A<7DTS7,,*E552J.1]XX';\:@M+&'5%?^TX!))#\F"YVXZ],X[UG.
M+:NMS6C-1?O;$GVB&11-(?,BG19$ Y52!QS4:?9Y[^" H8XT!>-2<!FZGBK-
MVMM:VD=O&BQQ,ZKM4<;<]*DU&V2-H;M4/[D%3M'12,5I%Z*Y#<;Z%34&D:W5
M(7>-W&Q6!Z$= :C5I]+86X=E9RKENVX\D?2MI;6(S1SMP50*%)XSZX]:QM6M
MIYM:!$#%&555EY!_P]*:?046GH=#!.EQ$)(V#(>XJC>:=)<NH$A5"^\D'ICH
M:329!'YEB0%>'D+_ +)IFK:D]DRF)%<YVL">_I4J]]";.]D&K!':*W5]MPV2
MGRYW#'(-4(KIA?>2)2J>045L<[^G\Q3VNY&OH9Q;AF?HIY*C')]O2M*W6&:(
MW<UNJ2+D, <X(SS^M5LA[+4AT\17D,J,2PQL=&Y(YXKJ?!-N;07,.YF51\NX
M]!DX%<CITZ133N(/)@8;MQ_B/K79>#[B.XEN60\[%R.XY-1/9DRN=91117.2
M>>?$EFCEM&7/[V-H0,]2S+_2N->"X2]M;9T255'!ZDKQP?<5Z%XYMENC:1L<
M$ LIQT((YKD--LTMEEDF??(';,C'Z5T4W[I2=D0:S/9O(EE/E9-OF(Y'RJ16
M.B20EI]ZJ5<%3C@]>GUJUJRPOJTKRDD)&O.>%I]II]W<HK%HQ$5SUYSVP.U:
MK1%*R1/#JMWN#2A,$ [-O3\:HWMZQF=SS*Q 4 <#T'UJVN@SSD>=.8E7&T*<
MD_6DN+.WL2EQ<[FCA885>6.>AI:7'>)H[HX=,C6*0 %1@J?O>OZUAM&C(_G\
M!CRW]W/:IGNFEB/[H1QQ9V(H_A[52DN)&MU^95WG!VGO0DP2L+9E("ERJ%PD
MK';Z<UN+ 1/#?P*S1LVYXUY(R.?R-8L$;PX0RCS P=MW;..HKI!>VULJC<JQ
ML-R[1P!1(4M#.2Z6=[M"ZAF=2B$\YW'G\L5KV]JJVZB50S[B[$\_,2355K>"
MW22^@0R,["1B!DE?0>E,:]>R5KNX=FCEBWK'W5AV%+?8DD5A;ZTL<11(Y%^=
M??L:UJY.ROA=:O'<NH7<P#%EX(P<$?C768XI25A2(YXA-#)&>C+BLK3]*EL[
M>1'6)BSC  XVYSS6M/(L,+R,<*HR363IUS*;D?/)+#,69689V^WTH5[ KV%U
M6:^:TD:V5H@HVG(Y;/I4.GZ:AM8I+M?WKL'8 XY'3-6=6DN=HBBC)C;!9P,@
M8/(-4%F-[F**Z4(5&W!^Z0<Y_I5+8:V-19Q%J<T990C('SZ$<'/Z5UG@V<32
MWVQ?W:E &]3S7%3%)9([:%7<LX\V=1D<')4FNM\!PK$^IF+<(S(H52> 1NSC
M\:SJ+W1%OQ8BF>U8CY@&P?RKF9DC9<NN[;72^,F=5A9/OA'*_7BN%M)I46=K
MX%01N(/3 [U,%[I45H4KA7^S2>3:2+;S,P>(8RO/WE/;ITJ6VOY;K39+N/:4
M *,0?X@/\?YU)<6Z:AMC3;-&VW86;Y<'J0![5H3V$%IHDUM BK&$/ &,GUH4
M6I76QT2J1<+/>Y4A@218X[GYC=.),J> 544XS1W-C;I)#)EGPO&#@-UI+ K:
MP1I+-&RDD1-WY7D?I4D[%/+3EU5]I91]T%>OMZUIU,>HD<XE\Q%E1)8Y#LY)
M4''3WJ*6"8:W:SR_,=A9F"<>FWVJ&ZL)8-JK(6^7Y"O5G)R2:M7\R1-;O/(\
M99,=< \=3_GO3] 6YH?)%<-E00<'IT)XS^M5[94AEOIB!AG)+ ]<#I^%0&)Y
MGDN]QD5D01KG  ]_QI]TIM8I'SE&.XXZ<GYC^M(1!>O#-91N%D,F0$"\\L>*
MW-BM$4<;E*X(/<5G0V?E,L _>Y<2DL<!0..*HZK<W@OI!;22*(4S@#Y3ZTK7
MT"U]"4/(-4DMF?\ =0[=BGN"1S_2M_BL*QLI))4N+DEY258D\=#W'M5MKLK?
M)&<F21CC:.%4'O0T*2[%=(PGB)CN.&&<'C''&/4=:FU*!(\W/E;CN!;;U/IU
MJ58HWU/>/+9E'..2/QJ#7+TV\(A5-[2#\A36K0U=M#;Z9+-5N5PRR, H49YQ
M4<&HM<@':/+F!1USC:<9S[\4VTF/E1PS&-XY'VHRCA<#(/\ .K%W$DLN$5=M
MOAV8-@AO?\*--@\BQY"7EE&""H7(P1C(Z5M>!X5M[N[A"LQ$:DNWU/%8MTS&
M*)@Y2-<.67OCM]*Z#P@$?4+Z4%MV%4@GC&<U,_A9.MCL:***YR3DO%^?M-KZ
M;&_F*X74;N*"S9'7?OD<,H[@')S^E=SXO8?:K5<_-L8X]LBO-)(7NM2O$CD!
MD7>P!'W3Q_,"NBFM"D1SR">\D=U#1RHC'</NC;FIM-N;C3S/))^^60YVKUR.
MGZ53LY#.S?:3M20;(VQW/ %7+>-VMI92P81MM=0.E:O8NRM9CI?$\KDI;V3A
MNFYCT]ZB6XENECGN9"55<A6&.?4TP7$8R2 L;# ;^]4L\(BTG[3*XB&X(HQG
MOBE:P[10*/W4MP#E2V$&>68#FJK6J2QI<0J5C*Y4 C.\G@?SK<TEX9;6&!HB
M"J[]Q[DYJ"'1_(UI5+!K55\U5)^Z0>/UIWL3S.X2V::99-=3?O;I@%12,@,>
MGU^M&AJCVDDUU.CLYV!6(^49/\R:9J.K)=/)!% 9$B<#?GOZ@5AA7@O=R "0
MH'5<=<'.*23:U"SL=$HO[%X[>--\$C%$#OG;^-:$]E%]AC0IEHUPGU/&/UK,
MM8+@:E9W,SDQS;G"9Z.1Z5HWDJW%['8(Y63!=RO50!P?SI,E[F7JFGO&Q,7S
M%TV*@X&<UTR!A&@8Y8*,_6LB8S7.FPRQNQD!(#!><@D=*ETG49+EI+>8?O8P
M,G&,]J'=H'JBSJ<1FTZ:,=6&./K5.WG6PL#;HA,L*'Y?4Y_K4]Y-*;Z"V0 (
MPW,Q/7':H+\LD\<T2!^#O&>R\TA="&?4KA%C$T0MY'3:2QRNX],>M47L'BFB
MN0@4LV)&7Y=W?@>YK>NK:*_MU$B=0&4D<J:H_9YK_3V0S$21OA6QW'&:I,:9
M<TN!H+,!T5'8ERJ=!FNC\%1R1ZCJF2WE,(V4'H#\V:Y^:1X+'(&Z78%5?[S8
MK;\ ?:3-J+3X'$:C![C=FLZGPL1H>*V'VBU7N58_J*Y.\D2%@&3S#*=H0C(
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M,7R<_+G!RX&#Z'GI4>J>+FM4NH[:U1KB*)I8P\H*D+(J-NVYVGY@0.??!XH
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MX;=$DN,"5A_'@!1G\ !^%7** ,>#PUHUL@2'3XD56C( SP4.4[_PGD>E2?\
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;=AACMH4AA18XT4*J*,  =@*EHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>rvph20211231_10kimg026.jpg
<TEXT>
begin 644 rvph20211231_10kimg026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H 20# 2(  A$! Q$!_\0
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MBB@ HHHH P+WQ,+2ZFA71M7N%A.))8;8%![C<P+#W4'I6Q!,MQ;QS('"R*&
M=2K $9Y!Y!]C7EGQ8M;4ZC:SRW:6TCPI [O=1)\C2%3\C?.R_.Q8+U 'I7I>
MD0Q6VBV%O!/]HABMT1)L@^8H4 -D<<CF@"_1110!2E_Y"UM_UPE_]"2KO>J4
MO_(6MO\ KA+_ .A)5WO0Q+<****!A1110 4444 %%%% !1110 4444 %%%%
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M%-O7OTYKHO!B^3%JL2V%Q9Q-?R2PI+;F)2C8QM! ]#QVKJ:* "BBB@ HHHH
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M@O\ D7=(_P"OQO\ T UMA_XJ,ZOP,^?ZM:=_R%+3_KNG_H0JK5K3O^0I:?\
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M+M7Y0!P.U4?%W_(KWW^X/YBM</\ Q8^J.?%_[O/T?Y'C]%%%?9'YJ>O>#O\
MD5;'_=;_ -"-;O>L+P=_R*MC_NM_Z$:W>]?&XC^++U9^DX/_ ':GZ+\BI+J5
MG!=K:R3HL[% $/4EMVW\]K?E4":[ICJ[I>1E4"EB,\!G9!V[LK#\*Y:_\(7U
MYXZ_M@QV9@6>-E=X%9MJPN!SNS]YL=.P/:L:P^'NIQ:8\$UOI@DE>RW[;92-
MJ-ODS\W/S,1[@>]9'2>G6US#=PB:WD62,LRAEZ$J2I_(@BIZPO">E2:)X8L=
M/F2)9HTS*(E"KO8EFZ$]SU[UNT %9>EW=Y=2Z@MUY!6"Y,4?E*RD@*IRV2>?
MF[>E:E96C?Z_5O\ K^;_ - 2@#5HHHH I7>IV=C(D=S<)&S#<H;J1N5<_P#?
M3*/QJ-M:TY9)D-V@:!9&D']T)MWD_3<OYUROBCPG>ZYXFM;Q(;1[:)+="9H%
M9@!-O?!+ ]%7MSN(]:R7\!:JYUF0P:=YEY!<(F+=0299B>3N[(JG\<=J /2+
M6\M[P2&WE601OL8KV. <?D15FN=\(:))H.F7$$R6ZRRW<TQ%O$$7:6(7@$_P
M@?3..U=%0 4444 %%%% 'E_C"TN_^$VL@;JVN#*$>WCN8K0>3B0;AF1=Y7:"
M1M);/X5Z<RJZ%6 *D8((R"*\P\8W%I>^.K/3-1N-/FM% /V6Z@G=4?*XW*K!
M&=MQVD@X"UZ7;V\5M;16\*!(HE"(HZ  8 _*@"@/#FB)%#$ND6(CAD\V-1;K
MA'_O#C@\#GV%6;73;&QEGDL[."WDN&WS-%&JF1O5B!R>3U]35RB@"E+_ ,A:
MV_ZX2_\ H25@^*O%4_A^[MX8;:.42H6)=B,8..U;TO\ R%K;_KA+_P"A)7!?
M$K_D*6/_ %Q;^=#$MV5YO'UW->6MR;&$-;ERH#MAMRXK6TCQY=:CJ]K9/90H
MDS["RN21Q7G=:_A?_D:=-_Z[#^1H&>T&O'_V@O\ D7=(_P"OQO\ T U[!7C_
M .T%_P B[I'_ %^-_P"@&ML/_%1G5^!GS_5K3O\ D*6G_7=/_0A56K6G?\A2
MT_Z[I_Z$*]E['"MS[6'2F/(D8W.P4>I.*=VKS_XQ_P#(C'_KYC_K7STY<L7+
ML>QAJ/MJL:5[7=CL-0UBVT[3Y;MLS+$,LD+*6(]@2!^M6A=P8!,T8)'0L./U
MKY"S1FN/ZYY'TKX:5OXGX'V$"&&0<@]*QO%O_(KW_P#N#^8JSX?_ .1<TW_K
MUC_]!%5_%O\ R*]__N#^8KTL.[U8OS7YGQN.CRT:B[)GCU%%%?9GYH>N^#O^
M15LO]UO_ $(UN\8YK#\'?\BK8_[K?^A&F>-;F>S\&ZK<V\KQ3);L4D0X*GU!
M[5\;B=*L_5_F?I>7P<Z-**ZI?D;K%@IV@%L<#/6J6D7TVHZ;'=3P1PLY/R)(
M7  )'4JOIZ5XA'-JK1HQ\0:QEE!/^EGTI(O[1@C6*+7M65%Z 73 "NA9=B6K
MV.:6;X",N5S_  9[\,'I3NWX5Y]\+[R]NK75XKR]N+KR;D*C7$A=@"H.,FO0
M,Y&:X9)JZZJYZ3235G=-)_>KG*2ZW?I,ZK(N Q ^4>M5H-3N[<S-$Z@S2&1^
M <L0!G\@*KW'_'Q+_OG^=1]J_,ZF8XM3:51[]SZ".'I67NK[CJM$OIKV.5IF
MW%2 ,#':M:L'PS_J;C_>'\JW3TK[K**DJF#A.;NW?7YGBXJ*C6:BK(R)/%?A
M^*5HY-9L$=2596G4$$=0>:R[7Q;HPUJ_\SQ):/;A(S$C3Q[5)W;L$8)Z#J37
M#Z#IME<6=Q)/902N;R<%GC4D_O&[D5K'1=+_ .@=:?\ ?E?\*\NMQ'&E4E3<
M+V;1Z;RVDM')G=V?B#1]1N!;V6J6EQ,02$BF5B0.O -:E>6:396UG\1-%%M;
MQ1!H+C=Y: 9X'7%>IU[> Q?UJ@JMK7//QF'C0FHQ=TU?\Q:***[#D"BBB@ H
MHHH ***Y_0_%-IKUY/!!!<1;$\V)Y0NV:/<R;UP20-R,,'!Z''- &G+_ ,A>
MV_ZX2_\ H25P7Q*_Y"EC_P!<6_G7<SSPKJ]N&E12(9006 QRE<'\1YHY-2L2
MDB,!"V2K _Q4VGH)/5G&5K^%_P#D:=-_Z[#^1K'ROJ/SK6\,.J^)].8LH F&
M23TX-%F%T>U5X_\ M!?\B[I'_7XW_H!KUK[7;_\ />+_ +[%>1?'R1)_#^DB
M)ED(NV)"G./D/I6V'3]JB*K7*SP*K6G?\A2T_P"NZ?\ H0J#RI/^>;_]\FK&
MGQN-3M"4< 3IDE3_ 'A7L-Z'$MS[5KS[XQ_\B*?^OF/^M=W]KM_^>\7_ 'V*
MX'XOS13>""L<B.WVF/A6!/>OG*R?LV>[ES7UJGZH^?J*=L?^XWY4;'_N-^5>
M3ROL?HKJ0MN?6/A__D7--_Z]8_\ T$56\6_\BO?_ .X/YBI-!N8%\/::K31@
MBUBR"XX^456\57,+^&+X+-&28Q@!@>XKWL.G[2'JC\IQ]O95/1GDE%)O7^\/
MSHWK_>'YU]CS1/S3DEV/7_!W_(JV7^ZW_H1J#Q]_R(FL?]>S4[PC<PKX6LE:
M:,,%;(+ ?Q&H/'EQ"_@;6%2:-F-LV K DU\=B;^TGZL_3,LTA1O_ '3RN'_4
M1_[H_E3JJQ7EJ($!N(P0HS\X]*?]LM?^>\7_ 'V*^LIU8<BU7WGY]6PM?VLO
M<>[Z'>?"G[FO?]?B_P#H KT8]*\U^%=Q"(M<8S(%:[!4E@,C8.E>A_:[?'^O
MB_[[%?(U=9R:[O\ ,_1EI&"?\L?_ $E'$W'_ !\2_P"^W\ZCI;B:+[1*/-3[
M[?Q#UJ/SHO\ GHG_ 'T*_)ZU*?M):=6?20E'E6ITWAG_ %-Q_O#^5;I[USOA
MNY@6&XS-&/F'5QZ5N&[M_P#GO%_WV*_0LEBU@8)^?YGAXMKV[/*_#7_(/G_Z
M_)__ $8U;=<YH&HV-O97$<UY!$_VN<[6D .#(V.*U?[8TS_H(6O_ ']7_&OA
M<=0J/$S:B]WT/H9--BV/_)1M$_ZX7'\A7IM>5:9?6MQ\0M&:&YAD5(+C>R."
M!D#&37J*2QR F-U<#KM(.*^WR.,HX**DK;GCYG_$CZ?JR6BBBO7/-"BBB@ H
MHHH *QM(\-Z;H=Q/-9)(&E&W#R%A&NYFVJ#]U=S,<#UK9HH @:U@=BSPQLQZ
MEE!)H^QVW_/O%_WP*GHHNQ61!]CMO^?>+_O@4?8[;_GWB_[X%<GX^.I'3XUB
MC;^S%DCDNYHIFC=45P64A?F8,N0 GS;L=C5SP;K$^K:=<)=QO#<6D[6YBF;=
M*H55(\Q@<,Y!!.W@$XZ@T7861O\ V*U_Y]X?^^!2_8[8=+>+_O@5/11=A9$'
MV.W_ .>$7_? H^QV_P#SPB_[X%<YXYCUR?P^T6C;PTC%;@P8\[R]IX3<5'+8
M!.00"2.:H>"M<:/P[!_:,\4=FKK;VUW-+M6=V)^2/<261<A%8DE]I/3DN["R
M.Q^Q6O\ S[P_]\"E^QVP_P"7>+_O@5/12N%B#[';?\^\7_? H^QVW_/O%_WP
M*H:^FI2:-.FE3K;W17'FE"[(O\11?XGQ]T'C.,UY[X(\5OI5S!H5](TWFN-[
M-*Q-M(4W,GSDL^&5R[ [49MOT"KON>H?8K7_ )]X?^^!1]BMO^?>'_O@5*CJ
MZ!T8,K#((.013Z+LFR(/L=M_S[Q?]\"C[';?\^\7_? J.^%V;&9;!HDNBA$3
M3 E0W8D#D@>E>:^$-<O])UB^TV_>9Q-?2N9+]RLCC>L8DY^6-#M.T$?.S;5X
M7)?,PY4>F_8K;_GWA_[X%+]BMO\ GWA_[X%3T4KL+(@^QVW_ #[Q?]\"C[';
M?\^\7_? I\F_RG\L*7VG:&Z9[9]J\@&OZMX1\37UWK%W]LN)6820;FB1T"*V
M\;B515(=$ &YV)SZAW861ZY]CMO^?>+_ +X%)]BM?^?>'_O@4VTNX;RW6>%L
MJP&1_$IQG##L1GD=JM4KL+$'V.V_Y]XO^^!1]CMO^?>+_O@5/7F6L-K&@^*H
M-:U'6(',ID$=K&75(X%5OE8$[0@RKO(1NRH50<@4K+L,]&^Q6W_/O#_WP*3[
M%:_\^\/_ 'P*98WUO?VD-Q;SPS)+&'5HFW*0>X]JMTQ6(/L=M_S[Q?\ ? H^
MQVW_ #[Q?]\"IZ\N\<7.LZ;XEM=3N;]H=/MP7MXX(W/(9/E ! DE<;UPPVHH
M+>IH&>E?8[;_ )]XO^^!3HX8X@1'&J9Z[5 S6/X8\10^(M,6Y")%.&=)(EF$
MBY5L%D8?>3/1AQ6[0 4444 %%%% !1110 4444 %%%% !7F>K^'[SPMJG]M:
M7<1BR@WM%#,2L5L74AV<C+,G!(51N9V&>@->F4A 88(!'H: ,3PYKZ^(-.\\
MVTMK=Q-Y=U;2@AH9-H;:?7A@?Q['BMRJ6G:=::5:"VLH!#%N9R 22S,<LQ)Y
M)).23S5V@ KSKQAX/D1K/4=)A1X[&;SQ:/&TB(<EOW42XRS.5)R0,*!D#->B
MT4 8WAN+6H=$A&OW,<^HL6>0QH%5 3D+QP2HXSWK9HHH *Y;QEH]_JNAR6VG
M&T171A*LZ-T)#;EV\D@KDJ1ALD&NIHH \S\*>-[2W>.SN7TZRTHP;X(XW8FW
M8MD1,Q)#-M)9E4 1C"GM7I2L& 92"",@CO7%^*/#9.JV_B&UBGFFM0H:V@C1
MF=07.5S@\ER64$;P ,\5J>#[?5X-!1]9?%S/(9A!R?LRL 1%DDDX.>_&<=!0
M!T5<QXI\*6FO6S.(T2YVD;S&&R",$[20K.%W!6;.TL2*Z>B@#SWP=XFE34SH
M>JS3?:Y"OV:!HL"U41[A SG#.ZJ,LV,9.,\C/H5<EXN\+MJUHTVG) +LR+),
MDC,J7(52H5F0AAC(/'7: >*Q?A_XB@B@;3+R6Y20RI&MSJ$F);BX*Y:/!)&Y
M0J_*O"@@'YLY /1ZH:C!/-93"S\A+H@%'FCW*2#D!AUQU&>V<BK]% 'D.DZU
M+X.U.33Y5TR K=A;_P"=R[JQ+F3)(VHBNJ^8X+2,,=<5ZE8W]KJ5HMS93I-"
MV0'0]P<$>Q![&LGQ9X:C\2:7Y&_RYXW\R-C&K!F"LH#!@01\Q(]#@]JR/"O]
MK1ZE<W>I>9INF11BUBM[ML/*ZA296.XJ2/G7<,;L;B.* .YJAJ.F6FIP+%=6
M\<H1Q(@D7*AP<J2.X! .#QP*NJRNH92"I&00<@BG4 >4Z6S>"O%>H3ZA:Q?9
M97 N=1:,^;*[+N!11T1G^58T#8VL201SZ?;W$-U;QSV\J212*&1T((93T(/I
M535M+M]6M?*D+1R@,(IX\"2(L,,48@[25)&1S@G%>:6VMW_@[5VT^XAL V4A
M#RAXU@@ !5E.,>4"2BKRS-N8D<X /7:8RJ2I(!*G()'0]/ZTR":.Y@2:%UDB
MD4,KJ<A@>00>XJ:@#R?63?\ AGQ.=1NSI8NYX2+:YV2$*L>5(" @L[[T41*=
MN5+=:[SP[XAM->L8WCG@-X(D:YAB?=Y3D?,,]P"&&1QD&M#4M/AU/3Y[.8LJ
M31O'O0X9=RE25/8X)YK@-.T76M)UBUTJS$EM8VL[W=QJ#1JL31Y3]TBJP558
M;P5*_*07SDT >ET5%%/#.A:&5)%!P2C!@#Z<5+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7)^+/"R:O"UU;PQ->*%#*
M^0)E5MP0MR47=AFVC<P4#-=910!Y_P##_7K[5M0U&"ZF>551)5) +!BS*QD
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M6&JO<1VLZM);RO%)&>&5E;:>.N,]ZXH_"Z/[++'_ &@GGR0O"T_V<;R&MDA
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M:']Q))<6XFB5<&.!B$?[2L[,I=F*D[2O7O\ A4:?#5DOK*<:E$5@>)V+6V9
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M+;B:4$8&2#G P0O\6>^*W;C1M-NKLW5Q912S$!2S+G< "!D=#@,1SZFM *H
M   '08Z4 <'INMZA=:G WVYY+J6ZA62R7:T:P- C.PP,@!BQ#9Y/'-=]4<<4
M<*!(HUC51@*J@ ?@*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>rvph20211231_10kimg027.jpg
<TEXT>
begin 644 rvph20211231_10kimg027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! 3H# 2(  A$! Q$!_\0
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M<>IV#T(_DS?F:KZ/X=LM$N;Z>U#F2\D#R%B.V< 8'0;F]^: -FBBB@ HHHH
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MZ^CU/3;:^A5UCN(UD0.N& (SR.QJW30     !T [4Z@ HHHH **** "BBB@
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M_8MOIO@^33#_ *1##;N,R(O)P3G:!@<] !Q6MI__ "#K7_KBG_H(H LT444
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M:W$XV*P()"C!./J?TKI#\1/"9'&MVV<<9)_PJ&U^(OAAK6(S:M:1RE061"2
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M\/?,TBW+SQ"U,4Z0L)=XPP9\J ,\Y!].]7=+8Z7X1@<1 &"V+E&G5\D DYD
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M_P#D2;3_ *_D_P#07KYSKUL%_"..O\05T'@;_D?M _["$/\ Z$*Y^N@\#?\
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M $(5XW7LG[07_(9T;_KWD_\ 0A7C=>SAOX2.&K\;"OL;P?\ \B7H7_7A!_Z
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M!/B9'E&GSS:?#;NBO:QQ':P9BQVMDX+L/G*C&W<!7H- !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>rvph20211231_10kimg028.jpg
<TEXT>
begin 644 rvph20211231_10kimg028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #/ F$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%06#$9P>F<9_&M^DP ,"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O-/$,XL_BAITZ.=1:0PP?8<RI):Y+'SD*_(RX/S ^G7M7I=)M&<X&?7% 'C
M_P#PL'Q'+HTI@^;4+;3Y7N%:S8!+A;A448QS\AS@?6MN[UKQ1IWB>T\.2SB\
M:\,4J7HM B+$N\S@@9 .%4#)S\U>BX'H/RHQSF@#R+1?$GB*UAT/28K?RQJD
M<1MW6V.VVVRMY^[/^P 0#W-4-2\4:QK@U.Q8SRV>Z":,M;"-XW6[52OR]!MY
MPQ)[]Z]LP..!QTHVKZ#GVH \I^*-OJESK< T^&:00Z5<S'9*Z%&#)\Z;/O.!
MDA21FI)_%FL/XIT_2-.O;B2VF$<+O+:*,!H"XE!^\3NQDG"Y.W'>O4L"C:,Y
MP,_2@#Q6Q\8>*+70]#@AU!99'M"\EQ>P[=TZLH:%R1G@9Y'S'/M77^*8)=2\
M9Z9I[7+6J/I=ZT,R_P#+.8A%W#IRJLQ_.NZVJ>PZYZ56N-/M+J[M;N>!7GM6
M9H7.<H6&UL?4<4 >7Z#?75KK%A9W\$]S97"NEDPW*BQN7W2;3DXPN!N/RJ0?
MXJ['X=2R2^ =*,C%ML;(C,<ED5F"G_OD"NEDA2:)HW4%&4J1[$8(IEI:06%G
M#:6L2Q6\*A(XU& J@8 % %BBBB@ HHHH **** "BBB@ HHHH **** ,2X\3Z
M;:W-Y;RO-YUHT2.@A;+-(<(%X^8D\<<5'IWB[1]4O(;:UG=WE+*C&-@I=5W,
MF2/O!>2/8U7OO"(O]4O+Y]1F5YV@=%6-,1/"X9&&1S@YR#US4>C^!K#1+Z&Y
M@N9W6*1YUB?&/.==K.3C/()XZ#- '59&<4M86OVL+OI]T4_?QW<*JX)! +C(
MX[&MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI*
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M\);JHZ^$=4Q[%30(ZRBN3_X2_4O^A2U;_OD4?\)?J7_0I:M_WR* .LHKD_\
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M..1D=: +%%%% !1110 4444 96O?\>]G_P!?L'_H8K5K*U[_ (][/_K]@_\
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M=/\ ^@KK/_@<U*\^WXB]GA_YW]W_  3M-P]11N'J*XO_ (5KI_\ T%=9_P#
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M%=9_\#FH_P"%:Z?_ -!76?\ P.:L[S[?B5[/#_SO[O\ @G:;AZBC</45Q?\
MPK73_P#H*ZS_ .!S4?\ "M=/_P"@KK/_ ('-1>?;\0]GA_YW]W_!.TW#U%&X
M>HKB_P#A6NG?]!76?_ YJ/\ A6NG?]!76?\ P.:B\^WXA[/#_P [^[_@G:;A
MZBC</45Q?_"M=/\ ^@KK/_@<U'_"M=/_ .@KK/\ X'-1>?;\0]GA_P"=_=_P
M3M-P]11N'J*XO_A6NG_]!76?_ YJ/^%:Z?\ ]!76?_ YJ+S[?B'L\/\ SO[O
M^"=IFEX(KB?^%:Z=_P!!36?_  .:NJTVQ33=/ALXY)9$B3:&E?<Q^I[FJ3;W
M1G4C32]R5_E8NT4451D%%%% &7KFK#1-,-V8'F/F)&J A0"S!068\!1G)/8"
MLC1O&4.L:A;0+:M;I<Q;XGF?'F-@EE3C#8VGH>V<5T5W:17UJ]M-YHC?[WER
MM&WKPRD$?@:I0^'],M[BUGCMV5K1=MNID8I%P5)5"=H8@D%L9.3SS0!%X@NK
M>/\ L^!YD2:2]@*(6 9L..@[UMUD:\JF"S8J"1>P8..GSBM>@#YIUJ1_[=U#
MYW_X^9/XC_>-4?,D_OO_ -]&KFM?\A[4?^OF3_T(U1H Z[X;.[>.;(%V(V2<
M%C_<:O>*\&^&O_(\V7^Y)_Z U>\T %%%% !1110 4444 %5;^^MM,L+B^NY5
MBM[=&DD=C@*H&35JLW7=*&N:'>:8TSPK<QF-I$.&4'KB@ T?7--\06C76EW4
M=S DAC9T.0& !(_45I5A^%_#\7AK23817$LX,\DK/*Q9B68GO[8_4]ZW* "B
MBB@ K#LO$MMJ&JR6-M9Z@PBD>)[DVS"$,OWAO/N,?6M2Z6=K:1;9UCG*D([I
MN53V)&1D>V:\[\/6F[Q_/<Q0&1%GF66YCL)$0R $-\YE*YSQ]WF@#TRBBB@#
M$/\ R.P_[!Q_]&"MNL0_\CL/^P<?_1@K;H **** "BBB@ I*6N?\3>+]'\(P
MV\NK3/$EPY6,JA;) R>GUH2;=D)M)79#/X*TZXU/5+]YK@2:C 8)5#_*H..5
M'8\"H;?P'IEO)HDBSW);2%VPY<8;K][CGDU@WOQA\%W5C/";N<[D( ,#=>WZ
MTMG\8O!EO900_;)QL15($#=<<UI[&IV8N>/<])KF_%_BVW\(Z?!=W%O).)9?
M+"(0",*6)Y/M5CPUXITOQ98RWFDRM+#'+Y3ED*D-@'H?8BI]:\/Z9X@ABBU*
MV6=(BS*K=BRE2?R)K-IIV8TTU='+Z-\1O[7\3QZ0--""0A0RW >1#Y2R;F0#
MA?FV[L]:Z:'Q#93Z[+HZ)<"YCSN)B(3@ \-T[U+INBV&DRW4EG (FN7#R8]0
MJJ /084<4]-(TV+4&U".PM5O&SNN!$H<YZY;&>U S#U#QQ:1(ZZ;!+?R_:DL
MT9?DA:=GV[-Y[CDG .,4U?&1D\,6^IQZ>QO)[P6"6C2@#S_,*8+X^[D$YQT[
M5H:CX4T?46F>:SV2S%6>6"1HGW*0ROE2/G! PW7MT)J$^#='.GBQ"7*6ZA=H
M6Y<%&5BXD!SD/N));J>] &)9_$5[O4M.MGTS[-!='RI+B:5MB3"1T:-6"E6.
M5XR1G<*[ZN=C\&Z/$;(*EP8;-@T<#74AB+ABP=E)PS[CG<<G-=%0 5'+-'!$
M9)I$C0=6=@ /Q-25R7CA-,6PM;O5M/MKZWAE(\N>3 W,, JA.'.?X>3C..:
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M &[0"2  3U.*H7'_ "';'_KE+_[+6C6=<?\ (=L?^N4O_LM &C1110 4444
M%%%% !1110 45FZU=7UEI$]QI]K]JND \N$Y^;D ]/;)KCO^$K\<?]"F/R;_
M !H ]#I,CCGKTKF_#&KZ]J<EP-9T@6"HJF-N?G))R.3VXKS^7^UAJ-U'IL\[
M2PZDUPNHF&1MW[J<^6Z/\N5P%RO!#+WH ]EHKRB3Q9XIN=7-I:&>%94A5FDL
MU(A8M&&91CD$.Q^8]NV*Z7P/J6O7S7":W)YI\B":-OLWDX+[PR^^-@/_  +Z
M4 =E1110 4444 %%%% !1110 4444 %%%% !1110!7N[J&QLY[NX;;#!&TLC
M8SA5!)/Y"O*/#L$D?C\#3[ZQ:?=,\KM!/NG1V5RC/NVLZ(RX&.,UZW)&DT;1
MR(&C8$,I&00>H(K.L?#ND:8MNMCI\%LMMO\ *$:;0F_&XCW.!S[4 :M%%% &
M5KW_ ![V?_7[!_Z&*U:RM>_X][/_ *_8/_0Q6K0!\SZU_P A[4?^OF3_ -"-
M4:O:U_R'M1_Z^9/_ $(U1H ZWX:_\CS9?[DG_H#5[S7@WPU_Y'FR_P!R3_T!
MJ]YH *QM3\3:)HURMOJ.IVUK,RAPDL@4E22,_3(/Y5LU\X?'L?\ %=VG_8.3
M_P!&25K0IJI/E9%23BKH]@OO''A9Y+,KKMB0LX8XE' VMS5S_A//"G_0?L/^
M_P *^0<4J@;EX[UV_48]V<_UA]C[@HI!]T?2EKS3K. ^,'_(AR_]=X_YU\\U
M]#?&#_D0Y?\ KO'_ #KYYKS<7_$/M^'?]T?J_P! [U]!?!O_ )$;_MZD_I7S
M[WKZ"^#?_(C?]O4G]*,)_$^0<0_[I\U^IZ'1117I'Q!'(K/$RJ0&((!(R ?<
M=Z\U\(P7MOXRO,2K<PR7#B>>+1/)B$B($*I+O.T?*.QR<^M>G5YAX;MH8_B%
M>R0PI<;KNX9KS[%/N5CG*^:3L.#\O3VH ]/HKFO$6M2Z3JVBPI=6R1W<[120
MR ;Y/E)&TD\<@#H>HJKX*\07VNBY-W)#*JQ02AX4VB-W5B\1Y/*D#WYYH U#
M_P CL/\ L''_ -&"MNN=BFED\=2+);M&J6!"L6!WCS.HQT_&MF_)73[EE)#+
M$Q!!Y!P: +-5+>[^T7%Q%Y+IY#A"S$8)(!XP?0BOG0:_K.T?\36^Z?\ /P_^
M-(NN:LK,1JEXI8Y8B=_F/3)YH ^EZ*\0\ :OJ5UXRLX;C4+J:-E?*/,S*?E/
M8FO;Z "O&/VA/^03HG_7Q)_Z"*]GKQC]H3_D$Z)_U\2?^@BM\-_%B9U?@9X+
M1117M' ?0_P _P"1/U+_ +"#?^BTKUJO)?@!_P B?J7_ &$&_P#1:5ZU7B8C
M^+([Z7P(2OF7XD_\E"U?_KHG_H"U]-5\R_$G_DH6K_\ 71/_ $!:\[&? CZ7
MAS_>9>GZHY2BBBO./LWL?6NB?\@+3_\ KWC_ /016A6?HG_("T__ *]X_P#T
M$5H5[:V/RZI\;]1:P?&,"7/A2_BD4,I13@W(MQD,"/WAX7D=:WJY?QG)JZZ4
MB:9I2:GYK-'+;R*K*<J=C,&.-H;!/? ID$7@"[:[\/2!WG=XKJ2)FEO_ +82
M1CI+@9'/;I5SQG+J<7ABZ&DQSM=.-NZW($D:_P 3+G^( <>Y%-\'65]INC26
M&H",O;SLB216ZPK*N =P1>!R6'OBNCH \X\'WVMW7B.,7SZ@";9OM$,X;RT4
M+%Y3#(QO8E\X.3SGI772M=GQ-:B2.$6P@D\MED)=C\F<C;@#Z$ULUG7'_(=L
M?^N4O_LM &C1110 4444 %%%% !1110 E%9/B33KW5M NK+3;^2PNY0H2Y0D
M,F&!/3GD C\:\\_X5MXY_P"BA7O_ '\D_P#BJN,5):NQ+DULCUFN;M_&^B7%
MW):I-,LRSK  \+*'9G* J2.5W C-4O!?AC7_  ]/=MK/B2?5UF51&LK,?+()
MR1N)ZY'Y5B+\.-4MM2N+ZTOK))3<K/&K*Y64B?S07YX(&5&WU-2TD[)W&FVM
M3J)O'&@P17KR7; 65\MC,/+;(F8@  =QD]>G!]*Z6O-[CX;WEUJ$UW)J$*F=
MY)I(@AVM(969&]?E5W'XCTKTBD,*S-3UFUTN2VBF6:2:Y<K%%!&78X^\V!T
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M>:\&^&O_ "/-E_N2?^@-7O- !7SC\>O^1[L_^P>G_HR2OHZOG'X]?\CW:?\
M8/3_ -&25TX/^*8U_A/+*5?O+]:2E7[R_6O79QGV^/NCZ4M(/NCZ4M?/GI'
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MEX6M(_,"RWMPP2WMMX7<20-S,>%0$C+'@5=T#6H-?T:WU&V&$E!RI(.&!*D
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MK&\$73W;ZS*;F_DMS>'R(;T.7B4#!Y8#AB&8 9 !%=A0!D?9?$'_ $%=/_\
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MT#6I[WQ-K.GSZA:W(MH[=XXX-O[O<&W#@DGD#D^O:@#J**** "BBB@ HHHH
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M[;CM6$#GTYR #V:BL#P]XFA\0VPFCM+FUW -&+@+^]4]U*L1D8((SE3U%;]
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M!Y'!ZUV%<9H'P[TC0M:;4(X(3Y("642QX$"XP6)))9SS\Q/ X %=G0 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>rvph20211231_10kimg029.jpg
<TEXT>
begin 644 rvph20211231_10kimg029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $( 4\# 2(  A$! Q$!_\0
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "DS2U#/-';PO+*ZI&BEF9C@*!U)- $N:*RM.UW3=68BQ
MOH;@@$[4<$X!P3CZ]ZNR7=O"<2SQH3T#. ?UIV: LT5%%*DJ[D967L5.14M(
M!K5S</\ R4&Z_P"P=%_Z$]=(U<W#_P E!NO^P=%_Z&]./4#C_'/CS5O#_B)[
M&RAA:-(E<LPR1DX]?I7%WWCN^U699+W2-.N9%.Q6=,D?K5OXJX_X36;.T_Z.
M@&3[G]:XMM@(^:+[Z^N.G\JX9U)<S1]+A,/2=)3:UL:T&N_9VN'.CZ?+YTA;
M$B9"_P"R!GI6_;?$_7;&VCM[>RLX850%%5?E5>P'-<4H4H<M$/F<]3_=)]*:
M-FX?ZO\ U?;/^<U*G);,Z9X>E+=7/I#P7K5SKWAN#4+I469V8-M&!PQ KHLU
MQGPO_P"1'M/]]_\ T(UU-^S)87#*Q#*A(([<5VPNTCY;$14:LHKHRQ*7$;%
M"^/E!/!-<_=:GKEG"));.U"EPO$A[_A7!C6M3S@7\IQ_M4R35K^= DEW(P!S
MR:[8X:74P<CTRSN-7>9!<VL"1'[S+(2?RQ6KD^E>0_VUJ0  OY1_P*M3PYJM
M_/KUK'-=RR1LQRK-P>#2GAI)-W&I7/3 :6FCBE'2N48M%(348<$D Y(Z\]*
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M>7%B;1P&=43#$$<?KBJ]BU'FOH7*K%JRB=>I)ZT^HU/S=:DJ2 HHHH ****
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M,A 'XU[1\,?^16;_ *[M_(5G>)]4@U;X;WDBRV\MPL8\X0CA&/.WZUH_"_\
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M[7<7YUI^'M<TJVURUFGOX(XU8Y9FP!P:FI\#!'LPZ?A7D'Q/_P"1BA_ZY5Z
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M6X'E16YC>4/E0';/S*,Y QU H ])W"C<*Y>Z'B7[?+Y$,AM]_P A^V1*-O\
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M%%% !C%+110 F/\ (H(HHH ,?6H6MU>X28L^5! 7/RY]<>OO110!,!01110
M 4M%% "8I,444 +3)(Q)$T9) 88X/-%% "Q1)%&J(H"J,  8I]%% "$48HHH
F ,48HHH ,8]:3'UHHH 6C%%% "T444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>rvph20211231_10kimg030.gif
<TEXT>
begin 644 rvph20211231_10kimg030.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M:=  %L2C]94&.="C%)0#S!FD/;ID W@ <,F4(YE7D8F&0":#DP9UQ9=UGB6
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M/ 9=Z^V4G!44[?7%8\D^YLQ9/$)]T0ZNL=[#*L)2F OUW'O.P_3IGN0FX-!
M<PA00!CE/;-C5WKC1'*K.J"0V>4KX(-WE8S;FKC6PI6ZU&JAWY<\[%F=6@F<
M1?,.I)\N2L@.4[?CB/-^).)J<IK@E+^:7^-:)N=-I(T^M! Z/D/;K*'@FT[[
ME/73Z5O/Y.Z46_\NGA"J0T6(6:&QVB=3QD[%B.' 0T$^(*Q7-%-TNH*'G%0'
M< KBFDK"V:%3A5QP2H<B%IK,/9IA_8^2AK-]7#^\P^1R&^CEG=!-/C[+.:ZA
M8&/:.J;'&0W(B>Q,'D$-P/<'D-Z6MS3UE0-:Z<5OW&CFK*MTHPE];&-3>21
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M+3JQH>E,</(^S C*8 X9"!!T)"N3N-J80NU'_U4I\Z?[-,;]_P<P0 '_VVA
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MWR6'PSF^M:R3;L[YQJ1)WJ" BA-GMY@FJK% A5/I**3>P'/(DAV  R/L,G(
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MX,B**0,D DKYHF]1"&(GXMM:P<68)/IU(2DSQ1C\]ZW3E"HFOL%K0\ZU6,;
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MADD<48G?RX0FB!$LYY%'A$6Q2CUHAQB_28]^%QRB,C011AR$\8M!M!@%V=+
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MJ?@,EV^*YB2*[ H6A0FET($>XU,JRV)::I+ 6V?(GB">ADR6(K;1;&2,[_+
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MI%VWNHE6NH(& (AA$C>8!!K20 Q-&#!M$)G(,.68AJ_A!P 'R$H 8*!*NL9
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M<8IE C,,=ZPO4S*;!'#0=K]8?@5@#^%?&!.SIYX!!B_/V$M=_G>7&T#&,<,
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M243,-*&,N<N69,XM&C61+KH ;@!N$NEPB Z T8@Y  #L ,!A*Z*"&D:Z, (
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MWD\6E;-$853_HQ/;%*C>=;UH=,T@3/L>J!"BGZ!,2C7*<!6LI,,JGL2./OG
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MD+/ KK2 MA.\B0>QBL@XJFB@!Z.XHL,8F$Q8@0L+ UEA'Q7XB].9!!40 T;
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M24T5C2=IH-*]A%/ QUN465?8UC*ME0BZ1' ,1#(XA<Q)TYTA2@[Q!4_T2T\
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M:T\<**ELR4+YV5#<"(8HX^2:2BG2G)'8A/R>H>FU),U5HC+"ZOR45B:8!=J
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M\NH#Q*1,8O9EFK0/H9A,RHC10[AO$II]-\0H&R81!S%--^J)(09Q$C&"FL)
M4Z9L69B'^Y01+%AQ7XR3Q/35.RESX#YB)RMFDM%2V3Z/")49+"CQ(3V%#V'B
MH*?L1M"'T,1 6WD5:U:M6[EVO2K5:UBQ8\F&%5D6;5JU:]FV=?L6;MRPF6(8
M1$,P9PPQ=_?=O0L-329B=<54C+K_4ED,-!'Q$MP[J3%DA@3KW8 <XVA$JIE8
M9JJWLC)+ )XK%LYD.>= J$4E0@:9"0TQ  H/#E,($V%.,9@UB:%75U(,8H&/
M[I,D<?'2&&G WOBX;\P-B(O1+!NHNF7$A3$F!5>&8]C+-&&(I7:)<)*!20(+
M4I08 \<D3,^)<91['W]^_3J1[O?_'\  !1RPLX@FL>HDH022RJ"@=BIHP9,^
M6\D@]EB2*J*'8/LH09861&^A"_>QZ2IH/JJ'LX+0"ZFHH%!D2,0$3YJQPDRB
M@1"L&(-*4!-)-%'&Q!T_LL[#%,N;$,6']/%LGS0DT7 2J91)([Q]-,GD1WTZ
M;##&YW*S](O)]7);C[F'GIN0P+5R3#/--=E\$\XXY1RP):O*LM/..05<1L\^
M2_034*_R#)300@T]-*[/E#D(K<_01&C0KB+5:D(WW]0G/TRCP90HA!X=<:Q/
M'^+S*D[#TN?&?29%%#%6XUK5U5AEG54M4<FRZE$[/X/&UDC7A'4JK/*TTU*M
M4G5(25(];4M12?_4"E,^3=TGU7KRY+2>5+62:MIE:3745K;"U0_8;\T]-]1.
M(9U1RE;9%17!1Z6:,$^I=G(Q*V705!0L$D%5==]R_S7IWI6TQ>K&;O=!]:IE
M]''XH4VQ8DA;8BH&:\:5E$7H8(6S4G;-?='_;350J\I[*,FB!#+2(,%0AA0A
M8@1B#^.K<AUQU3P?!#52>!_JD*@0<_-271'7$HA#DI_%ZD.=A"XO1:*X'5G
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8$1(C41(G<00IT1(O$1,S41,WT2T" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>rvph20211231_10kimg031.gif
<TEXT>
begin 644 rvph20211231_10kimg031.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
MS,R _\RJ ,RJ,\RJ9LRJF<RJS,RJ_\S5 ,S5,\S59LS5F<S5S,S5_\S_ ,S_
M,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\K /\K,_\K9O\KF?\K
MS/\K__]5 /]5,_]59O]5F?]5S/]5__^  /^ ,_^ 9O^ F?^ S/^ __^J /^J
M,_^J9O^JF?^JS/^J___5 /_5,__59O_5F?_5S/_5____ /__,___9O__F?__
MS/___P               "'Y! $  /P +      ( AH!  C_ )7M$U@/6KV!
M^PH>)&@0H4*'#1DN3!B1XL2'$B%>K(C1HL:/&4-Z%-FQ),>3&U."',G2I$J2
M*%>ZE!D3YLN6-7'>G&F3YLZ</'7Z'-JSJ%"C09,"77ISG].G4*-*G4JUJM6K
M6+-JW<JUJ]>O8,.*'4NVK-FS:-.J74M6(-NW<./*G4NWKMV[>//JW<NWK]^_
M@ ,+'DSXK]O"B!,K7LRXL>/'D"-+GDRYLN6YAR]KWLRYL^?/H$.+'DVZ=-S,
MIE.K7LVZM>O7L&/+1HQZMNW;N'/KWLV[M^^ZM7\+'TZ\N/'CR),+#JZ\N?/G
MT*-+GPZ;.?7KV+-KW\Z]^UGKWL.+$Q]/OKSYW.#/JU_/OKW[]X;ARY__3[^^
M_?M6T^/?S[^_?Z?Z_.>;?@)Z%F"!"";(UX$*_D8@9P<>6 \QDTS2R(6-,(+A
MAAQVZ.&'((8HXH@DEFCBB1].XLLR!]43354O'I20,KY8B.*-.&;(H88Y]NCC
MAI,00XQ3!S'8H%PQ[D-,(UQ8X>0*3K)@114L5&$%E%1:B6655T[)Y99:>AEF
MEEV2"6:97XJ)YIAIFJGFF7"^*:>;=+99Y9U.6M'D)/1(5214T.Q##Y-Y0CFG
MG6PFNN:B<9(II:.'A@GEI)$R6FFCB':9)Q>]+-/<@Y\1(X.53G(12).HZJEJ
MJJRNJFH7KK8J:ZRTSFIKK;C>JFNNO*(*"*JM_[(@QI!]1B6C4\6((<.JO[IJ
M2*W-[BIMK[P>\NJJ7/PZ[;;4MOILJBPP,N0^+QX9EXS$5,'%NLY> 4@7@%QA
MB+SNPDOOO._&^^RO^M*;[[WU]HNOO0,+'## _\Y;,,($^]OPP@H?'''"#O=K
M*A=78(QOMJ5R4848QT(5C81B6-EDQE98>^H55L!Z:K]Z2BRO%:<&DO+--=^L
MLJDZT\RSM1/S#&^I-C]K+<LN7VSSSCDS_;//34/]=,U"MPR(JUN,$7)QH')6
MCQBJ6@%PJ60W&7:J9Y>*LMFSILTVK:["W6K98>/J-MEQO_UVWLR&W6S+@'/,
M!0N-7#5)V(<(KBJ_:?_K>;7>>*,M.=UF-UZYV=]:\6S<SV:^]^1\\XTVW(LW
M.?2W54QB;EW$,-ODX[_.'*_F>KXL]K<S[VM%L_DZ3ONI-]_,\_"T/^MNMAG;
M3/O,N?MNM.8L<WSUQL#GFRWRQ5MM]<4^[_XZK(!'Z_W5O]ILMAB>.C4R5/68
M;:V3L(H/:[9#6XLQ_5?#JS'TWO_>9/7QN]F\KO>NF\$+5BQ;V?6Z![ZA<6^
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MVFLN?5@&9J- "B0&@#*XMY,S#00+93A!SLJ$W-*T%=ROVB-!S3N]9!L]!4O
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?O1UN<8^;W!8#=[G1G6YUKWLZYV;WN^$=;WG')2  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301479039640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001742927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REVIVA PHARMACEUTICALS HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-4306526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19925 Stevens Creek Blvd., Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cupertino<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">95014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-8881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,133,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">ArmaninoLLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Ramon, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase one share of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVPHW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RVPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301479057704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 29,687,944<span></span>
</td>
<td class="nump">$ 8,760,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,716,057<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">31,404,001<span></span>
</td>
<td class="nump">8,762,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">509,583<span></span>
</td>
<td class="nump">1,008,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,835,228<span></span>
</td>
<td class="nump">324,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,344,811<span></span>
</td>
<td class="nump">1,332,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">372,730<span></span>
</td>
<td class="nump">1,963,785<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,717,541<span></span>
</td>
<td class="nump">3,296,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.0001; 115,000,000 shares authorized; 14,433,286 and 9,231,737 shares issued and outstanding as of December 31, 2021, and December 31, 2020, respectively</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">95,516,986<span></span>
</td>
<td class="nump">63,774,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(66,831,969)<span></span>
</td>
<td class="num">(58,310,093)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">28,686,460<span></span>
</td>
<td class="nump">5,465,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 31,404,001<span></span>
</td>
<td class="nump">$ 8,762,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480860136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,433,286<span></span>
</td>
<td class="nump">9,231,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,433,286<span></span>
</td>
<td class="nump">9,231,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478921160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,851,602<span></span>
</td>
<td class="nump">$ 295,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,252,911<span></span>
</td>
<td class="nump">2,139,501<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,104,513<span></span>
</td>
<td class="nump">2,434,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,104,513)<span></span>
</td>
<td class="num">(2,434,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on remeasurement of warrant liabilities</a></td>
<td class="nump">1,591,055<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_InterestAndOtherIncomeExpenseNet', window );">Interest and other income (expense), net</a></td>
<td class="num">(2,414)<span></span>
</td>
<td class="nump">105,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,453,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,588,641<span></span>
</td>
<td class="num">(1,347,937)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(8,515,872)<span></span>
</td>
<td class="num">(3,782,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">6,004<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,521,876)<span></span>
</td>
<td class="num">$ (3,783,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding Basic and diluted (in shares)</a></td>
<td class="nump">14,790,843<span></span>
</td>
<td class="nump">3,061,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest and other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301482676776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">2,768,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,597,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 18,644,683<span></span>
</td>
<td class="num">$ (54,526,705)<span></span>
</td>
<td class="nump">$ 29,069,974<span></span>
</td>
<td class="num">$ (6,811,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued', window );">Issuance of common stock in lieu of deferred compensation</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">340,907<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">340,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Issuance of common stock in lieu of deferred compensation (in shares)</a></td>
<td class="nump">38,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature on conversion of notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">961,680<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">961,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of notes and accrued interest</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">8,499,233<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,499,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of notes and accrued interest (in shares)</a></td>
<td class="nump">1,099,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability', window );">Reclassification of warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,185,577<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,185,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization', window );">Proceeds from reverse acquisition, net of costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,375,961<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,375,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares', window );">Effect of reverse recapitalization, net of costs (in shares)</a></td>
<td class="nump">5,324,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,597,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_EffectOfReverseRecapitalizationNetOfCostsValue', window );">Effect of reverse recapitalization, net of costs</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">24,766,879<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (29,069,974)<span></span>
</td>
<td class="num">(4,302,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,783,388)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(3,783,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">9,231,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 923<span></span>
</td>
<td class="nump">63,774,920<span></span>
</td>
<td class="num">(58,310,093)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,465,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,521,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,521,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Units in public offering, net (in shares)</a></td>
<td class="nump">4,133,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Units in public offering, net</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">31,497,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,497,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued in connection with warrant exercises (in shares)</a></td>
<td class="nump">1,057,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_StockIssuedDuringPeriodValueWarrantsExercised', window );">Common stock issued in connection with warrant exercises</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">98,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued to consultant in exchange for services (in shares)</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued to consultant in exchange for services</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">39,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">106,713<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,713<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">14,433,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="nump">$ 95,516,986<span></span>
</td>
<td class="num">$ (66,831,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,686,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the proceeds from reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for reclassification of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_EffectOfReverseRecapitalizationNetOfCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of effect of reverse recapitalization, net of costs, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_EffectOfReverseRecapitalizationNetOfCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect on the number of shares from reverse recapitalization, net of costs, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total fair value of shares issued during the period under a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301482580696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,521,876)<span></span>
</td>
<td class="num">$ (3,783,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(1,591,055)<span></span>
</td>
<td class="nump">1,084,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Noncash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">961,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of stock in exchange for services</a></td>
<td class="nump">39,929<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">106,713<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,330,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,714,241)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(498,463)<span></span>
</td>
<td class="nump">775,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,510,531<span></span>
</td>
<td class="num">(773,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,668,462)<span></span>
</td>
<td class="num">(4,066,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation', window );">Issuance of common stock in lieu of deferred compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">340,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ProceedsFromReverseRecapitalization', window );">Proceeds from business combination, net of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,375,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Units in public offering, net</a></td>
<td class="nump">31,497,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of stock upon warrant exercises</a></td>
<td class="nump">98,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,110,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">31,595,944<span></span>
</td>
<td class="nump">12,826,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">20,927,482<span></span>
</td>
<td class="nump">8,760,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, beginning of period</a></td>
<td class="nump">8,760,462<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, end of period</a></td>
<td class="nump">29,687,944<span></span>
</td>
<td class="nump">8,760,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">327,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental schedule of noncash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,875,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_PaymentOfCertainDeferredCosts', window );">Payment of certain deferred costs from proceeds from business combination</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_PaymentOfCertainDeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment of certain deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_PaymentOfCertainDeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from issuance of common stock for deferred compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ProceedsFromReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ProceedsFromReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480728088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b>&#160;&#160;&#160;<b>ORGANIZATION AND NATURE OF OPERATIONS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">14,</em> <em style="font: inherit;">2020,</em> Reviva Pharmaceuticals Holdings,&#160;Inc. (the &#8220;Company&#8221;), a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp. (&#8220;Tenzing&#8221;), a British Virgin Islands exempted company, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#8220;Merger Sub&#8221;), and Reviva Pharmaceuticals,&#160;Inc., a Delaware corporation (together with its consolidated subsidiary), consummated a business combination (the &#8220;Business Combination&#8221;) through the merger of Merger Sub with and into Reviva Pharmaceuticals,&#160;Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">20,</em> <em style="font: inherit;">2020</em> (the &#8220;Merger Agreement&#8221;), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals,&#160;Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), Merger Sub merged with and into Reviva Pharmaceuticals,&#160;Inc., with Reviva Pharmaceuticals,&#160;Inc.&#160;as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals,&#160;Inc.&#160;becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings,&#160;Inc. (together with its consolidated subsidiary).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Reviva Pharmaceuticals,&#160;Inc. was originally incorporated in the state of Delaware and commenced operations on <em style="font: inherit;"> May 1, 2006 </em>and its Indian subsidiary, Reviva Pharmaceuticals India Pvt. Ltd. was incorporated in <em style="font: inherit;">2014.</em> The Company is an emerging research based pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective therapeutic drugs by using an integrated chemical genomics technology platform and proprietary chemistries. The Company is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), metabolic and inflammatory diseases.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480777288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b>&#160;&#160;&#160;<b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Basis of Presentation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The summary of significant accounting policies presented below is designed to assist in understanding the Company&#8217;s financial statements. Such financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Principals of consolidation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The preparation of&#160;consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are <em style="font: inherit;">not</em> limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company&#8217;s cash are held in demand deposit form by <em style="font: inherit;">one</em> financial institution. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are <em style="font: inherit;">not</em> limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company&#8217;s operating results <em style="font: inherit;"> may </em>be materially affected by the foregoing factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Cash</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of <em style="font: inherit;">three</em>&#160;months or less to be cash equivalents. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company&#8217;s cash was maintained in demand deposit forms at <em style="font: inherit;">two</em> financial institutions. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, have exceed federally insured limits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Property and equipment</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than <em style="font: inherit;">one</em> year for: (<em style="font: inherit;">1</em>)&#160;assets purchased; (<em style="font: inherit;">2</em>)&#160;existing assets that are replaced, improved or the useful lives have been extended. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs are expensed as incurred. Assets classified as property and equipment are stated at cost less accumulated depreciation and are depreciated using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:c81966522">three</span> and <span style="-sec-ix-hidden:c81966523">five</span>&#160;years, or the lease term of the respective assets, whichever is less. When assets are retired or otherwise disposed, their original cost and related accumulated depreciation are removed from the consolidated balance sheet, and any resulting gain or loss is reflected in related operating expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Leases</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">2,</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, as amended. The ASU introduces a new lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&#8217;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of consolidated financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this standard effective <em style="font: inherit;"> January 1, 2019, </em>and determined that there is <em style="font: inherit;">no</em> material impact that the new accounting guidance will have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Research and development costs</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are <em style="font: inherit;">not</em> limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">General and administrative costs</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are <em style="font: inherit;">not</em> limited to, payroll and personnel expenses, travel and entertainment, consulting costs, conference and meeting costs, legal expenses and allocated overhead, including rent depreciation, and utilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Income taxes</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company utilizes FASB ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is &#8220;more likely-than-<em style="font: inherit;">not&#8221;</em> that a deferred tax asset will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160; The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis.&#160; The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of <em style="font: inherit;">100%</em> has been established due to the uncertainty of the Company&#8217;s realization of the net operating loss carry forward prior to its expiration.&#160; In the event the Company determines that it would be able to realize its&#160;deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes.&#160; Conversely, in the event that all or part of the net deferred tax assets are determined <em style="font: inherit;">not</em> to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Stock-based compensation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC <em style="font: inherit;">718</em> which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Expected term</span>&#8201;&#8212;&#8201;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Expected volatility</span>&#8201;&#8212;&#8201;Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Expected dividend</span>&#8201;&#8212;&#8201;The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has <em style="font: inherit;">no</em> plans to pay dividends.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Risk-free interest rate</span>&#8201;&#8212;&#8201;The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury <em style="font: inherit;">zero</em>-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Forfeiture rate</span>&#8201;&#8212;&#8201;The Company made the <em style="font: inherit;">one</em>-time election to recognize forfeitures when they occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2019,</em> the Company adopted ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">07,</em> Compensation-Stock Compensation (Topic <em style="font: inherit;">718</em>): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting of share-based payment awards issued to employees and nonemployees. The adoption did <em style="font: inherit;">not</em> materially impact our consolidated financial statements. The Company recognizes fair value of stock options granted to non-employees as a stock-based compensation expense over the period in which the related services are received. Non-employee option grants that do <em style="font: inherit;">not</em> vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes-Merton option-pricing model, is determined, and compensation expense recognized during the period is adjusted accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value Measurements of Warrants</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">ASC <em style="font: inherit;">820</em> &#8220;Fair Value Measurements&#8221; defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC <em style="font: inherit;">820</em> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC <em style="font: inherit;">820</em> establishes a fair value hierarchy that distinguishes between (<em style="font: inherit;">1</em>)&#160;market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (<em style="font: inherit;">2</em>)&#160;an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <em style="font: inherit;">three</em> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#160;<em style="font: inherit;">1</em>) and the lowest priority to unobservable inputs (Level&#160;<em style="font: inherit;">3</em>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">three</em> levels of the fair value hierarchy under ASC <em style="font: inherit;">820</em> are described below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; Level&#160;<em style="font: inherit;">1&#8201;&#8212;&#8201;Quoted</em> prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;<em style="font: inherit;">1</em> inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; Level&#160;<em style="font: inherit;">2&#8201;&#8212;&#8201;Directly</em> or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are <em style="font: inherit;">not</em> active. Level&#160;<em style="font: inherit;">2</em> also includes assets and liabilities that are valued using models or other pricing methodologies that do <em style="font: inherit;">not</em> require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; Level&#160;<em style="font: inherit;">3&#8201;&#8212;&#8201;Unobservable</em> inputs that are supported by little or <em style="font: inherit;">no</em> market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Beneficial Conversion Features</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In accordance with FASB ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">20,</em> &#8220;Debt with Conversion and Other Options&#8221; the Company records a beneficial conversion feature (&#8220;BCF&#8221;) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301481775416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Public Offering<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#160;&#160;&#160;<b>STOCKHOLDERS</b>&#8217;<b> EQUITY (DEFICIT)</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our authorized capital stock consists of:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;">&#160;</td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">115,000,000 shares of common stock, par value $0.0001 per share; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;">&#160;</td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10,000,000 shares of preferred stock, par value $0.0001 per share.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were 14,433,286 shares of our common stock outstanding, and no shares of preferred stock outstanding. In <em style="font: inherit;"> November 2021, </em>the Company issued 11,000 shares of common stock to a consultant in exchange for services provided. In <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">2020,</em> the Company&#160;issued 38,992 shares of common stock to current and past employees in lieu of certain dues and obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Common Stock</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Voting.&#160;&#160;&#160;The holders of our common stock are entitled to <em style="font: inherit;">one</em> vote for each share held of record on all matters on which the holders are entitled to vote (or consent pursuant to written consent). Directors are elected by a plurality of the votes present in person or represented by proxy and entitled to vote.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Dividends.&#160;&#160;&#160;The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Liquidation Rights.&#160;&#160;&#160;In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Conversion Right.&#160;&#160;&#160;The holders of common stock have <em style="font: inherit;">no</em> conversion rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Preemptive and Similar Rights.&#160;&#160;&#160;The holders of common stock have <em style="font: inherit;">no</em> preemptive or similar rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Redemption/Put Rights.&#160;&#160;&#160;There are <em style="font: inherit;">no</em> redemption or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of common stock will be fully-paid and nonassessable.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Preferred Stock</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has the authority to issue shares of preferred stock from time to time on terms it <em style="font: inherit;"> may </em>determine, to divide shares of preferred stock into <em style="font: inherit;">one</em> or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were public warrants outstanding to purchase an aggregate of 6,325,000 shares of common stock and private warrants outstanding to purchase an aggregate of 556,313 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each public warrant entitles the holder thereof to purchase one share of common stock at a price <span style="-sec-ix-hidden:c81966876">of&#8201;$11.50</span> per share, subject to adjustment. <em style="font: inherit;">No</em> public warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to such shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We <em style="font: inherit;"> may </em>call the public warrants for redemption, in whole and <em style="font: inherit;">not</em> in part, at a price <span style="-sec-ix-hidden:c81966880">of&#8201;$0.01</span> per warrant:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the <em style="font: inherit;">third</em> trading business day prior to the notice of redemption to holders of the public warrants, and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire <em style="font: inherit;">30</em>-day trading period referred to above and continuing each day thereafter until the date of redemption.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">at any time while the public warrants are exercisable,</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">upon <em style="font: inherit;">not</em> less than <em style="font: inherit;">30</em>&#160;days&#8217;&#160;prior written notice of redemption to each warrant holder,</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The private warrants are substantially similar to the public warrants except such private warrants;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">are exercisable for cash or on a cashless basis, at the holder&#8217;s option</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The redemption price is to be calculated as the <em style="font: inherit;">10</em>-day average trading price ending <em style="font: inherit;">one</em> trading business day prior to the notice of redemption.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 26pt; text-indent: 18pt;">In <em style="font: inherit;">no</em> event will the Company be required to net cash settle either the public or the private warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company classified the private warrants pursuant to ASC <em style="font: inherit;">815</em> as derivative liabilities with subsequent changes in their fair values to be recognized in the consolidated financial statements at each reporting date. The Company calculated the fair value of the private warrants as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> as $372,730 using a Black-Scholes model. The key inputs used in the Black-Scholes calculation were, the risk-free interest rate, expected volatility, expected life, exercise price and stock price. The risk-free interest rate was estimated to be 1.11%, the expected volatility was estimated to be 73.0%, and the expected life was estimated to be 3.96&#160;years. The exercise price was $11.50, and the stock price $2.89. Due to fair value changes during the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company recorded a gain on remeasurement of warrant liabilities of $1,591,055.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The exercise price and number of shares of common stock issuable on exercise of the warrants <em style="font: inherit;"> may </em>be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or a recapitalization, reorganization, merger or consolidation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em> The fair value of these warrants on the date of issuance was $1,279,182.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0&#160;million and the Pre-Funded Warrants are exercisable into <span style="-sec-ix-hidden:c81966911">one</span> share of common stock at an exercise price of $0.0001 per share at any time after issuance. Additionally, in connection with the Offering, the Company issued Investor Warrants exercisable for&#160;6,900,000&#160;shares of common stock&#160;with an&#160;exercise price of $4.125 per share of common stock any time after issuance. The Investor Warrants expire on <em style="font: inherit;"> June 1, 2026. </em>During the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> Investor Warrants for 23,849&#160;shares of common stock were exercised with proceeds of $98,378 and Pre-Funded Warrants for 1,033,300&#160;shares of common stock were exercised with proceeds of $103. The Company has determined that&#160;as the&#160;Pre-Funded Warrants and&#160;Investor Warrants&#160;were issued at fair value in a public offering of Units with <em style="font: inherit;">no</em> debt funding included in the offering, the&#160;Pre-Funded Warrants and Investor Warrants should be classified as equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Common stock warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">2020,</em> the company issued warrants with a <span style="-sec-ix-hidden:c81966925">five</span>-year term to purchase 120,456 shares of common stock at $22.99 per share to certain current and past consultants (<em style="font: inherit;">&#8220;2020</em> warrants&#8221;). The <em style="font: inherit;">2020</em> warrants were exercisable immediately. The Company estimated the fair value of the <em style="font: inherit;">2020</em> warrants to be $1,178,182, using the Black-Scholes-Merton option-pricing model with the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Assumptions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yields</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The&#160;<em style="font: inherit;">2020</em> warrants are classified as equity and included in general and administrative expense during the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2016</em> Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company issued warrants in connection with the <em style="font: inherit;">2016</em> Notes (the <em style="font: inherit;">&#8220;2016</em> Warrants&#8221;) to purchase 5,812 shares of its common stock which will expire on <em style="font: inherit;"> April&#160;</em><em style="font: inherit;">28,</em> <em style="font: inherit;">2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of the warrants was originally estimated to be approximately $101,000 and they were classified as a liability on the balance sheet as the strike price was <em style="font: inherit;">not</em> established at the time of grant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Business Combination, the strike price was set at $42.29 based on the terms of the warrants at a common stock conversion rate of 0.152268.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be 0.36%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be 126%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be 1.4 years. The dividend yield was assumed to be <span style="-sec-ix-hidden:c81966947">zero</span> since the Company had <em style="font: inherit;">not</em> historically declared dividends and did <em style="font: inherit;">not</em> have any plans to declare dividends in the future</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 being recorded as a reduction of general and administrative expense during the year ending <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221;, the warrants should be reclassified to equity.&#160;</p>
  <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em></b>&#160;&#160; <b>PUBLIC OFFERING</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> June 1, 2021, </em>the Company completed a public offering (the &#8220;Offering&#8221;) of Units (each, a &#8220;Unit&#8221;), with each Unit consisting of (a) <em style="font: inherit;">one</em> share of common stock (or pre-funded warrant to purchase <em style="font: inherit;">one</em> share of common stock in lieu thereof, with an exercise price of $0.0001 per share, each a &#8220;Pre-Funded Warrant&#8221;) and (b) <em style="font: inherit;">one</em> warrant to purchase 0.75&#160;of a share of our common stock, with an exercise price of $4.125 per share (each, an &#8220;Investor Warrant&#8221;). Pursuant to the Offering, the Company sold 4,133,400 Units consisting of (a) <em style="font: inherit;">one</em> share of common stock and (b) <em style="font: inherit;">one</em> Investor Warrant (inclusive the underwriter&#8217;s overallotment option of 1,200,000 of such Units), and 5,066,600 Units consisting of (a) <em style="font: inherit;">one</em> Pre-Funded Warrant and (b) <em style="font: inherit;">one</em> Investor Warrant. The Units had <em style="font: inherit;">no</em> stand-alone rights and were <em style="font: inherit;">not</em> certificated or issued as stand-alone securities. Accordingly, as result of the sale of such Units in the Offering, the Company issued in aggregate 4,133,400 shares of common stock, Pre-Funded Warrants exercisable for 5,066,600 shares of common stock, and Investor Warrants exercisable for 6,900,000 shares of common stock. The offering price was $3.75 for each Unit consisting of (a) <em style="font: inherit;">one</em> share of common stock and (b) <em style="font: inherit;">one</em> Investor Warrant, and $3.7499 for each Unit consisting of (a) <em style="font: inherit;">one</em> Pre-Funded Warrant and (b) <em style="font: inherit;">one</em> Investor Warrant. Net proceeds from the Offering were approximately $31.5 million, after underwriter discounts, commissions, legal and accounting fees, and certain other costs of approximately $3.0 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480700824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em></b>&#160;&#160;&#160;<b>BUSINESS COMBINATION</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">14,</em> <em style="font: inherit;">2020,</em> Reviva Pharmaceuticals Holdings,&#160;Inc., a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp., a British Virgin Islands exempted company (&#8220;Tenzing&#8221;), Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#8220;Merger Sub&#8221;), and Reviva Pharmaceuticals,&#160;Inc., a Delaware corporation (together with its consolidated subsidiaries)&#160;Reviva Pharmaceuticals,&#160;Inc., consummated a business combination (the &#8220;Business Combination&#8221;) through the merger of Merger Sub with and into Reviva Pharmaceuticals,&#160;Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">20,</em> <em style="font: inherit;">2020</em> (the &#8220;Merger Agreement&#8221;), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals,&#160;Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), Merger Sub merged with and into Reviva Pharmaceuticals,&#160;Inc., with Reviva Pharmaceuticals,&#160;Inc.&#160;as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals,&#160;Inc.&#160;becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings,&#160;Inc. (together with its consolidated subsidiaries).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Upon the closing of the Business Combination, all shares of Reviva Pharmaceuticals, Inc. common stock and preferred stock issuance and outstanding immediately prior to the Business Combination converted into common stock of Reviva Pharmaceuticals Holdings, Inc., with a par value of $0.0001 per share at an exchange rate of 0.152268 for common stock and 0.414647 for preferred stock.&#160; Each issued and outstanding warrant to acquire shares of Reviva Pharmaceuticals, Inc. common stock were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into a warrant for Reviva Pharmaceuticals Holdings, Inc. common stock, with its price and number of shares adjusted based on the common stock exchange rate of <em style="font: inherit;">0.152268.</em>&#160; Each outstanding option to acquire Reviva Pharmaceuticals, Inc. common stock (all of which were vested at the date of the Business Combination), were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into an option to acquire shares of Reviva Pharmaceuticals Holdings, Inc. common stock at the common stock exchange rate of <em style="font: inherit;">0.152268.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In addition to the merger consideration set forth above, the Reviva Pharmaceuticals,&#160;Inc.&#160;Security holders also have a contingent right to receive up to an additional 1,000,000 shares of Reviva Pharmaceuticals Holdings,&#160;Inc.&#160;(the &#8220;Earnout Shares&#8221;)&#160;based on the stock price performance of the common stock and the achievement by the Company&#160;of certain clinical trial milestones during the <em style="font: inherit;">three</em> (3)&#160;year period following the Closing (the &#8220;Earnout Period&#8221;). In order to receive the Earnout Shares, during the Earnout Period, both:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.3%;">&#160;</td><td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the closing price of the Company&#8217;s&#160;common stock has to be equal to or greater than $15.00 per share for any 20 trading days within any 30 trading day period; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.3%;">&#160;</td><td style="vertical-align:top;width:1.4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="vertical-align:top;width:42%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company&#160;must receive positive data from (i)&#160;its <em style="font: inherit;">first</em> Phase <em style="font: inherit;">3</em> trial in Acute Schizophrenia and (ii)&#160;either a Phase <em style="font: inherit;">2</em> clinical trial in pulmonary arterial hypertension or idiopathic pulmonary fibrosis.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Business Combination was accounted for as a reverse merger in accordance with U.S. GAAP. Under this method of accounting, Tenzing is treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on the holders of Reviva&#160;Pharmaceuticals,&#160;Inc. having a majority of the voting power of the post-combination company, Reviva Pharmaceuticals,&#160;Inc. senior management comprising substantially all of the senior management of the post-combination company, the relative size of Reviva compared to Tenzing, and Reviva Pharmaceuticals,&#160;Inc. operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Reviva&#160;Pharmaceuticals,&#160;Inc. issuing stock for the net assets of Tenzing, accompanied by a recapitalization. The net assets of Tenzing are stated at historical cost, with no goodwill or other intangible assets recorded.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The accompanying financial statements and related notes reflect the historical results of Reviva Pharmaceuticals,&#160;Inc.&#160;prior to the merger and do <em style="font: inherit;">not</em> include the historical results of Tenzing prior&#160;to the consummation of the Business Combination.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480775896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em></b>&#160;&#160;&#160;<b>PROPERTY AND EQUIPMENT, NET</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">Property and equipment, net consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">32,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">32,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,208</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,208</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(41,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(41,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Property and equipment, net</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">Depreciation expense for the&#160;years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $0 and $591 respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301481707800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em></b>&#160;&#160;&#160;<b>EMPLOYEE BENEFIT PLAN</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In <em style="font: inherit;">2014,</em>&#160;Reviva&#160;Pharmaceuticals,&#160;Inc. implemented a tax deferred savings plan, commonly referred to as a <em style="font: inherit;">401</em>(k) plan. Employee&#8217;s contributions are withheld from standard payroll checks and are automatically withdrawn from the Company checking account and deposited into individual employee retirement accounts a few days following each payroll period. Employees can defer or contribute the statutory legal limits. There has been no Company matching of employee contributions to the plan through <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480667832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em></b>&#160;&#160;&#160;<b>CONVERTIBLE PROMISSORY NOTES</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2016</em> Notes</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">From <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">2016</em> through <em style="font: inherit;"> April&#160;</em><em style="font: inherit;">2017,</em> the Company issued an aggregate of $4,795,088 in convertible promissory notes to various investors (the <em style="font: inherit;">&#8220;2016</em> Notes&#8221;). Upon next equity financing close of at least $5,000,000, (&#8220;Qualified Financing&#8221;), the <em style="font: inherit;">2016</em> Notes were to be converted if the entire balance had <em style="font: inherit;">not</em> been paid, at which time the then outstanding balance and accrued interest was to automatically be cancelled and converted into that number of conversion shares at a price equal to the lower of either (i)&#160;a 20% discount to the price paid by investors in the qualified financing (&#8220;Qualified Financing Event Share Price&#8221;), or (ii)&#160;an $85,000,000 pre-offering valuation divided by the number of shares of the Company&#8217;s common stock outstanding on a fully diluted basis immediately prior to the closing of such a qualified financing event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Interest was initially accrued at 8% per annum and was scheduled to be paid in cash at maturity date. The <em style="font: inherit;">2016</em> Notes were scheduled to mature <span style="-sec-ix-hidden:c81966657">twelve</span>&#160;months from the dates of issue. The <em style="font: inherit;">2016</em> Notes were neither converted nor paid back, and therefore were in default since <em style="font: inherit;">2017</em> and were accruing interest at a default rate of 12% per annum. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2019,</em> the Company owed $3,490,087 and $1,192,496 as principle and accrued interest, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The original&#160;stated conversion term for the <em style="font: inherit;">2016</em> Notes created a contingent BCF that was <em style="font: inherit;">not</em> measurable due to a contingency in the conversion mechanics that would allow a conversion to take place at the lower of either a <em style="font: inherit;">20%</em> discount to the Qualified Financing Event Share Price or a <em style="font: inherit;">$85</em>&#160;million valuation. Consequently, the BCF would have been recognized as additional interest expense had the conversion taken place under the original terms of the <em style="font: inherit;">2016</em> Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 10, 2020, </em>Reviva executed an amendment to the <em style="font: inherit;">2016</em> Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the <em style="font: inherit;">2016</em> Notes (with the exception of $1,200,000 principal on <em style="font: inherit;">one</em> note which was repaid in cash subsequent to the Business Combination) automatically converted into 3,788,461 shares of Reviva common stock at a conversion price equal to $1.329698. On consummation of the Business Combination, these shares converted into 576,836 shares of the Company&#8217;s common stock. The holders have <em style="font: inherit;">no</em> further rights under the <em style="font: inherit;">2016</em> notes. The Company evaluated whether there was a BCF to be recognized at the time of conversion and determined that there was <span style="-sec-ix-hidden:c81966680">none.</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2,</em> <em style="font: inherit;">2020,</em> there was a judgement issued by the District Court of Harris County, Texas, pursuant to an agreement reached between the Company and an investor in the <em style="font: inherit;">2016</em> Notes. Under the terms of the judgements, the Company was obligated to repay an investor of the <em style="font: inherit;">2016</em> Notes, the principal investment of $1,200,000, accrued interest of $242,236, and legal fees of $5,000. The $1,447,236 obligatory payment accrued interest at 5.5% per annum and was fully paid, (including accrued interest of $79,840 subsequent to the judgement).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2018</em> Notes</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">From <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">2018</em> through <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">2019,</em> the Company issued an aggregate of $275,000 in convertible promissory notes to various investors (the <em style="font: inherit;">&#8220;2018</em> notes&#8221;). Upon a Qualified Financing, the <em style="font: inherit;">2018</em> Notes could have been converted if the entire balance had <em style="font: inherit;">not</em> been paid. The principal and accrued interest of the <em style="font: inherit;">2018</em> notes would have automatically been converted into that number of shares at a price equal to a 20% discount to the Qualified Financing event price (price paid by investors in the Qualified Financing).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Additionally, the holders of the <em style="font: inherit;">2018</em> notes were also eligible for an equivalent number of contingent warrants (i.e. as the number of converted shares), to purchase common stock (<em style="font: inherit;">&#8220;2018</em> Contingent Warrants&#8221;) with a strike price equal to the Qualified Financing event price with a maturity of 5&#160;years from the date of such a conversion event. These warrants are no longer exercisable and were cancelled during the year ended&#160;<em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2019.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Interest on the <em style="font: inherit;">2018</em> Notes accrued at 8% per annum and was scheduled to be paid in cash at maturity unless converted. The <em style="font: inherit;">2018</em> Notes were scheduled to mature <span style="-sec-ix-hidden:c81966709">six</span>&#160;months from the date of issue with an option to extend the maturity by an additional <em style="font: inherit;">six</em>&#160;months with certain additional conversion privileges. Pursuant to the option, the maturity dates of all <em style="font: inherit;">2018</em> notes were extended an additional <span style="-sec-ix-hidden:c81966712">six</span>&#160;months. The <em style="font: inherit;">2018</em> Notes were neither converted nor paid back and continued to accrue interest at a default rate of 8% per annum.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 10, 2020, </em>Reviva executed an amendment to the <em style="font: inherit;">2018</em> Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the <em style="font: inherit;">2018</em> Notes automatically converted into 370,811 shares of Reviva common stock at a conversion price equal to $0.831018 for each holder of the <em style="font: inherit;">2018</em> Notes who purchased at least <em style="font: inherit;">$50,000</em> in aggregate principal amount of <em style="font: inherit;">2018</em> Notes or (ii)&#160;$1.330045 for each holder of the <em style="font: inherit;">2018</em> Notes who purchased less than <em style="font: inherit;">$50,000</em> in aggregate principal amount of <em style="font: inherit;">2018</em> Notes. On consummation of the Business Combination, these shares converted into 56,461 shares of the Company&#8217;s common stock. The holders have <em style="font: inherit;">no</em> further rights under the <em style="font: inherit;">2018</em> notes. The conversion terms included in the amendment created a BCF of $159,025 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Notes</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">From <em style="font: inherit;"> March&#160;</em>through <em style="font: inherit;"> May&#160;</em><em style="font: inherit;">2020,</em> the Company issued an aggregate of $610,000 in convertible promissory notes to various investors (<em style="font: inherit;">&#8220;2020</em> Notes&#8221;). Upon a Qualified Financing, the <em style="font: inherit;">2020</em> Notes could be converted if the entire balance had <em style="font: inherit;">not</em> been paid. The principal and accrued interest of the <em style="font: inherit;">2020</em> notes was to automatically be converted into that number of shares at a price equal to a 20% discount to the Qualified Financing event price (price paid by investors in the Qualified Financing).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">Additionally, the holders of the <em style="font: inherit;">2020</em> Notes were also eligible for an equivalent number of warrants (i.e. as the number of converted shares), to purchase common stock (<em style="font: inherit;">&#8220;2020</em> contingent warrants&#8221;) with a strike price equal to the Qualified Financing event price with a maturity of 5 years from the date of such a conversion event. The holders of the <em style="font: inherit;">2020</em> Notes, for entering into the Notes agreement, were also eligible to receive common stock when the <em style="font: inherit;">2020</em> Notes were converted into preferred shares in a Qualified Financing event (<em style="font: inherit;">&#8220;2020</em> Contingent Stock&#8221;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 10, 2020, </em>Reviva executed an amendment to the <em style="font: inherit;">2020</em> Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the <em style="font: inherit;">2020</em> Notes automatically converted into 744,916 shares of Reviva common stock at a conversion price equal to $0.831009 for each holder of the <em style="font: inherit;">2020</em> Notes who purchased at least <em style="font: inherit;">$50,000</em> in aggregate principal amount of the <em style="font: inherit;">2020</em> Notes or (ii)&#160;$1.329770 for each holder of the <em style="font: inherit;">2020</em> Notes who purchased less than <em style="font: inherit;">$50,000</em> in aggregate principal amount of <em style="font: inherit;">2020</em> Notes. On consummation of the Business Combination, these shares converted into 113,422 shares of the Company&#8217;s common stock. The holders have <em style="font: inherit;">no</em> further rights under the <em style="font: inherit;">2020</em> notes and the warrants issued in connection with the notes are no longer exercisable. The conversion terms included in the amendment created a BCF of $317,730 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Between <em style="font: inherit;"> August 2020 </em>and <em style="font: inherit;"> October 2020, </em>the Company issued and received an aggregate principal amount of $500,000 in unsecured convertible promissory notes to certain investors to finance its ordinary course of administrative costs and expenses and other expenses incurred in connection with the consummation of the Business Combination. These notes were interest free. These notes provided that they automatically converted, immediately prior to consummation of the business combination, into 601,632 shares of Reviva common stock at a conversion rate equal to $0.831063. The conversion terms created a BCF of $274,083 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In addition, the Company entered into a contingent capital commitment with certain investors for $2,000,000 (&#8220;Reviva Contingent Interim Period Notes&#8221;) that became effective upon consummation of the Business Combination. The Reviva Contingent Interim Period Notes were interest free. The Reviva Contingent Interim Period Notes provided that the notes automatically converted, immediately prior to consummation of the Business Combination, into 1,718,280 shares of Reviva common stock at a conversion price equal to $1.163953. On consummation of the Business Combination, these shares converted into 261,626 shares of the Company&#8217;s common stock. The holders have <em style="font: inherit;">no</em> further rights under these notes. The conversion terms created a BCF of $210,842 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480763528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em></b>&#160;&#160;&#160;<b>INCOME TAXES</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As a result of the Company's history of net operating losses and full valuation allowance against its deferred tax assets, there was <em style="font: inherit;">no</em> current or deferred income tax provision other that current state minimum taxes for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Reconciliations to the statutory federal income tax rate and the Company's effective tax rate consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Statutory federal income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,788,135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(794,343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal tax benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(58,152</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(114,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,924</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,414</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(334,122</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">227,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beneficial conversion feature related to notes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">201,953</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,301</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,173,051</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">461,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The components of deferred tax assets included on the balance sheet are:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NOL carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,262,916</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177,607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accruals and reserves</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,911</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">197,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">237,976</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed assets/capitalized start-up costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,544,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,429,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,544,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,429,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81966836">&#8212;</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81966837">&#8212;</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets.&#160; The total increase in valuation allowance is $2,115,079 for the year ending <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company currently has net operating loss carryforwards of approximately $49.2&#160;million and $13.2&#160;million for U.S. Federal and state purposes respectively. Approximately $35.3 million of the U.S. federal losses begin to expire in <em style="font: inherit;">2029.</em> The balance, all post-<em style="font: inherit;">2018</em> federal net operating losses <em style="font: inherit;"> may </em>be carried forward indefinitely. The deferred tax asset relates to the NOL carryforwards. Management has determined based on all the available information that a <em style="font: inherit;">100%</em> valuation reserve is required.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company had no research and development credit carryforwards to offset federal and California state income taxes, respectively, available to reduce its future taxable income, if any.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Tax Reform Act of <em style="font: inherit;">1986</em> limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company.&#160; In the event that the Company has a change in ownership, utilization of carryforwards could be limited.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company has elected to recognize interest and penalties related to uncertain tax positions as components of income tax expense.&#160; As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company has no accrual for payment of interest related to unrecognized tax benefits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company&#8217;s income tax returns for all years remain open to examination by federal and state taxing authorities.&#160; The Company does <em style="font: inherit;">not</em> expect that its unrecognized tax benefit will change significantly in the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company has no unrecognized tax benefits that, if recognized, would change its effective rate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">On <em style="font: inherit;"> March&#160;</em><em style="font: inherit;">27,</em> <em style="font: inherit;">2020,</em> the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law. Certain provisions of the CARES Act impacted the <em style="font: inherit;">2019</em> and <em style="font: inherit;">2020</em> income tax provision computations of the Company and were reflected in the appropriate periods. The CARES Act contains modifications on the limitation of business interest for tax&#160;years beginning in <em style="font: inherit;">2019</em> and <em style="font: inherit;">2020.</em> The modifications to Section&#160;<em style="font: inherit;">163</em>(j) increase the allowable business interest deduction from <em style="font: inherit;">30%</em> of adjusted taxable income to <em style="font: inherit;">50%</em> of adjusted taxable income. As the company is in losses, there is <em style="font: inherit;">no</em> modification for the current year.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301481695832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em></b>&#160;<b> </b>&#160;<b>LOSS</b>&#160;<b>PER SHARE</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Loss per share calculations for all periods prior to the Business Combination have been retrospectively adjusted for the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Subsequent to the Business Combination, earnings per share is calculated based on the weighted average shares of common stock then outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. The weighted average shares of common stock outstanding is based on the 9,231,737 shares of common stock outstanding immediately after the reverse recapitalization in connection with the Business Combination and assumes these shares have been outstanding as of the beginning of the earliest period presented.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the Company has excluded the potential effect of warrants to purchase shares of common stock totaling 13,883,732 and 7,007,581 shares and the dilutive effect of outstanding stock options totaling 192,898 and 65,471, as described in Note&#160;<em style="font: inherit;">11,</em> in the calculation of diluted loss per share, as the effect would be anti-dilutive due to losses incurred. Additionally, 1,000,000 earn-out shares have been excluded as they are <em style="font: inherit;">not</em> considered issued for accounting purposes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480804568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em></b>&#160;&#160;&#160;<b>STOCKHOLDERS</b>&#8217;<b> EQUITY (DEFICIT)</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our authorized capital stock consists of:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;">&#160;</td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">115,000,000 shares of common stock, par value $0.0001 per share; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;">&#160;</td><td style="vertical-align:top;width:3.3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10,000,000 shares of preferred stock, par value $0.0001 per share.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were 14,433,286 shares of our common stock outstanding, and no shares of preferred stock outstanding. In <em style="font: inherit;"> November 2021, </em>the Company issued 11,000 shares of common stock to a consultant in exchange for services provided. In <em style="font: inherit;"> September&#160;</em><em style="font: inherit;">2020,</em> the Company&#160;issued 38,992 shares of common stock to current and past employees in lieu of certain dues and obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Common Stock</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Voting.&#160;&#160;&#160;The holders of our common stock are entitled to <em style="font: inherit;">one</em> vote for each share held of record on all matters on which the holders are entitled to vote (or consent pursuant to written consent). Directors are elected by a plurality of the votes present in person or represented by proxy and entitled to vote.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Dividends.&#160;&#160;&#160;The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Liquidation Rights.&#160;&#160;&#160;In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Conversion Right.&#160;&#160;&#160;The holders of common stock have <em style="font: inherit;">no</em> conversion rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Preemptive and Similar Rights.&#160;&#160;&#160;The holders of common stock have <em style="font: inherit;">no</em> preemptive or similar rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Redemption/Put Rights.&#160;&#160;&#160;There are <em style="font: inherit;">no</em> redemption or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of common stock will be fully-paid and nonassessable.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Preferred Stock</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our board of directors has the authority to issue shares of preferred stock from time to time on terms it <em style="font: inherit;"> may </em>determine, to divide shares of preferred stock into <em style="font: inherit;">one</em> or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were public warrants outstanding to purchase an aggregate of 6,325,000 shares of common stock and private warrants outstanding to purchase an aggregate of 556,313 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each public warrant entitles the holder thereof to purchase one share of common stock at a price <span style="-sec-ix-hidden:c81966876">of&#8201;$11.50</span> per share, subject to adjustment. <em style="font: inherit;">No</em> public warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to such shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We <em style="font: inherit;"> may </em>call the public warrants for redemption, in whole and <em style="font: inherit;">not</em> in part, at a price <span style="-sec-ix-hidden:c81966880">of&#8201;$0.01</span> per warrant:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the <em style="font: inherit;">third</em> trading business day prior to the notice of redemption to holders of the public warrants, and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire <em style="font: inherit;">30</em>-day trading period referred to above and continuing each day thereafter until the date of redemption.</p> </td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">at any time while the public warrants are exercisable,</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">upon <em style="font: inherit;">not</em> less than <em style="font: inherit;">30</em>&#160;days&#8217;&#160;prior written notice of redemption to each warrant holder,</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The private warrants are substantially similar to the public warrants except such private warrants;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">are exercisable for cash or on a cashless basis, at the holder&#8217;s option</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;">&#160;</td><td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The redemption price is to be calculated as the <em style="font: inherit;">10</em>-day average trading price ending <em style="font: inherit;">one</em> trading business day prior to the notice of redemption.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 26pt; text-indent: 18pt;">In <em style="font: inherit;">no</em> event will the Company be required to net cash settle either the public or the private warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company classified the private warrants pursuant to ASC <em style="font: inherit;">815</em> as derivative liabilities with subsequent changes in their fair values to be recognized in the consolidated financial statements at each reporting date. The Company calculated the fair value of the private warrants as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> as $372,730 using a Black-Scholes model. The key inputs used in the Black-Scholes calculation were, the risk-free interest rate, expected volatility, expected life, exercise price and stock price. The risk-free interest rate was estimated to be 1.11%, the expected volatility was estimated to be 73.0%, and the expected life was estimated to be 3.96&#160;years. The exercise price was $11.50, and the stock price $2.89. Due to fair value changes during the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company recorded a gain on remeasurement of warrant liabilities of $1,591,055.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The exercise price and number of shares of common stock issuable on exercise of the warrants <em style="font: inherit;"> may </em>be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or a recapitalization, reorganization, merger or consolidation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em> The fair value of these warrants on the date of issuance was $1,279,182.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0&#160;million and the Pre-Funded Warrants are exercisable into <span style="-sec-ix-hidden:c81966911">one</span> share of common stock at an exercise price of $0.0001 per share at any time after issuance. Additionally, in connection with the Offering, the Company issued Investor Warrants exercisable for&#160;6,900,000&#160;shares of common stock&#160;with an&#160;exercise price of $4.125 per share of common stock any time after issuance. The Investor Warrants expire on <em style="font: inherit;"> June 1, 2026. </em>During the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> Investor Warrants for 23,849&#160;shares of common stock were exercised with proceeds of $98,378 and Pre-Funded Warrants for 1,033,300&#160;shares of common stock were exercised with proceeds of $103. The Company has determined that&#160;as the&#160;Pre-Funded Warrants and&#160;Investor Warrants&#160;were issued at fair value in a public offering of Units with <em style="font: inherit;">no</em> debt funding included in the offering, the&#160;Pre-Funded Warrants and Investor Warrants should be classified as equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Common stock warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;"> July&#160;</em><em style="font: inherit;">2020,</em> the company issued warrants with a <span style="-sec-ix-hidden:c81966925">five</span>-year term to purchase 120,456 shares of common stock at $22.99 per share to certain current and past consultants (<em style="font: inherit;">&#8220;2020</em> warrants&#8221;). The <em style="font: inherit;">2020</em> warrants were exercisable immediately. The Company estimated the fair value of the <em style="font: inherit;">2020</em> warrants to be $1,178,182, using the Black-Scholes-Merton option-pricing model with the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Assumptions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yields</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The&#160;<em style="font: inherit;">2020</em> warrants are classified as equity and included in general and administrative expense during the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2016</em> Warrants</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company issued warrants in connection with the <em style="font: inherit;">2016</em> Notes (the <em style="font: inherit;">&#8220;2016</em> Warrants&#8221;) to purchase 5,812 shares of its common stock which will expire on <em style="font: inherit;"> April&#160;</em><em style="font: inherit;">28,</em> <em style="font: inherit;">2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of the warrants was originally estimated to be approximately $101,000 and they were classified as a liability on the balance sheet as the strike price was <em style="font: inherit;">not</em> established at the time of grant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Business Combination, the strike price was set at $42.29 based on the terms of the warrants at a common stock conversion rate of 0.152268.&#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be 0.36%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be 126%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be 1.4 years. The dividend yield was assumed to be <span style="-sec-ix-hidden:c81966947">zero</span> since the Company had <em style="font: inherit;">not</em> historically declared dividends and did <em style="font: inherit;">not</em> have any plans to declare dividends in the future</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 being recorded as a reduction of general and administrative expense during the year ending <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC <em style="font: inherit;">480,</em> &#8220;Distinguishing Liabilities from Equity&#8221;, the warrants should be reclassified to equity.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480724680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock Option Plan and Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em></b>&#160;&#160;&#160;<b>STOCK OPTION PLAN AND STOCK-BASED COMPENSATION</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2006</em> Equity Incentive Plan</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Reviva&#8217;s board of directors adopted, and Reviva&#8217;s stockholders approved, the Reviva Pharmaceuticals,&#160;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan, effective as of <em style="font: inherit;"> August&#160;</em><em style="font: inherit;">2006.</em> The Reviva Pharmaceuticals,&#160;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan provided for the grant of incentive stock options, or ISOs, within the meaning of Section&#160;<em style="font: inherit;">422</em> of the Code, to Reviva&#8217;s employees, and for the grant of nonstatutory stock options, or NSOs, and restricted stock awards to Reviva&#8217;s employees, officers, directors and consultants; provided such consultants render bona fide services <em style="font: inherit;">not</em> in connection with the offer and sale of securities in a capital-raising transaction. As of <em style="font: inherit;">2016,</em> <em style="font: inherit;">no</em> new grants of awards are permitted under the Reviva Pharmaceuticals,&#160;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon the Business Combination, the Reviva Pharmaceuticals,&#160;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan was amended to change its name to the Reviva Pharmaceuticals Holdings,&#160;Inc. <em style="font: inherit;">2006</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2006</em> Equity Incentive Plan&#8221;), and each outstanding option to acquire Reviva common stock (whether vested or unvested) under the <em style="font: inherit;">2006</em> Equity Incentive Plan was assumed by the Company and automatically converted into an option to acquire shares of common stock, with its price and number of shares equitably adjusted based on the conversion of the shares of common stock of Reviva into shares of common stock of the Company pursuant to the Merger Agreement. Pursuant to such assumption and automatic conversion, as of the consummation of the Business Combination there are outstanding options under the <em style="font: inherit;">2006</em> Equity Incentive Plan exercisable for an aggregate of 65,471 shares of Company common stock, and <em style="font: inherit;">no</em> new grants of awards are permitted under the <em style="font: inherit;">2006</em> Equity Incentive Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; "><em style="font: inherit;">2020</em> Equity Incentive Plan</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">14,</em> <em style="font: inherit;">2020,</em> the Reviva Pharmaceuticals Holdings,&#160;Inc. <em style="font: inherit;">2020</em> Equity Incentive Plan (the <em style="font: inherit;">&#8220;2020</em> Equity Incentive Plan&#8221;) became effective. The general purpose of the <em style="font: inherit;">2020</em> Equity Incentive Plan is to provide a means whereby employees, officers, directors, consultants, advisors or other individual service providers <em style="font: inherit;"> may </em>develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to us, thereby advancing our interests and the interests of our stockholders.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2021, </em>an aggregate of 1,384,761 shares of common stock <em style="font: inherit;"> may </em>be issued under the <em style="font: inherit;">2020</em> Equity Incentive Plan, subject to equitable adjustment in the event of stock splits and other capital changes (the &#8220;Share Reserve&#8221;). The Share Reserve will automatically increase on <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1st</em> of each year, for a period of <em style="font: inherit;">not</em> more than <span style="-sec-ix-hidden:c81966986">ten</span>&#160;years, commencing on <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1st</em> of the year following the year in which the effective date of the <em style="font: inherit;">2020</em> Equity Incentive Plan occurs, and ending on (and including) <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2030,</em> in an amount equal to the lesser of (i)&#160;<em style="font: inherit;">ten</em>&#160;percent (10%) of the total number of shares of Common Stock outstanding on <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31st</em> of the preceding calendar year or (ii)&#160;such number of shares of common stock determined by the Company&#8217;s board of directors (the &#8220;Annual Increase&#8221;). Notwithstanding the foregoing and, subject to adjustment as provided in the <em style="font: inherit;">2020</em> Equity Incentive Plan, the maximum number of shares which <em style="font: inherit;"> may </em>be issued in respect of Incentive Stock Options shall be equal to 1,384,761.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Stock-Based Compensation Expense</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the Company recorded stock-based compensation of $106,713 and $0, respectively. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company had unrecognized stock-based compensation expense of $281,397 and $0.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Determining Fair Value</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Valuation and Recognition &#8211; The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Expected Term &#8211; Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Expected Volatility - Expected volatility is based on the Company&#8217;s historical stock volatility data over the expected term of the awards.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury <em style="font: inherit;">zero</em>-coupon issues with an equivalent expected term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Dividend Yield &#8211; The Company has <em style="font: inherit;">not</em> paid a dividend and does <span style="-sec-ix-hidden:c81967008">not</span> anticipate paying a dividend in the foreseeable future.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The assumptions used in estimating the fair value of options granted in <em style="font: inherit;">2021</em> are summarized as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Expected Term in years - 5.20 - 6.08</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Volatility &#8211; 87.1% - 93.9%</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Risk-free interest rate &#8211; 0.95% - 1.31%</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Dividend Yield &#8211; 0.00%</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company granted no stock options during the year ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Activity under the stock plans for the years ending <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2021</em> is as follows.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Shares</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Available for</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Grant</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Options</b><br/> <b>Outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Weighted</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Average</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Exercise</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Price per</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Share</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2019</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">343,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">112,932</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options authorized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">461,587</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">47,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(47,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Effect of plan amendment on business combination</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(391,332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2020</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">461,587</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">65,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">16.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options authorized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">923,174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(127,427</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">127,427</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2021</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,257,334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">192,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested and expected to vest, December 31, 2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">192,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Options outstanding under the stock plans are as follows as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b><br/> <b>Outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br/> <b>Average</b><br/> <b>Remaining</b><br/> <b>Contractual</b><br/> <b>Life (Years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b><br/> <b>Exercisable</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br/> <b>Average</b><br/> <b>Exercise</b><br/> <b>Prices per Share</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;">48,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;">16,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;">81,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">46,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">192,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">95,803</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301479008440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em></b>&#160;&#160;&#160;<b>COMMITMENTS AND CONTINGENCIES</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline; ">Clinical trials</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Since <em style="font: inherit;">2010,</em> the Company has entered into multiple clinical trial agreements with medical institutions in the United States, Europe and Asia for the purpose of enrolling patients into various clinical trials. The agreements are substantially similar by trial and include a detailed listing of the clinical trial services for which the Company will pay, how much will be paid for each service, a set-up charge (if any), Investigational Review Board fees, contractual term, and other provisions. The clinical trial services provided by each site generally include the screening of prospective patients and, for those patients to be enrolled in the study, administration of the Company&#8217;s investigation drug according to the trial protocol, any required hospitalization, ancillary medical supplies, and <em style="font: inherit;">2</em>-week patient follow-up. Further, each agreement requires the Company to indemnify each respective clinical site against any and all liability, loss, or damage it <em style="font: inherit;"> may </em>suffer as a result of <em style="font: inherit;">third</em>-party claims; the Company maintains general product liability insurance of <em style="font: inherit;">not</em> less than $5&#160;million in conjunction with this indemnification. The agreements <em style="font: inherit;"> may </em>be terminated upon <em style="font: inherit;">30</em>&#160;days&#8217; written notice, subject to conditions of paying all liabilities incurred through the date of termination. Additionally, with each screened patient, the Company incurs expense with other entities engaged to provide independent review of patient medical records.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline; ">Indemnification</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">From time to time, in its normal course of business, the Company <em style="font: inherit;"> may </em>indemnify other parties, with whom it enters into contractual relationships, including lessors and parties to other transactions with the Company. The Company <em style="font: inherit;"> may </em>agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or <em style="font: inherit;">third</em>-party infringement claims. It <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be possible to determine the maximum potential amount of liability under such indemnification obligations due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Historically, there have been <em style="font: inherit;">no</em> such indemnification claims. The Company has also indemnified its directors and executive officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual <em style="font: inherit;"> may </em>be involved by reason of such individual being or having been a director or executive officer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="text-decoration: underline; ">Operating Leases</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">The Company adopted ASC <em style="font: inherit;">842</em> to its existing lease on <em style="font: inherit;"> January 1, 2020. </em>The Company has elected to apply the short-term lease exception to leases of <em style="font: inherit;">one</em> year or less. Presently, the Company has a single <span style="-sec-ix-hidden:c81967087">twelve</span>-month lease on its Corporate Office located at <em style="font: inherit;">19925</em> Stevens Creek Blvd., Suite <em style="font: inherit;">100,</em> Cupertino, CA <em style="font: inherit;">95014.</em> The monthly lease payment is approximately $1,200 and the lease was renewed on <em style="font: inherit;"> February 1, 2021, </em>for another 12-month term.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480789240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em></b>&#160;&#160;&#160;<b>SUBSEQUENT EVENTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2022, </em>the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent (&#8220;Wainwright&#8221;), pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell, from time to time through Wainwright, shares of its common stock for aggregate gross proceeds of up to $12.9 million (the &#8220;Shares&#8221;). As of the date of this filing, the Company has <span style="-sec-ix-hidden:c81967095">not</span> made any sales pursuant to the ATM Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478948424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Basis of Presentation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The summary of significant accounting policies presented below is designed to assist in understanding the Company&#8217;s financial statements. Such financial statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Principals of consolidation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The preparation of&#160;consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are <em style="font: inherit;">not</em> limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company&#8217;s cash are held in demand deposit form by <em style="font: inherit;">one</em> financial institution. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are <em style="font: inherit;">not</em> limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company&#8217;s operating results <em style="font: inherit;"> may </em>be materially affected by the foregoing factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Cash</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of <em style="font: inherit;">three</em>&#160;months or less to be cash equivalents. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company&#8217;s cash was maintained in demand deposit forms at <em style="font: inherit;">two</em> financial institutions. Deposits in financial institutions <em style="font: inherit;"> may, </em>from time to time, have exceed federally insured limits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Property and equipment</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than <em style="font: inherit;">one</em> year for: (<em style="font: inherit;">1</em>)&#160;assets purchased; (<em style="font: inherit;">2</em>)&#160;existing assets that are replaced, improved or the useful lives have been extended. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs are expensed as incurred. Assets classified as property and equipment are stated at cost less accumulated depreciation and are depreciated using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:c81966522">three</span> and <span style="-sec-ix-hidden:c81966523">five</span>&#160;years, or the lease term of the respective assets, whichever is less. When assets are retired or otherwise disposed, their original cost and related accumulated depreciation are removed from the consolidated balance sheet, and any resulting gain or loss is reflected in related operating expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Leases</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">2,</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, as amended. The ASU introduces a new lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&#8217;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of consolidated financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this standard effective <em style="font: inherit;"> January 1, 2019, </em>and determined that there is <em style="font: inherit;">no</em> material impact that the new accounting guidance will have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Research and development costs</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are <em style="font: inherit;">not</em> limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">General and administrative costs</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are <em style="font: inherit;">not</em> limited to, payroll and personnel expenses, travel and entertainment, consulting costs, conference and meeting costs, legal expenses and allocated overhead, including rent depreciation, and utilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Income taxes</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company utilizes FASB ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is &#8220;more likely-than-<em style="font: inherit;">not&#8221;</em> that a deferred tax asset will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160; The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis.&#160; The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of <em style="font: inherit;">100%</em> has been established due to the uncertainty of the Company&#8217;s realization of the net operating loss carry forward prior to its expiration.&#160; In the event the Company determines that it would be able to realize its&#160;deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes.&#160; Conversely, in the event that all or part of the net deferred tax assets are determined <em style="font: inherit;">not</em> to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Stock-based compensation</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC <em style="font: inherit;">718</em> which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Expected term</span>&#8201;&#8212;&#8201;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Expected volatility</span>&#8201;&#8212;&#8201;Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Expected dividend</span>&#8201;&#8212;&#8201;The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has <em style="font: inherit;">no</em> plans to pay dividends.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Risk-free interest rate</span>&#8201;&#8212;&#8201;The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury <em style="font: inherit;">zero</em>-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; <span style="text-decoration: underline; ">Forfeiture rate</span>&#8201;&#8212;&#8201;The Company made the <em style="font: inherit;">one</em>-time election to recognize forfeitures when they occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">As of <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2019,</em> the Company adopted ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">07,</em> Compensation-Stock Compensation (Topic <em style="font: inherit;">718</em>): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting of share-based payment awards issued to employees and nonemployees. The adoption did <em style="font: inherit;">not</em> materially impact our consolidated financial statements. The Company recognizes fair value of stock options granted to non-employees as a stock-based compensation expense over the period in which the related services are received. Non-employee option grants that do <em style="font: inherit;">not</em> vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes-Merton option-pricing model, is determined, and compensation expense recognized during the period is adjusted accordingly.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Fair Value Measurements of Warrants</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">ASC <em style="font: inherit;">820</em> &#8220;Fair Value Measurements&#8221; defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC <em style="font: inherit;">820</em> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC <em style="font: inherit;">820</em> establishes a fair value hierarchy that distinguishes between (<em style="font: inherit;">1</em>)&#160;market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (<em style="font: inherit;">2</em>)&#160;an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <em style="font: inherit;">three</em> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#160;<em style="font: inherit;">1</em>) and the lowest priority to unobservable inputs (Level&#160;<em style="font: inherit;">3</em>).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;">three</em> levels of the fair value hierarchy under ASC <em style="font: inherit;">820</em> are described below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; Level&#160;<em style="font: inherit;">1&#8201;&#8212;&#8201;Quoted</em> prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;<em style="font: inherit;">1</em> inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; Level&#160;<em style="font: inherit;">2&#8201;&#8212;&#8201;Directly</em> or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are <em style="font: inherit;">not</em> active. Level&#160;<em style="font: inherit;">2</em> also includes assets and liabilities that are valued using models or other pricing methodologies that do <em style="font: inherit;">not</em> require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8226; Level&#160;<em style="font: inherit;">3&#8201;&#8212;&#8201;Unobservable</em> inputs that are supported by little or <em style="font: inherit;">no</em> market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#8203;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_BeneficialConversionFeaturePolicyTextBlock', window );">Beneficial Conversion Feature [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Beneficial Conversion Features</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;">In accordance with FASB ASC <em style="font: inherit;">470</em>-<em style="font: inherit;">20,</em> &#8220;Debt with Conversion and Other Options&#8221; the Company records a beneficial conversion feature (&#8220;BCF&#8221;) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_BeneficialConversionFeaturePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_BeneficialConversionFeaturePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480725240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">32,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">32,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,208</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,208</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(41,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(41,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Property and equipment, net</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480658664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Statutory federal income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,788,135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(794,343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal tax benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(58,152</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(114,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,924</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,414</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(334,122</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">227,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beneficial conversion feature related to notes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">201,953</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other permanent differences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,301</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,173,051</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">461,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NOL carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,262,916</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177,607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accruals and reserves</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,911</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">197,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">237,976</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed assets/capitalized start-up costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,544,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,429,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,544,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,429,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81966836">&#8212;</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81966837">&#8212;</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480748792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Assumptions</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yields</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480639608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock Option Plan and Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Shares</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Available for</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Grant</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Options</b><br/> <b>Outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Weighted</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Average</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Exercise</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Price per</b></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b><b>Share</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2019</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">343,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">112,932</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options authorized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">461,587</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options cancelled</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">47,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(47,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Effect of plan amendment on business combination</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(391,332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2020</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">461,587</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">65,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">16.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options authorized</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">923,174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(127,427</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">127,427</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance, December 31, 2021</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,257,334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">192,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested and expected to vest, December 31, 2021</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">192,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b><br/> <b>Outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br/> <b>Average</b><br/> <b>Remaining</b><br/> <b>Contractual</b><br/> <b>Life (Years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b><br/> <b>Exercisable</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b><br/> <b>Average</b><br/> <b>Exercise</b><br/> <b>Prices per Share</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;">48,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.85</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">48,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;">16,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;">81,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">46,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">192,898</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">95,803</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301485273944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301482899512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Public Offering (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,133,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_NumberOfUnitsOneIssued', window );">Number of Units, One, Issued (in shares)</a></td>
<td class="nump">4,133,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_NumberOfUnitsTwoIssued', window );">Number of Units, Two, Issued (in shares)</a></td>
<td class="nump">5,066,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_SharesIssuedPricePerShareOne', window );">Shares Issued, Price Per Share, One (in dollars per share)</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_SharesIssuedPricePerShareTwo', window );">Shares Issued, Price Per Share, Two (in dollars per share)</a></td>
<td class="nump">$ 3.7499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Proceeds from Issuance or Sale of Equity, Net</a></td>
<td class="nump">$ 31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember', window );">Public Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">4,133,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_NumberOfUnitsOneIssued', window );">Number of Units, One, Issued (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PreFundedWarrantMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">5,066,600<span></span>
</td>
<td class="nump">1,033,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_InvestorWarrantMember', window );">Investor Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 4.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_NumberOfUnitsOneIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First portion of units issued during period. Each unit is consisting of (a) one share of common stock and (b) one Investor Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_NumberOfUnitsOneIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_NumberOfUnitsTwoIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second portion of units issued during period. Each unit is consisting of one Pre-Funded Warrant and (b) one Investor Warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_NumberOfUnitsTwoIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ProceedsFromIssuanceOrSaleOfEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ProceedsFromIssuanceOrSaleOfEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_SharesIssuedPricePerShareOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of first portion units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_SharesIssuedPricePerShareOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_SharesIssuedPricePerShareTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of second portion units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_SharesIssuedPricePerShareTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_InvestorWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_InvestorWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478878760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Business Combination (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 14, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rvph_RevivaPharmaceuticalsIncMember', window );">Reviva Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance', window );">Additional Shares to be Issued to Security Holders, Contingent on Stock Price Performance (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_StockPricePerformanceMilestonePeriod', window );">Stock Price Performance, Milestone Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays', window );">Threshold Closing Price for Specified Number of Trading Days (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ThresholdTradingDaysForSaleOfShares', window );">Threshold Trading Days for Sale of Shares (Day)</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ThresholdConsecutiveTradingDaysForSaleOfShares', window );">Threshold Consecutive Trading Days for Sale of Shares (Day)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rvph_RevivaPharmaceuticalsIncMember', window );">Reviva Pharmaceuticals, Inc. [Member] | Conversion of Reviva Common Stock into Company's Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ConversionOfStockConversionRate', window );">Conversion of Stock, Conversion Rate</a></td>
<td class="nump">0.152268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rvph_RevivaPharmaceuticalsIncMember', window );">Reviva Pharmaceuticals, Inc. [Member] | Conversion of Reviva Preferred Stock into Company's Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ConversionOfStockConversionRate', window );">Conversion of Stock, Conversion Rate</a></td>
<td class="nump">0.414647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents additional shares to be issued to security holders contingent on stock price performance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ConversionOfStockConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion rate of stock conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ConversionOfStockConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_StockPricePerformanceMilestonePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the milestone period for stock price performance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_StockPricePerformanceMilestonePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold closing price, as adjusted for stock splits, stock dividends, reorganizations or recapitalizations, for any 20 trading days within any 30-trading day period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ThresholdConsecutiveTradingDaysForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which closing stock price must exceed a price per share amount for specified number of trading days, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ThresholdConsecutiveTradingDaysForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ThresholdTradingDaysForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that the closing price of ordinary shares must meet or exceed a price per share, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ThresholdTradingDaysForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rvph_RevivaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rvph_RevivaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480804568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment, Net (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478885512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 13, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">$ (41,708)<span></span>
</td>
<td class="num">$ (41,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 9,208<span></span>
</td>
<td class="nump">$ 9,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480784376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Employee Benefit Plan (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301473149704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Convertible Promissory Notes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 14, 2020</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th"><div>Jun. 01, 2016</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 15, 2020</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Mar. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2018ContingentWarrantsMember', window );">The 2018 Contingent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020ContingentWarrantsMember', window );">The 2020 Contingent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2016NotesIntoCommonStockMember', window );">Conversion of 2016 Notes into Common Stock [Member] | Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="nump">576,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockMember', window );">Conversion of 2018 Notes into Common Stock [Member] | Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="nump">56,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockMember', window );">Conversion of 2020 Notes into Common Stock [Member] | Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="nump">113,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember', window );">Conversion of Reviva Contingent Interim Period Note into Common Stock [Member] | Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2016NotesIntoCommonStockMember', window );">Conversion of 2016 Notes into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,788,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.329698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockMember', window );">Conversion of 2018 Notes into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member', window );">Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.831018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member', window );">Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.330045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockMember', window );">Conversion of 2020 Notes into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member', window );">Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.831009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member', window );">Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.329770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember', window );">Conversion of August 2020 to October 2020 Notes into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.831063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember', window );">Conversion of Reviva Contingent Interim Period Note into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,718,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.163953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember', window );">The 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,795,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_QualifiedFinancingMinimumThreshold', window );">Qualified Financing, Minimum Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors', window );">Qualified Financing, Discount Rate to Price Paid by Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_PreofferingValuationPriorToQualifiedFinancingEvent', window );">Pre-offering Valuation Prior to Qualified Financing Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_DebtInstrumentDebtDefaultInterestRate', window );">Debt Instrument, Debt Default, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,490,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,192,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="nump">$ 7,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember', window );">The 2016 Notes [Member] | One Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,447,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_The2018NotesMember', window );">The 2018 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors', window );">Qualified Financing, Discount Rate to Price Paid by Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_DebtInstrumentDebtDefaultInterestRate', window );">Debt Instrument, Debt Default, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_DebtInstrumentRenewalTerm', window );">Debt Instrument, Renewal Term (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_The2020NotesMember', window );">The 2020 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors', window );">Qualified Financing, Discount Rate to Price Paid by Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_August2020ToOctober2020NotesMember', window );">August 2020 to October 2020 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_RevivaContingentInterimPeriodNoteMember', window );">Reviva Contingent Interim Period Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_DebtInstrumentDebtDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate of outstanding debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_DebtInstrumentDebtDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_DebtInstrumentRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Renewal of the maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_DebtInstrumentRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_PreofferingValuationPriorToQualifiedFinancingEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of pre-offering valuation prior to the qualified financing event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_PreofferingValuationPriorToQualifiedFinancingEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of discount to the price paid by investors in the qualified financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_QualifiedFinancingMinimumThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of money that must be raised by the Company through a future equity financing in order for the principal and interest due on the note to convert into the same equity issued in that financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_QualifiedFinancingMinimumThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2018ContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_The2018ContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020ContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020ContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2016NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2016NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rvph_ClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rvph_ClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2016NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2016NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=rvph_OneInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=rvph_OneInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvph_The2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvph_The2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvph_The2020NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvph_The2020NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvph_August2020ToOctober2020NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvph_August2020ToOctober2020NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvph_RevivaContingentInterimPeriodNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvph_RevivaContingentInterimPeriodNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478835144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 2,115,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">49,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">35,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478819800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Provision for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,788,135)<span></span>
</td>
<td class="num">$ (794,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,152)<span></span>
</td>
<td class="num">(114,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,924<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount', window );">Warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,122)<span></span>
</td>
<td class="nump">227,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount', window );">Beneficial conversion feature related to notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">201,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,301<span></span>
</td>
<td class="nump">19,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,173,051<span></span>
</td>
<td class="nump">461,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 6,004<span></span>
</td>
<td class="nump">$ 8,281<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to warrant expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301478843560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 11,262,916<span></span>
</td>
<td class="nump">$ 9,177,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Accruals and reserves</a></td>
<td class="nump">81,911<span></span>
</td>
<td class="nump">10,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">197,508<span></span>
</td>
<td class="nump">237,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts', window );">Fixed assets/capitalized start-up costs</a></td>
<td class="nump">2,557<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross, Total</a></td>
<td class="nump">11,544,892<span></span>
</td>
<td class="nump">9,429,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,544,892)<span></span>
</td>
<td class="num">(9,429,813)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment and start up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301481503992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Loss Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">14,433,286<span></span>
</td>
<td class="nump">9,231,737<span></span>
</td>
<td class="nump">9,231,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">13,883,732<span></span>
</td>
<td class="nump">7,007,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">192,898<span></span>
</td>
<td class="nump">65,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvph_EarnoutSharesMember', window );">Earn-out Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvph_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvph_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301473486968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stockholders' Equity (Deficit) (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 14, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,433,286<span></span>
</td>
<td class="nump">9,231,737<span></span>
</td>
<td class="nump">9,231,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued', window );">Deferred Compensation Arrangement with Individual, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,591,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,591,055)<span></span>
</td>
<td class="nump">$ 1,084,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember', window );">The 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.152268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total | $</a></td>
<td class="nump">$ 19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | The 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | The 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | The 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | The 2016 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember', window );">Private Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liability, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax, Total | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,591,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember', window );">Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liability, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember', window );">Private Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liability, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember', window );">Private Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liability, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember', window );">Private Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative Liability, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,268<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ClassOfWarrantOrRightRedemptionPricePerShare', window );">Class of Warrant or Right, Redemption Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays', window );">Threshold Closing Price for Specified Number of Trading Days (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ThresholdTradingDaysForSaleOfShares', window );">Threshold Trading Days for Sale of Shares (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ThresholdConsecutiveTradingDaysForSaleOfShares', window );">Threshold Consecutive Trading Days for Sale of Shares (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,279,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PreFundedWarrantMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">5,066,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_InvestorWarrantMember', window );">Investor Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">The 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,178,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">The 2020 Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">The 2020 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">The 2020 Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">The 2020 Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">The 2020 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2016WarrantsMember', window );">The 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2016WarrantsMember', window );">The 2016 Warrants [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ClassOfWarrantOrRightRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ClassOfWarrantOrRightRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold closing price, as adjusted for stock splits, stock dividends, reorganizations or recapitalizations, for any 20 trading days within any 30-trading day period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ThresholdConsecutiveTradingDaysForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which closing stock price must exceed a price per share amount for specified number of trading days, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ThresholdConsecutiveTradingDaysForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ThresholdTradingDaysForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that the closing price of ordinary shares must meet or exceed a price per share, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ThresholdTradingDaysForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued pursuant to the terms of a deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvph_The2016NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rvph_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rvph_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_InvestorWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_InvestorWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_The2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301482587768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details) - The 2020 Warrants [Member]<br></strong></div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant, assumptions</a></td>
<td class="nump">2.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant, assumptions</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant, assumptions</a></td>
<td class="nump">0.0028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant, assumptions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant, assumptions</a></td>
<td class="nump">1.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rvph_The2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301482806408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="nump">192,898<span></span>
</td>
<td class="nump">65,471<span></span>
</td>
<td class="nump">112,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 106,713<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="nump">281,397<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">127,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">93.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">87.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2006Member', window );">Equity Incentive Plan 2006 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="nump">65,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2020Member', window );">Equity Incentive Plan 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="nump">1,384,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percent of Increase</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2020Member', window );">Equity Incentive Plan 2020 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">1,384,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of increase, based on total number of common stock outstanding, in shares to be issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rvph_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301473346936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, number of shares outstanding (in shares)</a></td>
<td class="nump">65,471<span></span>
</td>
<td class="nump">112,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 16.86<span></span>
</td>
<td class="nump">$ 15.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options outstanding, options cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled, weighted average exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options outstanding, options granted (in shares)</a></td>
<td class="nump">127,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, number of shares outstanding (in shares)</a></td>
<td class="nump">192,898<span></span>
</td>
<td class="nump">65,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="nump">$ 16.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">192,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning balance, number of shares available for grant (in shares)</a></td>
<td class="nump">461,587<span></span>
</td>
<td class="nump">343,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for grant, options authorized (in shares)</a></td>
<td class="nump">923,174<span></span>
</td>
<td class="nump">461,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled', window );">Number of shares available for grant, options cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination', window );">Effect of plan amendment on business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391,332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares available for grant, options granted (in shares)</a></td>
<td class="num">(127,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending balance, number of shares available for grant (in shares)</a></td>
<td class="nump">1,257,334<span></span>
</td>
<td class="nump">461,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in shares associated with the effect of plan amendment on business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares cancelled under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301473122744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">192,898<span></span>
</td>
<td class="nump">65,471<span></span>
</td>
<td class="nump">112,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Year)</a></td>
<td class="text">6 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">95,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range1Member', window );">Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">48,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Year)</a></td>
<td class="text">10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">48,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range2Member', window );">Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">16,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Year)</a></td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">16,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 31.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range3Member', window );">Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">81,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Year)</a></td>
<td class="text">9 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">17,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range4Member', window );">Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">46,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Year)</a></td>
<td class="text">9 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable (in shares)</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rvph_Range4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301473337400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=rvph_CorporateOfficeLeaseMember', window );">Corporate Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Month)</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_LesseeOperatingLeaseMonthlyLeasePayment', window );">Lessee, Operating Lease, Monthly Lease Payment</a></td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Month)</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_GeneralProductLiabilityInsurance', window );">General Product Liability Insurance</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_GeneralProductLiabilityInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of general product liability insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_GeneralProductLiabilityInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_LesseeOperatingLeaseMonthlyLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly lease payment for lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_LesseeOperatingLeaseMonthlyLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=rvph_CorporateOfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=rvph_CorporateOfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140301480730008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member] - H.C. Wainwright &amp; Co [Member] - The Market Offering Agreement "ATM Agreement" [Member]<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds', window );">Sale of Stock Agreement, Maximum Aggregate Gross Proceeds | $</a></td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued, Ending Balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on the maximum aggregate gross proceeds to be received from the agreement with H.C. Wainwright &amp; Co.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rvph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rvph_HCWainwrightCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rvph_HCWainwrightCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rvph_TheMarketOfferingAgreementAtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rvph_TheMarketOfferingAgreementAtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>rvph20211231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rvph="http://revivapharma.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rvph-20211231.xsd" xlink:type="simple"/>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2022-03-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:InvestorWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="d_2021-06-01_2021-06-01_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="i_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaCommonStockIntoCompanysCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOfRevivaCommonStockIntoCompanysCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:RevivaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-01</instant>
        </period>
    </context>
    <context id="d_2016-06-01_2016-06-01_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-01</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-10_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2016NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2016NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOf2016NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rvph:OneInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="d_2020-01-02_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rvph:OneInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-02</startDate>
            <endDate>2020-01-02</endDate>
        </period>
    </context>
    <context id="i_2020-12-15_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rvph:OneInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-01</instant>
        </period>
    </context>
    <context id="i_2018-11-01_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2018ContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-01</instant>
        </period>
    </context>
    <context id="i_2019-12-31_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2018ContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2018-11-01_2018-11-01_DebtInstrumentAxis-The2018NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-01</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_DebtInstrumentAxis-The2018NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOf2018NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2018NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i_2020-03-01_DebtInstrumentAxis-The2020NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2020NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-01</instant>
        </period>
    </context>
    <context id="i_2020-03-01_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020ContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-01</instant>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOf2020NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020ContingentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2020NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2020NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i_2020-08-01_DebtInstrumentAxis-August2020ToOctober2020NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:August2020ToOctober2020NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="d_2020-08-01_2020-10-31_DebtInstrumentAxis-August2020ToOctober2020NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:August2020ToOctober2020NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i_2020-08-01_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:RevivaContingentInterimPeriodNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-01</instant>
        </period>
    </context>
    <context id="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">rvph:ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="d_2020-12-10_2020-12-10_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rvph:ClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">rvph:ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="d_2020-08-01_2020-10-31_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:RevivaContingentInterimPeriodNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-10_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2021-01-10</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rvph:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2021-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="d_2020-09-01_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rvph:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-InvestorWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:InvestorWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2020WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2016WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-01</instant>
        </period>
    </context>
    <context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvph:The2016NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-The2016WarrantsMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rvph:The2016WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2006Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvph:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rvph:Range4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">rvph:CorporateOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">rvph:CorporateOfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvph:HCWainwrightCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:TheMarketOfferingAgreementAtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvph:HCWainwrightCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvph:TheMarketOfferingAgreementAtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001742927</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityCentralIndexKey">0001742927</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityRegistrantName">REVIVA PHARMACEUTICALS HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2021-01-01_2021-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2021-01-01_2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2021-01-01_2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2021-01-01_2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-12-31"
      id="c81966282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c81966283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966287"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966288"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966289"
      unitRef="Share">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966290"
      unitRef="Share">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966291"
      unitRef="Share">14433286</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966293"
      unitRef="Share">14433286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966292"
      unitRef="Share">9231737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966294"
      unitRef="Share">9231737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      id="c81966522">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      id="c81966523">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      decimals="-3"
      id="c81966622"
      unitRef="USD">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2016-06-01_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      id="c81966657">P12M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2016NotesMember"
      decimals="-3"
      id="c81966680"
      unitRef="USD">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2018-11-01_2018-11-01_DebtInstrumentAxis-The2018NotesMember"
      id="c81966709">P6M</us-gaap:DebtInstrumentTerm>
    <rvph:DebtInstrumentRenewalTerm
      contextRef="d_2018-11-01_2018-11-01_DebtInstrumentAxis-The2018NotesMember"
      id="c81966712">P6M</rvph:DebtInstrumentRenewalTerm>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966836"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966837"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-3"
      id="c81966784"
      unitRef="USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81966788"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81966793"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966876"
      unitRef="USDPerShare">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rvph:ClassOfWarrantOrRightRedemptionPricePerShare
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966880"
      unitRef="USDPerShare">0.01</rvph:ClassOfWarrantOrRightRedemptionPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966911"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember"
      id="c81966925">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c81966947"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember"
      id="c81966986">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81967008"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember"
      id="c81967087">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SharesIssued
      contextRef="i_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember"
      decimals="-3"
      id="c81967095"
      unitRef="Share">0</us-gaap:SharesIssued>
    <dei:DocumentType contextRef="d_2021-01-01_2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2021-01-01_2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2021-01-01_2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2021-01-01_2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2021-01-01_2021-12-31">001-38634</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2021-01-01_2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2021-01-01_2021-12-31">85-4306526</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2021-01-01_2021-12-31">19925 Stevens Creek Blvd., Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2021-01-01_2021-12-31">Cupertino</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2021-01-01_2021-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2021-01-01_2021-12-31">95014</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2021-01-01_2021-12-31">408</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2021-01-01_2021-12-31">501-8881</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">RVPH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">Warrants to purchase one share of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">RVPHW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2021-01-01_2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2021-01-01_2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2021-01-01_2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2021-01-01_2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2021-01-01_2021-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d_2021-01-01_2021-12-31">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2021-01-01_2021-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2021-06-30" decimals="1" unitRef="USD">41400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2022-03-10" decimals="INF" unitRef="Share">15133286</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2021-01-01_2021-12-31">32</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2021-01-01_2021-12-31">ArmaninoLLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2021-01-01_2021-12-31">San Ramon, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966263"
      unitRef="USD">29687944</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966264"
      unitRef="USD">8760462</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966265"
      unitRef="USD">1716057</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966266"
      unitRef="USD">1816</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966267"
      unitRef="USD">31404001</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966268"
      unitRef="USD">8762278</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966271"
      unitRef="USD">509583</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966272"
      unitRef="USD">1008046</us-gaap:AccountsPayableCurrent>
    <rvph:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966273"
      unitRef="USD">1835228</rvph:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <rvph:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966274"
      unitRef="USD">324697</rvph:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966275"
      unitRef="USD">2344811</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966276"
      unitRef="USD">1332743</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966277"
      unitRef="USD">372730</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966278"
      unitRef="USD">1963785</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966279"
      unitRef="USD">2717541</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966280"
      unitRef="USD">3296528</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966285"
      unitRef="USD">1443</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966286"
      unitRef="USD">923</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966295"
      unitRef="USD">95516986</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966296"
      unitRef="USD">63774920</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966297"
      unitRef="USD">-66831969</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966298"
      unitRef="USD">-58310093</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966299"
      unitRef="USD">28686460</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966300"
      unitRef="USD">5465750</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966301"
      unitRef="USD">31404001</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966302"
      unitRef="USD">8762278</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966304"
      unitRef="USD">4851602</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966305"
      unitRef="USD">295150</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966306"
      unitRef="USD">5252911</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966307"
      unitRef="USD">2139501</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966308"
      unitRef="USD">10104513</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966309"
      unitRef="USD">2434651</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966310"
      unitRef="USD">-10104513</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966311"
      unitRef="USD">-2434651</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966313"
      unitRef="USD">1591055</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966314"
      unitRef="USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <rvph:InterestAndOtherIncomeExpenseNet
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966315"
      unitRef="USD">-2414</rvph:InterestAndOtherIncomeExpenseNet>
    <rvph:InterestAndOtherIncomeExpenseNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966316"
      unitRef="USD">105183</rvph:InterestAndOtherIncomeExpenseNet>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966317"
      unitRef="USD">-0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966318"
      unitRef="USD">1453120</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966319"
      unitRef="USD">1588641</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966320"
      unitRef="USD">-1347937</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966321"
      unitRef="USD">-8515872</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966322"
      unitRef="USD">-3782588</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966323"
      unitRef="USD">6004</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966324"
      unitRef="USD">800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966325"
      unitRef="USD">-8521876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966326"
      unitRef="USD">-3783388</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966328"
      unitRef="USDPerShare">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966329"
      unitRef="USDPerShare">-1.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-12-13"
      decimals="INF"
      id="c81966331"
      unitRef="Share">14790843</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966332"
      unitRef="Share">3061670</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966333"
      unitRef="Share">1597585</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966334"
      unitRef="USD">29069974</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966335"
      unitRef="Share">2768346</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966336"
      unitRef="USD">618</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966337"
      unitRef="USD">18644683</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966338"
      unitRef="USD">-54526705</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c81966339"
      unitRef="USD">-6811430</us-gaap:StockholdersEquity>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966341"
      unitRef="USD">0</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966342"
      unitRef="Share">38992</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966343"
      unitRef="USD">25</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966344"
      unitRef="USD">340907</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966345"
      unitRef="USD">0</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966346"
      unitRef="USD">340932</us-gaap:DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966348"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966350"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966351"
      unitRef="USD">961680</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966352"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966353"
      unitRef="USD">961680</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966355"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966356"
      unitRef="Share">1099947</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966357"
      unitRef="USD">110</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966358"
      unitRef="USD">8499233</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966359"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966360"
      unitRef="USD">8499343</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966362"
      unitRef="USD">0</rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966364"
      unitRef="USD">0</rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966365"
      unitRef="USD">1185577</rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966366"
      unitRef="USD">0</rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966367"
      unitRef="USD">1185577</rvph:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability>
    <rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966369"
      unitRef="USD">0</rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization>
    <rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966371"
      unitRef="USD">0</rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization>
    <rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966372"
      unitRef="USD">9375961</rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization>
    <rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966373"
      unitRef="USD">0</rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization>
    <rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966374"
      unitRef="USD">9375961</rvph:AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization>
    <rvph:EffectOfReverseReverseRecapitalizationNetOfCostsShares
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="0"
      id="c81966375"
      unitRef="Share">-1597585</rvph:EffectOfReverseReverseRecapitalizationNetOfCostsShares>
    <rvph:EffectOfReverseRecapitalizationNetOfCostsValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966376"
      unitRef="USD">-29069974</rvph:EffectOfReverseRecapitalizationNetOfCostsValue>
    <rvph:EffectOfReverseReverseRecapitalizationNetOfCostsShares
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966377"
      unitRef="Share">5324452</rvph:EffectOfReverseReverseRecapitalizationNetOfCostsShares>
    <rvph:EffectOfReverseRecapitalizationNetOfCostsValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966378"
      unitRef="USD">170</rvph:EffectOfReverseRecapitalizationNetOfCostsValue>
    <rvph:EffectOfReverseRecapitalizationNetOfCostsValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966379"
      unitRef="USD">24766879</rvph:EffectOfReverseRecapitalizationNetOfCostsValue>
    <rvph:EffectOfReverseRecapitalizationNetOfCostsValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966380"
      unitRef="USD">0</rvph:EffectOfReverseRecapitalizationNetOfCostsValue>
    <rvph:EffectOfReverseRecapitalizationNetOfCostsValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966381"
      unitRef="USD">-4302928</rvph:EffectOfReverseRecapitalizationNetOfCostsValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966383"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966385"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966386"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966387"
      unitRef="USD">-3783388</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966388"
      unitRef="USD">-3783388</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966389"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81966390"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966391"
      unitRef="Share">9231737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966392"
      unitRef="USD">923</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966393"
      unitRef="USD">63774920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966394"
      unitRef="USD">-58310093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966395"
      unitRef="USD">5465750</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966396"
      unitRef="Share">9231737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966397"
      unitRef="USD">923</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966398"
      unitRef="USD">63774920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966399"
      unitRef="USD">-58310093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966400"
      unitRef="USD">5465750</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966401"
      unitRef="Share">4133400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966402"
      unitRef="USD">413</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966403"
      unitRef="USD">31497050</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966404"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966405"
      unitRef="USD">31497463</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rvph:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966406"
      unitRef="Share">1057149</rvph:StockIssuedDuringPeriodSharesWarrantsExercised>
    <rvph:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966407"
      unitRef="USD">106</rvph:StockIssuedDuringPeriodValueWarrantsExercised>
    <rvph:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966408"
      unitRef="USD">98375</rvph:StockIssuedDuringPeriodValueWarrantsExercised>
    <rvph:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966409"
      unitRef="USD">0</rvph:StockIssuedDuringPeriodValueWarrantsExercised>
    <rvph:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966410"
      unitRef="USD">98481</rvph:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966411"
      unitRef="Share">11000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966412"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966413"
      unitRef="USD">39928</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966414"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966415"
      unitRef="USD">39929</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966417"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966418"
      unitRef="USD">106713</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966419"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966420"
      unitRef="USD">106713</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966422"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966424"
      unitRef="USD">-8521876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966425"
      unitRef="USD">-8521876</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966426"
      unitRef="Share">14433286</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81966427"
      unitRef="USD">1443</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81966428"
      unitRef="USD">95516986</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81966429"
      unitRef="USD">-66831969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966430"
      unitRef="USD">28686460</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966432"
      unitRef="USD">-8521876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966433"
      unitRef="USD">-3783388</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966435"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966436"
      unitRef="USD">591</us-gaap:Depreciation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966437"
      unitRef="USD">-1591055</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966438"
      unitRef="USD">1084052</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966439"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966440"
      unitRef="USD">961680</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966441"
      unitRef="USD">39929</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966442"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966443"
      unitRef="USD">106713</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966444"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966446"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966447"
      unitRef="USD">-2330738</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966448"
      unitRef="USD">1714241</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966449"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966450"
      unitRef="USD">-498463</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966451"
      unitRef="USD">775101</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966452"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966453"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <rvph:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966454"
      unitRef="USD">1510531</rvph:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <rvph:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966455"
      unitRef="USD">-773922</rvph:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966456"
      unitRef="USD">-10668462</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966457"
      unitRef="USD">-4066624</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <rvph:ProceedsFromIssuanceOfCommonStockForDeferredCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966459"
      unitRef="USD">0</rvph:ProceedsFromIssuanceOfCommonStockForDeferredCompensation>
    <rvph:ProceedsFromIssuanceOfCommonStockForDeferredCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966460"
      unitRef="USD">340932</rvph:ProceedsFromIssuanceOfCommonStockForDeferredCompensation>
    <rvph:ProceedsFromReverseRecapitalization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966461"
      unitRef="USD">0</rvph:ProceedsFromReverseRecapitalization>
    <rvph:ProceedsFromReverseRecapitalization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966462"
      unitRef="USD">9375961</rvph:ProceedsFromReverseRecapitalization>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966463"
      unitRef="USD">31497463</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966464"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966465"
      unitRef="USD">98481</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966466"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966467"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966468"
      unitRef="USD">3110000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966469"
      unitRef="USD">31595944</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966470"
      unitRef="USD">12826893</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966471"
      unitRef="USD">20927482</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966472"
      unitRef="USD">8760269</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966473"
      unitRef="USD">8760462</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c81966474"
      unitRef="USD">193</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966475"
      unitRef="USD">29687944</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966476"
      unitRef="USD">8760462</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966478"
      unitRef="USD">2400</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966479"
      unitRef="USD">800</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966480"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966481"
      unitRef="USD">327076</us-gaap:InterestPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966483"
      unitRef="USD">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966484"
      unitRef="USD">6875088</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <rvph:PaymentOfCertainDeferredCosts
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966485"
      unitRef="USD">0</rvph:PaymentOfCertainDeferredCosts>
    <rvph:PaymentOfCertainDeferredCosts
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966486"
      unitRef="USD">1000000</rvph:PaymentOfCertainDeferredCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060581">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;ORGANIZATION AND NATURE OF OPERATIONS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;14,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; Reviva Pharmaceuticals Holdings,&#160;Inc. (the &#x201c;Company&#x201d;), a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp. (&#x201c;Tenzing&#x201d;), a British Virgin Islands exempted company, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#x201c;Merger Sub&#x201d;), and Reviva Pharmaceuticals,&#160;Inc., a Delaware corporation (together with its consolidated subsidiary), consummated a business combination (the &#x201c;Business Combination&#x201d;) through the merger of Merger Sub with and into Reviva Pharmaceuticals,&#160;Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;20,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; (the &#x201c;Merger Agreement&#x201d;), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals,&#160;Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), Merger Sub merged with and into Reviva Pharmaceuticals,&#160;Inc., with Reviva Pharmaceuticals,&#160;Inc.&#160;as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals,&#160;Inc.&#160;becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings,&#160;Inc. (together with its consolidated subsidiary).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Reviva Pharmaceuticals,&#160;Inc. was originally incorporated in the state of Delaware and commenced operations on &lt;em style="font: inherit;"&gt; May 1, 2006 &lt;/em&gt;and its Indian subsidiary, Reviva Pharmaceuticals India Pvt. Ltd. was incorporated in &lt;em style="font: inherit;"&gt;2014.&lt;/em&gt; The Company is an emerging research based pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective therapeutic drugs by using an integrated chemical genomics technology platform and proprietary chemistries. The Company is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), metabolic and inflammatory diseases.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060582">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The summary of significant accounting policies presented below is designed to assist in understanding the Company&#x2019;s financial statements. Such financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Principals of consolidation&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Use of estimates&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The preparation of&#160;consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Concentration of credit risk and other risks and uncertainties&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company&#x2019;s cash are held in demand deposit form by &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses on its deposits of cash.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company&#x2019;s operating results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be materially affected by the foregoing factors.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Cash&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;months or less to be cash equivalents. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company&#x2019;s cash was maintained in demand deposit forms at &lt;em style="font: inherit;"&gt;two&lt;/em&gt; financial institutions. Deposits in financial institutions &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;from time to time, have exceed federally insured limits.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Property and equipment&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year for: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;assets purchased; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;existing assets that are replaced, improved or the useful lives have been extended. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs are expensed as incurred. Assets classified as property and equipment are stated at cost less accumulated depreciation and are depreciated using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:c81966522"&gt;three&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c81966523"&gt;five&lt;/span&gt;&#160;years, or the lease term of the respective assets, whichever is less. When assets are retired or otherwise disposed, their original cost and related accumulated depreciation are removed from the consolidated balance sheet, and any resulting gain or loss is reflected in related operating expense.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Leases&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2016,&lt;/em&gt; the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;2,&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;, as amended. The ASU introduces a new lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&#x2019;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of consolidated financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this standard effective &lt;em style="font: inherit;"&gt; January 1, 2019, &lt;/em&gt;and determined that there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material impact that the new accounting guidance will have on its financial statements and related disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Research and development costs&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;General and administrative costs&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, payroll and personnel expenses, travel and entertainment, consulting costs, conference and meeting costs, legal expenses and allocated overhead, including rent depreciation, and utilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Income taxes&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company utilizes FASB ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is &#x201c;more likely-than-&lt;em style="font: inherit;"&gt;not&#x201d;&lt;/em&gt; that a deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160; The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis.&#160; The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of &lt;em style="font: inherit;"&gt;100%&lt;/em&gt; has been established due to the uncertainty of the Company&#x2019;s realization of the net operating loss carry forward prior to its expiration.&#160; In the event the Company determines that it would be able to realize its&#160;deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes.&#160; Conversely, in the event that all or part of the net deferred tax assets are determined &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC &lt;em style="font: inherit;"&gt;718&lt;/em&gt; which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Expected term&lt;/span&gt;&#x2009;&#x2014;&#x2009;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Expected volatility&lt;/span&gt;&#x2009;&#x2014;&#x2009;Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Expected dividend&lt;/span&gt;&#x2009;&#x2014;&#x2009;The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; plans to pay dividends.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Risk-free interest rate&lt;/span&gt;&#x2009;&#x2014;&#x2009;The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Forfeiture rate&lt;/span&gt;&#x2009;&#x2014;&#x2009;The Company made the &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time election to recognize forfeitures when they occur.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company adopted ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Compensation-Stock Compensation (Topic &lt;em style="font: inherit;"&gt;718&lt;/em&gt;): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting of share-based payment awards issued to employees and nonemployees. The adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; materially impact our consolidated financial statements. The Company recognizes fair value of stock options granted to non-employees as a stock-based compensation expense over the period in which the related services are received. Non-employee option grants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes-Merton option-pricing model, is determined, and compensation expense recognized during the period is adjusted accordingly.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Fair Value Measurements of Warrants&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; &#x201c;Fair Value Measurements&#x201d; defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; establishes a fair value hierarchy that distinguishes between (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) and the lowest priority to unobservable inputs (Level&#160;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels of the fair value hierarchy under ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; are described below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; Level&#160;&lt;em style="font: inherit;"&gt;1&#x2009;&#x2014;&#x2009;Quoted&lt;/em&gt; prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; Level&#160;&lt;em style="font: inherit;"&gt;2&#x2009;&#x2014;&#x2009;Directly&lt;/em&gt; or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. Level&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt; also includes assets and liabilities that are valued using models or other pricing methodologies that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; Level&#160;&lt;em style="font: inherit;"&gt;3&#x2009;&#x2014;&#x2009;Unobservable&lt;/em&gt; inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Beneficial Conversion Features&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;In accordance with FASB ASC &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20,&lt;/em&gt; &#x201c;Debt with Conversion and Other Options&#x201d; the Company records a beneficial conversion feature (&#x201c;BCF&#x201d;) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968005">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The summary of significant accounting policies presented below is designed to assist in understanding the Company&#x2019;s financial statements. Such financial statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968006">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Principals of consolidation&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2021-01-01_2021-12-31" id="c81968007">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Use of estimates&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The preparation of&#160;consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2021-01-01_2021-12-31" id="c81968008">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Concentration of credit risk and other risks and uncertainties&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company&#x2019;s cash are held in demand deposit form by &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced any losses on its deposits of cash.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company&#x2019;s operating results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be materially affected by the foregoing factors.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968009">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Cash&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of &lt;em style="font: inherit;"&gt;three&lt;/em&gt;&#160;months or less to be cash equivalents. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company&#x2019;s cash was maintained in demand deposit forms at &lt;em style="font: inherit;"&gt;two&lt;/em&gt; financial institutions. Deposits in financial institutions &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;from time to time, have exceed federally insured limits.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968010">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Property and equipment&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year for: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;assets purchased; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;existing assets that are replaced, improved or the useful lives have been extended. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs are expensed as incurred. Assets classified as property and equipment are stated at cost less accumulated depreciation and are depreciated using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:c81966522"&gt;three&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c81966523"&gt;five&lt;/span&gt;&#160;years, or the lease term of the respective assets, whichever is less. When assets are retired or otherwise disposed, their original cost and related accumulated depreciation are removed from the consolidated balance sheet, and any resulting gain or loss is reflected in related operating expense.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968011">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Leases&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2016,&lt;/em&gt; the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;2,&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;, as amended. The ASU introduces a new lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&#x2019;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of consolidated financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this standard effective &lt;em style="font: inherit;"&gt; January 1, 2019, &lt;/em&gt;and determined that there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material impact that the new accounting guidance will have on its financial statements and related disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2021-01-01_2021-12-31" id="c81968012">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Research and development costs&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968013">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;General and administrative costs&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, payroll and personnel expenses, travel and entertainment, consulting costs, conference and meeting costs, legal expenses and allocated overhead, including rent depreciation, and utilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968015">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Income taxes&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company utilizes FASB ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is &#x201c;more likely-than-&lt;em style="font: inherit;"&gt;not&#x201d;&lt;/em&gt; that a deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160; The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis.&#160; The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of &lt;em style="font: inherit;"&gt;100%&lt;/em&gt; has been established due to the uncertainty of the Company&#x2019;s realization of the net operating loss carry forward prior to its expiration.&#160; In the event the Company determines that it would be able to realize its&#160;deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes.&#160; Conversely, in the event that all or part of the net deferred tax assets are determined &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2021-01-01_2021-12-31" id="c81968016">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC &lt;em style="font: inherit;"&gt;718&lt;/em&gt; which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Expected term&lt;/span&gt;&#x2009;&#x2014;&#x2009;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Expected volatility&lt;/span&gt;&#x2009;&#x2014;&#x2009;Expected volatility is estimated using comparable public companies&#x2019; volatility for similar terms.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Expected dividend&lt;/span&gt;&#x2009;&#x2014;&#x2009;The Black-Scholes-Merton valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; plans to pay dividends.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Risk-free interest rate&lt;/span&gt;&#x2009;&#x2014;&#x2009;The risk-free interest rate used in the Black-Scholes-Merton valuation method is based on the U.S. Treasury &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; &lt;span style="text-decoration: underline; "&gt;Forfeiture rate&lt;/span&gt;&#x2009;&#x2014;&#x2009;The Company made the &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time election to recognize forfeitures when they occur.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company adopted ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Compensation-Stock Compensation (Topic &lt;em style="font: inherit;"&gt;718&lt;/em&gt;): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting of share-based payment awards issued to employees and nonemployees. The adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; materially impact our consolidated financial statements. The Company recognizes fair value of stock options granted to non-employees as a stock-based compensation expense over the period in which the related services are received. Non-employee option grants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes-Merton option-pricing model, is determined, and compensation expense recognized during the period is adjusted accordingly.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2021-01-01_2021-12-31" id="c81968021">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Fair Value Measurements of Warrants&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; &#x201c;Fair Value Measurements&#x201d; defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; establishes a fair value hierarchy that distinguishes between (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) and the lowest priority to unobservable inputs (Level&#160;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The &lt;em style="font: inherit;"&gt;three&lt;/em&gt; levels of the fair value hierarchy under ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; are described below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; Level&#160;&lt;em style="font: inherit;"&gt;1&#x2009;&#x2014;&#x2009;Quoted&lt;/em&gt; prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; Level&#160;&lt;em style="font: inherit;"&gt;2&#x2009;&#x2014;&#x2009;Directly&lt;/em&gt; or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. Level&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt; also includes assets and liabilities that are valued using models or other pricing methodologies that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022; Level&#160;&lt;em style="font: inherit;"&gt;3&#x2009;&#x2014;&#x2009;Unobservable&lt;/em&gt; inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#x200b;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <rvph:BeneficialConversionFeaturePolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81968019">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Beneficial Conversion Features&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;In accordance with FASB ASC &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20,&lt;/em&gt; &#x201c;Debt with Conversion and Other Options&#x201d; the Company records a beneficial conversion feature (&#x201c;BCF&#x201d;) related to the issuance of convertible debt or preferred stock instruments that have conversion features at fixed rates that are in-the-money when issued. The BCF for the convertible instruments is recognized and measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The intrinsic value is generally calculated at the commitment date as the difference between the conversion price and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If certain other securities are issued with the convertible security, the proceeds are allocated among the different components. The portion of the proceeds allocated to the convertible security is divided by the contractual number of the conversion shares to determine the effective conversion price, which is used to measure the BCF. The effective conversion price is used to compute the intrinsic value. The value of the BCF is limited to the basis that is initially allocated to the convertible security.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</rvph:BeneficialConversionFeaturePolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-IPOMember"
      id="c2060583">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&#160;&#160; &lt;b&gt;PUBLIC OFFERING&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; June 1, 2021, &lt;/em&gt;the Company completed a public offering (the &#x201c;Offering&#x201d;) of Units (each, a &#x201c;Unit&#x201d;), with each Unit consisting of (a) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of common stock (or pre-funded warrant to purchase &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of common stock in lieu thereof, with an exercise price of $0.0001 per share, each a &#x201c;Pre-Funded Warrant&#x201d;) and (b) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; warrant to purchase 0.75&#160;of a share of our common stock, with an exercise price of $4.125 per share (each, an &#x201c;Investor Warrant&#x201d;). Pursuant to the Offering, the Company sold 4,133,400 Units consisting of (a) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of common stock and (b) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Investor Warrant (inclusive the underwriter&#x2019;s overallotment option of 1,200,000 of such Units), and 5,066,600 Units consisting of (a) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Pre-Funded Warrant and (b) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Investor Warrant. The Units had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; stand-alone rights and were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; certificated or issued as stand-alone securities. Accordingly, as result of the sale of such Units in the Offering, the Company issued in aggregate 4,133,400 shares of common stock, Pre-Funded Warrants exercisable for 5,066,600 shares of common stock, and Investor Warrants exercisable for 6,900,000 shares of common stock. The offering price was $3.75 for each Unit consisting of (a) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share of common stock and (b) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Investor Warrant, and $3.7499 for each Unit consisting of (a) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Pre-Funded Warrant and (b) &lt;em style="font: inherit;"&gt;one&lt;/em&gt; Investor Warrant. Net proceeds from the Offering were approximately $31.5 million, after underwriter discounts, commissions, legal and accounting fees, and certain other costs of approximately $3.0 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966577"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966579"
      unitRef="Share">0.75</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966580"
      unitRef="USDPerShare">4.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rvph:NumberOfUnitsOneIssued
      contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="INF"
      id="c81966581"
      unitRef="Share">4133400</rvph:NumberOfUnitsOneIssued>
    <rvph:NumberOfUnitsOneIssued
      contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c81966584"
      unitRef="Share">1200000</rvph:NumberOfUnitsOneIssued>
    <rvph:NumberOfUnitsTwoIssued
      contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="INF"
      id="c81966585"
      unitRef="Share">5066600</rvph:NumberOfUnitsTwoIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-06-01_2021-06-01_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="INF"
      id="c81966590"
      unitRef="Share">4133400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966591"
      unitRef="Share">5066600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966592"
      unitRef="Share">6900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <rvph:SharesIssuedPricePerShareOne
      contextRef="i_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="INF"
      id="c81966593"
      unitRef="USDPerShare">3.75</rvph:SharesIssuedPricePerShareOne>
    <rvph:SharesIssuedPricePerShareTwo
      contextRef="i_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="INF"
      id="c81966596"
      unitRef="USDPerShare">3.7499</rvph:SharesIssuedPricePerShareTwo>
    <rvph:ProceedsFromIssuanceOrSaleOfEquityNet
      contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="-5"
      id="c81966599"
      unitRef="USD">31500000</rvph:ProceedsFromIssuanceOrSaleOfEquityNet>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="-6"
      id="c81966600"
      unitRef="USD">3000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060584">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;BUSINESS COMBINATION&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;14,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; Reviva Pharmaceuticals Holdings,&#160;Inc., a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp., a British Virgin Islands exempted company (&#x201c;Tenzing&#x201d;), Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (&#x201c;Merger Sub&#x201d;), and Reviva Pharmaceuticals,&#160;Inc., a Delaware corporation (together with its consolidated subsidiaries)&#160;Reviva Pharmaceuticals,&#160;Inc., consummated a business combination (the &#x201c;Business Combination&#x201d;) through the merger of Merger Sub with and into Reviva Pharmaceuticals,&#160;Inc., contemplated by the previously announced Agreement and Plan of Merger, dated as of &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;20,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; (the &#x201c;Merger Agreement&#x201d;), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals,&#160;Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger (the &#x201c;Effective Time&#x201d;), Merger Sub merged with and into Reviva Pharmaceuticals,&#160;Inc., with Reviva Pharmaceuticals,&#160;Inc.&#160;as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals,&#160;Inc.&#160;becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings,&#160;Inc. (together with its consolidated subsidiaries).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Upon the closing of the Business Combination, all shares of Reviva Pharmaceuticals, Inc. common stock and preferred stock issuance and outstanding immediately prior to the Business Combination converted into common stock of Reviva Pharmaceuticals Holdings, Inc., with a par value of $0.0001 per share at an exchange rate of 0.152268 for common stock and 0.414647 for preferred stock.&#160; Each issued and outstanding warrant to acquire shares of Reviva Pharmaceuticals, Inc. common stock were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into a warrant for Reviva Pharmaceuticals Holdings, Inc. common stock, with its price and number of shares adjusted based on the common stock exchange rate of &lt;em style="font: inherit;"&gt;0.152268.&lt;/em&gt;&#160; Each outstanding option to acquire Reviva Pharmaceuticals, Inc. common stock (all of which were vested at the date of the Business Combination), were assumed by Reviva Pharmaceuticals Holdings, Inc. and automatically converted into an option to acquire shares of Reviva Pharmaceuticals Holdings, Inc. common stock at the common stock exchange rate of &lt;em style="font: inherit;"&gt;0.152268.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;In addition to the merger consideration set forth above, the Reviva Pharmaceuticals,&#160;Inc.&#160;Security holders also have a contingent right to receive up to an additional 1,000,000 shares of Reviva Pharmaceuticals Holdings,&#160;Inc.&#160;(the &#x201c;Earnout Shares&#x201d;)&#160;based on the stock price performance of the common stock and the achievement by the Company&#160;of certain clinical trial milestones during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; (3)&#160;year period following the Closing (the &#x201c;Earnout Period&#x201d;). In order to receive the Earnout Shares, during the Earnout Period, both:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:2.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.4%;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:42%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;the closing price of the Company&#x2019;s&#160;common stock has to be equal to or greater than $15.00 per share for any 20 trading days within any 30 trading day period; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:2.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.4%;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:42%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;the Company&#160;must receive positive data from (i)&#160;its &lt;em style="font: inherit;"&gt;first&lt;/em&gt; Phase &lt;em style="font: inherit;"&gt;3&lt;/em&gt; trial in Acute Schizophrenia and (ii)&#160;either a Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; clinical trial in pulmonary arterial hypertension or idiopathic pulmonary fibrosis.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Business Combination was accounted for as a reverse merger in accordance with U.S. GAAP. Under this method of accounting, Tenzing is treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on the holders of Reviva&#160;Pharmaceuticals,&#160;Inc. having a majority of the voting power of the post-combination company, Reviva Pharmaceuticals,&#160;Inc. senior management comprising substantially all of the senior management of the post-combination company, the relative size of Reviva compared to Tenzing, and Reviva Pharmaceuticals,&#160;Inc. operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Reviva&#160;Pharmaceuticals,&#160;Inc. issuing stock for the net assets of Tenzing, accompanied by a recapitalization. The net assets of Tenzing are stated at historical cost, with no goodwill or other intangible assets recorded.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The accompanying financial statements and related notes reflect the historical results of Reviva Pharmaceuticals,&#160;Inc.&#160;prior to the merger and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include the historical results of Tenzing prior&#160;to the consummation of the Business Combination.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      decimals="INF"
      id="c81966606"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <rvph:ConversionOfStockConversionRate
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaCommonStockIntoCompanysCommonStockMember"
      decimals="INF"
      id="c81966607"
      unitRef="Pure">0.152268</rvph:ConversionOfStockConversionRate>
    <rvph:ConversionOfStockConversionRate
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember"
      decimals="INF"
      id="c81966608"
      unitRef="Pure">0.414647</rvph:ConversionOfStockConversionRate>
    <rvph:AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance
      contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      decimals="INF"
      id="c81966611"
      unitRef="Share">1000000</rvph:AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance>
    <rvph:StockPricePerformanceMilestonePeriod
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      id="c81966613">P3Y</rvph:StockPricePerformanceMilestonePeriod>
    <rvph:ThresholdClosingPriceForSpecifiedNumberOfTradingDays
      contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      decimals="INF"
      id="c81966615"
      unitRef="USDPerShare">15.00</rvph:ThresholdClosingPriceForSpecifiedNumberOfTradingDays>
    <rvph:ThresholdTradingDaysForSaleOfShares
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      id="c81966616">P20D</rvph:ThresholdTradingDaysForSaleOfShares>
    <rvph:ThresholdConsecutiveTradingDaysForSaleOfShares
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      id="c81966617">P30D</rvph:ThresholdConsecutiveTradingDaysForSaleOfShares>
    <us-gaap:Goodwill
      contextRef="i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember"
      decimals="-3"
      id="c81966621"
      unitRef="USD">0</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060585">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;PROPERTY AND EQUIPMENT, NET&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;"&gt;Property and equipment, net consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computer equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;32,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;32,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and fixtures&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,208&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,208&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(41,708&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(41,708&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;"&gt;Depreciation expense for the&#160;years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $0 and $591 respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060586">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computer equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;32,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;32,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and fixtures&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,208&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,208&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(41,708&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(41,708&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="INF"
      id="c81966630"
      unitRef="USD">32500</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="INF"
      id="c81966631"
      unitRef="USD">32500</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-13_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c81966632"
      unitRef="USD">9208</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="INF"
      id="c81966633"
      unitRef="USD">9208</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-12-13"
      decimals="INF"
      id="c81966634"
      unitRef="USD">41708</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966635"
      unitRef="USD">41708</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-13"
      decimals="INF"
      id="c81966636"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966637"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81966628"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966629"
      unitRef="USD">591</us-gaap:Depreciation>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060587">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;EMPLOYEE BENEFIT PLAN&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt;2014,&lt;/em&gt;&#160;Reviva&#160;Pharmaceuticals,&#160;Inc. implemented a tax deferred savings plan, commonly referred to as a &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan. Employee&#x2019;s contributions are withheld from standard payroll checks and are automatically withdrawn from the Company checking account and deposited into individual employee retirement accounts a few days following each payroll period. Employees can defer or contribute the statutory legal limits. There has been no Company matching of employee contributions to the plan through &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81966641"
      unitRef="USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060588">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;CONVERTIBLE PROMISSORY NOTES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;From &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2016&lt;/em&gt; through &lt;em style="font: inherit;"&gt; April&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2017,&lt;/em&gt; the Company issued an aggregate of $4,795,088 in convertible promissory notes to various investors (the &lt;em style="font: inherit;"&gt;&#x201c;2016&lt;/em&gt; Notes&#x201d;). Upon next equity financing close of at least $5,000,000, (&#x201c;Qualified Financing&#x201d;), the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes were to be converted if the entire balance had &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been paid, at which time the then outstanding balance and accrued interest was to automatically be cancelled and converted into that number of conversion shares at a price equal to the lower of either (i)&#160;a 20% discount to the price paid by investors in the qualified financing (&#x201c;Qualified Financing Event Share Price&#x201d;), or (ii)&#160;an $85,000,000 pre-offering valuation divided by the number of shares of the Company&#x2019;s common stock outstanding on a fully diluted basis immediately prior to the closing of such a qualified financing event.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Interest was initially accrued at 8% per annum and was scheduled to be paid in cash at maturity date. The &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes were scheduled to mature &lt;span style="-sec-ix-hidden:c81966657"&gt;twelve&lt;/span&gt;&#160;months from the dates of issue. The &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes were neither converted nor paid back, and therefore were in default since &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; and were accruing interest at a default rate of 12% per annum. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company owed $3,490,087 and $1,192,496 as principle and accrued interest, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The original&#160;stated conversion term for the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes created a contingent BCF that was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; measurable due to a contingency in the conversion mechanics that would allow a conversion to take place at the lower of either a &lt;em style="font: inherit;"&gt;20%&lt;/em&gt; discount to the Qualified Financing Event Share Price or a &lt;em style="font: inherit;"&gt;$85&lt;/em&gt;&#160;million valuation. Consequently, the BCF would have been recognized as additional interest expense had the conversion taken place under the original terms of the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December 10, 2020, &lt;/em&gt;Reviva executed an amendment to the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes (with the exception of $1,200,000 principal on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; note which was repaid in cash subsequent to the Business Combination) automatically converted into 3,788,461 shares of Reviva common stock at a conversion price equal to $1.329698. On consummation of the Business Combination, these shares converted into 576,836 shares of the Company&#x2019;s common stock. The holders have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further rights under the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; notes. The Company evaluated whether there was a BCF to be recognized at the time of conversion and determined that there was &lt;span style="-sec-ix-hidden:c81966680"&gt;none.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; there was a judgement issued by the District Court of Harris County, Texas, pursuant to an agreement reached between the Company and an investor in the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes. Under the terms of the judgements, the Company was obligated to repay an investor of the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes, the principal investment of $1,200,000, accrued interest of $242,236, and legal fees of $5,000. The $1,447,236 obligatory payment accrued interest at 5.5% per annum and was fully paid, (including accrued interest of $79,840 subsequent to the judgement).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;From &lt;em style="font: inherit;"&gt; November&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; through &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company issued an aggregate of $275,000 in convertible promissory notes to various investors (the &lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; notes&#x201d;). Upon a Qualified Financing, the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes could have been converted if the entire balance had &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been paid. The principal and accrued interest of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; notes would have automatically been converted into that number of shares at a price equal to a 20% discount to the Qualified Financing event price (price paid by investors in the Qualified Financing).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Additionally, the holders of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; notes were also eligible for an equivalent number of contingent warrants (i.e. as the number of converted shares), to purchase common stock (&lt;em style="font: inherit;"&gt;&#x201c;2018&lt;/em&gt; Contingent Warrants&#x201d;) with a strike price equal to the Qualified Financing event price with a maturity of 5&#160;years from the date of such a conversion event. These warrants are no longer exercisable and were cancelled during the year ended&#160;&lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Interest on the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes accrued at 8% per annum and was scheduled to be paid in cash at maturity unless converted. The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes were scheduled to mature &lt;span style="-sec-ix-hidden:c81966709"&gt;six&lt;/span&gt;&#160;months from the date of issue with an option to extend the maturity by an additional &lt;em style="font: inherit;"&gt;six&lt;/em&gt;&#160;months with certain additional conversion privileges. Pursuant to the option, the maturity dates of all &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; notes were extended an additional &lt;span style="-sec-ix-hidden:c81966712"&gt;six&lt;/span&gt;&#160;months. The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes were neither converted nor paid back and continued to accrue interest at a default rate of 8% per annum.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December 10, 2020, &lt;/em&gt;Reviva executed an amendment to the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes automatically converted into 370,811 shares of Reviva common stock at a conversion price equal to $0.831018 for each holder of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes who purchased at least &lt;em style="font: inherit;"&gt;$50,000&lt;/em&gt; in aggregate principal amount of &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes or (ii)&#160;$1.330045 for each holder of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes who purchased less than &lt;em style="font: inherit;"&gt;$50,000&lt;/em&gt; in aggregate principal amount of &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Notes. On consummation of the Business Combination, these shares converted into 56,461 shares of the Company&#x2019;s common stock. The holders have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further rights under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; notes. The conversion terms included in the amendment created a BCF of $159,025 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;"&gt;From &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;through &lt;em style="font: inherit;"&gt; May&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company issued an aggregate of $610,000 in convertible promissory notes to various investors (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Notes&#x201d;). Upon a Qualified Financing, the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes could be converted if the entire balance had &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been paid. The principal and accrued interest of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; notes was to automatically be converted into that number of shares at a price equal to a 20% discount to the Qualified Financing event price (price paid by investors in the Qualified Financing).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;"&gt;Additionally, the holders of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes were also eligible for an equivalent number of warrants (i.e. as the number of converted shares), to purchase common stock (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; contingent warrants&#x201d;) with a strike price equal to the Qualified Financing event price with a maturity of 5 years from the date of such a conversion event. The holders of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes, for entering into the Notes agreement, were also eligible to receive common stock when the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes were converted into preferred shares in a Qualified Financing event (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Contingent Stock&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; December 10, 2020, &lt;/em&gt;Reviva executed an amendment to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes with the holders pursuant to which, immediately prior to the closing of the Business Combination, all of the issued and outstanding principal and accrued but unpaid interest under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes automatically converted into 744,916 shares of Reviva common stock at a conversion price equal to $0.831009 for each holder of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes who purchased at least &lt;em style="font: inherit;"&gt;$50,000&lt;/em&gt; in aggregate principal amount of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes or (ii)&#160;$1.329770 for each holder of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes who purchased less than &lt;em style="font: inherit;"&gt;$50,000&lt;/em&gt; in aggregate principal amount of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Notes. On consummation of the Business Combination, these shares converted into 113,422 shares of the Company&#x2019;s common stock. The holders have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further rights under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; notes and the warrants issued in connection with the notes are no longer exercisable. The conversion terms included in the amendment created a BCF of $317,730 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Between &lt;em style="font: inherit;"&gt; August 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 2020, &lt;/em&gt;the Company issued and received an aggregate principal amount of $500,000 in unsecured convertible promissory notes to certain investors to finance its ordinary course of administrative costs and expenses and other expenses incurred in connection with the consummation of the Business Combination. These notes were interest free. These notes provided that they automatically converted, immediately prior to consummation of the business combination, into 601,632 shares of Reviva common stock at a conversion rate equal to $0.831063. The conversion terms created a BCF of $274,083 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;In addition, the Company entered into a contingent capital commitment with certain investors for $2,000,000 (&#x201c;Reviva Contingent Interim Period Notes&#x201d;) that became effective upon consummation of the Business Combination. The Reviva Contingent Interim Period Notes were interest free. The Reviva Contingent Interim Period Notes provided that the notes automatically converted, immediately prior to consummation of the Business Combination, into 1,718,280 shares of Reviva common stock at a conversion price equal to $1.163953. On consummation of the Business Combination, these shares converted into 261,626 shares of the Company&#x2019;s common stock. The holders have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further rights under these notes. The conversion terms created a BCF of $210,842 at the time of conversion. This amount was recorded at conversion to interest expense and additional paid-in capital.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966648"
      unitRef="USD">4795088</us-gaap:DebtInstrumentFaceAmount>
    <rvph:QualifiedFinancingMinimumThreshold
      contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966650"
      unitRef="USD">5000000</rvph:QualifiedFinancingMinimumThreshold>
    <rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors
      contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      decimals="1"
      id="c81966653"
      unitRef="Pure">0.20</rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors>
    <rvph:PreofferingValuationPriorToQualifiedFinancingEvent
      contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966654"
      unitRef="USD">85000000</rvph:PreofferingValuationPriorToQualifiedFinancingEvent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      decimals="2"
      id="c81966655"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rvph:DebtInstrumentDebtDefaultInterestRate
      contextRef="i_2020-12-31_DebtInstrumentAxis-The2016NotesMember"
      decimals="2"
      id="c81966660"
      unitRef="Pure">0.12</rvph:DebtInstrumentDebtDefaultInterestRate>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2019-12-31_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966663"
      unitRef="USD">3490087</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2019-12-31_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966664"
      unitRef="USD">1192496</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2020-12-10_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966673"
      unitRef="USD">1200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966675"
      unitRef="Share">3788461</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966676"
      unitRef="USDPerShare">1.329698</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2016NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966677"
      unitRef="Share">576836</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966685"
      unitRef="USD">1200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InterestPayableCurrent
      contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"
      decimals="INF"
      id="c81966686"
      unitRef="USD">242236</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"
      decimals="INF"
      id="c81966687"
      unitRef="USD">5000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="d_2020-01-02_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"
      decimals="INF"
      id="c81966688"
      unitRef="USD">1447236</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2020-01-02_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"
      decimals="3"
      id="c81966689"
      unitRef="Pure">0.055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPayableCurrent
      contextRef="i_2020-12-15_DebtInstrumentAxis-The2016NotesMember_LineOfCreditFacilityAxis-OneInvestorMember"
      decimals="INF"
      id="c81966690"
      unitRef="USD">79840</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember"
      decimals="INF"
      id="c81966694"
      unitRef="USD">275000</us-gaap:DebtInstrumentFaceAmount>
    <rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors
      contextRef="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember"
      decimals="1"
      id="c81966699"
      unitRef="Pure">0.20</rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2018-11-01_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember"
      id="c81966702">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2019-12-31_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember"
      decimals="-3"
      id="c81966703"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2018-11-01_DebtInstrumentAxis-The2018NotesMember"
      decimals="2"
      id="c81966707"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rvph:DebtInstrumentDebtDefaultInterestRate
      contextRef="i_2020-12-31_DebtInstrumentAxis-The2018NotesMember"
      decimals="2"
      id="c81966714"
      unitRef="Pure">0.08</rvph:DebtInstrumentDebtDefaultInterestRate>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966717"
      unitRef="Share">370811</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member"
      decimals="INF"
      id="c81966718"
      unitRef="USDPerShare">0.831018</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member"
      decimals="INF"
      id="c81966722"
      unitRef="USDPerShare">1.330045</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2018NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966726"
      unitRef="Share">56461</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2018NotesMember"
      decimals="INF"
      id="c81966729"
      unitRef="USD">159025</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-03-01_DebtInstrumentAxis-The2020NotesMember"
      decimals="INF"
      id="c81966732"
      unitRef="USD">610000</us-gaap:DebtInstrumentFaceAmount>
    <rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors
      contextRef="i_2020-03-01_DebtInstrumentAxis-The2020NotesMember"
      decimals="1"
      id="c81966737"
      unitRef="Pure">0.20</rvph:QualifiedFinancingDiscountRateToPricePaidByInvestors>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-03-01_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember"
      id="c81966740">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-12-10_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966747"
      unitRef="Share">744916</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member"
      decimals="INF"
      id="c81966748"
      unitRef="USDPerShare">0.831009</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-12-10_DebtConversionByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member"
      decimals="INF"
      id="c81966752"
      unitRef="USDPerShare">1.329770</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-12-14_2020-12-14_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOf2020NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966756"
      unitRef="Share">113422</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-The2020ContingentWarrantsMember"
      decimals="-3"
      id="c81966759"
      unitRef="USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="d_2020-12-10_2020-12-10_DebtInstrumentAxis-The2020NotesMember"
      decimals="INF"
      id="c81966760"
      unitRef="USD">317730</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-08-01_DebtInstrumentAxis-August2020ToOctober2020NotesMember"
      decimals="INF"
      id="c81966761"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966762"
      unitRef="Share">601632</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember"
      decimals="INF"
      id="c81966763"
      unitRef="USDPerShare">0.831063</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="d_2020-08-01_2020-10-31_DebtInstrumentAxis-August2020ToOctober2020NotesMember"
      decimals="INF"
      id="c81966764"
      unitRef="USD">274083</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-08-01_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember"
      decimals="INF"
      id="c81966765"
      unitRef="USD">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-08-01_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember"
      decimals="INF"
      id="c81966766"
      unitRef="Share">1718280</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2020-10-31_DebtConversionByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember"
      decimals="INF"
      id="c81966767"
      unitRef="USDPerShare">1.163953</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-12-10_2020-12-10_BusinessAcquisitionAxis-ClosingMember_ConversionOfStockByUniqueDescriptionAxis-ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember"
      decimals="INF"
      id="c81966768"
      unitRef="Share">261626</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="d_2020-08-01_2020-10-31_DebtInstrumentAxis-RevivaContingentInterimPeriodNoteMember"
      decimals="INF"
      id="c81966770"
      unitRef="USD">210842</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060589">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;INCOME TAXES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;As a result of the Company's history of net operating losses and full valuation allowance against its deferred tax assets, there was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; current or deferred income tax provision other that current state minimum taxes for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Reconciliations to the statutory federal income tax rate and the Company's effective tax rate consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,788,135&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(794,343&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State income taxes, net of federal tax benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(58,152&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(114,864&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8,924&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Foreign rate differential&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,414&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(45&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(334,122&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;227,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Beneficial conversion feature related to notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;201,953&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,301&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,173,051&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;461,244&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;8,281&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The components of deferred tax assets included on the balance sheet are:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;NOL carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,262,916&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,177,607&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accruals and reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;81,911&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;10,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;197,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;237,976&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fixed assets/capitalized start-up costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,557&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,332&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,544,892&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,429,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(11,544,892&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,429,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81966836"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81966837"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets.&#160; The total increase in valuation allowance is $2,115,079 for the year ending &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company currently has net operating loss carryforwards of approximately $49.2&#160;million and $13.2&#160;million for U.S. Federal and state purposes respectively. Approximately $35.3 million of the U.S. federal losses begin to expire in &lt;em style="font: inherit;"&gt;2029.&lt;/em&gt; The balance, all post-&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; federal net operating losses &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be carried forward indefinitely. The deferred tax asset relates to the NOL carryforwards. Management has determined based on all the available information that a &lt;em style="font: inherit;"&gt;100%&lt;/em&gt; valuation reserve is required.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company had no research and development credit carryforwards to offset federal and California state income taxes, respectively, available to reduce its future taxable income, if any.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Tax Reform Act of &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership of a company.&#160; In the event that the Company has a change in ownership, utilization of carryforwards could be limited.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company has elected to recognize interest and penalties related to uncertain tax positions as components of income tax expense.&#160; As of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company has no accrual for payment of interest related to unrecognized tax benefits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company&#x2019;s income tax returns for all years remain open to examination by federal and state taxing authorities.&#160; The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect that its unrecognized tax benefit will change significantly in the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company has no unrecognized tax benefits that, if recognized, would change its effective rate.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; March&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;27,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act was enacted and signed into law. Certain provisions of the CARES Act impacted the &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; income tax provision computations of the Company and were reflected in the appropriate periods. The CARES Act contains modifications on the limitation of business interest for tax&#160;years beginning in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; The modifications to Section&#160;&lt;em style="font: inherit;"&gt;163&lt;/em&gt;(j) increase the allowable business interest deduction from &lt;em style="font: inherit;"&gt;30%&lt;/em&gt; of adjusted taxable income to &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; of adjusted taxable income. As the company is in losses, there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; modification for the current year.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060590">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,788,135&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(794,343&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State income taxes, net of federal tax benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(58,152&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(114,864&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8,924&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Foreign rate differential&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,414&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(45&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(334,122&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;227,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Beneficial conversion feature related to notes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;201,953&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,301&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,173,051&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;461,244&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;8,281&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966804"
      unitRef="USD">-1788135</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966805"
      unitRef="USD">-794343</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966806"
      unitRef="USD">-58152</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966807"
      unitRef="USD">-114864</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966808"
      unitRef="USD">8924</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966809"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966810"
      unitRef="USD">1414</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966811"
      unitRef="USD">-45</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <rvph:EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966812"
      unitRef="USD">-334122</rvph:EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount>
    <rvph:EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966813"
      unitRef="USD">227651</rvph:EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount>
    <rvph:EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966814"
      unitRef="USD">0</rvph:EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount>
    <rvph:EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966815"
      unitRef="USD">201953</rvph:EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966816"
      unitRef="USD">5301</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966817"
      unitRef="USD">19204</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966818"
      unitRef="USD">2173051</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966819"
      unitRef="USD">461244</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966820"
      unitRef="USD">8281</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81966821"
      unitRef="USD">800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060591">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;NOL carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,262,916&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,177,607&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accruals and reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;81,911&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;10,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;197,508&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;237,976&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fixed assets/capitalized start-up costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,557&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,332&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,544,892&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,429,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(11,544,892&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(9,429,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81966836"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81966837"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966822"
      unitRef="USD">11262916</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966823"
      unitRef="USD">9177607</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966824"
      unitRef="USD">81911</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966825"
      unitRef="USD">10898</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966826"
      unitRef="USD">197508</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966827"
      unitRef="USD">237976</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <rvph:DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966828"
      unitRef="USD">2557</rvph:DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts>
    <rvph:DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966829"
      unitRef="USD">3332</rvph:DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966830"
      unitRef="USD">11544892</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966831"
      unitRef="USD">9429813</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966832"
      unitRef="USD">11544892</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966833"
      unitRef="USD">9429813</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966834"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81966835"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2021-01-10_2021-12-31"
      decimals="INF"
      id="c81966775"
      unitRef="USD">2115079</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"
      decimals="-5"
      id="c81966776"
      unitRef="USD">49200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c81966777"
      unitRef="USD">13200000</us-gaap:OperatingLossCarryforwards>
    <rvph:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"
      decimals="-5"
      id="c81966778"
      unitRef="USD">35300000</rvph:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-3"
      id="c81966783"
      unitRef="USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81966787"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81966792"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060592">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; &lt;/b&gt;&#160;&lt;b&gt;LOSS&lt;/b&gt;&#160;&lt;b&gt;PER SHARE&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Loss per share calculations for all periods prior to the Business Combination have been retrospectively adjusted for the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Subsequent to the Business Combination, earnings per share is calculated based on the weighted average shares of common stock then outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. The weighted average shares of common stock outstanding is based on the 9,231,737 shares of common stock outstanding immediately after the reverse recapitalization in connection with the Business Combination and assumes these shares have been outstanding as of the beginning of the earliest period presented.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company has excluded the potential effect of warrants to purchase shares of common stock totaling 13,883,732 and 7,007,581 shares and the dilutive effect of outstanding stock options totaling 192,898 and 65,471, as described in Note&#160;&lt;em style="font: inherit;"&gt;11,&lt;/em&gt; in the calculation of diluted loss per share, as the effect would be anti-dilutive due to losses incurred. Additionally, 1,000,000 earn-out shares have been excluded as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered issued for accounting purposes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-14"
      decimals="INF"
      id="c81966839"
      unitRef="Share">9231737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c81966841"
      unitRef="Share">13883732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c81966842"
      unitRef="Share">7007581</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81966843"
      unitRef="Share">192898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81966844"
      unitRef="Share">65471</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EarnoutSharesMember"
      decimals="INF"
      id="c81966846"
      unitRef="Share">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060593">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;STOCKHOLDERS&lt;/b&gt;&#x2019;&lt;b&gt; EQUITY (DEFICIT)&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Our authorized capital stock consists of:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:3.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:3.3%;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:auto;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;115,000,000 shares of common stock, par value $0.0001 per share; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:3.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:3.3%;"&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:auto;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;10,000,000 shares of preferred stock, par value $0.0001 per share.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there were 14,433,286 shares of our common stock outstanding, and no shares of preferred stock outstanding. In &lt;em style="font: inherit;"&gt; November 2021, &lt;/em&gt;the Company issued 11,000 shares of common stock to a consultant in exchange for services provided. In &lt;em style="font: inherit;"&gt; September&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company&#160;issued 38,992 shares of common stock to current and past employees in lieu of certain dues and obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Common Stock&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Voting.&#160;&#160;&#160;The holders of our common stock are entitled to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; vote for each share held of record on all matters on which the holders are entitled to vote (or consent pursuant to written consent). Directors are elected by a plurality of the votes present in person or represented by proxy and entitled to vote.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Dividends.&#160;&#160;&#160;The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Liquidation Rights.&#160;&#160;&#160;In the event of the Company&#x2019;s liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Conversion Right.&#160;&#160;&#160;The holders of common stock have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; conversion rights.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Preemptive and Similar Rights.&#160;&#160;&#160;The holders of common stock have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; preemptive or similar rights.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Redemption/Put Rights.&#160;&#160;&#160;There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; redemption or sinking fund provisions applicable to the Common Stock. All of the outstanding shares of common stock will be fully-paid and nonassessable.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Our board of directors has the authority to issue shares of preferred stock from time to time on terms it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;determine, to divide shares of preferred stock into &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there were public warrants outstanding to purchase an aggregate of 6,325,000 shares of common stock and private warrants outstanding to purchase an aggregate of 556,313 shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Each public warrant entitles the holder thereof to purchase one share of common stock at a price &lt;span style="-sec-ix-hidden:c81966876"&gt;of&#x2009;$11.50&lt;/span&gt; per share, subject to adjustment. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; public warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to such shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;call the public warrants for redemption, in whole and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; in part, at a price &lt;span style="-sec-ix-hidden:c81966880"&gt;of&#x2009;$0.01&lt;/span&gt; per warrant:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period ending on the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; trading business day prior to the notice of redemption to holders of the public warrants, and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day trading period referred to above and continuing each day thereafter until the date of redemption.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;at any time while the public warrants are exercisable,&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;upon &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than &lt;em style="font: inherit;"&gt;30&lt;/em&gt;&#160;days&#x2019;&#160;prior written notice of redemption to each warrant holder,&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The private warrants are substantially similar to the public warrants except such private warrants;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;are exercisable for cash or on a cashless basis, at the holder&#x2019;s option&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 36pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;The redemption price is to be calculated as the &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-day average trading price ending &lt;em style="font: inherit;"&gt;one&lt;/em&gt; trading business day prior to the notice of redemption.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 26pt; text-indent: 18pt;"&gt;In &lt;em style="font: inherit;"&gt;no&lt;/em&gt; event will the Company be required to net cash settle either the public or the private warrants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company classified the private warrants pursuant to ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt; as derivative liabilities with subsequent changes in their fair values to be recognized in the consolidated financial statements at each reporting date. The Company calculated the fair value of the private warrants as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; as $372,730 using a Black-Scholes model. The key inputs used in the Black-Scholes calculation were, the risk-free interest rate, expected volatility, expected life, exercise price and stock price. The risk-free interest rate was estimated to be 1.11%, the expected volatility was estimated to be 73.0%, and the expected life was estimated to be 3.96&#160;years. The exercise price was $11.50, and the stock price $2.89. Due to fair value changes during the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company recorded a gain on remeasurement of warrant liabilities of $1,591,055.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The exercise price and number of shares of common stock issuable on exercise of the warrants &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or a recapitalization, reorganization, merger or consolidation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 shares of common stock. These warrants were classified as equity as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; The fair value of these warrants on the date of issuance was $1,279,182.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;In connection with the Offering, the Company issued Pre-Funded Warrants exercisable for 5,066,600 shares of common stock. Total proceeds from the sale of Units including the Pre-Funded Warrants were approximately $19.0&#160;million and the Pre-Funded Warrants are exercisable into &lt;span style="-sec-ix-hidden:c81966911"&gt;one&lt;/span&gt; share of common stock at an exercise price of $0.0001 per share at any time after issuance. Additionally, in connection with the Offering, the Company issued Investor Warrants exercisable for&#160;6,900,000&#160;shares of common stock&#160;with an&#160;exercise price of $4.125 per share of common stock any time after issuance. The Investor Warrants expire on &lt;em style="font: inherit;"&gt; June 1, 2026. &lt;/em&gt;During the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; Investor Warrants for 23,849&#160;shares of common stock were exercised with proceeds of $98,378 and Pre-Funded Warrants for 1,033,300&#160;shares of common stock were exercised with proceeds of $103. The Company has determined that&#160;as the&#160;Pre-Funded Warrants and&#160;Investor Warrants&#160;were issued at fair value in a public offering of Units with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; debt funding included in the offering, the&#160;Pre-Funded Warrants and Investor Warrants should be classified as equity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; July&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the company issued warrants with a &lt;span style="-sec-ix-hidden:c81966925"&gt;five&lt;/span&gt;-year term to purchase 120,456 shares of common stock at $22.99 per share to certain current and past consultants (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; warrants&#x201d;). The &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; warrants were exercisable immediately. The Company estimated the fair value of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; warrants to be $1,178,182, using the Black-Scholes-Merton option-pricing model with the following assumptions:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Assumptions&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yields&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The&#160;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; warrants are classified as equity and included in general and administrative expense during the year ended &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Warrants&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company issued warrants in connection with the &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; Notes (the &lt;em style="font: inherit;"&gt;&#x201c;2016&lt;/em&gt; Warrants&#x201d;) to purchase 5,812 shares of its common stock which will expire on &lt;em style="font: inherit;"&gt; April&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;28,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The fair value of the warrants was originally estimated to be approximately $101,000 and they were classified as a liability on the balance sheet as the strike price was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; established at the time of grant.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the Business Combination, the strike price was set at $42.29 based on the terms of the warrants at a common stock conversion rate of 0.152268.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 using the using the Black-Scholes option pricing model. The assumptions utilized in the Black-Scholes model included the risk-free interest rate, expected volatility, and expected life in years. The risk-free interest rate was based on the U.S. Treasury yield curve rates with maturity terms similar to the expected life of the warrant, which was determined to be 0.36%. Expected volatility was determined utilizing historical volatility over a period of time equal to the expected life of the warrant, which was determined to be 126%. Expected life was equal to the remaining contractual term of the warrant, which was determined to be 1.4 years. The dividend yield was assumed to be &lt;span style="-sec-ix-hidden:c81966947"&gt;zero&lt;/span&gt; since the Company had &lt;em style="font: inherit;"&gt;not&lt;/em&gt; historically declared dividends and did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any plans to declare dividends in the future&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 being recorded as a reduction of general and administrative expense during the year ending &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; &#x201c;Distinguishing Liabilities from Equity&#x201d;, the warrants should be reclassified to equity.&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966855"
      unitRef="Share">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966856"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966857"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966858"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81966861"
      unitRef="Share">14433286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81966862"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-11-01_2021-11-30"
      decimals="INF"
      id="c81966863"
      unitRef="Share">11000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued
      contextRef="d_2020-09-01_2020-09-30"
      decimals="INF"
      id="c81966865"
      unitRef="Share">38992</us-gaap:DeferredCompensationArrangementWithIndividualSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966873"
      unitRef="Share">6325000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-PrivateWarrantsMember"
      decimals="INF"
      id="c81966874"
      unitRef="Share">556313</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966875"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <rvph:ThresholdClosingPriceForSpecifiedNumberOfTradingDays
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966881"
      unitRef="USDPerShare">21.00</rvph:ThresholdClosingPriceForSpecifiedNumberOfTradingDays>
    <rvph:ThresholdTradingDaysForSaleOfShares
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      id="c81966882">P20D</rvph:ThresholdTradingDaysForSaleOfShares>
    <rvph:ThresholdConsecutiveTradingDaysForSaleOfShares
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      id="c81966883">P30D</rvph:ThresholdConsecutiveTradingDaysForSaleOfShares>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c81966894"
      unitRef="USD">372730</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c81966895"
      unitRef="Pure">0.0111</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c81966896"
      unitRef="Pure">0.730</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c81966897"
      unitRef="Pure">3.96</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c81966898"
      unitRef="Pure">11.50</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c81966899"
      unitRef="Pure">2.89</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2021-01-01_2021-12-31_DerivativeInstrumentRiskAxis-PrivateWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c81966902"
      unitRef="USD">1591055</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966903"
      unitRef="Share">126268</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember"
      decimals="INF"
      id="c81966908"
      unitRef="USD">1279182</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966909"
      unitRef="Share">5066600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember"
      decimals="-6"
      id="c81966910"
      unitRef="USD">19000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966912"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966913"
      unitRef="Share">6900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-06-01_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966914"
      unitRef="USDPerShare">4.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rvph:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966917"
      unitRef="Share">23849</rvph:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-InvestorWarrantMember"
      decimals="INF"
      id="c81966918"
      unitRef="USD">98378</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966919"
      unitRef="Share">1033300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantMember"
      decimals="INF"
      id="c81966920"
      unitRef="USD">103</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember"
      decimals="INF"
      id="c81966926"
      unitRef="Share">120456</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember"
      decimals="INF"
      id="c81966927"
      unitRef="USDPerShare">22.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember"
      decimals="INF"
      id="c81966931"
      unitRef="USD">1178182</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060594">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Assumptions&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.25&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yields&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;126&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c81966952"
      unitRef="Pure">2.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c81966953"
      unitRef="Pure">3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c81966954"
      unitRef="Pure">0.0028</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c81966955"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c81966956"
      unitRef="Pure">1.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember"
      decimals="INF"
      id="c81966936"
      unitRef="Share">5812</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember"
      decimals="INF"
      id="c81966939"
      unitRef="USD">101000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2016-06-01_ClassOfWarrantOrRightAxis-The2016WarrantsMember"
      decimals="INF"
      id="c81966941"
      unitRef="USDPerShare">42.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2016-06-01_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966942"
      unitRef="Share">0.152268</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember"
      decimals="INF"
      id="c81966943"
      unitRef="USD">7395</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c81966944"
      unitRef="Pure">0.0036</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="2"
      id="c81966945"
      unitRef="Pure">1.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2020-12-14_DebtInstrumentAxis-The2016NotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c81966946"
      unitRef="Pure">1.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-The2016WarrantsMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c81966950"
      unitRef="USD">94175</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060595">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;STOCK OPTION PLAN AND STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Reviva&#x2019;s board of directors adopted, and Reviva&#x2019;s stockholders approved, the Reviva Pharmaceuticals,&#160;Inc. &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan, effective as of &lt;em style="font: inherit;"&gt; August&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;2006.&lt;/em&gt; The Reviva Pharmaceuticals,&#160;Inc. &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan provided for the grant of incentive stock options, or ISOs, within the meaning of Section&#160;&lt;em style="font: inherit;"&gt;422&lt;/em&gt; of the Code, to Reviva&#x2019;s employees, and for the grant of nonstatutory stock options, or NSOs, and restricted stock awards to Reviva&#x2019;s employees, officers, directors and consultants; provided such consultants render bona fide services &lt;em style="font: inherit;"&gt;not&lt;/em&gt; in connection with the offer and sale of securities in a capital-raising transaction. As of &lt;em style="font: inherit;"&gt;2016,&lt;/em&gt; &lt;em style="font: inherit;"&gt;no&lt;/em&gt; new grants of awards are permitted under the Reviva Pharmaceuticals,&#160;Inc. &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Upon the Business Combination, the Reviva Pharmaceuticals,&#160;Inc. &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan was amended to change its name to the Reviva Pharmaceuticals Holdings,&#160;Inc. &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2006&lt;/em&gt; Equity Incentive Plan&#x201d;), and each outstanding option to acquire Reviva common stock (whether vested or unvested) under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan was assumed by the Company and automatically converted into an option to acquire shares of common stock, with its price and number of shares equitably adjusted based on the conversion of the shares of common stock of Reviva into shares of common stock of the Company pursuant to the Merger Agreement. Pursuant to such assumption and automatic conversion, as of the consummation of the Business Combination there are outstanding options under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan exercisable for an aggregate of 65,471 shares of Company common stock, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; new grants of awards are permitted under the &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; Equity Incentive Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;On &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;14,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Reviva Pharmaceuticals Holdings,&#160;Inc. &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Equity Incentive Plan&#x201d;) became effective. The general purpose of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan is to provide a means whereby employees, officers, directors, consultants, advisors or other individual service providers &lt;em style="font: inherit;"&gt; may &lt;/em&gt;develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to us, thereby advancing our interests and the interests of our stockholders.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;an aggregate of 1,384,761 shares of common stock &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be issued under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan, subject to equitable adjustment in the event of stock splits and other capital changes (the &#x201c;Share Reserve&#x201d;). The Share Reserve will automatically increase on &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of each year, for a period of &lt;em style="font: inherit;"&gt;not&lt;/em&gt; more than &lt;span style="-sec-ix-hidden:c81966986"&gt;ten&lt;/span&gt;&#160;years, commencing on &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of the year following the year in which the effective date of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan occurs, and ending on (and including) &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2030,&lt;/em&gt; in an amount equal to the lesser of (i)&#160;&lt;em style="font: inherit;"&gt;ten&lt;/em&gt;&#160;percent (10%) of the total number of shares of Common Stock outstanding on &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31st&lt;/em&gt; of the preceding calendar year or (ii)&#160;such number of shares of common stock determined by the Company&#x2019;s board of directors (the &#x201c;Annual Increase&#x201d;). Notwithstanding the foregoing and, subject to adjustment as provided in the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan, the maximum number of shares which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be issued in respect of Incentive Stock Options shall be equal to 1,384,761.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company records stock-based compensation expense in connection with the amortization of the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company recorded stock-based compensation of $106,713 and $0, respectively. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company had unrecognized stock-based compensation expense of $281,397 and $0.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Determining Fair Value&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Valuation and Recognition &#x2013; The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Expected Term &#x2013; Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Expected Volatility - Expected volatility is based on the Company&#x2019;s historical stock volatility data over the expected term of the awards.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon issues with an equivalent expected term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Dividend Yield &#x2013; The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; paid a dividend and does &lt;span style="-sec-ix-hidden:c81967008"&gt;not&lt;/span&gt; anticipate paying a dividend in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The assumptions used in estimating the fair value of options granted in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; are summarized as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Expected Term in years - 5.20 - 6.08&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Volatility &#x2013; 87.1% - 93.9%&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Risk-free interest rate &#x2013; 0.95% - 1.31%&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Dividend Yield &#x2013; 0.00%&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company granted no stock options during the year ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Activity under the stock plans for the years ending &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; is as follows.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Available for&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Grant&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Price per&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Balance, December 31, 2019&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;343,871&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;112,932&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15.37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options authorized&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;461,587&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;47,461&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(47,461&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Effect of plan amendment on business combination&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(391,332&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Balance, December 31, 2020&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;461,587&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;65,471&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16.86&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options authorized&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;923,174&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(127,427&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;127,427&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Balance, December 31, 2021&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,257,334&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;192,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Vested and expected to vest, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;192,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Options outstanding under the stock plans are as follows as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Remaining&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Contractual&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Life (Years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercisable&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Prices per Share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;48,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.85&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;48,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.89&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;16,747&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16,747&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31.33&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;81,227&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.31&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,832&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.89&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.72&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;192,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.76&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;95,803&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2006Member"
      decimals="INF"
      id="c81966972"
      unitRef="Share">65471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member"
      decimals="INF"
      id="c81966982"
      unitRef="Share">1384761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <rvph:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease
      contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member"
      decimals="1"
      id="c81966992"
      unitRef="Pure">0.10</rvph:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2020Member_RangeAxis-MaximumMember"
      decimals="INF"
      id="c81966995"
      unitRef="Share">1384761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81966999"
      unitRef="USD">106713</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81967000"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81967004"
      unitRef="USD">281397</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81967005"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      id="c81967010">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      id="c81967011">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      decimals="3"
      id="c81967012"
      unitRef="Pure">0.871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      decimals="3"
      id="c81967013"
      unitRef="Pure">0.939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      decimals="4"
      id="c81967014"
      unitRef="Pure">0.0095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      decimals="4"
      id="c81967015"
      unitRef="Pure">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81967016"
      unitRef="Pure">0.0000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81967017"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060596">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Available for&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Grant&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Price per&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;b&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Balance, December 31, 2019&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;343,871&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;112,932&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15.37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options authorized&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;461,587&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;47,461&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(47,461&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Effect of plan amendment on business combination&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(391,332&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Balance, December 31, 2020&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;461,587&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;65,471&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16.86&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options authorized&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;923,174&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(127,427&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;127,427&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Balance, December 31, 2021&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,257,334&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;192,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Vested and expected to vest, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;192,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2019-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967024"
      unitRef="Share">343871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c81967025"
      unitRef="Share">112932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c81967026"
      unitRef="USDPerShare">15.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967027"
      unitRef="Share">461587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <rvph:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967030"
      unitRef="Share">47461</rvph:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81967031"
      unitRef="Share">47461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81967032"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <rvph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967033"
      unitRef="Share">391332</rvph:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967036"
      unitRef="Share">461587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81967037"
      unitRef="Share">65471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81967038"
      unitRef="USDPerShare">16.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967039"
      unitRef="Share">923174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967042"
      unitRef="Share">127427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81967043"
      unitRef="Share">127427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81967044"
      unitRef="USDPerShare">4.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81967045"
      unitRef="Share">1257334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81967046"
      unitRef="Share">192898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81967047"
      unitRef="USDPerShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81967049"
      unitRef="Share">192898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81967050"
      unitRef="USDPerShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060621">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Remaining&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Contractual&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Life (Years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercisable&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Prices per Share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;48,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.85&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;48,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.89&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;16,747&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.93&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16,747&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31.33&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;81,227&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.31&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,832&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.89&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.72&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;192,898&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.76&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;95,803&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.46&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member"
      decimals="INF"
      id="c81969461"
      unitRef="Share">48724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member"
      id="c81969462">P0Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member"
      decimals="INF"
      id="c81969463"
      unitRef="Share">48724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range1Member"
      decimals="INF"
      id="c81969464"
      unitRef="USDPerShare">11.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member"
      decimals="INF"
      id="c81969465"
      unitRef="Share">16747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member"
      id="c81969466">P2Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member"
      decimals="INF"
      id="c81969467"
      unitRef="Share">16747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range2Member"
      decimals="INF"
      id="c81969468"
      unitRef="USDPerShare">31.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member"
      decimals="INF"
      id="c81969469"
      unitRef="Share">81227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member"
      id="c81969470">P9Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member"
      decimals="INF"
      id="c81969471"
      unitRef="Share">17832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range3Member"
      decimals="INF"
      id="c81969472"
      unitRef="USDPerShare">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member"
      decimals="INF"
      id="c81969473"
      unitRef="Share">46200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member"
      id="c81969474">P9Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member"
      decimals="INF"
      id="c81969475"
      unitRef="Share">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-Range4Member"
      decimals="INF"
      id="c81969476"
      unitRef="USDPerShare">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81969477"
      unitRef="Share">192898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-12-31" id="c81969478">P6Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81969479"
      unitRef="Share">95803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81969480"
      unitRef="USDPerShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060598">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;Since &lt;em style="font: inherit;"&gt;2010,&lt;/em&gt; the Company has entered into multiple clinical trial agreements with medical institutions in the United States, Europe and Asia for the purpose of enrolling patients into various clinical trials. The agreements are substantially similar by trial and include a detailed listing of the clinical trial services for which the Company will pay, how much will be paid for each service, a set-up charge (if any), Investigational Review Board fees, contractual term, and other provisions. The clinical trial services provided by each site generally include the screening of prospective patients and, for those patients to be enrolled in the study, administration of the Company&#x2019;s investigation drug according to the trial protocol, any required hospitalization, ancillary medical supplies, and &lt;em style="font: inherit;"&gt;2&lt;/em&gt;-week patient follow-up. Further, each agreement requires the Company to indemnify each respective clinical site against any and all liability, loss, or damage it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;suffer as a result of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party claims; the Company maintains general product liability insurance of &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than $5&#160;million in conjunction with this indemnification. The agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated upon &lt;em style="font: inherit;"&gt;30&lt;/em&gt;&#160;days&#x2019; written notice, subject to conditions of paying all liabilities incurred through the date of termination. Additionally, with each screened patient, the Company incurs expense with other entities engaged to provide independent review of patient medical records.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Indemnification&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;From time to time, in its normal course of business, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;indemnify other parties, with whom it enters into contractual relationships, including lessors and parties to other transactions with the Company. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party infringement claims. It &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be possible to determine the maximum potential amount of liability under such indemnification obligations due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Historically, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; such indemnification claims. The Company has also indemnified its directors and executive officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be involved by reason of such individual being or having been a director or executive officer.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;margin:0pt; text-indent: 36pt;"&gt;The Company adopted ASC &lt;em style="font: inherit;"&gt;842&lt;/em&gt; to its existing lease on &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;The Company has elected to apply the short-term lease exception to leases of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less. Presently, the Company has a single &lt;span style="-sec-ix-hidden:c81967087"&gt;twelve&lt;/span&gt;-month lease on its Corporate Office located at &lt;em style="font: inherit;"&gt;19925&lt;/em&gt; Stevens Creek Blvd., Suite &lt;em style="font: inherit;"&gt;100,&lt;/em&gt; Cupertino, CA &lt;em style="font: inherit;"&gt;95014.&lt;/em&gt; The monthly lease payment is approximately $1,200 and the lease was renewed on &lt;em style="font: inherit;"&gt; February 1, 2021, &lt;/em&gt;for another 12-month term.&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rvph:GeneralProductLiabilityInsurance
      contextRef="i_2021-12-31_RangeAxis-MinimumMember"
      decimals="-6"
      id="c81967080"
      unitRef="USD">5000000</rvph:GeneralProductLiabilityInsurance>
    <rvph:LesseeOperatingLeaseMonthlyLeasePayment
      contextRef="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember"
      decimals="INF"
      id="c81967091"
      unitRef="USD">1200</rvph:LesseeOperatingLeaseMonthlyLeasePayment>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember"
      id="c81967092">P12M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2060599">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2022, &lt;/em&gt;the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, as sales agent (&#x201c;Wainwright&#x201d;), pursuant to which the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell, from time to time through Wainwright, shares of its common stock for aggregate gross proceeds of up to $12.9 million (the &#x201c;Shares&#x201d;). As of the date of this filing, the Company has &lt;span style="-sec-ix-hidden:c81967095"&gt;not&lt;/span&gt; made any sales pursuant to the ATM Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <rvph:SaleOfStockAgreementMaximumAggregateGrossProceeds
      contextRef="d_2022-01-01_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember"
      decimals="-5"
      id="c81967094"
      unitRef="USD">12900000</rvph:SaleOfStockAgreementMaximumAggregateGrossProceeds>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M16<GWRN:[U>?F7H0M0Y*O@+7\%T",=3^D]#^PLA-^PGC7AHCJ_9TS5G!56,
M_Z^D-,\7S5>1PX>YJ[\!4$L#!!0    ( &Z*;U2.Y'[#2 8  (@8   8
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M>)0V'):V:4?ZR.JV$&2O6T3VS&3%E3\7L2MP4*2+TRKB,9MR8A1 ?$X IYR
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M$Z2HC)+#X:+ZVXMPSAA%W%@\0MC)!WO^H\9,YF!<DM87V\20\=A28+5>IDJ
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MIG);T?!6@R>6B@A+A7X*EX-%74M).N4UJBK2 F76J<%>A%&F&Y /5HN-3,M
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M$7>9_(5) 3H)D4'2%0"P:U=7#1&A6A0F.)GKKUR/ >#(80!N??==6P16F2'
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MP((-/R&$"V\*?FT_--Z;,7]-E41P:0&>CPQ"6UW0!LWO..?_!E!+ P04
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M*RG6J Q?% A3)4NNM51;L-_UH&-H*VO021O8L8>-C\!&,=Q+87(--R+#[#5
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M^;R>XD,F(A)EM!PWTO#)Z#?HH"B)/O2ZQX8S)-,('O85>2$;#\C3#6@V82Q
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MB+M,_XG) 3H)D4'2U0"P&[97/1&A6A0F.EGI;UR/ >#(80!N=_?-4 1662#
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M' /^ 5E].+WUC[9[[? $],L-WMS2, /V5QJ/E?J##;2O^//_ 5!+ P04
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MRF%T'4&!>U8+]Z"/7_"DI^_Y<BUL^,*Q\>WW(LAKZ[0\@2D#R56SLN=3'<X
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M'X%IYD5C.%V%'MUI1QT?MB6-6#3>@>[WFA[KR? !VJ$]^@M02P,$%     @
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M+W=O<FMS:&5E=',O<VAE970R,RYX;6R-5%%/VS 0_BNG:&@@09.FA2'45J+
MM$D#(6#L8=J#FUR:4QT[V YM__W.3@A,@FHOB>]\WW??V7>>K+59V1+1P::2
MRDZCTKGZ+(YM5F(E[$#7J'BGT*82CDVSC&UM4.0!5,DX39*3N!*DHMDD^&[-
M;*(;)TGAK0';5)4PVSE*O9Y&P^C%<4?+TGE'/)O48HGWZ'[6MX:MN&?)J4)E
M22LP6$RC\^'9?.SC0\ CX=J^68.O9*'URAO?\VF4>$$H,7.>0?#O&2]02D_$
M,IXZSJA/Z8%OUR_L7T/M7,M"6+S0\A?EKIQ&IQ'D6(A&NCN]_H9=/<>>+]/2
MAB^LN]@D@JRQ3E<=F!54I-J_V'3G\#^ M .D07>;**B\%$[,)D:OP?AH9O.+
M4&I LSA2_E+NG>%=8IR;W6B',$S@".Z=SE:EECD:^QFNGAIR6]B_Q((R<@>P
M_R 6$NW!)':<UH/CK$LQ;U.D'Z08IG"ME2LM7*D<\W\)8M;;BTY?1,_3G8R7
MF U@-#R$-$F'._A&_2&, M]HQR%8: O<03?NZ<:!;OP!W5=!!AZ%;/ 0SJU%
M9T&H''Z06) D1YSK&H5M#.; C7FCE<&L,8;4$N;"DCT,:!':]@&S4M%3PZ#?
M02%[-@[FDF_KSWN7L5L;ZVFJVC-;N-!5Q1FLOWAX]GKA$Z2#]!BN-C5/#<N3
M5"#LDX(M"F,/8 1W9%='A4$$4@X-6@=&< \E@_04]EZ1.3U3CESVEE#F%A+>
M?-22BY*^L8;I">R]=];QFUZNT"S#Q%K(=*-<V]:]MW\4SMM9> UO7Y1K89;$
M=4HL&)H,OAQ'8-HI;0VGZS 9"^UXSL*RY(<-C0_@_4)S8W2&3] _E;._4$L#
M!!0    ( &Z*;U1E,^GZTP,   X)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;(U6;6^C1A#^*R,:58G$@5FPP:EMR<ZE+U+OSDJN.555/ZQA;*,
MR^VN7])?W]D%4R(Y;K[8N\O,,_/,/L,P.0CYK+:(&HYE4:FIL]6ZOO5]E6ZQ
MY,H3-5;T9"UDR35MY<97M42>6:>R\-E@,/)+GE?.;&+/EG(V$3M=Y!4N):A=
M67+YLL!"'*9.X)P.'O+-5IL#?S:I^08?4?]1+R7M_ XERTNL5"XJD+B>.O/@
M=C$T]M;@*<>#ZJW!,%D)\6PVOV539V 2P@)3;1 X_>WQ#HO" %$:WUM,IPMI
M'/OK$_K/ECMQ67&%=Z+XEF=Z.W42!S)<\UVA'\3A5VSYV 1342C["X?6=N!
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M9)R03^)%(WA"94!-4^.QIJK01@O8T_%9G-?>%]I@V+7!\-UM\.I5TNL%6+W
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M67VHRAC;:$JG;D?0BO_A$ $PHEE=GZCH'>GI?1^I+5T^3:WEPH[,(B4 :(@
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M _[%&Q%M\H>L[R(AHB!_N>9LP>/L OG],I))*M]DSVU7_V9Q_"]02P,$%
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MUI<%,_'>S50WC3LFYEDI20XS-.E<A<@CJN%=+11?FOGWPA5.4_.ZP L/""V
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MED8B"Y9&O#%1A#QXL>7&OD=VLX5K[^ =B]GY/C=2GQO_S><G'JQ *OTZ2>J
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MABE)-.3CX'IP-1VY?)_PC4%M]M;$=;)6ZM$%-]DXB)P@X)!:AT#QL849<.Z
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M8#7B"*8 -&!(%)GGX,[S*-@\IX+FK_O1'U!+ P04    " !NBF]4EXJ[',
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M9]T/F_DG4$L! A0#%     @ ;HIO5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !NBF]4G5U[^.X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ;HIO5'0A'810 @
M8@8  !@              ("!A1,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( &Z*;U036/^ )P0  $P.   8              " @0L6
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !NBF]40O9
M?U &  "D&P  &               @(%H&@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ ;HIO5([D?L-(!@  B!@  !@
M ("![B   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &Z*
M;U1*K21:J (  (L%   8              " @6PG  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !NBF]4 +37+#H*   \&@  &
M        @(%**@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
M  @ ;HIO5/X-@DS)"0  TQD  !@              ("!NC0  'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &Z*;U3*2Y .^ 4  )L.   9
M              " @;D^  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L!
M A0#%     @ ;HIO5-!=75FX @  W@4  !D              ("!Z$0  'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !NBF]4''!2HSD"
M  "_!   &0              @('71P  >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;%!+ 0(4 Q0    ( &Z*;U3U,HP*B 0  (0*   9              "
M@4=*  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ;HIO
M5#'V+ BS!0  D@P  !D              ("!!D\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !NBF]4L<HQD&\#   0"   &0
M        @('P5   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( &Z*;U09E=2U<0D  "(8   9              " @998  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ;HIO5/O\6AO.!@  T0\
M !D              ("!/F(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !NBF]448>UCL0"  # !0  &0              @(%#:0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &Z*;U3[:KL!
M)P(  )P$   9              " @3YL  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ ;HIO5.'Q+P4Q"P  T"(  !D
M ("!G&X  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !N
MBF]4*#$Q/6H"   \!0  &0              @($$>@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &Z*;U0T@2//W0,  %@(   9
M          " @:5\  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ ;HIO5+<PGS&) @  -@4  !D              ("!N8   'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !NBF]493/I^M,#   .
M"0  &0              @(%Y@P  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( &Z*;U1N4PRU2@(  *D%   9              " @8.'
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ;HIO5%-Y
M9F$5!   _P\  !D              ("!!(H  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    " !NBF]4[(4#XBT$  "H#0  &0
M    @(%0C@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M &Z*;U36WA3$( (  *X$   9              " @;22  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ ;HIO5"T4CT%S @  \@8  !D
M             ("!"Y4  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !NBF]4B2V'MQ4"   Z!   &0              @(&UEP  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &Z*;U0SKHT*6@@
M '(Q   9              " @0&:  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ ;HIO5*(?I.9S P  _0D  !D              ("!
MDJ(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !NBF]4
MRFW^H(\#   -"P  &0              @($\I@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( &Z*;U07\F%J)@,  $X)   9
M      " @0*J  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ ;HIO5 XQ,U,' P  +@D  !D              ("!7ZT  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !NBF]4OB=V*'\)  !>.
M&0              @(&=L   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( &Z*;U34<$]KE0(  ,,'   9              " @5.Z  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ;HIO5&E$(0K9
M!   #Q8  !D              ("!'[T  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !NBF]4S8_FAD8$  #H$   &0
M@($OP@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &Z*
M;U27^3"9 P0  (\2   9              " @:S&  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ ;HIO5%]I_229 @  O08  !D
M         ("!YLH  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " !NBF]4%.>:,)<"  !<!0  &0              @(&VS0  >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &Z*;U1T8"./: ,  ,<7
M   -              "  830  !X;"]S='EL97,N>&UL4$L! A0#%     @
M;HIO5)>*NQS     $P(   L              ( !%]0  %]R96QS+RYR96QS
M4$L! A0#%     @ ;HIO5%4^E1GW P  QAP   \              ( ! -4
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &Z*;U2^RS-!F0$  '49   :
M              "  239  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( &Z*;U0CU6X-J $  +@9   3              "  ?7:  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     R #( E0T  ,[<      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>328</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations</Role>
      <ShortName>Note 1 - Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Summary of Significant Accounting Policies and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Public Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-3-public-offering</Role>
      <ShortName>Note 3 - Public Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-4-business-combination</Role>
      <ShortName>Note 4 - Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net</Role>
      <ShortName>Note 5 - Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan</Role>
      <ShortName>Note 6 - Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes</Role>
      <ShortName>Note 7 - Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-8-income-taxes</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-9-loss-per-share</Role>
      <ShortName>Note 9 - Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit</Role>
      <ShortName>Note 10 - Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation</Role>
      <ShortName>Note 11 - Stock Option Plan and Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies</Role>
      <ShortName>Note 12 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-13-subsequent-events</Role>
      <ShortName>Note 13 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 5 - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables</Role>
      <ShortName>Note 5 - Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 8 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables</Role>
      <ShortName>Note 8 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-8-income-taxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 10 - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables</Role>
      <ShortName>Note 10 - Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables</Role>
      <ShortName>Note 11 - Stock Option Plan and Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 3 - Public Offering (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual</Role>
      <ShortName>Note 3 - Public Offering (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-3-public-offering</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 4 - Business Combination (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual</Role>
      <ShortName>Note 4 - Business Combination (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-4-business-combination</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details</Role>
      <ShortName>Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 6 - Employee Benefit Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual</Role>
      <ShortName>Note 6 - Employee Benefit Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 7 - Convertible Promissory Notes (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual</Role>
      <ShortName>Note 7 - Convertible Promissory Notes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 8 - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details</Role>
      <ShortName>Note 8 - Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details</Role>
      <ShortName>Note 8 - Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 9 - Loss Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual</Role>
      <ShortName>Note 9 - Loss Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-9-loss-per-share</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 10 - Stockholders' Equity (Deficit) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual</Role>
      <ShortName>Note 10 - Stockholders' Equity (Deficit) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details</Role>
      <ShortName>Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual</Role>
      <ShortName>Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details</Role>
      <ShortName>Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 12 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rvph20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 13 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual</Role>
      <ShortName>Note 13 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://revivapharma.com/20211231/role/statement-note-13-subsequent-events</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="rvph20211231_10k.htm">rvph20211231_10k.htm</File>
    <File>ex_345157.htm</File>
    <File>ex_345158.htm</File>
    <File>ex_345159.htm</File>
    <File>ex_346563.htm</File>
    <File>rvph-20211231.xsd</File>
    <File>rvph-20211231_cal.xml</File>
    <File>rvph-20211231_def.xml</File>
    <File>rvph-20211231_lab.xml</File>
    <File>rvph-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a1.jpg</File>
    <File>rvph20211231_10kimg002.jpg</File>
    <File>rvph20211231_10kimg003.jpg</File>
    <File>rvph20211231_10kimg004.jpg</File>
    <File>rvph20211231_10kimg005.jpg</File>
    <File>rvph20211231_10kimg006.jpg</File>
    <File>rvph20211231_10kimg007.jpg</File>
    <File>rvph20211231_10kimg008.jpg</File>
    <File>rvph20211231_10kimg009.jpg</File>
    <File>rvph20211231_10kimg010.jpg</File>
    <File>rvph20211231_10kimg011.jpg</File>
    <File>rvph20211231_10kimg012.jpg</File>
    <File>rvph20211231_10kimg013.jpg</File>
    <File>rvph20211231_10kimg014.jpg</File>
    <File>rvph20211231_10kimg015.jpg</File>
    <File>rvph20211231_10kimg016.jpg</File>
    <File>rvph20211231_10kimg017.jpg</File>
    <File>rvph20211231_10kimg018.jpg</File>
    <File>rvph20211231_10kimg019.jpg</File>
    <File>rvph20211231_10kimg020.jpg</File>
    <File>rvph20211231_10kimg021.jpg</File>
    <File>rvph20211231_10kimg022.jpg</File>
    <File>rvph20211231_10kimg023.gif</File>
    <File>rvph20211231_10kimg024.jpg</File>
    <File>rvph20211231_10kimg025.jpg</File>
    <File>rvph20211231_10kimg026.jpg</File>
    <File>rvph20211231_10kimg027.jpg</File>
    <File>rvph20211231_10kimg028.jpg</File>
    <File>rvph20211231_10kimg029.jpg</File>
    <File>rvph20211231_10kimg030.gif</File>
    <File>rvph20211231_10kimg031.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="410">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rvph20211231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 148,
   "dts": {
    "calculationLink": {
     "local": [
      "rvph-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rvph-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rvph20211231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rvph-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rvph-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rvph-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 392,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 29,
    "http://revivapharma.com/20211231": 2,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 37
   },
   "keyCustom": 41,
   "keyStandard": 287,
   "memberCustom": 38,
   "memberStandard": 24,
   "nsprefix": "rvph",
   "nsuri": "http://revivapharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://revivapharma.com/20211231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Business Combination",
     "role": "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
     "shortName": "Note 4 - Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - Property and Equipment, Net",
     "role": "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net",
     "shortName": "Note 5 - Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Employee Benefit Plan",
     "role": "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan",
     "shortName": "Note 6 - Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Convertible Promissory Notes",
     "role": "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
     "shortName": "Note 7 - Convertible Promissory Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8 - Income Taxes",
     "role": "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
     "shortName": "Note 8 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 9 - Loss Per Share",
     "role": "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
     "shortName": "Note 9 - Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 10 - Stockholders' Equity (Deficit)",
     "role": "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
     "shortName": "Note 10 - Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation",
     "role": "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
     "shortName": "Note 11 - Stock Option Plan and Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 12 - Commitments and Contingencies",
     "role": "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
     "shortName": "Note 12 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 13 - Subsequent Events",
     "role": "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
     "shortName": "Note 13 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 5 - Property and Equipment, Net (Tables)",
     "role": "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables",
     "shortName": "Note 5 - Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 8 - Income Taxes (Tables)",
     "role": "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables",
     "shortName": "Note 8 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 10 - Stockholders' Equity (Deficit) (Tables)",
     "role": "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables",
     "shortName": "Note 10 - Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation (Tables)",
     "role": "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
     "shortName": "Note 11 - Stock Option Plan and Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual",
     "shortName": "Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 3 - Public Offering (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
     "shortName": "Note 3 - Public Offering (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-06-01_2021-06-01_SubsidiarySaleOfStockAxis-PublicOfferingMember",
      "decimals": "INF",
      "lang": null,
      "name": "rvph:NumberOfUnitsOneIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 4 - Business Combination (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
     "shortName": "Note 4 - Business Combination (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2020-12-14_BusinessAcquisitionAxis-RevivaPharmaceuticalsIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual",
     "shortName": "Note 5 - Property and Equipment, Net (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-13",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)",
     "role": "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details",
     "shortName": "Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-13",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 6 - Employee Benefit Plan (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual",
     "shortName": "Note 6 - Employee Benefit Plan (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2018-11-01_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 7 - Convertible Promissory Notes (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual",
     "shortName": "Note 7 - Convertible Promissory Notes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2018-11-01_ClassOfWarrantOrRightAxis-The2018ContingentWarrantsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-10_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 8 - Income Taxes (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
     "shortName": "Note 8 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-10_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 8 - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details",
     "shortName": "Note 8 - Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets (Details)",
     "role": "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details",
     "shortName": "Note 8 - Income Taxes - Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2020-12-14",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 9 - Loss Per Share (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual",
     "shortName": "Note 9 - Loss Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 10 - Stockholders' Equity (Deficit) (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
     "shortName": "Note 10 - Stockholders' Equity (Deficit) (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2020-07-31_ClassOfWarrantOrRightAxis-The2020WarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)",
     "role": "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
     "shortName": "Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
     "shortName": "Note 11 - Stock Option Plan and Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)",
     "role": "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
     "shortName": "Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-13",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "role": "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-13",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)",
     "role": "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details",
     "shortName": "Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rvph:LesseeOperatingLeaseMonthlyLeasePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
     "shortName": "Note 12 - Commitments and Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_LeaseContractualTermAxis-CorporateOfficeLeaseMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rvph:LesseeOperatingLeaseMonthlyLeasePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2022-01-01_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "rvph:SaleOfStockAgreementMaximumAggregateGrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 13 - Subsequent Events (Details Textual)",
     "role": "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
     "shortName": "Note 13 - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2022-01-01_2022-01-31_CounterpartyNameAxis-HCWainwrightCoMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-TheMarketOfferingAgreementAtmAgreementMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "rvph:SaleOfStockAgreementMaximumAggregateGrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "role": "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Organization and Nature of Operations",
     "role": "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations",
     "shortName": "Note 1 - Organization and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies and Basis of Presentation",
     "role": "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
     "shortName": "Note 2 - Summary of Significant Accounting Policies and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Public Offering",
     "role": "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
     "shortName": "Note 3 - Public Offering",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rvph20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-IPOMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets",
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information",
      "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual",
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets",
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information",
      "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual",
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rvph_AccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and current liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional shares to be issued to security holders contingent on stock price performance.",
        "label": "rvph_AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance",
        "terseLabel": "Additional Shares to be Issued to Security Holders, Contingent on Stock Price Performance (in shares)"
       }
      }
     },
     "localname": "AdditionalSharesToBeIssuedToSecurityHoldersContingentOnStockPricePerformance",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the proceeds from reverse recapitalization.",
        "label": "Proceeds from reverse acquisition, net of costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for reclassification of warrant liability.",
        "label": "Reclassification of warrant liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_August2020ToOctober2020NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the August 2020 to October 2020 Notes.",
        "label": "August 2020 to October 2020 Notes [Member]"
       }
      }
     },
     "localname": "August2020ToOctober2020NotesMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_BeneficialConversionFeaturePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for beneficial conversion feature.",
        "label": "Beneficial Conversion Feature [Policy Text Block]"
       }
      }
     },
     "localname": "BeneficialConversionFeaturePolicyTextBlock",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rvph_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "rvph_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_ClassOfWarrantOrRightRedemptionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption price per share or per unit of warrants or rights.",
        "label": "rvph_ClassOfWarrantOrRightRedemptionPricePerShare",
        "terseLabel": "Class of Warrant or Right, Redemption Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionPricePerShare",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "rvph_ClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the business combination referred to as \"Closing\".",
        "label": "Closing [Member]"
       }
      }
     },
     "localname": "ClosingMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2016NotesIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2016 Notes into common stock.",
        "label": "Conversion of 2016 Notes into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOf2016NotesIntoCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2018NotesIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2018 Notes in common stock.",
        "label": "Conversion of 2018 Notes into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOf2018NotesIntoCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2018 Notes into common stock with aggregate principal amount less than $50,0000.",
        "label": "Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]"
       }
      }
     },
     "localname": "ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2018 Notes into common stock with aggregate principal amount of at least $50,0000.",
        "label": "Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]"
       }
      }
     },
     "localname": "ConversionOf2018NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2020NotesIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2020 Notes in common stock.",
        "label": "Conversion of 2020 Notes into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOf2020NotesIntoCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2020 Notes into common stock with aggregate principal amount less than $50,0000.",
        "label": "Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]"
       }
      }
     },
     "localname": "ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountLessThan50000Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of 2020 Notes into common stock with aggregate principal amount of at least $50,0000.",
        "label": "Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]"
       }
      }
     },
     "localname": "ConversionOf2020NotesIntoCommonStockWithAggregatePrincipalAmountOfAtLeast50000Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of August 2020 to October 2020 Notes into common stock.",
        "label": "Conversion of August 2020 to October 2020 Notes into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfAugust2020ToOctober2020NotesIntoCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOfRevivaCommonStockIntoCompanysCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of Reviva common stock into Company's common stock.",
        "label": "Conversion of Reviva Common Stock into Company's Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfRevivaCommonStockIntoCompanysCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of Reviva Contingent Interim Period Note into common stock.",
        "label": "Conversion of Reviva Contingent Interim Period Note into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfRevivaContingentInterimPeriodNoteIntoCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the conversion of Reviva preferred stock into the company's common stock.",
        "label": "Conversion of Reviva Preferred Stock into Company's Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfRevivaPreferredStockIntoCompanysCommonStockMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ConversionOfStockConversionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The conversion rate of stock conversion.",
        "label": "rvph_ConversionOfStockConversionRate",
        "terseLabel": "Conversion of Stock, Conversion Rate"
       }
      }
     },
     "localname": "ConversionOfStockConversionRate",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "pureItemType"
    },
    "rvph_CorporateOfficeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the corporate office lease.",
        "label": "Corporate Office Lease [Member]"
       }
      }
     },
     "localname": "CorporateOfficeLeaseMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_DebtInstrumentDebtDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate of outstanding debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.",
        "label": "rvph_DebtInstrumentDebtDefaultInterestRate",
        "terseLabel": "Debt Instrument, Debt Default, Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultInterestRate",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "rvph_DebtInstrumentRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renewal of the maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "rvph_DebtInstrumentRenewalTerm",
        "terseLabel": "Debt Instrument, Renewal Term (Month)"
       }
      }
     },
     "localname": "DebtInstrumentRenewalTerm",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "rvph_DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment and start up costs.",
        "label": "Fixed assets/capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_EarnoutSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to earn-out shares.",
        "label": "Earn-out Shares [Member]"
       }
      }
     },
     "localname": "EarnoutSharesMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_EffectOfReverseRecapitalizationNetOfCostsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of effect of reverse recapitalization, net of costs, during the period.",
        "label": "Effect of reverse recapitalization, net of costs"
       }
      }
     },
     "localname": "EffectOfReverseRecapitalizationNetOfCostsValue",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_EffectOfReverseReverseRecapitalizationNetOfCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect on the number of shares from reverse recapitalization, net of costs, during the period.",
        "label": "Effect of reverse recapitalization, net of costs (in shares)"
       }
      }
     },
     "localname": "EffectOfReverseReverseRecapitalizationNetOfCostsShares",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to beneficial conversion feature.",
        "label": "Beneficial conversion feature related to notes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to warrant expense.",
        "label": "Warrant expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_EquityIncentivePlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2006 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2006 [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2006Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2020 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2020 [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_GeneralProductLiabilityInsurance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of general product liability insurance.",
        "label": "rvph_GeneralProductLiabilityInsurance",
        "terseLabel": "General Product Liability Insurance"
       }
      }
     },
     "localname": "GeneralProductLiabilityInsurance",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_HCWainwrightCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents an agreement with H.C. Wainwright &amp; Co.",
        "label": "H.C. Wainwright &amp; Co [Member]"
       }
      }
     },
     "localname": "HCWainwrightCoMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other current liabilities.",
        "label": "rvph_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_InterestAndOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest and other income (expense), net.",
        "label": "Interest and other income (expense), net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeExpenseNet",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_InvestorWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the investor warrant.",
        "label": "Investor Warrant [Member]"
       }
      }
     },
     "localname": "InvestorWarrantMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_LesseeOperatingLeaseMonthlyLeasePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly lease payment for lessee's operating lease.",
        "label": "rvph_LesseeOperatingLeaseMonthlyLeasePayment",
        "terseLabel": "Lessee, Operating Lease, Monthly Lease Payment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyLeasePayment",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_NumberOfUnitsOneIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of units issued during period. Each unit is consisting of (a) one share of common stock and (b) one Investor Warrant",
        "label": "rvph_NumberOfUnitsOneIssued",
        "terseLabel": "Number of Units, One, Issued (in shares)"
       }
      }
     },
     "localname": "NumberOfUnitsOneIssued",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_NumberOfUnitsTwoIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of units issued during period. Each unit is consisting of one Pre-Funded Warrant and (b) one Investor Warrant.",
        "label": "rvph_NumberOfUnitsTwoIssued",
        "terseLabel": "Number of Units, Two, Issued (in shares)"
       }
      }
     },
     "localname": "NumberOfUnitsTwoIssued",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_OneInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to one investor.",
        "label": "One Investor [Member]"
       }
      }
     },
     "localname": "OneInvestorMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "rvph_OperatingLossCarryforwardsSubjectToExpiration",
        "terseLabel": "Operating Loss Carryforwards, Subject to Expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_PaymentOfCertainDeferredCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment of certain deferred costs.",
        "label": "Payment of certain deferred costs from proceeds from business combination"
       }
      }
     },
     "localname": "PaymentOfCertainDeferredCosts",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Pre-Funded Warrant.",
        "label": "Pre-Funded Warrant [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_PreofferingValuationPriorToQualifiedFinancingEvent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of pre-offering valuation prior to the qualified financing event.",
        "label": "rvph_PreofferingValuationPriorToQualifiedFinancingEvent",
        "terseLabel": "Pre-offering Valuation Prior to Qualified Financing Event"
       }
      }
     },
     "localname": "PreofferingValuationPriorToQualifiedFinancingEvent",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_PrivateWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to private warrants.",
        "label": "Private Warrants [Member]"
       }
      }
     },
     "localname": "PrivateWarrantsMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from issuance of common stock for deferred compensation.",
        "label": "rvph_ProceedsFromIssuanceOfCommonStockForDeferredCompensation",
        "verboseLabel": "Issuance of common stock in lieu of deferred compensation"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockForDeferredCompensation",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_ProceedsFromIssuanceOrSaleOfEquityNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "rvph_ProceedsFromIssuanceOrSaleOfEquityNet",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNet",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_ProceedsFromReverseRecapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from reverse recapitalization.",
        "label": "rvph_ProceedsFromReverseRecapitalization",
        "terseLabel": "Proceeds from business combination, net of costs"
       }
      }
     },
     "localname": "ProceedsFromReverseRecapitalization",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the public offering.",
        "label": "Public Offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to public warrants.",
        "label": "Public Warrants [Member]"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of discount to the price paid by investors in the qualified financing.",
        "label": "rvph_QualifiedFinancingDiscountRateToPricePaidByInvestors",
        "terseLabel": "Qualified Financing, Discount Rate to Price Paid by Investors"
       }
      }
     },
     "localname": "QualifiedFinancingDiscountRateToPricePaidByInvestors",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "rvph_QualifiedFinancingMinimumThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of money that must be raised by the Company through a future equity financing in order for the principal and interest due on the note to convert into the same equity issued in that financing.",
        "label": "rvph_QualifiedFinancingMinimumThreshold",
        "terseLabel": "Qualified Financing, Minimum Threshold"
       }
      }
     },
     "localname": "QualifiedFinancingMinimumThreshold",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_Range1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to first range of exercise price.",
        "label": "Range 1 [Member]"
       }
      }
     },
     "localname": "Range1Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_Range2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to second range of exercise price.",
        "label": "Range 2 [Member]"
       }
      }
     },
     "localname": "Range2Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_Range3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to third range of exercise price.",
        "label": "Range 3 [Member]"
       }
      }
     },
     "localname": "Range3Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_Range4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to fourth range of exercise price.",
        "label": "Range 4 [Member]"
       }
      }
     },
     "localname": "Range4Member",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_RevivaContingentInterimPeriodNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Reviva Contingent Interim Period Note.",
        "label": "Reviva Contingent Interim Period Note [Member]"
       }
      }
     },
     "localname": "RevivaContingentInterimPeriodNoteMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_RevivaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Reviva Pharmaceuticals, Inc.",
        "label": "Reviva Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "RevivaPharmaceuticalsIncMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the maximum aggregate gross proceeds to be received from the agreement with H.C. Wainwright &amp; Co.",
        "label": "rvph_SaleOfStockAgreementMaximumAggregateGrossProceeds",
        "terseLabel": "Sale of Stock Agreement, Maximum Aggregate Gross Proceeds"
       }
      }
     },
     "localname": "SaleOfStockAgreementMaximumAggregateGrossProceeds",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in shares associated with the effect of plan amendment on business combination.",
        "label": "rvph_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination",
        "negatedLabel": "Effect of plan amendment on business combination (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantEffectOfPlanAmendmentOnBusinessCombination",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum percentage of increase, based on total number of common stock outstanding, in shares to be issued under share-based payment arrangement.",
        "label": "rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percent of Increase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumPercentOfIncrease",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "rvph_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares cancelled under share-based payment arrangement.",
        "label": "Number of shares available for grant, options cancelled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_SharesIssuedPricePerShareOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per unit amount of first portion units issued.",
        "label": "rvph_SharesIssuedPricePerShareOne",
        "terseLabel": "Shares Issued, Price Per Share, One (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareOne",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "rvph_SharesIssuedPricePerShareTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per unit amount of second portion units issued.",
        "label": "rvph_SharesIssuedPricePerShareTwo",
        "terseLabel": "Shares Issued, Price Per Share, Two (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareTwo",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "rvph_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for warrants exercised during the current period.",
        "label": "Common stock issued in connection with warrant exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "rvph_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Common stock issued in connection with warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rvph_StockPricePerformanceMilestonePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the milestone period for stock price performance.",
        "label": "rvph_StockPricePerformanceMilestonePeriod",
        "terseLabel": "Stock Price Performance, Milestone Period (Year)"
       }
      }
     },
     "localname": "StockPricePerformanceMilestonePeriod",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "rvph_The2016NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2016 Notes.",
        "label": "The 2016 Notes [Member]"
       }
      }
     },
     "localname": "The2016NotesMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_The2016WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 warrants.",
        "label": "The 2016 Warrants [Member]"
       }
      }
     },
     "localname": "The2016WarrantsMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_The2018ContingentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2018 Contingent Warrants.",
        "label": "The 2018 Contingent Warrants [Member]"
       }
      }
     },
     "localname": "The2018ContingentWarrantsMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_The2018NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2018 Notes.",
        "label": "The 2018 Notes [Member]"
       }
      }
     },
     "localname": "The2018NotesMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_The2020ContingentWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2020 Contingent Warrants.",
        "label": "The 2020 Contingent Warrants [Member]"
       }
      }
     },
     "localname": "The2020ContingentWarrantsMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_The2020NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2020 Notes.",
        "label": "The 2020 Notes [Member]"
       }
      }
     },
     "localname": "The2020NotesMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_The2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2020 warrants.",
        "label": "The 2020 Warrants [Member]"
       }
      }
     },
     "localname": "The2020WarrantsMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_TheMarketOfferingAgreementAtmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on an At The Market Offering Agreement (the \u201cATM Agreement\u201d).",
        "label": "The Market Offering Agreement \"ATM Agreement\" [Member]"
       }
      }
     },
     "localname": "TheMarketOfferingAgreementAtmAgreementMember",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold closing price, as adjusted for stock splits, stock dividends, reorganizations or recapitalizations, for any 20 trading days within any 30-trading day period.",
        "label": "rvph_ThresholdClosingPriceForSpecifiedNumberOfTradingDays",
        "terseLabel": "Threshold Closing Price for Specified Number of Trading Days (in dollars per share)"
       }
      }
     },
     "localname": "ThresholdClosingPriceForSpecifiedNumberOfTradingDays",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "rvph_ThresholdConsecutiveTradingDaysForSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which closing stock price must exceed a price per share amount for specified number of trading days, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.",
        "label": "rvph_ThresholdConsecutiveTradingDaysForSaleOfShares",
        "terseLabel": "Threshold Consecutive Trading Days for Sale of Shares (Day)"
       }
      }
     },
     "localname": "ThresholdConsecutiveTradingDaysForSaleOfShares",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "rvph_ThresholdTradingDaysForSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that the closing price of ordinary shares must meet or exceed a price per share, as adjusted for stock splits, stock dividends, reorganizations and recapitalizations.",
        "label": "rvph_ThresholdTradingDaysForSaleOfShares",
        "terseLabel": "Threshold Trading Days for Sale of Shares (Day)"
       }
      }
     },
     "localname": "ThresholdTradingDaysForSaleOfShares",
     "nsuri": "http://revivapharma.com/20211231",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "rvph_statement-statement-note-10-stockholders-equity-deficit-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "statement-statement-note-10-stockholders-equity-deficit-tables",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stockholders' Equity (Deficit) - Warrant Assumptions (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock Option Plan and Stock-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock Option Plans and Stock-based Compensation - Shares Outstanding Under Option Plan (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment, Net - Property and Equipment, Net (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-property-and-equipment-net-property-and-equipment-net-details",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-5-property-and-equipment-net-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment, Net"
       }
      }
     },
     "localname": "statement-statement-note-5-property-and-equipment-net-tables",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-8-income-taxes-deferred-tax-assets-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Deferred Tax Assets (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-deferred-tax-assets-details",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-8-income-taxes-provision-for-income-taxes-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Provision for Income Taxes (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-provision-for-income-taxes-details",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-note-8-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-tables",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rvph_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://revivapharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r84",
      "r85",
      "r165",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r164",
      "r197",
      "r220",
      "r222",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r374",
      "r375",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r164",
      "r197",
      "r220",
      "r222",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r374",
      "r375",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r164",
      "r197",
      "r218",
      "r220",
      "r222",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r374",
      "r375",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r164",
      "r197",
      "r218",
      "r220",
      "r222",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r374",
      "r375",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r84",
      "r85",
      "r165",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r336"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r254",
      "r336"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r251",
      "r252",
      "r253",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r210",
      "r213",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Beneficial conversion feature on conversion of notes payable"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r224",
      "r226",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r226",
      "r247",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r54",
      "r65",
      "r184",
      "r326"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r125",
      "r127",
      "r131",
      "r134",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r300",
      "r303",
      "r316",
      "r334",
      "r336",
      "r351",
      "r364"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r227",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r219",
      "r221",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r23",
      "r67"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r60",
      "r67",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r317"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r77",
      "r80",
      "r100",
      "r101",
      "r102",
      "r104",
      "r106",
      "r112",
      "r113",
      "r114",
      "r134",
      "r150",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r195",
      "r196",
      "r200",
      "r204",
      "r316",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r214",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r148",
      "r356",
      "r369"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r149",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r336"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value of $0.0001; 115,000,000 shares authorized; 14,433,286 and 9,231,737 shares issued and outstanding as of December 31, 2021, and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r216",
      "r217",
      "r223",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r117",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "us-gaap_ConversionOfStockSharesIssued1",
        "terseLabel": "Conversion of Stock, Shares Issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r12",
      "r353",
      "r365",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "us-gaap_ConvertibleNotesPayable",
        "terseLabel": "Convertible Notes Payable, Total"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of convertible promissory notes into common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r178",
      "r185",
      "r186",
      "r187",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r79",
      "r86",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r189",
      "r190",
      "r191",
      "r192",
      "r329",
      "r352",
      "r353",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature",
        "terseLabel": "Debt Instrument, Convertible, Beneficial Conversion Feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r163",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r161",
      "r189",
      "r190",
      "r327",
      "r329",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "us-gaap_DebtInstrumentFeeAmount",
        "terseLabel": "Debt Instrument, Fee Amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34",
      "r79",
      "r86",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r189",
      "r190",
      "r191",
      "r192",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Month)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement.",
        "label": "Issuance of common stock in lieu of deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.",
        "label": "Issuance of common stock in lieu of deferred compensation (in shares)",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Issued (in shares)"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r65",
      "r81",
      "r281",
      "r288",
      "r289",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "us-gaap_DeferredIncomeTaxExpenseBenefit",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Deferred Tax Assets, Gross, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r274"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r277",
      "r279",
      "r280"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r65",
      "r138"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r41",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Warrant liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "us-gaap_DerivativeLiabilityMeasurementInput",
        "terseLabel": "Derivative Liability, Measurement Input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r99",
      "r111",
      "r135",
      "r210",
      "r213",
      "r251",
      "r252",
      "r253",
      "r284",
      "r285",
      "r310",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r376",
      "r377",
      "r378",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r65",
      "r194"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Change in fair value of warrant liabilities",
        "terseLabel": "Fair Value Adjustment of Warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.",
        "label": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on remeasurement of warrant liabilities",
        "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax, Total"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r136",
      "r137",
      "r336",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "us-gaap_Goodwill",
        "terseLabel": "Goodwill, Ending Balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r125",
      "r126",
      "r129",
      "r130",
      "r132",
      "r349",
      "r357",
      "r360",
      "r372"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r142",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r266",
      "r270",
      "r276",
      "r286",
      "r291",
      "r293",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r98",
      "r99",
      "r124",
      "r264",
      "r287",
      "r292",
      "r373"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r262",
      "r263",
      "r270",
      "r271",
      "r275",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State income taxes, net of federal tax benefits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r62",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Deferred cost"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r48",
      "r123",
      "r325",
      "r328",
      "r359"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r59",
      "r61",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_InterestPayableCurrent",
        "terseLabel": "Interest Payable, Current"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r355",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "us-gaap_InterestPayableCurrentAndNoncurrent",
        "terseLabel": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of stock in exchange for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
        "terseLabel": "Lessee, Operating Lease, Renewal Term (Month)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Month)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r80",
      "r128",
      "r134",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r301",
      "r303",
      "r304",
      "r316",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r80",
      "r134",
      "r316",
      "r336",
      "r354",
      "r367"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r80",
      "r134",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r301",
      "r303",
      "r304",
      "r316",
      "r334",
      "r335",
      "r336"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r28",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r28",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset.",
        "label": "Measurement Input, Exercise Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputExercisePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r42",
      "r43",
      "r47",
      "r50",
      "r66",
      "r80",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r103",
      "r125",
      "r126",
      "r129",
      "r130",
      "r132",
      "r134",
      "r150",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r311",
      "r316",
      "r358",
      "r371"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental schedule of noncash financing and investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r125",
      "r126",
      "r129",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r227",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "us-gaap_PreferredStockParOrStatedValuePerShare",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "us-gaap_PreferredStockSharesAuthorized",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "us-gaap_PreferredStockSharesOutstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from issuance of convertible promissory notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of Units in public offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "us-gaap_ProceedsFromIssuanceOfWarrants",
        "terseLabel": "Proceeds from Issuance of Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from issuance of stock upon warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r143",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r141",
      "r336",
      "r361",
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "us-gaap_PropertyPlantAndEquipmentNet",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r141",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r8",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "us-gaap_RepaymentsOfConvertibleDebt",
        "terseLabel": "Repayments of Convertible Debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r261",
      "r347",
      "r388"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r213",
      "r254",
      "r336",
      "r366",
      "r379",
      "r380"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r99",
      "r135",
      "r251",
      "r252",
      "r253",
      "r284",
      "r285",
      "r310",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r232",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of shares available for grant, options authorized (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "periodEndLabel": "Ending balance, number of shares available for grant (in shares)",
        "periodStartLabel": "Beginning balance, number of shares available for grant (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Shares exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Number of options outstanding, options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of options outstanding, options granted (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r234",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding (in shares)",
        "periodEndLabel": "Ending balance, number of shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance, number of shares outstanding (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Ending balance, weighted average exercise price per share (in dollars per share)",
        "periodStartLabel": "Beginning balance, weighted average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, weighted average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
        "negatedLabel": "Number of shares available for grant, options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Options cancelled, weighted average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Options granted, weighted average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r227",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
        "terseLabel": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r242",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "us-gaap_SharesIssued",
        "terseLabel": "Shares, Issued, Ending Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r77",
      "r80",
      "r100",
      "r101",
      "r102",
      "r104",
      "r106",
      "r112",
      "r113",
      "r114",
      "r134",
      "r150",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r195",
      "r196",
      "r200",
      "r204",
      "r210",
      "r316",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r45",
      "r46",
      "r47",
      "r88",
      "r89",
      "r90",
      "r92",
      "r97",
      "r99",
      "r111",
      "r135",
      "r210",
      "r213",
      "r251",
      "r252",
      "r253",
      "r284",
      "r285",
      "r310",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r376",
      "r377",
      "r378",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets",
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual",
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r111",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets",
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-1-organization-and-nature-of-operations",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-stock-option-activity-details",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plans-and-stockbased-compensation-shares-outstanding-under-option-plan-details",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://revivapharma.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation",
      "http://revivapharma.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-and-basis-of-presentation-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination",
      "http://revivapharma.com/20211231/role/statement-note-4-business-combination-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-property-and-equipment-net-details",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan",
      "http://revivapharma.com/20211231/role/statement-note-6-employee-benefit-plan-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-provision-for-income-taxes-details",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual",
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r36",
      "r179",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of common stock upon conversion of notes and accrued interest (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Common stock issued to consultant in exchange for services (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of Units in public offering, net (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r210",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Issuance of common stock upon conversion of notes and accrued interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Common stock issued to consultant in exchange for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r210",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of Units in public offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r80",
      "r133",
      "r134",
      "r316",
      "r336"
     ],
     "calculation": {
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets",
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-stockholders-equity-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r324",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r324",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r324",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events",
      "http://revivapharma.com/20211231/role/statement-note-13-subsequent-events-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering",
      "http://revivapharma.com/20211231/role/statement-note-3-public-offering-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-tables",
      "http://revivapharma.com/20211231/role/statement-note-11-stock-option-plan-and-stockbased-compensation-tables",
      "http://revivapharma.com/20211231/role/statement-note-5-property-and-equipment-net-tables",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes",
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
        "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-document-and-entity-information",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share",
      "http://revivapharma.com/20211231/role/statement-note-9-loss-per-share-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrant, assumptions",
        "terseLabel": "Warrants and Rights Outstanding, Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-warrant-assumptions-details"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-note-10-stockholders-equity-deficit-details-textual",
      "http://revivapharma.com/20211231/role/statement-note-7-convertible-promissory-notes-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average shares outstanding Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://revivapharma.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r389": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r390": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r391": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r392": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r393": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r394": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r395": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r396": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r397": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r398": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r399": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001437749-22-006332-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-006332-xbrl.zip
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M])F@Z@.-8*LRY.6M^F*ZR$A 8$D!3=PQBMR G]7%HO)GV2P>GF*[E(_IRF@
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M-#V5 F_ =VOG<*(%YT \--8:/H3#2EXN^U.:Q\PUQ) IS/_2FO&4=MSX/2G
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MP NO(-6[Y08(K09_XMNS;B4*'?VEP.:E4>XS%Q)O2#I%=C5=,_)"5ZPDGK(
M 7,E+E42-#!GB!3VUJ:+"!S%0^[(R#LU^^8AN8ZS\$Y[A(F3XW.XY1%1F\VC
MUH\O#57$"'7I%/)R8@;ORF5>R7O_6O)BJ.@!5VSL#YE6JQ8^"FQZX#O,T!/$
M/HH.J/"9M:\LL_[JI!ITD7D(E\!8TV)K'GGN\-SF@2Q0,Q*5:E37V=EAO[2B
MS5XQ&*<LLK9\OXF\L6%#G#XGQ(_?/)\BOA7)FT]QR^SQ2/ZLD_GXDJ3E'7/
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M,!X?K]R!0J?2I0 /9-TDS\,/"V"ENN!'V!&=!\11RX-WD)X5BM<V^G7KIH)
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M- @B$!;A3I#:,>@)V;7Q$$)Z,#A/H(T--1/!0)P #]&<C'ZMXKDB/HP&ST;
M)ISFWB$"K0_5U]X*I<)#Q"\7D3DGR[AWT(//$P.KRYG2&K@K[DPAT3ZUI BU
MT>KC)8&T^S?\5-T="]U^FGB%<5L,VJ)7VB57?3OOQ,<'!F=ELCFB2]!6]2M[
M6QRO,*-V/BMKO<%(;F8R;5IDDL)EOK"FGC5)O-GI0=:8E60MO$3IQ?XL$/WC
MEFLVW'=_PHH_2MW5?2?@K'1PA"5$@PA=0G[<N<3=H@)P3@RAETV35VFU,,4&
MTV!6ORG0#0T4+$T._.A683@VQC;O.D)Y3>JKZ_3M5RN(S5]L:+;MO!IUH:O
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M<*CFT(2DS.<,A8^<S9W 8!ZZ9)LD94-)#8O 0*4P*?<'$*#QD'01WB:3V)#
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M$)BB^+.,=8$@-)N_:'(=#Z%[=O$EW$LO,? 3/(0$GM!  ,-Z%A%P^_QT]3+
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M\C,,,T*O?LE*R;9)T'LV)>6[Q_<Z$$!DQ<)DT  S>(AUG),\Q/L%Y.^N )L
MMN@(1\QQ'W2HZ-/%; QH"6Q_L\A#Q-48\!#"**!&[RB:&<F-7X$KX#!G-C\!
M6#XB/H]D;\'V0;=_I(!V9$KE"-<5R()+47[FIF0G'?3P3;@P!I8#ULXC!0(H
M?PD%YF\HB. SP G-.0%LAXO4]S7@G-&O((X#,(@$3=^_@2!Z+A\1 ^H.#&%6
MUM72(6I&3])J-9"40 -O5^_V>Q<(O(>;PUL\Q.Q<S_0LFDP#]7V55W;AX [E
M-K2+AQ@.)/SN"N4>&HR8@[8>:^2885YG0]+H^SA@^ ITZ1XDB(,E-QIH?;@J
M'QL(U!:#87#UW?1#!K1'61IH%81IR)^4M 1_J$ )J-O(7F]\/)TXIP[T4SCD
M.: =3:;_I>E58)JL6;KVY(S"XB78C8\Y9T9X"!4^ST ^SBYXRHUPD_D4_J==
M?_."$%P[QE'A[L)!;>Q.[=K3W:-P8?][/W@!M \]JV3"C HDW&\$X9%BP" :
MCUY.S_CF]Z+!9FCO+[9Z\1!BII-PP1E.8THBEQ^A90^A6=YK 8)"B9_.SW5
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MEC-NXW,)4V8PUQ%OZ[I:.&Z9B+<#%=!9RP?NA2IH_I1A(MHP&)=FTW;QJ=C
MOH35<QHM$R[>-C<%#)3[HJM5RMD=6GU%3T8>CO(=?.@-!"SO7*5U?!TI6C7B
M(8*%;#B!W#=H5Z$HN%Q#[<<=9[&Y61RA59DC]->$^J*8WL6DPC$Z/VH/&-2
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M$T*$1\-B0;$0L855XPO4&<4";%4ULII 9XI?UC0;T;"(7N [__CIQD]&L^F
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M36J#[JBU=+ZX\IP^TZFYD4K:K(F4 5?6]N[E2=+ZNX%(2+$"S.*@Q,'.R>J
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MGAM W_?X1'3;T[VV$7?K&Y0Z3=9VNQIKM9KNY=*R+]V]5%**+7>08VI0)/#
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MNN'ULS(#X\<6ETEWUT?\>N>.JQHK,C6MQ#NFQQG01FTO\^?9\0\+<M0T&6%
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M;M"TA 7'M^$F@?X7R0:$'N847.C\HJ]NK$YCR^H:K-YJ;K+8[&8JV7"<O//
MB$CF*-1\!;TXTW5WB^S94=*W',,!Y@+O^ ZG8,U<60U1'45->_6CNZ7<#MS%
M=NUY4LPHU;=[0DUMN?]M N']Z81$J:#X!=#L9"1$5,;&"Q&H'.*&X1(_/'#.
M)Y_ZY M.VVAOF;HNG,GKQJ(FACZ"0Z5A;Q%BJQW*8ZH6;Q5)+CY-D6TC=]QN
MP[3VM>]I'7O9/KMN\[?'U:;AWVKFYUL-=T0;.CD7VI6<F<B7.+,K_=M8#*[
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MN/\(G3^#<]VQ'C+,$B(*-<96"I*O!K8)UG<S4=,-S'"QQ)>/S4A7Z]&\0;A
MK<NJVTPLRWI9Y/Z2::I-'\UL]2_.;>UVSPO3$"(:YW?J? \W,Z-EH/(R;OHB
M1/CTL36'EH/6??D_N<]H8G]D?>ERXH,N@K,P?4P<THZB1A:C<DFFY&.*0*$&
M:U'D,M G2Q<BI,F.<UEU]OY#O9U%%=F>4).),T;)PK360^V>A_*7F6B,2>Z!
M<?))&+<(&+<H>1@W;X#O';_D 5?*OW^"NZM 934(_3]0WE+U8&SY.SYE8'
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M3J,=]!KP'9\E!2=?5?78?/T:3:E][,']Y0.)34SC'39;K8UWK%N&Y9U(EQT
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M*MBV@AP3(O:[4* (WB;8'E6X]GZX'X=:\>.3!OZ[7D./PKV.<S"E/%=!6)O
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M/['+X2T,W<1Z!2Q*FNC*#+;V"#B/\1WF6]0+CG*4@\E(XE3MX,X"B)+OF8H
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MOSX5W5.\,?\Q1'C&TQ@:;MDS.&^<T"=$F!??G3<\ =K/"3;[<5R'36,%>XB
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M48!<'TF*3YDQ0.:1,)S$VU42)--N\CX>H9/G<9V.FS CL&>0#KUDI0$\P?]
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M]SS1N.JFZ(CFS^$^'K\L"!%.OUODOH: K K/=^E^6RCK-CEFJO1D^_KB<SL
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M=<.=4'Y&U<YK+3%EW.RE$T?:9AV.3E^_?ZQ72H@0L3O"#S'4CGL]3Q*C)AH
M-;[,06"+SYM6Q"*=?:?_^C1Q?8C8BD3%DD$2'W>GXGCSD5RUNE'9:2^2HN>Y
M99N[:1ZVG[G7"ZYY&2\?Z,[H-^>BHZONX<Q<5$%\5,&SH/UOOI"F1'Z]-BAU
M-#OJG8ONX327?,(CIK/83Y.V8;4F2>4Y&=U'=*EJ%JMV\+0ZR;\+1_9SE30P
M+$2<A;T BR!?036P< ,GA@:!'(!3)E!3H1<($>&'?H$#.R<G1-R]#)?;;>CF
M5[QEN/*=:V0LF%ZC8HH? 7X"6"#F&KX1P *'609/FHR5HZ@0*H3N1D,#2'
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MHA(QV@";W?3(DX_3;;0BMQ3;3CZ8M,U:\79L57.VFY[.)X2L!%QOZWE>?,A
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MBWS[E?8'R[W*HC/?Y_O_&AMMLG%/%451]+W#W0GJ%ZE.(6**"_\R'Z8'P(V
M6A-.:IEL\H(\N2SXN=UXY_XU*8W^;-6%GII?.^4\S"Q_Y24J OBB/"1$],[^
M=LAYW-HAYZ^7YUF7<MEY8J\']_>0Y2"'6A<]3D_R3[TN2B MBH?U'R9(X&6V
MM4@YU^80LYIK70Y3S2/%OW<9J%<!2PH*G;']?;]ZU0D17B6\"5"&MZ.@S1I2
MO<"19)76#B@SE^H(,CQQCO+,?G#LM8M<KZ$*SQY\!D_O1>)B=HQ.GC4'PW(/
M(V_&>C#$6'&.8%;VDTDQS2B6<L'EZ3@++W>;KEX,.MMAF['!C7K5W1<=]QZ[
MF1M_SU'QQVCO[?&$U+/V1.B7'7:7D ?HTUZK>D37UTZ)P>X=OI;JK]_#\II:
M,)AKF,F.^;E' 74[:\JA:ZZH?\#]3-?/NHDEZ0Z,FQR[D<]Z-^U_VM]2<T)J
MYQ1-#7\_Y=2\J=NM(<N2*48>]^B!T?N?S<JG B4-?MLD16O8+\Q'B%""\"=Z
M?.7(*"+A-;!51T/*M)LDRM'M9Y9D<Z1>#XDJ0]7*M7.0XQ)9IH.$!/(^$7U_
MZG$X&>;2R3/.OGS/V=(5K]@=7UN*!;VY8Y DQ[9A<#UTL.H@%A=;I0[*A!I8
MYA+MFVL$AS ;^HFYUI ?DQZN+T3<6: K#7K8$$VM.9?N/,%SEY;(LE%U#H9[
M.[5_M<<.&+0HJ;_S04+*C=6R%5@.@074T:6(80U.>C&+<S)07$V '!3"%E=@
MKAWD* HU#X>&@(!M5V/H)<Z^0?$N@X#4]9TZJ[> J+L];6>C:LN6Q7TXV!:5
MQ:%0] O*-!OL9<6F<-C,3$I$49N4)3-/W2IH]1@+':&#"JO:\SRL6E=I4P''
MLC?$9H4@,:4_,!1<E*>K6H$1N=]"YC8ZK%Z<K^A42GH YAS^'(+/^!0XY_TP
MTRM^)G!UJO!0E1I_!Q8BT"RF*JET[P0.CK<CB'L*-'G(.HZK<]'FI,130@QW
M$X.8\8LM]&IJ5,#++@-7YI%%!F1YA728Z[(I%27M,;A>?L/CJB.]VL@919F:
MDKDLR[R!B1N#?8VH],955T&;C-K^ LY<7]X(=$>R5@P_9;F^3J;/K2WZ$J1+
M+=HA;5]:LN)84E;T$K(9 N]A)]_J<77JGFD#)4*$A[;]SG<\(WX0VAT=H;2E
MDR?".KZ^P5[^:@3'EH5JT)"R X?J,#)$7(,^,D:@/B4_6LH161C:>;DLI237
M_0DQ<K5./MC!12ETU/+ ,9&BPA*[TH+"K1>G<,]E7JL/R7A2M_E$$10GJO12
MD'8=K$06+G:N"EG-[@>" ZC5SL=82ME@2W$=F%K,:H-.Z&Q<\/(^GXBA./5<
M.9C7@U\@GOAYZ^N7C:F9YUI[DZ*?K#KNWZ\<Z.M7^@E&QO+>)09J:N2S?V C
M;Z<KURFY 2E6(<<\1]:".L]"R2Q 8OQF=B9/!&J\<#UCG'P0',QC8<2( DLM
M._!X*HTE*4(,\?%_YA/H4-NS9$;VXIGF7"@B;,8OZ9,,X7+Z;@II<PDA=*4W
MB/=#B6#S2XAS'0QC!R[52W[+,X+P+$*8$XDJ(E#FG6E'+<R)$VN-06ZA?S:^
M=%"T<R%&KO/''HW%SD#O"VDG O.*,\SRP"'!IHA5-/$8$T9[Q5&6%X:5&,7S
M9F+1(?==>)9(68'J1V*LI2F3$%0\M-'#22]$1Z["SC<7TF.22@PU.#%EO$,=
MB]N8[5D0U;X@X6A([Z.RU+4JTUG00)9][PZ^!D4C2):/!X@)M?6) 4!LU6Z(
MT6#AFSN!D^2Y@:6GI,[C ^+K/SQOYXFS*[W-.@[^E+JC<_;G]L7P\YY]QGG#
MW0:5CMCMT_%]G[M7R^A^G> 7";B,?"M9N0Q0QSXL,D*$B)+2Z0E.%*N$!J*K
ME31[+T+4#(^ _!>^:SN8$44;#;<[=M:R36$EE'NJ<Q'8?EG_TIUL8E2U#;[/
MC1)K<(B&&YH2;._>PI7_).UPZ$W\HD7@PDJIX"[^<UL0^@7J-?4VL,T7%XD6
M9T$1>%:,W^GRSL7P"B,.ND%)#>2F>S^MSJC-)4:.U2;UI%W/*(TJSO8)IR]2
MMF>6>?JMQ(]F$[_D>OI-7%],#AP7Y,%2+.ES_OB\Z0>U1Q4Y@LZ$69?SV1YX
MOR_O.R2\#'WBJB)P>.7>V659\MIKG("E$'%C3(BPR,\E/S> P[]'D"P8:1,D
M.MOS?SIG;\40(KY3]/O;2X;VQ1>)0>@/\J,;,%S=[#OQ<N@+U.ARM>B50K78
MS-MO'TN59 ::FI7T\G0"'P\N-]2>!Q='*62-@;T/G_E:HE8-ER_XB=@SG\VZ
M8_VNA(^J,!5OKQ^VD(3V-TYW5*WK-EC'<K[%!NJ^?072;_-$F( L48A@!0_N
MXP"UDAMY.KW/2-;# Y),GR]$<K\1F)68CE_Q3<CJF2>ZVP2>Q*M;>-DX8ZU*
M0ML-.47=B^B"ON=@*ZUTNH2)G2G;O1U(K_/+TD&])#;,):<:GQ-\Z&*,.W7!
M<D'+6(@82?&PRC.WMJ9I8O?1NS.':,Q7AX.5-3U_L9U.F2Z9^9PWCS[:R)/2
M>IUH>!R<PO%.0N&P_"/I@%&O<9*?H5LT8A&1O,HR*60BHP</056-;-GW!L<R
MQ@U1H%L#C:5X[%*<ZX4GGI;>6>\(*'8DUP^PAF ]_.T\GRI0)DK6#G[30S?<
MXZ%;M0U*Y#BP&*$D(^:<E =7H-9I8,PIQ?86SX4G77[5S=/(NZQGJ-A#6)QZ
MP4_T9Y9GY\WL+0B::3E>B!L(I/!?9 /OB[.%B.%+\-.;]=$E.J@5Z6(T;TL[
ML.SN=-!^-]#\D8R,KP@G!H@/?33V5^^?9=SBC]6D:L+YY$Y:QVGF6<6=YP"-
M*@ZL"D.Q3A)&XAY[!FE:%/8#N,\F/X(Y)SG1HR0EG63_Z.(#,^];.L6#C"L]
M)5[,&5?C4QK#I3TPRTL%<0'.D2X7Y%:2)QC24_F,9%O!,<D>1D?VT<)\<=)$
M/-L<<A5(N]?BM@^)_Q_LO7E4$]NZ+QI$1'J1OI&HH*B($>D40J*R !$Q*BI*
MEZ6(-!&B A(A) A"I(W8P%*4J("@"!&E$44"A$9E89!60 A)5'JI4IH2*I4;
M][WOWK/7/O?L?<:X[XT[WCA_!$(Q:];7_N;WJU3FM^5;K(=@.IF7,&,9^=!G
M=_^G4)6WE> 2UZC,.?9<<X$$M;M'2H\NW<9(4)M'_^HT3,E)<S+)++0SK/\!
MK<0%B677$K]2Q=*L_/ACN"JQQD/ UQX]6FO:R<::@BG3HJ1+#^N%<K':+<VV
M:+DUT)+-6<TDO7RRB@OP7G<JU*KR%2DU]+QZ[/I[S1XK%E*JIZ?2W9#$$H($
M)6M%1(Y_^*MY4VX&>-YL/7J3S6_[N6!@<LW5S.2:V[.];T:#2F,6_0])22M)
MR@SKVJ3L,2N"?B:$.&,>0H?T'DA0W]\_UVO_X#/_3S5$15AY.OS';MVY2D6+
M]Y?9F7\O>;N\HU,X?T _6ZSDQ4*6!7'@YWG_(*#,_Z<"_4%KYR^O,0:G!=("
MN@%C5%E:JPZ65MSKFW"_QW^877PE8J"LU"O'[*<Y>>5@$Y)-^FKIU5;+;TM5
M]-G#DJN"U1ES%E=1 ="? TH;>(WVJJ@PUO>-GT5E6#%IIM"[:U;'SFA:=?Q@
MIM! 3R=V*#V9\X'<VWHE?8^@SOZ/6AW4<*Y<*)T4XL:"'E989M-_4C_$6*!G
M5K*]S7GA3W(U"K)._S$IMZ/GYH6G-[\X^W3&7[YVP^/"A=Z2G/3)?IQ&"M4"
M6$P'9\+W8X:_H86&7+7$POB\]#^?]6N!AX'R"2&X(D__VGX<CZ5W:/S S:[?
MO]T=@*4TA[&%UHSF0VW2=ZI<_$*RM-+'"UI99?1YQ)(N:'PJ07W=RSE(_SMK
MNOS5)1-29_A"'"2%*N4PJD=J.&_%(VWT1@YEG03EW/KK.?)NZ8\OIE]ZX1WA
M<](S<EEZ'$!XC/YCG<L_'"$6<?Y)6-!+?_7R=OJU>P9CTQ#QOW_&3 ,(2'JV
M@@0E*)27H-Y1.<7/OT\@AM6+TE/H(EO$T$T-.57T/Q3^T?GKB+WT2/&LSC_+
M"^8L7QI2HX4\#O#%NQ5F#:%!S) "_<,S 1ZV$N!_NOZ4TC95'[%T$ ?,D;Y=
MQY"@MCG^^@[7?S\Z4MA,AK=GH>&WGN.8?QK.Z F.5(H/!!9=\*XJ^R>^!B\D
MUFA(4'D!#70HN%XJT?7_J1B/D,:'SFW&_[R6]U=5_X\H%H$?3N64Q>U0 W,&
MD"U&K);]],^'IB2H\<^>;@(R9"(_Z2M@KQCS$O<D@CI-;PM\"MX%^6T!WW91
M'2+>T YWE0_:NW[XVF6>C']=&5.1<D1NG<ON=_0]^'\23CO ;*TC[D>%ROTU
M/C[Z)>G%A]X6XSPC1+17.0)X.4"6]\LP59+ZN8/-*-:?,9.@_$_<#3ER GBG
MD?;[M:.$K(/70GWZ*\HKGE96E)555CU[5A9OYF9FOT>4U-/1,:156551E;1N
M3UZ\$J5#-\])P3!(:V<3X5] &FI7P<9WAZZ?OY%SHV#]P(V<5Z&OO4,'JU[A
MCU[6VNY1J*6U/TUS0^=E8\6(^[I%19V7-?UUB_*O[7T;E-7SKP!P9N#_=9CX
M7P+]WR70A5L2U!H'/,()Q<^4*L[?;X^5_\Z^-7/7VR/6PQT-I(=L*#Q0YGES
M.B(VT\QOI]*SA_>^0<BX<F_'J*O3>\M+=R)XA;2;:8CI=SBS'*?U VXY^+^]
MA</ZNULX.]$K:-(Z#:Q*Q0=@^C4:)"@5JETM!KK$AC&@S:UAOF+EK;P)$AN*
M%WY24L&.OH3/CR[<R]WU)35TM]Z4FUWYU=9$QY]\,+R!"!S Z#J"_%TUK\#L
M5)P6O+==@@HE7.['U_< G@V+*O*N@"%:]C,Y#K>I W8O[/\(#8T< #G,L*]
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M>+YVP&-1ZT]2+-GPZ+R%NSY*6NX32Z+QL!E>1;H2^]*E1G4(E*"N;Y!>+U#
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M.46*GM_A6Q8Z9_C?$I65/YV?TRS;_KC[4<=75]R>_6$6H2;E?@PFUT>^GFJ
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M+^B>Q&O.#,;,Q;73['PI>0WTBK"J "$F)3LZ.P5K?TXD-FT,+0JVFYW+7/?
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M[]NL[%]O<7-W<7KQK*RVL[2$';KV=AQ>#[&D?9)RBU"SEE\]T0)?>PO(DR*
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MY/"RC[]8MNO_\QSK_PLOVM+H_P)02P,$%     @ ;HIO5'"?:F72!P  >"0
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M:)<N_F@<-_7FAPK.=JKYX,$KG/]%T^""<BJ(I"[82[#\E+M4G$<AA7$D) E
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M]6Z'LML[AI (5^HG!89ER>K.PLEA+'&<#$RJDY="1#N7/(B6YCYS?& 2(6F
M&%8AV@3!F@27XLG/?<*]CAHO:"!]6^%J)Q*(GE?O#03U$*EQ1\THO,:7BHMR
M8X';)G3&$BG4=4L&^G8YWQX=&]F]$ FSZZDR1'>6WG?<W-P#AW.?XAZ!P-1%
MJ$;Q"$ 5'>+)@K&+<J\DV[;?$1I+%(!?92(N4LK,LI<DP8;>RBP!BI$2E&3K
M:)&D:/U<^P>!Z;,&SE;<NNP&G( DR6GIRIA:VMBX,+6SB6E\5.](-F;'%WUK
MLC/F>YJ(YG<'%<Z%\<7P^M,M-URA7N7<\X525-6K'4SE[!75/U!+ P04
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M9C=7]]G(PSSBG_D0"ML\ZNGBE3]._@!02P,$%     @ ;HIO5(4G?7? $
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M:. R*S1-!B]'1!< U!FZ$JO!(R;J+=-TH:0F65VX4>?_:BP2CSC2N=6"NXD
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MYQY?"SE$=%"0G9=+I:P:FG?V&OY+F[:BW/?M,^S_J:&@G/9MTTF^ Q2[D[F
MO!:7%*:K0:_W=L,5[JC4RC6!DNE!KX1D@W;D#Q))/O%!2,739SNTUD].>3S%
M6Z<>\)>HU[8-#[G6^_GZ%ZZZ)PI/I*Z]K-%RREIA*PXE"BN/&RS_W[G1EI3(
M0Y38P]*LB[9YGI1FY+HEYEXZU4BFKSA8B[^S7NL"DUP8W_%)DP4>C::)+([S
M"EL!9,A+8QQ][-"=R^6TYP8+9R6NQV@%#6)9RE=O&T!S;0=9L(GWD;B\<QX
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M5QP$"P&J)?96P0SDPY&A<&Y[?%&DA0I]_&4ZD4=:,VN!EXC__#]02P,$%
M  @ ;HIO5"&W&H0,"0  %&\  !4   !R=G!H+3(P,C$Q,C,Q7V-A;"YX;6SM
M75M3XS84?N],_T.:/IN0T&W+SM).2& G,^S"P-+VK:/8"E$K6ZDDAZ2_OD>^
M9 /8LGPA$C-]6,#VD7R^HZ-SD^3]\.LFI+TUYH*PZ*P_/#KN]W#DLX!$#V?]
M^SMO?#>9S?H](5$4(,HB?-:/6/_77[[]YL-WGO<11Y@CB8/>?-O[LHRC /,I
M"W'OC_/;JY[7.QZ]?W=Z\ZEW_V72&QV/1M[QB3=\YWF_?* D^ON]^C%' O>
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MQO5BBN=R2H3/XDA%6"&)PV>0:K>S@&D",U3]N_@GAME.U<2%7$=RXL-L5@]
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M*#BLL@DD*0"*$:N  @GCA6+$*J!H8L*AT/!))L8 6"@T? (*.&L#:F#')ZO
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MA' /HEWG04*MGAA4Q7H^K'_-TS]+<D9XS-*5X7/9=L> 4!HG],%QYAYCQX&
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M(2_8QU^Y?;SQXH'S1W&,IX(SG96R6F)=7;?);&[?NR^2KTE"EJMB6V9KRYO
M1!OZ.R![6TE39]HP-W1 R!4C%Z7<]$9*]"V=D"+X7$&:+[!X3HFFH0M"RMLL
MC>>;\J :.C3MG)$!F Y-.P=DJ"]XWB?"= VT"Q+,4Z%MZ(J0=R= 0E0-G1"R
MJ3^\N12SXE,7E'U9D;BJ7?NYE&^<+VY8)$73LVA]>)1T'L<I#)J+X[$2.O?>
M) F),C)?U**V'H#-""Y);TFO6R)=^99,%\P=.I9@UP8.CT'K](/<MS1R'!C\
MECKQL.([NX=\\Y2?VB"%CH4%^Y:U/FG9LRC+2/)A?1[%]\_;VLQ#FW'QS\GA
MYW0S(ZI1A_7K7T5LSNJ"[#(P6J7 M.B)(5YADS;T3V6- $ /##A&&W?QO.2F
MYGA7-QR<:F,DC_$VJ=$B0'"6;Y,SI"F8Y+S.W)"<]*XR1<J[]R[%*G](DS+*
M]JN!*Z%V'&^0.:C,$$+?D#=0L2@N;@01AB]J[C)^)"C6YY:\O=+"*?]#R^O,
M709%\C&-;M,L+=:?2,1+1NH+7%:E2C:TZ#D KHLH996$,DW^I^2%).E)9%<@
M O49 ,LO8M'+-*=YWK2(^&=27#%21(\*6+;=AT!(<L*B;)HGTV29YJD@KB+S
M_%&R:Z*-S+/J.UB%S2?GJ'RW/'Y,)4^U/?#@ )0*-?0Y!BP(SJ1#YOO,7*'=
M018]4>!:D5CHGV=27"-Y(K/@+.&9!D"$4MY4T K=RXX(4%4KZC>:B9U3RPL6
MP+1]$6"3PMP%(V3_FC0K@.8!$*"LE"-[EJ+JA@"15"PTA[&I.1($VJ/+W&'<
M*!"<OD*$KDT,;0RL=IT'1P<TL\(Z(4%C-K8">PV"A\:$)%P&3TJSE2QO8E1V
M89VPH-DXL,^K:$,;1(T=A\B(JQWPV]OGJX"'G$>Q4>V =SPN5 AX>LB]]$&M
M6 *UK7T_@G/?!B_#5^JRC>KY;S/($&C+6YXF:<36>QM (WP:VP^7+:N]+[ Y
M>19PQ2 :)$ C>)LAD"'=OPO1 MW+*Q2;$84\:&=YT!"[\(M2L"#C*T:T((<9
M;6IO<G[B1*L,A5#>)XPC)1V&SQS)20V-QX+4:#"B]H89C#C-L@EMK\6,MJH"
M,&(974T$R):CX(005'G3KEG02&H96'U1<\;3Z)+[K>0(G)L2)-*@_8; ;>E2
MSNNT-?'5_8?YGM M6X!4HP&I=Q6B7,)N1+Z1G"O=OB[4R8VNND4WV(#@!2!B
M?U78NR$VQ:$ X?JKPMX5KB%F"MV"MI,/S;GY?M>OPU,6:&1'=\Q:Z-047%$
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MK#E_TU#SUL9")'"DK&K<>#M\;^./:8YT\I;T>ZFN.NW_A:%R[["5>T,%SLY
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M#](9<":PI2$XT7" V%'E);BQ6 "1HTI0Z,$.!9P&;'D+K=04(%9L^0JNK3K
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MSY+N93R>"A:\8W!''>_]M/W=>.B-:L-Q8.X07('!%1A<@<$5> !)I\CZW5\
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M>2W*P0&7&2D+5ZQCXU7C_?B5PKWF2Q+QZS.H)9:F..E3%IY!&[]/=(^B<V7
ML8%'5LU+K 8A'FQ\ )06B-9>8=R@-?VIVQQ)9_:>[8B$.RIQ016_KO7IMK[6
MC':K#?5NS:-\T9 [;Z$@1M%7&Z'7S!D?;5KXHG]6'\9"(:EV$2!358&\5)-F
M?X;<HI]IRJ9)F1OAZ]'),.0YY17M8_BJLXKVES*;G**I%)YI1M%N67^2UR<C
M,NLZFVB(39R=T<O[HLRCN-0[JP^_LGMF-[,'/;O1KPT:?@/BNI0?/\[[R>GY
M6.^4;3NK\ISA)3F%Y0,-#\WC"7V=<<>038XD&_B7DEK+ XO@Q0E1+""B=(=$
M$#T_P!54G50A3%D3;V[HE+C#^>9TR()U"G"*X>H$,:_VJI,5&)NI,Z'G3*U3
M6 UZ\W<<Y7[#[!YE\= @]< 0OC5HO,9)E>(ZL'5D<?.;&'&U4C1WKW<0^!I+
M[K WL:E&G(R \^(M?<*W8ZA%?:6UV%UZ_\H11*%322SN+76W8:\EK%8OZ6=<
ME+S^<JL<*/RJ<]$I0M"V8VN&X'T'V#31="V[ @]^68V; [&DZ!$JA2C?3,TM
M9&/*"C;B-I/V]T\GZOQO.(])P16<TH$["Z1FJQ:&D/=YT!M:X]>-^=U1/!<=
MQ0._7NQEQ8@1[8IG8SO,@TV]JBQUWOO3*;)?,'E8PYA'G$</N"8#OLE);/V6
MT"I2LU5D0\@'M'H6Z*E&#$4",S9$H(:V@!O:-HDHW$!*:)I&>;'[[9_55E)B
M-J_J2)V#7IDZZBC9 'I'$WH@!:.(I6M-\LN(LO@3J0A=OK"H"XPV^_4*O=,
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M3F<N3V>.@(@XR$!'3A\!J1)5O-Q_Y&=1B1]H+K<[>D=-N@5I9_-X$9*C!FC
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MFSH .);XJ/"%(9<.S.R:,07H!1+ 9Q/J5:$U-2#@W)1DUVDP5I6]D[A2F'O
M_&5_Z6!EYI:[7;>1+WY?HAU."]1BU;FEF9__;<2L.J?'P$X$%>\/+S]EY/<*
MG^,BS@E_AC^0<:;UK15AEL#PT@2B8_]TP(=,2-.COY0_E8@:E"T_19OA1+6Q
MX5:8;S>M9WY;(  =-D=ME,)2]I*1S3-'M74@ZPS?8J1,U>AX0YZ2SNN:J5K
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MQVR!F(<!S>&9:)]C\=-7"Z1"#$=B;<RXU-:.!*K?V:!6'&,OD7&-+R?6Y!R
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MP(E@*#"^)O$9W"[D+X.NP^!80U;JG=,U'S5 #SDII'LP3%RJ13'K5ZG0P1#
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M3#"!N."M!IA'*>26H7[+)/<6\M=CAC=W436EPGS*R:*A#]JG?+38H5J_@YP
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MG7 IT=G^^B)?N',3PW>.J8-RZ!CA.L':(F+$"]NY$"'(7!%L'F \3AW"0W*
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ML\H5;+QM>@P;K:5\PPV4,+'3%3P@&X22\<0;\[TQW[FC0M&8W\=&8L!V_WU
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M47\^V-H'6XLLG#(1"'>6^UQ!2/DLQ!V.'%? DL>K@&1N5R*[ *M+V?+A"C:
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MRO\NW&26IO@;50?1>6,D8L(8(:B8/X39/;K*A)N/ZC"^9N8+LY^OF>EXS4R
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MY\3Y)V/AU/KAW1;=@G>:#?N[WM0IM+:\($YXX CS?.R6K0R>;6S][Z]?.LY
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MQ'* ]26>B,\>'#]UA7L>A4-9,Y\GI*+HQM\@C'8&/!+'X_(/$#VO1.?7%P1
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M=UT0@,WO>,0=_;MDBL49%H @\4D'HIQ3U1>]Y! 1J"^0BB&OP%23;NB",):
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ML+GZ:\@9OX'@8!<.+*D;R/*U M]HDOG*T%>7;*+<OBR1_\;3A%E1+=?SBPY
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MF2^!7PR[A +8-K"^71H:IH1WV\#P?'-K_YUNWH#]DP<IXJ11K[!FO=FL$+P
MU&38(C-8&N<LY"-LG:IMIFC/ &D."+(E,V,)Y!+Z< X$[%QT(SF _CX:7H,
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M1%Z5>, Z!)N/*'':LHNBOW@0U.[(\M[:&"EX;TO<?QFU5 I+YVKQ:NV2\]A
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MLHME*<\3W*A09D]V.Y;\JT)%!%+3(?G1&:HN?#$V-$E8/_7<K)>%GA+Y9:)
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M2R/TJI-:+*^T8UND4 >RR)^01I#3NQ!WB-3:\YL*Y$7MJ0>:<2*O*_>$/I%
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MQD4 N$THXK/'OJ+YWV>?R<C*-BXOOG[>S"%?% "(J^-#-$02Y+A+^ASOP\-
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M9G3GW5&.-RX0X5%(+">DXG?VL:E4RX8^7-S5#<!W"C>PA[?5=ZW8#.I8@$#
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MLR+.IOF-FUY7CZ.ZIBO1"I=F*KXD2@*EYJTZO9"R P84SM>"PCD<4#@#"F=
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M_%>6(C([RV36LFWH2P9)8E2@T#7>*X46L@SNG([8J089M#P+>)0,8>&L7N4
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M)V,PB\;\H&^#)K8(#VL-DJQ++E>G/^9U(BM.'B*$Z7>2,[U0TNCQ_,T/64]
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M(O10V8$=U;/@?NPMGS%'VGJIOH5:=SNKT7;:T&&CH/7EI9R]DY78?_F9SS[
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M06D3YTRD U?1C2->; '+CHW'WYE64)'%556I!2,'-6O<T:Y7'A!'7POBZ&A
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M"O"H0=W3<XRDO1_5PT?Y.00-PIO^Z.!@1,%,Q/;7-Q$CAW3Y35_;1 ZYHF;
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MF(52?V2J!R-;7TQ'WXKB5<YJO>!U<](TV@)M#=!<ALGKV;YP;2[3=54'P/'
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M"H\+C70 [C7PCD/]#GC0KP4/>G_ @PYXT $/>A<\Z(_>"?^)(OF=#J6>JH:
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MG!R>G#ST/!\_OGQ[&M)\ +VZD&Y(703N-CX[_SZ;7I9T_%Q(R/:<7FZUT!K
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MLPV0A'>4Y6ZD[+:*@GJMJV:A8;54B:')QC3M<0\GO\G@"PNF&Y8K29Z@,D_
MEQR"&)I[!3/WV.1,P 5:E>S!]M1C(U+6Z 1PY1'<ZV*5"VJ,J\M:;KS*&YD^
M,G\F01=(%P#FLK;EQH)VDAI!U.:.C%CX+,@+N"?0L%>JJSMI/7XVNG9U\7T[
MK#E.SM\:A5A%/7=&<5X+[JHK4[DB(E?"/!>OY.=&211U6U7(8VI@!J 2N##.
M^>C,1#G*CQ75.2FRTUNCBW_[[RJQ_YW8(?@SI\[^3[5*GH$2.T?TB;1&D!_:
MV3/NYTQE%3F:&H%-&OJRFK^PY*^$7)S.K3ZNPR#1>VIA2.50J.?/GXV3-[2\
MZ!\JZ2M>6<3Q+RD(,M)3#X[-%1R;* $D7<";M.MLTH!P*&UUTO*_7[;M\H?O
MO[^^OAXWV71\45V-X9S(WWM'P.S8;AAZLMQ\95PQT5\U]#M8RZM4I##'%(%\
M[V\)UL@*#E03"NURB*>@4J?.(S3@PA^NK/BH0)=R9NG\8";]P[AA:NXZG'PM
MG NZ5+C9RD =%51,N?($B:#MM*KI]:9B2/@SY/"<\H(@GX.#;;K2"UB@PX/]
M?XX3[!E)@F-?Z$1-M,$N&T6_Q .1PQ3];DH3=M'Y7%M%/R+<C"_.6;;H5WP\
M&[%2+73U#H8@GQ\Q9G*II.HW/E8$#6?="*M==Y9[SQ\X[X*<C=-!0986!^B8
M[4IS*<*LG+ZSH9HZ!M1(9]5T92[9#[<;FXVR[I;:H*LAJBU(^@K(8?&-[>$[
M7M7)VTCAM4E^I$!*4FDOR^GXSQ[DX<G)T8/DO 4FHTF>U5GV(7E:7,W&H^1\
MA?5]>'#P9X_Q&=0OR(>MR!$_34X>'!S>_[.'=-JV].-+SAI5(+I1S_#/'M?S
M!1GB'Z+M_=_-DF%'OM(_0Q\0C_<'<>51D'^2@.YR7HWKY?_7M<?__3VN\6=$
MJ)\5=G(;)"2ZR>_#A]#>^BN"0!3\D2@8I/^U#8B0WX@(^19\8TF'I4D^^Y^_
MI8?IWQ*63/F?O^&?^N[H(S0I+^G(C^S4X>G8_[SY7QRH+\__F;PX??;^S;OS
MW8@D_H;,X6D9EQ\TD\'"[G2Z"*,HR*Y6EN5!P:(H\O^L-,=+7Z\*"'6E+!I/
M,>D%'>2,'\Z;#QV'C'_%+*!%)9GF-6ZHC)9^))'+A?!9*K F:^ZNI:HSI=:Z
MN1CH97 F65%=._]Z,\3Q7K;@/AM?EYKQ1,A7-'(*O?M6Y#Y1@;=$S',KY3ZC
MV1/B4DEMR3B;C &D]%T=E;KN/#(T"5: ^\ZYISE915GRK4^*- V#824DD"R!
MQ$22!>M/W(SN O%,7LX#)2,:>E&(-)@.9MI*Y<[@I;3J1IV[]%P6M_L>V0H_
M !EULT(5G=-@[/JS$)LDPJ1@9U"F<&G*5\FC@ F7RAHM)_UU 9]<>]?2B)=.
MN63MT>AZF79CX=N&^._>;2QY\AW8]5PR.%\M%H"SO\..?"%%R]VI!/SM[V_"
M3&6<_/>]S/W[2K:M7_$-3Q7=NDD^T$K9MAN#/6B; ONONQ.QMP/C5F?I3&Q/
MHV^DK2ZDZ<%9&@;HS#*Z$PP0V]"YO+' A+%9^=*IO8&IX5ME:KC.I%Y2H@:D
MO2>M"IQ;@X$V2PQL<L,"_"P+T&HK#+I!+TK8QDS^86;I-<:H94W&8O$.PFSX
M0E[! -IDTK&_4!9<[6+7&MRPB(=%_#D6,1SYRRR]RKEQ#_W(C%Q3Y<R5L.F3
MJ_GN[8.#A\?B([/#3YY!RFS"&_U<@=9UTZ),*#7O/D4J\7ISNWPRJ[*&XPK5
M3^[M]0<.53ZEX[/H*F3$C;UY5ZY$7BZ;#9MIV$R??"C8,,_>_/OEV?[A"2V^
M=@+I30$Y%-4$@1O].P.B7R-=YUH;-.4N71RLOS&X-,,"_BRG 9M)HS</,!C3
ME/&_PI1NV267!'%6_%J8C((V[C*#@4X9IL7I%(#:%?0("PX$B9;@'8M*5WM&
M^K&]<7>()STT4$1Z>WAT\'C8%<.N^.1#$;7SQ '1;,FCDW!AW?._K&87BKW,
M %]DQ%R-3@ !U_56\H4<2B""#(&HN:W(0X)C,0G!(<=7T[[W402TTL[Y<@50
M/3,4]/?0-\+]->R:8==\>B;-V%_A,(/1NBRXTI!K/V*!E7WA1>1C <UY^108
M06X>8H4Q/E@,BAL6;$2PS9H$R=VB$R(;EO*PE#^'6S1/IUG<K$R^2M9*38A[
M[J34-LG1(&M=O$(Y$R*8E#S/R?H$;A2CS(7$A)TPJ2AUG"JY;2 74PQYH6')
M?Y8E/ZM\YS,OT^NRJ[24+B4W:25D#1ZX&"R=<L*K*3V3DB;RDN<=M][W5P;)
M)G'KI0ND7%OF="/A-.R!80]\CCVP=2TKSP+ZHY9H)6PTG:_B7CT)&Q<B"]@V
MOB)=@YLKT"((KZ:A\Z"1$BD0"F4)'KR\U2XA^F"8*1H6_[#X/T?0J[6!56GY
M&<WH2-W*2E1IJYR8K0@*.NQ)UP\*>GLTHI8V7N/)W;B0T?GZ7#^B Y#Y%<JI
M?5,BJ>,E&31,F&Z^_CWS23;*[X5B;B/'NA$E_'NVY2<;X&W[^Q/>Z,Z&XE,^
MW)9M_D=>:;0N'5 ^!L7_5H.T X\<QUO.SG454877)J#P)3,&U-7KM)FE_TF>
M:;K\%9L;MHF>7KB0YO71)B!0TWZS#!_)9@[Z*?RD?1!""R*#1ET50.?>6!V&
M6CU-#TZ FKE(S3!R[6DHB0YNQ.?( EIZ3I;N-=/V*2E&*CQJQL7<..9_"R=Y
M!:N:;UYZ'"T#;-VEHI2W2W3')+$;^?)AL0^+_7.!:2B"<TP5%W5U#<)]E<S
MT:%]\I 64BG2#A@?E!J._[A-/V2E0&U:I5!VQ'X?L\52,.B<@83<15$U75VJ
MN,VY?V1TVR<"XC7\[P=)^C1^6$RMD[:LUY)+V2K7%C[/E<=?1*#*B-\PG<\W
MTF*8AKN!OC@G3[7]V@]IV*3#)OU\F4TE%N#8D&)/(U]+F**/?G9,+W$[4;D%
MSZEZ/K0=T5I=,D,BLQ727M4=FM[:K,09U"+_D#DP'O/Q+Y=U1L>7,6/>Z!)^
MY=J(GZ59@O/3,#9,ZRHM[LQ]I_RE2O_+\P-]*5#ID?FLITC<Q64=9N1/',7]
M,['<(Y_?=A^1>6>[OAWEV^WHUSJE%N5!8JC&FALU_/@<V'%\E_G[MEJ'OVG&
M^H=VVX&Q?F"L_XLSU@M3![>3O?,$INA<>^I0K"]<Z/76>+^9SUHS$^\"3W57
M6O>D0?'GW]"@--Z=SL5^?B>.BUQ)C+8N8IE)7O6B(];CY+0 8\^%$-V#&0OQ
M@O0YOTK7\A1'!P</F7Y36PYLOLFUNWFV%;"Q1< F\ I#$"JS"KH;K+,6Y&55
MR4J;?)\P!==M2Q!8:YH4X!S:;^A1:<#+_(K5)^-"X<C*+ $GO[H"HY"Z6(08
M7>T<E[3'8;)G%4APRE*>MA8S1D.L')%A=ID6\Y'2-/%\L"R !G5N%$YY-L3T
MLG"9/:R?SRY8]]NG;.M;V,\B9]\O0 ON,25!I[AP18E4&T7BR&<9H+/#29@Y
MP:AT0AZCY+ $^^ Z<NKDRI0RHQH8>MMI$>/*J2K!N;2O)+<OTQF3'31<7I:$
MFE^NNN9-#")\E4S"%^_8W>9/?!-GULVL1"I<DXP=>NO5*S(-W/1]=Y+S_9:A
M"WB_02A+(>].^*W.4L<UWDPO\U_)II(!RU/6Q%KF-?=.?;]<%62ML&7),Q.M
M,*-V?>O^=%IK]O3'-4BC1 >7#</;TQ\E!'HY(Z.=DCF9!M][D4]J.MQ%GN/E
MVQ<C$S#1Q$Z9K>IJV:QI>" <G[HQ>'[92;ZLP'A,?V&/F"_U] PF[Q>6U&/R
M1^2=HD^\.J./G!:_DJ],J]23\_'-,*3OTPO5(N3/G]+'WY))HY"\*GL^+@][
MIAIO('5CCP7TZM.\32XQ+VH(U_%(3L]^//O^]$R_JKBEWK=DSV)*YY.,_"*3
M[O/:=][(]K3 N<;2O.XQMDGL>TRRK S6Y\B9*<]1;6+.4JCRQTI:*+^?G++;
M3EC;#WRPVJKE0V0W[<)SB/Z*,;VI3]%>_PV]*WQL:$(* A#0T%$NEXW=+_F'
MKA$27=D65"%C6W<Y%TQHF>WW]5P*&V:?7>MX2LZ2L2:D;R=0\H9NBYJ_X@\#
MC<.0CKW34/K/PXWF 6\:;]IGWEG=>H .-85A$7_Z10R*X)*!%TMYBY*=OT%P
M-5C1L7KQC (*L>Z1=*NHQW>5>X;5/*SF3SX4+Q/>JPY(7B]9Y8GHE#?KAC55
MMJ_T88D.2_23#X7>D4^L(#'F 3XJ^9>*-FA$EVB+E7,L3,U=9D7HQ+I?2J2^
M%'[N ,L_ZG3 \)4*X/.=,.FFKZ]"@&+R739HV!?#OOCTJ'TN>BDGOP%.542O
M@B3>LC'XJG<E8CT\ASP*T@#DD9A2X5;'.KS,C.-1[PU!628I$( .RWY8]I_A
M.!!4FFK-:9,*-YK7><845<&)(%[V%7)W:P@<+H8E.2S)3[\DE<Y/)-C$@S:3
M6'K@ELO .E3HS JA"TAKF82OF>PDTFTUP!GX8 ?+.BSC3S^4(EV53"L3E02Z
M;H!(OW.I)RVJ,A.A:&"6BG2B:AD!T+?YRB&*PW+]5I>KM6N-</@+:8!3ME=Y
MQ);>7<;D[_@#RIQK)E2?5T5>C;_>1?EE"EM/,XB-NZ;<VYC&D[1I*@"335?
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M%D6=/*L7C78\V38#X@N:/2WH1DU'*A:PCE5M6"^LS+*95-JK,KH@[C"2MCX
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MY-,@ITP_*6R:!4^[ET6H!J(A)3K<O8WQ*,%7)^[@6IXQMTG)"VH[?\Z1;J1
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MT&*:]\Q35#WW:'/U"'HH_K/6ZP(2VHQGBK^'B&3F-H176M'%6YY5PKC/CFE
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MBT]X[H<\=WA'DTU(CP@:$I,%RJ;A\RUNA,MMN-/ML8;RU&ERB $=H#]VLBJ
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M 4U6)*X,OM/5ZMJL'*5:RZG\^K<0=HKS+P ;8D]?H;#!8/_FG')% MD.DP9
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M?/\],(%DW?:"C=]7/60YZC4#5=)MB'ROKH,XHW!\8P 9;0VMI1X0UA0\XG[
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MBTO=IDS.#Q\MFZ=];[,1WC;MO?B5-LY.R^+D/0?!'.ZJKC^F:28(:3&8$V/
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MU"XR<4K.]+R;CC2B/=<:.JV9J!;?332V=T'M9#SRQ(X14F44FR[-8^>6?)=
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MYIF)H:GIP;HW_0W%2<@(<Y_<!"45[:&GD)2'!U#F$0(W%@;N']TC9.?4ILQ
M_6M;(6EQAL;7""7-=\EGS,W=+4$T!:+W'JI@6I08Z_,  Y<G2?S@CV*]SA/:
M*+9%[PH@*<Y^\L30<Q3D,"941#7T8Y%R6I@:00%8^H)!\F"0TW5,I4Y?(RGW
MZ#-6/)G00?Q\U7,\ILW#_SB% K\TBC_Z_7WM6HZWF+PY\)\:($_ ;BQZZ##U
M^#[QQB<G1I#SJDT>#!_&L]@R@2&(2G^HCBF-I0._7&.VK).,ZR"0HI$GC? 3
M=!%% <R)IV=+.Q/LY%K914J4FLFO)EQD!'9LE# JFS3'^7WK$D?&8=-VAU;G
M0PJ:TC-M)7 H<F4AJ6QDJWH._ZRY+T$'_)%1BI%R>E2,H[.2]F7--E)6CG-5
M&7IS9+J\55(43.]B5$7/YXA7/1?CBIX3(E)S]V,W?VYTGK1JG1[9 BRMW!9.
MDGM3+FC4CPJ-^E\+&G5!HRYHU+/DX"-&XG/F6]F!!2IGM,#_L-=!GA>3Z_*$
MS-'T@FQ4P=A>U$>>9H6'2$_-<2^W56KU2 DZ#HE]V& BZB:@-8(XOD8(H>F=
M1]986%$E@IKYO%&S\GAIXHI,X]['CMS([_!3=C/'OLM>AEM]S=6@)J/4RI5O
MANN;OEI=_Q*C^WAC^K@I79<2Q<^.X'ICF=K+B(E]O@+\,O HF:ZUU<ZC-!F]
MC^;AK3:6A7=45D)5W?";*QT$;:?G)8A-3Q+_4L;!/B*RAOA5F.RH#!^#.!YF
MCI@V@UJ[.C5Z>0G?H.D4Q@;8\]G<B0O*8/S'N7UZ:)ON_Q][[]H4-Y:LC7X_
MOT(QT;,#[Q ,=YOQ[(DH ^YFVC9LP-/OO"?.!U5)!1JKI!JI!*[^]2>?S%P7
MJ50%N'V!HB+V[#:@R]):N7+E]7FNX07FB8 '(;0!<AP+[;[W9Y?706&/W!S:
M2NJK*_0 3#@+U7H(>TZ8?B 00=$+'7Q9?$[A%=-5NUL;+P_L"U"),(DD(#V(
M2$V;H3*DQ3!XS^[I5AAL;VYOMS "V:U*E+9;V\7H4$_C&GS'4J[O3K.0$17X
ML+E*)/0KGCT+'O<.9 [TG!DR&E/9$C3KBUGHI<4B9VN[_AJLI2]0R9*45\**
M'G'YKS?ELCG64K[._$WKX[U$'W+(0@O$QTQ5R:E)8Z5;<2^=([$E2N-GHY(!
MNW*2R(%BOL*H\_X4"6RNF$%B((=Y7MH#Z*:06HSBENN=8SM[#48+?^NK7Y7F
M@O'#&0ED(,I2D:DU^BO9"9U*#1IQE;8+R?<33]K,!VG(Q)=M_@QV?;E*'_A;
M16UGH+D-3/83U@\.Q2&#N$Q,_1'"$_/DRP1#?)%SA/,+U9_CKAP763HP#X^&
M0SIN*Q%\V<Z:]S9BV)2093E4Z:CIR=+?2,P%PJ!X*A9CU=-#W"7"'+/-'$-5
M5Y(06B+MWF'1__&Y:L"$8^^A#EBHF_1/B.QTS2Q7A9GBPL@.Y"$#4*/2YL]M
M.Y37PU;!@Y7$W=QG2;&8=LF 3^B6&0O<S2/3XZTY=5-?QKX#JM]*K_+%5*!8
M5'QL1?-=E@)!AJ1'G'1;S!F<AID\"]K[/*D[-*>='D*\"MQ?@SBC#33!T,<7
M\;'BER(L>D$TD%B[1Y/<G:B3,T.J"6RGBO>6RLX5C^;I[R>K<-RQVBB=<9B@
M;I47BK2!.I1Z%!48.0Y=%;C^VM9V+'PB<M>T/LT.J-!6337BDRD*]#F@38N[
MW&KOTB^.63B!A@,/5-F,.V L1EY6-%H9&%7PMSYXQ0U5!\I^QLY<D=B*/%Y&
MP&S?QDRP_5_="5O_;JXG$*9P-BC$$&)&H'0B5CHL%50B3A1QP>H];AZ>^GNX
MA5DS4:Y2[4EM:D< 7"6D.+W,[Q(8&7=%Q1HS9/N$E(32:=!NM1\V!,/KX%9"
MV?[$7PS2ILCG<)NM)A8]*>LHS8L,O3EW$$&M&[8:KSZ3=/@DT_)WVRS-H[IJ
M)1=A2'N$=)9GIXV4V^S%SFI35,,1-'12MKP<$_9KJKW[ZSO9JTL@:QYGN4J!
ME[[6ZD%MJ3)143\'2VXS1R>C?J']2E;5%XXY442SSH?135%JA^](,:M9ZL@1
MO^)XWJ*)#Q^P1@V5NOSGS'T,:PY=F?EAI(8&PJH6HKK*!;.TTF$]3S:,4(@
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MW>MRQ+J]1FOK'15QO/Z6-OFGX#?P]%Y,2H1:SV'@C_@J)(]J$HG@S(&[F9@
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M9JT*:S!\\5*\.0H#.MS# $=U&.!P#8.SH[.0CP%5^!O!>SH\"X:"J/[ : W
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M5'67Y^']NZY0-S[CB[VU*N"Q%0I^JP#A VH"L84-2+>R4+%PYE-6Y&3D5:Z
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M_ ^7X^?;FKV]/VT?;+QL)0,O"_XJ:4-1:!&7\&+4)'Y5(\551LR.[$4CI )
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M4%&T.$4\\*\5+.9**+^?-G48;ATX"$\NYOYM 'LT<,L;MQ>/$)H SAFBNTL
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ML:=6X0(_=7U93*)L::("2W46;85[KUZ%^[NK<JIGN/ADB.SLO@P/=KZ#X_Q
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M>SEM\7QZ'[_FHF^*$MQNGQ]W+_K!QFXPLV1=*,LAH]C/7MNTMW*.6T*)T5N
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MF:PXO/8H5.U7IR:3)L0H2./_^5/T,OH3B>@$+\4_U6JC2\@<.KD\?A^\[&U
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M000%>QG:N=_XK=G PV)0*Y0*"?>5%+,#@"083,F:34BVA)P7U1HE0%)&@MO
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M[UEI %(PJ$3Q'+Q0/9E.S/?V4X&435 *FU,P]W8_:_1+Z=%*,S^8[ +G$+4
M"4IK->\.)RMH#ZD1K(J]=,-H1%6]V3VJ/3+WN9MCWIF?(9A!G50X?"QM:"QA
MGM? U=W9<_\??/,6M!X.C'+XY3LF1Y]A?Q"9OBVUHHMS%N7M3J2S[C[KM OO
MJ+L>YAW-Z&J<[F@6C["9 #6=]21Y"#"M2]8]4^F7_7,G!K\B;E7]9S,NTPWM
MLD%ETSS9N""B.O"JYT"D_H2N#US^(P($%5(?TA4'=1ND&FQK\P!FY0$<V3P
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MI06=BU<2[E$)G5@0X8%[O@Q2ROR?1P%F9U*-?M>K2?K)$UGV,N(X*Y4GFKS
MX$P'&(OQ19GA-A%T+%RCF1UO+%_%W+#CC(4/!781?3KRF(<8UQ)L_#)[A39$
M9V5YM66Y8?X5?"9%BIX0VAQ$/-V)SYD(3$21W;G0K7JMJ6=YX%7P@,P20;+O
M4 EP%"$R7^7[%"_XR#&QI79+[:^3V@VWN!':HOOU.1L4*)YN%8!%U_?P'I/A
MS)#7!*E"*/P!1$!NC%#JAHQNS;Y/0+[!8&PH3*@5B;#_,Q8'P6_'<IV]H;IM
MI=<J'KB?<E7H!]-R@1$=M:!#Y.%>9E!*32M[(;R(,_*YK#4AC9]I5J8O?Q-C
MPP>*E2@\+'J2".NJL<S^VIE]R+_ACUE&EC)X@(=GL"J81?!9@>&F44(A0E%W
M1&:S/IN7^&QF6)=[X[JY+EXT.L\N&OV67S3:2X_.4C>PM*-'7SP](.?,6Z<T
M*WK:L^.4N8">=O<L>4ELAA=HZ9&>X1Q:L4MHN>5:3Y%5):JM2CQ?8Y"]$'"J
MV;<FG4S0J5IP3SU*\:!8,G0?ZXO VAYX%]-P9)AVQJITZH^LT#%[%FO-6Z[<
M::Z4#!?A/2R/FLS,XQA3KI)0'G@CRR&60UX!A^01#L<(;QA)/#K'IU1#,X(=
MA20$ZP.R#/!*&. %(J*4)>Y3KR?P7GZL/$F4UFD]/"_Q\"QG+%;.\6,K?LRJ
M^'&LI[45/VS%#UOQ(V_+BL7H,B_<SOIL9P@%<CHF8?B-&HFB3DJYLDEL>D!*
M72+JF:PPY=1%)GGMEHI6Z?EJ[ -%1-,1U6"E^[I9M0D14[M(+.>G-%QY [$S
M+@ZBKW[H2J<A5O*/#&!Q5+ T2X/G_;[G>U+;,,/&<J\9W8'$OX$I&3NS=)$!
M5=>84<5#IR&6EDV9*D)?FJ[8"P%+$UDMA!?6).=Z#%._)[.8^UBV-;N/)KZ+
MJ.O)B@#F-;*_TMZ];A'?Y5$TEN9%HES1T_7%>+[%\C1A5J/F6"R*I<5T>1)C
M3K,2"7T=MTN6(9-E27(?]]>"NUIV*J#B:;!)WT1^,>[VXGQ7@D?G84_(RO2J
MPB+ ,572QG>]2$"5VMU:?[H.3HD"JG8EJSO9-79%T*Y(6J*HB,C,A2PAPBDF
M2Q@UK\]T56@8<S3.TWY[%.7 ?KIYQ^+24%Z,5PAR#[#2:9U<[07E@*Y/8]/>
M)!G]].Y=1*749?>(&N#C.ZH!A&P;]&1B"MTJP-:*5%R7HR$D(T+P5W@+JA="
MX!?K,(_T"3RY30Y"X2.GDJS4R""%11HC%9,D,=UEE+7/F<H\<8P_YI=*2_YH
M7K#3%:XC?6/"QV=E!9(8EV!4(HD]H#0>877^KD+F_.9%YF O6A.,JN9BC:0>
MWO7#U5)3%X3WX#[.,7&'4.,S[%.B0WX!^^QQPFQYRP55EV&0E:*AOIDF,^Q^
M$5&,17_\[?PSXVDR"",8*<Z,5NU=\'$+D50$_A0@DZN*(3&UQO&S/2U(?.1'
M<R0EDKQ"*2 9]QF"%91@PZH>'_)[E;?9B5!Z2MF:C9KU!N][P+X>?2=-J%-1
MG';^PF+=!@Z([ZJ=?:RR^]%Q0Z>MQ+VQ0(?*AB&<B)[6<@0U3]<0H$2ZWH1X
MH5V8^7H((/(5\0N%UQG+RL!Z$$>]!WTMG^; >RM)9GHTLW&L4;XXE8L#W.<^
M_ @;):%;]G3112J,PW%@DL(LW804QE#5.X])YX*-O@]#T#TYX@>"J,3WX"'T
M'Q1XJRY*0^Q4+8$7AZ,V&A3P\T(_8T&?/]+$>F:I]=Q*82(_<H];^CV)>F&P
M ^]A8C\2K#7/I0@BO5BNJ]!5%T;6-;NIQ<M(1/F1JEQ)65)6WHC+E3E#,GA$
M[$7N(%](EF6@]U@7YR]N<C( Q?M^4/@T(W1:(2?9$J?XW4SBTI#Y\7;$@/M]
M2M]$%R$V+)@F/#(/\M?/^>QI(LP5_XPS9:6'K(SX/?:V 8L@$/=@D*+B@&N"
MLP7+Y??P$1O^$BVG_D@>=B\4DH10MHZU6,U6YQ4I6;K@NHFLS]?ABN(<346^
MI.&<W. #25A"*L-$6!G0P2A8XQS.&2QTE(P]HFULFS <*8%13B"*+N1+&S:4
MI+6XN'$[($AGV,.+HFFFF'3&< *Q-DV572;8,(T3,KU0%*NJ];+9 %5H#&*I
MM18#F9G2JE"LG\)AQHDLM)Z8IZP*[2!.D#*)V5/4   &!P*FP@?YTR@]T-HK
M$3GFM-F'.1Y[09Q&*M:$+RA3+(L*!O*;J9Z9RD8FM+)49<J]QJ8<>A+JQV%4
MJI=&HNK/49S)V$6R8DU%ELI[Z<7B=J2Q@/TC_DL2#)2I.T2T'EU7LS=Q M/9
MUKM)Z@C^?J9%DH#29^XLL^V>U,47UT$FV&;(QV3^P$?8]J.H1"$2=3"KGB(/
MB'0H+!B_AQ,$KBCJ(P5%P8LF<%]W?#$I!MD%YR<C-"E(PPA[H.DT!-_[!J0Y
M0&T M:!<="'QWJLMFEJ3R5@@(!X$2C@I$5/J&:B0E4I%PD>8+P3TZH Z 4+6
M**2N@?DID5L#S9]A$%6..I;U@(PF26,LX@7GB'%EQ =Z6XD.TF=$( /8->)C
ME3$)YK#J:Y\D?EZ=2$I>=;?BB7?'XI1QBCU8Y3PE;)T?RBP@R)]P2L')]#3"
MR"CGL<&<M*$1# +J&H344(X'"?<QF-)3(*"[64S"PVZ#PF40AWTPOWE<BO$&
M8,.>RI9#N?,.5-DTDG\\ZV;D-D+?:**H;-*.+P@*Y1R@4C_:,U"D'&I@=!^J
M8D 9/811SBP.DB_Q,_6#I,Y(VC&KRA]CLH679P!CJBPQY.0;>SEAJXI;=,^4
M-$@E9(V:RL67EZV!''EA"%?MP$8)]&UW!?I:=I-\[O!M<=_ROFM!R$:JHNZ0
M4RZ7;Z(F>H$P:44HO0)M*UV64/FXT"DMBW:4DDZA$E3?,-.F#C-&[$UL[+DJ
ML><3&WNVL6<;>T;88/K_;EM[>.$0O=ZO;[CKOF&)E^!T^*,Z6'@$=NSR[N**
MN6X-_;ARC=/_AJ$N_OOB_(^[RS\OV/F7JYN+Z]NSN\LOUSOK_#W#IH'2'D:S
M4T1D/0"+/R8#W>HY5Q-DY(F\NGFG)Q5!589@X7Z;40#*O(93+#51.JEN.TEM
MGE&QQ*: ,X:C%ID8$"H.K*.K,>R"CQ7GJ9J[OA$M>]N;X5;2:R;#K4IC,:8#
M$3Q,_7OR*,W2YW1\2UU7FKDI.E-[3A0I,P&31["_P,)@ T EW[B8*<KL<">[
M:\0#=<=B3J#JD;8O"1,J[F6L%1?8J#=<<C\+=.3\ &CM .#3NN![L@,J70]'
M5:2LF )UNNJSCV!48+ZYW,:FZ]#(9,, G^):#8L'W7$I]^F[^B #/BQ]UUIV
MBG17:\93V/XLB+$_!\79%MIW2N<#IEEZ\W4N(#60E1ZP\M=W:/_L73";4KRM
ME.+/_#O&+"(^!J3X *:?S-^9U7L9V2+KOCKOVL@VSN]Y7U;[._7E+;_,/A+C
MM:+#FXAW!JE)B9^R# I%B4_=VK#T9^EOZ:5=\:C+SCGVY_31+9S3WY7H4>-D
M17W[=46"C"S2 V_3X9#+_M>YED@6ZLZ:2'?D2P5ZD&5R275"AR9YRXLIN.9U
MS!)MFB( 9$ YNK-W9RRSN[B7^7QG*;"LET9Z\+Z'=I'<#M0QX[E*)@EM^*&^
M:7^>W*RGE$OETP&#BPBIW.NW*G\*,T^8U=')M8!#<9:".@.N0+5.DG#X_$5.
MONV;$HA<U=C:#=>JST']%TU0=)$INM&;#-!>W'6Y=WK;L60,,(32.[6Y=J/2
MZ#/0F2%&9OI@5_%:TW2C=O)DLQM9]I*FDXXV\7\ )9[:K553E#M;!^F&" '!
MKV\:3_O+UWI6;@7/"OZYY3Z(63JP3H2^=?CLX(>W\@0K<XJ6;JI&-Q_"((WW
MF6Q^Z623XOM:ZEF&>KZ,,J&:D<\9I:U,D10[</>)K"P:/8>>[M &JC :37A8
M-J7-EX31H_O.0:/> GNM>0+_:K??[K'.7^*2OAE\9 >-MU;7?Y+ST."?MTTY
M0ZS0.IT+R-N;$1T'YHZ10;].JGCSOB7#HYO;BK)%5/0X]H( &D@ [5:%"6#S
M*MEV"6"-0F":MF1XH^ZV-K@7%@*J!0%'E80 J^Q64MG]Q7N_4*[%+^\\Z^I>
M2/VM6_5W>]I/Z]@Y;3>V"WT'[;<5/1&K %5# ;(J\+Y3P+YAP#[*@:JHP)M3
M;C<*>B=5"L7LSHR;/\B]V%9[D'9&>Y#[/6-5#M*ZXBKIBIO,_K_ZR Z:-N9L
M8\X5-[::)VT;<Z[,C%L@ -<]<DY/W H3@'6X68>;A8 U[GV[[E80 JRB6TE%
M-XLY3]QJM3%F&V.N/M2UCIQZJVJAA6J<AE5VJD$!5MW==PK8-PRP,J!RVFZ[
M38KNQK5=&X1^_3-6)5)B9[0':6>T![E#,U;E("NFK5C?G-0JBR40V4'+!J!M
M +KBUECCV :@JS/CWCID#H[LO9]M9B$<-1RW6;5KK]4XCKT@@%;SN(($8/7<
M2NJY60QZJK*WC4+;*'3UP<YM.NWC9L6PKAJGL1?GWW2=XV;5\JUL#'K/3)Z*
MGL=>($"K[33K%=9V?]G!/A0'KC+QSX:@62<QM@[SL0TU=D6XC[#];0_;:O>Y
M%[$'[J?4.3$<Y?T78OF8[.U6Z(Z '_!N-XQZU"69FMN=P>\P#_9=N$W@01K@
M/.SES5+OPI'79<?N28U]"J,9#2%X'*=#6D0LF\;Y8]W* 1?)=5MQ[!>'[9AI
MH4@(@EV'\#JNJ[M#G,,0H>_UJ/58KCK#XA+5P-D+NG[:T[WKO%@UOM,]O;G:
MN%X(NF;"X'6Q:6P89)VM>3=)842Y>=0+6'4GCD17> _4M$)V1IO5J,*3S8*I
MW;;:>]E7&IZ-NMAC> =:^@(M-A0M3M4K90/L)R@BW"SX::'Z3BSVD.I4Y^9A
M1A)?_![[*AZ\!XX'>L7'<LY&O7ZT&[O85+M8O'TWL84S&_&H;0-1W-R-[6BI
M[9B( W4 2P+:$-5G<4YK+ ;;5^P$X[:<K32 6<\6Z?).EQ+I@$ZH6X*"MJRU
M3II@&T\!^-:;[IWS9&O&NNP_*MOX%"? ;CW4M@<0$[NVTZ_ G%T>#_"SCU%-
M#D58\(RIV2,<,!^-HO"[AYW _3'[P3VABBHU=F/T>>< _ BRES%^!'QP=A\)
MD@,$+E^%+SA@/OD/2"+@=Z@;YZT8)30S:[3TI"CP8.VJY++;;#CM^A&+!P#=
M,78R&@)=*5#O:TQZE%W,XU0VABV^.NQ)/_5Q^Q(O[H-@,5K)PYJP-6IV0FJ+
M._ ??)'PL63 2I#O/!5N21^9$;A@9W0L"((#YK;I2!J.%,B2ZN"O'>SN@.)!
M4Q+I+XB4*,K'(@%R% 'L*;:QQ?ZUDH:51)\<Q\-FK=@N7NYT1QA?-*DV%EU4
M#_Z=\BA!<.EK"=1H5.) 7HHGV/5Y./+#,?%-QD'QSG8TP^+\WG25]9ITO.H&
M&N:_O\P2*-@:NH@NK)L"1E"3.)'O*L]P2:., 1,'2&5_5UU^Z9.R\_B[ZO+[
M5A+US.<8P.:#AV(!&:4X$RR0=(IY6EG>)UJIW)T0M'%DFQX 5C<)L:,Q\$-A
M&MA"'@3(91T$7 5F\)T?5$'PB9?$AV2/'^.U+F&07H\:6SF32 J\"H:MIWI;
M*U7<G)98&B9,1_A W^LG2E,<@<Z-VW+0KO_X%I] FP 6$QP:JR@N[P[(!\"$
MFLEDZP-S).W\1;:6-!0F41TV+^$ ^>HQ,@D +K)?NI$'A.)Q)F(T1KUX@+H=
M["1).F58X(87FN:AW/&21(BBY*,6>P!6L98G,^EAP:TLF%Y&9^]SV01=;L/I
MS[%^$-7.@-YK!!+K*9H$!,6]B0WN@(_ZI/F#YD8SXT[$L7<?T#?@M;S@ ?^,
MUA,16XP_3I#)(QJJ(&*1PX>!UY?C#$*P&HJO#5)\Z(L8K$JU>T,.RD4Z!!F0
M$-<@\B=Y5W.CF;K/'QW6C\*A7.,]O@@J&&/F>[SC^=3W'/MKQPG^Q^?>4+((
MBI<@%F23II'$")+X\"&^( YQ$X786ASY[8!/-5Z?N:-OI6DZ=;1#W@.V )TL
M@BU-PDT+J)[WH/L9WOSVX9_EO0P7:#BH^PT6QOMT]W5NGQEC$AU7- <8] ^C
M\#&/.!;_A%T9V<UOUW]</=W+9DJ_T:K1I*AZ\U[.Q=C1J9[V'<R;.:NRG\T?
M!UF0]N;LMXO##U\OSOYY>/;I[N+K3XS[CWP<_ZR:EZ-"%8C"F__,!D)N8P.;
M.ZK0Z]_J]+^RJ*SZTQML4#.]Y[]_+-]S/+Q5[/C=E_//7O MFZ/GQ8 GL)5>
MX ,C''9\T+>+KDV:.AN4_<+9(!+]7]_\#53S8JOV1[437N ARNC3PR<F/\PT
MU(EG9YWTXG[,-^^IK2?R^SF,(#4K_GY1<C!^*E?'IWAX03]JB6\?=W9+.MEE
M'Z%<JM_HP"P FR%\<BA$12H$&_><IS%)V@E51P\5D\ WOHCZRF]AB.8ACT'"
M'@@.-L<RV#LI4DD"=:1-E_C2G-!R]<!3UCH.>=;M1F@I:N_M4HCOD$PQE)!9
M>R15.G3XPO, $)%X"+N90XW#TJ19C#H+"2L'5JF722R#5M2!>_*6@<F;#&*M
M-9D*T\A'?2N0G4GAOX<#[H,F0G2!SRJ]S%2EV &(P+0K]R?VOK,L82V?QIRB
M,+):0MFP7G\!<D&E3Y,$"/%^HO2;9.!%J(8%<%A1K+16,M#[?:6XD4?]*37K
M+<C<,3$Z'"3H2!QU$E#T?%^[I:><ZZ7JE>06'"P*@:I&$2J872'/**.E1^$C
M;;D-\XC(.]9%11/TB43K,3 (L$F,WGM4,E)0JF+<@BD];B(\H"S@IW=V@5.=
M6%E%#@SIZ\![4*N-A#?L@(8MM/IY_N7#US,0H# -OR>OM#(NRE@$U-+E7RJ4
M-*&\$DC>/<&!,!#,O%BJEN-E06)Q:"I#)-)PF9\. ?9!.08RI DD0<]X]RFF
M-;ES0E_WMH?S.!#NWS3OY.W-.9C%/+@G)D9I#3RXOOV?*QI@'YVU@_V\DW9K
M;0/.YQTQ[32^ SEV88L>!UYWD)FH>#JTG"X8044< ^J'Y47$# A+> 2X:L0L
MR1 F=,U"+%P/^9X-FU2^3;Q:'M]);]@M6,$^;+$(T]@?YY(IIRR%I%<"CCR:
M[5@H^,& $@_)CY%X)G4>8O"VZR62(G*O6,']<@W/G1O?G7:!,4?16$=TL3MZ
M#OTS0S\.&QGN$_GMXOII-3UR)<,3<O%*4M^)X/^  AWM]<>W@15[Z"V+1VIJ
MWN\#8!,2&=[C!(P3P;(H'['("!1SP*4<=D@3\,,8?P;^N0XCC+T/X;$N=]A%
M&H4C@KY+8 3.*,Q.SH,0OABA/O]-2!5#OI=:KHJ!R!5C^#FX!R+OU2;?VX]#
M_?*)$;&)4V+BZ>7#.R>P,F1:]2:)#*:KPU4@+& C8*G2XX-Q<50$<$S"0D_$
MTFDT\[3EPI[P'-$[#E-R\"-]H?W(D9=S5ZAT&^TD[TI/=C%4.L>-S6;ZL=&V
MP 0&H"9?)*AJ*;HI,#7Q0G$VA\E4C"_=),Q'/=6C3O%G@=%5;/<+S?N9YIWP
M<I<\470\7VE25D].>[BGP\-3'NY9KG!TW[[8 :XNATV[;TO>S9E\GYD:D6D\
M9$H&3P[QQ]VD]8(:.7GLIE.;C@/.*@9K Y^FL*I411<Z D/IDIYY/%29\C--
M"=-+P=BUMJ%X(0D(1P0AU!T@A1AQ"H8*;DR:2IN")6]UT!ESMV1 ((\]FV(,
M_TAAJ NI&EUF"M"-CPP-:#J*/)\I-G>?B"$L0I&XU03,)4$$Y25'K9'&A_\Z
MI8&%^>NFW()<O)4&'*2D>A24G,5[L,%:-^^#,(B$HV6T>D/2$<- TD\NBG2F
MF4?.>"?C)",2K((R94=/A)8%:'"V2(1]1ZT$M(.<"'>3)V=!] K#/3NY;U)N
M%S.^M-B&O]48_F!DOA5#S$%QLZ=5W@9RN]N0@F(BKPS0R4OB&<ED!>E,0\R0
MS0#&!8D/G[<->R"?;B(XKI2+B7"X\:9SE'3C'92R&I)]VTME"!:X#BU&DK]*
M%BLQ# _^X,HX=*U>U_(:CZ2/[GZAU=A0.C"GMJ$-J].SE&T%9:UD&W%4[8UH
M/G\?CJ;VP=$; 4/?"X+K3#N9HI\,DDNW5";[Y*JA!ZO+WW2.CEC^D,PAP[QC
MB>$I_";3I"\R913Y6DN&&,R/E&1VH/6HT@2.&BK11:GJ3&>!!.9WU5EG^67Y
M@B<VN.$:?S/<2Z6O38]//01B#0XQ%JB72I$^>Q_GCE.>19(/E$C3S M245"Z
M2YW:Y6A3T,/G?*]4,4<0>YEBKMH&.+".) JY) GTM"DPU6EH*G>E!XI&T6+_
MD(+!+F),B!]VE)<+#N>/+'>B?&M+X6%*@3726BB!@ ;,]0FMLDUM69F>@JF@
M1-!9WHR</L^GHY5FKK]F_4?M?Z,_&#L'-&.FWRC-NO25AB#[R?4IO0%9WKRV
M6A0[$M+ ;,IE5RL="I4\5#HS1?-E&[)PLLL\Y7I!'=5\Y1G*ZK1:OCCE+&$A
MFOQJ6(OS4& 1%\S>:W/E[%P%(\G:1S91:<E$I>.Z352RB4HV42E/CO]BA" 5
M%)^IP&/"/LF+"/\C>'1X$?24W[U1KY_^_'=U0UK_#D/).FT[FE9_1U?W,@69
M: G,+_@2# JGC'HFI5HI36W6_4EI" 8IZ> HB&;[0HV[I&:@N'CS<B#\GKKU
MDZGVZJ:1NVFQ(W<% 66$SNS@_M<W &CX>SSBW>QW"3U@E!-'E@NG5;$],X\2
M6.W[0G)/X]HO^1WKC9876FOA("FSU/N[H^\4V.Q1_2(P%_&?M]E#NJK/$X]1
M-:!9SVRA?/@BRUKN#15M//&.<ZIH@)@')@A^?>.>/*W9K*?0Q1K.]+AJ=9.^
MR%B4%&'S"BBM;*4*ZLQM7>E6KX  MU0D[=6@V/80:N/H<U1Q\-&OTJP:L%QG
M&MLMJ'01I?A(9ZC4T/X(LOH73()0]>%G\V72%Z/GJB]_90M;*P\NM]CVYG9Q
M!1+SQ8!8=<JH[,(J1++N!K?Q5<+L[B_,4N,V$'07[0G#!EBE;5&UTLR3_K"D
M5/?%1B5#L1']=5N&4..5&$)5LX,NE)6#KMNM&SA[;T=8<GXA.>=F>R4(NK*D
MNO><5CV%TUKLU: ,B\&KB=EHS0*S>KN"'?PPMS=>)6B[LE1KU>6JT?;(B^2U
M\(\\J;Z>L5M.@E7&"M?A<'@"/%9Z9JM>_]/8MZ6-K>S"3NV!VX558F$KH\2M
M[=AJS-*].?#*+NQI6]9BHEW81A96W959'MFSA>VD&*R07;AJK\SJDU&K'#P^
MI5V=:C3AL)O!1W9P?O%EKO]N'2WT5HE_F^^%N'!&P2(+.UU;:T*W?K+$7E>D
MN6:I+^RE-R1VFH JN[ U4G;C:,\I>WNDL1(-YI53=GN]?8Z?0==9.MB!^W:;
MK7#7'\MXY:13W86MCS#<=M/"=35I8S]X;HVDW6SO.6D_FX(JY%ZP8>=]=-I5
M=6$V[&P75HV%V;#SGAUX91=FP\YV81596'579GEDSQ:VDR=>(;O0AIU?'G8N
M]GUPV!6&G+_8D/.6 W/3KJCM1S3>O'?;3J-QM'>NL-=$/)5=F TW[V+\PH:;
MJQUN;MAP<Y5)I[H+<ZNKA+BUD],=1>I*JM,OO]Y<%>*IP.UFM17%R\WUTW>-
M.OS3:&S]0O,&ZI-8#\(2'H2*2I&]D,[5-<2;=:?5;KY6(;@7Q%/9A5E#W!KB
ME5O^SAOB36N(5YETJKLP:XA;0]P:XALRQ-W&NWK+&N+6$+>&>)6$8'4-\6/G
MR+5V>)5II[(+LW:XM<,KM_R=M\-;U@ZO,NE4=V'5M<.;;JWY:G40:X=;.WR.
M'=[:NAV^ 8JID!UNKUJO;_W5O:A2U879J]9V8=58F+UJO6<'7MF%V:O6=F$5
M65AU5V9Y9,\6MI,G7B&[L/KQV>I?M;Y6Q;UO(MX9I.S@_).]9FV#RF6)50VG
M7:^_5H_N7A!/91=67:IN'K]FJK8191M1+H\HMVU$N<JD4]V%53>BW*HU=Q6H
M*ZE)VX#RVF]8M]ZYS7>->M/=>D!YLXG=\&,G[(WI#_ S[_A"_EQZ-/\Q\;K_
M\7/^:O1FA>U7NZ]V6FZT7LM(SD(3JG?Z]4W]#<A-WU>[D_T.A-W5OQ=@QJV#
M:6^N;V)YDZM3GHM?\E<FQ\E,&&NU"FLNI8D);PM8_3^KQ9W(&<MW\HF5/KF/
MU"AD-J66K&IM2SF+6=AG'T57##LB8DW788UZPV5A&K%1Y 5=;\1])KZ+;IIX
M#P(>[GM=>+ '1!N$"1N$?H_Q8 Q?2.*$!WCV3/P[]9(QXX\\ZL6UR5==A( M
M:3V7M!J5(:VO8A2)&%1I(+%1XH5!S)*0C=*H.^"Q8/& PY^1^I#6NN%P& :P
MC+#[C=U',*;H,?C@5HP2(DVYV0VB3[<!$)D,@.Z0,J.N!\,!L7:1/-D/='6-
MC8!(:8H:NQMDLZ4!$)0_1B)-X%.Y+O8@X@2FCCBB]Z'O!0*GY@Q6E S\,>OP
MV(.5PN:Q1DM^&K-^% [9/U)XEA8$KW;%Q_AS2\ZHQJ9W88\\!J'5$_CZ<8J?
MP//XWHUZ_8A=2'ZY#-#P0"Z[\7E@^6:C?-/<+;[1B"[WNETMKLG$C>:<:WA*
M?V#9YS6R3VOWV:<UCWTH3WM#[/-)=**41U+8X,O]@P?Z]R/+/:^0>]J[Q3UG
MP!>^W&BWI0R*.;R#'JGGL Z';8$_&-*D49?S--H_,MY/X#,.ZQ&'8\%AM;[7
M[S,O*'P!]$D8.%B0$7$-_=#WPT><N'E4U 4S+FR04#.G44*-+*)R?L2AZ056
MQX^;\0)L<9:7$OLOG?<?O4ATDS!BY^%P)(*8(X']\J[S_I6^G^$L^RN-$Z\_
M-J9E^O\R9^&N0,T2O6,!G-\/(V B+^CCF,1QW1#(,0HT'W:-S6(C[O60@N&!
MA -[*7 (PN!0#$=^.!:"]=0VQZR71C@*LEYMPWLLW[ @E!K30JGK\SB&E7C!
M'3Z?22GE-54>/IXF89DG5;GN3NH_SO)O/L,%6<@WJ8^^SY)].Y%$I':PB6%!
MY2_MAGX8_53N2Z7I?Y)NU.Q#[4"56U7!Y*')0",@T34?B@QX-A3@H)6NTUF]
M2'A#;4(%XAN+[,KV8R!ZOXI!$* @^.>3$+$D(DU(55OA!8\"T:OV&D$=N &A
M5NU%@J0]Y_&@VHL\^.%M<8%;C,TM G8;B-]9/+=XOC#_?!GE]DA5>?R,PGS5
M7B/@$*.H:T6P:#&<62$[-RP662QZ&0_=A0GW*\_FE6'QBJ@;]I[1"G/XFNT*
MWD8J0)+T['V&%7Q*@\078WBY:MY#>NT9OLW*9OBV7:?1;E0VQ]?>>:CRPJI+
MUHT3QVVVYB^_\>KO8VRVJY^EZ2V7&#YUFB?5;;J[+JBV2ND>*J5?O>X TQ^N
MX$_P-H%52_<+ZUIMIU[A.\)6+:WRPJI+UA572U=$UIOM<65I>LMJ:?-IFJ[N
M+>%G7WW?8;5TP2U;2'O=+;7T)HWX [OAB?"M1KI?,-=N.L=MM[(P9S72*B^L
MNF1]?.R<N">5U4A7Y2C=:+<72]-;+IO7=)WV474[DEI/J?64KDXEY1&_9[?\
MNPBXU4GW"^B.ZS9X7W7JJ>S"JDO6>^(EW6B]2$O3VZ7ITY-*!^\WX"6U!>A>
M:<&)"A6@&X8I5IN(1-\7W82NE_/[^TC<\T2H B8]_+'/O8@]<#^EHA&"=P>J
M\(19ZT3TL, #%9R __)N%VB#!UTART+@V&?P&4R(=]!OL5X=WEUAYV'/Z\,;
MTT!WX<CKLF/WI,8^A5'A&CRN*J(2=SR.TZ$JD#%1I +7*!_'=9JE\)"S!;L.
MX6U<5Q=A.8<AD.\X+OZ3%\!R/>[CXA(QI$(<7M#UTYY\M63@X5Z-PBBADA(Q
M[);:P5Y(%?G@E2,1C\*@I\M*\&Z2PHAR[Y(!3P SQJPC8)RN\!Y@X,Z8'LQO
MZ7M]^L#<X)CQ2&3E.WJV0LR>EO6[*S!HD%*)$Z#TO#1,H2R,P1Q%:C(+1O(9
M52@'PB?BO(IJ1CX[%5 Y=9KUNB7"/:V1MPTB_ A$J'/7+ GN?9VY;>$@1:J)
M_AHMI]TXM@2XIZ7:MD6 TB_]0@3<C('8\QYT/:>;WS[\<X*,&=%QB0%=+/4$
M'VD"+HSWZ>[KW#O'QB0ZG&(.,.@?1N%C'F@I_@GYC]W\=OW'U=/WFF>6F)JD
ML#?OY5P,K!L][3N8-SNW[&?SQT$6=;HY^^WB\,/7B[-_'IY]NKOX^A/C_B,?
MQ]J7@)&/0!3>_&<@';F-#716J$I.?ZO3_^![O/OM/@+[I7=8_-,;]JYLSW__
M6+[G>'BKV/&[+^>?O>!;-D?/BT<^AZWT BP,>-CQ@7.*_BB:.AN4_<+9 &S9
M7]_\#9CL38'*']5.>(&7>!@?DJ<G"U@5/\Q"21//OKR8&. &83^P.5B>"1J8
MO[SC[Q<E!^.G\BC:% \OZ( KJ8Z%.[M8H;QY[[]DM,Z\4.Z]OPZ#PPM=Q&Y&
MK4"/[IM7IRKB&C;C2QH!B^/E#2";W$O 1Z,H1/\!+Z_V-U$G$!3G[AAK:U+5
M=+<M90NZ,;Q8_Q4']'J":A!.E-LT!_MI1S<:9?K3-,=NGMXL'@^VNF/5UC ;
MQVO3,%>RDXUVM_]S513-"_2UEC,X,"Y6J4U\0=Y&Y5#$.K\\"-#I2'08"2P,
M"OID7ZAJV=0$TV'B>U>,$NF31/H]'W /YB?/*?[^@3#GF9.TJ2?AU"Z^?O/(
M$N]JB#?V$HH#A(&,#*0]+T&<'<+G\-PSR>YX,=)>T6PN7:JS1&Z)?#$B+Z@1
M+Z8^(KZG:7VUD[IU2_*6Y!<G^=^P='] 4> 7TQY>&%F X%<YY3%.^3,\T[,4
MO]<4?QU2DXRA$$3=0!\Q^GI]'T/Y6(2_PH[83=G/9[ ;L[A))6H0@RYN8S]Z
M^0:S?Z<\2M"+3MDE421X%&^ZBT$U71'<C\/<'W$O8,^!,L<EG@F5$5-P#>4'
M@V/S8(R\5W=/?P;(_.[%B>H8,:,YBL-@$NI!"2-$>@(O>V8$SYB#4_H+[X6
MX)[\0S]-TDA8%XG%YDVY2!R6CH#PE7N?"<Q] TYP5,.B!-:3_U$2M,R% Y4
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M6)MA9#X[[*^T=T^( #@+1^4G'GZ*4B&F)<4B ;%&Y* O)<B[![ZD4K"7XS"
M=9!UED:2>\AT0U4-<!?D"XU-RU )!+X@CE-*6@RRP,&T'6^(2R;0ON?R;UZ
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M9R4#>TI<$C $J!UCHBY:K;[DP)@/A93-/)[/Y<68!;*:O%2&4$, $./C:""
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MP)Q"NKMC+I7F.%=8T'7,NGSD)=P_C#CZD.Y9 CL22V=QC9T11<"K'#DP"PN
M+6C'Z&/UXEC5)O>6YV;N2RAF!_!NAJOJ17Q$GNTATH%TB0YX *+(@^,(4) K
MG_!2VL3,N2:TB5G/9=J$8\31C OQJK@4.GF[%)HQN*1XO_X % :2^ _2BPE<
MEP;RY[<&63VU/>1*5JYK6A('GL;R4UWR^@&38!Z##CMBRO'4"F=G[D@XHAT'
M!:,K:(*I) !*0* H#>^A?HC+X3&^DL0QN8;8RV,;,TH.P._&;M&"YV05@<*&
M%D<6_;\2T3VL*_<K5>>*[29T[KM"UJ3,#<I"-691,CI2G=RABHH5+]ZBF:9(
M4'K_RW(PB?IR$W!&)8A-(]O2.5'*NP0Z,/E9RMU*RSGJF'DZK#[Z/BMW:D:F
MD:[._611[:F))]?Y1/K5:@;KAKBAP:]O&D^7GEAXLFD'["ISKXSUJ>5-N9LZ
M[Z\USBW0PWY=:\BU%UI )T*?*WRN8I< _J*WQ>5A3NH6I]?%!;=[1H;XW^8J
ME/:^Q26 ?DS*\A:70!8+A<F*BU@G_EDP7>!@_D6QE*V"%0<QR^]%!?!JBTN0
M:KS%2XN7%B^KC)<55#ZWLPB9A+]=K. /W//)L 0K>HOKD-<.M[@ 3\5XMVER
MD%M".B2VN(QNH:3;]L1Y'E'?ROP',L]TN^Q9$9RB?@3D:-TJ7?KI,&#\[4;D
M^7+=YE[NS]+I8ZWZO,9L3P]3V-ZEVJ_1/I/W'3.:[\-HO!FE:5?UG(,-4:H]
MD85/I&-/I&(GTGU+K10J!^@EN<'8#*I1QVROY@G\J]U^NY(PQG:@_J(D["6#
M8UDEV\Y89QB,F<I6>:)9TJQ&7R_EH36/>[I 6[5G,9-[VG!.3I]H/[W\6Y5-
M15UQ7L>AE"W_ARV=T$FMM6S7NF?-LTWR?GULXS3:QT[SJ1Z9*V*<0N_TU0B)
M=IODPPX+";K*-D=0K+A5\\I(?PUSG+YHCI+;6-,\)8NZU-W66E]W9;AE#](>
MI#W(31VDM6MRD57<L%-:QUV8<-]:+96T6EZ76FP-EZJ?T+8Y9Y.&RPXV(U_"
MXV@4>C3W!F\(Z ]D.0/Z9/$"C[/+-M;:<P(S:[AQNUQC<B7>==/(FKO9Q=X9
MA8WB0?@8Y VZPT==8,6\L+30+1!]H7+VA=5YQ0FK?\)+=;+>\@E?ZB(Y1VVG
M=>SFM?3<QK'3:AS+#V;<?J'D"L0$JO1KY#:77#"*IVZ_/$$A\ZIAJ[L@\($_
M=N9?Y'BM1+14)^JM$Q'CW2[(!:JFD%UMU'?3!*P6KSAE5]$D4>5%F=0M[WDG
MCD0!@@8IB?O,=5JMIM-LG!;(\U%$8N(R&5:L8X5D**8S@O1=+UG<J<?'\B)E
MH^&H*T21&,&H6+X$I/6/^B+8=$%9D]2#:3+\&;\69S?(\#*F*G76TR6; 4]A
MN=W4)U_<ZZ;;I=I7;YUN%?C5#=S3RMY<Y)M!4@N+O[6"FVU)7-&6Q,U%:R#M
M1WTLVY)X07*H9DOB%50;N=7QI2^/@9"E8'"+5!G"#R(0?8_*O,B_$W1>\8#?
MTW7IG:U(4G8Q.A8)U:_%R^W&U>A(W/,HJ]?:R7<L-'?4J/7HH))RQ2-0<*0H
M 7VG,WXMC6&J[$HXJAW]^)2K:N:7F[7F'-UG:^TCY.+T#JT'!Z@BA:S^Q+X%
MZ&10U9=U=5*Z.DQ%7K#4)V4LJX_*:![I?8BU0I,!*%OM'Z=[/TQU8#*+-#R[
M#YUE',LX6V"<630]W0N!I&=6V*C"!L1FA.R',EGIQ69-=NG44&7SJ1YZZ@O5
M;T+M^^W%N?87Y"WA=*$]*@?--;8-P)2;):!YGFKC]4%[!\5M0%7PO82-PC@6
M^ ^+L:,-MO]$..MAK7'51$!V"9"U[L-'D36'PE+\:ERSM+OVR"%!Z"N=:K&
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MEWQ/1:QAB_@]N^7?1<"533K@'DPRJ62C<87WBR,93>6R<4N<C]:3-NJ?9^R
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MT6SWI'K=6CG2MRW25^0L,O4::SY1)6G$W6XQ>< $ZA7"9ZLB\'E[V'JYRGU
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M<00%.G^15DEQE_4<[[)DB,=J'#S&S-HI\Q;+O,5#R%L\*@=R3*PPT"(L9/Y
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MUTMLKU=3Y>?*IY!9IDN!7Z[ 8";?%/5+^#];IL8X>*U)U_=J)>@Q<%%74NV
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M.XS< JGG78!@:5J>Z[?UI"HC)VS]ADIO#, 17N[#_:J[4%'X[0P*"]B Z%:
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M2J+G>YO=T%N)OTGB]N .:9T?CU?WS*:DYH5)H7&K7HM3W^.A_3\ZXJ\.V$]
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M/LQTB44K8)8:+_;/R'<"VZ&%#P""6F,E")!&?ZO<5PPQ!)-@$M#@Q%GDS[P
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M[SX(/(Q.<BI[=DA1NXAF9HH'+"(5%7P-TH@EHL$Q6CF<MX@F/[R4C7+18KS
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M&0ME3U"<2OVGVB>I2&MUN ?03AQ8R%X<1/&(AR])"OI+D7-)??<GV=84F/S
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M3B*&;'BR54'ZPG5QKOV@VI[>@J7,5/C"/^=GEO7-+R_<@;L:3CS4%&Y'B 9
M_L3XOC.:\7'I!6% KHQ/:!S=67/J7:ROV&EI*W9V%&@:Y+G%:S7)?08?51>'
M@.W@X_W#[>6_C-N[A^O;&^/N:__&Z-]\-NC3BT_]^ZO/QN7MM[NKF_L^/H'+
MG (CVUY\KBKB1)R4#9">.#88),@=:$O''JS+9_W?V9/S9"7#  >>Y9.A:#O
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M(G_F!0P[SC#7]R83;%,S@QNEM]!N$ Q>%"QL)J@8#_!]94O8QB:(!JCKA_#
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M>?B>U_58]/4WOES4JV*<12RF^$_P(S!C3$;XVS]^&H?3R<>__3]02P,$%
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M-UY8@!0,NG0>F!R0 0Y_<64%7?G_!$_"ME,M_^M"!%%*(@;M!?M$.?2IUKU
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M@^+V!E7)<BLIGCN34UP )<>0P?/#\GD#KDQ"-EX$.>5MKC; '*0U< &P>%X
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M1.<\I];H5]/2@*D+Z@Y[>:Y3S/H,_B61\>1J75E>)+ @*3)3?J3D,;FN>_(
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ME(:N8/[-!NB_>]X(O/CV/U!+ P04    " !NBF]4:$-D.9$A  !Y(P  &@
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M@^-J/5(R_2_W,2_%6,'=7%SU],@1MAZ5U )U_:I^9\D^&;$.$)9-]J;AP$>
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MX"L4K[[HAHGKY+^F)N[;Q"*3234-<$(1/T\(-K[B_.+A#1G_M!<D0Q/[L[*
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M#,3PK'4<RB(.B_5$(R?/QJGZ)Q11E)-4WYS[776?KDO68#EA&$LFJB=Y)22
M9@>R1)T&3:*L@[%_;#S%?M-NK>WQUFT6J5\2$ "-_\ETNKE+>+AY<YSW7R"M
MY5?5R.^UI#^N$M0O\'@=KOC+\*$N+B_=!/6WJU78.]O8.C#WZ+0LO$K:-5/O
M-)AEY?#!CI,AZ1AUVPSHG]Q'_)D>"6#SF-M\!+*:I8\2'P',K<F^!IU=4HC0
MC-[D,%["$ ;%ZN^^3B-Z#JD]_/2U^?IS23/XF_&*>C69/>S?B01<,]H8VN@7
MR/@R).IMLR*M"9(=ND^W*#0VS;=6KB]&.Y?!3\MMVZ#F]J7+^B;0181D1:VQ
M5[RBT!!%.L%7IDQE  ]CE%@5]U.J>M?.?@,\QPF)Q!ROM^,&VW[3K4\?O\\&
M7'0GL7QVQ?+G]/N*NKU/U%Y$L]!9*]OWE=<2\JMDOL)FW(X57)L-.G=S=+IO
M"=9QAN-%MAK4+=1/<)4;VZ;H/!T?@;'$S\X1#7+EI8/?A607=OEFT22?QM[_
MFD=:Z[0'__6G44?OGJTAJJR[8L?E#2(_KF\C^5TI^ 6$3;:3L5@B6,%J:!7A
M66\_S'\G=;T(E9LL#3-Z"?M!4.1!%7?5L!DH!%E:HY5$;+'D5KT\F<_X9RTU
M_Y'NNZ3(VZF>0Q@/,>^2JQYHK6>;%61Q3CK3.8RXQ/4ZO5GT"Q^$9C$8W->/
M)I,("W\; )\) (+MHT,-![?W<[H[-SH=H\+W?P8> =^J:SUNTAYC!EN!:7UN
M-W\9VM8WBX3<7X1]%^[7:+D.17<,;X4_[=<CAE7G?ZFJAW:QN!NQQ_,G2O8C
M6T]1 ./_)9U0G\B&O<8^?R.V\_O2\*I5-4Z21T"]IHF@;3YT#]N>XA 13^KF
MS;6IE:5CT-]/LJ18NE>PJ_[\Z]#E)X@ 9UV):?=F'T_^FNA._U.%^OUGA1;6
M$482-[O*4A$;X6?ZZ)0[KDQQ<!Z9,N<T15E&Q@7KABO1RAL-]_?@/$>=(J9O
M22D_U$:LZR+I.2P[UX("M8*8@A*SGW7 -LHE/ KLQ!(S\O%-'%I>S_$KA.K9
MW'>2B_YT")'D/3)6_Y=MW'5>(S2@5D)>*!<^*L!V5E^'RB.1)_XQ@?/^#<_:
MF)ZFHJ*DK4TVKGC6BF7CK6G]--=?>JB,Z\;^MXS5*0TUZ8[:4)$#V/ZY)/<=
MJ7SMI.]5TYV G+3@PYE9W5/+TB#8#NFA4-,_:C3ZYC")^!Q\%ZC<>2XXNI.%
M\ZZN"F]N%P(7@4TS8F9J'S$SG 8NPVTU,4Q2B!?'97!$V9R=73H9"[SN'P$<
MJ-;XX?X%IYEUID'E<YB]Y6FP0/<F=K-XN(^WBTG8$X3WFZ *@1BB  ?H\K(H
M3YL#]B0IQ(I-S>WA2,/$[@HFH-;NW8<%A9[7G1Z:9T3(;SJR=G[Y0+:.N?0T
MI]B/@M3<BNV\(RE"(1YP9PG\42>;TO&/EER_W)+-2(&3R,R+R6UOGQTQSHJ0
M-N[+]Z=3W;1)K4HRI"Q4YNVV>BRKMA<^?FYR$1K34D-.7LZFJ=*U>5N8P[$:
M=.EF@71IG03+N[<5(P4E;3-7O\(@ J<;85HA#&4A7<'\D:Y>@HK]*ZFS:<IY
MTX<TBQ3\KC6L5FE#7W^%>!ROQ$C59Q5>WT&$&H1FYNV6DO6UBIK;9C<V;>6L
MT67!0^NW[H(!2M<QSZLK;1MXMFMN]'CZX 1E_%X<*Y_6N2:R"_GT:1314 .%
M[W56[K[C,7_1?%/0)G3V>2-<6:(GO8J-S,("/")&@.H-01GM5FSNF#I,TS>%
M#W96._+=9>B7I]]O"SE@]1%_*J5(CA <DK13.7!Q(])K+)VI4=DH2D16]@YC
M$>50*F&L_Y!)-FTU)8CSEBENB2B)W!0W,E<-4VI)$D,Z S ZGHEX!- OPYYE
M;*6$6GX56LSQX'4H_=Z5)P+^1ASE]KN$2Q!QH'>05,;<@PO$[*MJ3<.REK$?
MKBB=^2>?M[*Q@D<.'DB@W5+)+)?AE[6(YJB6PQLKON+(1V"(!X,]*"L9=O !
M*OQ]XI"3T>;+8&N 'WHB^BC]E^,?T;QZV]FX8C$KKGFV3=/K""M$4RB8_.QE
MJ)SLGUG169G1H5XG3_/.AB7B]N])$Z>'-I5)S/J'3-P;H<C.&I7V1;F!H@%X
MGEQPD^D#07XO+X</CL=9BZIR?'UW/QCA3&<&I+2X7 4?=?'M\1$=!1SJ8K)6
M)82Y),P&KT^'6['G!L#$R^,RQ!7TGN^RPR'R#(JE?0+S^4'1:&\/YIM4_(D-
M<XT4K$L6O CJ6/:O0D8C,%HW+)D<::64<HBWOVBBX>=?@^]8M&K3[<X6H B^
MEV:)(.N,MSP?.>&4&HL71\;M_Y@6_B?25+-'Z:E6X5 ^ A]^_FIM;AH9(Q_\
MM(&B7,?)1M"A&];BP#I4#W1J]P8P#,>4%/:N_&' :K7_6H>PR%ST;;+0_V%A
MXHEV(IU!I(FLY>GQ"K9YZ!'ZTK' 2U\5A&Z@^\8IVS1/4"HC'VK+[<6!,F2L
MRN0\V[6B2ZP'#L/,?GH!J.#_\D*TQ[E_ U!+ P04    " !NBF]4$#%MW0H;
M  !V'0  &@   ')V<&@R,#(Q,3(S,5\Q,&MI;6<P,#0N:G!GI7@).)3MW_8]
M]C61?1M+91DJHA!&-(0TINQCJ>SK1,@20X52E@A%V?<QY+&,I1!9LF2G+ G9
MPXS=&#/?J/_S?,?_?=_O^+[O?:\YKKGNX]Y_U^_\G>=YW92OE!_ <0-=?5T
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M[7H+!=CGU3N\CUZP,?))!XY>J:.)<7=]Z"!Z69$"3(+?AIB!CXI*CY/D&I2
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MBE6M:CSI">?AC*(6T3R-I+H74[R7V,JGYK?<RGVCZV0A[IA.!'!; J3E*)P
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MS]O#-/% =)@.'B@\5A4K'1(-.N$2F&,1BW$>VOL%QO,\CF%7CFKFH*LO[J]
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M9VG20> %V2CK7KD2OT+RRD#=7T/(&M:@P!4,R7_8MF][$^ML>)'"V9D99=N
M!VKJ9RPR_K*A<,W[[+<^MC-O9OF7/#1QQPAM$L=^*DZZ$YWD8W@=VO[08NC?
M#>P,7SFI#DAF&NIG=C-TN01 "Q15T5?;,L[CRK+!BWPMMP)JYX9>1$2"XO<O
M<: JKM+Z]F/=I,"VP/:>J6^(-^.0BRMO)+- )LW7UPZ$7XP"N/XF0.:O ^0<
MU>+XF7GH9+?F7]==1XR#:/^.G*Y6FBHJ)Z_(N$FY)=OW4LD=_^X/^)3-1P7?
M8F\[#6O2?:RL?31T/3764K0IKF%V1K+:9*PNQCE_C*]L\C4=GWILAD=^8?8%
M)<['-TC%::/22W3X#2I:.BTEG[[F-<]O"&(U>"U*ZK$!:9/,R+Y?/FGVZ,=2
MW%9M2VW1F_9.!2.^H&=3V!]I[4=Z]0^]6"[/CM4MDG,]+JCLN#=;V?O9-VA\
M/W='A]K,<7)LCETX]YNZ]WG=$M<I0#?X"TW=VSY".<'\WGR3ZQ=9#8](*-V!
MA]..QCE6^>PQ(X^DN:O8.@=*\ZAY=?;TNH4_K2>J\XIL70*H/LQ. <17T+[J
MLJ\2'0=_=&.LXLH9SD>KBG<NR,ND4LM>2$G*-74Z\I(->=;D;((*T -4OZ\\
M@N2] G3U,P8+^ 874#:O)6?IWA:K!6_ET3,NG%ZX@WFW"C#J7J?GDJ9Z>V0?
M!%6Q3_959\O>,QG\T0I*)X4L[VU9AS7P^SEIFY=#W*D_OU^Y3*_F)'ZOX][C
M/\2??2"=PS@26D2TXX''2<JX7O.K:/M//Z[C3,<#TWQ8<(MW9Q2&K,T=-"NJ
M'@V[* ]?>=*Z: -_)1',VOEL-@*H-RBROSS,PI!#G/[D#6'?"_*<4JR9]E#T
MI'9=>;7Q5YM2^KP0A3#28,.L)_RAUVQ9U1GS:&^H4@/WQA"116GEC\RM*>W-
M"N3=IIU]Z4*(7XE]B XZ/?Y19B%%\*KVYEI\[H3)5R7J]KCU+D?]G,/H?B3"
MLNKR>_Y!_0\'M,J:.B6O[>\QT=G"1U,DK\92C!XJRDW=S*\YD[UTM!J:Z5IM
MV-0\JL3*RJ7IP/=DX3F,09%1LI=E<C'Q>1%CW MUZK)\<3,7(?,Q=2*;>X19
M,WV>$9,;N"S)0(%;K"]-F,9D-/[H7_66OF!02>0_9-9+MI3X/,T7[B7"^W*>
MBRK"WJI:B>KCF?#;'^GZAI\G9(XM,2/L2I5S*Y.?BMK;V[QL!JN'6L#R]]7P
M3RU+(:"<L)!:(0+8ZJ5QK$JNB!!V2&R:EXY3%5IG!:BS:[6<I] K>(!C13:Y
M'RV?7)<NXM)G9JT^V4Y&]@)9V4$$Z3CCC'),I:48V,$#S*/?#K1/>ZUJC[K<
M+E>G>!M"\;+Q$Z:1A9656%VF1_5"=W=8^-Q&C6@;;?CM6JD([S"OESJ75A&)
M?$9Z'=6N/J=$*PJI_>T8(=_W$Z7";]YX9!ML^7'0M*GSBO^7_G3="^USGZ=$
M&RC@1"EU655G*%#-A*WO.]QI"BL$O>^Y+20D_?!0])PC:_596/-B/2U3I),>
MQ.8'S80/QV=:MDT+\/G+Q$DFN=LK ZPKB3M.UWT+_;YX&VIHC;6I4%W/:547
MG##>BKSY::P4><IA2.M-\=*3=V/5S7$S_A":_@OJ(T[EA (SK#D!\E-WOF^T
M=.,JSO38EL3UW\TO(-#.0;$(C<KX3-$US)3Y89GZ/%.$L<D%;R_[^CV/RG4R
MO:OC3UQ6$Q?N2E E$#FKTL 1RO[A!5FW^+5^.=U4YSBG82DI&NL2-8(AOL=-
MT2[1UPLZJUXHY_#P[G<?!V,!0>N%_NKB;UD5U[-W13.8-E9^]=W7SCDE8F41
MDI894H[9W:(__L/_3_Y/&W[TOP!02P,$%     @ ;HIO5&\]P='W60  (W0
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M+G\8?PF=(8>AO\"48]FL4(UQ5\4W;-F?L[ 1Q:>13%]?()M]X"V>I:=K9>/
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M^A@3H!X8;3[T*<7[Q11GMU[<6=MUT=ZL=V4]3!E#.ZUH7"<)G6>9"'7),PD
M^L<W D,-PQ:N&#'C.OWQ5;!=SXT-:%-<]J@"QBI.J8]-_<NHB#Q%5E><XRDT
M6SA2W=-_1#O@T=*G5E,7T5S%!/D[PVZ49G,)@M\CM(T5.6HAO:S?51D[J]S.
M2+0R9'%P> I%OI%[:*-T5%_JCET! -,)O0!]EY_0=%0#QQVO@6/LW97Z16?<
MSC^0GXD>#J[/Q:IAT1'8W>A]G5(3C,:VE">XP3@SV<1$7_Q'R4B#HT3T5H1G
M-<=L4=?G&]//I$]\NE2%B% >7B^ EJ800*[(&(!I/4D?UIT,R@KA;NU%&(62
M))U_LVFV?=J#%Q.A/):S%_MF7%_)3F(U7-9_29I\^]R$_]+E$VR=E[[M*<)5
MHAA5;DQ;C5T/K"W::9+0$L#(B42L++BF$K]O225/:QN^?I:J]/H($>1ZITJJ
M45>\2_NFZDH&V3MYF6[P>HM,-?GRU]TFURSB* +H)><W=.->Q6IR?$@[0^S&
MU6]G&$(O\\-=7YV+3)P6Y8,_%Z$@XR.AGU%B:YXSE-R_)3:6]?[UT(OR(=ZL
ME.<W0A!$"SIOFMD+[TGECQEP=>2EIVV=(G&1S!F+F%05N-W'C\@;F"S@?P"1
MVJ/A[R-YDUN62!GE:/#VMVH>=:#SQOA_A%./46=QA'+K1B8N3,=D50$XE^]J
M*0;Q?9AYG?T0V@3;%!WSH3^R =I@H4"\VE9AN?%^O+WY&Y 7N$M4KC+< "94
MP786 8V;$EMN\SL_>I2-1O;ZC;[K6V.#M=@,XVMWD=@KUD6_MFPIN9M<M3'W
M[&O@ZVJXUZP"AYX*N-RYTUA8+723RPJYLPC>S"^$GQ9.+@^81NR?,H"A(#AT
M3$'NL>+ZG<E$PU8AM-&B'<BR\DP@R_1@[W*T7(%[-NP%;B</V:'%LVE+ #$I
MY-_&V'[/GS+99Q(!0.@ J/-D&5M01K_O^/(<?^*Z([3!,M>;'^CDQ?%#-[Q?
M122@)H$*'95  "W8&=M.(AGE)J&GE5SY<D=.(;P_9M4Z;EI*'?+(;MAWV/!Y
M'$8Z1Y.'."34I,UG5GN4)8AR:]^[O)BI3^NGFE2HUP7\%A=T9Y$;'Q@3/PEF
MDIMJ-W@]510U*'ON%H>_)40Z5Q6X_<=!^"K@6=Y6GGYK:!3?RW*%-\7V4 :E
M67P@/<-[X;$0-I4Z-#/GT[+"A4\IU7"U#;ZP\)R#$%DA ^,S(#@?)V,E[T9O
M\I(TV7T]B8 \YHKBZN*.1XJ/BQ*%D@@@*9/\\PE].LPYF H!4N-!ZZ$&A"/5
M3"YC\5>PT%;$6%+B8^>Q2IFJ8-"Q>?BN_FU;::<>20-,QYNTUFOJCEOG6[I*
MO+0#G).NLT:N-W1FW#.-YPI+X[WV.N%:O6>0U!5(Z/>3(]K:)6LU;%9F3\R<
MY(F:)S51">Z7^ S=/[VOUE":82K ON3SO?0@<EPP)>/>:$@M!#17+?3S>KR_
M3)0A?N6@'.@_.) <A[L[T8R[G/<;W^1%#A07J^U3&,-0;D#DAVF;[BI]]4FI
M@J'-?N9*)@*#,"S:(#VL8GWYFD'S<\KSZZ!^0#X--!^999T8.%[^@R:^QF2_
M;W8]-*,OLH9'54XW@8;9MIM+/2/U<AA(2YT,]%12IZ11*#_46?7<:0CEMV:0
MXT"-N]I."'X=D<('G6ZCP<XAVQ""+\W:V_+N,:F.S7%&^C@X9%=_*!X19W7M
M%M*3NI=76,;B[D3#_0&]K.NBOX"FDZ19$: P^,HE>/>"0N#]@1O,,0[>9X0D
M0_UK19V5:VS1YWIRTOL4VLK#[CU3E(C(=%PB%YWC",#^\]-X=V$MK./X"N1V
M%H\C 73.%H9=(H!Z/A[9QMJ>[V"3=_*G8/M,V^/8_;C]TS.V!1M07(BGPZ%W
M.R[ 273E(>QY.+O:!@O:A.*(T\H P@42\[MVA<#^>^A*,P%D60"NK8'T>HM/
MBK_7B)E6<M"C?V*^^>S*,@\*=S6""N9PB%C1W(>:;V[MNAT,;RT:W[N0.*NM
MRI]ISO,FE.[)-L^,<L;K:14#[;($:9G=&UR!%RUTI]X[/7WJ&'CUJ>#>NW G
MTB<+QA=ZJQ1L^;Z]YVUEU_!XHB]4-<&);TKNXWM4@YHL>4?/'DN?75L+EC+T
M'T0)JTH*N_3JR,\R1J89MW&J\N]O^3Q)Y2. I%/QS)PU^/U\S]NG_\YP3P;$
M@V%_N,*\RM"&B.P/)I-?.G)O*Q% )L#S,NZ!\73E4W$?^C0?>BGA<H<1N"N>
MG-(T4P(:$D/K"%Q0\D\R>S2 "H#-2-,<Y.-ROTK7%_9+$4"7A$G[8N<[M"XR
MWI.=QKS(S2%7IV ZYZ3FF9M% &5%X"NYMW+?$L7GZK8[11KI,QH<:(]37)L,
MVCB_:]I<2I;%*/,^ZW;VCXL=DF_IM*8= \."2'4]_8&(G2K0IMK'UR%]M-Q\
M@B=C'!@X(=(D'WW#5OR'GHMGI9%<(SDCRT*B\?U_KV><!V>%M?2[XF=@V!,#
MA8MZ,@# 1N:@#X&<VB9-CR6 &+%LC_#$\$Q,%UZ^LBL%MG A7FT#C@MS@]\!
M DC.T[6&ZZE/],D*^)%X,H9BMTL)H&X5P^+?B*=JQ+YEL1: 7+<PY(RH'0'T
M\,#DD*%HZ%BS.)!^6B+7FUO<1 W#C;\3QHROAN"UMDA]H!/P?3H1$^QVQ+[V
M8%< R_>1NE^+):U?6>?(MO48A$]],3_&+!6 $..W!A3@@,D<3XP'4-N$0 :2
M<:(+VAL"N!!6V*%/ZQ$M'V7.\?:/KS B]NOP*2$\H* OL$-W@8X.R9?K+Q4+
M[)\!J/P3'-\CVM:]"\]^B>6,F #3WIY$4)J,J1)W(-PC26\1D21#>XJ'IP)>
M]YM5XK^5#7X2>>S TFH.[2GS G[ 'KG,#<8'>[8BP/1_)')JWX[#ZQZ!0,M^
MD4I&/=/R<"8#^+LSM>&^&C>FR@8PC07%?6XGZU6W(/)R^UP+C4IXZ*Z<Y0BL
M5:8/MGR>#.^WTZ0CS_GV(D61G%ZKRNUQ;Z)I"B0;&Z98A??<&U(>R&U_N%$#
MZB/HQ 0UF?+&N!\8O0/;T\2B"G7XW+,ZT^Q42]D*K5*"6S[]=6ZPP&#JY ?'
M;(R&KIW=?-+DI6#=GHO:[;PGQ$^>8YR.3%BRC=]8%ON"N;4I.0K51)9>=!NV
M3MOOZBHDXZSI(ZK%B9SIFFK<M!,@&[2[J&1_]\IGI;0W(N_3Y,^'NY\6#F7=
MY=D4"-@L[GIM/U54;54T3*&E]1G?G8".F__0P!/31'ZJ;P=AE-' <%_N?,Q_
M8[H0SZ#-86OP (C$XC^89T 1K3^4B0M 0-&5@$"0S[UVP#4ATVT,W2D\2I@/
MSKY V$9F F<@XO"N/0I_E#<%#@U ^(@LP7<V":!OH:68B"/YE<H''1 XJ*MY
M]84 BK@,10.*@V=_]"_[BB#+3YT)H*NH?>UX^ \(69^_/' 7HO!#)_WD+/^T
MI<*EC8AMZYN!&$^:B6C.CXE@LV6>W5"%75$XY%!C;S?768ZC08 RB_,&0^Z5
M!5FTL=*(DMRC!2=5FRVK/:XO0Q.U$-IX4ZC+H<(H5'GHIV-.#?FE\''% ] 5
M$2*PQ[8?/,,[4@<CY>3GQ>3U@C=/ @E:@#CD.9WX-T;A;6V ,28=S3WRNL/Q
M<M7B^!IS_*UR5G05H!4OC+T',%0((&G#,"]=\ 0DB!XG;P)4C;>*@>!/A /Z
M$)!ZP .+/(W"USG!%M(+M)/M#_7"5+MT,*:Y@U9C3-7P^^6Z%[Q6@CM.M6ZB
M>BJN2%E/]DY1>$7FR)L:Z)E9#(X(NK=P2$?,&AL &<JUJ79  5LYK\<X<U1M
M:=+@1+RZ*PLW&$P<OJ]J>+4S[9\UOVV9]T1QH7[SNBA'5:Q^"3)CO X15U+&
MG]? $,EY\7R@8XQDT+PA 50'W3^Y!-L9A6VS#O5U>'*'+.]<# VQ#;'&#]X&
M%7I_CP#@;CJY?$%X<.!2L]ZOU=-S61;&B"GX/C-_C?]^<$_$!F3)4@?S9(OG
M>P\,!11T1?"V+^A?Z647#=20QD$1MS$A?>'Y>HH;?#.%A4IT/1;:9&^>L>9J
M\R'[3&"H1$#E$"%.@^FDL[VOSK 9]R>"AF):03,6R@M5C'DV.L97OP1.8:=T
M!V7NCY_#990-+4J1 B(T)J(; &1Z$UGC1*TKDBY2;4YQ$GT[HX_$HEH8DMR5
M*W#?:WH\3A1X*#_<--E[I6/K,/]T;R<'"\>YP_< "+S%Z%3CLG-76G"F9VU8
MOHS_^R<AO;OC#1^FN?N]/ NDJ>RU.+1K1=F87K;.M*5)"1-%,_C'F&Y+5P+R
M)<-:XG5-L**E"?_NCZK*=X=L+)0U.?5O8-0?GQ.E_H>:_J^A)@[1.-PK<9-=
M^@B@ZI-^/%!\K(F*>(7GE;X+7>].!<*9Z^ ^</)+,)8"Q6+TH1D7O:* KSL#
M6Q P-'>=A ::FTQ).TP$X;QM"*#5YD/;P=QF7W)8<Q,"OPP;J ZI=GH$>]6Y
MZ'VB6X[QQ<>_KIO0$9Y&KCA@Y(,7T.Z]Q0VW[EO<C&L;$5_A3F[V7,SZ2$WV
M-?_9UG+_-L5VWX4M;;Y[NR1;E&SX.]9D7-/@&+>^/R8C_SLK1OY/4$#&AL_*
MB._5/CK)[.[;!8R/S]%$VC 00+K(M=-2P%A#?-/Q6.!2%,9AYAZ00/SDVU*4
MS8G\T:_WOY\R",8:J(YA19.I@L06 R%2*XQ;9] F:M;033+@=@I.'8WTYD8V
M5Y[KP^%*P3&4>F7ORLY]+LTEL? N\G ! 4]+&O!5WW5VY[[38U\J@K'?V++8
M7#2RS*$F:'5K\"9%R-(XEC;G6G9W<<ESXET.Y5L;\/U91S\]'_\79; BMH.Z
M,NHMIW]']OB6U(M7FH'O,@$Q?>LSK_&Q5DL#C/;HDE;;)D$)8_"/"ZPQ8^E/
MS[T<O7#R7-*S@<:N!@$*E?RASL-,E@ [R[#6T#<4(KIDZ"*\UER<R>8]!&SY
M(C/^N6U(OM7D]/4MP0<Y4\L1/AAK5T>1A Z^_/KLP48NF-GF@RP_X4K:%:G0
MAVY0_24I+: [LZCO,$%CCW7)0_E2/ [:BOZ..]J]<K1;_6.RD9S;[;>)V>(S
M'C%6UE#T*A0]I#:KMY.<!@334=%E#8WQW"& 7A[27 K:8,[FT 4>YWT?@$
MJ;!P,K<_!+;#/+XS#P7NK3YS S(45_?M1(4 L43S%%KAV>F<S\*"4D2?4)+Z
M-6 @GD.1._- MJ8DU(0?+5_QN/8LRK)@2>9\=U)'SM*SEVO&)*D'=0C9 FL=
MS;QK-DP]RN.N3#>5$._6I<EFC02>@X#[F%>9QNN##TE0D5*L]^WG'SC:M?)R
MKN4;R#IG*):>41#R(Z<[9YH8H9^;J]=NLV%3X0*K*5:-NNG_.ID]AOB@/@?[
M.'P.L03?I([#$^,:#0N(R_QZEMC0B@7Y,W2W>8+D.6JST:#"[ZX.[R%W:WQ/
M'91L<8ZU 13(/%"Z )+F;5Z#3N].XRM*MT27CZ_29$=Z</I"K4+_U"7+N_YG
MCIHPU=19JOA83VVU,.B,#0"J3M!#(EO=8SS2TPX+/J0JA!%U]>(L@<0TFN\&
MF.CN+Q12+3%.=UVFU=]([<C]%0 ?>AH 0Y->H/\;C1C;BS]VF2BU$)5L&M]D
M!8KI3SX(?+"^W?%F_:F-#UHU].\1F3C@[ OR(<!01Q[)1+]C7MH3R[K0!?O_
M8CK(@ADC*+6LMJ'W^1A7&,'VF8\<,;3 %J-R%: _&R/1ZGC6;5[W.+Q<&!1?
M,W-$A$ZBJ-_:RQ/0/_P F :0>=3@ P!F5B"&^:[Z "L M#P(9*XUZZS5@5I?
MG0]U0CO^#AOBX%0S$&M)GVWUCS>;_Y+]5MU @$?Y $7QX"V:0U)T:,&W:;S2
M;BH!9$H.W68N$*I8A]<+(38X2]=OXV5$87MF^.)E(_0_01U_;.=GU$\ ( T3
M77FK__8-)NY!<)V1VO*M*=L ,Z8&_D;= @;F.@+HJUJ^ITG@ZJH 3C1C='3+
M4?2S5-#9UG/.MTX \NROKWK8MNT([)_^J\?D^=S-3D[\CCHYG.2-<QLJ;LED
MDZ$*0+FUHP5.VP!TO4X\2P %_*MS)8;C1P%DW0]%SQ) 'UR 4<__N:3X_084
M%R:1>>B-W$KEPT.VQ1IQE]M_ND^I32:;XDLF:PC\\R)N;",0]O>G!?;9=@3V
M4 303?UM6V_%"1A1H 2J7+R!C_N.H@OZO1<JX>R%D>X4QAMR4N9!^>Y6:".%
M8.2,Z7M\62TP/!I5'?8M2[7V73<_8^ I^D-<?+99@AKW[EB/1!]BE^<#J=SD
M3M\M;'8^Z^(J:2Q<JTWVA=A/NM%[QE.G.^$:=_TNB$[X26+X^&6$U#:Q8DW4
MZH^4"B('.WA;F3HY:9 \<7?@65=TZ QK-T*F'[+!_\'+-,?*L>:C19FMG6PF
MC^)+Q5MO<I@O>LR7 (-"!7+D_)54$!OS.&\]6-EXA\YYXSEZS.4-1Y-&BW='
M-1+RT!6VJ/Y@^I<9&^-[$$S>SC5 T+\V..)AOD7DSI; YD]7^%?;:^@K ?07
M200,S05&Q.'+F9^B#PCM3-PK;>0N??3/6>%B"K>E#AM[EUWXIAH7D*VE^![&
M2/UC+6-Y"";TZ)KU\C$H7'3N^,$I.0!G6*?010"X1+EZ 9%]&;E-;&CT;!+V
M4Q2%3+AAPQP.,;!HG61,)EYN&/D1_ZAJZ\_VEL_BUZOOPS9GL9SF^JQJV(.?
M<S#:/G]G#>-TV*3*]\T%&*UGY"^\8%-]G#.J)& _:XD)7IWZ\4W:.'S5*FQ;
M4UO+!N.%OP4$+^I#%S[8!BLQ7N<;% U^-8U.7A?Q [-8;WZ2-.-OH#&_5+XT
MNNZ&"V,:7VT'>B?J] #/=@G>%'&W&I.:,J(OI62=9?_$3# 3<;"3GH%3[-Y1
M51YKHC"8C74C3^\&D6!Q_5-)Q:43!- ^NP@2B]'?H+':R\W5=; S+RX/5:+,
M+>[;8^Q:-(84EPPTOUQ;NY/0X!@/V8>A[DB(LQ,/AM.03+,/'([.5K\\Z95]
MQ]'?KT'++-U:9RB@X/.3B:A-QDML^>^>DD,0A@^3J$!623'3>_"- X#TC SV
M$W:/O[$4;E(5 047R=\F@,"T/Y6<O;L__C8*2,9#$FUVZ,8&^*!^?V#^%71&
MV@V_?H2$+($;E"<[VJ5YN9O@FZ)&L'(P_GEQWG$&L39'-OH&#B*?SR_^LAHA
M0_,7_C#^X/":'?RXMB#S*#:9(_#5?$"-HH'B^XU$$.)LGR6>&GQA_3#ML$]E
M !N401T%H]CQINE+S+><\5.=J%X\ ,N1$"#H$(H$4(QW[;':HT1X4MY%_-JQ
M9?S]QQCD"P7N;-(S;DS>CU]IHN"7!07&JK"IEITL&)4G8Y4*D"]-<$"L 2+L
MPI%Z^VW'[E/P5P5J;DPH$I#8032'+PF@W<@"[8I\%?R=Z[!E0#,7A3D5^60N
MF<H$J0*B]P(5ZO#E-)!\:GJB^;^UI_^RSDK$ZKAQ9?E[\>&N-AFO@XDPP)P'
M!I45>0!(8OU=_IUI) ET>EJ' 'H&11LWCI4+0ALLMFN(K%*"OWZ_G!(,^G5+
MYX_.5+.^F%8BMFG0,J?P>II4[W4KE^=<?DZ >@Y(_1J(XTJ?.BG !&]>FNP
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MP;K2J1Z'IE7A<F@38A'*[#*JJ?6E-[5G[?ZJN6[,CVA0=&@BZWKFP<J.:#$
MWAPB)MC#D"-C?T&%2E5^84;K\6A$5N6OJX]^L^)9?#>%?GW-]9CGSACT9P:]
MO&G5;:(O0EW'%Q_9<L9$3ZOMLQ8@1R*.E(>>PX9)<HG Q WL+^N/KKPE@%B
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M(_6.02+()4N[7B]ECPRH=L91]_S5PLS?E&B90N"H1J KS_G&RV!$NRHR9_[
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MO&)#Q!%31C)R?$G%'H",^RXV^V<'"C6'R@G>)Z=Q5'P:SK77I_^ ]A_(_F?
M O]_(?M/8/_"-0^@P\$\#QX<-B "7$4R8#L:5LDQ'?3,FH_Y!H12]&BT]A%<
M;T.!MN,G+IWW4"#F$Q28D8("OR(M?B'X_>QYO(4")Z^@0&_T'W;9N"C>/\NU
M?X4"Q,)_V-5*/]9U@OW[6YVS7>4?>L2 -"_8KO,L1)\HUN,Q*!" ]<3Y+Y/+
M+!P 7?&VM8D\P8O<C/^G-9U26B0@4: G_:4TCV6PZR>J@P6,[]_\X2D94H_P
MJ\J3BY2#&>TIL+B,>8J>,MXG'OEWO88V)A'Q&;.E8>N/3MMKBY8%5OM^H-E]
M%(L9Y-5O^32-OZ.&VUA7+>!F_P[,&<>ZCW$/O\3E<J2SVTEK,2%WY8=874]]
MV>H^;#L>1I/8J=5)>RX?IVNQB:VJ::[2)AV7>H+ *1J-4_Y6W &B^[U,E^ ]
MKU](%?\]^LZ;:JUIK*X6JONNNX"XNRUOM7"?5,'#;A/V\\BEOI9/\Y^5$K17
M5KKAM_:5P^?GT<)0\YL\44?+U&0(#;L(!5. 2\6_&:'F)\4P][C>.FY^]MHR
MI?F6M12G:)(/"VIJ;@^SO^/[K$K7*4+O$@B(KU*-[<UHP37U<?,F:0WJH46V
M*RQ+LY_>!4I3(^'"[!H8?[L_AP*KXE @DN(/VP'_B;-IDHND<-J("J\1''C8
M_#A@9_+5P920XHT-7*;NE/)GU<1:9N%EA=?*9M(TZ9][V1F&NU^IH8IUKJ72
M.'AD8;V_)S58R80"L!0/%O\RK>'Z4A*W4M?*9G5],M:WMDB4'0!:;.I@)HY>
M44'S5L;T:3_P9PY[>VOCBI&2X?G:&L<N9ZHP;+T/*I)P IH/2QSAP 7%WW7)
MOO)-IFO!C=>0B@__Y(C9#SO0_.]C<M5@DB$8&<J8#UOM9"/Z!J$:<A6<+W>E
M&PU;,OIUF6Z=3GNVS,WX#;%G0( ;%/B;_O <O\GVMBX<<B^R^-59881W6207
M>)^D]=Z"8O/609J.Z*HT)?I;K9#XFMG/,DW1I/G@J@%L1FI;E4*$\?! 24Q)
MT2S,[0-'/U^_!V2_T]S_M"H$:D];*_(MKQUT+;\Y-+K/'3QL-S.=+PX6J>)H
M'&W>&A_V*(AT"VE3,B5+@/EKG!?%' GF%1,*>+\T)8)_!Q86P(P [BM_TV:G
M)YQ3UY70_/KP?44Y[GM2@DJ;U.$ETJS$I?8N=!=29UV*P&8)4*3.N_JVENFG
MD<]U5.9M)MS7Z-GAH:%$*MS;S '^%G!SPG_C.>=<-Q4>+BVR?@>EYDD038*1
M0(TX!!GQST<=/"^:'&0#,24Q=.+7O^N)R]>%#Z),6% F;69_;UWA"@\@)\"H
M@T]?\-@  5Y8L^M/#U#@Y@44V)#ZP];7,-ZP/N3NL+?+6+]<JYVRXZYI4NYV
M?Z6*'95%"C>KGK_2_6T?S7.M>>(P>RKN3,#CUR*'1.W&.1P'PE),+CS,S+R_
M$-Q_T^$E&>33O4U96E:!^$&';%_9>%3Y.BB^<Q7_FW G :C_'-+4X># 9WM#
MDW:%JS+KU\\_\U1?>(:KA*#W\DGL&Q30HX "[[CRM1KI'H((GAI%GKY8R_JC
MTN?XH_:D/DG)L=XC/0>$7"I0R5\>LS!*_O%)N&:2ATF(6$*L;"52$35B?H[_
MV^A@SOB<W3MQ4>W>G@V+3^8TIGQZ*\O >9"\']).13$7%)@3;,C0-#,BP5,Y
M-3>V)36QHUYN1*6'2ZH_0?I:SGR4C5\E?I7:]7D,?H0DK]NP*L:I@6AWSXKH
MB>3&R1M-1PQAF-&*2%W33N^U81\+6< 0HF#:97EK.#"8+#9I,GE@XSN* ^F5
MWJR+)"R2C-@4@0D?2FW71O^I3Z4SA*:G[U/[.]!,2@9\R)1'6BXI15[0F$(/
M-RHH?K)N*Z?UT_NE)=X7Y0Z2YCBY;?JP:TR8A5<':&?L7I"Y&\^UK8;&=- V
M[:ZYE&2]4TFU,Z7:* %=AL",E@3@3'$2N*.8;V 9U\$$N1XB7O2LYN"X-400
M"!N51.+BZ@NJ\8Y47U ^*PBWP,-EXFBD+O%IW\,DL;>9$9< #/O62F4$.>_(
M<[2OEE5ZQ:FY/VPQO76.#?3@VX MG?4@>3\)FJ W2I^SFS@9XCPZ$PQ_F_\C
MC E8A>MQF5)"HO8\V>^J.RUS%G,H#E/[XH[9!)%BZ:CT)(D2/=3H^^*2X!+[
MRIZ-)>-4[B?UB,NL#%GO\A*C;SAP+H+QP,;MM >GI2-9ES%M:QP^(:,X6$6
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M',)ICF&L>1]Q^%J:QGLCXCY3N^5?W B$:4S1A5^)0:#0I#FERY7P3'U+Z8F
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M$Y. ^7R)#-*-#%SLXF%YD^BI7=BZQ< DZWJ<Q/U)W1 #^5K"&4-=.$9"2E*
MI:O#3\&9R$TC,'@-;;7X$KYBBQ%)XIRKQ,RI(*79Q5>*(/^F2:&R;7*CH:4^
M"MM'0 ;CP(;FRT\'S*,OGU?>'O@1[W-%8UD^4<5RZ5$HR2GH8]^G+IAA9%[I
M8A+Y1&I,"O*ST@0>W>2?AE_M&@Q'P*LR[3FD121UT-VA-KB>W'<E8VUUF4$X
MW.(&U;]$=WP0D>U%E;$J5WLS'?B!V?91]ZO$J<NN;R-%F.U$G[J@9/O3UHY7
M;U_;/5W*OAY\;!5Y!#+O=3F<YHUWL16Q]UQAZ'9#G6">=H3<FX^SI1'LL7N,
M7*['^ _"DQO1W?C699;];J#+YJ^?K6>%I82[-_95"U^?,F,&6S7V:%T]N^[X
MIVH%$0E\QY\6:_XY27NBNLYJ%]Y%24,?:@?.]:>DD6Q8?GG>59:SG*^[@L;E
MQ$CO7)S;1U[W='N>=?1.-#F1.- A9?&"1#"78XMV8A4=XJ6X4^GFS,E,B2(2
M#47"'&?:9CAOU^>K^=;H!]T.HK;"Z4%H;(+/7(G*K!H*Z*L\DQW:FJ.CW*K:
MN"W=@TAW;L0/;^H@#GO<!/@:0,W+WO%Z)/AB0D$(77C%G,O0D,#[E[JW.FGX
MG=VM93[WF(6['^E,'67F=']594A!:J739_L($BO)@QAD>JPTT"S+]D[VM(<G
M->?R8@F;;UI_W?OWPAC$;R'-!.C].GQOZF*IK#T<^-]+UAS4/XZKAEHI][CW
MU\FT!8+!IF!PY/SROF8]F$<L85.%1L"@@'?O X:7;_3S /WN/9RP'9,_XJUX
M4_^MC^=*TKN(R^.HC,J>)N]%4LKERB;:S MZN Q>3IC=1M/E8JP0WW'W@IZK
M[^M+>/FI\0WO(DO0C#$6$!NLL<+.]WQ?_9R@.IE>=!H=K<J;S!G 7#2I,J<T
MW,[(+;!N Y^W#F'-<]_>$PPO3+KQ]8&MF2\(-T\_\]\F;X>,@-X+(*D;+M2Y
M(L$17G#"E J>+(B>*S)(X+PQ]R1D*+JD.4%PALRWII;<#$[MS@?G;R<7CK4=
MG)>E.M-HCDXX_II1U*SVZ]\UC[[[Y]8]_$P[AT5[1% 1/>7U+7F\RDEK?/$W
M]Z1YWCRPJ8=IV+LJV]%?F+QP0F]<G\S&*QW\:@B0)G][Z7WJO#IBVY1_'>Q@
M4L, I&&6Z(!]^-T$7TIQ1!4I2E0.*:)9OA4UCH,(U+)S=I0KF[Q*C9.4(A(\
M53BU[4[R)6QBTQ1W)WH7UR/820AAQSP;F7NW7<CY2/&AK59Z>(:*UY/J%SW5
M6R]ZNV8OEP/>(D%SOIJ3BV21^7'+;Z2EC5J@A]\.'[C9,:5M-J*\E(<W2Y&;
M0&6.(@O:KX\:<I='UA(TU^IJHSR7W3!L3#7.DLVE4&%NHZD=>JRTK2DP[6CJ
M:@,F69A70PD+@)*?%I[4).XFB#N*1%QAIED[EL465R\\,CC(#M[*7IWI5%J'
M?/-+&OS #1=_EB&MSYC]=:TC:GE9Y/ U+8DW/<>FZ]EK%D6#]5&A(J)A">,<
MJ?+].NYY4&W/RMQ1H#A&:D\] <)LPZV!9>=#/=&8UY75::HMEF956YL6R&Y]
MXF)?H!\T?%KB3Y/ 'FSZR:!A%!$12?O*"J!_EAW_*Y=ZFR7_*E/!AS'1@D%J
MK#1Z*!EAQG7YQYD(W/=3I$!.C,^/)7LS!]>A/*\/JST_T@H<D?F1SB0LZ>_A
MG\_K"3<4> 0N-O79)1/$=KFB!COD@=T"G9OHXMX%>FFT:J3?U'5[03+7K35M
M!06OE19^QJ'@UAVG]=!N$NIGO>6]$KSL4T!_GYL[C9(KTIF)QQG*64W>0#82
MT;FNS-SQI1EA;LA0N@'^H;,%37Z&$V3&0?NC6'N9EOWS#W'L2[C8FRE(T-AD
M+L=\GJ3J$@UA/T*#H1.B)YV@ADC1 \])>3Y=FDM-;2,IJ">5D$RQB#$@LS.[
MD=V;ZP8*Q,19:NXS\%')Y%AL2K@8A:@3P7N'KR-]^:R6YYSMT>EI;-!D7])-
M9U!P&I)GC^O1)\D+:::QIS)H<<[[0+,Q,V3#1=X+!= 43QX&6R+(G+N(OP8_
MO*MK?2G.Q&S+%+=;Q:U*NXE>A/5)FO<PBD$1]2;1G@8\E31W1#S?J>H1.^63
MQDBK^N8W*5R<IWU6@<X-1.3%3?[QQ6ZA1/7/!.Y,3J8X0>]D3\H3G7H@L^'(
MZA'\0S 9<HWO)9&GP=,H'SH!FE-F2/?G -(ECWU;/,JLE5SR*@I2R7"W4>/L
MK(X6%B\L\G"Z2+]=ZXFCWV&G)&751O18H]M&]@=\X#=!5[T@9&-,."6KN3/[
M4:*K+;7=X1!QUI7Y0]>?Y\T1+Q%98[3LWC[L%5\MAN+'R2_YQM:$LB&;:C_R
MX#=V<L_R-H9#XQKY]GUXM*:Y0"K>WP^,TM=#V+-G;V5%/_%_'CF+:L9<.E^)
M"JPZR'&=X=(B(J2^%9#9F?V8I@ZB[^VM)3MH0?Z3G_YQ,%!"^9?-/BB@=VH0
MQJDGI5+7..-":(P9ABSW9C..>7 DKL0K6*6/QA_1 V^'^%^Q=K#UU<(R71@7
M2;^+@-D7T<J:,REG:GD]K"7L2J4/2S]Z/7^O_D*JF.?SYB4<K$J*E(E!1]HH
M(O\*TBP!DUI"NH;.VIPR:1=M5QVC9B]*5?^MT*5MZ[[C1E2\"CS=/Q-2@=2V
MJ(^.ZPMQ90V71#+%42,@":[RG%^6-MYVW[$)PA31*C[ [+H:8.^FJ$=SES)W
MRECCNW/*DQ3J/S;=JUAM2LH(U#I%A95;S20IT#0:*X9IX;^/Q64/ZNBPWY2*
MM$4X_OI+IG!E68JL6Z6&&^<@S=;FR.#XA8,#\AC(PL*7:M+UGM#.IE!\J^ R
MHNIX8=_?.7SP)M;5T7Q50=);RRS*E"W8@L+Z; _YXVR,X\VOQ$ 5A25&4DYB
MI'#M(\+CLO*MC.L#=\3#'XHQE%B);J/NJQ7ROW_F_3Q):K"]8DP,^DB @IG)
M>-3@?'_,]>5WX&R_/"S_)Y#V\OX\QG3"_)<9\+RW_J)0#7%ZOSLV<S6I]%!F
MLD,_::R>>\!G9>]U.1\Q5V2JJ/511_*=V'$]+;P.5"CP=JWI<E\^?M2&-O/>
MZHPH9>TH./&V.6W),U97)(V;O<BX!J']-PN_6X5KN;7^1,V]$)IF$[BJ+F1]
M'9]#CM2J;/LQAW]&[B^'4?^93:V4Y%@*\Z1CJVDT6(Y$U\1"1%$>I"DBK<85
M!/ZQ)>'/@/8=?VM>DRA=78)!EO0MO''0[-2%<B4IHR4^]S)CU<2D9DN4XL$M
MWLM#. >E 7_>7?\/0B4Z%.CE\1MD;-E3=K_KZB9?AQDE#IE\_2 #!0(P1>;P
M"AT+M64V%DBN0TF*+FYC*>I))J% .%?!E<U\-T] R%3 .N-BD@DE%-@H/"])
MRSMT"-=)WLD)C\&IWR=S&=@HK;'V 7.(X;[0/;H?K6"%=X,_ JX9CQBS(90M
M]1/EE)/I.'L2LR!J/.#E0#\2$E%'QS;>8&U4J7"V=T%?X>YX467=>]A;*.!>
MFS???JO53RWBOYT"28E,[QX]"@=97B56?]%+X'D%)/2EY_\<(.HC*N6*)_J?
M;+C7LY+?:*BG/%T;?/M8%]XI('DNN)7LTX@@$&&$B75]3]95SM@R+NE22\9^
M//FXH7LXUA4I?/3&J![R(,'$\48CLE8&E3TC*^K[519F24?0+F3XM:?X^SSI
M+O0'3,6&??62<MN:)1%V:2HP^%MR;"6>JBO-'0RD*KE7GXSGZ@I.L]:ZU+^
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MB*!/H[6%9)"WR.!XE!.1_J0>V=%6?M-'L4R1C#=EWP8%,JWM'Y#MGZ@BKZ'
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M0_BXZAV>.SZCK8==@8.M:@D8&?H)<KO,8;8*984#J7UA]!GBL/8MU=9[JN?
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M\#KLJ%T1\;&*%_:3T733^G@X8E6^H$!S-@28>P'W7]2'<MW>%W3[@AF&01!
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M!/$YQ"X/YLC=QCDFUE5HFLWB?X.:H6&TII(T,C-Q$5/,LHL>$B$+1QJ#MX$
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ME]OO']KO#X1^P9;3G\NVOJW>P# QM&'G[05OFLW$B141N-"^D>*3"K"J],&
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MR&^ 7$\@0'FFC+TY([A*Q"%GF0(<*V7'/C[/1["?#*>8TM&A_$>XR8X!L#\
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MJX9@-W[A,*,]HG?M"76F"63^_P!02P,$%     @ ;HIO5-].LH"*/0  L4,
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M$YC1Z6;K5+2*B?1U>OLGT$""A+2,@C*;,7'RC9[ &J'TY[!W-IX?%N>DDY#
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MD+HR6XZ+]+!06)O&L5I;Z0E\VF<:XZUD3QX.VJYE6106V^U*<O!!$J/1Z-F
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MMSB8[VG6"HGTK#<,;TQ4&7WF*3+B!RA;$/PNPCFI\^:$1#6350_B:3,KL1<
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M=@[ZGT-'[']<&;Z*K/B3E:1OLW;_SJ3"VJWXDGYQNLNL/MBUW;P\DHRI4/F
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MGG<^V_>MGU.B.!Y9B32NK?O32%$M+__7%KKYM86RL-!7ND.][XOL2T 6[19
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MO6Q,P)F%8<3A)0FPCL+UO8SFV+7!?:#S\.(';L3+Y^%5,P=97T/F5DCZ.4X
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M?_GO]^[_!:6 ^T-'57J3N1 U<(*Q2F5-,DBHE*P9X1]G_Q]02P,$%     @
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M\K,<".I;7@>'3NV7?W*A?.B(6FC(A!8%')9 FC; RM-<#.I@&G><W8D'[/'
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M03]ZL/5%+?&OM<AM%&<0[KK\]/ZN$.Z-;4'),F1!LKJ"_UWJHY$)SS*I8^F
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MMI ',6WB?")L<0:)-"G!!L3]I,U2N5UT9'D?C_)^QNX1#[_3)39_[B& 1--
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M\<8VM1=A;]W[/&B7OH.;?5@9N:DUVHC)9_I1=N1B/3BX<&>.J.<\K1VA-Z8
M^?)RAH4" _8_CQR0'E:M4(_K>V#F"QJ6MV<L(T\$9 !WR,1Y@I\6ZUCF&'RW
M&3 @WU(5Y$;H(6J*VT=\)'D+'FQ,H%4((H9BE$<-UYY!^0/1;%*$R]DJ3('.
M%AGB 0.T+JG9YH3LIJ*=7II(GW##*F/E"7\=^^$&^V&:C#8VSGI7_/@-CN=
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M<7,+BV&>7^@>6!GL7KHK5]ZG*.=Z-T.L+F<Y\/W0GKUZ^5N%.X595Q:HNC4
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MKO2'D0(^-ARTP6.O[!Y^!U56?ZE*%NX$=.WC!IQBHZ/2'$()SOXL!JV@*5A
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M+K)Q;3:(G[NZ9"W!>I#[:*&2)W$^;'U&N,WF]W_CL]J_/\#XT?\ 4$L#!!0
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M'2<<O9W ?7EH ,)$1R%F7SM4R>$!38+SZ@;@V2:;#=U-PI[;)RKGNA##]WC
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MU2TX-669PO9GC&E!+*\IK 86\%E\6?M2FA^0&,9.GZ3U%?T8?DTGBX<JB[H
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M'VRF-M_=WIC#MO!Z^9+-6VR!5*H<MS&E6 ?,)CAXU4^7.%-V/N'9657EZ80
M<OZ, *Z7C*%(<EC\.8%%WR431;K>M>W[0HMK09R5M;&>!N?BC2@^,Y!7M2D
M,^Q;%N $4@W A HDV_XNC6I%I]#47'LG WSFZ[,[M\=CG61'(P.K/&*2O4@"
MI']XC!Z#FD'TGF IQH86,L7&N 7%IP<]X&+^^C<G 3FM3:^L[A.:4XFJ/I/H
MU6E7=1"W?Q0"7"8*=S[MG03R!0P](2"C3P+R!'9GHB^7L&^D/4Z/]F@R'LBN
M0,3KEQ^&UB;A 3J$2D==(/PJRAH/<+X2/=C3.28U'N)./S!N&T1@8"<GON@1
M'N@)\7=F*%;TV"=?;CBZL%'Y8J]X&YU^1"XF4'/Z."<"-&.K+>X_@3."_/=
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M:6UG,#$S+FIP9^U8=U04^Y)N)$H0D $!A1$!04 0)$@<06$(2A!)2E"""(B
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M;'R2$_QK^ZG]S.Q_E]B3?RJS/Q+[6UY# #TY&;1XY,P  MAY7#6J,RKQ_!X
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MB5A_596UW?=R\+$/&ZRJU%]#(Q'#K)NO]S??=4'PJ%(.73:A>=<P9[7?/.%
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MN_R0[U,3#V]K*/ N,UN0)FCY'T"BN"R"87#1D<["J_ V7W;_\(M)1:78&!+
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M9)\2;P?*<9R38X)D<82).?%RO %4=LF"NDX1,2AZ"._HD-R;!9T CL<RN;[
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M%HH=E; (; IE8)P;=-KTATLC)#7\(!7##M[)77'H(Q1 ='=R";<D4O!/4HC
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M[-,;JRL0$$!8C)*#,LE,[AX99?H.I@FI&RGGN,;XV?*P^M\IF ?^P!=_=[+
M(SC4,.0%P2'0! 1:%7<XXF#(W7ZJV83!07:]S_"EIUKCQ D0D,XF8==[[YBI
MU-?;/K\PKSJ1U!M?A;[1OV'R@^[#[W2]"0&-% 6QL[^3M4" OV?Q5MVEHM<!
M:W*-47S:!S_@#^U2?EK<GP'?<_"TYVA;2SG[4UZ"D6/./P*+7F8WY08!:UGB
M:)O)2>S">PH(+',90^"CR600F)$Z?FM;P^8)$'@J/'7J OHPWV"E5U.AU'%\
MLZ^@ 07&DS%@\:K*SG6!_:&YQQ%=P2>P;Y.D(<\F0?>N&2 G5XJ<AZ#02/9+
MD%:0:\U9[*CQ:Z3KO<B5'B29T2J^C]R^7.37LRRI2)9;)O8[[U9F/>%TP$G@
MEK<[NVQ4D"B"17UA0@0$EA0@T[AY2S\0V"S?M"K"U%=WR&%5%BA$-$4\.WDL
MXX;\[<Z1SYMZ=21#P'/]'V37O9=-W7=.8Z2%:6]+1:RCX:L]D;Q\&F7N3IF$
M+A 8%0F%ZP2.O@4!OJ\C;.6=3ITZ+U-3!-&?8BH &KEP=?=0=,S(?J]'U%@8
MI<;Z^)/]/3&">4&\MH6UXFI=<Q?,9C26K5IQ$Q+12%SZ-?+&!8I4_*Z8#(GX
MU9$]0IGE^A:G-F32.*%K7Q$W'@S'M9LA&CIO)CQ=R]0R,8F\C5W)QW-YW*$$
M91(GK;0FL#F56(X [.E.Q:F2DC"GBD-/D@X=%GR;%A-QJZNOVN!I,7T6  *]
ML"*56F?=W].<TGOC>@WH3?,"$VL)+W(J[XRKN[ +HXGX;ECFN.?%673)\WO#
MEB-6PH/-]IK,1K:?+]+K"/3$6DLVJ-8)M]*:<ER\_)R@VB*E'H]I-0.!*]%'
M]*DA;D3&'^A2:N7M1DYZ=]?-3H+ \8Z;\\RSTXM'4C1R?8((MAN=+RYO- YE
M:D6G!6B\1G&V@D#(KL6B^,;)OGO=MKGN1X(KKS3&JKC)UWP2<<3SO_R\:X/?
M"P1FJ:<]8V!G1ET3Q5I"/<YCI/V;5I$>I<%?9&6<,S_&'3FR2N>X;[FIS#W9
M62E&W5EYH#GFC$:BVTF.FD_A*;*;*<AA9,N=';?%Y5XV9<VGLR?EU*9_"WBX
M^!&13V($ 949LZS"QZ-CJW<\*87NM2\VTHV6GSC6P]3O9Q+@8VCX]7=R9JD)
M'B'TTI]^=SQ_*:(*!,S=<];=04 H*)E\91>9SO+E^F&CV_;O-=3O8B)MVZO5
M/;.:Y*W?[=^CL4I@]/*YI<0]G#B5N-@=^/CTR(GI)D=7J_SW>X?Z<W*W)9[K
ML8VP-@9/LW,#&*)7XD&@ADS/!<Q02'4+(*!E:NZSD^EIHB5_ZKL$UJDKA?AY
MR/[)U-FGEQY6,:^BL75+8]F8WD#,,G<1_\VLHJ/<2W#W-R P/]L=G_E2GTI#
MV$9V<SYS<_=]Y.7X7HIV$GIE&+DL;+M,$0U6&ATS:".R79VYGP?W->TMO>K
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MM<:IW&/XN1,P:0!W*[#H>-[ X336S?&D4 1Y_B2S8P4#=A3S;(/_TB$=Z0#
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M]YQI?4\?4/F?2_M_Q\HB&YZR[WG6#@!\3R5;FRX!O&%;78@RU@(2 &$B3I$
M60V X;N]2 (47MN>[WUZ6?%1GWC3[I(W+TP.$U<7O3E=9 W#8N$[9KME-TG
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MGL'\C8@Q?1R:S'V^4DTJXVMO+TW1X00":7 #JP,3,#8X.ANRMQE' FYF,(Y
M)HLV2,"QK1!;O'P]O#^(%02[U+5-?!&+<+P 'S];UT=F63_H:B)1?C+9#1_-
MY48(R"/>%_LZ3R&N1R O4:^/15)A'D'Q8A+G/"C]'FU"-GN<NYU#L.WD8VS9
M)YI'^T3S*OU3AP/\B&K^[NN1C**[T!J+(U^IG%'>/^DDA+EK)R:0;BV:[*>
MYR5H]F+_=T3,_7M$E/\.E.,IKHU<%=(QKT1*M+%9RK_VUA,)KTW?(0]Q)40!
M<;]BD;L.6Q4FK,.;7V;])5E_\9%!BY':223N0J<U!8GK\'%AO).N",5_V&LW
M917GC98 >K+/&/CT) D8A<TZ9/ZV,D#?S:^PV?[VAQ&N$CE5:1JQ'(]J8UM
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M0K7,T8]GH&.@HY^/SB[)8BI)QN[BT#FNX+J#!NAB+66D[TAY:F672S<%,B3
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M<#,N2C6@GKS?=DOR?H?AF_Q7A-)1506]3-$^"6>HMZWAXYK55Z!E 4*.>--
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M(KUW)$!(\H/7>^\K]XW[WF_OCW\RLC.R]SKKK+G77'/M0_Q*_ 8<4U=64P9
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M@H62&JP=6WQN=X@].W [+1VZT(A>E@0\&Y.Q!K7>VM]O?+0A FYVV:3ZOJ'
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M//_@?AV(V57$5A=R+4$V"#V70#HR2XHR_^]X5$(O\1$!;U*]]>#WD..$@&"
M&Q>(GR4Q)LPENS7!? /HE7U5_RJYU+>X@U.A&H/N&$U<Q:R$#Q4%_ZS&0<XQ
MBIBE3;.B_,KWQ9^R*I^-,)[Q:7@4LCJC#+9O,]L&Y>;M9F&4!PH*'):+WYI=
MJ]P8+5"W8#S'=_TUIFPS*1CNRM+:/:%IN]9B8E;H4H31$K&$'U,S?^CYFO,Z
MF0++U]MD5^PI@Y=S0%+TNGN#\0<.7+M(]69*O!01N&V[/<7.%!6LC:N8A9YD
M,7RW;P! %QH"<70*G/;_F%CHHZ5$X*U4UJ;\U!!)J$MA[\\>JO9PO1P[]*A-
M1MK<\L*!_'(PT#_2F+Z59U(#_3HX@B*U=#2.OW!/EPC\V&ZX_D"Z8CK"@I4@
M-_Z&L'#8W+_\27-7I2FZ'?[FL+8%?TBUT)4S-=7@CW+*WI(&K+M!G?)$P 5Y
M]N/.K<Y%>6FILSD'"XW7D8=9C%2)A1YF;IK$-&#E'Z[J@*M(T_.'46?]'B?G
M3RN%HX<+Z<[[J$^O9E1^X1&SYV]F@,SA2MBA<\>?_G1_,_MW/I24]3Z?'"+P
M@\;<*&'Y0^Y^2(&@UCH)1&";6=\0?QN]AE2$ ](_&=D?>^KWTR*05B,S?A)C
M[/%DX5GKS+?@V9,:(>]AI4*9H$A5 :<3L"@*BHE;=P"6F?&3Z&E$+WH)^PNO
MN,$!B_2X@5EY=K1WBHVE?&+(2$3]U+0ML'7K9T_(?]4W&2$\2^)AHZ;KER""
MX8ACA[_@&'YPW[!RUYT [Y(B-$03 466R?C(&L.W4MJK"3LH^MKB0-=OQHK'
MVR.TM6-T*"K^IE^4S;81 3E6PCZ+OD'D490/.%?^WJ%4)E!R=(?9DWCE3>*5
M>.^8;SI6'#G.7['"%7,.WY^,;2[F+YJ;OTBM$GGTK_I&?=XLFQKI9"* 7[<;
M:*0 ,RXEF0_%!9ZL[J;3ICEL*>IGJ59F]I+:X.>[4 2OL_AMP2TKDHZ$D YP
M1[YK!T#A2@[FE!36S=LB0O 6@8P>4A*4LE\>_1@7'-(=2/#*)MV (VG-@/Q:
MJHJL=R",+^WEKQ"8/4M(B29)5N-3G4!=H\L"&\(>CFJLK:-%6\)M,ZU-G"[=
M2/66BMWP>"Z&S&LUWYT(+-VF3.HAY:-A-CVY^A.&,GFPEZCW2]QSRWKTNZQ$
MP.2E0.@-D+Q%Q!0^E<#2A<]_2G!L3L"KHQW?<\!9KFCV6_5+[#J4S'BFRYP(
M#7?""\^]@AYL(SX:^MS.B#8]_S+K]8O-!W2>=,DM*\Z3DU<]1!2,V91Y'/RG
M< -+FB+>VI\:Y. ^<UGON>J2!8G 4O*N-C;,<^BU2<Q"-N7=A^8V;YUM;>=R
M378[]1/IVATN!R%;"]4F\[^?$H%B2><\]AG7[^84-P(G3)A@]E"A@_SIN1=6
M^KW7=AISG]5B=?MVW1%U \6KHJO'N4I:V=2%*"^U.=ME%]$W(_E+/! S%"S-
MLNY%<S^R, M;*JV-%;:(R9-IT*8_2:54%\H2\7='HP:F"-??B"Y\\2\ZM8#G
MMQ!O-,/E+,<BQC&[%PYSI3IUO E\1\(2'< @9]!T3E%IL"#H0G'*0>Z%7 +#
MGGY."L4R8A75$1:"[_G]7[SM/GU'7#"@F3\O+_S#VCJ%PM,&__X@9S,:%[*G
M/Y_B;B5+JLUJ=.S)8ZXW#G*W=5@M[1&*>[H5OI0S&G RV?.3]%"&5> ;J4L)
MO]*<KZ!OX2$"K)Q3A&KX09Z]Q'K%1DT#/K]DV]BW(4&J>S]5Q]BE:&'\^V;R
MIVP!K%)*J?R&7!]Z:4;^M>?%RXX%5P;\[MTP]1;R.M^_<QC.P\/!6Q>1 >7G
M']B&QO*W$!8)UQ>%C('10R"Z)<A:=*QT\"6=6\\/ U(^M!%E;OJ!1_/YKU"U
M5XMGE-\3Y@]R^_5*.;Z.YI,6]%9(*/1ZKEUU^MD7>7";1 "-)V<&,=V\8G>_
M3UO"2;D DZ1\)#VZ/V%&)?R=QQ/CK 2$IK1_G]]868#?9ROZL!>X:BZ'T<$*
M-T83S-BP7,- O?[;CYCT6+#0]'?*X"8B\(1)@[T3T28WHC:'S[S?TZ\0O3PT
MF[?RP;RZ[2($' SXU4S:%;+>[%W&:!BO2-(\K5#KG:8&O[%413FHYYQ*#+U;
MZS5#'Y NO1+WQJW+:'38M+ VWN.%^.,H+9UOE9<MJ[LKW%Q!; E<JN)</#DB
M@EMII,K./:SLJ&  ]2GDE_+]EV8G_UL]Y'7>XUES>_0*UT*&E-:IM$KQ]Q4S
M$+*]:8F]4@<C B0'?=#>:#SS,<5 G@B/R0)=C2BYQR]#?_<A.X^>RT..*V6D
M%5SU\_DI0Z]9#[YKX^:O'[Z]_M&<Z\^YY/_"W%_X^\<OM_VQ$&=R/2ID_2@#
MRF5%>RN>I)YK&.130 VN,G<VG22EE43@B.S,-A*W,SZAP&@82\_LD80\MO0
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MO&\P.&:13XZ6I/ITO]6YS''!AG=PF[+%8SY7]DI9H-B3=QU!PL1O(BYD _4
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M%''13ZHK4O:$ :DZ>^[E<0N2TN0%%N]6U@G"M.Y'WWTWA7+(?NW='.2L';O
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M.K[]ILOAE!?^G>Z>\?L8&>:Z]UX:;(^<AHN@QHKX0G5L%7/@L-W'^K!(X.
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MN935A^DZ\7JAO%7J-'3(H9^J>U-KN?RFG_?AI5O6+W:?8RF?-[VYO(BZO:8
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M% )L<V*H_4\_P_^/D+N>^R]02P,$%     @ ;HIO5+L!2D*_MP  Y[<  !H
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M5S3GKV@DVT*R+X:?"S!.01K=& W*CM$+(_U9?4K2Q>5!3Y7:)Y.#FN^&-%?
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M/R]_[G)Z[M%X/L_X^\SS[RF^_.])Z]]S3OS7^_@#8SSZ(7,:#97Q^Y#;AU>
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M:PZ:9?5"'1'FVWS12;UI1ZX7,/^5WRN8EKL]^BG[G45QC-GXU0A]=@6I/VD
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M%M@(;9BN"$BT"$@E$\<UT./1:%T!F+%PW]9[2?+VN+C$2)[+TPW;ECP1K>5
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M07F]W=^[JW<<UV/)YQCU9:C=G#@T <*H3TN'?8'19)VL9_L]1FE(Y+NK&^@
MMF<34JA3$V(;)!B,$K PIK[AH$8/TW -TAR>@G:;061GRB39<_MHSKW!=W^!
MZRU@:;QV403"35[.]<6]@&A#\PFI7.B$R;+38P_>MF\^0E,K:6)UHM_V"8AI
M$S:S)3!)6K"=[%7Z;C>#:A-HG_SR\+BU7'I2K["O;R"1H]*>^/S%D4G5:*Q2
M758#64ZBR0 F=M3BDZT-U39RJ3IQ"C.X?(_[Z)ZG6!ZL6+/J3*L";TK5<32/
M>U?V0N#7^MRFC[V^__A_2AYUF8X2="]:_XM[D1P[*H04D!K^U16OO<R->'JJ
M$^#\>-[*]@;@NBKAFCJ]1*FSR@W"!H?N?A05V@+80HC8N "A"[]_H.^BHT'H
M84C-4(//\-U80NK=P9]B(S0H0L+8X;I/S;,^T;<=#N@Q;#YDWUU).PF91RG&
M9?_G16D?8JQY-O529Q9'&>IY(J)F:UVE]N?):-N"?D0+Z4ZM643I:!^9'Q!U
M+Q_A1D 2AYH<CY3)Z7MQ=%U)%6E@@?!;IMIRW:L92GTZG>!A MF=0JEJN\^]
M5T5H"MP0/7-85XV-9?RNJ4^50#WF*Y6+9PN?C2=2VQOAV<DY3=G02R(Y1[[M
M%4[ %B)E.*I1FXZ;0LY28,]XI,:Z):%N:?^G\Y6Y6#?J.P@<^<VZEUX%HVY<
M4N=IZE7J%X'_5*7ZHZA56F$6-$)<Z!_Q/@+H:' 8%B04\RQ0A#HV6F +3?,'
MB.TG^(><W_KAE4P0*UH=) ?\-F(R(LA;\='%ZXVSI9PE=,>E3Y)L]_J=S1_0
M%AD*5H*I$Q/$NT?!4TF00Y<QE+:%A4$EU6SC'F0P:>CY_!%!IZ3;\EKN*@4K
M>(1 SBI>" 3>4H7T,D]2$*V?CC"VSVA#YF3N:MK&!;]6&JL,U 0**>/!"49R
M5D\/B:@'\8.HDM4 >68U(M7>0R(TJU$+.(&"#5VL2T@]'],H0<GT"?+^OYE2
MK9-D;;Z'>G<U'B&7>M^]DPOIQ!+#WHU*OK7^=45,4DZ=39)*>K*0MTO*_N'\
M*0SC5YI12YC-/?:!)I:0D&V0INWK[/[@K,+7RVA"293X8M57@IJH6_]C@HL0
M@5AUUN5FGI>M( ,8=< Q+(3HG0BG,/2P$(=M2VI!*/'EA.6.4FG662Y3%3B%
MMY4%IX[;GLR*WW$P5"VA'^X6H(U9HV4I[DM015224052S,0R#L/UE'?EC,#+
M9\AVBSB!!E7U0LJG;"PS8 U@DEQ@5'7\@2;'ZWP8;8C6;GLW&UX30C:5EY1L
MBF9T^9QCT)#F2]!0*PR*;M")7^;0:P9J2XTIV=%ANTZ;, / ZDM*4EUU:DA&
M;V&VD/#P^,;YI/Z9A5M"Y=;7D D)A)6^8;1 A>%CZ6^HWHE"HZH52ZX_;5HB
M31WK'ZS9N^=L*SXXORK"<:@ZB(R T.*QFJ'US-)"OD$W,MV7Y\T"-^@?'("Y
M#HR:3_J&/N8KIO569C"Z[K'YYHY&@[=;[$NW9EBK]F0\4[!6[9 1ZDZDOQ$\
M:\:H1D?78'B^<7*\CT0'07CWS&[JV:,U%''L6I*W2=%S1 [?*=&'PIO,I,G0
MJ.&A^358R:7'Y8..*"<5[H260HK __!M!!?)ZPXLJ,("]8^T6RJ:3W1S+#[2
MRJ_H-9'%QFIJTM+]^^7&Y="0DA( 8#95T?\#$4#NOR]+,VU7.=$R<)0(VJKN
MBMY2ZV$,B\B5F)*;S= NE-B@=S[)C/D/:]Y'\!0Z[.#.G$!&H;/589]=C$"Q
M'HI2RN%7SQI2S@E23DLO* CRT((O''RR4=N4)B. 47]O]^8 ^=KL&RB#S8*"
M&KR!S8:O]52OS=JLT_J>JPWF[CF&_K9/I(LM>+I8&F@.%\[UFH<&IM%#L8@!
MG7&$UQ:'#/6-;+!9=YT$HGK($E.3BL!3#"R#$E9W17$ADS&91K74?TS= /+9
MEJ"D8(@4B'@<#@Q#&EC_4WY\AFOU8\9)!&@0Z'XND>5QA$$LPW9<!%?>T+RS
M1Y?% $,(Q.28AH8,A3C1IWBTAC[TD&ELWT9HQ1LP.SFET$(\3">*YL3^C"3N
M9E[YX?\EX(T0Y;$NC4@/8AKGH=+\9BH!D-OZ:]WES*@Y3_MPH$WMUZJEKR4;
M+=%G#]-:#ZDJK2!EC\Y:,M):LB4C/=%7CR6+:J5#DLL1)BJ7=Y> ]+4V79G0
M2[73!#&D@41<MW&  DC=1N!217_X#5!HA"2HAS[((5!X6558VJ945S/I0\E6
M>PL%(7D00VT[.Y*)YGWL^F1P;L.PV&')-D1@W)9_#<M\R@'  'E!/*!ND#[Q
M_SA#&$ZK)(B5J^OEC,2S&, *E$8,!$"KI+:*7(NH6!J#H/X!?$A-T"?HU&'?
M.#QP; 1UT&+-DQUQ_NHN*A>-0?'_.'BPV4@IQE*-FFD#N635582'P3SME'SC
M6X2X/@>$/[@S+_ZYD*I3K=P\TAH\HB-_:=*KE;\Z.L ;?&H;;G7W'\:O8QC2
M^4RT]G[9RT2-5S= 9((F1M.P2<IPT(NV3UF,3,24#<.A3$P,>C'&#!,#39,8
M99DR==PW<I^83/OH32R925D:96&(93) ;!*:3#CV91*S#\TDG1]C[NR)!DV]
M?=!0[M-GE!Y)IT^A1I7J-%J]:/H66AWY41DQHQ!'9O\ZN&]9TIPA1X*%-NPK
M2V7*M)XEMI48TK+TW"HC"5(O0[YS/T(#"[9K6I#Z&/;UFI/8PK?1YC*<BW7I
MOJMELUK6VI3LR'J(,1N-IE!?:-"6EUX=G7EJ:\LCZ>F]ZWGDZGU62V/M?-NS
M[MM7C?[F738U0Z7U[&JVK/ V5JVCX;Z5'CUZO>K7HT.S3GUZ=^GU-'D7/YY\
M^;?T-+'$@>"! P</$+AW$'_^^_KUV\-WG\!^_/CYV9NO/?<&') ^]^CS3SX#
MX4, AVC,BW \R"2LT,+IB-''NV5B4V:9"RW\T,/'8JJKKZI&PBPGFQ 30PQ)
M3F)(DC2&R2DX929)0Y(WND+_(Z:/,O$QK)JLJW$9Q,"*)A.CE$&#D9.(L0DB
M'&/:AQA-)%OQH,+>(B8-Q+0J2[N^7"NSM<\^XXVTN&I#C"PW1RHNN*?F1.JI
MXN)TBK.%2$K3S*G(I.THH^Q4JBREMB*I+.3,TDNAII:RLRGM%H*44<[2! VQ
MIG +CE% _S2NN"-'<PK,WE!2C3DFCW/L.*3<K,K-0],D+<[/9$U*1+W@&M-7
M9:#I%=BWM O6NM&@.9+#4I55J)XCW_KLKFE3K<=99Y$S*EOCMM7V3:.6&2:3
M9=9[+T$'^)-/0?@&3#<!'.KC+T!T%Y1/7OWF?4"&]@*<5U[[W,-!V7JLLXJ>
M90\N_\W9TJIM&,VW& *WM&Q[M>XV[;C-6"^"M<NVV&VC+6M1AII5F"QG94/Y
MY*I29GEE>AY5&$B+CTQUJ<J<,JE/J'(+%4ZJ\.3LYU 1A8I/SY"R-%&BF2:I
M*E=[0Q/1FH,KKN=$;:4UQ=2J[DS902M+LZR->PX.8]%(^]HIW"Z&#<6DK#+;
M*.>V[@Q,/O5ZNZFG>7MSH;%31$VXF@^-:LXR93ON[J[X&C2Y4N=&KJ^:]_84
MPLF(,X[O[9[#=;.F00<U]-$AWB>'^_@;$#\"[TOP!TW@T 3>-V!'X%P%#\Q=
M/P$1Y+= _^#[873$AR^^].*13RQ1.5^#W+$3?:/4LZ.;X__3<K:_WGO4NI<C
MB5>EKAKT;TV3LG7PHXQ+OC7M-LVJ6,TN4]2Y2OL^,C@4]<JM5,$31^Q4S9#R
MM,K$SS@80PK&^A8G96&E*;3BD_[0Q[!$X0I3IV%?<-(&M@)B\#C+B]NFEB:5
M0A$O*7\;R21N()8M8$E/5/',#2*SOACN!E56PH&;5H4H95!/?:&:80]#5:[[
MQ,M>JVN/O.  AP,<P %JT(0#-/$&!\4'!_"J8GUR<,5T[:>( %N7?' "1#T5
M3HQF"E090[<Q^ET0-7."'&T<!9Q(=>N C*H,9]9V*P9N#6VL&9F?NN<TSX@I
M*6$[(QKYUC;>I"ER=JK50BZ#F*K_L"]P@K)?WYPE0*HUYS<XP]2@>'.SU2Q,
M:Z\J7V:\=;&J'8J0Q!&-WR*G**?D[3F<.51Q-G:F/UG,59 JR23"LI,F36(A
M8G&)E6R2D&C41"\@\5$F)$&=2<Q(+S6)C%C0L!.J,5!6AT-C:W;XS3)%XW3T
M,F?OZ(,O,"( %%',00,T\8,#O $.\<F!,F('.U"D 0=1# 4HRO4O<RIHB\!S
MD#@/*4ZHP$6A:52@<O97CT](S3$]B5%P5+0G3@4N3,L)#TL8$A[:8(Q^U?/E
M1T:B"4FP<)@,J5'2SO>^AD**:JJ9'\-D%1HY8A1.-9LC4DZ4P4+R5#6,(I16
M]() 6K(F_U5N8Y@#W^0XX_0%IS;3UDT9"3[<4,XVEB(I30,)'-&946J5[,E(
M>D(1BDSB(M#T" PK0@^+>B0&)HF!3\0@$0UI @9!><E'/!*&&'A/.2D:84,7
MBD?$0D6(6^3/%EMGKOHDL9\Y  4:$) &4-@S&E6,A@/2 #M-'" -RQCB0,VE
MNG2"D8<]_-!BI9)0V$YE61QL7TE@@)FF$,,DO$7#2.P$I_T]4(^(BA(] +"3
M?<!0D4CK#$D[4Q&&F"2O)='$685T*#D^%+%O<R5O(LHP-[D)J1W,7]R.%KG_
M,4JW8LVJ!#_9MD?FIG Y;-]XXR:H5I5O>J TBY@^R,FX[&TWN?_Z7/<^93S4
MD*HR:;A!-C=2#Y;<0 S1",.1Q'!6:,2 &&&DKEYNL(R!Z 2MP$PA1;*)I8Y(
M,"GLJ]ELGR);V);S7*@S9[INQT0XT.X'F;6#/4$!6DUD%A0 18 /0@$O]IQK
M=\"K3WSX$T8TRABQQX.Q:ZAJ&Q5) @<[&6 88O21>F03(BXZR5@D$247S25^
M91%#8\+@D>7.!:C$& 8H(H,SLV2BKBO)21I(3)%]B 0Q:NP,0Q7Z*+!I<G*^
MX9R'W#0Y4&;N446=I 8_@VCVPO*FI%I5<FY%P QF13I.];0 GR,JT>"T@J\A
MU:6R<K-"7IHYE3MLC$/5%T^11!([<='_="<QB9W<<!D9!N9*PE!BCQ0[-@01
M9@RT<P-& )JWO+H!;#1W(V_"V$-7=DJY]'/$_B!(7>(&K0,.$,4H!B!V\_G!
M9C7K@-=%\0 "&V+J$I0?<JO. 3D09VR\[1DJ![Q[6KL9D^1<*3E';,,9(H@R
M;D"1N> @$P$ +,8X,Y!@47<?,%'44#)QL*-8$V(<UQEOIWF;B"\WEVSCS,"!
MJ!4_-:0OG$(*,:[-7*5V<&KI\Q9Y^\L3Y2(03'3#F:=.-<>2YBV4:1(# (#I
MOKYEE;^\P9BL264<SL0WZSJUY7[C:[A<;S Y9UTN2'PM!GTDA"(DYK/$1^P1
M?<3 0V#^+8='O4(0*T$##9(HR4X@.6M<B7';8_5V9^5#+R;3BUWDGL\FX) &
M./1[GT:FO /&L%EZXJ#RRN"BNKQ(1"(>])MDB@A=0-<5H/J$)#XYG)4)OM!;
M ;5YTX4I0M#J(D&#(MDK\4C<1X(#-C>'M].-QDKE+&/&H2$-<@U/LM^\HB!-
M5R\>#U\#MZ+8TJLZ.3@7I-,.1O>H0&UM=D(@^F1/%6]2RC>U=XV?^$9S;..:
M3X5R%4EE_C\31G)_ENKIW9I*IO^BXM9$!^E.*$8ZHDF(PB.:+QIV0B=<Y$/,
MC"?@ @WTPD<F >>R:1(&@LR$SD709%1 0_N4YS9@#C84(T:LA#!BC 1G*P>@
M+/'^0T%:QW?<XP=^8#T:( ?XZ4#*Z0=QX ?&X TVP<;ZY<86Y$ <X$%*[U"4
M 0!. N)DK/!RP@",PB1L8A]JHB9P+?9B*UM8HRF:@B*>)9O:CB3" "'TH</0
MZB=^Z;<Z+AFJAR&N#>*L0PQN@(6F*YLL\/SB! <8X08.($J@! OIT"B8:WNX
M";'\)/\88@O0( ;$K]<<HOE6KB(<0@LKXBUB( #43N+V0?@&X@ X#.( 0!)!
M@B5<) #_T* I^&P%?JL1T>  5. D=.*N $T%/ ('H) .DRM_2N(4U>S:,F$%
M# "8E$$2)L$ &J$A#J!&ID?6F,/3ADI0ENI-J"9IZ(<*=\9,+":I'''^$F@
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MQV#^1,Z,[E/_FG)X1NGZ%L+[;H/NF&LHEP$F:I//Z$%G@/,H8L#-8  IQ.
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M2)'$>*8N \G>Q#*W+;"\"@!@L5?<-+$NWZ$!#9H 0!AP$ /?F4UQT4CC#<(
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MUR8!*T;HTE<=;9O4HH;.P.#L;8BCGC*VD E-Z*Z*XA+# 3RG+&EM*S"J>Q[
M;@!&,0PC&BI ' XR]Z!,@#2(7I$?4*\:I$Y>%6@ZA4A>NF)6A/S&4%LYW_M<
M,S/9)J@ITFR?3&(R)Z40)38_Y:1LXGL>!(MUP4L+)@-#XCRWZJXE4]F594W2
ME:D$ABA!/)!1SI:>K\+D.0:B1V!"K&']#(DH4^')Y_\\69@A)=2G(@-.3:8R
M$#!*B1A0"3$Q%)JE:A%8)P!LU0J8:3QM#>9;?'S)'LE&#$WLCJ'[H"KL8'
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M+9GAM55LQ7T#DZ0KL*J()B*LG$.3#;L2 X/H0U++BM#)" J!G;$H#AS2'*V
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MN@/O5IH$A(RF YL$H9.+!!,#&(C*.=*)<1X-K.2B3"! J%8F?9COQ=J3*S(
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M,=./."B#QF4QG&J JM_A $ ,,61Y*@ W*,.2;C?@6NRKRD CK1C0L"K&)&A
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ME4<F0,-"^83D@9W!4,6>V83"T!!W $C A8>EY%=\R(1$Z,SJ]4\E69)/: (
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M*XHL7@'J*%?,*2/JJU@<+8PL#OQ<X9@2_PIW6A7,AD7^KE4N\MO]*</QC,&
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MGH')?B@3D=H_%C)VS:_2O'AA:!*DB3,6;;PFB%JO&2TE('XK;F7T3: >I.U
M><C#<;?_6&4D71+H,7<:NKP?,43#T>_N2!B8(G(T3((85QY&P2%_9JC?(-.V
MHNOZ#P9ZHN3LBQ%B+BI0[LP^0?%B0.K0;)WX[?SV(0V4#.4",,S6B=,0 A/>
M#\TV[M-$+0S0XP;H >6&X<C S.@<+0 !SXI@8$/6+,RB(0;HH>XRK?\@CQC>
M( S&;A@8K0.'#"@<B;T0#O(X1!)Z@KPVY.[H+]/H(0W"CA@P =WBCM/J@='&
M#.2&(0TR[>KN;T-6 .K>( +7;?)$[M)B0@R6004A3^1Z#@UR:/1B(N(6BQ@
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MGI=1T # ;%/X;Y%5&0Y !<)4DF/ :BGV[<06  Y@(")3$W::*+5T4I8Q>F-
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ME41EO*#4(O$I:5_+N,%D0F*S'3TI(R*91#2(L9M#$NR2?ORFC5A4(X99Z9<
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MM#VMI$P-]J#R\YM8YGI5"LJ10( 8K06YB[[J(XWVW# ]$:W! $OO$%]O9F.
M 6-5#(#G#D49VP_*TV& W7 ]LE.[7,1\]Q(&>)LIQ_BY@W)#]7#$"EVLXYI;
MY'#(#+<34AMQ&Q)ETW46H(K[LM,O4< LYTBE=_)8S9ULRA4_D2K$C4;O#=0C
MQJ]$<GT#7Q22BP$(1K/M&C1\DU[/C>;"%ABJMA!YQ4-GZANV00UY)T%C8["?
M%T+Q=CIN4=R)]R869?.^FR#>_F!NV"0\VG+V%A!7]AZNF$/Y,')17+%?<INI
MGJD+,Y>0;)=,(\U'7WWC99M4+9=^M Y;H%<_N[()/:%#?"VMY\[9/&98CMJ\
MPH=7KD^O(UPZU4A.99_30Z$7=I,._Y5Q _ $\544MB92@)C7Q0 &">BK8Q@@
M;:P8 [RZ@@%:QU:H("'@S%'(0^91#+"SC]@3;9J@)#N-M,4 Q_LP]+7*G#1B
MTY_T&& -EH\!YIP1>U3("5KHH= &.&#:%/6L<BV-6/U$<1NQ9C:&CR*"HF\I
M@P^\&+@@]ARX.";# (R%W3S8Q-:T\AB@LZ, FG\; [1OD$@8?S_YM-AN#-_8
M)ROEZ!; LM"KP_;/:_#;-&9VP=8?QH^<;=9<VR"Q+RG='WA'A1>[XXEJ09]1
M08;_&7'_:) 8-.-@JG9<>8_IS:<'=PG\3DOP/,[(.K53=-&W72[P#ZB1T+>B
M(<]B1@68BQ@L_>#7')K?79>DFW_R;C7[6KF8Z2GNP"&T]R'N)!B+1&"3:6F;
MHV/=1;[9%G4?7*ZQUM;KYB8BG2=3RQZKR4'+&G)E.;M>O+I)T<;DY3LB,:FW
MNGT\<Z;+O!>)5K',0"^;G@%%I TJ>@::_@XO)+EU5-2X?!3G!4.</7Z<;4_*
MWMPB*3>[TR?DO;S$! G=L?L"L]HY);.#'FT@SZB]+IP663]JM$LS#L>^>]:6
M'LI'*9\>RH/-IS]JJJKZA"1YIL]%*$AB=/3EI"%'*O UJ4A,S>-P=\W4LO$^
MVF^XHC-)=8;Y7=&U!@HY/6*!#J.#\7CLO<):H 4]-#Z@AL6V/;YY035TT=0*
M/<2JQ #-P1C@B>&+AWBWIF3N8@!Y.RB*K@H#,.2^\%$Q5G@VYF51E3HVWWRM
M('DD)>\[R:OH8.9@R4*5SL&?J^5U8QSO[Q2V[26Q?UCQSAF7F\Y_B-=PF0^I
MNPTW:QLZ(HH./7XN^8A/\,0[O1:UR" F=)@PTUNR?BB_*O9$YB%4?42@J4Q0
M?2)1,#ZT:.@Y7 M[..S#KS32B-"%\ATFM9>+"I_?VW\L=XQ+Z.6Z=]&MQ'$C
M2IQB"K];DME+1Q-U;R2\M-KQY\HK$_&X:/U)*I^EGJEZFBAJ^H[CQIT<_&P-
M)4GZK#2<(F_K26\Y$34%_O&MLF;VBN:H9?,>3:S#]2ID<:'B(AGMY(GGMK1-
MX:>XS$B/I^U %]WRN:[,W%7[9,V@-;WI+:7,L.*>&/VHU>)S[H.LWNC7>Z(?
M!?1EU172:]1H.VB2QC[%"TVJ4];&$Y\[?QDP-S8FS"[-Y(6GUQM_*]>D]%,N
M<O_:*%BV9SH5GDG1'A]#\!U)9^8R#%4?>V^EJ$#U$*(\62;6TY,BK53=4*ET
MY4XX^_L>7*V'JDP\'!]( PHM/<Q;8^PTIUM$#)0YV!YL/KD6\&&9VHF -0QZ
MM[D-T&:!E/.O[%ARJ0Y4U.AE/*I;65 RC97&6ZRO?.!EGC;&%F$L?O<:'W7+
M=78)2:;0IAH?12-?L4?:&"#*" /<1K4!QF!L 9?QM5(<AMA_) 8]OH8!ON$Z
MN<YZFV. F.0<#%!#B_;C"RAVB]P=3Y?@];[_2_#[,?KN6<>%9S8ZT 0#F$#.
MY4!<(_0P0+$6^.'\N<WN-@Q G:+EBT.E8UE3,+4F93@WPU](4<O%?J=7M43#
M3W9"JU8G@Z4P<W*#/"/3_69!3E'U8X+.SC-=R5S/4%[Z(K8J^6&5Z.L2N!,\
M TOPA=*ND_P6VMJY-X>&$T7FH4-]+2H%O?2-%O;$0M"O4@'&<4]LC\]>C U>
MKZOPJ;HJA*<@T1+A.>8W*KKO)%@8(@O$(=J1''64 RPK(,*C;U_Z_9_,]R#G
MQX_9V^@ND#G"H2&'IP_5B&F+F?RHH_FG@YG?2"P_P@ +G" ;(HU!> !S*%Y3
MDGSN(-%R5PN+BC#R%ASFC-#1-&+*PO6?*QB@K%@5#(8))(?GBTSTQ'"DL<#.
MSC,,$$ES/ML@=3YV005151]Y/&(6HR3SQ=PG(H9-1^>+!.OA?,#)Z&3K((0A
MM:[#<! #I&> @-UO"D'N,X%O+D9<)(Y3&E>USIV23B+&F]"]=B$%634'$TU+
M99]VR5#AO^:V8>@ DPX3R7GH*>-6TS3B J_AU;+>8$JG]D-ECET@/Z@C*P$#
M$)Y%L+/Z2XW)O;(QMZ(><:.Y-DCC!G_H4IV#[6[0 Z.L9R#$-PR._ 5%\<:G
M[#%^?>B3WS?VT51X9<87OO) R%-C@&4U]\BSJ1N]5)M>^D*=:JWQFHVN2F/$
MRD>@DYQ<5U;JE:&V<G:>R#LCX\P",X^"^]YB7LOOL0FZS,+IOB[]F'YZZK8D
M.6 _=JO%RY!C=V?R<2B;"[M]=30.3(2''FC;W\+YX'Y4.$=9X+APX\G3J Y&
M_?OT7[=YQ<4?2"\-E7GCBK7.,LTX&34E?:%]WD%'MUP'4I)I():D^RYI!>?(
M=I-YZ/6BS"0)U# ZK-?LFO:D'PTC$\3/UR5^TQA=PS20?3,4P7\=M_W+5) B
MT^'96(KF*&*9%O8-<5.>UCH]%. !VZG=$A3U;D;QHK/I$&+$[(X$M<+RIPW8
MM@+(F43SFS,9*+&U""(DI>S;7[X@C-"E( ! XO^HVZ3KAQYHVH>.P39'88>\
MQV]S&P?L1"=F5C[:>\Y;4:\L8H#0_EJB/:7\_+5?##.1W\487Z1.2W65?F'G
M?4XF)I#B:&>3;3BE]YJF%)Y+?I^:" ]?/>LE-TJP>@\#7#M S(/X6K1M".X@
M*+ WKS0E*R5,5?B&':.NUGC4LI5[+ O[66^ZC^9##3PKPE\<0(5^0XQW@_ZY
M88S_VAL,74+%8(>C)_8.J*&6'L$Z.K,&)UE9/N1)&?CL<NC185-7?A7.<#%-
M72I<3CB0OFT[DC:?!K9/#E)$T:5Y1,4Z_$W+; X8P!A$Q!WJHT>J<4A.O--H
MD'JNV^#?5C5E\$F?Z)7:3A1#_G1Q"WXXR=C9/!-&<]@AK[ZRP?>@QMK[UA/:
M2*LQ],26]YX(HWD8[^=TO*..3L1.L>V&-9W.L]J$YVM2KST]S#W&MDL"'V>_
MQ*?CSI;=5$FN]@Q5RZJF8R$I&2F?(\MD*(@X]K6+GQ-,O+/]-7QNVP_!L&9W
M2R%N>3B@AT^:_NE*Q /L$NQ]ZG123XW>Q"L*5(]^Y[=N-!>8I-R&T0T8X)>Y
MD9K;'"5B6=H&7#T,<'ZSB.MS_.J &0:(Z$_^ MN_-84!JC' &8EG8R$&8/7:
M.9L'KPB+>7[##0/\QEMQ/J*3Y1A=#4/[VV;LIG[2W_4>2"ZW\V!4KK(,$C<C
M59977A[=^3R%&*@W/?Z25\N->K6%!NGVCMA'O38^]DBH07J;EHJZ^\B&W-7T
M[-"*%05M#1P)(B'I\9+Q*&].#!!=90IZGQS4;$=G8PE?O<H<<FZA2E%AD11W
M9?M?O70@=E(J:Q]4*5-;#@_+,B2I\'OFT=GV:#<E*..3S;[A[%2FQO8,"[<^
MTVJ16WH.$[$Y5_)2XL>$K^,LWKHQ[45AFD.<T1-!=-TEK,5%MQ?S4=(U\3M?
M'Y9-EW=11>+<GF$>)/])U*8-]S4Z["?X42XBM#B&DM_OD#*:5;-WI;U7Z>4:
MX?Z6!T\]7A?8L??.MH&**[A+M2C5VB>3"TE,JYICLZ=^& O_OX28SU\@5K.!
MW"<"05\D"(Y,VAWX,P^MYB$Z!7;0U4UH?[ON=@1U2J)#]-XHE88)Y$QXXLQ\
M 8J*39&^6$<<BN?X\H.14$AVX2.X;YO\=QW'ST&X#9]"4U9A^\>C:*NWHV\%
M3PD,$>.7%!>HFT]C^B=PG'6A^$^JO97.G,A:J)?EV$[RBVQFN49$IYBENA;*
M$WI(KCOT[31C-7@P1=J>EK5!]^5. M"-D?O%L2V#VG;P#\G*<^9;W+H33U9U
MNLKCBC>B&^7X3A*V'%PO$K(=;[X9Z)WXPG%VM#PV'HCFV?2L"K47S=^2ZV*O
MLV1<M)RNUG3I8J]X6=(UKU,<@%C.6(,>@3K^D-+X9+HQA4@@T["V$FW%9?R^
MA]KT^X.KRI\.FQ0V?%A\U\]T<9[Z=/QXUC0K-HNL]8W[ JWWK3A=I5(NMG(4
M61.>J]@'>C,@B63R=GF[!S3#(1RQ]4=BW6Y%^2U-^Z2PG:3YA>]=2V(^])6R
M@A8'8IL1>S]BBVT'UW?7B@;SNN__+$O<S<;^MNH_.JXLZE2TSJSAH^?'&XXN
M=;"R/,@LZ=;*F>34^! %*_197WI>:0WQPT_+UC;=NJ)^>A: 1@N>C/K=%;C=
M*?<.6^W92\<_4U_1U*(C*M@!MCD'EJABK6.:TZ?3IGO?ASWPT?!SQ#$4U#7%
MNJ--RV1>&,#H\DILA04"@JEQ[J(#7#J[T2/'4^Q9##".#UZI:?E2CO3(D;T_
MB ^Y!#KB(W@SW%K']R]7&B<:JY;0'5=8:W_^@B JO!8#7#@%GXT7_^\X'8KO
M&%1?"#XQ/V7';B?ON158;""=7;5/WO\S^;.&G*5I=%P-=BFUX9<J]UN^="%%
MV1&+2HEM/SYJ&O$ -+R]5UA6)0NW[G0SJSZH+?U 2=*K3IS\@'1,DU1VUY:9
M6R52Z?,YO\N U/:-VN=9-5O[?C=/=(*LN 5;Z1V6WS\=BHLGM""YIEYC(C$I
M9GDW\GV "IZL=DU1L=Y[\V&+F;K5+XP/JR29G210ME2[[0$T X**I<8QISV5
MN(RFYRT1]63=A1M-^U>0:[#$M"OE_]@B\*ZX+&J>_;.HJ1NX5(FN?ZC$[4$T
MPZ$BKGI(:MN_B,#I(_53W!G0S;27;O:P^GF. =@NS-$-E_11[#(*6Z9U!Q?(
M]/<"F<-"^WO%.T\V0GF*@0MZ>Y^;NY%HY?X4]&'3&:,6C :QK!.,;DPX%5/[
MF_M>-8@]&U1D_P'RU NL2D7:-MH24*]O-&WF(=;NY/\%NCY/?UFUM2PJ#K=L
MHZD/=$-ARSY[(.2A*Z8JD76F8AX9:,4Y<"W'!]':!W1DQSD(8[)B4,[6:!^:
M)HGD&S;/[6N4DYV!+SF#%"2-[;JCWCE@HVN;T'YVW_L0,\@\U  CZ!P?DQ@,
M,*1_^/(\>-T(<MZQ:7QZC@QTPM^!%OKJM\'V=U;/H#;Q%\51*?EYNSNH@,CS
M'S4FHZ,>[NC;'1<')@@2#-#H_;[R"4KP?3O*H$JU&B7K(,1%[TI2E!8=77ZF
MPXUB;6090'E$8P ')*@LB@(6(\\P /$!!KC)=ID=$9Y;B_P*!MJ+'[G*U_I*
MU"Y,Q ]0_=+ZN\\"[=)-C>Y:ZNBEN<,/C!;\8TBOZ.:>\,3.IS#%*)]S>"./
M[4+W:%%O/9$7GEV7C]J2N0JJ!/A;, V#KUL3^]X2EZ?]^L/R;(-QKPO7#/7F
M&9-5Z\ IJ<&_1^CXMQZ7^3U$NY7:;WF* 7[K4U,=,+7+[EPX(2YPQM_]/7@U
M3M0?\9_(6?4;_(D_]<_^?*&XH)B2B&@8P0"44L6OF_;%-S' T5?HIDF3R>W=
M!#1\!H&NOGMA-[ZI8@A5@ 5!%R*7 \&Z^JX(H8QNIK+,54698HZ#KF>O6-TX
MO_E]_S*/U1+;(?8Q#PQG 40:VJS$M%E(A=YJY-D*O.%6 1&<=+%[0N=*#5SK
M!>OYV%@9D>JG3N.[U,U&OR2I( E+4'*C$W?UJNJ*4$D&_<JK7$YX0UX^?$'5
M)R&YT^7$ORI;NJ*4ZMR)HPB:5[/%AKPU0"]P)EQX8X"?A2;Z2M:')"*+7-D^
M>=\G&RKR,@\R[;7$Y2V!):3GX>SHO"<^*LS3ZL*G[9)SCOM'FI$W_J5**SKX
M"[=ZE2."&JZNCIR\_VE:MH,*/HH\.U*_(&H8 )$093QWX7SI_"#?/\M6677T
M;7?$4=LE@YCHB)P4_&RQCXS(20_=)1N,[QB&$H!D_6%];D<5G$/%W3TKM((U
M8G,=$:LU]W<]NG5@[4&#[$3M2&* A,;B QF3 GU$YYTI=&TV^C5O@]YG<#*!
M51>NZA<$NF,#EMY&<AP^,G);WJ.+D:?02^UJJGBJ.Y2Q/=YGP@-FV^-64*\B
MXKP;L2\VH.-W-_<0V]H^M#_"MH\*Y^=.>2;Q+UP1%\"8NN?8KN.?P0G[ YS>
M)C&H]R TL_^ YC_.3..=U5%UI^C@28LFNV5NVXUZ:9 'EM"G1;H5KB;,X#R=
MP4^/(UL0.T@NAT3$E1_/3:F:QD^LT%_!:=X6/1A[OZ=Z@0A"_.2 '5*JR]KY
M<F, C\B/15<N9F&PWMY_ RNY/V#5=O(6K="GCFYX>IDQW1I!?T:SP\%\>@^M
M/=4";4'F1IBCZ,[0P;1[M]!W*Y%'.V#!R;!H5WF2#*;6*?6S8PSP/=Q9['!H
M^N3^_XN,R 8JP&^]3USI>B"QKP80*OE_0*Q:NAA[H^I>>E:!QMN>$'.6)W)*
MT4NNT1[GFZ7!*+)B@ZVC=^[#3Z_IA@E<P06VZ9F8(E?DF9K:R$ZQ]!'C ^CN
MT96X#005;)G0 @P6V#F?;KSF=7OK->C^S77DT3$M^C7?[&:S*-DIW>' V?G;
MR_IEYT7K0#SZ)@;H4AM!3(.WY*F;QU_^A>L:)F$M)F\.-OYUQV/]3TKS*P:P
MFCLEV_S'WMTG4 VRUC6=+?ZN%OCH43IN3RH5.T0U%#SPUWK,UR-?(_8?O-@Y
MS@*]./GQ/XHOV&7QE>?X=SWY,ST8X*WZLJ_[!PS0,Z=[FBKXUTKLSV#BV[0J
MDQ. 4LBE0MT:;?<449&-K&  9:#RUS6.[7X44R$ZSQ?)SLY@W8VF$/01V>;'
MHY.F8][&MP=P][_"A;O!SN,66D7\%?@:<"WEQ7[^0&X/C/I:A4<C&@65?>^?
MR5P,'Q8!%TM'1:A_GA7W2&2CC5$8X.[6I7RD_#-F^"9KBTG!]98 B<UN8*'I
M>"!6O!<6>" I&&JZB1+! $]^T];+S?LG6>BF%M@O"N@9879J11,E!JA7_#:.
MB]Z!(G]8>OP]1MK^B[Y_X,?B_P/\\,;G@T^J00><AK;N*<QF6+EG-?A5QX@G
M%E3NPMNRNAX*+]!K0:I3VEPVV^SLN"R&G^YGP/$9WTH:9[!'-P\,AP(K:!Y$
M)T4/NA'Q2Z>8O_C1"3@I5E7!LU/0?H/ZS]&JYHKRX!PB[X.^JVXZ9#,Y-B%,
M0W1V?$*,3YN>D1=[?>+RKOIOR$+DHT6KTK^0B]JC/Y$+[;\HQAFQ/RO&EWH#
MBV5E))_E)$&J_@*#&T+O>[.#7.>2C6@01 >-DK4A3ZG!B1=GH=4>_6V/R;8I
MR@#!?E"_BC8Y:^K=\RP%,P3;%<<S$*[D>4=F/>@[-'-'X-S83/5EW^\YG40?
M[IY7_$,5XO]5%0Z0(_Z]**P;J[JLNZS_H^["UI?=-&QN^D,E$A9;B6( -]_\
M QG[MQ=[GJK[5H.KV\BLWUK0?>M8?:@:>^3";K__.LB."-BW\_M56]ZOMXQU
M@Q'+3(@YL>Y??U1<!R>.%P?+?65D"][]JHL)EWH/ TPH(=:X4CV'Y:XCBG<'
M+EX'H_UM5@L=6S' SM5#L69$7<?JZ?M4<&&B7<!\4:P/$I-QL3]L66FP:7,0
M%N=L<MGE^.^ZW'8[=E<WS!,Q )Y<T\<VE!J(Y:WL"Q %/]NKD[8:_[JAXB-:
M)4=)BW)[,?OWV'BIZ(=8=JS" &!*.&0X\C%$RQ\W'35?AH,V]/61\$# #^^5
M=$0GR]P:XI#=@!KYI_-WOE0OOP>?SZCOB>2=@!J#_5D3"$<V=,7FT3*4$+'L
M,(X!-E_#QAI\R[-*#Q^=/$'3H94,>-++18BR_B":4I3Z8L#"NL.H \V\,N,
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M-.:E3BE$V?536%61K&0E@W&1_TY]A&MV5"\#^C)6_'Z$CRH8<U<5M6N=Q)-
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M8J>M@LG5P0S9^(90B"=,ICBFW<F6^'-34A\%(4_F1"Z=W9O!=M<G+"$<>D<
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M-C, B2@W4@;QR/5=$C]F9&N%0*9'&L=W>2V,"R!5^F];W@S$0,MH.",JZ;^
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M.I)R1WX_P)H WZ*** $.<''/I7%P:)K,7A:RTPV]F9;,Q2JQG)WNDRMM!V\
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MJ-MSRJ_='/IFM"B@ HHHH S3HNG&[:Z-K'Y[3"<OSGS-NS=]=H ^@J >&-$
MB TZ$")$C3 QM53N0?\  3R/2MFB@#*_X1W2#-+,=/A,DP<2$KG<'QO!'3YL
M#- T#2Q]GQ9)FWR(F).5!P2,YR1P.#Z5JT4 9L.AZ9;7OVV"RBCN-S/O48(+
M?>/X]Z=-H^GS_:O-M$?[64:?.?G*XVD^XP,?2M"B@#,CT+3()89(K.-7AD>2
M-AG*L_WC^/>EFT339[F2>2SC:65T=VY&YD(*D^X(&/I6E10!FR:)IDUU/<26
M<32SKLE8C[XQCD=#QQFF+X?TE-H6RC&V59@><[PNT-G/7: /I6K10!DCPYI
MMI+<6$(AD<.R ' 8'((].>>,5.FDZ?'ITVGI:1BSFW^9#CY6WDE\CW))/UJ_
M10!G2:)IDL-Q$]G$4N0HF&W[X4 +GZ8%-_L/3/M)N!9QB5IQ.6&1^\ (W?7!
M(S[UIT4 9YT?3VTH:8;6,V(  AYVX!R/UYICZ'ICW?VMK.,S^<L^_G/F*NT-
M]<<9]*TZ* *,VF65S<"XEMT>4%3N;N5.5..G!Y%(-(T]7F<6D69@ROE<A@WW
MACWQSZU?HH S?[%TW;@6J@[]^X9W;MNW.>OW3CZ5=AACMH4AA18XT4*J*,
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M_1S)R6M(Y:Q1%)VX.;A]/I5SFHT TD.1?C%OTVN9;Q3>3&8H8,@EVKQ;(D,
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MRT%:^3!=A7+:5ZV7R#%3/D=[4O9!D1_:,HOBOWSU\/_+$+/_"U!+ P04
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M:VYO7W.NQG3A+S0Q,8\(1@H>=*9^WN5-?%88^AB7VMG%65[1>Y:^FE?K&WU
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M1-\+]%BL-W]5)GV/3<<A=(?$HTCC"P0N=0G3>,4>N,%]M5;_KIKAX1OV_TC
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M7(@VX@@<N)2\KA=H-F),'5%M=3Q5(193^O6@[(8^A9TV$[I8+"(.!H:T[4[
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M[PVQX='/'I0%\]\.H#XYYJU_JWUYYS8# Z;W*&^("K6!ZQ1M&!!^D0$#]+G
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MIE]5Z;CQJQ&]B7R$"M"MC:#$_S?[K[A^H[F5OR]]IN+&G?\9^/2FFM=$<N$
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MR0E>I"\QFJ,+\%84BE9!W+1RZ71ZHX*6<B<RS6HP5LCS=AWQ/-G M\34G=.
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M*/>*CV"\7K=H^]/2^KMU!WZ'=:NS>9BN2*9MT1]L6!G(C^HQ;]]MACZTD+2
M'<(0BMY(H'SO-@QB#0T'$0VWK?CNE:UEZH8J<L-&B6L'H%V#A_5@)'#K-H5
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M/^,R_K0M('9C^+%=7$D' ]W?*CX+4>MA>1BEX5&F!2J(_/2[7[5E+A3[R?9
MDF3,TMPG48Q:L5[I&5J:=U%]N:[<-.R?;/NV-CCY.=%%0T>.T':-FGA*+=BF
MRG\+8R5XAS_2EAH,X6EVTUL-[HS(ZFKFX>M*3@UH*<]19; 4U\WIN=RT=R/)
M=S+Y:3J+?<RD,DA7J;^&$#8[BJAY]LK4ET4A1$M$PWY#J=,'<902P*?$= _M
MVO I)JEI5^53&AA-%&=1!_DC)2XNG4EXUP:M/%DLQ*WTU2PV?$#PK2I=ZO!Q
MXKQ=>J+R/0:;B,_;C<$CFT;^L C/.V;/.F]!"Q5!^A:S9JCF9(_E_(X,6QC-
M?I]\T7:ISHE6=-V!TIH W;%<K_%8"X%/T?:@2*'4X0_>:4*Y!TH[/5SVK(1%
M9A'C"1P6SY^A./>]%VVE]%GI>"0?#\,LN?X<GS:GC-]WQN$ZSRSL;9.P_)AL
MB ON,7[.4O'Q3/B+@+<-NZG;UJ.G6RO'O3GDA):8]PD8"H_*R/7U\0%\,< [
M;P?D$!8UJ$6R76<28MGI2+$]RJ4R-.0F+:!"7DK,D?!-Y>=[=B =K;_\$1+H
ME8@>3F$HS#4Y^$9HH,T<*Q3L-D/[K8%:^MJS2$W'6A+/U7DU1AF42T#%-KQ\
M_&;7+.-7],NVF.-!1>X+.YP;H:$&Y8\8QU$7Y^4*TTKMD[P\J[7UC<=V\T0[
MWSB$GHO98ZY)I+OA""^"9.[55C$XPTNGN?M9]K#T5')I/WJSMSHN4^U<D Z
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MSV-RZ8.( &^$Y\NW5Y$MI^;=CY+8E.WTO>QTWZ+U,YH<\P@LWGE:I4#XIY#
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M_]MKKW6>VF>M<U34E,7$;0*?RS^[!_R_ @, $   #@ @ 0 T@ < X $#>"
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MP"$() 2!AJ  $!08@H) 4' ("@E!H2%H  0-AJ A$#0<@D9"T/]9\)_C8#@
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M>==JK>7U9?9%S'*D9-L91:3Z! ^_<"E-6?4;YB]+P![FBH4)Q1_!@08B'U_
MT@P<F%A-EFLKA&NL1UU4FKITFV4::QR.7)3Y5%?X/X*QJ32 7'N&G(RG*75F
M%.<";0B=-B'#NK"_-=QS7:B!C9;L(.E:D[^Y>CK'RQ5Q6R ,)7'%:+YC]2G/
M72GG+EW;)Y(:2\W:%W+X9HW<3:5I#&Y4FN\V%O?]ZL)[2[5LJB4#T%D7>N*
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M@X>/((MY-0UH4AQXEZ("37-%IP3V ZO.9A08A>0IR@CX-"N<,HAYD;#C[Y^
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MG,!QJ@0)JE(U>$=L#EIFRNW$R0G'A%17>.41B;03@I(O?N,3L1![>?)BO2;
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MGL2M;- KQZH<A=];?TQ\%YLK^)3=$OQ>KZ_)&TX?U62)Z'Y5ODLV[3:[OTB
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M"GD4L^WX2$@N-ZUA0*@C*T$0B4&7- 7Q5XK1?:W3_#=D)6L,7ZU3"HST!<L
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M,U52'3\Y3U%:T9/,,$W6HYA7%;')%C&3I+AMS#*_96!@=]EI6,Y[D:R/8?I
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M4A&F&#-M51("N5/'@2FSA8[L<D82N QBX(V_X9?@TO\9Q-"-*D ,.1F3N @
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M030,8B )*!.8(26/[BAW@\,PO:MP1M0;R^!8%R%(),%NB#I+JFLC2BHH%+A
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M"W>8!, RG7"T0GKHA7'4AX')N<52,"2$C ,I"X9KQH5HB4D N\BRPSO)A#1
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M2S"8L\:]0K6&@<?I?,?%LLZDZ\Y="XR@2 SZ\*X58C<'<9>3>Z":' BOPH2
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M;AN1_,KT^09E=W:'=(BN3(>V8#!.*C0X_W:C2GYR!O6'ZXS94/:&F-:S8$V
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MH&@ % N X@%P   .!L!A #@: ,<"X'@ !@# @ $8& "#!F"P  P>@ , <&
M#@; H0$X+ "'_^]L !X,P,, >#0 CP7@_TO^JPT& V!@ !H,P/ZW!@8!P" P
M& 0#@]!@$!8,PH.A # 4#(;"P% T&(H%0_%@.  ,!X/A,# <#89CP7 \& ,
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M&J*"HETX7:S'B6:?O(Y@Y#L+OVESLSH(?!==".235_U\$/3R3^;>K8*N3$]
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M\CUBS3&*THRBO8[MHK!Q'C/DQ0@MK7JYW#:O[MKK[\D-:MOF>VJ+A)0L0>5
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M$,=+HNEG/O6X-R9)L,IM\4<>59/7I4_\\V5@_D2&>4]IS:Z#6X,^H,UDA/
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M>SKG9O>[X1UO><<E(  [4$L! A0#%     @ ;HIO5(,]_+KB9@$ P;D!  8
M             ( !     &$Q+FIP9U!+ 0(4 Q0    ( &Z*;U1PGVIET@<
M '@D   -              "  09G 0!E>%\S-#4Q-3<N:'1M4$L! A0#%
M  @ ;HIO5).R$'?0!P  @R0   T              ( ! V\! &5X7S,T-3$U
M."YH=&U02P$"% ,4    " !NBF]4,04@R^<%  "I&@  #0
M@ '^=@$ 97A?,S0U,34Y+FAT;5!+ 0(4 Q0    ( &Z*;U1U>""MI0,  *,,
M   -              "  1!] 0!E>%\S-#8U-C,N:'1M4$L! A0#%     @
M;HIO5(4G?7? $   OL(  !$              ( !X( ! ')V<&@M,C R,3$R
M,S$N>'-D4$L! A0#%     @ ;HIO5"&W&H0,"0  %&\  !4
M ( !SY$! ')V<&@M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( &Z*;U2U
MMQC\ED,  $&N!0 5              "  0Z; 0!R=G!H+3(P,C$Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " !NBF]40+3)4()9   ;W 0 %0
M@ '7W@$ <G9P:"TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ ;HIO5)B-
M1#'O1   8O\% !4              ( !C#@" ')V<&@M,C R,3$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( &Z*;U0R.JUA!NH" '&>&0 4              "
M :Y] @!R=G!H,C R,3$R,S%?,3!K+FAT;5!+ 0(4 Q0    ( &Z*;U3*YNY'
M3A@  /\:   :              "  >9G!0!R=G!H,C R,3$R,S%?,3!K:6UG
M,# R+FIP9U!+ 0(4 Q0    ( &Z*;U1H0V0YD2$  'DC   :
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M,# W+FIP9U!+ 0(4 Q0    ( &Z*;U0KK'K\H3P  +A"   :
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M,#$R+FIP9U!+ 0(4 Q0    ( &Z*;U2FZT.R21P   ,D   :
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M,#$W+FIP9U!+ 0(4 Q0    ( &Z*;U2^PM)>9Q<  / >   :
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M,#(R+FIP9U!+ 0(4 Q0    ( &Z*;U2[ 4I"O[<  .>W   :
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M,#(W+FIP9U!+ 0(4 Q0    ( &Z*;U3!MFS;Z3@  /P_   :
M  "  4[Q"0!R=G!H,C R,3$R,S%?,3!K:6UG,#(X+FIP9U!+ 0(4 Q0    (
M &Z*;U2LAH@S&C0  "LW   :              "  6\J"@!R=G!H,C R,3$R
M,S%?,3!K:6UG,#(Y+FIP9U!+ 0(4 Q0    ( &Z*;U3.I=\)E:$  *.A   :
M              "  <%>"@!R=G!H,C R,3$R,S%?,3!K:6UG,#,P+F=I9E!+
M 0(4 Q0    ( &Z*;U3K#@4:7$H  'I*   :              "  8X "P!R
M=G!H,C R,3$R,S%?,3!K:6UG,#,Q+F=I9E!+!08     *0 I !T+   B2PL
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
